

Feldmann, Heinrich (NIH/NIAID) [E]

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:23 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: inactivation methods -your talk in Germany

Heinz, what--if anything--would you like me to send in response to the email below?

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Rettenbacher-Riefler, Sophie [Sophie.Rettenbacher-Riefler@nlga.Niedersachsen.de]
Sent: Monday, October 20, 2014 1:13 AM
To: Haddock, Elaine (NIH/NIAID) [E]
Subject: inactivation methods -your talk in Germany

Dear Elaine!

We met at the National Zoonoses Conference in Berlin last Friday.
I was sitting next to you in the session where you gave your talk. Sorry that there wasn't time for any formal introduction!

I found your lecture particularly interesting and, given the fact that our lab is currently implementing Ebola diagnostics I was wondering whether you could send me your presentation or any published protocols on virus inactivation from your group.

Thank you very much in advance,

Yours,
Sophie

Dr. Sophie Rettenbacher-Riefler
Niedersächsisches Landesgesundheitsamt
Roesebeckstr. 4-6, 30449 Hannover
Tel.: 0511 4505-248
E-Mail: sophie.rettentbacher-riefler@nlga.niedersachsen.de
Internet: <http://www.nlga.niedersachsen.de>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Somba Sow

Dr. Sow is involved in the clinical trials of the VSV/Ebola vaccine in Mali. I read it in a news story tonight on a CTV website.

Dave

Sent from my iPhone

Feldmann, Heinrich (NIH/NIAID) [E]

From: Caldwell, Harlan (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 7:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: question

Interesting. Be fun to discuss over a beer.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 07:33 PM Eastern Standard Time
To: Caldwell, Harlan (NIH/NIAID) [E]
Subject: Re: question

Harlan,

Redacted by agreement

Heinz

From: Caldwell, Harlan (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 05:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: question

Hello Heinz,

Redacted by agreement

Harlan

Harlan D. Caldwell, Ph.D
Chief and Senior Investigator
Laboratory of Intracellular Parasites
Rocky Mountain Laboratory
National Institute of Allergy and Infectious Diseases
903 South 4th Street
Hamilton, MT 59840

Email: hcaldwell@niaid.nih.gov
Phone: 406-363-9333
FAX: 406-363-9355

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Monday, October 20, 2014 6:50 PM
To: Geisbert, Thomas W.
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Banner design for conference
Attachments: EboZ.PPTX

Please see attached.

Hope you can find someone who are good at coloring.

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Handle: Geisbert, Thomas W.
Mail Address: twgeisbe@UTMB.EDU
Subject: RE: Banner design for conference
To: Kawaoka <kawaokay@svm.vetmed.wisc.edu>
CC: feldmannh@niaid.nih.gov <feldmannh@niaid.nih.gov>
Date: Mon, 20 Oct 2014 19:51:46 +0000
Date Local: 2014/10/21 4:51:46
Message:

> Yoshi,
>
> This is what I was thinking. Does Noda have any others that we can look at and can he maybe color enhance them?
>
> Thanks for the link. Hope things work out on that.
>
> Tom
>
> -----Original Message-----
> From: Kawaoka [mailto:kawaokay@svm.vetmed.wisc.edu]
> Sent: Saturday, October 18, 2014 3:52 PM
> To: Geisbert, Thomas W.
> Cc: feldmannh@niaid.nih.gov
> Subject: RE: Banner design for conference
>
> Tom,
>
> I see.
>
> We could use attached although we need to get a permission from a journal; we use it recently for a commentary
Heinz and I wrote.
>
> The link below should work:
>
> <http://www.whitehouse.gov/blog/2014/10/17/doing-diligence-assess-risks>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 6:27 PM
To: Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: T705 / Ebola study

Don't care... ribavirin knocks down titers too. And you still die (if you are a NHP or hamster).

Darryl

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 1:02 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: T705 / Ebola study

Marshall invited me to sit in on teleconference to discuss NIH's plan for prioritizing / scheduling Ebola treatment studies.

Redacted by agreement

Redacted by agreement

What do you guys want to do? Redacted by agreement

Redacted by agreement

Dave

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Monday, October 20, 2014 6:21 PM
To: CARL F. BARRENAS; Marzi, Andrea (NIH/NIAID) [E]; Ilhem Messaoudi Powers
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; RICHARD GREEN; Matthew J. Thomas; Lynn Law; Michael G. Katze; halfmanp@svm.vetmed.wisc.edu
Subject: Re: Updated - Unpublished manuscript

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: CARL F. BARRENAS <barrenas@uw.edu>
Sent: Monday, October 20, 2014 6:10 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Ilhem Messaoudi Powers
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA; RICHARD GREEN; Matthew J. Thomas; Lynn Law; Michael G. Katze
Subject: Re: Updated : Unpublished manuscript
Attachments: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 6:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fw: Recap of today's meeting

Let's discuss when you return
Kathy


Sent from my BlackBerry Wireless Handheld

From: Dowling, William (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 04:56 PM Eastern Standard Time
To: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Jahrling, Peter (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]
Subject: Recap of today's meeting

Hello all

I just wanted to re-cap some of the therapies that we discussed today requiring pre-clinical studies. If I am incorrect or missed anything, please add/subtract/modify:

Redacted by agreement



You all now have the list of current requests to DMID. Some of these are not high priority for testing, but I wanted to list them all. If anyone has data on any thing on our list (especially negative data), please let me know. Also, if any of the same people have called you, please let me know and we can decide on the most appropriate way to handle it.

Some other issues :

- a) Mike is going to set up a meeting with NCATS and Gene regarding whether NCATS has some drugs not included in the screens he ran
- b) We will provide NHPs once we have the number and species of animals
- c) More coordination will be happening regarding upcoming WHO meeting.
- d) To answer the questions about the Amiodarone study - published in Journal of Antimicrobial therapy 2014:69:2123-2131. Cells were incubated with virus and drug for one hour , medium was exchanged, then cells were stained for Ebola antigen 20 hrs later.
- e) Mike proposed setting up a web site for negative data, hopefully curated by WHO. One detail that may be an obstacle are the agreements with companies. In our case, we have agreements signed in which all data are confidential unless the company agrees to make it public. I am guessing that DoD has similar

Feldmann, Heinrich (NIH/NIAID) [E]

From: Risi, George <George.Risi@providence.org>
Sent: Monday, October 20, 2014 5:58 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

I certainly think so but will defer to others.

There unfortunately is near panic on the part of our hospital administrators as well as some nurses and a few of the physicians. But the technical process of handling blood once it has been drawn is really a pretty small part of the process and would not really address their concerns.

George

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 20, 2014 5:51 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Risi, George; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]
Subject: Re: explain PCR / blood handling at St. Patrick?

Can this wait until I am back?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 06:41 PM Eastern Standard Time
To: 'Risi, George' <George.Risi@providence.org>; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

Paul, can you meet with Dave and Andrea to fill them in on what Joyce requested ... to make sure it's relevant to the staff there.

George, can you offer some thoughts to Dave, Andrea and Heinz about why a presentation to the St. Pat's staff might be good given the background of last week?

From: Risi, George [mailto:George.Risi@providence.org]
Sent: Monday, October 20, 2014 4:11 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

Would be great. We will buy them lunch

Feldmann, Heinrich (NIH/NIAID) [E]

From: "Regina Schädler" <chuzpe3@gmx.de>
Sent: Monday, October 20, 2014 5:53 PM
To: ENIVD%chuzpe3@gmx.de
Cc: niedrigm@gmx.de
Subject: IMPORTANT: ENIVD support
Attachments: Dear president of the Robert Koch Institute.pdf


Dear colleagues,

Most of you received the mail from Anna in the name of the steering committee (see below) by listserv. We got a good number of nice and helpful letters from members. If you also want to support the ENIVD please read the letter thoroughly and answer the questions as soon as possible. The more the better. One answer of each institute would be great! Sorry for nagging, but I'm afraid the time is running out...

Please send the answer to enivd@rki.de and delete this part above the line

Best regards,
Regina

Personal Info



Feldmann, Heinrich (NIH/NIAID) [E]

From: Hanley, Patrick (NIH/NIAID) [C]
Sent: Monday, October 20, 2014 5:36 PM
To: NIAID RML ACUC Committee
Cc: Clark, Terri (NIH/OD) [E]
Subject: ACUC meeting packet for October 23rd 2014
Attachments: Protocol Baseler Defining Early Target Cells of Nipah Virus Infection Oct 2014.doc; Protocol Addendum Bauler 2014-072.1 Oct 2014.docx; Protocol Bosio Role of GM-CSF in pneumonic tularemia in the mouse Oct 2014.doc; Protocol Hoenen Modulating effects of the Ebola virus L gene upstream open reading frame on virulence in mice Oct 2014.doc; Protocol Williamson Antibody Production against Phlebovirus NSs Protein Oct 2014.doc; Protocol Moore The mechanism of Treg suppression during persistent infection Oct 2014.docx; 807E3825.doc; Protocol Addendum Raymond 2014-005.3 Oct 2014.docx; Agenda Oct 2014.2.pdf; Minutes Oct 2014.1.pdf


Hi all,

Attached is the packet for the full committee meeting on October 23rd, 2014. Please see below for reviewer assignments for the ASPs attached. In addition, the minutes from the last meeting, and two addenda are attached for your review. A preliminary agenda is also attached. If there are any changes prior to the meeting, then a final agenda will be sent. In addition, we will be discussing the animal program as part of the semi-annual ACUC inspection. I will be sending the program description soon with assignments for review. Please send me your comments from the walk through so that I can tabulate them for the meeting.

Thanks and please let me know if you have any questions,

Patrick

Redacted by agreement



Patrick Hanley DVM

Rocky Mountain Veterinary Branch
Rocky Mountain Laboratories
Nat'l Institute of Allergy and Infectious Diseases (NIAID)
Nat'l Institutes of Health (NIH)
903 South 4th St.
Hamilton, MT 59840

Feldmann, Heinrich (NIH/NIAID) [E]

From: Juergen Richt <jricht@vet.k-state.edu>
Sent: Monday, October 20, 2014 5:10 PM
To: Robert and Sylvia Kahn; Jessica L. Green
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Request to help post article on Ebola on CEEZAD website
Attachments: Can We Stop Ebola Oct 14 JAR.docx

Bob:
Enclosed my corrections in track mode.
Heinz: Can you please go over the write up and comment/correct.

Best,
Juergen

From: Robert and Sylvia Kahn [mailto:Personal Info]
Sent: Monday, October 20, 2014 5:10 PM
To: Jessica L. Green
Cc: Juergen Richt
Subject: Request to help post article on Ebola on CEEZAD website

Hi Jessica,

I trust all is well in your busy life.

Would you please make sure that the attached article on the Ebola virus which has been approved by Juergen is posted as soon as possible on the CEEZAD website?

Any pictures would be welcome; and I will then forward the details to Bruce Kaplan at the One Health Initiative who is keen to post this article as soon as possible.

Many thanks

Bob

Feldmann, Heinrich (NIH/NIAID) [E]

From: malik <malik@hku.hk>
Sent: Monday, October 20, 2014 4:51 PM
To: Marzi, Andrea (NIH/NIAID) [E]; yhwongb
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Ebola antibody

Dear Andrea,

Our courier accounts are as follows:


FedEx: Redacted by agreement

World Courier: Redacted by agreement

Our detailed shipment address:

School of Public Health

Redacted by agreement



We will be happy to sign the MTA if you send us one.

Malik Peiris

From: Marzi, Andrea (NIH/NIAID) [E] [marzia@niaid.nih.gov]
Sent: Tuesday, October 21, 2014 1:24 AM
To: malik
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola antibody

Dear Malik,

The serum samples can be handled in BSL2, we do that all the time for ELISA, cytokine analysis etc.

In order to get the samples to you we will also need a MTA in place. It's the standard NIH simple letter agreement and Kay Menk (copied here) will contact you to set it up.

Once the MTA is in place and we receive your FedEx account info we will be able to send the serum samples.

Thanks,
Andrea

Feldmann, Heinrich (NIH/NIAID) [E]

From: Carlson, Paul (NIH/OD/ORS) [E]
Sent: Monday, October 20, 2014 4:48 PM
To: Pekoc, Ken (NIH/NIAID) [E]; 'Risi, George'; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

Sure – Dave/Andrea let me know when would work for you two to meet with me, should not take more than 10 minutes. Basically, the nurses at St. Pats are a little nervous related to the thought of handling a patient's blood sample that may be Ebola positive.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:41 PM
To: 'Risi, George'; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

Paul, can you meet with Dave and Andrea to fill them in on what Joyce requested ... to make sure it's relevant to the staff there.

George, can you offer some thoughts to Dave, Andrea and Heinz about why a presentation to the St. Pat's staff might be good given the background of last week?

From: Risi, George [<mailto:George.Risi@providence.org>]
Sent: Monday, October 20, 2014 4:11 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

Would be great. We will buy them lunch

From: Pekoc, Ken (NIH/NIAID) [E] [<mailto:kpekoc@niaid.nih.gov>]
Sent: Monday, October 20, 2014 4:09 PM
To: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Risi, George; Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: explain PCR / blood handling at St. Patrick?

Dave / Andrea ... I can provide details later, but would either or both of you be interested / available in going to St. Patrick Hospital (soon) and presenting to their staff on how you handle a blood sample from a suspected Ebola case? If yes, please let me know some ideal days / times and I'll work back with the hospital.

If this comes together Paul and I would like to accompany you to observe.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:37 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: explain PCR / blood handling at St. Patrick?

Ken explained this differently on the phone.

Redacted by agreement

Personally, I'm not sure if us talking with them will do any good especially since our role and their role is so different. We cannot give them advice on blood collection, PPE, etc; that should come from the CDC.

What is your thoughts on this request? I guess it's too late and we have essentially committed to going unless you tell us not to.

Dave

-----Original Message-----

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:29 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Risi, George; Safronetz, David (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

I've spoken to Dave ... am going to try and set this up with the hospital for Friday before lunch. I think it will be good for both Dave and Andrea to present from both the lab / blood handling perspective and the field / diagnostic perspective in Liberia.

George / Paul, can you fill Dave and Andrea in on some of the background from last week on why the hospital would like this presentation?

-----Original Message-----

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:24 PM
To: Risi, George; Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: explain PCR / blood handling at St. Patrick?

Maybe Dave can go earlier?

On 10/20/14 4:18 PM, "Risi, George" <George.Risi@providence.org> wrote:

>I will not be here but I think everyone else is.
>George

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:24 PM
To: Risi, George; Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: explain PCR / blood handling at St. Patrick?

Maybe Dave can go earlier?

On 10/20/14 4:18 PM, "Risi, George" <George.Risi@providence.org> wrote:

>I will not be here but I think everyone else is.

>George

>

>-----Original Message-----

>From: Marzi, Andrea (NIH/NIAID) [E] [mailto:marzia@niaid.nih.gov]

>Sent: Monday, October 20, 2014 4:14 PM

>To: Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]

>Cc: Risi, George; Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich

>(NIH/NIAID) [E]

>Subject: Re: explain PCR / blood handling at St. Patrick?

>

>Can do - Friday schedule is open. Rest of the week pretty packed.

>A.

>

>From: <Pekoc>, "Ken [E] (NIH/NIAID)"

><kpekoc@niaid.nih.gov<mailto:kpekoc@niaid.nih.gov>>

>Date: Monday, October 20, 2014 4:09 PM

>To: "Safronetz, David (NIH/NIAID) [E]"

><safronetzd@niaid.nih.gov<mailto:safronetzd@niaid.nih.gov>>, Andrea

>Marzi <marzia@niaid.nih.gov<mailto:marzia@niaid.nih.gov>>

>Cc: "Risi, George

>(George.Risi@providence.org<mailto:George.Risi@providence.org>)"

><George.Risi@providence.org<mailto:George.Risi@providence.org>>,

>"Carlson, Paul (NIH/OD/ORS) [E]"

><pcarlson@od.nih.gov<mailto:pcarlson@od.nih.gov>>, Heinz Feldmann

><feldmannh@niaid.nih.gov<mailto:feldmannh@niaid.nih.gov>>

>Subject: explain PCR / blood handling at St. Patrick?

>

>

>Dave / Andrea ... I can provide details later, but would either or both

>of you be interested / available in going to St. Patrick Hospital

>(soon) and presenting to their staff on how you handle a blood sample

>from a suspected Ebola case? If yes, please let me know some ideal days

>/ times and I'll work back with the hospital.

>

>If this comes together Paul and I would like to accompany you to observe.

>

>George, looping you in on this request that just came today via

Feldmann, Heinrich (NIH/NIAID) [E]

From: Risi, George <George.Risi@providence.org>
Sent: Monday, October 20, 2014 4:19 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

I will not be here but I think everyone else is.
George

-----Original Message-----

From: Marzi, Andrea (NIH/NIAID) [E] [mailto:marzia@niaid.nih.gov]
Sent: Monday, October 20, 2014 4:14 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Cc: Risi, George; Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: explain PCR / blood handling at St. Patrick?

Can do - Friday schedule is open. Rest of the week pretty packed.
A.

From: <Pekoc>, "Ken [E] (NIH/NIAID)" <kpekoc@niaid.nih.gov<mailto:kpekoc@niaid.nih.gov>>
Date: Monday, October 20, 2014 4:09 PM
To: "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov<mailto:safronetzd@niaid.nih.gov>>, Andrea Marzi <marzia@niaid.nih.gov<mailto:marzia@niaid.nih.gov>>
Cc: "Risi, George (George.Risi@providence.org<mailto:George.Risi@providence.org>)" <George.Risi@providence.org<mailto:George.Risi@providence.org>>, "Carlson, Paul (NIH/OD/ORS) [E]" <pcarlson@od.nih.gov<mailto:pcarlson@od.nih.gov>>, Heinz Feldmann <feldmannh@niaid.nih.gov<mailto:feldmannh@niaid.nih.gov>>
Subject: explain PCR / blood handling at St. Patrick?

Dave / Andrea ... I can provide details later, but would either or both of you be interested / available in going to St. Patrick Hospital (soon) and presenting to their staff on how you handle a blood sample from a suspected Ebola case? If yes, please let me know some ideal days / times and I'll work back with the hospital.

If this comes together Paul and I would like to accompany you to observe.

George, looping you in on this request that just came today via conversations with Joyce / Paul. This would be a good-will gesture the way I see it.

Thanks.

Ken Pekoc
Public Affairs Officer
Rocky Mountain Laboratories
NIAID Office of Communications and Government Relations

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:14 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Cc: Risi, George (George.Risi@providence.org); Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: explain PCR / blood handling at St. Patrick?
Attachments: image001.gif

Can do – Friday schedule is open. Rest of the week pretty packed.

A.

From: <Pekoc>, "Ken [E] (NIH/NIAID)" <kpekoc@niaid.nih.gov>
Date: Monday, October 20, 2014 4:09 PM
To: "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov>, Andrea Marzi <marzia@niaid.nih.gov>
Cc: "Risi, George (George.Risi@providence.org)" <George.Risi@providence.org>, "Carlson, Paul (NIH/OD/ORS) [E]" <pcarlson@od.nih.gov>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Subject: explain PCR / blood handling at St. Patrick?

Dave / Andrea ... I can provide details later, but would either or both of you be interested / available in going to St. Patrick Hospital (soon) and presenting to their staff on how you handle a blood sample from a suspected Ebola case? If yes, please let me know some ideal days / times and I'll work back with the hospital.

If this comes together Paul and I would like to accompany you to observe.

George, looping you in on this request that just came today via conversations with Joyce / Paul. This would be a good-will gesture the way I see it.

Thanks.

Ken Pekoc
Public Affairs Officer
Rocky Mountain Laboratories
NIAID Office of Communications and Government Relations
406-375-9690

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Borchert, Matthias <Matthias.Borchert@charite.de>
Sent: Monday, October 20, 2014 4:12 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'Nora Love (Nora.Love@rescue.org)'
Subject: Introductions

Redacted by agreement

Redacted by agreement

Redacted by agreement

Cheers,

Matthias

Matthias Borchert
International Rescue Committee - Liberia
Ebola Treatment Unit
Senior Health Coordinator
Cell: Personal Info
Email: matthias.borchert@charite.de
Skype: Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Risi, George <George.Risi@providence.org>
Sent: Monday, October 20, 2014 4:11 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

Would be great. We will buy them lunch

From: Pekoc, Ken (NIH/NIAID) [E] [mailto:kpekoc@niaid.nih.gov]
Sent: Monday, October 20, 2014 4:09 PM
To: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Risi, George; Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: explain PCR / blood handling at St. Patrick?

Dave / Andrea ... I can provide details later, but would either or both of you be interested / available in going to St. Patrick Hospital (soon) and presenting to their staff on how you handle a blood sample from a suspected Ebola case? If yes, please let me know some ideal days / times and I'll work back with the hospital.

If this comes together Paul and I would like to accompany you to observe.

George, looping you in on this request that just came today via conversations with Joyce / Paul. This would be a good-will gesture the way I see it.

Thanks.

Ken Pekoc
Public Affairs Officer
Rocky Mountain Laboratories
NIAID Office of Communications and Government Relations
406-375-9690

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

This message is intended for the sole use of the addressee, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the addressee you are hereby notified that you may not use, copy, disclose, or distribute to anyone the message or any information contained in the message. If you have received this message in error, please immediately advise the sender by reply email and delete this message.


Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:03 PM
To: Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Recap of today's meeting

From: Dowling, William (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 2:56 PM
To: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Jahrling, Peter (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]
Subject: Recap of today's meeting

Hello all

Redacted by agreement



You all now have the list of current requests to DMID. Some of these are not high priority for testing, but I wanted to list them all. If anyone has data on any thing on our list (especially negative data), please let me know. Also, if any of the same people have called you, please let me know and we can decide on the most appropriate way to handle it.

Some other issues :

- a) Mike is going to set up a meeting with NCATS and Gene regarding whether NCATS has some drugs not included in the screens he ran
- b) We will provide NHPs once we have the number and species of animals
- c) More coordination will be happening regarding upcoming WHO meeting.
- d) To answer the questions about the Amiodarone study - published in Journal of Antimicrobial therapy 2014:69:2123-2131. Cells were incubated with virus and drug for one hour , medium was exchanged, then cells were stained for Ebola antigen 20 hrs later.
- e) Mike proposed setting up a web site for negative data, hopefully curated by WHO. One detail that may be an obstacle are the agreements with companies. In our case, we have agreements signed in which all data are confidential unless the company agrees to make it public. I am guessing that DoD has similar arrangements. So maybe this is something we need to work on now. In the case of FDA approved drugs that were purchased off the shelf, I am not sure if this applies.

Regards
Bill

Feldmann, Heinrich (NIH/NIAID) [E]

From: Lane, Cliff (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 3:48 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID)
Subject: RE: MOU

Heinz,

I have taken the non-NIAID individuals other than Frank Mahoney and Stuart Nichol off the string. As can be seen this string began with someone from NIAMS indicating that they were working with Dr. Fauci's group when in fact such was not the case. That is a problem and required some immediate action. I am very supportive of what you want to do and am fine with however we can work to appropriately get samples out of the country for your studies. I spoke with Stuart today about doing our best to make sure we do not duplicate efforts and he assured me that you, he and Peter would work together to minimize this chance. I think if we are able to generate a very tight list of, in general terms, what we are each doing it will be helpful - but not a pre-requisite to doing things. I want as little bureaucracy as possible.

If there is a way to get your samples out as part of the CDC effort that would be one possibility. Alternatively, once CDC has an approved MOU (as Frank suggested) we could do an MOU merely referencing what has already been approved if Frank and Stuart were Ok with that approach. Please work directly with me if that is the path we take.

Redacted by agreement That will provide additional opportunities to look at variety of parameters and I look forward to working with you, Peter and Gary to decide the best things to do in the context of that study from a laboratory perspective. Sequencing the vaccine breakthroughs will be of particular interest.

Cliff

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:41 PM
To: Lane, Cliff (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: MOU

Dear Cliff,

Here is a request for sample shipment from the CDC/NIH Lab to the US. We urgently need sequence information on currently circulating strains/variants to improve diagnostics. We are already seeing false-negatives with our GP-based assay which is likely due to mutations. We also need virus isolates for diagnostics and urgently needed pathogenesis studies. It would also be good to test the vaccine candidates against currently circulating strains which has not been done yet. The outbreak response is severely hampered by the lack of information.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Caldwell, Harlan (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 3:14 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: question

Hello Heinz,

Do you know if Ebola virus with GP mutations that prevent the formation of sGP or a sGP that fail to dimerize are attenuated?

Harlan

Harlan D. Caldwell, Ph.D
Chief and Senior Investigator
Laboratory of Intracellular Parasites
Rocky Mountain Laboratory
National Institute of Allergy and Infectious Diseases
903 South 4th Street
Hamilton, MT 59840

Email: hcaldwell@niaid.nih.gov

Phone: 406-363-9333

FAX: 406-363-9355

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Monday, October 20, 2014 3:01 PM
To: Pierre Formenty; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

Pierre,

This is correct. The problem is that Ebola-Zaire is pretty much uniformly lethal in macaques at the doses and routes we use. Redacted by agreement

Redacted by agreement

Tom

From: FORMENTY, Pierre B.H. [mailto:formentyp@who.int]
Sent: Monday, October 20, 2014 3:24 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

Great, Thanks!

Only 3? ... and in fact only 1 was really an untreated survivors of virulent ZEBOV infection

In total, how many NHP that survive Ebola infection were rechallenged (even if non published data)?

From: Geisbert, Thomas W. [mailto:twgeisbe@utmb.edu]
Sent: 20 October 2014 22:17
To: FORMENTY, Pierre B.H.; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

Pierre,

Yes, a number of examples. Please see the first two sentences of the Materials and Methods of the attached paper where we re-challenged three surviving monkeys.

Tom

From: FORMENTY, Pierre B.H. [mailto:formentyp@who.int]
Sent: Monday, October 20, 2014 2:59 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

And are you aware of NHP surviving Zaire rechallenged with Zaire?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 2:35 PM
To: Menk, Kay (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola trVLP system
Attachments: RE: Ebola trVLP system

Hi Kay,

Personal Info

I got the OK from Heinz to go forward with the letter. Would you mind printing it and getting it signed, so that I can send a scanned version to [REDACTED] have attached the email with the original draft.

All the best, Thomas

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 2:27 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

If it is important to you - please go ahead with the letter. I never really had anything to do with her.

Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 04:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I understand where you are coming from - I guess one can argue both ways whether or not it is a reasonable collaboration or not (particularly if we include the establishment of an improved protocol for 96-well format screening which we would do in the letter). There is a strong mutual interest and benefit, but the actual wet-work is certainly mostly in their hands.

Personal Info

Moving forward, you will have to make a definitive decision whether or not we are willing uphold our agreement to provide a letter of collaboration or not - I get the impression that you rather would not want to do that. I certainly hate to disappoint [REDACTED] but I can also appreciate your position, so I will see how we can back out of our agreement to provide such a letter without causing too many damage to our relationship with her. I'll start working on an email to her, and send you the draft.

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:50 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 2:32 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

I will do that, then. Thank you very much!

All the best, Thomas

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 2:27 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

If it is important to you - please go ahead with the letter. I never really had anything to do with her.


Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 04:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I understand where you are coming from - I guess one can argue both ways whether or not it is a reasonable collaboration or not (particularly if we include the establishment of an improved protocol for 96-well format screening which we would do in the letter). There is a strong mutual interest and benefit, but the actual wet-work is certainly mostly in their hands.

Moving forward, you will have to make a definitive decision whether or not we are willing uphold our agreement to provide a letter of collaboration or not - I get the impression that you rather would not want to do that. I certainly hate to disappoint  but I can also appreciate your position, so I will see how we can back out of our agreement to provide such a letter without causing too many damage to our relationship with her. I'll start working on an email to her, and send you the draft.

All the best, Thomas

Personal Info

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:50 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

Every letter will be evaluated carefully. If it is a reasonable collaboration - no problem. If not - I would rather not write a letter.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 2:26 PM
To: Garvey, Anne (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]
Cc: Barron, Karyl (NIH/NIAID) [E]; Blaney, Joe (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Mays, Gary (NIH/NIAID) [E]
Subject: RE: Avoiding contact on return

I think we can make a case that critical work needs to be done back at RML when they return as because of their diagnostic mission in Liberia for the Ebola epidemic.

-----Original Message-----

From: Garvey, Anne (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:52 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]
Cc: Barron, Karyl (NIH/NIAID) [E]; Blaney, Joe (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Mays, Gary (NIH/NIAID) [E]
Subject: RE: Avoiding contact on return

Dr. Zoon, Dr. McGowan -

There are some options for utilizing business class on the return under the policy for Premium Class. These are the prevailing exceptions, including the 14 hour rule, which apply to all travelers - and are unrelated to contact concerns.

If you want to pursue those, the options include:

No space available in business class - presuming that they'd have to at this stage change dates/times for their return flights (I believe they all, with the exception of Dr. Feldmann, are scheduled to return tonight), if no coach seats are available on the rescheduled flights that would be a justification for using business class.

Travel in excess of 14 hours - for return flights in premium class, the traveler must show an urgent mission related need to return via premium class. This is meant to be critical work to be done back at NIH that cannot be skipped or postponed and must be dealt with immediately upon return.

I'm happy to work with the AO staff in RML as needed.

Thanks,

Anne Garvey

-----Original Message-----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:55 AM
To: McGowan, John J. (NIH/NIAID) [E]
Cc: Barron, Karyl (NIH/NIAID) [E]; Blaney, Joe (NIH/NIAID) [E]; Garvey, Anne (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Mays, Gary (NIH/NIAID) [E]
Subject: RE: Avoiding contact on return

JJ

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 2:25 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Geisbert, Thomas W. (twgeisbe@UTMB.EDU)
Subject: FW: Your Unpublished

Unpublished

Dave

-----Original Message-----

From: Unpublished

Unpublished

Sent: Monday, October 20, 2014 2:07 PM

To: Safronetz, David (NIH/NIAID) [E]

Subject: Your Unpublished

20-Oct-2014

Dear Dr. Safronetz:

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pierre Formenty
Sent: Monday, October 20, 2014 2:24 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

Great, Thanks!

Only 3? ... and in fact only 1 was really an untreated survivors of virulent ZEBOV infection

In total, how many NHP that survive Ebola infection were rechallenged (even if non published data)?

From: Geisbert, Thomas W. [<mailto:twgeisbe@utmb.edu>]
Sent: 20 October 2014 22:17
To: FORMENTY, Pierre B.H.; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

Pierre,

Yes, a number of examples. Please see the first two sentences of the Materials and Methods of the attached paper where we re-challenged three surviving monkeys.

Tom

From: FORMENTY, Pierre B.H. [<mailto:formentyp@who.int>]
Sent: Monday, October 20, 2014 2:59 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

And are you aware of NHP surviving Zaire rechallenged with Zaire?

From: Geisbert, Thomas W. [<mailto:twgeisbe@utmb.edu>]
Sent: 20 October 2014 21:56
To: Feldmann, Heinrich (NIH/NIAID) [E]; FORMENTY, Pierre B.H.; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

I agree with Heinz. Even for survivors I think you would still want some form of PPE.

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Monday, October 20, 2014 11:19 AM
To: Pierre Formenty; Geisbert, Thomas W.; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Monday, October 20, 2014 2:17 PM
To: Pierre Formenty; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?
Attachments: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 2:15 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I understand where you are coming from - I guess one can argue both ways whether or not it is a reasonable collaboration or not (particularly if we include the establishment of an improved protocol for 96-well format screening which we would do in the letter). There is a strong mutual interest and benefit, but the actual wet-work is certainly mostly in their hands.

Moving forward, you will have to make a definitive decision whether or not we are willing uphold our agreement to provide a letter of collaboration or not - I get the impression that you rather would not want to do that. I certainly hate to disappoint [REDACTED], but I can also appreciate your position, so I will see how we can back out of our agreement to provide such a letter without causing too many damage to our relationship with her. I'll start working on an email to her, and send you the draft.

All the best, Thomas

Personal Info

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:50 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

Every letter will be evaluated carefully. If it is a reasonable collaboration - no problem. If not - I would rather not write a letter.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 12:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

Personal Info

What we would do is to help her get the system up and running, as I initially wrote you. In addition, I am thinking of developing protocols to downscale the system for HTS screening (probably using reverse transfection) - this would be something that would be very applicable to [REDACTED] work, and might also be good for us in the future. What we get in return is basically that they validate the usefulness of our system as an actual screening system prior to BSL4 screening of antivirals - something I would love to do myself, but just don't have the time / manpower to do. So I do think in this case there is a mutual interest, even though my own contributions are relatively small.

For your information, [REDACTED] also had asked for a letter of collaboration to support a grant application, but I did not agree to this because a) I don't think his proposal makes any sense, at least not for that particular call, and b) I didn't think there was a real mutual interest.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pierre Formenty
Sent: Monday, October 20, 2014 1:59 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

And are you aware of NHP surviving Zaire rechallenged with Zaire?

From: Geisbert, Thomas W. [mailto:twgeisbe@utmb.edu]
Sent: 20 October 2014 21:56
To: Feldmann, Heinrich (NIH/NIAID) [E]; FORMENTY, Pierre B.H.; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

I agree with Heinz. Even for survivors I think you would still want some form of PPE.

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 20, 2014 11:19 AM
To: Pierre Formenty; Geisbert, Thomas W.; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

I don't think there is a guaranty that they will be all immune. I would at least wait a month which would also be good in regards to their full recovery. Overall, I would assume that survivors are immune to immediate reinfection with the same species.

MSF is using survivors here in Monrovia on the ward. They still wear PPE but less than other health care workers. I would think a low grade PPE should be used.

Heinz

From: Pierre Formenty
Sent: Monday, October 20, 2014 04:06 AM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

Dear Tom, Gary and Heinz,

Over the week-end UNICEF supported a conference on Ebola Survivors in Sierra Leone. Their assumption n°1 was "all recovered Ebola patients are immune" and will not be reinfected. Assumption n°2 was that "Survivors could take care of Ebola patients without PPE".

Do we have solid evidence for this?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Risi, George <George.Risi@providence.org>
Sent: Monday, October 20, 2014 1:57 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: presentation for the public

I wish they had not said it would be a "nightmare scenario" if the virus became airborne transmissible. they might be right, but what I would have said is we will deal with that extremely unusual situation if it were to happen. The news media loves the term "nightmare".

Redacted by agreement

george

-----Original Message-----

From: Marzi, Andrea (NIH/NIAID) [E] [mailto:marzia@niaid.nih.gov]
Sent: Monday, October 20, 2014 1:15 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Risi, George; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: presentation for the public

My thoughts:

I would encourage you to do this the sooner the better, Nov 7th if possible. People in the community are worried and have a lot of questions.

Got approached twice about air travel and pets already.

A Q&A format as suggested by Ken seems to me the best option - people come up with so many different questions.
Andrea

From: <Pekoc>, "Ken [E] (NIH/NIAID)" <kpekoc@niaid.nih.gov<mailto:kpekoc@niaid.nih.gov>>
Date: Monday, October 20, 2014 12:58 PM
To: "Bloom, Marshall (NIH/NIAID) [E]" <MBLOOM@niaid.nih.gov<mailto:MBLOOM@niaid.nih.gov>>
Cc: "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov<mailto:safronetzd@niaid.nih.gov>>, Andrea Marzi <marzia@niaid.nih.gov<mailto:marzia@niaid.nih.gov>>, "Risi, George (George.Risi@providence.org<mailto:George.Risi@providence.org>)" <George.Risi@providence.org<mailto:George.Risi@providence.org>>, Heinz Feldmann <feldmannh@niaid.nih.gov<mailto:feldmannh@niaid.nih.gov>>
Subject: RE: presentation for the public

Dr. Fauci participated in something similar this morning on WTOP radio; checking to see if audio is available, but here's the written coverage.

WTOP Town Hall on Ebola airs public concerns <http://www.wtop.com/41/3725862/WTOP-Town-Hall-on-Ebola-airs-public-concerns>

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:49 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Monday, October 20, 2014 1:56 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Pierre Formenty; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

I agree with Heinz. Even for survivors I think you would still want some form of PPE.

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 20, 2014 11:19 AM
To: Pierre Formenty; Geisbert, Thomas W.; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

I don't think there is a guaranty that they will be all immune. I would at least wait a month which would also be good in regards to their full recovery. Overall, I would assume that survivors are immune to immediate reinfection with the same species.

MSF is using survivors here in Monrovia on the ward. They still wear PPE but less than other health care workers. I would think a low grade PPE should be used.

Heinz

From: Pierre Formenty
Sent: Monday, October 20, 2014 04:06 AM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

Dear Tom, Gary and Heinz,

Over the week-end UNICEF supported a conference on Ebola Survivors in Sierra Leone. Their assumption n°1 was "all recovered Ebola patients are immune" and will not be reinfected. Assumption n°2 was that "Survivors could take care of Ebola patients without PPE".

Do we have solid evidence for this?

As NHP surviving Reston infection were rechallenged with Sudan or Zaire, I wonder if someone rechallenge NHP surviving Zaire with Zaire, and which findings? May be rechallenges studies were conducted in BLS4 and not published? I would happy to read any anecdotal report or grey litterature on rechallenges with Zaire.

Thank you for you support.

Kind regards,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Monday, October 20, 2014 1:52 PM
To: YOSHIHIROKAWAOKA
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Banner design for conference

Yoshi,

This is what I was thinking. Does Noda have any others that we can look at and can he maybe color enhance them?

Thanks for the link. Hope things work out on that.

Tom

-----Original Message-----

From: Kawaoka [mailto:kawaokay@svm.vetmed.wisc.edu]
Sent: Saturday, October 18, 2014 3:52 PM
To: Geisbert, Thomas W.
Cc: feldmannh@niaid.nih.gov
Subject: RE: Banner design for conference

Tom,

I see.

We could use attached although we need to get a permission from a journal; we use it recently for a commentary Heinz and I wrote.

The link below should work:

<http://www.whitehouse.gov/blog/2014/10/17/doing-diligence-assess-risks-and-benefits-life-sciences-gain-function-research>

Yoshi

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Handle: Geisbert, Thomas W.
Mail Address: twgeisbe@UTMB.EDU
Subject: RE: Banner design for conference
To: Kawaoka <kawaokay@svm.vetmed.wisc.edu>
CC: feldmannh@niaid.nih.gov <feldmannh@niaid.nih.gov>
Date: Sat, 18 Oct 2014 16:22:09 +0000
Date Local: 2014/10/19 1:22:09
Message:

> Yoshi,

>

> The one that I used was Marburg. I am wondering if we should use Ebola for this meeting?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Risi, George <George.Risi@providence.org>
Sent: Monday, October 20, 2014 1:41 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: presentation for the public

I will probably be in Panama on the 7th, sorry. Am home all the following week.
George

From: Pekoc, Ken (NIH/NIAID) [E] [mailto:kpekoc@niaid.nih.gov]
Sent: Monday, October 20, 2014 12:49 PM
To: Bloom, Marshall (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Risi, George; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: presentation for the public

The PAC is available Friday, Nov. 7 from 6-9 p.m. ... and Friday, Nov. 21 from 6-9 p.m.

I realize Andrea will be overseas, but I believe the others are available on these dates.

I think the sooner this can be done, the better.

I also think this should be done more informally than prior presentations with less time presenting and more time for community questions. I'd propose to have Heinz, Dave and George on stage simultaneously seated; each can stand to give a 5-7 minute overview of their involvement, show a couple slides, discuss a few pre-arranged key points, and then open the floor to Qs and dialogue for 30-45 minutes. Listening to the audience Qs will be the most important part of this.

A key will be to not try and persuade or disrespect any critics to believe what the presenters are saying, but just to answer the Qs with the facts as known and let people make up their own minds whether they believe.

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 9:37 AM
To: Bloom, Marshall (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Risi, George (George.Risi@providence.org); Marzi, Andrea (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: presentation for the public

I'm in Utah somewhere around November 12-14.

Dave

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 2:03 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 1:33 PM
To: Jean-Vivien MOMBOULI; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Conakry bound

Hi Jean-vivien,

Good to hear from you. Heinz is currently in monrovia, and I'll be back there in December. Currently our focus is perform diagnostics for the MSF and government etu in monrovia

We really need to get the NPHL set-up, I think RC is not adequately prepared. We need to get the infrastructure solved before it is too late,

Take care in Conakry,

Vincent Munster
Chief, Virus Ecology Unit
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH
903 South 4th street
Hamilton, MT 59840
[406-375-7489](tel:406-375-7489)

From: Jean-vivien Mombouli Personal Info
Date: Saturday, October 18, 2014 10:30 PM
To: Vincent Munster <munstervj@niaid.nih.gov>, Vincent Munster <munstervj@niaid.nih.gov>, Heinrich Feldmann <feldmannh@niaid.nih.gov>
Subject: Conakry bound

Dear Vincent,

I willing flying into Conakry on thursday. With such a huge outbreak on hand, one can imagine that ebolavirus spillovers may be happening in some mammal or insect species? Wouldn't you think that there maybe some opportunity for investigation of that novel question?

Also, how Redacted by agreement
JV M

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 1:15 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; 'Risi, George (George.Risi@providence.org)';
Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: presentation for the public

My thoughts:

I would encourage you to do this the sooner the better, Nov 7th if possible. People in the community are worried and have a lot of questions.

Got approached twice about air travel and pets already.

A Q&A format as suggested by Ken seems to me the best option – people come up with so many different questions.

Andrea

From: <Pekoc>, "Ken [E] (NIH/NIAID)" <kpekoc@niaid.nih.gov>
Date: Monday, October 20, 2014 12:58 PM
To: "Bloom, Marshall (NIH/NIAID) [E]" <MBLOOM@niaid.nih.gov>
Cc: "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov>, Andrea Marzi <marzia@niaid.nih.gov>, "Risi, George (George.Risi@providence.org)" <George.Risi@providence.org>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Subject: RE: presentation for the public

Dr. Fauci participated in something similar this morning on WTOP radio; checking to see if audio is available, but here's the written coverage.

WTOP Town Hall on Ebola airs public concerns

<http://www.wtop.com/41/3725862/WTOP-Town-Hall-on-Ebola-airs-public-concerns>

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:49 PM
To: Bloom, Marshall (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Risi, George (George.Risi@providence.org);
Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: presentation for the public

The PAC is available Friday, Nov. 7 from 6-9 p.m. ... and Friday, Nov. 21 from 6-9 p.m.

I realize Andrea will be overseas, but I believe the others are available on these dates.

I think the sooner this can be done, the better.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 1:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: T705 / Ebola study

Marshall invited me to sit in on teleconference to discuss NIH's plan for prioritizing / scheduling Ebola treatment studies. It appears that T705 remains high on the list of compounds to be tested despite the results of the DoD study. Apparently in the DoD study the animals were not euthanized because of EHF but rather they developed a side effect most likely related to being gavaged three times a day. According to people on the call the treated animals had reduced titers suggesting the drug had an effect.

What do you guys want to do? Redacted by agreement

Redacted by agreement

Dave

Feldmann, Heinrich (NIH/NIAID) [E]

From: Joel Kettner [Personal Info]
Sent: Monday, October 20, 2014 12:56 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Terri Nevile
Subject: Re: Greetings from an old colleague from Winnipeg

Sorry, Heinz - I have been in meetings all day.

I am at my ICID office at [Personal Info] My assistant is Terri; if the phone rolls over to her phone, she will find me.

My mobile phone is [Personal Info] but it gets very poor reception in my office.

Thanks,
Joel.

On 20 Oct, 2014, at 11:15 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

I can call now or in a few hours - otherwise tomorrow.

What is a good number to call?

Heinz

----- Original Message -----

From: Joel Kettner [mailto:[Personal Info]]
Sent: Sunday, October 19, 2014 08:53 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Greetings from an old colleague from Winnipeg

Well I can't wait till then to get your thoughts on the situation! Do you have adequate internet access for a Skype call? If so, is there a best time for you?

On Oct 19, 2014, at 6:32 PM, Feldmann, Heinrich (NIH/NIAID) [E]
<feldmannh@niaid.nih.gov> wrote:

> Until November 3.

>

> ----- Original Message -----

> From: Joel Kettner [mailto:[Personal Info]]
> Sent: Sunday, October 19, 2014 07:06 PM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: Greetings from an old colleague from Winnipeg

>

> Thank you for your quick reply, Heinz. How long are you planning to be there?

> Joel.

>


> Joel Kettner.

>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mahoney, Frank (CDC/CGH/GID)
Sent: Monday, October 20, 2014 11:45 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: MOU

Records Originating Outside of NIAID



From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 11:41 PM
To: Lane, Cliff (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: MOU

Dear Cliff,

Here is a request for sample shipment from the CDC/NIH Lab to the US. We urgently need sequence information on currently circulating strains/variants to improve diagnostics. We are already seeing false-negatives with our GP-based assay which is likely due to mutations. We also need virus isolates for diagnostics and urgently needed pathogenesis studies. It would also be good to test the vaccine candidates against currently circulating strains which has not been done yet. The outbreak response is severely hampered by the lack of information.

We also need a quick answer on a possible shipment in order to make decisions on already collected material here at the lab. If sample shipments are not going to happen we will be forced to destroy the material as security and safety could become problems at certain locations. We are waiting for those decisions now since mid-August.

I am looking forward to hearing from your office as soon as possible.

Thanks and best wishes, Heinz

----- Original Message -----

From: Lane, Cliff (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 04:56 PM Eastern Standard Time
To: Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: MOU

Colleagues,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 11:25 AM
To: malik
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola antibody

Dear Malik,

The serum samples can be handled in BSL2, we do that all the time for ELISA, cytokine analysis etc.

In order to get the samples to you we will also need a MTA in place. It's the standard NIH simple letter agreement and Kay Menk (copied here) will contact you to set it up.

Once the MTA is in place and we receive your FedEx account info we will be able to send the serum samples.

Thanks,
Andrea

On 10/18/14 4:13 PM, "malik" <malik@hku.hk> wrote:

>Dear Andrea,
>
>Yes 0.5ml would be ample.
>
>Most appreciated.
>
>Can I clarify that these sera can be handled at BSL2?
>
>Malik
>
>_____
>From: Marzi, Andrea (NIH/NIAID) [E] [marzia@niaid.nih.gov]
>Sent: Sunday, October 19, 2014 12:51 AM
>To: malik
>Cc: Feldmann, Heinrich (NIH/NIAID) [E]
>Subject: RE: Ebola antibody
>
>Dear Malik,
>
>Heinz forwarded me your request for antibodies.
>We can provide a few inactivated NHP serum samples from animals that
>survived challenge. But only up to 0.5ml. Would that be enough?
>
>Please let me know.
>
>Thanks,
>Andrea

Feldmann, Heinrich (NIH/NIAID) [E]

From: Li, Hongmin (HEALTH) <hongmin.li@health.ny.gov>
Sent: Monday, October 20, 2014 11:17 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: L Protein, methyltransferase

Dear Dr. Feldmann,

This is Hongmin Li from Wadsworth Center, New York State Department of Health. My lab studies methyltransferases from viruses. We accumulated rich experience in viral methyltransferase, from function, structure to antiviral development. We are interested in investigating the structure and function of the Ebola methyltransferase and would like to seek collaboration with you on this project. You have done tremendous work on developing Ebola reporter and other pioneer work in Ebola research. Due to recent outbreak, it will be very interesting to investigate the structure and function of important proteins encoded by this deadly virus. May I request if you can send us your construct encoding the L protein. I believe that this collaboration will result in excellent collaborative publications. Your contribution will be either as co-author or properly acknowledged if anything will be generated from the clone. Thank you very much for consideration.

Sincerely,

Hongmin Li, PhD
Research Scientist V
Wadsworth Center
New York State Dept of Health
120 New Scotland Ave
Albany, NY 12208
<http://www.wadsworth.org/resnres/bios/lihongmin.htm>

Feldmann, Heinrich (NIH/NIAID) [E]

From: goarn <goarn@who.int>
Sent: Monday, October 20, 2014 11:13 AM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]; goarn; UMALI DALANGIN, Khristeen
Subject: RE: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation

Dear Andrea, Heinz,

Thanks for the heads-up.

Kindly note that it is essential that you inform us (GOARN admin) of any changes on your travel plans to revise your contracts accordingly.

Best,

Khristeen

-----Original Message-----

From: Marzi, Andrea (NIH/NIAID) [E] [mailto:marzia@niaid.nih.gov]

Sent: 17 October 2014 18:49

To: goarn

Subject: Re: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation

Importance: High

Khristeen,

The travel for myself and Heinz Feldmann has changed. For everyone else you have the correct dates.

Please see attached my new itinerary. Heinz Feldmann will leave on the flight to Brussels SN1247 when I get into Monrovia on Oct 31st.

Sorry for this short notice, but hopefully you can accommodate the changes.

Thanks so much,
Andrea

From: goarn <goarn@who.int<mailto:goarn@who.int>>

Date: Friday, October 17, 2014 10:21 AM

To: "GRAAFF, Peter Jan" <graaffp@who.int<mailto:graaffp@who.int>>, "GASASIRA, Alex Ntale"

<gasasiraa@who.int<mailto:gasasiraa@who.int>>, "WERTSCHNIG, Brian Adam"

<wertschnigb@who.int<mailto:wertschnigb@who.int>>, "WAI, Lokky" <wail@who.int<mailto:wail@who.int>>

Cc: "DAVIS, Raphael" <davisr@who.int<mailto:davisr@who.int>>, "KOLLIE, Robert K."

<kollier@who.int<mailto:kollier@who.int>>, "FREEMAN DELINE, Nancy" <delinen@who.int<mailto:delinen@who.int>>,"

"UMALI DALANGIN, Khristeen" <umalik@who.int<mailto:umalik@who.int>>, SEOCC

<afrgoseocc@who.int<mailto:afrgoseocc@who.int>>, goarn <goarn@who.int<mailto:goarn@who.int>>, SHOC

<shoc@who.int<mailto:shoc@who.int>>, "KASHYAP, Sanjeev" <kashyaps@who.int<mailto:kashyaps@who.int>>, Pierre

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 11:10 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: FW: Repurposing against Ebola
Attachments: Ebola therapeutic candidates 10_20_14.xlsx

From: Dowling, William (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 11:01 AM
To: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Jahrling, Peter (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]
Subject: FW: Repurposing against Ebola

Here is the spreadsheet of the Ebola requests we have received.

Regards
Bill

From: Kurilla, Michael (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:56 PM
To: Dowling, William (NIH/NIAID) [E]
Subject: FW: Repurposing against Ebola

Bill,

Lisa is in Liberia. Can you forward your spreadsheet, please?

Michael G Kurilla, MD-PhD
Director, Office of BioDefense, Research Resources, and Translational Research
Associate Director for BioDefense Product Development
DMID, NIAID, NIH, DHHS
5601 Fishers Lane 8G61
Rockville, MD 20852
301-402-4197

*You can get the monkey off your back,
But the circus never leaves town.
- Anne Lamont*

From: Hensley, Lisa (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:55 PM
To: Kurilla, Michael (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]
Subject: Re: Repurposing against Ebola

It will be Martin. I can contact him if you want.

The spreadsheet should be updated as we get data -

Can you ask bill to send what he has?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Miller, Samuel (NIH)
Sent: Monday, October 20, 2014 10:54 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola and clinical care at the UW

Tx Heinz

Sent from my iPhone

> On Oct 20, 2014, at 9:20 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>

> I am still in Monrovia until the end of the month. If wished we can talk after my return. Otherwise, I agree with Marshall's remarks. We can talk about therapy.

>

> George Risi is the contact in Missoula.

>

> Best wishes, Heinz

>

>

> ----- Original Message -----

> From: Samuel Miller [mailto:millersi@uw.edu]

> Sent: Monday, October 20, 2014 11:04 AM Eastern Standard Time

> To: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID)

> [E]

> Cc: Ann Stapleton <stapl@uw.edu>

> Subject: Ebola and clinical care at the UW

>

> Heinz and Marshall, My colleagues in infectious diseases and the
> Clinical and Translational Research Center at the UW have asked me to
> reach out to you to assist in the planning **Redacted by agreement**

> **Redacted by agreement** Can you help us establish contacts with the

> clinical facility at St. Patrick's in Missoula as well as establish

> good training and access to possibly experimental therapies as needed.

> It will be important for us to get some education that I am sure you

> can help us with. I am sure you are very busy at this time but would

> appreciate a response. If there are experimental therapies that we can

> access together we can apply for IND in case they become necessary.

> In any event at a recent meeting it was felt to be important for us

> regionally to reach out to you at this time. I or my colleagues would

> be happy to discuss with you as necessary. best and thanks for

> considering this request, Sam Miller

>

> Samuel I. Miller M.D.

> Professor of Medicine, Microbiology, and Genome Sciences U of

> Washington

>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 10:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

Personal Info

What we would do is to help her get the system up and running, as I initially wrote you. In addition, I am thinking of developing protocols to downscale the system for HTS screening (probably using reverse transfection) - this would be something that would be very applicable to [REDACTED] work, and might also be good for us in the future. What we get in return is basically that they validate the usefulness of our system as an actual screening system prior to BSL4 screening of antivirals - something I would love to do myself, but just don't have the time / manpower to do. So I do think in this case there is a mutual interest, even though my own contributions are relatively small.

For your information, [REDACTED] also had asked for a letter of collaboration to support a grant application, but I did not agree to this because a) I don't think his proposal makes any sense, at least not for that particular call, and b) I didn't think there was a real mutual interest.

That being said, if you prefer not to provide the letter, please let me know, and I will communicate that to Judy.

All the best, Thomas

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:27 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola trVLP system

I am fine with the letter but what does she need us for? If she collaborates with Gene and we give her the system why does she need a collaboration?

I am saying this as we may want to save letters for future collaborations. I do not want to provide a letter to just help her get a grant.

Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 19, 2014 05:02 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:29 AM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; 'Thomas Thomas Steiner'
Subject: RE: FX06

Dear all,

Redacted by agreement

Redacted by agreement

Dave

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:52 PM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; 'Thomas Thomas Steiner'
Subject: RE: FX06

Hi Petra,

Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

Thanks in advance,

Dave

From: Safronetz, David (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 3:48 PM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Thomas Thomas Steiner
Subject: RE: FX06

Hi Petra

The FX06 arrived safe and sound at RML today.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:25 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola and clinical care at the UW

Thanks!

What date do you get back and do you have other travel planned in November?

How is the weather and are you able to do anything else while you are there?

Let me know if I can email anything to you.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:21 AM
To: 'millersi@uw.edu'; Bloom, Marshall (NIH/NIAID) [E]
Cc: 'stapl@uw.edu'; George Risi
Subject: Re: Ebola and clinical care at the UW

I am still in Monrovia until the end of the month. If wished we can talk after my return. Otherwise, I agree with Marshall's remarks. We can talk about therapy.

George Risi is the contact in Missoula.

Best wishes, Heinz

----- Original Message -----

From: Samuel Miller [mailto:millersi@uw.edu]
Sent: Monday, October 20, 2014 11:04 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Cc: Ann Stapleton <stapl@uw.edu>
Subject: Ebola and clinical care at the UW

Heinz and Marshall, My colleagues in infectious diseases and the Clinical and Translational Research Center at the UW have asked me to reach out to you to assist in Redacted by agreement Can you help us establish contacts with the clinical facility at St. Patrick's in Missoula as well as establish good training and access to possibly experimental therapies as needed. It will be important for us to get some education that I am sure you can help us with. I am sure you are very busy at this time but would appreciate a response. If there are experimental therapies that we can access together we can apply for IND in case they become necessary. In any event at a recent meeting it was felt to be important for us regionally to reach out to you at this time. I or my colleagues would be happy to discuss with you as necessary. best and thanks for considering this request, Sam Miller

Samuel I. Miller M.D.

Professor of Medicine, Microbiology, and Genome Sciences U of Washington


Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:18 AM
To: Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Unpublished

That would be great!

On 10/20/14 9:27 AM, "Safronetz, David (NIH/NIAID) [E]"
<safronetzd@niaid.nih.gov> wrote:

>
Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 9:53 AM
To: Samuel Miller; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Ann Stapleton; Risi, George (George.Risi@providence.org); Bloom, Marshall (NIH/NIAID) [E]
Subject: RE: Ebola and clinical care at the UW

Sam,

Heinz is in Liberia at the moment, so I am not sure how quickly he will be able to respond to your message. He may have some better information or insights, but here is my take.
You are asking 2 salient questions:

* Contacts with the facility at St Patrick. I would advise you to contact George Risi who is the RML Infectious Disease advisor and who developed the patient care modules and training program at St. Pat in conjunction with NIH Safety and Occupational Medicine. George also just spent a month doing volunteer ebola patient care in Kenema in Sierra Leone. I am copying George on this message. Note that he is pretty busy and has been asked by CDC to help train workers in Alabama.

* Experimental therapies. Heinz has more insight than I, but I think that this requires some interactions with the FDA. You are being prudent to do this in advance.

I would also urge you all to look carefully at the latest CDC guidelines (which are exhaustive), particularly as they relate to the initial patient contacts. The CDC guidelines are the authority in managing suspected or identified cases - for better or worse. In essence, once you identify what CDC calls a Patient Under Investigation (PUI) using their checklist, the instructions are basically to isolate the person in place, to limit staff contact, to restrict access, and to immediately notify the CDC Emergency Operations Center for guidance on how to proceed. As I understand it, they would dispatch a "SWAT" team to assist in the management of an actual patient or to arrange transport to another facility, but the guidelines and protocols are pretty dynamic.

It would also be worth determining whether the Washington State Health Dept has been qualified by the CDC LRN to perform ebola testing. Only CDC can authorize this testing, but if the state can do it, it will save a day or so in getting the results back. A duplicate sample is still sent to Atlanta for confirmation. You should also make sure that you have a carrier service that would accept a sample bound for Atlanta. This has been an issue in a couple of places.

Heinz may have some other information about process, who to call for treatment info, etc.

My cell phone is Personal Info Let me know if you have any questions. Good luck.

Marshall

Marshall E. Bloom, M.D., Chief
Biology of Vector-Borne Viruses Section
Laboratory of Virology
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases National Institutes of Health
903 South 4th Street

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 9:37 AM
To: Bloom, Marshall (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Risi, George (George.Risi@providence.org); Marzi, Andrea (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: presentation for the public

I'm in Utah somewhere around November 12-14.

Dave

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 2:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Risi, George (George.Risi@providence.org); Marzi, Andrea (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Subject: presentation for the public

Ken Pekoc and I are trying to arrange a presentation at the high school on the Ebola outbreak. The excellent talks that Andrea and George gave on Thursday provide a good basis, although they will need to be shortened to about 15 minutes and recalibrated for a general audience.

My hope is to partner with Marcus Daly; they have a very good plan for initial contact response based on the current CDC and are doing detailed buddy system training on proper PPE, but would never try to hold anybody there.

When we did this for West Nile back in 2004 (?), we had short talks and then a moderated roundtable for Q&A.

In order to make this timely, it would be nice to do in November before Thanksgiving.

One key factor is planning is the dates that you all will be in Montana and available. I would really appreciate it if you could send me those dates in the next 4-5 days. I already know Andrea's travel.

Thanks very much.

Marshall

Marshall E. Bloom, M.D.
Associate Director
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: 406-375-9707
FAX: 406-375-9661
email: mbloom@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 9:28 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: FW: Unpublished

FYL...
Unpublished

Dave

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Samuel Miller <millersi@uw.edu>
Sent: Monday, October 20, 2014 9:04 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Cc: Ann Stapleton
Subject: Ebola and clinical care at the UW

Heinz and Marshall, My colleagues in infectious diseases and the Clinical and Translational Research Center at the UW have asked me to reach out to you to assist in the planning for [Redacted by agreement] Can you help us establish contacts with the clinical facility at St. Patrick's in Missoula as well as establish good training and access to possibly experimental therapies as needed. It will be important for us to get some education that I am sure you can help us with. I am sure you are very busy at this time but would appreciate a response. If there are experimental therapies that we can access together we can apply for IND in case they become necessary. In any event at a recent meeting it was felt to be important for us regionally to reach out to you at this time. I or my colleagues would be happy to discuss with you as necessary. best and thanks for considering this request, Sam Miller

Samuel I. Miller M.D.
Professor of Medicine, Microbiology, and Genome Sciences U of Washington

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 9:03 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Plasmids request (Would you do me a favor)

Dear [Redacted by agreement] Redacted by agreement

Heinz forwarded me your email since he is currently in Liberia leading a diagnostic team from our laboratory. We can supply you the plasmids you requested, but we will have to do a very basic MTA – Kay Menk, our administrative person taking care of this will be in touch with you about this.

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:55 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Plasmids request (Would you do me a favor)

Do we have those plasmids? We need an SLA.

From: [Redacted by agreement]
Sent: Sunday, October 19, 2014 11:07 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Plasmids request (Would you do me a favor)

Dear Dr. Feldmann,

I am sorry to disturb you. After read your interesting paper titled "The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence *In Vivo*", I would like to request :
(1)pCAGGS empty vector, (2)pCAGGS-NP, (3) pCAGGS-VP35, (4)pCAGGS-VP30 and
(5)pCAGGS-L mentioned in your important paper. You would be very appreciated for your great help.

We promise that:

The research materials you provide and their derivatives will only be used in our lab for non-commercial research and educational purpose.

The research materials you provide and their derivatives will not be transferred to other investigators without your permission.

We will cite the origin of the plasmids in any future publications using them.

My Fedex account is [Redacted by agreement]
Thank you very much for your consideration!

Sincerely yours

[Redacted by agree]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 8:58 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Plasmids request (Would you do me a favor)

We do. I will contact them and get the process started. Also, I found the pDisplay-GP1,2 **Personal Info** requested; Darryl suggested for him to contact Winnipeg about the antibodies **Personal** asked for. Unless I hear different from you, I'll pass this recommendation along.

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:55 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Plasmids request (Would you do me a favor)

Do we have those plasmids? We need an SLA.

From: **Redacted by agreement**
Sent: Sunday, October 19, 2014 11:07 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Plasmids request (Would you do me a favor)

Dear Dr. Feldmann,

I am sorry to disturb you. After read your interesting paper titled "The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence *In Vivo*", I would like to request :
(1)pCAGGS empty vector, (2)pCAGGS-NP, (3) pCAGGS-VP35, (4)pCAGGS-VP30 and
(5)pCAGGS-L mentioned in your important paper. You would be very appreciated for your great help.

We promise that:

The research materials you provide and their derivatives will only be used in our lab for non-commercial research and educational purpose.

The research materials you provide and their derivatives will not be transferred to other investigators without your permission.

We will cite the origin of the plasmids in any future publications using them.

My Fedex account is # **Redacted by agre**
Thank you very much for your consideration!

Sincerely yours


Redacted by

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Weiss, Carol <Carol.Weiss@fda.hhs.gov>
Sent: Monday, October 20, 2014 8:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: a few more questions

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Rosenke, Kyle (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 8:19 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Spreadsheets
Attachments: CDC_NIH_lab_data_CTs_new version_oct11.xlsx

Heinz,
Here is the lab spread sheet. Complete with the Cts. Sorry I forgot to do this before we left.
Kyle

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]
Sent: Monday, October 20, 2014 8:19 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: AW: Reston ebolavirus

Thank you again. I will discuss your comments with my supervisor/colleagues. Maybe I can find an alternative way to test the agents, at least in cell culture (surrogate systems).

Best regards,

[Personal I]

Von: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Gesendet: Montag, 20. Oktober 2014 16:13
An: [Personal Info]
Betreff: Re: AW: Reston ebolavirus

I do not know any lab that would be able to do that. Honestly, I would not work with Reston in BSL2 or BSL3.

Heinz

From: [Personal Info]
Sent: Monday, October 20, 2014 10:07 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: Reston ebolavirus

Dear Dr. Feldmann,

First of all thank you for your quick reply. Indeed, the big problem I am facing is that all people I asked have (store) Reston Ebolavirus under BSL-4 conditions. In Germany, REBOV is belongs to the risk group 2 but I understand that you can only send the virus to BSL-4 laboratories. Can you suggest me anyone who might be able to send me the virus?

Thanks for your help,

[Personal In]

Von: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Gesendet: Montag, 20. Oktober 2014 15:39
An: [Personal Info]
Betreff: Re: Reston ebolavirus

[Personal I]

Unfortunately not from us and you might have problems in general. In many countries all filoviruses are BSL4 pathogens including Reston ebolavirus. I can only send Reston to a certified BSL4 facility.

The general problem you might be facing is that most Reston stocks are stored in BSL4 labs and can only be shipped to BSL4 facilities.

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]
Sent: Monday, October 20, 2014 8:08 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: Reston ebolavirus

Dear Dr. Feldmann,

First of all thank you for your quick reply. Indeed, the big problem I am facing is that all people I asked have (store) Reston Ebolavirus under BSL-4 conditions. In Germany, REBOV is belongs to the risk group 2 but I understand that you can only send the virus to BSL-4 laboratories. Can you suggest me anyone who might be able to send me the virus?

Thanks for your help,

[Personal Inf]

Von: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Gesendet: Montag, 20. Oktober 2014 15:39
An: [Personal Info]
Betreff: Re: Reston ebolavirus

[Personal]

Unfortunately not from us and you might have problems in general. In many countries all filoviruses are BSL4 pathogens including Reston ebolavirus. I can only send Reston to a certified BSL4 facility.

The general problem you might be facing is that most Reston stocks are stored in BSL4 labs and can only be shipped to BSL4 facilities.

Best wishes, Heinz

From: [Personal Info]
Sent: Monday, October 20, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Reston ebolavirus

Dear Dr. Feldmann,

My name is [Personal Info] and I am a Post-Doc at the [Personal Info] I write to you since we are trying to find a laboratory that can provide us with a Reston ebolavirus (REBOV) isolate like that one you have used in some of your published studies (Marzi et al., 2011, J Inf Dis; de Wit et al., 2011, J Inf Dis).

Our plan is to assess the ability of certain chemical compounds to interfere with filovirus replication, first in cell culture and later (long term goal) in macaques. At our institute we have the possibility to work under BSL-3 conditions (so we have to rely on REBOV rather than the African filoviruses) and trained staff for the animal experiments is available. Furthermore, our institute has a proven history on the work with pathogenic viruses (e.g. monkeypox virus, herpes B virus, SIV).

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Monday, October 20, 2014 7:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Reston ebolavirus

Dear Dr. Feldmann,

My name is Personal Info and I am a Post-Doc at the Personal Info I write to you since we are trying to find a laboratory that can provide us with a Reston ebolavirus (REBOV) isolate like that one you have used in some of your published studies (Marzi et al., 2011, J Inf Dis; de Wit et al., 2011, J Inf Dis).

Our plan is to assess the ability of certain chemical compounds to interfere with filovirus replication, first in cell culture and later (long term goal) in macaques. At our institute we have the possibility to work under BSL-3 conditions (so we have to rely on REBOV rather than the African filoviruses) and trained staff for the animal experiments is available. Furthermore, our institute has a proven history on the work with pathogenic viruses (e.g. monkeypox virus, herpes B virus, SIV).

My question to you is, if it would be (generally) possible to obtain a REBOV isolate from you (your lab)?

Sincerely,

Personal Info

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: KINCAID, Janet <kincaidj@who.int>
Sent: Monday, October 20, 2014 6:53 AM
To: ROTH, Cathy Ellen
Cc: KINCAID, Janet; MCLELLAN, Martha Faith; Brenes, Lizette
Subject: Agenda and Dial-in Information: WHO Science Working Group on Ebola

Dear Colleagues:

Following is the agenda and dial-in information for the WHO Science Working Group on Ebola teleconference.

Provisional Agenda:

1. Update by members
2. Update by WHO, including Vaccine Meeting ,Thursday 23 October
3. Comments on note on the Group's remit
4. Next meeting's agenda: invitation for suggestions and comments on draft
5. AOB

The teleconference will take place on **Wednesday, 22 October 2014 at 15:00 Geneva Time**. The dial-in number is: **Persona**
Personal Info

Best regards,

Janet Kincaid
On behalf of Cathy Roth

Janet M Kincaid, M.A.
Technical and Communications Officer
Health Systems and Innovation Cluster
World Health Organization
kincaidj@who.int
Mobile / Portable: **Persona**
Office phone: **+41 22 791 3840**
Ext. 13840

Feldmann, Heinrich (NIH/NIAID) [E]

From: editor@erivjournal.org
Sent: Monday, October 20, 2014 5:35 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Reg: EBOLA Series by ERIVI Journal

**Dear Prof. Heinz Feldmann,
Greetings!**

Hope this mail finds you good. ERIVI Journal wishes you the best on your ongoing research.

www.erivjournal.org

EBOLA Virus is a new challenge to the world, is this deadly disease cured? What is the present and future of the virus.

ERIVI Journal has taken a step towards to present the current research on EBOLA virus; therefore, you are requested to submit a review paper or mini review or commentary.

ERIVI aimed to publish a series of papers from expert researchers those who have done excellent research on this virus.

Looking forward to hear from you

With Regards
DR Vana
Managing Editor
ERIVI Journal

Feldmann, Heinrich (NIH/NIAID) [E]

From: Thomas F. Meyer <meyer@mpiib-berlin.mpg.de>
Sent: Monday, October 20, 2014 3:03 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RNAi screen Ebola

Dear Heinz,

Greeting from the Max Planck Institute in Berlin! We haven't met since quite some time and I hope you are doing well!

I am contacting you since we consider to perform a genome-wide RNAi screen with the intention to not only identify essential host cell targets but to also determine putative drugs that might be of immediate use in the fight against Ebola. As you may be aware, we have accumulated substantial experience with this fast-track strategy in the past (and current) in the context of e.g. Influenza, Chikungunya, and Chlamydia. We are currently forming a leadership team here in Berlin involving several key players in the field and I would be delighted if you would also be prepared to support us with advice and support to the extent possible.

I am aware that you must be very busy in these times but I wonder if you had time for a brief telephone conversation. I am sure you could provide us with valuable information and your personal opinion on our plans. Thus, I would be delighted if you give me a telephone number and a time slot at which I could reach you.

With best wishes!
Thomas

Professor Dr. Thomas F. Meyer
Director
Max Planck Institute for Infection Biology
Department of Molecular Biology
Charitéplatz 1
D-10117 Berlin, Germany
Phone: ++49/30-28460-400/-402
Fax: ++49/30-28460-401

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pierre Formenty
Sent: Monday, October 20, 2014 2:06 AM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

Dear Tom, Gary and Heinz,

Over the week-end UNICEF supported a conference on Ebola Survivors in Sierra Leone. Their assumption n°1 was "all recovered Ebola patients are immune" and will not be reinfected. Assumption n°2 was that "Survivors could take care of Ebola patients without PPE".

Do we have solid evidence for this?

As NHP surviving Reston infection were rechallenged with Sudan or Zaire, I wonder if someone rechallenge NHP surviving Zaire with Zaire, and which findings? May be rechallenges studies were conducted in BLS4 and not published? I would happy to read any anecdotal report or grey literature on rechallenges with Zaire.

Thank you for you support.

Kind regards,

Pierre

Pierre Formenty
World Health Organization

Mobile in Geneva : Personal Info

Envoyé de mon iPad

From: Geisbert, Thomas W. [<mailto:twgeisbe@utmb.edu>]
Sent: 11 October 2014 15:21
To: FORMENTY, Pierre B.H.; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Anti-reston antibodies from the Philippines as a source of convalescent plasma or Ig for the current outbreak?

Pierre,

Feldmann, Heinrich (NIH/NIAID) [E]

From: ROTH, Cathy Ellen <rothc@who.int>
Sent: Monday, October 20, 2014 1:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: WHO Science Working Group on Ebola - Teleconference on 22 October @ 15:00 GVA Time

Hi Heinz,

I hope you will be able to join this week for the teleconference. It will be followed by a face-to-face meeting in Geneva on 13-14 November.

Best wishes,

Cathy

Sent from my iPad

On 20 Oct 2014, at 09:39, "KINCAID, Janet" <kincaidj@who.int> wrote:

Dear Dr Feldmann,

On behalf of the Director-General of the World Health Organization, I wish to invite you to participate as an independent expert in a WHO consultation on how science can inform our response to the Ebola virus disease (EVD) epidemic in west Africa.

The objective of the consultation is to obtain perspectives from the review of the science in relation to the diagnostic and virological findings, clinical features, epidemiology, and the impact (including the behavioural aspects) of the disease control measures on the evolution of the outbreak. These observations could be used by WHO to:

- Consider if any changes in any aspect of our control strategy are warranted, whether immediately or later after further observation generates stronger or clearer data (if required).
- Facilitate or coordinate the gathering of important data not currently available, but needed to achieve a more profound understanding of the situation for decision-making.

The group convened its first teleconference on 7 October 2014. A follow-up teleconference will take place on Wednesday, 22 October 2014 at 15:00 Geneva Time. This teleconference will our review of the constantly changing Ebola situation, to consider any major new scientific findings which have appeared in the interim, and to look comprehensively over the many scientific subject areas covered to consider if new studies or other actions are indicated.

Attached, please find a Declaration of Interest and a Confidentiality Agreement, both of which we kindly ask all participants to review, sign, scan, and return to WHO by 21 October 2014. In keeping with current WHO policy on transparency, the names of all participants will be made public on the WHO website prior to the teleconference.

A dial-in number for the teleconference will be provided upon receipt of these two documents. Background documents will be provided by email prior to the meeting.

Please reply to Ms Janet Kincaid at kincaidj@who.int.

Yours sincerely,

Feldmann, Heinrich (NIH/NIAID) [E]

From: KINCAID, Janet <kincaidj@who.int>
Sent: Monday, October 20, 2014 1:39 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: KINCAID, Janet; ROTH, Cathy Ellen
Subject: WHO Science Working Group on Ebola - Teleconference on 22 October @ 15:00 GVA Time
Attachments: Confidentiality undertaking October 2 2014 Consultation.pdf; WHO 850 E - DOI.pdf
Importance: High

Dear Dr Feldmann,

On behalf of the Director-General of the World Health Organization, I wish to invite you to participate as an independent expert in a WHO consultation on how science can inform our response to the Ebola virus disease (EVD) epidemic in west Africa.

The objective of the consultation is to obtain perspectives from the review of the science in relation to the diagnostic and virological findings, clinical features, epidemiology, and the impact (including the behavioural aspects) of the disease control measures on the evolution of the outbreak. These observations could be used by WHO to:

- Consider if any changes in any aspect of our control strategy are warranted, whether immediately or later after further observation generates stronger or clearer data (if required).
- Facilitate or coordinate the gathering of important data not currently available, but needed to achieve a more profound understanding of the situation for decision-making.

The group convened its first teleconference on 7 October 2014. A follow-up teleconference will take place on Wednesday, 22 October 2014 at 15:00 Geneva Time. This teleconference will our review of the constantly changing Ebola situation, to consider any major new scientific findings which have appeared in the interim, and to look comprehensively over the many scientific subject areas covered to consider if new studies or other actions are indicated.

Attached, please find a Declaration of Interest and a Confidentiality Agreement, both of which we kindly ask all participants to review, sign, scan, and return to WHO by 21 October 2014. In keeping with current WHO policy on transparency, the names of all participants will be made public on the WHO website prior to the teleconference.

A dial-in number for the teleconference will be provided upon receipt of these two documents. Background documents will be provided by email prior to the meeting.

Please reply to Ms Janet Kincaid at kincaidj@who.int.

Yours sincerely,

Dr C.E. Roth, FRC Path
Advisor
Office of the Assistant Director-General
Health Systems and Innovation Cluster
World Health Organization
20 Avenue Appia
1211 Geneva, Switzerland
Tel: +41 22 791 38 96

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kate Yandell [Personal Info]
Sent: Sunday, October 19, 2014 11:16 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request from Matter

Dear Dr. Feldmann,

I am a freelance science journalist who mostly writes about biology. I have been asked by the editors of the online magazine [Matter](#) to write a description of what contracting Ebola virus involves, from initial infection through recovery or death.

I was wondering if you might be able to answer a few questions about Ebola for me Monday, Tuesday, or perhaps Wednesday.

I've read some very helpful review articles on Ebola's clinical presentation and pathobiology, but I have a few lingering questions. Primarily, I'm still trying to connect what I've learned about its symptoms to what I've learned about its pathology. For instance, what is happening during the incubation period of the virus? What events cause the onset of fever?

Please let me know if you think you might be able to help or if you can think of anyone who you think may be able to answer my questions.

Thanks,

Kate Yandell

--

Kate Yandell
www.kateyandell.com
[Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 19, 2014 10:33 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola diagnostic reagents?

I have that plasmid in one of my boxes in the -20 in my rack. Would be labeled pDis-sGP. I cannot recall the plasmid number. I definitely did a Giga at some point so there should be lots. Maybe ask Julie. Wpg. will have the antibodies. I would contact Qiu.

I would also consider VP40 a potential target.

Darryl

Sent from my iPhone

On Oct 19, 2014, at 9:55 PM, Hoenen, Thomas (NIH/NIAID) [F] <thomas.hoenen@nih.gov> wrote:

Hi Heinz,

I'll look into the plasmid when I'm at the lab tomorrow - I might have it, otherwise maybe Darryl can help, but he's in transit right now. I'll keep you posted.

Regarding their second question about Dr. Suresh I have no clue, but maybe we could recommend them to contact Ayato instead - he must have lots of antibodies, some of which should work against sGP.

Regarding the third question, my take on this would be that we do diagnostics mainly by RT-PCR due to it's sensitivity, and maybe also because it allows us to use targets that might be more conserved/genetically stable than (s)GP.

If you want I can get in touch with them regarding all three of their questions.

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:02 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Ebola diagnostic reagents?

Thomas,

Can you please help here? If we have the plasmid, please contact them on my behalf. Sorry for all the extre work.

Thanks, Heinz

From: Michael Gunn, M.D. [<mailto:michael.gunn@duke.edu>]
Sent: Friday, October 17, 2014 02:32 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Sunday, October 19, 2014 9:08 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Plasmids request (Would you do me a favor)

Dear Dr. Feldmann,

I am sorry to disturb you. After read your interesting paper titled "The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence *In Vivo*", I would like to request:
(1)pCAGGS empty vector, (2)pCAGGS-NP, (3) pCAGGS-VP35, (4)pCAGGS-VP30 and
(5)pCAGGS-L mentioned in your important paper. You would be very appreciated for your great help.

We promise that:

The research materials you provide and their derivatives will only be used in our lab for non-commercial research and educational purpose.

The research materials you provide and their derivatives will not be transferred to other investigators without your permission.

We will cite the origin of the plasmids in any future publications using them.

My Fedex account is # Redacted by agree
Thank you very much for your consideration!

Sincerely yours

Personal Info

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jean-Vivien MOMBOULI [Personal Info]
Sent: Sunday, October 19, 2014 7:23 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Conakry bound

Hi Heinz,

It is a pity, because those guys are being hit too hard, it would be key to kill two birds with one stone. Also, the prophylactic benefit of rVSV can be best tested in newly infected aid workers! I have just heard that a thousand doses have been transferred to WHO for a trial in Geneva! I hope this is not the case, I wish those trials could focus on the affected countries, since that is where we urgently need some solid answers!

JV M

2014-10-19 11:02 GMT+01:00 Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>:

Dear Jean-Vivien,
Good to hear from you. It will be tough to get the vaccine. They are doing a trial in Monrovia not including aid workers as far as I know.

Heinz

From: Jean-Vivien MOMBOULI [Personal Info]
Sent: Sunday, October 19, 2014 12:30 AM Eastern Standard Time
To: Munster, Vincent (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Conakry bound

Dear Vincent,

I'm willing to fly into Conakry on Thursday. With such a huge outbreak on hand, one can imagine that ebolavirus spillovers may be happening in some mammal or insect species? Wouldn't you think that there maybe some opportunity for investigation of that novel question?

Also, how [Redacted by agreement]

JV M

Feldmann, Heinrich (NIH/NIAID) [E]

From: Joel Kettner [Personal Info]
Sent: Sunday, October 19, 2014 6:53 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Greetings from an old colleague from Winnipeg

Well I can't wait till then to get your thoughts on the situation! Do you have adequate internet access for a Skype call? If so, is there a best time for you?

On Oct 19, 2014, at 6:32 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

> Until November 3.

>

> ----- Original Message -----

> From: Joel Kettner [mailto:Personal Info]
> Sent: Sunday, October 19, 2014 07:06 PM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: Greetings from an old colleague from Winnipeg

>

> Thank you for your quick reply, Heinz. How long are you planning to be there?

> Joel.

>

> Joel Kettner.

>

>> On Oct 19, 2014, at 8:50 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>>

>> Joel,

>> Long time no see or whatever people say. Glad to hear from you after all those years. I hope you and the family are well. I am currently in Monrovia until early November running an Ebola lab that supports what is known as ELWA Hospital. I would love to discuss things - let me know when. We can do it when I get back or while I am here.

>>

>> Best wishes,

>> Heinz

>>

>>

>> ----- Original Message -----

>> From: Joel Kettner [mailto:Personal Info]
>> Sent: Saturday, October 18, 2014 04:29 PM Eastern Standard Time
>> To: Feldmann, Heinrich (NIH/NIAID) [E]
>> Subject: Greetings from an old colleague from Winnipeg

>>

>> Hello Heinz:

>>

>> I am Joel Kettner, previous chief medical officer of health of Manitoba - do you remember me?

>>

>> You are probably too busy for emails these days, but I have been meaning to tell you that you were excellent on CBC radio a few weeks ago, discussing the situation in West Africa. I liked your mix of science and cultural sensitivity and understanding.

>>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 5:28 PM
To: Risi, George
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: presentation for the public

Thanks. Pekoc and I will huddle with the others.

Sent from my iPhone

On Oct 19, 2014, at 1:01 PM, "Risi, George" <George.Risi@providence.org> wrote:

Marshall,
I will be doing CDC training down in Alabama every other week (Monday Tuesday Wednesday) beginning November 3 and continuing through the end of December.
I do get home on Thursdays so that evening of those weeks is possible as well as the weeks when I am in town.
George

From: Bloom, Marshall (NIH/NIAID) [E] [<mailto:MBLOOM@niaid.nih.gov>]
Sent: Saturday, October 18, 2014 12:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Risi, George; Marzi, Andrea (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Subject: presentation for the public

Ken Pekoc and I are trying to arrange a presentation at the high school on the Ebola outbreak. The excellent talks that Andrea and George gave on Thursday provide a good basis, although they will need to be shortened to about 15 minutes and recalibrated for a general audience.

My hope is to partner with Marcus Daly; they have a very good plan for initial contact response based on the current CDC and are doing detailed buddy system training on proper PPE, but would never try to hold anybody there.

When we did this for West Nile back in 2004 (?), we had short talks and then a moderated roundtable for Q&A.

In order to make this timely, it would be nice to do in November before Thanksgiving.

One key factor is planning is the dates that you all will be in Montana and available. I would really appreciate it if you could send me those dates in the next 4-5 days. I already know Andrea's travel.

Thanks very much.

Marshall

Marshall E. Bloom, M.D.
Associate Director

Feldmann, Heinrich (NIH/NIAID) [E]

From: Joel Kettner [Personal Info]
Sent: Sunday, October 19, 2014 5:07 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Greetings from an old colleague from Winnipeg

Thank you for your quick reply, Heinz. How long are you planning to be there?
Joel.

Joel Kettner.

> On Oct 19, 2014, at 8:50 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:
>

> Joel,

> Long time no see or whatever people say. Glad to hear from you after all those years. I hope you and the family are well. I am currently in Monrovia until early November running an Ebola lab that supports what is known as ELWA Hospital. I would love to discuss things - let me know when. We can do it when I get back or while I am here.

>
> Best wishes,
> Heinz

>
>
> ----- Original Message -----
>

> From: Joel Kettner [mailto:Personal Info]
> Sent: Saturday, October 18, 2014 04:29 PM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Greetings from an old colleague from Winnipeg

>
> Hello Heinz:

>
> I am Joel Kettner, previous chief medical officer of health of Manitoba - do you remember me?

>
> You are probably too busy for emails these days, but I have been meaning to tell you that you were excellent on CBC radio a few weeks ago, discussing the situation in West Africa. I liked your mix of science and cultural sensitivity and understanding.

>
> I would be interested in your view of the present situation and what needs to be done. I am considering volunteering for public health work in West Africa, but am not sure how useful that would be.

>
> Keep up the good work.

>
> Best regards,

>
> Joel Kettner.

> Medical director, International Centre for Infectious Diseases, Winnipeg.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Jarvis <michael.jarvis@plymouth.ac.uk>
Sent: Sunday, October 19, 2014 4:32 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: various

Thanks. Until your return.

Michael

"Art requires philosophy, just as philosophy requires art."
-Paul Gauguin

On Oct 19, 2014, at 7:25 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

> [Redacted by agreement]
>

> ----- Original Message -----

> From: Michael Jarvis [mailto:michael.jarvis@plymouth.ac.uk]
> Sent: Sunday, October 19, 2014 02:11 PM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: various

>
> Heinz,
> One last question before we talk. Is there detectable viremia with the 7A in VSV-GP vaccinees?
>
> Michael

>
> Dr Michael A. Jarvis, PhD.
> Reader in Virology & Immunology,
> Director of Graduate Studies,
> School of Biomedicine & Healthcare Science, University of Plymouth

>
> E-Mail:
> michael.jarvis@plymouth.ac.uk<mailto:michael.jarvis@plymouth.ac.uk>
> michael.jarvis@plymouth.ac.uk [Personal Info]

>
>
> On Oct 19, 2014, at 4:08 PM, Feldmann, Heinrich (NIH/NIAID) [E]
<feldmannh@niaid.nih.gov<mailto:feldmannh@niaid.nih.gov>> wrote:

>
> The 7A versus 8A story is complicated. We should discuss over the phone. 7A is wildtype meaning what we see in humans and apes. Tom Geisbert and I think that protection needs to be shown against 7A challenges. Many of the previous studies have used 8A challenges. This is a big thing in the field but others like to ignore this. [Redacted by agreement]

[Redacted by agreement]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 19, 2014 3:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system
Attachments: Personal Letter_of_Collaboration_2014.doc

Hi Heinz,

I have used the letter we sent to Personal Info in 2014 as a template, and worked in the draft that [redacted] sent. It would be great if you could have a look and make any changes you would like/think are necessary, and then send the final draft to Kay/me for signing - I can then take it from there.

Thank you very much for doing this!

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 11:16 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola trVLP system

Ricki,
Can you please go on my computer and open a folder from the desktop entitled 'collaborations' or something similar. This folder should include recent examples for 'Letters of collaboration'. Take one for [redacted] or [redacted] from 2014 and send it to Thomas.

Thomas, please modify the letter accordingly and send the draft to me. Once we have a final draft - Kay can use the stamp to sign.

Let me know if you need my help.

Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Tuesday, October 14, 2014 01:10 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I just got off the phone with [redacted] and asked Kay to prepare the SLA. [redacted] has asked me if we could provide her with a letter of collaboration regarding the trVLP system for an R01 application - basically affirming our help in getting the

Feldmann, Heinrich (NIH/NIAID) [E]

From: Lane, Cliff (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 2:56 PM
To: Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: MOU

Colleagues,

Dr. Jahrling has pulled me into this discussion.

Letters exchanged between the Liberian Minister of Health, Walter Gwenigale and the HHS Secretary of Health and Human Services, Sylvia Burwell have identified me as the point of contact for the development of a clinical research program between our two countries. In this regard anything having to do with NIH investigators seeking permission to work with clinical material must be coordinated through my office and the take into account the relationships we are developing with the Liberian Ministry. These have been greatly facilitated by Dr. Frank Mahoney who is on this string as well.

To be clear, if someone from NIAID has a request of this type it should go to me. From there I will discuss with Frank whether or not it seems appropriate and whether or not it is of sufficient critical priority to take forward. It is likely that any such work will take place in a larger context of clinical trials and as such provide a richer research environment for everyone with the ability to cleanly and appropriately link clinical and laboratory observations in a robust fashion.

Cliff Lane

Deputy Director for Clinical Research and Special Projects NIAID, NIH _____

From: Jahrling, Peter (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 4:24 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: MOU


Dear All,

This will require a coordinated approach not only within NIAID but also with our partner agencies, CDC and DOD. At least for the IRF-Frederick, our participation has been a joint effort with USAMRIID at LIBR and my understanding is that on behalf of both USAMRIID and the IRF-F, negotiations are underway to facilitate shipment of banked samples from LIBR to Frederick.

I am copying Lisa Hensley because she is in Monrovia now and plans to attend a meeting on this subject with the Liberian MOH tomorrow. I am also copying Dr. Lane since I know he has expressed concerns about forging any agreements with the Liberian MOH without a clear understanding about the intended use of these samples.

One solution might be to develop two separate agreements, one with ELWA 3 and one with LIBR/DOD. But I have little experience in such matters and defer to those of you who do.

Personal Info



Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 19, 2014 1:56 PM
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola diagnostic reagents?

Hi Heinz,

I'll look into the plasmid when I'm at the lab tomorrow - I might have it, otherwise maybe Darryl can help, but he's in transit right now. I'll keep you posted.

Regarding their second question about Dr. Suresh I have no clue, but maybe we could recommend them to contact Ayato instead - he must have lots of antibodies, some of which should work against sGP.

Regarding the third question, my take on this would be that we do diagnostics mainly by RT-PCR due to its sensitivity, and maybe also because it allows us to use targets that might be more conserved/genetically stable than (s)GP.

If you want I can get in touch with them regarding all three of their questions.

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:02 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Ebola diagnostic reagents?

Thomas,

Can you please help here? If we have the plasmid, please contact them on my behalf. Sorry for all the extra work.

Thanks, Heinz

From: Michael Gunn, M.D. [mailto:michael.gunn@duke.edu]
Sent: Friday, October 17, 2014 02:32 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola diagnostic reagents?

Dr. Feldmann,

I am part of a group at Duke University that develops diagnostics for infectious diseases. The engineering part of our group has recently developed a novel point-of-care assay platform that is essentially a miniaturized sandwich ELISA on a small portable cassette. The key advantages of this platform are 1) that no mixing of reagents is required (the assay goes to completion with just a drop of blood) and 2) that we can achieve limits of detection in the 1 pg/ml range.

Given the pressing need for an Ebola diagnostic, I am trying to determine if we can use existing reagents to develop a point of care assay to detect ebola sGP in the blood that would actually work in the field. From what I can tell, the POC assays currently being tested have an LOD in the 100 ng/ml range, which I do not think will provide sufficient sensitivity. I have three questions for you.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 1:04 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: MOU

Hienz: I presume these are clinical samples. I also presume the bit about a separate agreement is motivated by their sharing concerns and desire to get first. Dibs. Does it make sense in your mind to have one agreement to cover both agencies?

Mark

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 02:24 PM
To: Pineda, Mark (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

If CDC does not want the samples they should go to RML.

----- Original Message -----

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 01:12 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

Heinz: will coordinate with Gray

First, what role will Rafael play in this? If he is from NIAMS, how will he have access to an appropriate containment facility to use samples (IRF Fred?) or will these all be inactivated?

In terms of the agreement, if I am correct (Gray: Fatoumata noted an agreement with Liberia was in review when I was inquiring about the Mali ICER agreement), the CDC agreement has not yet been approved formally on the US side. While I see get why CDC would want us to have our own agreement, in this case it would likely be more efficient to have the agreement between HHS and the MOH to cover both opdivs. If I am correct about the status, that should not be difficult.

While I do not know how the GOL review process works, I think it would be easier for an already overextended government to sign one agreement as opposed to two.

Of course, this approach is predicated on the idea that the provisions in the current draft would suit our needs as well. If this is principally about sample access, I would be surprised if that were not the case.

Gray: your thought on this.

Sincerely,

Mark

Feldmann, Heinrich (NIH/NIAID) [E]

From: Risi, George <George.Risi@providence.org>
Sent: Sunday, October 19, 2014 1:01 PM
To: Bloom, Marshall (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: presentation for the public

Marshall,

I will be doing CDC training down in Alabama every other week (Monday Tuesday Wednesday) beginning November 3 and continuing through the end of December.

I do get home on Thursdays so that evening of those weeks is possible as well as the weeks when I am in town.

George

From: Bloom, Marshall (NIH/NIAID) [E] [mailto:MBLOOM@niaid.nih.gov]
Sent: Saturday, October 18, 2014 12:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Risi, George; Marzi, Andrea (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Subject: presentation for the public

Ken Pekoc and I are trying to arrange a presentation at the high school on the Ebola outbreak. The excellent talks that Andrea and George gave on Thursday provide a good basis, although they will need to be shortened to about 15 minutes and recalibrated for a general audience.

My hope is to partner with Marcus Daly; they have a very good plan for initial contact response based on the current CDC and are doing detailed buddy system training on proper PPE, but would never try to hold anybody there.

When we did this for West Nile back in 2004 (?), we had short talks and then a moderated roundtable for Q&A.

In order to make this timely, it would be nice to do in November before Thanksgiving.

One key factor is planning is the dates that you all will be in Montana and available. I would really appreciate it if you could send me those dates in the next 4-5 days. I already know Andrea's travel.

Thanks very much.

Marshall

Marshall E. Bloom, M.D.
Associate Director
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: 406-375-9707
FAX: 406-375-9661
email: mbloom@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Jarvis <michael.jarvis@plymouth.ac.uk>
Sent: Sunday, October 19, 2014 12:12 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: various

Heinz,
One last question before we talk. Is there detectable viremia with the 7A in VSV-GP vaccinees?

Michael

Dr Michael A. Jarvis, PhD.
Reader in Virology & Immunology,
Director of Graduate Studies,
School of Biomedicine & Healthcare Science, University of Plymouth

E-Mail:
michael.jarvis@plymouth.ac.uk<mailto:michael.jarvis@plymouth.ac.uk>
michael.jarvis@plymouth.ac.uk
Personal Info

On Oct 19, 2014, at 4:08 PM, Feldmann, Heinrich (NIH/NIAID) [E]
<feldmannh@niaid.nih.gov<mailto:feldmannh@niaid.nih.gov>> wrote:

The 7A versus 8A story is complicated. We should discuss over the phone. 7A is wildtype meaning what we see in humans and apes. Tom Geisbert and I think that protection needs to be shown against 7A challenges. Many of the previous studies have used 8A challenges. This is a big thing in the field but others like to ignore this. Redacted by agreement

Heinz

----- Original Message -----

From: Michael Jarvis [mailto:michael.jarvis@plymouth.ac.uk]
Sent: Friday, October 17, 2014 12:50 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: various

Heinz,
The meeting is now over, but was good. I introduced myself to Jürgen, and we got talking about the African Swine Fever Virus. I like him. I was also good to see Elaine, Cynthia, and Alison (who I have never really spoken to before today), and Elaine gave an excellent, and very clear presentation - probably as expected.

On other fronts, I am starting to put together the RhCMV Ebola paper. I am trying to get to terms with efficacy of 7A versus 8A challenge. Other than a Profectus talk back in Aug 23, where only protection and disease was discussed (no viremia data), there seems to be very little on the state of vaccine trials using this low passage virus. I did find a link which discusses the issue:
<http://www.biosciencetechnology.com/articles/2014/09/two-anti-ebola-vaccines-historic-race> wherein citing Tom, Gary Kobinger and John Eldridge indicate that the Ad vaccines may not hold up to 7A challenge.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Jarvis <michael.jarvis@plymouth.ac.uk>
Sent: Sunday, October 19, 2014 12:10 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: CMV

Heinz,

Let's also chat about this when you're back. I will be Skyping with Allard Blom later this week, and will also discuss.

Michael

Dr Michael A. Jarvis, PhD.
Reader in Virology & Immunology,
Director of Graduate Studies,
School of Biomedicine & Healthcare Science, University of Plymouth

E-Mail:
michael.jarvis@plymouth.ac.uk<mailto:michael.jarvis@plymouth.ac.uk>
michael.jarvis@Personal Info

On Oct 19, 2014, at 4:44 PM, Feldmann, Heinrich (NIH/NIAID) [E]
<feldmannh@niaid.nih.gov<mailto:feldmannh@niaid.nih.gov>> wrote:

Peter,

Sorry for the long delay in getting back to you. I copied Michael Jarvis on my response. You may want to discuss the CMV approach with him as he is the one who got us involved. He also makes the vaccine vectors.

Heinz

----- Original Message -----

From: Dr P.D. Walsh [mailto:pdw36@cam.ac.uk]
Sent: Saturday, October 04, 2014 10:15 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CMV

Hi Heniz

I forgot to mention that I am also interested in the CMV vaccine, as a self-disseminating vaccine is something that I have always thought is the long term solution for Ebola and many other pathogens. I think that this is the kind of bold research that Paul Allen might like to fund.

But getting the people in Africa to accept the use of a self-disseminating vaccine in the wild will take some confidence building. As a step in that direction have you thought of doing captive trials in group housed NHP's (perhaps Chimps) to see how well the CMV vaccine spreads? Some work on the host specificity of CMV would also be useful in predicting spillover potential, while development of non-invasive fecal or urinary assays would allow for assessment of spillover rates in the field.

--

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Jarvis <michael.jarvis@plymouth.ac.uk>
Sent: Sunday, October 19, 2014 12:07 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: various

Heinz,

Just been having one of your styled entries into the UK, and am actually on the Heathrow Express train rushing for a train late Sunday evening down to Devon after being rerouted from Berlin. At least it's not raining. Spent the morning with Elaine and RML compatriots shopping at Mauer Park.

We definitely need to chat about this issue, especially in terms of how we present this in the CMV study. However, we should do this once you're back at RML. When will you be back? In the meantime, I am starting to put together the paper, and we can modify once we have spoken.

Michael

Dr Michael A. Jarvis, PhD.
Reader in Virology & Immunology,
Director of Graduate Studies,
School of Biomedicine & Healthcare Science, University of Plymouth

E-Mail:
michael.jarvis@plymouth.ac.uk<mailto:michael.jarvis@plymouth.ac.uk>
michael.jarvis Personal Info

On Oct 19, 2014, at 4:08 PM, Feldmann, Heinrich (NIH/NIAID) [E]
<feldmannh@niaid.nih.gov<mailto:feldmannh@niaid.nih.gov>> wrote:

The 7A versus 8A story is complicated. We should discuss over the phone. 7A is wildtype meaning what we see in humans and apes. Tom Geisbert and I think that protection needs to be shown against 7A challenges. Many of the previous studies have used 8A challenges. This is a big thing in the field but others like to ignore this. Redacted by agreement

Heinz

----- Original Message -----

From: Michael Jarvis [mailto:michael.jarvis@plymouth.ac.uk]
Sent: Friday, October 17, 2014 12:50 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: various

Heinz,

The meeting is now over, but was good. I introduced myself to Jürgen, and we got talking about the African Swine Fever Virus. I like him. I was also good to see Elaine, Cynthia, and Alison (who I have never really spoken to before today), and Elaine gave an excellent, and very clear presentation - probably as expected.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 11:12 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

Heinz: will coordinate with Gray

First, what role will Rafael play in this? If he is from NIAMS, how will he have access to an appropriate containment facility to use samples (IRF Fred?) or will these all be inactivated?

In terms of the agreement, if I am correct (Gray: Fatoumata noted an agreement with Liberia was in review when I was inquiring about the Mali ICER agreement), the CDC agreement has not yet been approved formally on the US side. While I see get why CDC would want us to have our own agreement, in this case it would likely be more efficient to have the agreement between HHS and the MOH to cover both opdivs. If I am correct about the status, that should not be difficult.

While I do not know how the GOL review process works, I think it would be easier for an already overextended government to sign one agreement as opposed to two.

Of course, this approach is predicated on the idea that the provisions in the current draft would suit our needs as well. If this is principally about sample access, I would be surprised if that were not the case.

Gray: your thought on this.

Sincerely,

Mark

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 12:24 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

Mark and Gray - can you please help here - it is urgent.

Thanks, Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 11:37 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 9:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

This will involve Mark Pineda and Gray Handley.
Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 11:12 AM Eastern Standard Time
To: Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)
Subject: Re: MOU

Kathy and/or Peter - can you please weigh in?

Thanks Stuart.

Heinz

----- Original Message -----

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Sunday, October 19, 2014 10:59 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)
Subject: Fw: MOU

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dr P.D. Walsh <pdw36@cam.ac.uk>
Sent: Sunday, October 19, 2014 9:25 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Personal Info
Subject: Re: Gorilla vaccination

Hi Heinz

I figured you were over there so did not want to pester you.

Great. I need to get back to the Allen Foundation with a proposal. Is it OK if I say something vague like

"in discussions with the developers of the VSV vaccine about its use in wild gorillas"?

Stay safe.

Peter

Peter D Walsh, PhD
Division of Biological Anthropology
University of Cambridge
(0)1223 764701
ApesInc.org
http://www.bioanth.cam.ac.uk/s_pwalsh.html

On 2014-10-19 15:47, Feldmann, Heinrich (NIH/NIAID) [E] wrote:

> Peter,
> We would certainly be interested in a project using VSV in apes. We
> may want to discuss this further some day soon. I am still in Monrovia
> until early November. Please contact me then again if you are
> interested. I am afraid I might forget otherwise when I get back.

>
> Best wishes, Heinz

>
>
> ----- Original Message -----

> From: Dr P.D. Walsh [mailto:pdw36@cam.ac.uk]
> Sent: Saturday, October 04, 2014 06:49 AM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Cc: chris_whittier@hotmail.com <chris_whittier@hotmail.com>
> Subject: Gorilla vaccination

>
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Delgado Vazquez.Rafael <rafael.delgado@salud.madrid.org>
Sent: Sunday, October 19, 2014 9:16 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Request of advice for lab facility

Thank you very much Heinz for your prompt response.

I might be visiting Monrovia at the end of October since there is a location consisting in a hospital run by Spanish missionaries that could be suitable as an Ebola hospital with lab facilities. If it is compatible with your schedule I would very much appreciate to visit your unit and get experience from first hand activity.

I wish you the best in Monrovia and a safe trip back. In the case that we can meet there it will be an honor and a great pleasure to me.

Kind regards

Dr. Rafael Delgado
Servicio de Microbiología
Hospital Universitario 12 de Octubre
Madrid 28041 Spain
Phone +34 91 7792423
Cell Personal Info
rafael.delgado@salud.madrid.org

De: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov] Enviado el: domingo, 19 de octubre de 2014 15:56
Para: Delgado Vazquez.Rafael
Asunto: Re: Request of advice for lab facility

Dear Rafael,

I am currently in Monrovia until early November. My expertise is Ebola in general. Lab diagnostics and high containment but not patient management. I would be more than happy to discuss things with you when I get back. If you wish to talk, please contact me again at the beginning of November.

Best wishes, Heinz

----- Original Message -----

From: Delgado Vazquez.Rafael [mailto:rafael.delgado@salud.madrid.org]
Sent: Saturday, October 18, 2014 03:45 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request of advice for lab facility

Dear Dr Feldmann

My name is Rafael Delgado, I'm a physician researcher in Madrid, Spain. Since my postdoctoral training in Gary Nabel's Lab, I began working in the Ebola field and once back in Spain, where I (try to) combine clinics and lab, I have continued

Feldmann, Heinrich (NIH/NIAID) [E]


From: Casellas, Rafael (NIH/NIAMS) [E]
Sent: Sunday, October 19, 2014 9:02 AM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)
Subject: Re: MOU

Great, I'll coordinate with Peter tomorrow

Rafael Casellas, Ph.D.
National Institutes of Health
10 Center Drive, MSC 1930
10/13C103-D, Bethesda,
MD. 20892, 301-402-7858
<http://casellaslab.github.io/index.html>

On 10/19/14, 10:59 AM, "Nichol, Stuart T. (CDC/OID/NCEZID)" <stn1@CDC.GOV> wrote:

Records Originating Outside of NIAID



>
>Sent from my BlackBerry 10 smartphone.
> Original Message
>From: Casellas, Rafael (NIH/NIAMS) [E] <casellar@mail.nih.gov>
>Sent: Sunday, October 19, 2014 10:22 AM
>To: Nichol, Stuart T. (CDC/OID/NCEZID)
>Subject: Re: MOU
>
>
>Will do, thank you for your quick reply
>
>R
>
>
>Rafael Casellas, Ph.D.
>National Institutes of Health
>10 Center Drive, MSC 1930
>10/13C103-D, Bethesda,
>MD. 20892, 301-402-7858

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:39 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

Thanks,

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 08:38 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

You cannot but I can. Ask Dawn for the stamp unless you can wait until my return.

Heinz

----- Original Message -----

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 10:34 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

Thanks

I also thought about it.
I can tell him about Gary.

Another question: can you sign simple letter agreement with noncommercial institute?

From now, I have to sign SLA to receive the virus from CDC Fort Collins. If I can sign by myself, I will do, but I guess that I cannot so it.

Hideki

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 08:28 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

I thought Gary had done similar this work. Best might be to refer them to Winnipeg.

Heinz

----- Original Message -----

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 10:26 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:35 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

Thanks

I also thought about it.

I can tell him about Gary.

Another question: can you sign simple letter agreement with noncommercial institute?

From now, I have to sign SLA to receive the virus from CDC Fort Collins. If I can sign by myself, I will do, but I guess that I cannot so it.

Hideki

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 08:28 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

I thought Gary had done similar this work. Best might be to refer them to Winnipeg.

Heinz

----- Original Message -----

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 10:26 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fw: Collaboration to test DEF201 in hamster Ebola model

Are you interested?

Unfortunately, my group does not have any manpower and time to do this kind of things for now. I have not responded, yet, but I can guide him to you and/or someone in DMT.

Have a safe travel.

Hideki

----- Original Message -----

From: K Peri [mailto:[Personal Info](#)]
Sent: Sunday, October 19, 2014 08:12 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Cc: K Peri <kperi@hnplabs.com>
Subject: Collaboration to test DEF201 in hamster Ebola model

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:27 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fw: Collaboration to test DEF201 in hamster Ebola model

Are you interested?

Unfortunately, my group does not have any manpower and time to do this kind of things for now. I have not responded, yet, but I can guide him to you and/or someone in DMT.

Have a safe travel.

Hideki

----- Original Message -----

From: K Peri [mailto:[Personal Info](#)]
Sent: Sunday, October 19, 2014 08:12 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Cc: K Peri <kperi@hnplabs.com>
Subject: Collaboration to test DEF201 in hamster Ebola model

Dear Dr. Ebihara,

H&P Labs is a private biotech company in montreal, Canada, focusing on viral hemorrhagic fevers including Ebola, Lassa. We have DEF201, an adenoviral vectored interferon alpha for prophylaxis and post exposure prophylaxis. The vector has been tested in 8 different viral families in over 70 animal models. Many of the results have been published already.

Redacted by agreement

Redacted by
agreement

We would like to explore the efficacy of DEF201 as prophylactic in Ebola infection in hamster model and see if it could be used to protect suspected cases of human ebola infections.

I would be very happy to call and discuss in detail the above results and our projects.

DEF201 is undergoing formal IND-enabling studies for a phase 1 in Q2 2015.

I look forward to hearing from you.

Regards

Krishna

Krishna Peri
CSO, H&P Labs
Bureau 102, 7140-Albert Einstein
Montreal, Quebec, H4S2C1
CANADA

Ph. 514-956-2525 x 3320

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jean-Vivien MOMBOULI Personal Info
Sent: Saturday, October 18, 2014 10:31 PM
To: Munster, Vincent (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Conakry bound

Dear Vincent,

I willing flying into Conakry on thursday. With such a huge outbreak on hand, one can imagine that ebolavirus spillovers may be happening in some mammal or insect species? Wouldn't you think that there maybe some opportunity for investigation of that novel question?

Also, how Redacted by agreement

JV M

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 5:44 PM
To: Ilhem Messaoudi Powers
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; barrenas@uw.edu; YOSHIHIROKAWAOKA; greener@uw.edu; mnkyboy@uw.edu; gllaw@uw.edu; honey@uw.edu
Subject: Re: Ebola Unpublished

Same here. Getting ready to leave again and need at least a week...

Unpublished

Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ilhem Messaoudi Powers <Ilhem.messaoudi@ucr.edu>
Sent: Saturday, October 18, 2014 4:21 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'barrenas@uw.edu'; Marzi, Andrea (NIH/NIAID) [E]; YOSHIHIROKAWAOKA
Cc: 'greener@uw.edu'; 'mnkyboy@uw.edu'; 'gllaw@uw.edu'; 'honey@uw.edu'
Subject: Re: Ebola Unpublished

I second Heinz' comments. I already have a ton of things on my plate this weekend and the upcoming week- I can get you my comments by next Monday the 27th

Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: malik <malik@hku.hk>
Sent: Saturday, October 18, 2014 4:14 PM
To: Marzi, Andrea (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola antibody

Dear Andrea,

Yes 0.5ml would be ample.

Most appreciated.

Can I clarify that these sera can be handled at BSL2?

Malik

From: Marzi, Andrea (NIH/NIAID) [E] [marzia@niaid.nih.gov]
Sent: Sunday, October 19, 2014 12:51 AM
To: malik
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola antibody

Dear Malik,

Heinz forwarded me your request for antibodies.

We can provide a few inactivated NHP serum samples from animals that survived challenge. But only up to 0.5ml. Would that be enough?

Please let me know.

Thanks,
Andrea

Andrea Marzi, Ph.D.
Staff Scientist
Laboratory of Virology
Rocky Mountain Laboratories, NIAID, NIH
903 South 4th Street
Hamilton, MT 59840

Phone: 406-375-7421
Fax: 406-375-9620
email: marzia@niaid.nih.gov

From: Malik [mailto:malik@hku.hk]
Sent: Wednesday, October 15, 2014 09:46 PM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 3:02 PM
To: Feldmann, Ricki (NIH/NIAID) [C]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

All I have to add is that I diluted in sterile DPBS. Sorry, email here has been down since yesterday afternoon.

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Ricki (NIH/NIAID) [C]
Sent: Friday, October 17, 2014 10:28 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Haddock, Elaine (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz,

I can't find Elaine's actual protocol, but what we have talked about is to dilute the

Redacted by agreement

Redacted by agreement

Redacted by
agreement

Ricki

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:51 AM
To: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Fw: conference call re hyperthermia treatment for Ebola virus

If you have time, can you make a quick listing of what was tested so that I can forward it? Please do it in the email text rather in an attachment.

----- Original Message -----

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 03:27 PM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Saturday, October 18, 2014 2:52 PM
To: Geisbert, Thomas W.
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Banner design for conference
Attachments: EBioMedicine.pptx

Tom,

I see.

We could use attached although we need to get a permission from a journal; we use it recently for a commentary Heinz and I wrote.

The link below should work:

<http://www.whitehouse.gov/blog/2014/10/17/doing-diligence-assess-risks-and-benefits-life-sciences-gain-function-research>

Yoshi


From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Handle: Geisbert, Thomas W.
Mail Address: twgeisbe@UTMB.EDU
Subject: RE: Banner design for conference
To: Kawaoka <kawaokay@svm.vetmed.wisc.edu>
CC: feldmannh@niaid.nih.gov <feldmannh@niaid.nih.gov>
Date: Sat, 18 Oct 2014 16:22:09 +0000
Date Local: 2014/10/19 1:22:09
Message:

> Yoshi,
>
> The one that I used was Marburg. I am wondering if we should use Ebola for this meeting?
>
> I can't open the link.
>
> Tom
>
> -----Original Message-----
> From: Kawaoka [mailto:kawaokay@svm.vetmed.wisc.edu]
> Sent: Friday, October 17, 2014 9:35 PM
> To: Geisbert, Thomas W.
> Cc: feldmannh@niaid.nih.gov
> Subject: RE: Banner design for conference
>
> I think the one you used for your meeting was magnificent.
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 2:18 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: for review

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Delgado Vazquez.Rafael <rafael.delgado@salud.madrid.org>
Sent: Saturday, October 18, 2014 1:46 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request of advice for lab facility

Dear Dr Feldmann

My name is Rafael Delgado, I'm a physician researcher in Madrid, Spain. Since my postdoctoral training in Gary Nabel's Lab, I began working in the Ebola field and once back in Spain, where I (try to) combine clinics and lab, I have continued active on Ebola and our group has made some contribution specifically on the interaction of Ebola GP with C-type lectins working with pseudotypes.

I'm contacting you due to your expertise in the field, your condition of scientist and doctor, and also on your recent activity on the affected area in Africa. You probably are aware that we have had in Madrid two patients that were infected in Liberia and Sierra Leone respectively and a secondary case of a nurse that unfortunately got infected while providing care to the second patient. Redacted by agreement

Redacted by agreement

The Spanish Government has designed a Scientific Advisory Committee, of which I'm a member, to deal with the Ebola outbreak both at the national level and also is considering to increase its participation on the affected area through the deploy of 1-2 units for treatment of patients (25-50 beds each) as some other countries are already doing. As you probably may know Spain has a relatively advanced National Health System with experienced professional in areas such as Infectious and Tropical Diseases and a good network of diagnostic microbiology laboratories with wide experience in molecular biology techniques. This effort is planned to be implemented with the help of one of the agencies already active in the zone that would be most probably the International Red Cross.

At the present moment I'm trying, in collaboration with other colleagues in different clinical areas, to organize all the logistics related to this project and specifically on the requirements of laboratory facilities to serve one of this projected units. I would very much appreciate your advice in this particular matter or the indication of a reference source of information to have an estimation of equipment, organization, biosafety issues and whatever information could be useful to be helpful as soon as possible.

Even though this is a primarily humanitarian project scientific and research issues will also be incorporated so any suggestions in this area will specially be welcome.

Thank you very much for attention and I look forward to having your comments or references and hopefully the opportunity of scientific collaboration in the near future related to this unprecedented situation.

My best wishes

Dr. Rafael Delgado
Servicio de Microbiología
Hospital Universitario 12 de Octubre
Madrid 28041 Spain
Phone +34 91 7792423
Cell Personal Info
rafael.delgado@salud.madrid.org

"Este mensaje, o sus anexos, pueden contener información confidencial, en especial datos de carácter personal, y se dirigen exclusivamente al destinatario del mismo que está obligado al secreto profesional respecto de la información y los datos contenidos en el mensaje. Si usted lo ha recibido por error, por favor, comuníquenoslo por este medio y

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 1:36 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola antibody

Ok. Will email Malik and Kay tomorrow.
Thanks

On Oct 18, 2014, at 12:19 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Yes we do - SLA.

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:51 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola antibody

Do we need an MTA in place for this?

From: <Marzi>, Andrea Marzi <marzia@niaid.nih.gov>
Date: Saturday, October 18, 2014 10:51 AM
To: "malik@hku.hk" <malik@hku.hk>
Cc: Heinz Feldmann <feldmannh@niaid.nih.gov>
Subject: RE: Ebola antibody

Dear Malik,

Heinz forwarded me your request for antibodies.
We can provide a few inactivated NHP serum samples from animals that survived challenge. But only up to 0.5ml. Would that be enough?

Please let me know.

Thanks,
Andrea

Andrea Marzi, Ph.D.
Staff Scientist
Laboratory of Virology
Rocky Mountain Laboratories, NIAID, NIH
903 South 4th Street
Hamilton, MT 59840

Phone: 406-375-7421
Fax: 406-375-9620
email: marzia@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koita, Ousmane
Sent: Saturday, October 18, 2014 1:27 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone; ssow@medicine.umaryland.edu; Bintakeita11@yahoo.fr; aksidibe@yahoo.fr
Subject: My absence

Dear Samba,

I will be absent for 4 days, Sunday through Wednesday 22, I will be back at work on Thursday, in my absence if there is a suspected case of Ebola, please contact:

Dr Bassirou Diarra (bdiarra@icermali.org, cell: **Personal ID**)

Dr Amadou Kone (amadoukone@icermali.org, cell: **Personal ID**)

Dr Sarro Yeya (sadio@icermali.org, cell: **Personal ID**).

Best regards,

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]

Sent: Wed 10/8/2014 1:32 PM

To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert

Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'

Subject: Re: New suspected case to be tested

This was negative, wasn't it. I cannot see the attachment on the Blackberry.

----- Original Message -----

From: Koita, Ousmane

Sent: Wednesday, October 08, 2014 07:12 AM Eastern Standard Time

To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert

Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone

<amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>

Subject: RE: New suspected case to be tested

Dear Dr Heinz,

Please find as enclosure the pictures of the screen of the tests done on patient 26 (screening and confirmatory tests) the last Sunday (October 5, 2014).

Best regards,

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]

Personal Info

1. Name, institution, affiliation, country

Feldmann, Heinrich (NIH/NIAID) [E]

From: Herrera, Victoria L M <vherrera@bu.edu>
Sent: Saturday, October 18, 2014 12:38 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: question re [Redacted by agreement]

will wait for you to get back.
not too crazy then?
thanks
vh

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Saturday, October 18, 2014 2:18 PM
To: Herrera, Victoria L M
Subject: Re: question re [Redacted by agreement]

I am away until early November - we can discuss when I get back. If this takes too long you may want to contact Tom Geisbert.

From: Herrera, Victoria L M [mailto:vherrera@bu.edu]
Sent: Saturday, October 18, 2014 01:47 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: question re [Redacted by agreement]

Hi Dr. Feldmann

Allow me to introduce myself - Victoria Herrera, MD, Professor of Medicine at the Whitaker Cardiovascular Institute at Boston University School of Medicine. One aspect of my research is the microvasculature in cardiovascular disease. I am considering submitting [Redacted by agreement] based on an observation of published histology images of Ebola infected patients.

I have been thinking about studying the endothelium and the endothelial glycocalyx integrity since Ebola hit the news this year. I know papers have been published reporting that the endothelial cells do not harbor the virus in the pre-symptomatic stage and only exhibit viral presence after symptoms are present.

However, upon looking at the histology presented in those papers, (and based on my visual picture of what a normal endothelium looks from my animal model research in vascular disease), I strongly suspect that something has happened to the vascular endothelium earlier and therefore, I propose to study this to gain insight into potential mechanism(s) for earlier potential contagion (not 100% 'penetrance') prior to symptom presence, and to gain insight into figuring out a potential test that could be informative earlier for exposed individuals prior to symptoms for the detection of EBOLA using existing clinical technologies. This would help in containment which does not seem to be working when based on the concept that contagious phase begins when symptoms begin. I think this concept is not watertight.

I was wondering if you have, or know where I can get histology slides of Ebola animal model tissues at different time points from infection with Ebola --ie, especially early stages before symptoms appear in the animal models. I would like to propose to study them.


May I invite you as collaborator or consultant, depending on your availability, for this [Redacted by agreement] understand if it is not possible. We do have the NEIDL here at BUSM, and I can avail of their microscopes.

My naïve question: if paraffin embedded sections from fixed tissues are on slides which are stained and mounted and coverslipped, are they still considered infectious or can they be viewed in a regular lab microscope?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael G. Katze <honey@uw.edu>
Sent: Saturday, October 18, 2014 12:35 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Unpublished manuscript

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael G. Katze <honey@uw.edu>
Sent: Saturday, October 18, 2014 12:25 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Risi, George (George.Risi@providence.org); Marzi, Andrea (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Subject: presentation for the public

Ken Pekoc and I are trying to arrange a presentation at the high school on the Ebola outbreak. The excellent talks that Andrea and George gave on Thursday provide a good basis, although they will need to be shortened to about 15 minutes and recalibrated for a general audience.

My hope is to partner with Marcus Daly; they have a very good plan for initial contact response based on the current CDC and are doing detailed buddy system training on proper PPE, but would never try to hold anybody there.

When we did this for West Nile back in 2004 (?), we had short talks and then a moderated roundtable for Q&A.

In order to make this timely, it would be nice to do in November before Thanksgiving.

One key factor is planning is the dates that you all will be in Montana and available. I would really appreciate it if you could send me those dates in the next 4-5 days. I already know Andrea's travel.

Thanks very much.

Marshall

Marshall E. Bloom, M.D.
Associate Director
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: 406-375-9707
FAX: 406-375-9661
email: mbloom@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Herrera, Victoria L M <vherrera@bu.edu>
Sent: Saturday, October 18, 2014 11:48 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: question re [Redacted by agreement]

Hi Dr. Feldmann

Allow me to introduce myself - Victoria Herrera, MD, Professor of Medicine at the Whitaker Cardiovascular Institute at Boston University School of Medicine. One aspect of my research is the microvasculature in cardiovascular disease. I am considering submitting [Redacted by agreement] - based on an observation of published histology images of Ebola infected patients.

I have been thinking about studying the endothelium and the endothelial glycocalyx integrity since Ebola hit the news this year. I know papers have been published reporting that the endothelial cells do not harbor the virus in the pre-symptomatic stage and only exhibit viral presence after symptoms are present.

However, upon looking at the histology presented in those papers, (and based on my visual picture of what a normal endothelium looks from my animal model research in vascular disease), I strongly suspect that something has happened to the vascular endothelium earlier and therefore, I propose to study this to gain insight into potential mechanism(s) for earlier potential contagion (not 100% 'penetrance') prior to symptom presence, and to gain insight into figuring out a potential test that could be informative earlier for exposed individuals prior to symptoms for the detection of EBOLA using existing clinical technologies. This would help in containment which does not seem to be working when based on the concept that contagious phase begins when symptoms begin. I think this concept is not watertight.

I was wondering if you have, or know where I can get histology slides of Ebola animal model tissues at different time points from infection with Ebola --ie, especially early stages before symptoms appear in the animal models. I would like to propose to study them.

May I invite you as collaborator or consultant, depending on your availability, for this Rapid proposal grant? understand if it is not possible. We do have the NEIDL here at BUSM, and I can avail of their microscopes.

My naïve question: if paraffin embedded sections from fixed tissues are on slides which are stained and mounted and coverslipped, are they still considered infectious or can they be viewed in a regular lab microscope?

I can imagine you are very busy. I appreciate your consideration and feedback - hope this is not a crazy idea. I am thinking that this work can be done within a year or shorter once I get the slides. Meticulous proper documentation is necessary - and will be tedious but can be done.

Question: does animal model research qualify for "non-medical" research according to [Redacted by agreement] for Ebola?

Best
Victoria

Victoria L. Herrera, MD
Professor of Medicine
co-director, Nanotheranostics ARC

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 10:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola antibody

Do we need an MTA in place for this?

From: <Marzi>, Andrea Marzi <marzia@niaid.nih.gov>
Date: Saturday, October 18, 2014 10:51 AM
To: "malik@hku.hk" <malik@hku.hk>
Cc: Heinz Feldmann <feldmannh@niaid.nih.gov>
Subject: RE: Ebola antibody

Dear Malik,

Heinz forwarded me your request for antibodies.
We can provide a few inactivated NHP serum samples from animals that survived challenge. But only up to 0.5ml.
Would that be enough?

Please let me know.

Thanks,
Andrea

Andrea Marzi, Ph.D.
Staff Scientist
Laboratory of Virology
Rocky Mountain Laboratories, NIAID, NIH
903 South 4th Street
Hamilton, MT 59840

Phone: 406-375-7421
Fax: 406-375-9620
email: marzia@niaid.nih.gov

From: Malik [mailto:malik@hku.hk]
Sent: Wednesday, October 15, 2014 09:46 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola antibody

Dear Heinz

Given our success with H5N1 and MERS-CoV pseudotypes for sero-diagnosis, we have developed ebolavirus pseudotypes for use in serodiagnosis purposes, just to be prepared for the future.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 10:51 AM
To: malik@hku.hk
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola antibody

Dear Malik,

Heinz forwarded me your request for antibodies.
We can provide a few inactivated NHP serum samples from animals that survived challenge. But only up to 0.5ml.
Would that be enough?

Please let me know.

Thanks,
Andrea

Andrea Marzi, Ph.D.
Staff Scientist
Laboratory of Virology
Rocky Mountain Laboratories, NIAID, NIH
903 South 4th Street
Hamilton, MT 59840

Phone: 406-375-7421
Fax: 406-375-9620
email: marzia@niaid.nih.gov

From: Malik [<mailto:malik@hku.hk>]
Sent: Wednesday, October 15, 2014 09:46 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola antibody

Dear Heinz

Given our success with H5N1 and MERS-CoV pseudotypes for sero-diagnosis, we have developed ebolavirus pseudotypes for use in serodiagnosis purposes, just to be prepared for the future.

Would you be able to provide us with a bit of ebolavirus antibody, either from immunized animals or other sources to allow us to optimize our assays?

Best wishes

Feldmann, Heinrich (NIH/NIAID) [E]

From: CARL F. BARRENAS <barrenas@uw.edu>
Sent: Saturday, October 18, 2014 10:21 AM
To: ilhem.messaoudi@ucr.edu; Marzi, Andrea (NIH/NIAID) [E]; YOSHIHIROKAWAOKA; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: RICHARD GREEN; Matthew J. Thomas; Lynn Law; Michael G. Katze
Subject: Unpublished manuscript
Attachments: Unpublished

Dear all

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Saturday, October 18, 2014 10:22 AM
To: YOSHIHIROKAWAOKA
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Banner design for conference

Yoshi,

The one that I used was Marburg. I am wondering if we should use Ebola for this meeting?

I can't open the link.

Tom

-----Original Message-----

From: Kawaoka [mailto:kawaokay@svm.vetmed.wisc.edu]
Sent: Friday, October 17, 2014 9:35 PM
To: Geisbert, Thomas W.
Cc: feldmannh@niaid.nih.gov
Subject: RE: Banner design for conference

I think the one you used for your meeting was magnificent.

>Also, do you both think we should privately start lining up some people that we need to have speak. We are running short on time.

Agree.

I am currently busy dealing with the announcement made this afternoon:

<http://www.whitehouse.gov/blog/2014/10/17/doing-diligence-assess-risks>

So, please go ahead and list speakers.

Yoshi

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Handle: Geisbert, Thomas W.
Mail Address: twgeisbe@UTMB.EDU
Subject: RE: Banner design for conference
To: Kawaoka <kawaokay@svm.vetmed.wisc.edu>, Heinz Feldmann <feldmannh@niaid.nih.gov>
CC: --
Date: Sat, 18 Oct 2014 02:03:46 +0000
Date Local: 2014/10/18 11:03:46
Message:

>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 10:05 AM
To: ebier@ucsd.edu
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Subject: FW: glycoprotein cDNA clone request

Dear Ethan Bier,

Dr. Feldmann forwarded me your request below, he is currently out of the country. We can certainly provide you with an expression plasmid for full length ZEBOV-GP.

In order to do so we will need an MTA in place. I copied Kay Menk here, she will send you the standard NIH Simple Letter Agreement.

Once that is in place we will be able to send the plasmid.

Thanks & best wishes,
Andrea

Andrea Marzi, Ph.D.
Staff Scientist
Laboratory of Virology
Rocky Mountain Laboratories, NIAID, NIH
903 South 4th Street
Hamilton, MT 59840

Phone: 406-375-7421
Fax: 406-375-9620
email: marzia@niaid.nih.gov

From: Ethan Bier [<mailto:ebier@ucsd.edu>]
Sent: Friday, October 17, 2014 05:30 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Redacted by a

Thanks and best regards,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 10:00 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: glycoprotein cDNA clone request

I'll reply and copy you.

A.

From: <Feldmann>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Date: Saturday, October 18, 2014 9:19 AM
To: Andrea Marzi <marzia@niaid.nih.gov>
Subject: Fw: glycoprotein cDNA clone request

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 11:19 AM Eastern Standard Time
To: 'marzia@niaid.nih.gov', <marzia@niaid.nih.gov>
Subject: Fw: glycoprotein cDNA clone request

Can you please look into this request. I may have asked you before.

From: Ethan Bier [<mailto:ebier@ucsd.edu>]
Sent: Friday, October 17, 2014 05:30 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Redacted by

Thanks and best regards,

Ethan

--

Ethan Bier
Section of Cell and Developmental Biology
Bonner Hall, Room 4218
University of California, San Diego

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]@gmail.com>
Sent: Friday, October 17, 2014 6:49 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Understanding Ebola

Hello Mr. Feldmann, I am [Personal Info] a citizen journalist and have been pouring through your research and science articles.

I would be most honored to interview you on Skype video in my effort to assist in educating the public on this, now, most sensitive national matter.

For example, specifically, what are the most notable methods of preventing infection? I read in a separate science journal apoptosis of bystander lymphocytes and loss of NK cells is the most notable mode of progression or maturation of the virus. Also, what are the role of monocytes transmuting to macrophages or dendritic cells if monocytes have an inhibitory effect on the progression of this apoptosis? Is there a correlation between a high production of monocytes and increased survival rate based on more dendritic cells or more macrophage cells?

Thank you for your time.

Best wishes,

[Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation

I already sent my updated info and yours as well. Waiting for their response.

On Oct 17, 2014, at 6:00 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Andrea,
Why are you scheduled to arrive on October 26 (see below)? Please clarify - this makes no sense as I leave on October 31.

Heinz

From: goarn [<mailto:goarn@who.int>]
Sent: Friday, October 17, 2014 12:21 PM Eastern Standard Time
To: GRAAFF, Peter Jan <graaffp@who.int>; GASASIRA, Alex Ntale <gasasiraa@who.int>; WERTSCHNIG, Brian Adam <wertschnigb@who.int>; WAI, Lokky <wail@who.int>
Cc: DAVIS, Raphael <davisr@who.int>; KOLLIE, Robert K. <kollier@who.int>; FREEMAN DELINE, Nancy <delinen@who.int>; UMALI DALANGIN, Khristeen <umalik@who.int>; SEOCC <afrgoseocc@who.int>; goarn <goarn@who.int>; SHOC <shoc@who.int>; KASHYAP, Sanjeev <kashyaps@who.int>; Pierre Formenty; NAIDOO, Dhamari <naidood@who.int>; DRURY, Patrick Anthony <druryp@who.int>; SAIKAT, Sohel <saikats@who.int>; NORTON, Ian <nortoni@who.int>; NYONPLUE, Richard G. <nyonpluer@who.int>; MWANAMWENGE, Abrahams <mwanamwengea@who.int>; mwanamwenge@who.int <mwanamwenge@who.int>; Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation

Dear WR, Dr Gasasira and Colleagues,

We wish to inform you of the flight details of the GOARN lab experts (team#4) from the National Institute for Health (NIH), USA:

Team#4 consists of:

1. **Dr Emmie de Wit** will arrive in Monrovia on **Monday, 20 October 2014 at 19h20** on flight SN1247 from Brussels. She will depart Monrovia on 14 November 2014 at 21:35 via the same flight SN1247.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 4:29 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: [Personal Info]
Subject: FW: Request for Lockheed Martin Reconsideration: Travel to Liberia for [Personal Info]

Hi Heinz,

Lisa has submitted the petition to Lockheed for [Person] to travel. She sends her thanks and appreciation for the information you sent which she felt was extremely helpful. You can read it below if you wish.

Also, since [Perso] [Redacted by agreem] MSC states that it is not a problem to pick up her contract—they had not done so previously since Lockheed had initially [Redacted by agreement] and no one had updated or pursued a move once [Redacted by agre] was obtained. I'm sure this was in part due to the fact that [Perso] was/is not an LV employee and there was no impetus to do so. We are only pushing the situation now for our purposes, which lead us to this determination. We should probably bring in [Person] as a courtesy too, since she is now part in his group. Lisa also suggests moving [Personal] to MSC, which I will discuss with her upon her return from Germany to see if she wants to do this. There will be no gap in employment benefits or health insurance for either one—MSC is working hard to accomplish this with us.

I will be discussing this further with Lisa and [Pers] on Monday, and I will notify Randy and Colleen (RMVB's AO) as needed.

I hope you have a good weekend, and I will update you further on Monday.

Dawn

From: Coronado, Lisa (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 5:13 PM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: FW: Request for Lockheed Martin Reconsideration: Travel to Liberia for [Personal Info]

Hi Dawn,

Petition submitted. Let's keep our fingers crossed.

Lisa

From: Coronado, Lisa (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 7:11 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]
Cc: Mays, Gary (NIH/NIAID) [E]; Blaney, Joe (NIH/NIAID) [E]; Sullivan, Kevin (NIH/NIAID) [E]; Kristen.Gehlhaus@nih.gov; Schmidt, Beth (NIH/NIAID) [E]; Hartley, Maggie (NIH/NIAID) [E]
Subject: FW: Request for Lockheed Martin Reconsideration: Travel to Liberia for [Personal Info]
Importance: High

Lockheed Martin, at the vice president level, denied approval for [Perso] to travel to Liberia. She is scheduled to depart 11/16 (and return on 12/13). We are requesting that they reconsider the travel request. Attached is the petition. Below is the text, for those reading via mobile device.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ethan Bier <ebier@ucsd.edu>
Sent: Friday, October 17, 2014 3:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Redacted by agr

Thanks and best regards,

Ethan

--

Ethan Bier
Section of Cell and Developmental Biology
Bonner Hall, Room 4218
University of California, San Diego
9500 Gilman Drive
La Jolla, CA 92093-0349

Tel. (858) 534-8792
Fax. (858) 822-2044
Email: ebier@ucsd.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sanderson, Philip (NIH/NCATS) [E]
Sent: Friday, October 17, 2014 2:53 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Zheng, Wei (NIH/NCATS) [E]; Michael, Sam (NIH/NCATS) [E]
Subject: repurposing screen for ebola

Dear Dr. Feldmann,

I am with NCATS and am contacting you concerning the use of our small molecule libraries of approved and investigational drugs for the identification of treatments for ebola infection. Sarah Anzick passed on your name to us.

Wei Zheng's group in our laboratories (BSL2) is performing a screen for inhibitors of viral entry. However, ideally, we want to have the compound set screened in a BSL4 facility against viable virus to try to hit the full range of targets. We do not want to miss a drug in our compound collection which could be an effective treatment.

We have a number of libraries, the most useful for this purpose being the approved drug library (2,800 compounds) and a library of clinical investigational drugs (2,000 compounds).

I am cc'ing Sam Michael, director of our automation and compound management group.

We are happy to discuss at your earliest convenience.

Best regards

Phil

Philip Sanderson, PhD
Therapeutics for Rare and Neglected Diseases
National Center for Advancing Translational Sciences
9800 Medical Center Drive
Rockville, MD 20850
philip.sanderson@nih.gov
office: 301 217 5818

NOTICE: This e-mail and any attachments to it are intended only for the identified recipients. It may contain proprietary or otherwise legally protected information for the National Center for Advancing Translational Sciences (NCATS). Any unauthorized use or disclosure of this communication is strictly prohibited. If you have received this communication in error, please notify the sender and delete or otherwise destroy the e-mail and all attachments immediately.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Gray Davis <gdavis@chimerix.com>
Sent: Friday, October 17, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola - BCV

Thank you

Sent from my Verizon Wireless 4G LTE smartphone

----- Original message -----

From: "Feldmann, Heinrich (NIH/NIAID) [E]"
Date: 10/17/2014 4:36 PM (GMT-05:00)
To: Gray Davis
Subject: Re: Ebola - BCV

I did forward your email to the POC in Missoula.

----- Original Message -----

From: Gray Davis [<mailto:gdavis@chimerix.com>]
Sent: Friday, October 17, 2014 04:29 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - BCV

Dr. Feldmann,

Fred Hayden gave me your name as a potential source of information. My name is Gray Davis and I am working with Chimerix as part of their Ebola response. As you know BCV is one of the therapeutic products being studied for the treatment of Ebola. We are trying to streamline our response times in case we get requests from the various crisis centers. To that end we are trying to get all of the regulatory paperwork and approvals completed prior to the need for drug shipments. Having the appropriate approvals and procedures established early can significantly improve response times.

Do you have a contact name at St. Patrick Hospital in Missoula, Montana? We are trying to get to this hospital so that we can work out the logistics for a rapid response. We appreciate any help that you could provide.

Gray

Gray Davis, Ph.D.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Gray Davis <gdavis@chimerix.com>
Sent: Friday, October 17, 2014 2:30 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - BCV

Dr. Feldmann,

Fred Hayden gave me your name as a potential source of information. My name is Gray Davis and I am working with Chimerix as part of their Ebola response. As you know BCV is one of the therapeutic products being studied for the treatment of Ebola. We are trying to streamline our response times in case we get requests from the various crisis centers. To that end we are trying to get all of the regulatory paperwork and approvals completed prior to the need for drug shipments. Having the appropriate approvals and procedures established early can significantly improve response times.

Do you have a contact name at St. Patrick Hospital in Missoula, Montana? We are trying to get to this hospital so that we can work out the logistics for a rapid response. We appreciate any help that you could provide.

Gray

Gray Davis , Ph.D.

Feldmann, Heinrich (NIH/NIAID) [E]

From: John Savage <Personal Info>
Sent: Friday, October 17, 2014 2:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Bats in Austin, Texas

Hi Dr. Feldmann,

I'm a reporter working on a piece that involves bats and Ebola, and I came across your study on the subject. Could I ask you a few questions? Give me a call anytime today if you get a chance, my numbers are below. Thanks!

Best,
John

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:07 PM
To: Kurilla, Michael (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Powell, Shunetta (NIH/NIAID) [E]
Subject: Accepted: Teleconference between Drs. Kurilla, Zoon and Bloom RE: Coordination of NIAID Ebola Rx evaluation

Mike,

Thanks for setting this up!

I am extending an invitation to Dave Safronetz and Heinz Feldmann who are the RML investigators likely to engage in studies like this. For their benefit, the time is 11:00 AM to 12:30 PM Montana time.

Dave – you can come down to my office if you are able to make this call.

Marshall

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 1:43 PM
To: Harper, Jill (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]
Subject: RE: Pending Discontinued Use of Large Cobalt-60 sources

Thanks, Jill.

I comprehend the issues re NEI, ANS or JLS!

Loss of these irradiators would be a crippling blow to both the intramural and extramural programs at a critical point in time.

Have a nice weekend.

Marshall

From: Harper, Jill (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 12:53 PM
To: Bloom, Marshall (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Subject: RE: Pending Discontinued Use of Large Cobalt-60 sources

Thanks, Marshall. Looping in Melinda here so that she can check in with the NIH legislative office on this one and alert them that this could be an issue.

Of course, none of us at NIAID can participate in the outreach effort by the NEI or ANS, nor can we have JL Shepherd advocate for us.

Jill R. Harper, Ph.D.
Associate Director for Science Management, and
Deputy Executive Officer
NIAID/NIH/DHHS
Bldg. 31, Room 7A-18, MSC 2520
Bethesda, MD 20892-2520
Phone: 301/594-3964
Fax: 301/496-9082
jharper@niaid.nih.gov

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:44 PM
To: Potts, Jeffrey (NIH/OD/ORS) [E]
Cc: Wilson, Deborah (NIH/OD/ORS) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]; Newman, Nancy (NIH/OD/ORS) [E]
Subject: FW: Pending Discontinued Use of Large Cobalt-60 sources

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Friday, October 17, 2014 1:27 PM
To: Khan, Ali S
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Annick ANTIERENS
Subject: Clinical trials - Ebola

Hi Ali,

I have put Annick Antierens in cc:, as she is leading the MSF clinical trials platform. Faripiravir is amongst the agents under consideration, but there are others interested as well, perhaps more so. I will discuss this with her and the rest of the group. It is not at the top of the list, but neither is it at the bottom. I'll get back to you.

Hope all is well there - Armand

Armand Sprecher MD MPH
Public Health Specialist
Médecins Sans Frontières
Operational Center of Brussels

-----"Khan, Ali S" <ali.khan@unmc.edu> wrote: -----

To: "armand.sprecher@brussels.msf.org" <armand.sprecher@brussels.msf.org>
From: "Khan, Ali S" <ali.khan@unmc.edu>
Date: 10/13/2014 05:21AM
Cc: Heinz Feldmann <feldmannh@niaid.nih.gov>
Subject: Clinical trials - Ebola

Dear Armand:

What a delight to hear from you. It has been a long time but I am glad for your leadership role in the current outbreak. And it is a small world if you worked in Omaha!

I am relishing my role as Dean to help educate the next generation of public health practitioners and discovery of new interventions. Also helping consult on the Ebola patients and help with communications.

We would like to participate in the clinical trial of possible and are in the process of writing one here to be a resource for others.

All my best and good luck.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

Begin forwarded message:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 1:27 PM
To: Harper, Jill (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]
Subject: RE: Pending Discontinued Use of Large Cobalt-60 sources

I concur with Marshall's comments

From: Harper, Jill (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:53 PM
To: Bloom, Marshall (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Subject: RE: Pending Discontinued Use of Large Cobalt-60 sources

Thanks, Marshall. Looping in Melinda here so that she can check in with the NIH legislative office on this one and alert them that this could be an issue.

Of course, none of us at NIAID can participate in the outreach effort by the NEI or ANS, nor can we have JL Shepherd advocate for us.

Jill R. Harper, Ph.D.
Associate Director for Science Management, and Deputy Executive Officer NIAID/NIH/DHHS Bldg. 31, Room 7A-18, MSC 2520 Bethesda, MD 20892-2520
Phone: 301/594-3964
Fax: 301/496-9082
jharper@niaid.nih.gov<<mailto:jharper@niaid.nih.gov>>

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:44 PM
To: Potts, Jeffrey (NIH/OD/ORS) [E]
Cc: Wilson, Deborah (NIH/OD/ORS) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]; Newman, Nancy (NIH/OD/ORS) [E]
Subject: FW: Pending Discontinued Use of Large Cobalt-60 sources

Jeff,

Feldmann, Heinrich (NIH/NIAID) [E]

From: FREEMAN DELINE, Nancy <delinen@who.int>
Sent: Friday, October 17, 2014 1:07 PM
To: goarn; GASASIRA, Alex Ntale; WERTSCHNIG, Brian Adam; WAI, Lokky
Cc: DAVIS, Raphael; KOLLIE, Robert K.; UMALI DALANGIN, Khristeen; SEOCC; SHOC; KASHYAP, Sanjeev; Pierre Formenty; NAIDOO, Dhamari; DRURY, Patrick Anthony; SAIKAT, Sohel; NORTON, Ian; NYONPLUE, Richard G.; MWANAMWENG, Abrahams; mwanamwenge@who.int; Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation

Acknowledged.
Nancy

From: goarn
Sent: Friday, October 17, 2014 4:21 PM
To: GRAAFF, Peter Jan; GASASIRA, Alex Ntale; WERTSCHNIG, Brian Adam; WAI, Lokky
Cc: DAVIS, Raphael; KOLLIE, Robert K.; FREEMAN DELINE, Nancy; UMALI DALANGIN, Khristeen; SEOCC; goarn; SHOC; KASHYAP, Sanjeev; FORMENTY, Pierre B.H.; NAIDOO, Dhamari; DRURY, Patrick Anthony; SAIKAT, Sohel; NORTON, Ian; NYONPLUE, Richard G.; MWANAMWENG, Abrahams; mwanamwenge@who.int; Feldmann, Heinrich (NIH/NIAID) [E] (feldmannh@niaid.nih.gov); McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; darryl.falzarano@nih.gov; Menk, Kay (NIH/NIAID) [E] (menkk@niaid.nih.gov); De wit, Emmie (NIH/NIAID) [E]; marzia@niaid.nih.gov
Subject: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation
Importance: High

Dear WR, Dr Gasasira and Colleagues,

We wish to inform you of the flight details of the GOARN lab experts (team#4) from the National Institute for Health (NIH), USA:

Team#4 consists of:

1. **Dr Emmie de Wit** will arrive in Monrovia on **Monday, 20 October 2014 at 19h20** on flight SN1247 from Brussels. She will depart Monrovia on 14 November 2014 at 21:35 via the same flight SN1247.
2. **Dr Darryl Falzarano** is traveling on the same flight as Dr Emmie de Wit arriving on **Monday, 20 October 2014 at 19h20** on flight SN1247 from Brussels. She will depart Monrovia on 14 November 2014 at 21:35 via the same flight SN1247.
3. **Dr Andrea Marzi (Team leader)** will arrive in Monrovia on **26 October 2014 at 20h15** on flight SN1247 from Brussels. She will depart Monrovia on 21 November 2014 at 21h35 via the same flight SN1247.

We would appreciate your support in organizing airport pick-up. Hotel and visa have been arranged by NIH. Please find attached a copy of their flight itineraries.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Harper, Jill (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 12:53 PM
To: Bloom, Marshall (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Subject: RE: Pending Discontinued Use of Large Cobalt-60 sources

Thanks, Marshall. Looping in Melinda here so that she can check in with the NIH legislative office on this one and alert them that this could be an issue.

Of course, none of us at NIAID can participate in the outreach effort by the NEI or ANS, nor can we have JL Shepherd advocate for us.

Jill R. Harper, Ph.D.
Associate Director for Science Management, and
Deputy Executive Officer
NIAID/NIH/DHHS
Bldg. 31, Room 7A-18, MSC 2520
Bethesda, MD 20892-2520
Phone: 301/594-3964
Fax: 301/496-9082
jharper@niaid.nih.gov

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:44 PM
To: Potts, Jeffrey (NIH/OD/ORS) [E]
Cc: Wilson, Deborah (NIH/OD/ORS) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]; Newman, Nancy (NIH/OD/ORS) [E]
Subject: FW: Pending Discontinued Use of Large Cobalt-60 sources

Jeff,

Please see this note from our Radiation Safety Officer, Barri Twardoski. According to the information that he has received from JL Sheperd, the continued use of cobalt-60 gamma irradiators may be in jeopardy.

The consequences of this for both intramural and extramural programs would be devastating because there is not a completely suitable alternative.

I am asking that you confer with the principal members of the HCTF as soon as possible and decide if and how NIH should respond.

Thanks a lot.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 12:44 PM
To: Potts, Jeffrey (NIH/OD/ORS) [E]
Cc: Wilson, Deborah (NIH/OD/ORS) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Twardoski, Barri (NIH/NIAID) [E]; Newman, Nancy (NIH/OD/ORS) [E]
Subject: FW: Pending Discontinued Use of Large Cobalt-60 sources
Attachments: EW_Bill_87223.pdf

Jeff,

Please see this note from our Radiation Safety Officer, Barri Twardoski. According to the information that he has received from JL Sheperd, the continued use of cobalt-60 gamma irradiators may be in jeopardy.

The consequences of this for both intramural and extramural programs would be devastating because there is not a completely suitable alternative.

I am asking that you confer with the principal members of the HCTF as soon as possible and decide if and how NIH should respond.

Thanks a lot.

Marshall

Marshall E. Bloom, M.D.
Associate Director
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: 406-375-9707
FAX: 406-375-9661
email: mbloom@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Twardoski, Barri (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:29 AM
To: Bloom, Marshall (NIH/NIAID) [E]
Cc: Kellar, Joshua (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Pending Discontinued Use of Large Cobalt-60 sources

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clauss, Matthias A <mclauss@iupui.edu>
Sent: Friday, October 17, 2014 12:35 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: TNF expression in HUVEC

Hallo Heinz,

I remember that the ebola/marburg strain you worked with in virus, [Redacted by agreement]

[Redacted by agreement]

RA drugs like ethanercept or embrell target TNF and are widely available, disadvantage, they need to be injected.

Have you thought about bringing this info into the Ebola treatment option discussion? [Redacted by agreement]

[Redacted by agreement]

Thanks

Matthias Clauss

[Associate Research Professor of Cellular and Integrative Physiology](#)

Indiana Center for Vascular Biology and Medicine

RLR-VA Medical Center - C 3108

1481 West 10th Street

Indianapolis, IN 46202

Phone: (317) 988-4076

MClauss@iupui.edu

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]

Sent: Thursday, May 26, 2011 11:26 AM

To: Clauss, Matthias A

Subject: RE: Meeting

Cell: [Personal Info]

Office: 406-375-7410

From: Clauss, Matthias A [<mailto:mclauss@iupui.edu>]

Sent: Thursday, May 26, 2011 6:19 AM

To: Feldmann, Heinrich (NIH/NIAID) [E]

Subject: RE: Meeting

Let's exchange number, my cell is [Personal Info]

Thank you

Matthias

--

Matthias Clauss

Associate Research Professor of Cellular and Integrative Physiology

Indiana Center for Vascular Biology and Medicine

VA Medical Center - C 3108

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Gunn, M.D. <michael.gunn@duke.edu>
Sent: Friday, October 17, 2014 12:32 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola diagnostic reagents?

Dr. Feldmann,

I am part of a group at Duke University that develops diagnostics for infectious diseases. The engineering part of our group has recently developed a novel point-of-care assay platform that is essentially a miniaturized sandwich ELISA on a small portable cassette. The key advantages of this platform are 1) that no mixing of reagents is required (the assay goes to completion with just a drop of blood) and 2) that we can achieve limits of detection in the 1 pg/ml range.

Given the pressing need for an Ebola diagnostic, I am trying to determine if we can use existing reagents to develop a point of care assay to detect ebola sGP in the blood that would actually work in the field. From what I can tell, the POC assays currently being tested have an LOD in the 100 ng/ml range, which I do not think will provide sufficient sensitivity. I have three questions for you.

First, we will need to use recombinant sGP to develop our assay. Would it be possible to obtain the pDisplay-sGP plasmid that you described in your 2005 *J. Virology* paper (Wahl-Jensen et al)? We have a lot of experience with protein expression and could construct an expression plasmid ourselves, but having one already shown to work well would save us significant time. If it is possible to obtain this plasmid, please let me know what I would need to do.

Second, I would like to test three monoclonal Abs that were described by Mavanur Suresh in a 2007 *J. Virological Methods* paper (Shahhosseini et al) on which you were a co-author. These would be the three mAbs that reacted to sGP per his data. However, when I tried to track Dr. Suresh down, it appears that he is no longer at the University of Alberta and his name does not pop up anywhere else. Would you by any chance know what became of Dr. Suresh or who should be contacted about any of the mAbs that he developed?

Third, I am in no way a virologist and have zero background knowledge of Ebola. In looking at the biology of Ebola, sGP seems like the clear choice for a diagnostic target, yet most of the assays described seem to target other viral proteins. Is this just based on the Abs that people have come up with or am I missing something important?

Thank you very much for any information that you can provide. Also, best of luck with your work in what is undoubtedly a very hectic time.

Take Care,

Michael Gunn

Michael Dee Gunn, M.D.
Professor of Medicine and Immunology
Chair, DoM Research Development Council
Duke University Medical Center
Phone:(919) 681-0840 Fax:(919) 681-9607

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dominik Wodarz <dwodarz@uci.edu>
Sent: Friday, October 17, 2014 12:28 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: mathematical modeling of virus dynamics

Yes, sure, I will email you in November.

Thanks,
Dominik

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 17, 2014 5:12 AM
To: 'dwodarz@uci.edu'
Subject: Re: mathematical modeling of virus dynamics

I am currently in Monrovia until early November. If you are still interested please contact me again after my return.

Heinz

From: Dominik Wodarz [mailto:dwodarz@uci.edu]
Sent: Friday, October 17, 2014 02:56 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: mathematical modeling of virus dynamics

Dear Dr Feldmann,

I'm a professor at University of California Irvine, and my area of research is mathematical modeling of the in vivo dynamics of viruses, and the interactions between viruses and immune responses. Much of my work has concentrated on HIV/SIV, as well as murine virus infections. We use mathematical equations to describe the dynamics of virus growth within hosts, to interpret experimental data, and to measure crucial kinetic parameters, such as the basic reproductive ratio of the virus, the rates of viral replication, cell death, etc. More info on my web page: wodarz.bio.uci.edu.

Out of curiosity, I have been reading about ebola growth in animal models and I realized that there could be a lot of potential to apply those types of mathematical approaches to data and to quantitatively characterize the infection kinetics. One interesting aspect might be to calculate and compare parameters in different animal models to see how they differ, although there are probably quite a few other questions where the interaction between math models and experimental data could provide interesting insights. So I wondered whether you would perhaps be interested in exploring a possible collaboration in this respect.

With best regards,

Dominik

=====
Dominik Wodarz
Professor

Feldmann, Heinrich (NIH/NIAID) [E]

From: W. Ian Lipkin <wil2001@columbia.edu>
Sent: Friday, October 17, 2014 12:11 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola Engineering Challenge

Redacted by agreement

On Oct 17, 2014, at 11:42 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

When and how did this happen?

From: W. Ian Lipkin [<mailto:wil2001@columbia.edu>]
Sent: Tuesday, October 14, 2014 02:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Kahn Ellie <ejk2162@columbia.edu>
Subject: Re: Ebola Engineering Challenge

Ok. Wish I were there. Stuck in U.S. Redacted by agree

On Oct 14, 2014, at 2:48 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Ian - having a hard time to get on interne to download the attachment. Currently in Monrovia until early November. I am sure the proposals are fine. I am happy to support. Exclude me from the article as this would need approval from Bethesda.

Sorry and best wishes, Heinz

From: W. Ian Lipkin [<mailto:wil2001@columbia.edu>]
Sent: Monday, October 13, 2014 10:32 AM Eastern Standard Time
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Cathy Roth <rothc@who.int>; Spiropoulou, Christina (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Rachel T. Moresky <rtm2102@cumc.columbia.edu>; Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Kahn Eleanor J. <ejk2162@cumc.columbia.edu>
Subject: Ebola Engineering Challenge

Dear Armand, Cathy, Christina, Heinz, Lisa, Rachel and Stuart,

Attached please find brief proposals that address needs that one or more of you have suggested might be amenable to low cost engineering solutions including improvements in decontamination of electronic equipment, disinfectant solutions, body bags, patient transport, and data collection and management. I will be vetting these proposals with the engineering faculty on Wednesday 15 October btw 11 AM and 3 PM EST. It would be helpful if you would fill in the attached score sheet by Tues evening. Please dont spend more than 30 minutes in total reading and scoring the proposals. What we want to know is whether you think the teams are meeting a need and whether a course correction or additional information is needed.

Thanks,

Ian

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Ricki (NIH/NIAID) [C]
Sent: Friday, October 17, 2014 11:27 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: anything??

Is there anything you want Emmie and Darryl to bring?
Everything is fine here.
Love you,
Ricki

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:51 AM
To: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Fw: conference call re hyperthermia treatment for Ebola virus

If you have time, can you make a quick listing of what was tested so that I can forward it? Please do it in the email text rather in an attachment.

Here is everything is fine. How about you and David?

Love you - miss you.

----- Original Message -----

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 03:27 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz, Ricki says all the flasks (three samples at time point infecting one flask each) Redacted by agreement

Redacted by agreement

Redacted by agreement

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:41 AM
To: 'roger@verthermia.com'
Cc: Personal Info; 'jan@verthermia.com'; Haddock, Elaine (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Jarvis <michael.jarvis@plymouth.ac.uk>
Sent: Friday, October 17, 2014 10:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: various

Heinz,

The meeting is now over, but was good. I introduced myself to Jürgen, and we got talking about the African Swine Fever Virus. I like him. I was also good to see Elaine, Cynthia, and Alison (who I have never really spoken to before today), and Elaine gave an excellent, and very clear presentation - probably as expected.

On other fronts, I am starting to put together the RhCMV Ebola paper. I am trying to get to terms with efficacy of 7A versus 8A challenge. Other than a Profectus talk back in Aug 23, where only protection and disease was discussed (no viremia data), there seems to be very little on the state of vaccine trials using this low passage virus. I did find a link which discusses the issue:
<http://www.biosciencetechnology.com/articles/2014/09/two-anti-ebola-vaccines-historic-race> wherein citing Tom, Gary Kobinger and John Eldridge indicate that the Ad vaccines may not hold up to 7A challenge.

Can you shed any further light? I asked Andrea, but received a somewhat nebulous answer.

I hope everything is going well.

Michael

ps. Although probably too early along my select agent training, but if you are needing help with the analysis in Monrovia let me know.

Dr Michael A. Jarvis, PhD.
Reader in Virology & Immunology,
Director of Graduate Studies,
School of Biomedicine & Healthcare Science, University of Plymouth

E-Mail:
michael.jarvis@plymouth.ac.uk<mailto:michael.jarvis@plymouth.ac.uk>
michael.jarvis@Personal Info

[http://www.plymouth.ac.uk/images/email_footer.gif]<<http://www.plymouth.ac.uk/worldclass>>

This email and any files with it are confidential and intended solely for the use of the recipient to whom it is addressed. If you are not the intended recipient then copying, distribution or other use of the information contained is strictly prohibited and you should not rely on it. If you have received this email in error please let the sender know immediately and delete it from your system(s). Internet emails are not necessarily secure. While we take every care, Plymouth University accepts no responsibility for viruses and it is your responsibility to scan emails and their attachments. Plymouth University does not accept responsibility for any changes made after it was sent. Nothing in this email or its attachments constitutes an order for goods or services unless accompanied by an official order form.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 10:51 AM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Mire, Chad
Subject: Re: Ebola-Zaire Guinea seed stock titers

Tom,

The titer we have for the [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

Andrea

From: <Geisbert>, Tom Geisbert <twgeisbe@UTMB.EDU>
Date: Friday, October 17, 2014 9:09 AM
To: Andrea Marzi <marzia@niaid.nih.gov>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Cc: Mire Chad <chmire@UTMB.EDU>
Subject: Ebola-Zaire Guinea seed stock titers

Andrea, Heinz

Joan just grew up two Guinea seeds stocks and both titer [Redacted by agreement]

[Redacted by agreement]

Tom

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 10:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola antibody

Will do and copy you.
Thanks

From: <Feldmann>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 17, 2014 9:51 AM
To: Andrea Marzi <marzia@niaid.nih.gov>
Subject: Re: Ebola antibody

Thanks for the update - can you contact Malik and let him know what we have?

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 10:36 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola antibody

We have some serum from immunized or immunized/challenged animals that we can share. Not a whole lot though.

I think the talk went ok. Received several emails already thanking for the info we provided and helping answer a lot of questions that are obviously posed by the community.

The seminar room was packed, have never seen it that full and I was a bit scared.

The 3 main things we got across were:

1. RML is providing a service doing diagnostics, no research
2. We don't have patient contact – so yes, we are welcome home and the OMS surveillance program was well received (people were worried we would just walk into a physicians office if we would get sick, but that is just not going to happen)
3. We volunteer for this work are not sent/deployed to do this

Think the talks were well received. It was certainly interesting to see George's pictures and hear his stories.

I decided to keep the background and science to a minimum, not wanting to give the expression that we do research over there.

Focused on our setups instead, what a day over there is like, the samples we processed etc. Pretty much very similar to what I showed at WIP when we got back and added the OMS slide in the end.

Hope all is well over there with you guys.

Andrea

From: <Feldmann>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 17, 2014 6:57 AM
To: Andrea Marzi <marzia@niaid.nih.gov>
Subject: Fw: Ebola antibody

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 10:42 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: glycoprotein cDNA clone request

Yes, we can and yes, MTA.

Do you want to reply or want me to setup the thing?

From: <Feldmann>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 17, 2014 9:41 AM
To: Andrea Marzi <marzia@niaid.nih.gov>
Subject: Fw: glycoprotein cDNA clone request

Can we do this? We need MTA.

From: Ethan Bier [<mailto:ebier@ucsd.edu>]
Sent: Tuesday, October 14, 2014 05:42 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Redacted by ag

Thanks and best regards,

Ethan

--

Ethan Bier
Section of Cell and Developmental Biology
Bonner Hall, Room 4218
University of California, San Diego
9500 Gilman Drive
La Jolla, CA 92093-0349

Tel. (858) 534-8792
Fax. (858) 822-2044
Email: ebier@ucsd.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Ricki (NIH/NIAID) [C]
Sent: Friday, October 17, 2014 10:28 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Haddock, Elaine (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz,

I can't find Elaine's actual protocol, but what we have talked about is to Redacted by agreement

Redacted by agreement

Redacted by agreement

Ricki

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:51 AM
To: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Fw: conference call re hyperthermia treatment for Ebola virus

If you have time, can you make a quick listing of what was tested so that I can forward it? Please do it in the email text rather in an attachment.

----- Original Message -----

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 03:27 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz, Ricki says Redacted by agreement

Redacted by agreement

Redacted by agreement

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: goarn <goarn@who.int>
Sent: Friday, October 17, 2014 10:21 AM
To: GRAAFF, Peter Jan; GASASIRA, Alex Ntale; WERTSCHNIG, Brian Adam; WAI, Lokky
Cc: DAVIS, Raphael; KOLLIE, Robert K.; FREEMAN DELINE, Nancy; UMALI DALANGIN, Khristeen; SEOCC; goarn; SHOC; KASHYAP, Sanjeev; Pierre Formenty; NAIDOO, Dhamari; DRURY, Patrick Anthony; SAIKAT, Sohel; NORTON, Ian; NYONPLUE, Richard G.; MWANAMWENG, Abrahams; mwanamwenge@who.int; Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation
Attachments: Itinerary Liberia AMarzi OctNov2014.pdf; ItineraryKV7B7W_26SEP.PDF; itinerary_E de Wit.pdf
Importance: High

Dear WR, Dr Gasasira and Colleagues,

We wish to inform you of the flight details of the GOARN lab experts (team#4) from the National Institute for Health (NIH), USA:

Team#4 consists of:

1. **Dr Emmie de Wit** will arrive in Monrovia on **Monday, 20 October 2014 at 19h20** on flight SN1247 from Brussels. She will depart Monrovia on 14 November 2014 at 21:35 via the same flight SN1247.
2. **Dr Darryl Falzarano** is traveling on the same flight as Dr Emmie de Wit arriving on **Monday, 20 October 2014 at 19h20** on flight SN1247 from Brussels. She will depart Monrovia on 14 November 2014 at 21:35 via the same flight SN1247.
3. **Dr Andrea Marzi (Team leader)** will arrive in Monrovia on **26 October 2014 at 20h15** on flight SN1247 from Brussels. She will depart Monrovia on 21 November 2014 at 21h35 via the same flight SN1247.

We would appreciate your support in organizing airport pick-up. Hotel and visa have been arranged by NIH. Please find attached a copy of their flight itineraries.

N.B.

We would also like to remind you that NIH lab team#3 members: **Drs Kristin McNally & Kyle Rosenke** need transportation (2 vehicles) to transport them from Kendeja hotel to the airport for their flight on **Monday, 20 October 2014 at 20h40 via flight SN1247**. NIH lab team would be very grateful if the drivers/vehicles can stay at the airport and wait for the next team's arrival.

Kindly acknowledge receipt of this request and confirm with us the names/telephone numbers of the drivers who will be picking them up.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 17, 2014 10:16 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: EBOV material request

They are a university, so no problem there – but I will keep that in mind should I get approached by a company. So far that has not been the case.

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 10:07 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: EBOV material request

SLA is fine unless it is a request from an industrial firm.

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 17, 2014 11:14 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: EBOV material request

Hi Heinz,

Another request for the trVLP system, this time from Spain. Can I go ahead as usual (i.e. we can share with an SLA)?

All the best, Thomas

From: PEREZ VILARO, GEMMA [<mailto:gemma.perez@upf.edu>]
Sent: Friday, October 17, 2014 7:58 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: JUANA MARÍA DÍEZ ANTÓN
Subject: EBOV material request

Dear Dr. Hoenen,

My name is Gemma, I am working as a PostDoc in the laboratory of Molecular Virology under the supervision of Dr. Juana Díez. Currently we are investigating the involvement of different host factors in viral RNA replication and we would like to expand to other viruses. In this context, we would be very grateful if you could provide us the plasmids detailed below to work with Ebola virus-like particles containing tetracistronic minigenomes described in your publication: "Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes, published in JOVE, 2014". The paper was extremely informative and nicely written!

The plasmids that we would need are:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Twardoski, Barri (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:29 AM
To: Bloom, Marshall (NIH/NIAID) [E]
Cc: Kellar, Joshua (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Pending Discontinued Use of Large Cobalt-60 sources
Attachments: EW_Bill_87223.pdf

Dr. Bloom,

Please see the below email w/ attachment from JL Shepherd. As we discussed, the HCTF should be made aware of this proposed legislation that could preclude RML from obtaining new cobalt sources.

Cobalt irradiation is an essential component of research conducted inside RML's Maximum Containment Laboratories (MCL). If new Co-60 sources were not obtainable, it would impact RML's ability to achieve research objectives in the MCL. RML scientists called upon for immediate response to any intentional spread of biological disease or naturally occurring outbreak, such as the current ebola crisis, would be impacted.

Sincerely,

Barry Twardoski
Rocky Mountain Laboratories, 903 South 4th Street
Hamilton, MT 59840
Phone: (406) 363-9216
Fax: (406) 363-9336
twardoskib@niaid.nih.gov

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mary Shepherd [mailto:sales@jlshepherd.com]
Sent: Thursday, October 16, 2014 12:00 PM
To: Twardoski, Barri (NIH/NIAID) [E]
Subject: FW: Pending Discontinued Use of Large Cobalt-60 sources

Dear Barry,

This email is to inform you about some proposed legislation which could impact your mission under Public Law 107-188 (June 2002) that requires the United States to improve its availability to prevent, prepare for and respond to acts of bioterrorism and other public health emergencies that could threaten public health and safety or American agriculture. With the current Ebola situation, this issue has become critical. This proposed legislation includes language (see below) which could impact the continued use or reloading of your Cobalt-60 Irradiator to meet your needs, as the proposed cut-off for permitted sources is 10 Curies, and there is no criteria listed for justification for continued use.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 17, 2014 9:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: EBOV material request

Hi Heinz,

Another request for the trVLP system, this time from Spain. Can I go ahead as usual (i.e. we can share with an SLA)?

All the best, Thomas

From: PEREZ VILARO, GEMMA [mailto:gemma.perez@upf.edu]
Sent: Friday, October 17, 2014 7:58 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: JUANA MARÍA DÍEZ ANTÓN
Subject: EBOV material request

Dear Dr. Hoenen,

My name is Gemma, I am working as a PostDoc in the laboratory of Molecular Virology under the supervision of Dr. Juana Díez. Currently we are investigating the involvement of different host factors in viral RNA replication and we would like to expand to other viruses. In this context, we would be very grateful if you could provide us the plasmids detailed below to work with Ebola virus-like particles containing tetracistronic minigenomes described in your publication: "Modeling the lifecycle of ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes, published in JOVE, 2014". The paper was extremely informative and nicely written!

The plasmids that we would need are:

pCAGGS-NP

pCAGGS-VP35

pCAGGS-VP30

pCAGGS-L

pCAGGS-T7

pCAGGS-Tim1

p4cis-vRNA-RLuc

pCAGGS-EGFPS (this last one is not mentioned in the publication but is mentioned in the video attached with the manuscript)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Friday, October 17, 2014 9:09 AM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Mire, Chad
Subject: Ebola-Zaire Guinea seed stock titers

Andrea, Heinz

Joan just grew up two Guinea seeds stocks and both titer

Redacted by agreement

Redacted by agreement

Tom

Feldmann, Heinrich (NIH/NIAID) [E]

From: nadia drake <nadiadrake@nih.gov> [Personal Info]
Sent: Friday, October 17, 2014 8:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Press Inquiry: Ebola transmission, for Wired?

Hi Dr. Feldmann --

I'm a science reporter and am working on a story for Wired about Ebola transmission. We'd like to address concerns about the virus mutating and becoming airborne by explaining as much as we know about how it gains entry to host cells, where those cells are in the body, and what would need to change for it to become respiratory.

Is there any chance you might be able to help me out with this? I've seen a few studies suggesting that Ebola can affect the lungs and congregate in alveoli ([here's a review with some of that](#)) but I don't know what that all means and if it's significant. Are you aware of any studies in rodents or primates that might be informative here?

I'm trying to collect all my information today, so if you're available for a phone call, that would be great! My day is free after about 12:30pm EDT.

Cheers,
Nadia

--
Nadia Drake
Science Reporter
San Francisco, CA
[nadiadrake@nih.gov](#) [Personal Info]
[Personal Info] (mobile)
Twitter: [Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 8:37 AM
To: Sakai, Richard
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]
Subject: RE: Malian Government Sets Up Well-Equipped Center To Diagnose Ebola Virus Effectively (Mali)

Dick

What was the audience of this?

Overall the only item really concerning is the mention of a Regional Reference Lab, which they are not. WHO and/or CDC would have to designate it as such so the staff should not proclaim they are part of such a lab.

Thank you for sharing

Joe

From: Sakai, Richard
Sent: Friday, October 17, 2014 10:24 AM
To: Shott, Joseph (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]
Subject: FW: Malian Government Sets Up Well-Equipped Center To Diagnose Ebola Virus Effectively (Mali)

[FYI](#)

Malian Government Sets Up Well-Equipped Center To Diagnose Ebola Virus Effectively

AFL2014101634441776 Bamako *ORTM Television* in French 2000 GMT 14 Oct 14

[Speakers provided by captions]

Health news: as you know the world is leading a fierce battle against Ebola virus and so far none has been reported in our area but as it is often said, "prevention is better than cure!" Because our country now has a Research and Training Center which makes it possible to diagnose a suspected case of Ebola in two hours. To ensure that it is operational, the minister of health and public hygiene went to visit the laboratory installed at G point. Here is the report by Aidiounia Tina.

[Begin recording] [Tina] This is obvious; the Ebola virus is gaining ground in the sub-region and elsewhere. In Mali, though no cases have yet been reported, steps are

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 8:36 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola antibody

We have some serum from immunized or immunized/challenged animals that we can share. Not a whole lot though.

I think the talk went ok. Received several emails already thanking for the info we provided and helping answer a lot of questions that are obviously posed by the community.

The seminar room was packed, have never seen it that full and I was a bit scared.

The 3 main things we got across were:

1. RML is providing a service doing diagnostics, no research
2. We don't have patient contact – so yes, we are welcome home and the OMS surveillance program was well received (people were worried we would just walk into a physicians office if we would get sick, but that is just not going to happen)
3. We volunteer for this work are not sent/deployed to do this

Think the talks were well received. It was certainly interesting to see George's pictures and hear his stories.

I decided to keep the background and science to a minimum, not wanting to give the expression that we do research over there.

Focused on our setups instead, what a day over there is like, the samples we processed etc. Pretty much very similar to what I showed at WIP when we got back and added the OMS slide in the end.

Hope all is well over there with you guys.

Andrea

From: <Feldmann>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 17, 2014 6:57 AM
To: Andrea Marzi <marzia@niaid.nih.gov>
Subject: Fw: Ebola antibody

Have you looked into this? Can we provide antibodies? Please let me know or contact Malik directly (please copy me).

How was your seminar? I heard very good things about it? Are we still welcome back home?

Heinz

From: Malik [<mailto:malik@hku.hk>]
Sent: Wednesday, October 15, 2014 09:46 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola antibody

Dear Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Moss, Bernard (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 8:31 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola

Heinz

Below are the data from the Sullivan paper. It is true that protection was not obtained with a single MVA. However, complete and durable protection was only obtained with an chAdeno prime and an MVA boost (Table 1). The description of the MVA vector suggests that it was made sub optimally and also they did not try MVA prime and MVA boost. We would make a MVA that expresses higher than the one used in the Sullivan paper and also we have a new experimental non-replicating vector that expresses much higher than any MVA – probably higher than any other vector. I don't know what Tom Geisbert is referring to.

Be safe

Bernie

Table 1 Durable vaccine protection against EBOV

Vector	Dose (PU)		Protection ^a
Single shot			
ChAd3	1 × 10 ¹¹	2/4	50%
ChAd3	1 × 10 ¹⁰	0/4	0%
Prime-boost			
ChAd3/ChAd3	1 × 10 ¹⁰ /1 × 10 ¹⁰	1/3	33%
ChAd3/ChAd63	1 × 10 ¹⁰ /1 × 10 ¹⁰	1/4	25%
ChAd3/MVA	1 × 10 ¹⁰ /1 × 10 ⁸	4/4	100%

Animals in single-shot groups were vaccinated with ChAd3 at the doses indicated and exposed to a lethal dose of EBOV 10 months after the prime vaccination. Animals in prime-boost groups were primed with ChAd3, boosted 8 weeks later, and exposed to a lethal dose of EBOV as in the single-shot groups.

^aProtection is shown as the number surviving/total challenged and as a survival percent

From: <Feldmann>, "Heinrich [E] (NIH/NIAID)" <feldmannh@niaid.nih.gov>
Date: Friday, October 17, 2014 at 9:15 AM
To: "Moss, Bernard (NIH/NIAID) [E]" <BMOSS@niaid.nih.gov>
Subject: Re: Ebola

Feldmann, Heinrich (NIH/NIAID) [E]

From: Willis, David <WillisD@ebsi.com>
Sent: Friday, October 17, 2014 8:28 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Rabies virus seed materials

Dear Dr. Feldmann,

I am writing in search of rabies seed stock sources. Emergent BioDefense has a product license (BLA) for a human Rabies Vaccine (Rabies Vaccine Adsorbed). Our original Kissling derived seed stock is no longer available and we are looking at other possible sources. One option would be to obtain the same Kissling line originally received from CDC. We are making requests at CDC in this regard, however they are somewhat preoccupied at the moment with Ebola. Given that your facility's involvement in both areas (Rabies and Ebola), we thought you might have access to original Kissling strain Rabies seed materials.

I would appreciate hearing from you at your convenience,

Sincerely,

David Willis, PhD
Senior Manager, Regulatory Affairs
Biodefense Division

Emergent BioSolutions
3500 N. Martin Luther King Jr. Blvd.
Lansing, MI 48906-9910

t 517 327 7295
f 517 327 6895
i 107295
e willisd@ebsi.com
www.emergentbiosolutions.com
www.linkedin.com/companies/emergent-biosolutions
@emergentbiosolu

This e-mail communication (including any attachments) contains information from Emergent BioSolutions or its affiliates that is confidential and may be privileged. The information contained herein is intended only for the use of the addressee(s) named above. If you are not the intended recipient (or the agent responsible to deliver it to the intended recipient), you are hereby notified that any dissemination, distribution, use, or copying of this communication is strictly prohibited. If you have received this e-mail in error, please immediately reply to sender, delete the message and destroy all copies of it. If you have questions, please email netops@ebsi.com. Thank you.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sakai, Richard
Sent: Friday, October 17, 2014 8:25 AM
To: Shott, Joseph (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]
Subject: FW: Malian Government Sets Up Well-Equipped Center To Diagnose Ebola Virus Effectively (Mali)
Attachments: ATT00001.bin; ATT00002.bin

FYI

Malian Government Sets Up Well-Equipped Center To Diagnose Ebola Virus Effectively

AFL2014101634441776 Bamako *ORTM Television* in French 2000 GMT 14 Oct 14

[Speakers provided by captions]

Health news: as you know the world is leading a fierce battle against Ebola virus and so far none has been reported in our area but as it is often said, "prevention is better than cure!" Because our country now has a Research and Training Center which makes it possible to diagnose a suspected case of Ebola in two hours. To ensure that it is operational, the minister of health and public hygiene went to visit the laboratory installed at G point. Here is the report by Aidiounia Tina.

[Begin recording] [Tina] This is obvious; the Ebola virus is gaining ground in the sub-region and elsewhere. In Mali, though no cases have yet been reported, steps are still taken at the center of research and training, which is now fit to diagnose cases of Ebola virus.

[Ousmane Kone, minister of health and public hygiene] Whenever we suspect a patient, we would diagnose him and send a sample to the Serefo laboratory and within a few hours we can get the results. So far, this has boost our assurance that patients we received were not carriers of the virus. And so it was important for me to come to inquire about the conditions in which these teams work, and then encourage and congratulate them for the good work they do every day.

[Dr Bassirou Diarra, head of the Tuberculosis Laboratory] In managing the Ebola crisis, the Serefo laboratory through [word indistinct] receives samples from the CENAM and now we conduct experiments that first aim to inactivate the sample and then, extract the arena of the virus. Thereafter, we would carry out the PCR [expansion not provided] to see if that virus is the same as the Ebola virus. Malians can be reassured; so far, up to 27 suspected cases of Ebola have been tested negative, Thank God.

[Tina] Today, the Research and Training Center is a reference in the sub-region, thanks to the support of American partners.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Auchincloss, Hugh (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 8:11 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

Fyi. No response necessary.

Hugh

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:24 PM
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

Please handle.

Begin forwarded message:

From: "Sengupta, Tapas K." <Tapas.Sengupta@inova.org>
Date: October 16, 2014, 2:35:20 PM EDT
To: "anthony.fauci@nih.gov" <anthony.fauci@nih.gov>
Subject: FW: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

Dr. Fauci,

Thank you for your leadership role in fighting Ebola. Thank you again for letting your colleague answer my question in my previous e-mail. I sent you the e-mail below in August and your colleague wrote me back saying that the hydrolase inhibitor would not work and was found too toxic in humans. May be, but I also found in another article that the antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from *Trypanosoma cruzi* ([Bioorg Med Chem](#). 2007 Dec 1;15(23):7281-7). Is there a way that the same principle may be researched further and customized to fight Ebola? This might be even body's natural mechanism to fight viruses, as some people have shown higher levels of S-adenosyl homocysteine (SAH) in blood without low levels of vitamin B12 and Folate (may be they just fought off a viral infection when blood was sampled?). It seems that the antiviral function of hydrolase inhibitor may come from higher concentration of SAH build-up in the cells and blood. In this regard, is it possible to use SAH directly as a drug to fight Ebola?

I am finding through my research how important and central roles the constituents of one-carbon metabolism (methionine cycle) play in our immune system and many other systems that keep us healthy. I would suggest and request that the team of scientists working on Ebola at NIH give this direction another try.

Feldmann, Heinrich (NIH/NIAID) [E]

From: susan.kamal@ethik.uzh.ch
Sent: Friday, October 17, 2014 7:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview for University of Zurich

Dear Dr.Feldmann,

I hope you are well. I am Susan a researcher at the institute of Biomedical ethics at the university of Zurich. I am currently working on a case study on Ebola, and I would like to ask you for a telephone interview for about 20 minutes. Would this be possible?

I look forward to hearing from you.

Best wishes,
Susan

Feldmann, Heinrich (NIH/NIAID) [E]

From: Casellas, Rafael (NIH/NIAMS) [E]
Sent: Friday, October 17, 2014 6:51 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Intramural Ebola project

OK, will do, thanks

R

Rafael Casellas, Ph.D.
Senior Investigator
Genomics & Immunity
NIAMS-NCI, NIH, 10/13C103-D
10 Center Drive MSC 1930
Bethesda, MD. 20892, 301-402-7858
<http://casellaslab.github.io/index.html>

From: <Feldmann>, "Heinrich [E] (NIH/NIAID)" <feldmannh@niaid.nih.gov>
Date: Friday, October 17, 2014 at 8:48 AM
To: Rafael Casellas <casellar@mail.nih.gov>
Subject: Re: Intramural Ebola project

Dear Rafael,

You should address CDC or MSF with your request. Work on clinical specimens needs an MOU with the ministry here in Liberia and ethics approval. We have samples but not under proper storage. We cannot do anything with the samples as proper paperwork is not in place for us. I heard that CDC has an MOU in place now. You might want to contact Stuart Nichol or Pierre Rollin from CDC.

Good luck and best wishes Heinz

From: Casellas, Rafael (NIH/NIAMS) [E]
Sent: Thursday, October 16, 2014 05:57 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Intramural Ebola project

Dear Heinz

Please see email below. if there is interest in pursuing that project we would love to help out

Best regards

Rafael

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dominik Wodarz <dwodarz@uci.edu>
Sent: Friday, October 17, 2014 12:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: mathematical modeling of virus dynamics

Dear Dr Feldmann,

I'm a professor at University of California Irvine, and my area of research is mathematical modeling of the in vivo dynamics of viruses, and the interactions between viruses and immune responses. Much of my work has concentrated on HIV/SIV, as well as murine virus infections. We use mathematical equations to describe the dynamics of virus growth within hosts, to interpret experimental data, and to measure crucial kinetic parameters, such as the basic reproductive ratio of the virus, the rates of viral replication, cell death, etc. More info on my web page: wodarz.bio.uci.edu.

Out of curiosity, I have been reading about ebola growth in animal models and I realized that there could be a lot of potential to apply those types of mathematical approaches to data and to quantitatively characterize the infection kinetics. One interesting aspect might be to calculate and compare parameters in different animal models to see how they differ, although there are probably quite a few other questions where the interaction between math models and experimental data could provide interesting insights. So I wondered whether you would perhaps be interested in exploring a possible collaboration in this respect.

With best regards,

Dominik

=====
Dominik Wodarz
Professor
Department of Ecology and Evolutionary Biology
University of California
Irvine, CA 92697
wodarz.bio.uci.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Casellas, Rafael (NIH/NIAMS) [E]
Sent: Thursday, October 16, 2014 3:58 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Intramural Ebola project

Dear Heinz

Please see email below. if there is interest in pursuing that project we would love to help out

Best regards

Rafael

Rafael Casellas, Ph.D.
Senior Investigator
Genomics & Immunity
NIAMS-NCI, NIH, 10/13C103-D
10 Center Drive MSC 1930
Bethesda, MD. 20892, 301-402-7858
<http://casellaslab.github.io/index.html>

From: <Auchincloss>, "Hugh [E] (NIH/NIAID)" <auchinclossh@niaid.nih.gov>
Date: Tuesday, October 14, 2014 at 9:17 AM
To: Rafael Casellas <casellar@mail.nih.gov>
Subject: FW: Intramural Ebola project

Dear Dr. Casellas, Your idea is certainly interesting although given the chaos that exists in West Africa I think it probably unlikely that you would be able to come up with sufficient samples with well documented clinical histories to make this work. However, you might want to talk with NIAID scientists Lisa Hensley or Heinz Feldmann, both of who have spent time on the ground. In addition you might want to contact CDC directly or Doctors Without Borders.

Sincerely,

Hugh Auchincloss

Hugh Auchincloss, M.D.
Deputy Director, NIAID
National Institutes of Health
Bldg. 31 (7A/03), 31 Center Drive, MSC 2520
Bethesda, MD 20892
Phone: 301-496-9677
Fax: 301-496-4409

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:22 PM
To: Darren Baker; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: PEG IFN beta

Thank you

From: Darren Baker [darren.baker@biogenidec.com]
Sent: Thursday, October 16, 2014 4:30 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: PEG IFN beta

Dear all

Good to attach what I said I would attach !

Cheers .. Darren

From: Darren Baker
Sent: Thursday, October 16, 2014 4:14 PM
To: 'Falzarano, Darryl (NIH/NIAID) [F]'; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: PEG IFN beta

Dear all

Based on the data you sent last week that showed that Redacted by agreement

Redacted by agreement

Redacted by agreement (the paper by Smith et al attached reports survival out to 29 days with IFN beta treatment so I'm not sure the effect is necessarily maximal).

I have also attached the paper by Hu et al that shows the PK parameters of unmodified and pegylated IFN beta in rhesus monkeys that shows the increased AUC, t1/2, tmax, and Cmax, and reduced clearance following pegylation. And while the pharmacodynamic marker neopterin is not different between unmodified and pegylated IFN beta, this does not preclude other IFN-induced genes/proteins being differentially regulated both in terms of fold-induction and when they reach maximal expression. We know that in humans, there is a temporal effect on gene induction between unmodified and pegylated IFN beta.

Redacted by agreement

Redacted by agreement

The data in the Hu et al paper also shows that tmax for pegylated IFN beta was reached 4.3 and 14.6 h post dose following IM and SC administration, respectively, Redacted by agreement

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Thursday, October 16, 2014 3:19 PM
To: Pete Halfmann
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Conflicts of Interest

None.

From: Pete Halfmann <halfmanp@svm.vetmed.wisc.edu>
Handle: Pete Halfmann
Mail Address: halfmanp@svm.vetmed.wisc.edu
Subject: Conflicts of Interest
To: Kawaoka, Yoshi (kawaokay@svm.vetmed.wisc.edu) <kawaokay@svm.vetmed.wisc.edu>
CC: Feldmann, Heinrich (NIH/NIAID) [E] (feldmannh@niaid.nih.gov) <feldmannh@niaid.nih.gov>
Date: Thu, 16 Oct 2014 10:13:22 -0500
Date Local: 2014/10/17 0:13:22
Message:

> Yoshi and Heinz,
>
> Do you have any Conflicts of Interests to declare with the Ebola virus commentary in EBioMedicine?
>
>
>
> Thanks
>
>
>
>
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Thursday, October 16, 2014 3:11 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Interview request from The Scientist magazine

Hi Ken,

I got an interview request, but I don't think I'm really qualified to comment on regulatory issues as well as plans for funding/distributing vaccines – that's way too political for me. Could you take care of this?

Thanks a lot, Thomas

From: Molly Sharlach [mailto:msharlach@the-scientist.com]
Sent: Thursday, October 16, 2014 3:03 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Interview request from The Scientist magazine

Dear Dr. Hoenen:

In light of the recent announcement about the start of clinical trials for NewLink's VSV Ebola vaccine, I'm writing an online news piece about fast-tracking clinical trials for Ebola vaccines and therapies. I found your opinion piece in BMC Biology very informative, and I'm interested in your thoughts on how the process is unfolding, both in terms of regulatory issues and potential plans for funding/distributing vaccines and therapies to affected areas.

Are you available for a ~15-minute phone interview early next week?

Here are some times when I'm available (all MDT):

Monday, Oct. 20, before 10 am or after 1 pm

Tuesday, Oct. 21, before 1 pm or after 4 pm

Thanks so much for your help.

--

Molly Sharlach, PhD
Intern | [The Scientist](#)
Phone: 203-858-2594

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:01 PM
To: 'darren.baker@biogenidec.com'; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: PEG IFN beta

Darren

Thank you for the information. I will mull over.

Kathy

Sent from my BlackBerry Wireless Handheld

From: Darren Baker [mailto:darren.baker@biogenidec.com]
Sent: Thursday, October 16, 2014 04:30 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: PEG IFN beta

Dear all

Good to attach what I said I would attach !

Cheers .. Darren

From: Darren Baker
Sent: Thursday, October 16, 2014 4:14 PM
To: 'Falzarano, Darryl (NIH/NIAID) [F]'; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: PEG IFN beta

Dear all

Based on the data you sent last week that showed that Redacted by agreement

Redacted by agreement

Redacted by agreement (the paper by Smith et al attached reports survival out to 29 days with IFN beta treatment so I'm not sure the effect is necessarily maximal).

I have also attached the paper by Hu et al that shows the PK parameters of unmodified and pegylated IFN beta in rhesus monkeys that shows the increased AUC, t1/2, tmax, and Cmax, and reduced clearance following pegylation. And while the pharmacodynamic marker neopterin is not different between unmodified and pegylated IFN beta, this does not preclude other IFN-induced genes/proteins being differentially regulated both in terms of fold-induction and when they reach maximal expression. We know that in humans, there is a temporal effect on gene induction between unmodified and pegylated IFN beta.

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Darren Baker <darren.baker@biogenidec.com>
Sent: Thursday, October 16, 2014 2:30 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: PEG IFN beta
Attachments: Smith et al 2013.pdf; Hu et al 2011.pdf

Dear all

Good to attach what I said I would attach !

Cheers .. Darren

From: Darren Baker
Sent: Thursday, October 16, 2014 4:14 PM
To: 'Falzarano, Darryl (NIH/NIAID) [F]'; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: PEG IFN beta

Dear all

Based on the data you sent last week that showed that unmodified [Redacted by agreement]
[Redacted by agreement]
[Redacted by agreement]
[Redacted by agreement] (the paper by Smith et al attached reports survival out to 29 days with IFN beta treatment so I'm not sure the effect is necessarily maximal).

I have also attached the paper by Hu et al that shows the PK parameters of unmodified and pegylated IFN beta in rhesus monkeys that shows the increased AUC, t_{1/2}, t_{max}, and C_{max}, and reduced clearance following pegylation. And while the pharmacodynamic marker neopterin is not different between unmodified and pegylated IFN beta, this does not preclude other IFN-induced genes/proteins being differentially regulated both in terms of fold-induction and when they reach maximal expression. We know that in humans, there is a temporal effect on gene induction between unmodified and pegylated IFN beta.

[Redacted by agreement]

[Redacted by agreement]

The data in the Hu et al paper also shows that t_{max} for pegylated IFN beta was reached 4.3 and 14.6 h post dose following IM and SC administration, respectively, [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement] by Smith et al. In that study, the last rhesus monkey died on day 29, and in that case they were given 10.5 µg/kg 18 h, and at 1, 3, 5, 7, and 9 days post infection (sans ribavirin) while in [Redacted by agreement]

[Redacted by agreement] Everything else being equal (strain of ebola used, pfu inoculation size, animal sex and age etc) [Redacted by agreement]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Darren Baker <darren.baker@biogenidec.com>
Sent: Thursday, October 16, 2014 2:14 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: PEG IFN beta

Dear all

Based on the data you sent last week that showed that [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

(the paper by Smith et al attached reports survival out to 29 days with IFN beta treatment so I'm not sure the effect is necessarily maximal).

I have also attached the paper by Hu et al that shows the PK parameters of unmodified and pegylated IFN beta in rhesus monkeys that shows the increased AUC, t1/2, tmax, and Cmax, and reduced clearance following pegylation. And while the pharmacodynamic marker neopterin is not different between unmodified and pegylated IFN beta, this does not preclude other IFN-induced genes/proteins being differentially regulated both in terms of fold-induction and when they reach maximal expression. We know that in humans, there is a temporal effect on gene induction between unmodified and pegylated IFN beta.

[Redacted by agreement]

[Redacted by agreement]

The data in the Hu et al paper also shows that tmax for pegylated IFN beta was reached 4.3 and 14.6 h post dose following IM and SC administration, respectively. [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

[Redacted] by Smith et al. In that study, the last rhesus monkey died on day 29, and in that case they were given 10.5 µg/kg 18 h, and at 1, 3, 5, 7, and 9 days post infection (sans ribavirin) while in [Redacted by agreement] ribavirin). Everything else being equal (strain of ebola used, pfu inoculation size, animal sex and age etc) [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

Cheers .. Darren

From: Falzarano, Darryl (NIH/NIAID) [F] [mailto:darryl.falzarano@nih.gov]
Sent: Thursday, October 16, 2014 12:02 PM
To: Darren Baker; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: PEG IFN beta

Is there a compelling reason to think that PEG-IFN-beta would exhibit a different outcome than IFN-beta? If not, then

[Redacted by agreement]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Relich, Ryan Ford <rrelich@iupui.edu>
Sent: Thursday, October 16, 2014 2:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Question about disinfection

Oh, wow...

How's the situation there? Our clinical research group (who you met during your visit) had a lot of contacts in Liberia: most of whom have contracted Ebola and died. From the sounds of it, things are not really getting any better. Also, if you haven't heard, two nurses from Texas Presbyterian Hospital (Dallas) have contracted Ebola from the patient who they cared for (Thomas Eric Duncan). One of the nurses travelled to Cleveland, OH during the incubation period.

Thanks very much for the information regarding disinfection: we're preparing protocols for dealing with suspected Ebola patients and their specimens. We will only be doing point-of-care testing (e.g., urinalysis by dipstick, iStat testing device for electrolytes and basic biochemical analytes), blood films for malaria diagnosis, and blood cultures. The malaria smears and blood cultures will be performed by me and a few other folks in our BSL-3 laboratory. We just ordered Tyvek suits, more PAPRs, etc.

I certainly will buy you beer the next time I see you. Also, I owe you a steak (as in a Porterhouse)! I'll try to touch base with you in November about another speaking opportunity in April, if you're still interested. There's probably not much I can do, but please let me know if there's anything that you need.

Stay safe, my friend!!!!

Ryan

Ryan F. Relich, Ph.D., MLS(ASCP)^{CM}

Visiting Assistant Professor & Fellow
Division of Clinical Microbiology
Department of Pathology and Laboratory Medicine
Indiana University School of Medicine
Room 6027E, IUH Pathology Laboratory
350 W. 11th Street
Indianapolis, IN 46202

E: rrelich@iupui.edu
F: (317) 491-6649
P: (317) 491-6645

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Thursday, October 16, 2014 2:09 PM
To: Relich, Ryan Ford
Subject: Re: Question about disinfection

Currently in Monrovia for the rest of the month.

Here we do 10 minutes in bleach - back home we do 10 minutes in 5 percent microchem. Thus, 10 minutes is certainly sufficient. Tripple bagging is fine as well.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 1:27 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz, Ricki says all the flasks [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:41 AM
To: 'roger@verthermia.com'
Cc: [Personal Info]; 'jan@verthermia.com'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: conference call re hyperthermia treatment for Ebola virus

I am currently in Monrovia until early November.

Elaine will do the testing when she will get back from Europe. Hopefully we can get this done by mid- or end-November.

Heinz

From: Roger Vertrees [mailto:roger@verthermia.com]
Sent: Thursday, October 16, 2014 10:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Z Forwarding Account for JW <banker2000@hotmail.com>; Jan Winetz <jan@verthermia.com>
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Morning Dr. Feldman,

I am sure you are being overwhelmed with the Ebola situation but was wondering if you had a chance to run the below pilot in vitro study? If not when do you think you would be able to do so? Sorry, just anxious to know what you come up with.


Thanks
Roger and Jan

From: Roger Vertrees
Sent: Wednesday, September 24, 2014 7:17 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 1:22 PM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Rayfield, Mark (CDC/CGH/DGHP)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID




From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:00 PM
To: Self, Joshua S. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: De wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 1:12 PM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID



From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:34 AM Eastern Standard Time
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Safe travels.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 1:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Sent from my BlackBerry 10 smartphone.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:00 PM
To: Self, Joshua S. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: De wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Dear ALL,

I just found out that Viktor and Collins from Nairobi both stay until October 28. I am staying until October 31. Emmie and Darryl are arriving on Monday October 20 to stay for almost 4 weeks.

This means if the two colleagues from Atlanta will come on Monday, October 20 we will have 7 people here for almost 10 days. There is no work for 7 people - we hardly find work for 5 people. I would highly recommend that the CDC people postpone their trip by a full week.

Please respond immediately so that we can plan. It makes no sense to have 7 people here for more than a week.

Heinz

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:34 AM Eastern Standard Time
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Safe travels.

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 4:12 PM
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Feldmann, Heinrich (NIH/NIAID) [E]

From: Molly Sharlach <msharlach@the-scientist.com>
Sent: Thursday, October 16, 2014 12:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview request from The Scientist magazine

Dear Dr. Feldmann:

In light of the recent announcement about the start of clinical trials for NewLink's VSV Ebola vaccine, I'm writing an online news piece about fast-tracking clinical trials for Ebola vaccines and therapies. I found your opinion piece in BMC Biology very informative, and I'm interested in your thoughts on how the process is unfolding, both in terms of regulatory issues and potential plans for funding/distributing vaccines and therapies to affected areas.

Are you available for a ~15-minute phone interview early next week?

Here are some times when I'm available (all MDT):

Monday, Oct. 20, before 10 am or after 1 pm

Tuesday, Oct. 21, before 1 pm or after 4 pm

Thanks so much for your help.

--

Molly Sharlach, PhD

[*The Scientist*](#)

Phone: 203-858-2594

Skype: molly.thescientist

E-mail: msharlach@the-scientist.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; [Personal Info]
Subject: FW: Heinz's comment on evacuation to incorporate into the letter RE: DRAFT for Review: Request for Reconsideration: Travel for [Personal Info] to Liberia

Hi Heinz,
Quick update: Lisa intends to submit the petition Friday, and states below that if it is not successful, Dr. Barron is ready to escalate the matter further since Dr. Zoon is out of town.

Dawn

From: Coronado, Lisa (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:03 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Cc: Mahyera, Anna; Barron, Karyl (NIH/NIAID) [E]; Mills, Desta (NIH/NIAID) [E]
Subject: RE: Heinz's comment on evacuation to incorporate into the letter RE: DRAFT for Review: Request for Reconsideration: Travel for [Personal Info] to Liberia

You are most welcome, Dawn.

I have Dr. Barron on stand-by. She will escalate this matter to NIAID and NIH management, if the petitions to LM and Kelly are not successful.

Lisa

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 1:01 PM
To: Coronado, Lisa (NIH/NIAID) [E]
Cc: Mahyera, Anna; Barron, Karyl (NIH/NIAID) [E]; Mills, Desta (NIH/NIAID) [E]
Subject: RE: Heinz's comment on evacuation to incorporate into the letter RE: DRAFT for Review: Request for Reconsideration: Travel for [Personal Info] to Liberia

Thank you, Lisa. I will pass along the info about submitting the letter, I know Heinz and [Personal Info] (and others) are anxious to hear the outcome.

Many thanks to you, Anna, Karyl, and Desta for keeping this on track and supporting this critical effort.

Dawn

From: Coronado, Lisa (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:47 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Cc: Mahyera, Anna; Barron, Karyl (NIH/NIAID) [E]; Mills, Desta (NIH/NIAID) [E]
Subject: RE: Heinz's comment on evacuation to incorporate into the letter RE: DRAFT for Review: Request for Reconsideration: Travel for [Personal Info] to Liberia

Hi Dawn,

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Thursday, October 16, 2014 10:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Thanks for responding. It's rather impossible to get through to the national organizations in a meaningful way.

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 15, 2014 5:39 PM
To: Personal Info
Subject: Re: Ebola

I do not do patient care. You may want to contact MSF or WHO. I cannot answer your question.

From: Personal Info
Sent: Wednesday, October 15, 2014 03:09 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola

Hi Dr. Feldmann,

As a practicing intensivist in the Chicagoland area, it has been difficult to find statistics on the survival rate of Ebola patients who suffer a cardiopulmonary arrest. I am hoping you may know the answer or that you can find the answer to this question. I understand that, for the most part, West Africa does not have the resources to care for these patients that we have in the US.

As experts in Ebola are guiding our leaders, it seems prudent to assess this question. If the survival rate of a person who has Ebola & has suffered a cardiopulmonary arrest is ZERO, I would endorse not providing ACLS support. Undoubtedly, I sound cruel & heartless. I am not cruel & heartless. In an attempt to save one life in a CODE, a situation which is often hectic and in which things are done very fast, many others are likely to be exposed. From a benefit / risk analysis, this is a question that must be asked and answered.

These are "no ordinary" times. The American healthcare workers are looking for guidance. The guidance comes top down. Our non-medical leaders are looking for expertise from those who have insight into the disease. It is imperative that we safeguard the nation immediately. I am hoping that I can gain insight into whether or not Ebola victims benefit from ACLS support.

Thanks for your consideration,

Personal Info

This message and any included attachments are intended only for the addressee. The information contained in this message is confidential and may constitute proprietary or non-public information under international, federal, or state laws. Unauthorized forwarding, printing, copying, distribution, or use of such information is strictly prohibited and may be unlawful. If you are not the addressee, please promptly delete this message and notify the sender of the delivery error by e-mail.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:39 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Thanks, Heinz. I really appreciate you taking the time under these very challenging circumstances.

How about this plan:

I offer Biogen the draft amendment to express our tentative interest in receiving the drug, but provide it with the caveats you mention. This puts it in Biogen's court but preserves our option to push it if that's what we want.

If we need more time to finalize a decision about these additional studies, there's always the option to do a separate but identical agreement down the road.

Mike

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:53 AM
To: Mowatt, Michael (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Disclosure of ebola-infected NHP data

Mike,

Sorry for the delay in the response. Personally I think the [Redacted by agreement]

[Redacted by agreement] If certain people planning to go into humans anyway independent of outcome of NHP studies - why doing NHP studies?

Putting my personal thoughts aside, the studies could most likely not run before January or February. Darryl will be in Monrovia until mid-November and is leaving RML by the end of November. The most logical person to take over would be Andrea Marzi but she will be in Monrovia for all November and January.

If Kathy and Darryl think we should do the study we will work it in somehow, but the pathogenesis and vaccine studies using the new West African virus should have have priority at the moment.

Finally, we are losing 60 percent of the animal BSL4 capacity for the period of mid-December to at least mid-January due to re-certification.

I know this is no answer - I wait until Darryl and Kathy weigh in.

Heinz

----- Original Message -----

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:00 AM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jim Strong <Jim.Strong@phac-aspc.gc.ca>
Sent: Thursday, October 16, 2014 10:21 AM
To: Shane Jones
Cc: Charlene Ranadheera; Bradley Cook; Anders Leung; Darwyn Kobasa; Cory Nakamura; Mable Hagan; Geoff Soule; Gary Wong; Kevin Tierney; Xiangguo Qiu; Steven Theriault; Jason Gren; Kaylie N Tran; Alexander Bello; Jingxin Cao; Hugues Fausther Bovendo; Julie Kubay; Kimberly Azaransky; Stephanie Kucas; Christine De Graff; Guillaume Poliquin; Greg Hansen; Sharon Hadder; cpress; Jim Kenny; saminian; Ray Saurette; btmitchell2; Mark Allan; mkesselman; Brendon Mitchell; Todd Mortimer; Justin Tolsma; Steven Guercio; Kobinger, Gary (Public Health Agency of Canada); Mike Drebot; George Risi; Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Ebihara, Hideki (NIH/NIAID) [E]; Sprecher, Armand (Médécins Sans Frontières Operational Center of Brussels); Kurtis Swekla; Julie Kubay
Subject: Re: NHP ICU Oct 27-Nov 12

Sorry, let me clarify: the Oct 27 to Nov 12 NHP-ICU is cancelled. Sorry for the confusion. Jim
Dr. J. Strong
Head, Diagnostics and Therapeutics
Special Pathogens
National Microbiology Laboratory
204-789-7032

▼ Jim Strong---2014-10-15 06:16 PM EDT---Hi all, Once again I regret to inform you that the NHP-ICU experiment scheduled for Nov 12 has to b

From: Jim Strong
To: Shane Jones
Cc: Charlene Ranadheera; Bradley Cook; Anders Leung; Darwyn Kobasa; "Cory Nakamura" <Cory.Nakamura@inspection.gc.ca>; Mable Hagan; Geoff Soule; Gary Wong; Kevin Tierney; "Xiangguo Qiu" <Xiangguo_Qiu@phac-aspc.gc.ca>; Steven Theriault; Jason Gren; Kaylie N Tran; Alexander Bello; Jingxin Cao; Hugues Fausther Bovendo; Julie Kubay; Kimberly Azaransky; Stephanie Kucas; Christine De Graff; Guillaume Poliquin; "Greg Hansen" <ghansen4@exchange.hsc.mb.ca>; "Sharon Hadder" <Shadder@exchange.hsc.mb.ca>; "cpress" <cpress@hsc.mb.ca>; "Jim Kenny" <jkenny@exchange.hsc.mb.ca>; "saminian" <saminian@HSC.MB.CA>; "Ray Saurette" <ray123@mts.net>; "btmitchell2" <btmitchell2@hsc.mb.ca>; "Mark Allan" <mark_allan@live.ca>; "mkesselman" <mkesselman@hsc.mb.ca>; "Brendon Mitchell" <btmitchell2@exchange.hsc.mb.ca>; "Todd Mortimer" <TMortimer@exchange.hsc.mb.ca>; "Justin Tolsma" <jtolsma@hushmail.me>; Steven Guercio; Gary Kobinger; Mike Drebot; "George Risi" <GRisi@saintpatrick.org>; grisi@mail.nih.gov; "Heinz Feldmann" <feldmannh@niaid.nih.gov>; "Dave Safronetz" <safronetz@niaid.nih.gov>; "Hideki Ebihara" <ebiharah@niaid.nih.gov>; "Armand Sprecher" <armand.sprecher@brussels.msf.org>; "Kurtis Swekla" <Kurtis.Swekla@inspection.gc.ca>; Julie Kubay
Date: 2014-10-15 06:16 PM EDT
Subject: Re: NHP ICU Oct 27-Nov 8

Hi all,
Once again I regret to inform you that the NHP-ICU experiment scheduled for Nov 12 has to be cancelled. The ebola outbreak in west Africa, the diagnostic case load, our training requirements and our subsisted CL4 staff are the reasons. We plan to carry forward our plans for the February 10, 2015 experiment unless things do not abate (or get worse).

I am sorry for any disruption this may have caused.

Please contact me via email if you have questions or concerns.(I am currently in Sierra Leone).

Thanks for understanding, Jim
Dr. J. Strong
Head, Diagnostics and Therapeutics
Special Pathogens
National Microbiology Laboratory

Feldmann, Heinrich (NIH/NIAID) [E]

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz, I set up the samples for 0, 2, 4, and 6 hours at 44 degrees last week. Ricki infected cells last Tuesday.

Ricki, is there any sign of CPE in the flasks yet?

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:41 AM
To: 'roger@verthermia.com'
Cc: [Personal Info]; 'jan@verthermia.com'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: conference call re hyperthermia treatment for Ebola virus

I am currently in Monrovia until early November.

Elaine will do the testing when she will get back from Europe. Hopefully we can get this done by mid- or end-November.

Heinz

From: Roger Vertrees [mailto:roger@verthermia.com]
Sent: Thursday, October 16, 2014 10:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Z Forwarding Account for JW [Personal Info]; Jan Winetz <jan@verthermia.com>
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Morning Dr. Feldman,

I am sure you are being overwhelmed with the Ebola situation but was wondering if you had a chance to run the below pilot in vitro study? If not when do you think you would be able to do so? Sorry, just anxious to know what you come up with.

Thanks
Roger and Jan

From: Roger Vertrees

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fritzen, Florentine <f.fritzen@faz.de>
Sent: Thursday, October 16, 2014 9:54 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: F.A.S.-Anfrage Ebola

Sehr geehrter Herr Feldmann,

für die nächste Ausgabe der Frankfurter Allgemeinen Sonntagszeitung, also für diesen Sonntag, planen wir einen größeren Artikel über Ebola. Und zwar unter der Fragestellung, ob der Kampf gegen die Ausbreitung zu gewinnen ist. Der UN-Ebola-Beauftragte Anthony Banbury hat am Dienstag vor dem Sicherheitsrat gesagt: „Wir sind dabei, das Rennen zu verlieren.“ Als denjenigen, der den VSV-Impfstoff in Marburg entwickelt und in Kanada weiterentwickelt hat, würde ich Sie gern fragen, wie Sie das sehen, und zwar mit Blick auf die rechtzeitige Entwicklung eines Impfstoffs: Ist es aus Ihrer Sicht zu schaffen, das Rennen zu gewinnen? Und: Was ist jetzt das Wichtigste? Über eine kurze Antwort bis zum morgigen Freitag würde ich mich sehr freuen.

Mit herzlichen Grüßen aus Frankfurt
Florentine Fritzen

Dr. Florentine Fritzen
Politikredakteurin
Frankfurter Allgemeine Sonntagszeitung

Hellerhofstraße 2-4
60327 Frankfurt am Main

Tel. (069) 7591-2412
www.faz.net

Frankfurter Allgemeine Zeitung GmbH
Hellerhofstraße 2-4 · 60327 Frankfurt am Main
HRB 7344 · Amtsgericht Frankfurt am Main
Vorsitzender des Aufsichtsrats: Karl Dietrich Seikel
Geschäftsführung: Thomas Lindner (Vorsitzender), Burkhard Petzold

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dr. Personal Info
Sent: Thursday, October 16, 2014 9:24 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: scientist position
Attachments: DDAS.pdf

Heinz Feldmann, M.D., Ph.D.
Chief, Laboratory of Virology
Chief, Disease Modeling and Transmission Section
Rocky Mountain Laboratories
Building 28, Room 2A100A
903 South 4th Street
Hamilton, MT 59840-2932
Phone: 406-375-7410
feldmannh@niaid.nih.gov

Dear Dr. Feldmann. Hope you will find this mail in good spirit. You may remember me during our association in Ebola project with Dr. Suresh in U Alberta, Canada. I was in UA (2000-2009) doing my post doctoral research in Faculty of Pharmacy and Pharmaceutical Sciences. Due to family reason I returned to India and working for a leading Vaccine development and Manufacturing Company (subsidiary of National Dairy Development Board) in Hyderabad.

Now I intend to return to USA/Canada and exploring for any scientific job opportunity. Please find my CV for any possible scientist position in your laboratory. Presently I am working as a Gr leader and working in different aspects Bioanalytical and analytical method development and validation for HepA, CHIKV, JEV and other glyconcojugate vaccines. My industrial working experiences would add to your institutes growth. Please find my detail resume for review and will let me know if you need any more informations.

Look forward to hear from you. Please extend your help.

Best regards,

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sakai, Richard
Sent: Thursday, October 16, 2014 8:52 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Shott, Joseph (NIH/NIAID) [E]
Subject: FW: WHO to test Ebola preparedness in Ivory Coast and Mali (Reuters)

FYI

Just saw this on the embassy's Public Affairs daily news coverage.

Dick

From: StateOpsSubscriptions
Sent: Thursday, October 16, 2014 2:20 PM
Subject: WHO to test Ebola preparedness in Ivory Coast and Mali (Reuters)

News Tickers
October 16, 2014 1020 EDT

WHO to test Ebola preparedness in Ivory Coast and Mali (Reuters)

GENEVA (Reuters) - The World Health Organization will send teams of experts to test the Ebola-preparedness measures at Ivory Coast and Mali's borders with countries affected by the epidemic, WHO's health security response chief Isabelle Nuttall said on Thursday.

A team of around 10 will leave for Mali on Sunday and another team will leave for Ivory Coast within days, she said, adding that Ivory Coast had checkpoints to monitor people coming across the border and had already done a simulation exercise to test its response.

You have received this email based on your [State Department Operations Center](#) subscriptions. Click [here](#) to customize your subscriptions.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Roger Vertrees <roger@verthermia.com>
Sent: Thursday, October 16, 2014 8:25 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Z Forwarding Account for JW; Jan Winetz
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Morning Dr. Feldman,

I am sure you are being overwhelmed with the Ebola situation but was wondering if you had a chance to run the below pilot in vitro study? If not when do you think you would be able to do so? Sorry, just anxious to know what you come up with.

Thanks
Roger and Jan

From: Roger Vertrees
Sent: Wednesday, September 24, 2014 7:17 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Z Forwarding Account for JW; Jan Winetz
Subject: Re: conference call re hyperthermia treatment for ebola virus

It was our pleasure. Tlx

Sent from my iPhone

On Sep 24, 2014, at 6:18 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Dr. Jim Strong (Jim.Strong@phac-aspc.gc.ca)

I will try to arrange for the pilot in vitro study.

Best wishes,
Heinz

From: Roger Vertrees [<mailto:roger@verthermia.com>]
Sent: Wednesday, September 24, 2014 1:20 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Z Forwarding Account for JW
Cc: Jan Winetz
Subject: Re: conference call re hyperthermia treatment for ebola virus

Dr. Feldman, thanks for the call today it helped us immensely in the understanding of the problem. I would like Dr. Strong's contact information as we would like to pursue this at least through the original heat-dose benching testing phase.

Minimally, we would like the sample to be Redacted by agreement

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:01 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data
Attachments: Amendment Number One to Biogen-NIAID MTA DRAFT 141016.docx

Heinz and Darryl,

I'm sure you are swamped, but I need to close the loop with Biogen today about NIAID's interest in obtaining **Redacted b**
Redacted by agreement

I've prepared a draft amendment in which I've added a second research plan (Exhibit B), in which I've substituted
Redacted by agreement

Please let me know asap:

1. Do you want to obtain the **Redacted by agreement**
2. If so, is Exhibit B an accurate description of the work you intend?

Thanks,

Mike
DIRECT **Personal Info**

-----Original Message-----

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 11:58 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Thanks, Kathy.

I'll begin preparing an amendment to the MTA to address data sharing with third parties, but I will await word from Darryl and Heinz regarding our request for **Redacted by agreem**.

-----Original Message-----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:39 AM
To: Mowatt, Michael (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I agree with Darren. I am at WHO in Geneva, so I am not sure we will be able to touch base. I can try. I think we need to see if Darryl and Heinz are willing to try the **Redacted by agreement**
Kathy

Feldmann, Heinrich (NIH/NIAID) [E]

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 7:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola
Attachments: image001.png

She spoke this morning, so I can find her, or be found, fairly easily.

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:57 AM
To: 'm.koopmans@erasmusmc.nl'
Cc: 'j.vankampen@erasmusmc.nl'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: Ebola

I cannot do much from here. Will be back early November. Please talk to Elaine Haddock. Elaine will present the data at the meeting.

Heinz

From: Archief Marion [mailto:m.koopmans@erasmusmc.nl]
Sent: Thursday, October 16, 2014 05:42 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: J.J.A. van Kampen <j.vankampen@erasmusmc.nl>
Subject: Ebola

Dear Heinz,

Had - against odds - hoped to run into you in Berlin. I saw the validation of inactivation protocols for Ebola. We have a group of IC specialists that have listed what they consider essential info, and want to validate the available or potential inactivation protocols for compatibility with other lab parameters for high care patients. Would it be possible to get the specifics of your protocols so we can reverse validate them for the other parameters (we were planning this with a p4 lab in Europe, but no need to repeat things).

I understand you are in Monrovia, but if you can link me to someone, I'll follow-up.

Kind regards,

Marion

Feldmann, Heinrich (NIH/NIAID) [E]

From: ijevr@sciforschen.org
Sent: Thursday, October 16, 2014 7:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Reg: Nominations for Editorial Board Members of Ebola Virus Research Journal

**Dear Dr. Heinz Feldmann,
Greetings!**

Hope this mail finds you good and [Sciforschen](#) wishes the best on your current research projects. We are honored to invite you to join us as an editorial board member of the journal "[International Journal of Ebola Virus and Research](#)", a new initiative with an objective to present cutting edge research in the field of **Virology**.

We aware of your efforts and reputation, therefore, we have taken advantage to contact you for this prestigious position, where you can provide us specific aims and objectives to improve the quality of the journal.

Let us know your willingness, you are requested to provide the following if you are interested.

1. Complete CV (Including all publications)
2. Biography
3. Photograph (most recent)
4. Research Interests

Looking forward to hear from you soon

With Regards
John Dixon
Managing Editor
International Journal of Ebola Virus and Research
Sciforschen
853 Erie Circle,
Milpitas, CA 95035, USA

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 7:13 AM
To: Elkins, Randy (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Fauci, Anthony (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

Thank you Randy. I appreciate your willingness to address this without compromising the studies and meeting our animal care requirements. Three weeks seems reasonable.

Kathy

From: Elkins, Randy (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 9:08 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: Re: Ebola Animal Work

Good morning all,

Don and I are willing to truncate the 30 day period to facilitate research. The NIH NHP Quarantine Policy is 60 days primarily due to tuberculin skin testing frequency and other conditions exacerbated by stress. This is conducted at the NIH Animal Center where NHP acquired from multiple sources will then be distributed to the ICs. The NIAID RML has more flexibility due to our Morgan Island Indian origin rhesus colony of known health status. Therefore, the RML 30 NHP quarantine is more of a needed conditioning period due to the long truck transportation time. Dr. Marisa St. Claire plans to bring NHP directly into her ABSL4 and acclimatize them over 3 weeks to this environment while allowing pre study activities such as physical examinations and blood work.

Sent from my iPhone

On Oct 16, 2014, at 4:55 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Not really needed - perhaps under certain circumstances. Increased holding space would be key.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 05:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

We are working on modifying ARMCO 1 for more holding space. If we could hold more animals, that reduces the delay in conducting experiments. The 30 days for quarantine of the animals is to ensure they have adapted and there are no health issues. We can check with Don and Randy if this time frame can be reduced.

Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 5:35 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: Re: Ebola Animal Work

Feldmann, Heinrich (NIH/NIAID) [E]

From: Elkins, Randy (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 7:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: Re: Ebola Animal Work

Good morning all,

Don and I are willing to truncate the 30 day period to facilitate research. The NIH NHP Quarantine Policy is 60 days primarily due to tuberculin skin testing frequency and other conditions exacerbated by stress. This is conducted at the NIH Animal Center where NHP acquired from multiple sources will then be distributed to the ICs. The NIAID RML has more flexibility due to our Morgan Island Indian origin rhesus colony of known health status. Therefore, the RML 30 NHP quarantine is more of a needed conditioning period due to the long truck transportation time. Dr. Marisa St. Claire plans to bring NHP directly into her ABSL4 and acclimatize them over 3 weeks to this environment while allowing pre study activities such as physical examinations and blood work.

Sent from my iPhone

On Oct 16, 2014, at 4:55 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Not really needed - perhaps under certain circumstances. Increased holding space would be key.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 05:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

We are working on modifying ARMCO 1 for more holding space. If we could hold more animals, that reduces the delay in conducting experiments. The 30 days for quarantine of the animals is to ensure they have adapted and there are no health issues. We can check with Don and Randy if this time frame can be reduced.

Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 5:35 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: Re: Ebola Animal Work

I agree with Kathy - no real problems with RML. Having said that things with NHPs could run better if we could have more holding space at RML. Shipping of animals from the East Coast is time-consuming and expensive. We then have a quarantine period of at least 30 days. This occasionally delays animal studies by 1-2 months, in particular at outbreak times.

Thanks,
Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sakai, Richard
Sent: Thursday, October 16, 2014 7:08 AM
To: Shott, Joseph (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

Joe,

The RM: had asked Ousmane for a complete inventory of the diagnostic reagents on hand and he promised to do so but to date I have not seen an inventory update. We need to follow up with Ousmane on this issue.

Dick

-----Original Message-----

From: Shott, Joseph (NIH/NIAID) [E] [mailto:shottj@mail.nih.gov]
Sent: Thursday, October 16, 2014 11:22 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Richard Sakai; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Subject: Update on Ebola activities in Mali

Good morning,

I just met with Ousmane Koita and wanted to provide you with a brief update on the Ebola diagnostic activities in the BSL3 lab at USTTB.

1. 26 potential cases have been screened in the BSL3 and all were negative for EBOV.
2. Consumption of traditional medicine causing GI toxicity and fever has been identified as the likely causes in most of these 26.
3. The MOH and the WHO AFRO Regional Director visited the lab on Monday this week for a tour.
4. They wish to see continued engagement between all parties for screening potential positives, and have offered \$ to assist. (We should talk to Ousmane further).
5. MOH and WHO AFRO hope we (NIAID/USTTB) can provide a wider array of diagnostics for other HFV etc., but I have advised Ousmane to hold off on responding until further instruction.
6. SEREFO staff have been training regional units of the MOH on phlebotomy and PPE (We should talk to Ousmane further about this).
7. I have asked the lab to do a thorough inventory today of reagents, consumables and PPE since they are not busy.
8. We have an estimate for repairing the broken pass-through autoclave which Ousmane is going to ask all programs to contribute to. \$10K total.
(Need to discuss sharing the purchase of a new autoclave possibly). The back-up benchtop autoclave is being used while the primary unit is inoperable.
9. Ousmane is asking if NIAID plans to respond to the letter from the Minister, sent to NIAID through the Embassy.

Please let me know if you have any questions.

Thank you,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Aamna Mohdin Personal Info
Sent: Thursday, October 16, 2014 6:01 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview for Scidev.net

Dear Heinz Feldmann,

I'm writing a feature for Scidev.net on promising Ebola research we've covered over the past 12 years. [In 2007, we covered a study](#) you were involved with, on the development of a rapid, cheap and reliable field test to detect two strains of the Ebola virus.

I've been reading your papers, and am interested in interviewing you for your opinion on the development of that study, you work and what it means for Ebola research today. I'm also interested in talking about the media's recent hype of Ebola becoming a health crisis within Europe and America.

Would you be available for a quick phone interview or Skype? If it's easier, I'm happy to send over my questions and conduct the interview via email.

Kind regards,

Aamna Mohdin

<http://www.scidev.net/global/author.aamna-mohdin.html>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 5:49 AM
To: Shott, Joseph (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Cc: Schmidt, Beth (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

I would like to have a conference call on this, maybe next week if possible

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 7:21 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Subject: Update on Ebola activities in Mali

Good morning,

I just met with Ousmane Koita and wanted to provide you with a brief update on the Ebola diagnostic activities in the BSL3 lab at USTTB.

1. 26 potential cases have been screened in the BSL3 and all were negative for EBOV.
2. Consumption of traditional medicine causing GI toxicity and fever has been identified as the likely causes in most of these 26.
3. The MOH and the WHO AFRO Regional Director visited the lab on Monday this week for a tour.
4. They wish to see continued engagement between all parties for screening potential positives, and have offered \$ to assist. (We should talk to Ousmane further).
5. MOH and WHO AFRO hope we (NIAID/USTTB) can provide a wider array of diagnostics for other HFV etc., but I have advised Ousmane to hold off on responding until further instruction.
6. SEREFO staff have been training regional units of the MOH on phlebotomy and PPE (We should talk to Ousmane further about this).
7. I have asked the lab to do a thorough inventory today of reagents, consumables and PPE since they are not busy.
8. We have an estimate for repairing the broken pass-through autoclave which Ousmane is going to ask all programs to contribute to. \$10K total. (Need to discuss sharing the purchase of a new autoclave possibly). The back-up benchtop autoclave is being used while the primary unit is inoperable.
9. Ousmane is asking if NIAID plans to respond to the letter from the Minister, sent to NIAID through the Embassy.

Please let me know if you have any questions.

Thank you,

Joe

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

We are working on modifying ARMCO 1 for more holding space. If we could hold more animals, that reduces the delay in conducting experiments. The 30 days for quarantine of the animals is to ensure they have adapted and there are no health issues. We can check with Don and Randy if this time frame can be reduced.

Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 5:35 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: Re: Ebola Animal Work

I agree with Kathy - no real problems with RML. Having said that things with NHPs could run better if we could have more holding space at RML. Shipping of animals from the East Coast is time-consuming and expensive. We then have a quarantine period of at least 30 days. This occasionally delays animal studies by 1-2 months, in particular at outbreak times.

Thanks,
Heinz

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 02:52 AM Eastern Standard Time
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

For RML, there are no issues I am aware of. Of course there are more things to test than we have capacity to do so we have to prioritize. Our ACUC is working well as is our IBC. No problem with supply of Rhesus. I would be happy to look into further if there is something specific. I suspect this relates to IRF Fred.

Kathy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 11:06 PM
To: Trevor Mundel
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

Trevor:
I am not aware of this problem, but I will check further.
Tony

From: Trevor Mundel [mailto:Trevor.Mundel@gatesfoundation.org]
Sent: Wednesday, October 15, 2014 8:47 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Archief Marion <m.koopmans@erasmusmc.nl>
Sent: Thursday, October 16, 2014 3:42 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: J.J.A. van Kampen
Subject: Ebola

Dear Heinz,

Had - against odds - hoped to run into you in Berlin. I saw the validation of inactivation protocols for Ebola. We have a group of IC specialists that have listed what they consider essential info, and want to validate the available or potential inactivation protocols for compatibility with other lab parameters for high care patients. Would it be possible to get the specifics of your protocols so we can reverse validate them for the other parameters (we were planning this with a p4 lab in Europe, but no need to repeat things).

I understand you are in Monrovia, but if you can link me to someone, I'll follow-up.

Kind regards,

Marion

Professor Marion Koopmans, DVM PhD
Head of Department
Viroscience



P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
Visiting address: office Ee-1726, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
Email m.koopmans@erasmusmc.nl | Telephone +31 031 10 70 44 | Fax +31 031 10 70 44
www.erasmusmc.nl | www.erasmusmc.nl/www.viroscience.com

Presence: Mo - Thu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Natasha Leeson <n.leeson@futuremedicine.com>
Sent: Thursday, October 16, 2014 3:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Interest in your work

Dear Dr Feldmann,

I hope this email finds you well. I appreciate that this is a very busy time for you, but I am just writing to ask if you got my email and if so whether you have had chance to consider my invitation?

I would be delighted if you would be interested in writing for ***Future Microbiology***.

If you have any questions at all then please do not hesitate to ask.

I'd appreciate it if you could let me know of your interested, either way.

Best wishes,

Natasha

From: Natasha Leeson
Sent: 08 October 2014 17:06
To: 'feldmannh@niaid.nih.gov'
Subject: Interest in your work

Dear Dr Feldmann,

I hope this email finds you well. I would like to introduce myself as the Commissioning Editor of the journal *Future Microbiology* published by *Future Medicine* (<http://www.futuremedicine.com/loi/fmb>).

Future Microbiology publishes reviews, comment and original research in bacteriology, virology, mycology and parasitology. The journal is indexed by Medline, EMBASE, Chemical Abstracts and Journal Citation Reports/Science Edition®, amongst others, and has an **Impact Factor of 3.819 (2013)**. You can find out more about the journal, including the Aims and Scope and list of Editorial Board members, on our [webpage](#).

Having read of your recent work and considering that you are an expert in the field, I would like to invite you to contribute an **Editorial** on the topic '**Ebola virus vaccines: are we close approval?**' for an upcoming issue of the journal. As commissioning has only just begun, there is plenty of flexibility regarding the title of the Editorial. I am happy for you to work with any co-authors you feel necessary.

Editorial articles provide authors with the opportunity to express their opinions, present criticism or address controversy; the intention is very much that authors offer a personal perspective.

The article should be **1500 words maximum** and would be provisionally scheduled for publication in the **April** issue of *Future Microbiology*, presenting a provisional copy deadline of **Monday 5th January 2015**; however, I am more than happy to extend the deadline should you be interested in writing for the journal.

Feldmann, Heinrich (NIH/NIAID) [E]

Personal Info

From: Europäischen Netzwerkes zur Diagnostik von "importierten" Virusinfektionen [mailto:ENIVD-L@LISTSERV.DFN.DE]
On Behalf Of Anna Papa
Sent: 15 October 2014 16:46
To: ENIVD-L@LISTSERV.DFN.DE
Subject: co-ordination of ENIVD

Dear colleagues,

I am writing to you in the name of the steering committee of ENIVD and as a member of the ENIVD network:

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 1:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: ASPA_0682: ASPR press release "HHS accelerates development of third Ebola vaccine"

Thank you

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 1:02 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Miller, Katherine (NIH/NIAID) [E]
Subject: Re: ASPA_0682: ASPR press release "HHS accelerates development of third Ebola vaccine"

This the Profectus VSV vaccine platform which still has the VSV G in a mutated form. We have done one preliminary pilot study in guinea pigs and one in NHPs (two animals only). Profectus is no working with UTMB Galveston - we do not have a role others than providing input in some of the scientific discussions. LV still works with serivatives of the Winnipeg VSV v accine (delta VSV G).

Overall, not our vaccine.

Heinz

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 10:23 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Miller, Katherine (NIH/NIAID) [E]
Subject: FW: ASPA_0682: ASPR press release "HHS accelerates development of third Ebola vaccine"

Heinz, is this the platform that LV developed / studies here ... if so please confirm asap, and if you can review the release let me know of edits / suggestions.

Under a one-year contract with Profectus BioSciences, Inc. of Tarrytown, New York, the ASPR's Biomedical Advanced Research and Development Authority (BARDA) will provide approximately \$5.8 million funding, subject matter expertise and technical assistance to further develop an experimental Ebola vaccine. [Redacted] by agreement manufacture vaccine for use in animal studies and Phase 1 clinical studies, and conduct animal studies to test safety and efficacy.

Thanks.

From: OS HHSPress (HHS/ASPA) [<mailto:HHSPress@hhs.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM
To: OS - ASPA - Clearance; DPAID (CDC) (dpaid@cdc.gov); Hoskins, Sharon (K.D.) (CDC/OD/OADC); NIH News Clearance (NIH/OD); OC OPA-PRESS (OCOPA-PRESS@OC.FDA.GOV)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 12:53 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

For RML, there are no issues I am aware of. Of course there are more things to test than we have capacity to do so we have to prioritize. Our ACUC is working well as is our IBC. No problem with supply of Rhesus. I would be happy to look into further if there is something specific. I suspect this relates to IRF Fred.
Kathy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 11:06 PM
To: Trevor Mundel
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

Trevor:
I am not aware of this problem, but I will check further.
Tony

From: Trevor Mundel [mailto:Trevor.Mundel@gatesfoundation.org]
Sent: Wednesday, October 15, 2014 8:47 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Ebola Animal Work

Hi Tony,

I heard some rumblings from the NIAID / BSL4 unit around some delays they were experiencing in initiating animal studies. Mostly the usual areas of legal, animal committees convening and transfers from other agencies. Do you have any sense whether there is any substance to this? The South Africans had offered to establish some Ebola animal capabilities in their BSL4 if there was a real constraint on this resource, but this would take a while to set up and would be costly.

Trevor

Trevor Mundel, MD, PhD
President, Global Health Program
V +1.206.709.3253
F +1.206.494.7041
E trevor.mundel@gatesfoundation.org

Amissa Cormier
Senior Program Assistant
V +1.206.709.3294
E amissa.cormier@gatesfoundation.org

Bill & Melinda Gates Foundation
www.gatesfoundation.org

 [Facebook](#)
 [Twitter](#)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Malik <malik@hku.hk>
Sent: Wednesday, October 15, 2014 7:47 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola antibody

Dear Heinz

Redacted by agreement

Redacted by agreement

Would you be able to provide us with a bit of ebolavirus antibody, either from immunized animals or other sources to allow us to optimize our assays?

Best wishes

Malik Peiris
The University of Hong Kong

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Wednesday, October 15, 2014 6:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ksiazek, Thomas (Galveston National Laboratory-UT); Uyeki, Timothy M. (CDC/OID/NCIRD); Robinson, Robin (HHS/ASPR/BARDA)
Cc: Kratochvil, Christopher J; Smith, Philip W; De Alba, Armando
Subject: Proposed Ebola MCM

Gentlemen: Thoughts?
Ali

From: Diane Berry [mailto:DBerry@Sarepta.com]
Sent: Wednesday, October 15, 2014 7:26 PM
To: Khan, Ali S
Subject: Ebola MCM

Hi Ali,

I am glad you are still on the front lines, even more so now at Nebraska! I'll get right to the point since your time is precious these days. Would you or your colleagues like an update about our Ebola drug candidate? I just worry that I haven't seen that there has been any systematic, objective way that information on available countermeasures has been disseminated and treatment centers may not have the full set of information on safety and efficacy for all those that may be available. You may recall it was developed with DOD funding until funding cuts halted development. But we have a robust set of data, having completed a Phase 1 clinical study and several NHP efficacy studies. So we have human safety data and efficacy in the NHP model. The technology is also based on a platform chemistry that we have also applied to our clinical stage Marburg and influenza drugs. Redacted by agreement

Redacted by agreement Some folks tend to lump them together but they are very different. We took some GMP drug substance we had remaining that still passed spec and filled it last week so it is now in vials. Limited supply but up to 24 treatment courses, depending on weight of course. We could make more from precursor material we have but that will take time and money. Again, not wanting to inundate you during this critical time, but want to be sure that people on the front lines are armed with complete info!

Just give a shout if you think it would be worthwhile to learn more of the scientific details to inform your risk:benefit decision-making.

Thanks for everything you are doing to assist in this outbreak. I wish there more of you.

My best,
Diane

Diane L. Berry, Ph.D.
VP, Global Health Policy & Government Affairs
p 617.274.4006 c 425.905.8377 f 617.945.1678
email dberry@sarepta.com



215 First Street, Cambridge, MA 02142

Personal Info

(Please answer the following 4 questions, take as much space as you need for your statement and return the answer to: enivd@rki.de)

1. **Name, institution, affiliation, country**

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]@jhu.edu>
Sent: Wednesday, October 15, 2014 5:11 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Questions from a Johns Hopkins Student

I understand. Would you be willing to answer a few questions over email? I would just like to know:

- 1) Can you confirm that this outbreak is Ebola Zaire?
- 2) In your 2011 article you say, "we urgently need strategies, financial support, and political will to bring these developments to the populations of endemic areas in equatorial." Do you think the US is doing its job in that regard, and if not, what kind of efforts are needed beyond this point to quell the outbreak?
- 3) Dr. Peter Jarhling said in an interview that his findings from Liberian patients show a higher concentration of the virus in the blood than ever seen before. Is this consistent with your findings? Do you think this is why the virus seems to be more contagious?

Thank you so much. I appreciate the work you are doing and will keep you in my thoughts.

[Personal Info]

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: Wednesday, October 15, 2014 6:39 PM
To: [Personal Info]
Subject: Re: Questions from a Johns Hopkins Student

Sorry but I am not. I am currently in Monrovia until November 2.

From: [Personal Info]@jhu.edu]
Sent: Wednesday, October 15, 2014 03:35 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Questions from a Johns Hopkins Student

Hi, Dr. Feldmann. I am a student at Johns Hopkins University, writing an essay on the current Ebola outbreak, and I was wondering if I could ask you a few questions about the virus and how we are handling it. I am currently reading through your 2011 study in the Lancet.

Are you available for a call sometime this week/weekend?

Thank you very much,

[Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Matteo Porotto <map2028@med.cornell.edu>
Sent: Wednesday, October 15, 2014 5:05 PM
To: Hoenen, Thomas (NIH/NIAID) [F]; Anne Moscona
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: [Redacted by agreement]

Hi Thomas,
I'll be happy to talk on Friday.
What time would work for you?
Best,
Matteo

From: Hoenen, Thomas (NIH/NIAID) [F] [thomas.hoenen@nih.gov]
Sent: Wednesday, October 15, 2014 6:53 PM
To: Matteo Porotto; Anne Moscona
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: [Redacted by agreement]

Dear Matteo,

[Redacted by agreement] We are very happy to share the system - can I call you on Friday to discuss the details, and when would be a good time to do so?

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:38 PM
To: 'map2028@med.cornell.edu'; Hoenen, Thomas (NIH/NIAID) [F]
Cc: 'anm2047@med.cornell.edu'
Subject: Re: [Redacted by agreement]

Please communicate with Thomas Hoenen on this. I am currently in Monrovia for the rest of the month.

Best wishes, Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 4:54 PM
To: 'map2028@med.cornell.edu'; 'anm2047@med.cornell.edu'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Redacted by agreement

Dear Matteo,

Redacted by agreement

Redacted by agreement

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:38 PM
To: 'map2028@med.cornell.edu'; Hoenen, Thomas (NIH/NIAID) [F]
Cc: 'anm2047@med.cornell.edu'
Subject: Re: Redacted by agreement

Please communicate with Thomas Hoenen on this. I am currently in Monrovia for the rest of the month.

Best wishes, Heinz

----- Original Message -----

From: Matteo Porotto [mailto:map2028@med.cornell.edu]
Sent: Wednesday, October 15, 2014 02:31 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Anne Moscona <anm2047@med.cornell.edu>
Subject: Redacted by agreement

Dear Heinz,


Redacted by agreement

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Brooks, John T. (CDC/OID/NCHHSTP)
Sent: Wednesday, October 15, 2014 4:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Damon, Inger K. (CDC/OID/NCEZID); Redd, Stephen (CDC/OID/OD)
Cc: George Risi
Subject: RE: Montana

Records Originating Outside of NIAID



-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 1:10 PM
To: Damon, Inger K. (CDC/OID/NCEZID); Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD)
Cc: George Risi
Subject: Re: Montana

Redacted by agreement

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:52 PM Eastern Standard Time
To: Damon, Inger K. (CDC/OID/NCEZID); Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD)
Cc: George Risi
Subject: Re: Montana

Inger,

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jim Strong <Jim.Strong@phac-aspc.gc.ca>
Sent: Wednesday, October 15, 2014 4:16 PM
To: Shane Jones
Cc: Charlene Ranadheera; Bradley Cook; Anders Leung; Darwyn Kobasa; Cory Nakamura; Mable Hagan; Geoff Soule; Gary Wong; Kevin Tierney; Xiangguo Qiu; Steven Theriault; Jason Gren; Kaylie N Tran; Alexander Bello; Jingxin Cao; Hugues Fausther Bovendo; Julie Kubay; Kimberly Azaransky; Stephanie Kucas; Christine De Graff; Guillaume Poliquin; Greg Hansen; Sharon Hadder; cpress; Jim Kenny; saminian; Ray Saurette; bmtchell2; Mark Allan; mkesselman; Brendon Mitchell; Todd Mortimer; Justin Tolsma; Steven Guercio; Kobinger, Gary (Public Health Agency of Canada); Mike Drebot; George Risi; Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Ebihara, Hideki (NIH/NIAID) [E]; Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Kurtis Swekla; Julie Kubay
Subject: Re: NHP ICU Oct 27-Nov 8

Hi all,
Once again I regret to inform you that the NHP-ICU experiment scheduled for Nov 12 has to be cancelled. The ebola outbreak in west Africa, the diagnostic case load, our training requirements and our subsisted CL4 staff are the reasons. We plan to carry forward our plans for the February 10, 2015 experiment unless things do not abate (or get worse).

I am sorry for any disruption this may have caused.

Please contact me via email if you have questions or concerns.(I am currently in Sierra Leone).

Thanks for understanding, Jim
Dr. J. Strong
Head, Diagnostics and Therapeutics
Special Pathogens
National Microbiology Laboratory
204-789-7032

▼ Shane Jones---2014-10-15 01:47 PM CDT---Hi Jim, In follow up to the Special Pathogens meeting this morning and commitments with the current

From: Shane Jones
To: Jim Strong
Cc: Shane Jones; Charlene Ranadheera; Bradley Cook; Anders Leung; Darwyn Kobasa; Cory.Nakamura@inspection.gc.ca; Mable Hagan; Geoff Soule; Gary Wong; Kevin Tierney; Xiangguo_Qiu@phac-aspc.gc.ca; Steven Theriault; Jason Gren; Kaylie N Tran; Alexander Bello; Jingxin Cao; Hugues Fausther Bovendo; Julie Kubay; Kimberly Azaransky; Stephanie Kucas; Christine De Graff; Jim Strong; Guillaume Poliquin; ghansen4@exchange.hsc.mb.ca; shadder@exchange.hsc.mb.ca; cpress@hsc.mb.ca; jkenny@exchange.hsc.mb.ca; saminian@HSC.MB.CA; ray123@mts.net; bmtchell2@hsc.mb.ca; mark_allan@live.ca; mkesselman@hsc.mb.ca; bjhancock@hsc.mb.ca; tmortimer@exchange.hsc.mb.ca; jtolsma@hushmail.me; BTsutsumi@exchange.hsc.mb.ca; rkeijaer@hsc.mb.ca; Lisa Fernando; pgpoliquin@gmail.com
Date: 2014-10-15 01:47 PM CDT
Subject: NHP ICU Oct 27-Nov 8

Hi Jim,

In follow up to the Special Pathogens meeting this morning and commitments with the current outbreak is still feasible to proceed with the upcoming NHP ICU experiment.

Also Jim if I am missing anybody please include.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Joe Cashion <joe@acacia-advisors.com>
Sent: Wednesday, October 15, 2014 3:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Paul Farmer Recommendation

Ok, thank you.

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
Date: Wednesday, October 15, 2014 at 12:49 PM
To: Joe Cashion <joe@acacia-advisors.com>
Subject: Re: Paul Farmer Recommendation

I am away until early November.

From: Joe Cashion [<mailto:joe@acacia-advisors.com>]
Sent: Wednesday, October 15, 2014 12:37 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Paul Farmer Recommendation

Dear Dr. Feldmann,

Dr. Farmer's office gave me your contact information and suggested you might be able to connect at some point. I've known Paul for many years through my work with the Clinton Foundation on HIV/AIDS issues, and am currently doing some research on possible impacts of Ebola in West Africa, with a particular focus on Cote d'Ivoire.

I currently run a small consulting company with a range of non profit and investment companies. I am trying to better understand the public health and economic to West Africa as a result of the Ebola crisis, and as part of this, I am looking into whether Cote d'Ivoire, should the virus spread, might follow the path of Liberia, or more hopeful examples like Nigeria, in terms of virus containment.

Given your work, I was wondering if you might have a few moments to connect with myself and a couple of colleagues. A bit out of the blue, I realize, but given your background, you were a natural port of call. And of course, we are happy to compensate for your time, if that's appropriate. Also, I realize you are certainly very busy these days, so either way, appreciate it very much.

Many thanks,


Joe Cashion

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Wednesday, October 15, 2014 3:07 PM
To: Pete Halfmann
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Your paper Unpublished

Thanks.

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Baric, Ralph
Sent: Wednesday, October 15, 2014 3:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Personal Info
Subject: RE: EBOLA RO1

Hi Heinz, Great to hear from you. [REDACTED] is very excited about the possibility of working as a special volunteer/guest researcher. She is very willing (as am I) to commit to the longer training period necessary for BSL4 research and to comply with the 3 month visitation schedule necessary to circumvent retraining requirements. [REDACTED] has had select agent approval for some time (VEE first, then SARS, and now 1918 IAV) with several years of experience so I don't think she will have any problems with the paperwork or psychological testing. Lets talk in Nov when you return. I've included [REDACTED] in the email. Take care, ralph

Personal Info

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Tuesday, October 14, 2014 9:57 AM
To: Baric, Ralph S
Subject: Re: EBOLA RO1

Ralph,

I am currently in Monrovia supposed to come back early November. We can discuss the option when I get back if it can wait that long. We now have slots for Special Volunteer and Guest Researchers that we cannot exceed. I need to talk to admin as there was nothing open when I asked last time.

The person would have to commit for a longer period as training for BSL4 is quite time-consuming. They also need to go through re-training when they haven't been in BSL4 for three months. On top we need all the select agent and biosafety paperwork and screening including an annual psychological test in person either at RML or in Bethesda.

Best wishes, Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Redacted by agreement
Sent: Wednesday, October 15, 2014 2:50 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Redacted by agreement
Attachments: WEEV Slides.pptx

Dear Dr. Feldmann,

Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

This communication and any files transmitted with it contain information that is confidential and may be privileged and exempt from disclosure under applicable law. It is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient- you are hereby notified that any use- dissemination or copying of this communication is strictly prohibited. If you have received this communication in error- please notify Redacted by agreement

Redacted Thank you for your cooperation.

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Wednesday, October 15, 2014 2:43 PM
To: halfmanp@svm.vetmed.wisc.edu
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fwd: Your paper Unpublished

Pete, can you take care of this?

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 2:20 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: review statement for [Person] travel to Liberia FW: DRAFT for Review: Request for Reconsideration: Travel for [Pers] to Liberia

Okay thanks!

Dawn

Dawn R. Clifton, Ph.D.
Scientific Operations Manager
Laboratory of Virology
Rocky Mountain Laboratories
903 S. 4th St.
Hamilton, MT 59840
406-375-9762
dawn.clifton@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 2:19 PM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: review statement for [Perso] travel to Liberia FW: DRAFT for Review: Request for Reconsideration: Travel for [Pers] to Liberia

Sounds good to me. The only thing I don't like is the statement about travel restrictions. I would take this out. Instead I would use a separate bullet stating that should an exposure or infection occur she will be medevaced to one of the designated treatment centers in the US on US chartered air service providers.

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 03:32 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: review statement for [Pers] travel to Liberia FW: DRAFT for Review: Request for Reconsideration: Travel for [Pers] to Liberia

Hi Heinz,

Lisa said that the information regarding the participation of [Pers] and [Personal] from your email was very helpful, and wanted to thank you. Additionally, as part of the justification to allow [Pers] (and [Personal] to travel, Lisa wanted to indicate briefly what plans are in place for an evacuation in the case of an exposure or active infection. I spoke with Vincent to get an idea of what might you all might have discussed and I wrote a revised statement. Both I have included Lisa's draft and my correction below. Would you please let me know if my statement is accurate? Or what might need to be corrected?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Unpublished
Sent: Wednesday, October 15, 2014 1:42 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA
Subject: Your paper Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Wednesday, October 15, 2014 1:36 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Questions from a Johns Hopkins Student

Hi, Dr. Feldmann. I am a student at Johns Hopkins University, writing an essay on the current Ebola outbreak, and I was wondering if I could ask you a few questions about the virus and how we are handling it. I am currently reading through your 2011 study in the Lancet.

Are you available for a call sometime this week/weekend?

Thank you very much,

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 1:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: review statement for **Pers** travel to Liberia FW: DRAFT for Review: Request for Reconsideration: Travel for **Pers** to Liberia

Hi Heinz,

Lisa said that the information regarding the participation of **Perso** and **Personal** from your email was very helpful, and wanted to thank you. Additionally, as part of the justification to allow **Perso** (and **Personal**) to travel, Lisa wanted to indicate briefly what plans are in place for an evacuation in the case of an exposure or active infection. I spoke with Vincent to get an idea of what might you all might have discussed and I wrote a revised statement. Both I have included Lisa's draft and my correction below. Would you please let me know if my statement is accurate? Or what might need to be corrected?

Lisa's draft statement: She will be traveling with select NIH federal staff. If travel restrictions prevent her from traveling on commercial flights (due to Ebola exposure), she will either wait to travel until after the 21-day incubation period for Ebola, or travel on charter flights (arranged and funded by US government).

My revision: She will be traveling with select NIH federal staff. If travel restrictions prevent her from traveling on commercial flights (due to Ebola exposure), evacuation arrangements would be made to return her to the US via travel on charter or military flights (arranged and funded by US government).

If you scroll down you can see the entirety of the draft letter. We are also moving forward with obtaining her visa and making travel plans for her as Lisa has indicated she believes that we will obtain approval. Maybe I told you that already??

Thanks,
Dawn

Dawn R. Clifton, Ph.D.
Scientific Operations Manager
Laboratory of Virology
Rocky Mountain Laboratories
903 S. 4th St.
Hamilton, MT 59840
406-375-9762
dawn.clifton@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Coronado, Lisa (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 8:35 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Cc: Coronado, Lisa (NIH/NIAID) [E]; Mahyera, Anna; Barron, Karyl (NIH/NIAID) [E]; Mills, Desta (NIH/NIAID) [E]
Subject: Re: DRAFT for Review: Request for Reconsideration: Travel for **Perso** to Liberia

Thanks, Dawn for your providing your revisions and for following up on the travel detail.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Wednesday, October 15, 2014 1:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola

Hi Dr. Feldmann,

As a practicing intensivist in the Chicagoland area, it has been difficult to find statistics on the survival rate of Ebola patients who suffer a cardiopulmonary arrest. I am hoping you may know the answer or that you can find the answer to this question. I understand that, for the most part, West Africa does not have the resources to care for these patients that we have in the US.

As experts in Ebola are guiding our leaders, it seems prudent to assess this question. If the survival rate of a person who has Ebola & has suffered a cardiopulmonary arrest is ZERO, I would endorse not providing ACLS support. Undoubtedly, I sound cruel & heartless. I am not cruel & heartless. In an attempt to save one life in a CODE, a situation which is often hectic and in which things are done very fast, many others are likely to be exposed. From a benefit / risk analysis, this is a question that must be asked and answered.

These are "no ordinary" times. The American healthcare workers are looking for guidance. The guidance comes top down. Our non-medical leaders are looking for expertise from those who have insight into the disease. It is imperative that we safeguard the nation immediately. I am hoping that I can gain insight into whether or not Ebola victims benefit from ACLS support.

Thanks for your consideration,

Personal Info

This message and any included attachments are intended only for the addressee. The information contained in this message is confidential and may constitute proprietary or non-public information under international, federal, or state laws. Unauthorized forwarding, printing, copying, distribution, or use of such information is strictly prohibited and may be unlawful. If you are not the addressee, please promptly delete this message and notify the sender of the delivery error by e-mail.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Yang, Jerry <Jerry.N.Yang@pjc.com>
Sent: Wednesday, October 15, 2014 1:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Consultation on ebola virus

Dear Dr. Feldmann,

My name is Jerry Yang, and I am on a biotech team with Josh Schimmer, MD at Piper Jaffray in New York. We are interested in having a discussion with you on ebola this Friday. The format of discussion is through a conference call, which is open to investors. We won't discuss any material non-public information, but will rather focus on the disease mechanism, emerging epidemic and implications.

Let me know if you are willing to speak with us for an hour on Friday (morning preferred). Piper Jaffray typically provides an honorarium of \$500/hour – let me know if this is acceptable to you.

Thank you and I look forward to hearing from you soon.

Jerry

Jerry N. Yang, Ph.D. | Biotech Equity Research Analyst
Piper Jaffray & Co | 345 Park Ave, Suite 1200 | New York, NY 10154
O: 212-284-9331 | M: **Personal Info**
Jerry.n.yang@pjc.com

Piper Jaffray & Co. Since 1895. Member SIPC and NYSE. Learn more at www.piperjaffray.com. Piper Jaffray corporate headquarters is located at 800 Nicollet Mall, Minneapolis, MN 55402.

Piper Jaffray outgoing and incoming e-mail is electronically archived and recorded and is subject to review, monitoring and/or disclosure to someone other than the recipient. This e-mail may be considered an advertisement or solicitation for purposes of regulation of commercial electronic mail messages. If you do not wish to receive commercial e-mail communications from Piper Jaffray, go to: www.piperjaffray.com/do_not_email to review the details and submit your request to be added to the Piper Jaffray "Do Not E-mail Registry." For additional disclosure information see www.piperjaffray.com/disclosures

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 1:06 PM
To: 'Victoria.Jensen@NBACC.DHS.GOV'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Endothelial activation by VP40/GP

Hi Vic,

If you want to go down that route, please ask them to send me a short email with their contact/shipment information, and I will ask Kay to get the SLA going.

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 1:04 PM
To: Hoenen, Thomas (NIH/NIAID) [F]; 'Victoria.Jensen@NBACC.DHS.GOV'
Subject: Re: Endothelial activation by VP40/GP

We can send the plasmid under an SLA.

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 02:57 PM Eastern Standard Time
To: 'Jensen, Victoria M. (CTR)' <Victoria.Jensen@NBACC.DHS.GOV>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Endothelial activation by VP40/GP

Hi Vic,

We have expression plasmids for VP40 and GP1,2, so from my end it would be no problem to send those if Heinz is OK with this (but if I get it right he was the person who contacted you in the first place). We get tons of requests for plasmids right now anyway, mostly for the tetracistronic trVLP system.

I'm not 100% sure what they mean with expression / purification protocols, do they want to produce VLPs? Redacted by
Redacted by agreement – but you are the one who did the endothelial work, so you probably know best...

All the best, Thomas

Feldmann, Heinrich (NIH/NIAID) [E]

From: Matteo Porotto <map2028@med.cornell.edu>
Sent: Wednesday, October 15, 2014 1:00 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Redacted by agreement

Hi Heinz,
Thank you very much for the answer. I hope that everything is well.
Best,
Matteo

On Oct 15, 2014, at 2:38 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

> Please communicate with Thomas Hoenen on this. I am currently in Monrovia for the rest of the month.

>

> Best wishes, Heinz

>

>

> ----- Original Message -----

> From: Matteo Porotto [mailto:map2028@med.cornell.edu]

> Sent: Wednesday, October 15, 2014 02:31 PM Eastern Standard Time

> To: Feldmann, Heinrich (NIH/NIAID) [E]

> Cc: Anne Moscona <anm2047@med.cornell.edu>

> Subject: Redacted by agreement

>

> Dear Heinz,

> I hope this e-mail finds you well. We have just seen your recent article using the tetracistronic minigenomes for mimicking Ebola infection. We have been working with Barry (and now with Dennis Bente) to develop fusion inhibitors for Ebola as we did for Nipah. It would be great to have your system if you are willing to share, to test our peptide inhibitors in BSL2. We would be of course be happy to do this as a collaboration.

>

> Take care,

>

> Matteo

>

>

>

> Matteo Porotto, Ph.D.

> Associate Professor

> Pediatrics Department

> Weill Medical College

> 12 floor 413E 69 street

> New York, NY, 10021

> 646-962-6250 (office)

> 646-962-6254 (lab)

> 646-962-0574 (fax)

>

>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 12:57 PM
To: 'Jensen, Victoria M. (CTR)'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Endothelial activation by VP40/GP

Hi Vic,

We have expression plasmids for VP40 and GP1,2, so from my end it would be no problem to send those if Heinz is OK with this (but if I get it right he was the person who contacted you in the first place). We get tons of requests for plasmids right now anyway, mostly for the tetracistronic trVLP system.

I'm not 100% sure what they mean with expression / purification protocols, do they want to produce VLPs? Redacted by

Redacted by agreement

the one who did the endothelial work, so you probably know best...

All the best, Thomas

From: Jensen, Victoria M. (CTR) [mailto:Victoria.Jensen@NBACC.DHS.GOV]
Sent: Wednesday, October 15, 2014 10:39 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: FW: Endothelial activation by VP40/GP

Records Originating Outside of NIAID

From: Lin, Charles [mailto:Charles_Lin@DFCI.HARVARD.EDU]
Sent: Thursday, October 09, 2014 5:49 PM
To: Jensen, Victoria M. (CTR)
Subject: Endothelial activation by VP40/GP

Dr. Wahl-Jensen,

Our laboratory, the Bradner lab, at the Dana-Farber Cancer Institute <http://bradner.dfci.harvard.edu> has a focus on chemical modulation of chromatin structure. Recently we have used models of endothelial cell activation to study cell state changes phenotypically and at the level of genome-wide chromatin structure. We had a paper this week in Molecular Cell on how chromatin active agents can abrogate cell state transitions (attached). With the outbreak of Ebola we are motivated to test our molecules and hypotheses in relevant models of Ebola activation of endothelium.

We therefore read your work with great interest and in particular your 2005 study with Dr. Feldmann on VP40/GP pro-inflammatory activation of endothelium. As a chromatin/chemistry/cancer laboratory, we are highly motivated to work collaboratively. We would like to test a panel of epigenetic molecules from my laboratory on this system to determine whether we can intercept VP40/GP mediated signal transduction in endothelium. We have established relevant endothelial

Feldmann, Heinrich (NIH/NIAID) [E]

From: Young, Howard (NIH/NCI) [E]
Sent: Wednesday, October 15, 2014 12:41 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: experiment?

Be safe, your efforts in the fight are greatly valued and appreciated.

Howard

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:10 PM
To: Young, Howard (NIH/NCI) [E]
Subject: Re: experiment?

Redacted by agreement Currently in Monrovia.

From: Young, Howard (NIH/NCI) [E]
Sent: Wednesday, October 15, 2014 09:36 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: experiment?

Dear Heinz,

I am certainly you are overwhelmed with inquiries but I wanted to know if you know the answer to this question. Redacted by agreement

Redacted by agreement

Regards,
Howard

Howard A. Young, Ph.D.
Deputy Chief & Principal Investigator
Laboratory of Experimental Immunology
Cancer & Inflammation Program
Center for Cancer Research
National Cancer Institute at Frederick
Frederick, MD 21702
Tel: 301-846-5743
Email: younghow@mail.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Matteo Porotto <map2028@med.cornell.edu>
Sent: Wednesday, October 15, 2014 12:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Anne Moscona
Subject: Tetracistronic minigenome for Ebola

Dear Heinz,

I hope this e-mail finds you well. We have just seen your recent article using the tetracistronic minigenomes for mimicking Ebola infection. We have been working with Barry (and now with Dennis Bente) to develop fusion inhibitors for Ebola as we did for Nipah. It would be great to have your system if you are willing to share, to test our peptide inhibitors in BSL2. We would be of course be happy to do this as a collaboration.

Take care,

Matteo

Matteo Porotto, Ph.D.
Associate Professor
Pediatrics Department
Weill Medical College
12 floor 413E 69 street
New York, NY, 10021
646-962-6250 (office)
646-962-6254 (lab)
646-962-0574 (fax)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael J Eichberg <meichberg@berkeley.edu>
Sent: Wednesday, October 15, 2014 12:29 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: UC Berkeley Invitation: Symposium Speaker/Panelist

Dr. Feldmann,

Thanks for your rapid response. Do you have any other suggestions for possible speaker? Perhaps Mathias Schnell from Thomas Jefferson, Maria Croyle from UT, Myron Levine from Maryland?

Best wishes on your important and ongoing work in Liberia.

Best,
Mike

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 15, 2014 11:26 AM
To: 'meichberg@berkeley.edu'
Subject: Re: UC Berkeley Invitation: Symposium Speaker/Panelist

Thanks for the invitation, but I may be in Monrovia at that time.

Best wishes,
Heinz

From: Michael J Eichberg [mailto:meichberg@berkeley.edu]
Sent: Wednesday, October 15, 2014 01:35 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: UC Berkeley Invitation: Symposium Speaker/Panelist

Dear Dr. Feldmann,

I am the Executive Director of the Berkeley Center for Emerging and Neglected Diseases (CEND) and each year we organize a high profile and very well attended symposium on areas related to our mission in infectious diseases (see the website, <http://cend.globalhealth.berkeley.edu>). This year's theme is Vaccines and Therapeutics: From Science to Solutions. Please see below for our current speaker line-up.

This year we are inviting speakers in the areas of vaccine and therapeutic development, and are planning a special panel to discuss the status of the Ebola vaccines and therapeutics pipeline, and their potential use in the current epidemic. We are interested in inviting and hosting you as a panel member to discuss the vaccine pipeline.

The symposium is all day on January 9th, 2015 with a dinner to follow. Please let me know if you would be interested in attending.

Best,
Mike Eichberg

Michael J. Eichberg, Ph.D.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 12:00 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: VP24

I'll talk to Nancy.

All the best, Thomas

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 10:47 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: VP24

Sure - we may need a letter from the quarantine office as this goes abroad. Ask Nancy about it.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 11:33 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: VP24

Hi Heinz,

I got a request from the ETH Zurich for an expression plasmid for VP24. Are you OK with me getting an SLA in place and sharing that plasmid?

All the best, Thomas

-----Original Message-----

From: Chi Celestine [mailto:chi.celestine@phys.chem.ethz.ch]
Sent: Wednesday, October 15, 2014 1:33 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: VP24

Hi Thomas,

I was wondering if it will be possible for you to lend me the gene for Vp24? I mean we could open up future collaborative works if you prefer this. My aim at the moment is to express the protein and carry out some preliminary works prior to my start in Sweden later next year. This will likely help me secure more funding

Kind Regards

Chi

Celestine Chi, PhD
ETH Zürich
Laboratory for Physical Chemistry
Vladimir-Prelog-Weg 2 HCI F 222

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael J Eichberg <meichberg@berkeley.edu>
Sent: Wednesday, October 15, 2014 11:35 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: UC Berkeley Invitation: Symposium Speaker/Panelist

Dear Dr. Feldmann,

I am the Executive Director of the Berkeley Center for Emerging and Neglected Diseases (CEND) and each year we organize a high profile and very well attended symposium on areas related to our mission in infectious diseases (see the website, <http://cend.globalhealth.berkeley.edu>). This year's theme is Vaccines and Therapeutics: From Science to Solutions. Please see below for our current speaker line-up.

This year we are inviting speakers in the areas of vaccine and therapeutic development, and are planning a special panel to discuss the status of the Ebola vaccines and therapeutics pipeline, and their potential use in the current epidemic. We are interested in inviting and hosting you as a panel member to discuss the vaccine pipeline.

The symposium is all day on January 9th, 2015 with a dinner to follow. Please let me know if you would be interested in attending.

Best,
Mike Eichberg

Michael J. Eichberg, Ph.D.
Executive Director
Center for Emerging and Neglected Diseases
University of California, Berkeley
444A Li Ka Shing Center
Berkeley, CA 94720-3370
510-664-4867 (t)
510-643-4966 (f)
Personal Info (c)
meichberg@berkeley.edu
<http://globalhealth.berkeley.edu/cend>

David Russell, Professor, Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University

Speaking Topic: "How host physiology impacts the drug susceptibility of *Mycobacterium tuberculosis*"

Roy Curtis III, Director, Centers for Infectious Diseases and Vaccinology and Microbial Genetic Engineering, Biodesign Institute, Arizona State University

Speaking Topic: TBD

Gerald Pier, Professor of Medicine, Harvard Medical School

Speaking Topic: Molecular factors mediating immunity targeting the conserved microbial surface polysaccharide, poly-N-acetyl glucosamine

Erica Ollmann Saphire, Professor, Department of Immunology and Microbial Science, Scripps Research Institute & Viral Hemorrhagic Fever Immunotherapeutic Consortium

Speaking Topic: TBD

Feldmann, Heinrich (NIH/NIAID) [E]

From: Damon, Inger K. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 11:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD); George Risi
Subject: Re: Montana

Records Originating Outside of NIAID

> On Oct 15, 2014, at 1:10 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>

> Redacted by agreement

>

> ----- Original Message -----

> From: Feldmann, Heinrich (NIH/NIAID) [E]

> Sent: Wednesday, October 15, 2014 12:52 PM Eastern Standard Time

> To: Damon, Inger K. (CDC/OID/NCEZID); Brooks, John T.

> (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD)

> Cc: George Risi

> Subject: Re: Montana

>

> Inger,

> Redacted by agreement

>

> Heinz

>

> ----- Original Message -----

> From: Damon, Inger K. (CDC/OID/NCEZID)

> Sent: Wednesday, October 15, 2014 12:41 PM Eastern Standard Time

> To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD);

> Feldmann, Heinrich (NIH/NIAID) [E]


> Subject: Montana

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Damon, Inger K. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 10:50 AM
To: Redd, Stephen (CDC/OID/OD)
Cc: Brooks, John T. (CDC/OID/NCHHSTP); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Montana


Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Damon, Inger K. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 10:42 AM
To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Montana

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Joe Cashion <joecashion@Personal Info> on behalf of Joe Cashion <joe@acacia-advisors.com>
Sent: Wednesday, October 15, 2014 10:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Paul Farmer Recommendation

Dear Dr. Feldmann,

Dr. Farmer's office gave me your contact information and suggested you might be able to connect at some point. I've known Paul for many years through my work with the Clinton Foundation on HIV/AIDS issues, and am currently doing some research on possible impacts of Ebola in West Africa, with a particular focus on Cote d'Ivoire.

I currently run a small consulting company with a range of non profit and investment companies. I am trying to better understand the public health and economic to West Africa as a result of the Ebola crisis, and as part of this, I am looking into whether Cote d'Ivoire, should the virus spread, might follow the path of Liberia, or more hopeful examples like Nigeria, in terms of virus containment.

Given your work, I was wondering if you might have a few moments to connect with myself and a couple of colleagues. A bit out of the blue, I realize, but given your background, you were a natural port of call. And of course, we are happy to compensate for your time, if that's appropriate. Also, I realize you are certainly very busy these days, so either way, appreciate it very much.

Many thanks,

Joe Cashion

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 10:20 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Redacted by agreement

Redacted by agreement

Redacted by agreement

-----Original Message-----

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:58 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Thanks, Kathy.

I'll begin preparing an amendment to the MTA to address data sharing with third parties, but I will await word from Darryl and Heinz regarding our request for pegylated IFN-beta.

-----Original Message-----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:39 AM
To: Mowatt, Michael (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I agree with Darren. I am at WHO in Geneva, so I am not sure we will be able to touch base. I can try. I think we need to see if Darryl and Heinz are willing to try the pegylated form of IFN beta in a NHP study.

Kathy

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:06 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Mellinger, Mary (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Kathy,

I spoke with Darren yesterday afternoon. We covered a couple points:

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:58 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Thanks, Kathy.

I'll begin preparing an amendment to the MTA to address data sharing with third parties, but I will await word from Darryl and Heinz regarding our request for pegylated IFN-beta.

-----Original Message-----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:39 AM
To: Mowatt, Michael (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I agree with Darren. I am at WHO in Geneva, so I am not sure we will be able to touch base. I can try. I think we need to see if Darryl and Heinz are willing to try the pegylated form of IFN beta in a NHP study.

Kathy

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:06 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Mellinger, Mary (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Kathy,

I spoke with Darren yesterday afternoon. We covered a couple points:

Redacted by agreement

Redacted

2. Darren indicated Biogen's receptivity to providing you with pegylated IFN-beta (approved in Europe and by FDA this summer) to perform NHP studies. He suggested that we could amend the current MTA to include this drug or use the terms on which we've agreed to or do a new MTA.

Please let me know if you agree with either or both of these points so I can get back to Darren. If so, I think the simplest solution is to amend the current MTA to achieve both.

Can you spare a few minutes to discuss this today? Other than a meeting from 9:30 to 11 I can be available.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 9:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Vaccines
Attachments: Unpublished

Hi Heinz,

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 9:34 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: VP24

Hi Heinz,

I got a request from the ETH Zurich for an expression plasmid for VP24. Are you OK with me getting an SLA in place and sharing that plasmid?

All the best, Thomas

-----Original Message-----

From: Chi Celestine [mailto:chi.celestine@phys.chem.ethz.ch]
Sent: Wednesday, October 15, 2014 1:33 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: VP24

Hi Thomas,

I was wondering if it will be possible for you to lend me the gene for Vp24? I mean we could open up future collaborative works if you prefer this. My aim at the moment is to express the protein and carry out some preliminary works prior to my start in Sweden later next year. This will likely help me secure more funding

Kind Regards
Chi

Celestine Chi, PhD
ETH Zürich
Laboratory for Physical Chemistry
Vladimir-Prelog-Weg 2 HCI F 222
CH-8093 Zürich
Email: chi.celestine@phys.chem.ethz.ch<mailto:chi.celestine@phys.chem.ethz.ch>
tele: 004144 63 37510


On 11 Oct 2014, at 16:05, Hoenen, Thomas (NIH/NIAID) [F]
<thomas.hoenen@nih.gov<mailto:thomas.hoenen@nih.gov>> wrote:

Good luck! Happy to help if I can!

From: Chi Celestine [chi.celestine@phys.chem.ethz.ch<mailto:chi.celestine@phys.chem.ethz.ch>]
Sent: Saturday, October 11, 2014 1:48 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: VP24

Feldmann, Heinrich (NIH/NIAID) [E]

Personal Info



Feldmann, Heinrich (NIH/NIAID) [E]

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 8:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Miller, Katherine (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: ASPA_0682: ASPR press release "HHS accelerates development of third Ebola vaccine"
Importance: High

Heinz—

FYI--Andrea spoke with Ken a few minutes ago with information on this platform, including the differences between it and the one we are working with. So, you do not have to respond to the request to review the document.

Dawn

Dawn R. Clifton, Ph.D.
Scientific Operations Manager
Laboratory of Virology
Rocky Mountain Laboratories
903 S. 4th St.
Hamilton, MT 59840
406-375-9762
dawn.clifton@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 8:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Miller, Katherine (NIH/NIAID) [E]
Subject: FW: ASPA_0682: ASPR press release "HHS accelerates development of third Ebola vaccine"
Importance: High

Heinz, is this the platform that LV developed / studies here ... if so please confirm asap, and if you can review the release let me know of edits / suggestions.

Under a one-year contract with Profectus BioSciences, Inc. of Tarrytown, New York, the ASPR's Biomedical Advanced Research and Development Authority (BARDA) will provide approximately \$5.8 million funding, subject matter expertise and technical assistance to further develop an experimental Ebola vaccine called rVSVN4CT1 EBOV, manufacture vaccine for use in animal studies and Phase 1 clinical studies, and conduct animal studies to test safety and efficacy.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Moss, Bernard (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 7:57 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola
Attachments: Journal of Virology 2003 Yang.pdf

Heinz

Would your group have an interest in working with us on developing an Ebola vaccine based on attenuated vaccinia virus? We made a preliminary construct in 2003 that was tested in mice in collaboration with the VRC. Paper is attached. We would make new constructs if you are interested and think it worthwhile.

Regards

Bernie

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 7:39 AM
To: Mowatt, Michael (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I agree with Darren. I am at WHO in Geneva, so I am not sure we will be able to touch base. I can try. I think we need to see if Darryl and Heinz are willing to try the pegylated form of IFN beta in a NHP study.

Kathy

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:06 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Mellinger, Mary (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Kathy,

I spoke with Darren yesterday afternoon. We covered a couple points:

Redacted by agreement

Redacted
by agreement

2. Darren indicated Biogen's receptivity to providing you with pegylated IFN-beta (approved in Europe and by FDA this summer) to perform NHP studies. He suggested that we could amend the current MTA to include this drug or use the terms on which we've agreed to or do a new MTA.

Please let me know if you agree with either or both of these points so I can get back to Darren. If so, I think the simplest solution is to amend the current MTA to achieve both.

Can you spare a few minutes to discuss this today? Other than a meeting from 9:30 to 11 I can be available.

You can reach me on my mobile: **Personal Info**

Or let me know when to call the best number to reach you.

Thanks,

Mike

-----Original Message-----

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 9:46 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Feldmann, Heinrich (NIH/NIAID) [E]

From: Young, Howard (NIH/NCI) [E]
Sent: Wednesday, October 15, 2014 7:36 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: experiment?

Dear Heinz,

I am certainly you are overwhelmed with inquiries but I wanted to know if you know the answer to this question. Did you ever try to infect interferon-gamma treated monocytes with Ebola? Sina said HeLa cells are resistant but neither he, Gene or Lisa knew if it applied to monocytes. Given that gamma is approved for human use, my naïve rationale is that maybe a low dose might offer some protection to health care workers.

Regards,
Howard

Howard A. Young, Ph.D.
Deputy Chief & Principal Investigator
Laboratory of Experimental Immunology
Cancer & Inflammation Program
Center for Cancer Research
National Cancer Institute at Frederick
Frederick, MD 21702
Tel: 301-846-5743
Email: younghow@mail.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Emily Ragobeer <emily.ragobeer@aljazeera.net>
Sent: Wednesday, October 15, 2014 7:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Urgent - Al Jazeera English Interview

Thank you – stay safe.

Is there a number where I may reach you for future?

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 15, 2014 2:41 PM
To: Emily Ragobeer
Subject: Re: Urgent - Al Jazeera English Interview

I am away in Monrovia and not available until early November.

From: Emily Ragobeer [mailto:emily.ragobeer@aljazeera.net]
Sent: Wednesday, October 15, 2014 06:30 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Urgent - Al Jazeera English Interview

Hello Dr. Feldman,
Any word on this request please?
Many thanks
Emily

From: Emily Ragobeer
Sent: Wednesday, October 15, 2014 11:48 AM
To: 'feldmannh@niaid.nih.gov'
Subject: Urgent - Al Jazeera English Interview
Importance: High

Dear Dr. Feldman,

I hope this email finds you well.

I am a producer with Al Jazeera English based in Doha Qatar and I would like to request you for an interview today on our flagship discussion program 'Inside Story' at 930 am ET (130 pm GMT) in-studio.

Today we're doing a in-depth show on Ebola and primarily containing and finding out the root cause of it and how the its host travels.

I've been reading your comments on this and I would like to have your expertise on this program.

This would be a paid appearance and would be pre-recorded between 930-10 am ET.

Please let me know if you would be available and the best number to reach you on.

Many thanks

Emily Ragobeer
Al Jazeera English
Doha Qatar
+974-4489-2497

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jeffrey Meshulam <meshulam@profectusbiosciences.net>
Sent: Wednesday, October 15, 2014 6:37 AM
To: Geisbert, Thomas W.
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; John Eldridge
Subject: Re: Comments on Ebola research funding

Great I was hoping that story would get told thank you

Sent from iPhone.

On Oct 15, 2014, at 8:14 AM, Geisbert, Thomas W. <twgeisbe@UTMB.EDU> wrote:

She sent me a similar note and I spoke with her. I told her that Heinz was the reason that the Canadians have a strong Ebola program as he got the BSL-4 up and going there.

Tom

From: Jeffrey Meshulam [<mailto:meshulam@profectusbiosciences.net>]
Sent: Tuesday, October 14, 2014 5:17 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: John Eldridge
Subject: FW: Comments on Ebola research funding

This reporter has been good.. she ran a story about our ebola funding. I am so not the person to get into this with her. I am not sure where she is going but would one of you want to talk to her?

Heinz stay safe!

Thank you

From: Kathleen Caulderwood [<mailto:k.caulderwood@ibtimes.com>]
Sent: Tuesday, October 14, 2014 3:48 PM
To: Jeffrey Meshulam
Subject: Re: Comments on Ebola research funding

Hi,

Thanks again for your help with my other stories, I'm still covering Ebola research and now I have a new query.

It seems to me that many of the most prominent experimental drugs are coming from Canadian research firms. Not sure if I'm getting all the

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Wednesday, October 15, 2014 6:26 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: ChAd trial
Attachments: NatureEbola.pdf

I need to run into the BSL-4 right now. Here is the paper. [Redacted by agreement] I would hope they do not use the MVA component. We did a study here on a contract for NIAID/NIH with MVA alone (a prime and

[Redacted by agreement]

[Redacted by agreement]

Tom

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 15, 2014 4:40 AM
To: Geisbert, Thomas W.
Subject: ChAd trial

Tom,

[Redacted by agreement]

[Redacted by agreement]

I would highly appreciate if you could get me that information if not too difficult.

Many thanks,

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Wednesday, October 15, 2014 6:15 AM
To: Jeffrey Meshulam; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: John Eldridge
Subject: RE: Comments on Ebola research funding

She sent me a similar note and I spoke with her. I told her that Heinz was the reason that the Canadians have a strong Ebola program as he got the BSL-4 up and going there.

Tom

From: Jeffrey Meshulam [mailto:meshulam@profectusbiosciences.net]
Sent: Tuesday, October 14, 2014 5:17 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: John Eldridge
Subject: FW: Comments on Ebola research funding

This reporter has been good.. she ran a story about our ebola funding. I am so not the person to get into this with her. I am not sure where she is going but would one of you want to talk to her?

Heinz stay safe!

Thank you

From: Kathleen Caulderwood [mailto:k.caulderwood@ibtimes.com]
Sent: Tuesday, October 14, 2014 3:48 PM
To: Jeffrey Meshulam
Subject: Re: Comments on Ebola research funding

Hi,

Thanks again for your help with my other stories, I'm still covering Ebola research and now I have a new query.

It seems to me that many of the most prominent experimental drugs are coming from Canadian research firms. Not sure if I'm getting all the information here. Can you tell me anything about Canada's reputation in the industry? Are they particularly known for Ebola funding or something?

Let me know!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Emily Ragobeer <emily.ragobeer@aljazeera.net>
Sent: Wednesday, October 15, 2014 4:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Urgent - Al Jazeera English Interview

Importance: High

Hello Dr. Feldman,
Any word on this request please?
Many thanks
Emily

From: Emily Ragobeer
Sent: Wednesday, October 15, 2014 11:48 AM
To: 'feldmannh@niaid.nih.gov'
Subject: Urgent - Al Jazeera English Interview
Importance: High

Dear Dr. Feldman,

I hope this email finds you well.

I am a producer with Al Jazeera English based in Doha Qatar and I would like to request you for an interview today on our flagship discussion program 'Inside Story' at 930 am ET (130 pm GMT) in-studio.

Today we're doing a in-depth show on Ebola and primarily containing and finding out the root cause of it and how the its host travels.

I've been reading your comments on this and I would like to have your expertise on this program.

This would be a paid appearance and would be pre-recorded between 930-10 am ET.

Please let me know if you would be available and the best number to reach you on.

Many thanks

Emily Ragobeer
Al Jazeera English
Doha Qatar
+974-4489-2497

Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Aliena Haig <aliena.haig@aljazeera.net>
Sent: Wednesday, October 15, 2014 3:22 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Al Jazeera INSIDE STORY

Dear Mr. Feldmann,

Al Jazeera's flagship current affairs show Inside Story is discussing the latest developments regarding ebola on today's show and we would very much like to invite you to join our guest panel and partake in the discussion, particularly since you have recently returned from Monrovia.

It is scheduled to take place at 9:30 (DC local time) this morning and would last half an hour.

I realize it is very short notice, but please do let me know if you would be at all interested and/or available.

I very much look forward to hearing from you.

Many thanks and kind regards,
Aliena



ALIENA HAIG
ALJAZEERA CHANNEL, NETWORK
PRODUCER | INSIDE STORY | NEWS DEPT
T +974 4489 2680 / 2494 |
M +974 3327 3430 |
E aliena.haig@aljazeera.net |
www.aljazeera.net/english | www.aljazeera.com

Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Emily Ragobeer <emily.ragobeer@aljazeera.net>
Sent: Wednesday, October 15, 2014 2:46 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Urgent - Al Jazeera English Interview

Importance: High

Dear Dr. Feldman,

I hope this email finds you well.

I am a producer with Al Jazeera English based in Doha Qatar and I would like to request you for an interview today on our flagship discussion program 'Inside Story' at 930 am ET (130 pm GMT) in-studio.

Today we're doing a in-depth show on Ebola and primarily containing and finding out the root cause of it and how the its host travels.

I've been reading your comments on this and I would like to have your expertise on this program.

This would be a paid appearance and would be pre-recorded between 930-10 am ET.

Please let me know if you would be available and the best number to reach you on.

Many thanks

Emily Ragobeer
Al Jazeera English
Doha Qatar
+974-4489-2497

Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sung-Soo Park <Sung-Soo.Park@hepahope.com>
Sent: Wednesday, October 15, 2014 1:47 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: In Vitro Ebola Virus Infection Model
Attachments: Dr Park CV-2014 (1).pdf; US5773285 (2).pdf; US5795710 (1).pdf

Dear Drs. Feldmann and Hoena,

My name is Sung-Soo Park, founder of HepaHope, Inc., in Newport Beach, CA, USA. I was a professor of medicine in Korea before I founded HepaHope in 1999 to research and develop Hepatic Assist device by using primary liver tissue cultivation. I have been doing the same research in Tissue Cultivation since 1987. I read your paper on "Ebola virus in West Africa and the use of experimental therapies or vaccines" (BMC Biology, 2014) and "A Novel Life Cycle Modeling system for Ebola Virus Shows a Genomic Length-Dependent Role of VP24 in Virus Infectivity" (Journal of Virology, 2014) about your research on Ebola virus and found your approach on developing an infection model very interesting. I am writing to you because I believe that I can share some information with you that can speed up or help your respective researches.

1. Introduction

I developed a methodology and apparatus for novel tissue slice cultivation (different from conventional cell cultivation system) to develop *in vitro* infection model for Human HBV and HCV, which today is being used in Bio-Artificial Liver application today. In light of recent events concerning Ebola virus, I began to read many publications by you and your colleagues doing research in BSL 4 environment. I learned that Liver is one of the major target organs for Ebola virus and found many parallels in your infection models with my research. I believe that my methodology of Tissue Cultivation will be beneficial for you and other researchers developing monoclonal antibody therapies and vaccine development because I believe that my model will be able to run a full life cycle of a wild type Ebola virus in a relatively a short time. Since I am the one who developed this methodology and technology, I wanted to share my knowledge to the people who are on the front-line of the Ebola research for a rapid and accurate response for this epidemic.

2. Summary of technology

Background

In 1989, I developed a tissue cultivation system to culture primary tissues for my research in Seoul National University in Korea when I was a PhD candidate. During my time as professor at various academic institutions in Korea, I used my tissue cultivation system to cultivate Human Hepatitis B and Hepatitis C viruses to understand the lifecycle of these viruses to develop *in vitro* cultivation model for those viruses. During those times, I also collaborated with Dr. Lee Jong-wook of WHO in 1994 and Dr. Jang H. Han of Chiron Corporation in 1996 on validation of HBV and HCV *in vitro* animal models until funding ran out of my research. Since then, my research shifted towards development of Hepatic assist device (Bio-Artificial Liver) and I eventually Immigrated to the U.S and founded HepaHope, Inc., to

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:05 PM
To: 'harvey.artsob@videotron.ca'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola - general information
Attachments: Marzi Feldmann vaccine review.pdf

Dear Harvey,

it has been a long time since we were in touch and I hope all is well!
Attached is a pdf of the vaccine review Heinz and I wrote earlier this year.
Please let me know if you need any further info.

Thanks & take care,
Andrea

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 7:06 AM
To: 'harvey.artsob@videotron.ca'; 'twgeisbe@UTMB.EDU'; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola - general information

Dear ALL,
Harvey needs some information but I do not have access to it here in Monrovia.

Tom - can you please send him the pdf of the latest Fields chapter?

Andrea, Darryl and Thomas, please send him pdfs of your latest review articles.

Please copy me if you do not mind.

Many thanks,
Heinz

From: Harvey [mailto:harvey.artsob@videotron.ca]
Sent: Thursday, October 09, 2014 01:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - general information

Heinz,

I hope this e-mail finds you well.

I have been asked to write about Ebola for an online news source.

By way of introduction, I would like to give a brief background on Ebola including history, different strains, outbreaks since 1976 and geographic distribution. I am not looking for any great detail.

Feldmann, Heinrich (NIH/NIAID) [E]

From: David Horn <dhorn@mid-atlanticbio.com>
Sent: Tuesday, October 14, 2014 9:01 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Studying IMT504 in an Ebola mouse model
Attachments: IMT504_mouse_model_diabetes_presented_at_Endocrine_Society_2014.docx; MABT_(DRAFT)_12JUL14_The_novel_immunotherapeutic_oligodeoxynucleotide_IMT504_protects_neutropenic_animals_from_fatal_Pseudomonas_aeruginosa_bacteremia_and_s_eosis.pdf; Zhao_2009_PyNTTTGT_prototype_oligo_IMT504,_a_novel_effective_adjuvant_of_the_FMDV_DNA_vaccine.pdf

Dear Heinz,

As you may recall, we have been developing IMT504 as an anti-infective agent for a number of years, and have shown very robust survival results against a number of different intractable viral and bacterial pathogens, including in highly lethal *Pseudomonas aeruginosa* and rabies models (see Chahin et al., 2014 - attached).

When we first spoke to you about IMT504, we had not thoroughly investigated whether IMT504 would signal in a mouse model, but recently, we have found evidence to suggest that it has broad utility in various mouse models (Bianchi et al., 2014; Zhao et al., 2009 – also attached).

Given the severity of the ongoing Ebola epidemic, and the scarcity of effective treatments, Redacted by agreeme

Redacted by agreement

Redacted by agreement

Please let us know the best way to proceed if you are interested in moving forward.

Regards,

David

David Horn, MD
CEO
Mid-Atlantic BioTherapeutics, Inc.
3805 Old Easton Road
Doylestown, PA 18902
dhorn@mid-atlanticbio.com
www.mid-atlanticbio.com
215-266-2301

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Tuesday, October 14, 2014 8:03 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Scientific Program for Filovirus meeting

At a tel conf, Peter Hoby stated that they are planning to do clinical trials with drugs (not specified).

Redacted by agreement

So, clinical trials of potential drugs would be another topic.

Inviting Margret Chan is an option too. She or Keiji Fukuda will likely come.

For modeling, who would be the one. I can think of flu epidemic modeling person. But, not shure they are doing one for Ebola.

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Handle: Geisbert, Thomas W.
Mail Address: twgeisbe@UTMB.EDU
Subject: RE: Scientific Program for Filovirus meeting
To: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>, YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>
CC: --
Date: Tue, 14 Oct 2014 16:39:02 +0000
Date Local: 2014/10/15 1:39:02
Message:

> Got it. Outbreak modeling would be interesting.

>

> -----Original Message-----

> From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]

> Sent: Tuesday, October 14, 2014 11:38 AM

> To: Geisbert, Thomas W.; YOSHIHIROKAWAOKA

> Subject: Re: Scientific Program for Filovirus meeting

>

> OK - three vaccine main talks.

>

> When I said moedeling I thought more about outbreak modeling - numb ers etc. Animal modeling would be good as well - this would be pathogenesis.

>

> ----- Original Message -----

> From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]

> Sent: Tuesday, October 14, 2014 12:33 PM Eastern Standard Time

> To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA

> Subject: RE: Scientific Program for Filovirus meeting

>

> Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 5:07 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 4:27 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fwd: A top scientist worries that Ebola has mutated to become more contagious - Vox

Sent from my iPhone

Begin forwarded message:

From: "Hoe, Nancy (NIH/OD/ORS) [E]" <nhoe@mail.nih.gov>
Date: October 14, 2014 at 4:00:42 PM MDT
To: "Wilson, Deborah (NIH/OD/ORS) [E]" <wilsodeb@ors.od.nih.gov>, "Bloom, Marshall (NIH/NIAID) [E]" <MBLOOM@niaid.nih.gov>
Subject: FW: A top scientist worries that Ebola has mutated to become more contagious - Vox

Care to guess the scientist?

Nancy P. Hoe, Ph.D., CBSP, NRCM(SM)
Biosafety Officer/Responsible Official for Rocky Mountain Laboratories
Division of Occupational Health and Safety
Office of Research Services, Office of the Director
National Institutes of Health
903 South 4th St.
Hamilton, MT 59840
Tel: 406-363-9334
Fax: 406-375-9705

-----Original Message-----

From: Joseph Hoe [<mailto:josephhoe@earthlink.net>]
Sent: Tuesday, October 14, 2014 3:53 PM
To: Hoe, Nancy (NIH/OD/ORS) [E]
Subject: A top scientist worries that Ebola has mutated to become more contagious - Vox

<http://www.vox.com/2014/10/13/6959087/ebola-outbreak-virus-mutated-airborne>

Sent from my iPad

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jeffrey Meshulam <meshulam@profectusbiosciences.net>
Sent: Tuesday, October 14, 2014 4:17 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: John Eldridge
Subject: FW: Comments on Ebola research funding

This reporter has been good.. she ran a story about our ebola funding. I am so not the person to get into this with her. I am not sure where she is going but would one of you want to talk to her?

Heinz stay safe!

Thank you

From: Kathleen Caulderwood [mailto:k.caulderwood@ibtimes.com]
Sent: Tuesday, October 14, 2014 3:48 PM
To: Jeffrey Meshulam
Subject: Re: Comments on Ebola research funding

Hi,

Thanks again for your help with my other stories, I'm still covering Ebola research and now I have a new query.

It seems to me that many of the most prominent experimental drugs are coming from Canadian research firms. Not sure if I'm getting all the information here. Can you tell me anything about Canada's reputation in the industry? Are they particularly known for Ebola funding or something?

Let me know!

Kathleen Caulderwood
International Business Times
<http://www.ibt.com/>

From: "Jeffrey Meshulam" <meshulam@profectusbiosciences.net>
To: "Kathleen Caulderwood" <k.caulderwood@ibtimes.com>
Sent: Friday, August 29, 2014 4:51:38 PM
Subject: Re: Comments on Ebola research funding

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ethan Bier <ebier@ucsd.edu>
Sent: Tuesday, October 14, 2014 3:43 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Redacted by

Thanks and best regards,

Ethan

--

Ethan Bier
Section of Cell and Developmental Biology
Bonner Hall, Room 4218
University of California, San Diego
9500 Gilman Drive
La Jolla, CA 92093-0349

Tel. (858) 534-8792
Fax. (858) 822-2044
Email: ebier@ucsd.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Tuesday, October 14, 2014 3:27 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Scientific Program for Filovirus meeting

> Do you want a big name person like Dr. Fauci?

Yes. How about Frieden? I do not know Frieden in person though

> One thing here I guess too is for some of these would we have to cover travel?

We should. I can approach Gates, DARPA, and Wellcometrust.

BARDA also is also supporting the Ebola activity, but I am not sure if they would support meetings. But, I can ask. For me to approach these funding agencies, we need speakers and topics of the meeting.

Yoshi

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Handle: Geisbert, Thomas W.
Mail Address: twgeisbe@UTMB.EDU
Subject: RE: Scientific Program for Filovirus meeting
To: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>, YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>
CC: --
Date: Tue, 14 Oct 2014 14:43:18 +0000
Date Local: 2014/10/14 23:43:18
Message:

> So Heinz for outbreak response and diagnostics you probably know better than we do who has been involved with this. I am guessing:

>

> Armand Sprecher

> Stephan Gunther

> CDC (Nichol, Towner, Knust, others)

> Companies doing rapid diagnostics?

>

> For patients:

>

> Someone from Emory [Personal Info]

> Someone from Nebraska ([Persona], [Personal Info]) - she was from UTMB so

> may be possible)

>

> For vaccines and treatments:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vickie Groth <vgroth@svm.vetmed.wisc.edu>
Sent: Tuesday, October 14, 2014 3:19 PM
To: YOSHIHIROKAWAOKA; Feldmann, Heinrich (NIH/NIAID) [E]; twgeisbe@UTMB.EDU
Subject: Unpublished
Attachments: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Gerhard Holt <ghol7955@med.usyd.edu.au>
Sent: Tuesday, October 14, 2014 3:17 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: ghol7955@med.usyd.edu.au
Subject: Q : How early can PCR detect Ebola ?

Dear Dr. Feldmann :

I was wondering, how early can PCR detect Ebola ?

Is there any reasonable probability that rtPCR can detect Ebola prior to the development of symptoms/signs (& higher infectivity) ?

Even if it can only detect it in a small subset of cases, this might reduce spread and substantially ease contact tracing...

Regards,

Dr. Gerhard Holt

P.s. I was also wondering, approximately how long can body fluids from Ebola patients stay infectious on surfaces like paper ?
(minutes, or hours or not at all ?)

(I realize that this is very unlikely, but I was wondering whether circulating paper money in infected areas might theoretically pose a risk).

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jana Schluetter <Jana.Schluetter@tagesspiegel.de>
Sent: Tuesday, October 14, 2014 2:12 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Press request: vaccines against ebola
Attachments: InterScan_SafeStamp.txt

Dear Dr. Feldmann,

According to the program of the Annual Meeting of the National Zoonosis Platform Germany, you will be in Berlin on Thursday. I would be very interested in meeting you at the conference venue - if at all possible. I am preparing a longer article about ebola vaccine research for the science page of a Berlin daily newspaper called "Tagesspiegel".

Thank you ever so much!

Jana Schlütter

--

Jana Schlütter
Der Tagesspiegel
Ressort Wissen & Forschen
Askanischer Platz 3
10963 Berlin

Tel.: +49 (0)30 / 29021-14408
E-Mail: jana.schluetter@tagesspiegel.de

Verlag Der Tagesspiegel GmbH

Askanischer Platz 3, 10963 Berlin

Geschäftsführung: Florian Kranefuß

Amtsgericht Charlottenburg HRB 43850 B

Hier finden Sie den Tagesspiegel im Netz:

<http://www.tagesspiegel.de>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Margalit, Ruth <Ruth_Margalit@newyorker.com>
Sent: Tuesday, October 14, 2014 1:21 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Query from The New Yorker

Understood. Thanks very much, and take care.

Ruth

From: <Feldmann>, "Heinrich [E] (NIH/NIAID)" <feldmannh@niaid.nih.gov>
Date: Tuesday, October 14, 2014 2:44 PM
To: Ruth Margalit <Ruth_Margalit@newyorker.com>
Subject: Re: Query from The New Yorker

Sorry but I cannot do this. I am currently in Monrovia until early November with little to no internet access.

Best wishes, Heinz

From: Margalit, Ruth [mailto:Ruth_Margalit@newyorker.com]
Sent: Tuesday, October 14, 2014 02:01 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Query from The New Yorker

Dear Dr. Feldmann,

I'm a fact checker at The New Yorker magazine working with reporter Richard Preston on an upcoming long article on the Ebola outbreak. In the course of fact checking I will be contacting many of the experts whom Richard has interviewed for the piece but, given the sensitivity of the issue at hand and given your all-round expertise and knowledge of the subject, we wondered whether you would be so kind as to read the entire article—in strict confidentiality—before we go to press and let us know if you find any inaccuracies or areas of contention. Since this is still a work in progress and isn't to be circulated in any way, we want to make sure that you will not show it to anybody.

I have no doubt that you're extremely busy. If you do find the time and the inclination to read this, we would be extremely grateful—the piece is attached. I'm also happy to discuss the details over the phone, if you prefer, and am available at 212-286-2941.

Our deadline is Thursday.

Many thanks in advance, and I hope this finds you well,


Ruth Margalit

--
Ruth Margalit
The New Yorker
4 Times Square
NY, NY 10036
212.286.2941 (work)
Personal Info (mobile)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 1:34 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Unpublished


Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Kahn, Eleanor J. <ejk2162@cumc.columbia.edu>
Sent: Tuesday, October 14, 2014 1:34 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola Engineering Challenge- plain text

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 1:28 PM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Thomas Thomas Steiner
Subject: RE: Redacted by

Good to know.

Thanks!

Dave

From: Petra Wülfroth [mailto:petra.wuelfroth@accella-advisors.com]
Sent: Tuesday, October 14, 2014 1:15 PM
To: Safronetz, David (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Thomas Thomas Steiner
Subject: Re: Redacted b

dave, Reda is stable in solution for at least several weeks at 4 degree. do not freeze!!!!

Von meinem iPhone gesendet

Am 14.10.2014 um 14:51 schrieb "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov>:

Hi Petra,

Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

make enough aliquots up front and freeze them prior to each treatment time point.

I apologize if you've already covered some/all of these points. I want to be sure everything is done here correctly so that we have the best chance of success.

Thanks in advance,
Dave

From: Safronetz, David (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 3:48 PM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Thomas Thomas Steiner
Subject: RE: Redacted b

Feldmann, Heinrich (NIH/NIAID) [E]

From: Decker, Jonathan <jdecker@theblaze.com>
Sent: Tuesday, October 14, 2014 1:05 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: TheBlazeTV interview request

Good afternoon,
My name is Jonathan Decker
I am a TV Producer for the Glenn Beck TV Show.
Glenn would like to speak with you or someone else who can talk to us about the possibilities of EBOLA being an Airborne Disease.
Also, about what people can do to stop this and on the numbers that WHO released about how there could be up to 10 thousand EBOLA cases weekly by December.

Glenn would like to speak with you today between 5-6 ET
We can set a remote up and transportation to and from as well.
Thanks again and I look forward to hearing from you soon,

Jonathan Decker
jdecker@theblaze.com

Jonathan Decker
Associate Producer
The Glenn Beck Program
TheBlazeTV

Feldmann, Heinrich (NIH/NIAID) [E]

From: W. Ian Lipkin <wil2001@columbia.edu>
Sent: Tuesday, October 14, 2014 12:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Kahn Ellie
Subject: Re: Ebola Engineering Challenge

Ok. Wish I were there. Stuck in U.S. Personal Info

On Oct 14, 2014, at 2:48 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Ian - having a hard time to get on interne to download the attachment. Currently in Monrovia until early November. I am sure the proposals are fine. I am happy to support. Exclude me from the article as this would need approval from Bethesda.

Sorry and best wishes, Heinz

From: W. Ian Lipkin [<mailto:wil2001@columbia.edu>]
Sent: Monday, October 13, 2014 10:32 AM Eastern Standard Time
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Cathy Roth <rothc@who.int>; Spiropoulou, Christina (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Rachel T. Moresky <rtn2102@cumc.columbia.edu>; Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Kahn Eleanor J. <ejk2162@cumc.columbia.edu>
Subject: Ebola Engineering Challenge

Dear Armand, Cathy, Christina, Heinz, Lisa, Rachel and Stuart,

Attached please find brief proposals that address needs that one or more of you have suggested might be amenable to low cost engineering solutions including improvements in decontamination of electronic equipment, disinfectant solutions, body bags, patient transport, and data collection and management. I will be vetting these proposals with the engineering faculty on Wednesday 15 October btw 11 AM and 3 PM EST. It would be helpful if you would fill in the attached score sheet by Tues evening. Please dont spend more than 30 minutes in total reading and scoring the proposals. What we want to know is whether you think the teams are meeting a need and whether a course correction or additional information is needed.

Thanks,

Ian

ps. The New Yorker Magazine will be writing this up as a feature story. Please tell me whether you do or dont want us to include your name.

W. Ian Lipkin, MD
John Snow Professor of Epidemiology,
Mailman School of Public Health

Professor of Neurology and Pathology,
College of Physicians and Surgeons

Director, Center for Infection and Immunity

Columbia University
www.cii.columbia.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:52 PM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; 'Thomas Thomas Steiner'
Subject: RE: Redacted by

Hi Petra,

Redacted by agreement

Redacted by agreement

The compound should be dissolved in sterile saline.

Redacted by agreement

freeze them prior to each treatment time point.

I apologize if you've already covered some/all of these points. I want to be sure everything is done here correctly so that we have the best chance of success.

Thanks in advance,
Dave

From: Safronetz, David (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 3:48 PM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Thomas Thomas Steiner
Subject: RE: Redacted by

Hi Petra

Redacted by agreement

Redacted by agreement

Redacted by agreement

Dave

From: Petra Wülfroth [mailto:petra.wuelfroth@acella-advisors.com]
Sent: Friday, October 03, 2014 11:55 AM
To: Safronetz, David (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Thomas Thomas Steiner
Subject: Re: Redacted by

great, thanks Dave!

Von meinem iPhone gesendet

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:45 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Unpublished
Attachments: Unpublished

Unpublished

-----Original Message-----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:43 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Unpublished

Will do.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:39 PM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Unpublished

Just go ahead.

----- Original Message -----

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 02:16 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished

Unpublished

d.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:54 AM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Janice E. Silverman <J_Silverman@acs.org>
Sent: Tuesday, October 14, 2014 12:35 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Invitation to write a Viewpoint for ACS Infectious Diseases

Thanks for the prompt response, Heinz. Please do consider writing a Viewpoint or Perspective/Review on the vaccine, and submit at your convenience.

Best,
Janice

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Tuesday, October 14, 2014 1:32 PM
To: Janice E. Silverman
Subject: Re: Invitation to write a Viewpoint for ACS Infectious Diseases

Thanks for the invitation but I would not be able to do that in the next six months or even longer.

Heinz

From: Janice E. Silverman [mailto:J_Silverman@acs.org]
Sent: Tuesday, October 14, 2014 02:28 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Invitation to write a Viewpoint for ACS Infectious Diseases



Dear Dr. Feldmann:

I hope you are doing well. I recently read your articles "**Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates**" published in **PNAS** with great interest. I know you are very busy, but I wanted to ask if you would be willing to write a Viewpoint article on Ebola vaccine/treatment for our new journal, [ACS Infectious Diseases](#). The American Chemical Society launched the journal in September 2014 to serve the Society's Mission of "*improving people's lives through the transforming power of chemistry*" along with the Society's vision "*to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people.*"

As you know, the Ebola virus outbreak in Africa has caused alarm worldwide. However, not many understand the science, or the mechanism of infection, as evidenced by the lack of available therapeutic when it is urgently needed. As such, I would like to ask if you would be interested in writing a Viewpoint on vaccination against Ebola virus, and/or the virus life cycle, and possibly use this forum as **a call for action to researchers**. Given the desire of our Editors to increase awareness on the actual infection mechanism, especially at this time when the disease is being highlighted by media, the *ACS Infectious Diseases* Editors would like to highlight this topic on the first Viewpoint for the journal. We collectively agreed that you are the most suited author for this piece.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Janice E. Silverman <J_Silverman@acs.org>
Sent: Tuesday, October 14, 2014 12:28 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Invitation to write a Viewpoint for ACS Infectious Diseases

Importance: High



Dear Dr. Feldmann:

I hope you are doing well. I recently read your articles "**Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates**" published in **PNAS** with great interest. I know you are very busy, but I wanted to ask if you would be willing to write a Viewpoint article on Ebola vaccine/treatment for our new journal, [ACS Infectious Diseases](#). The American Chemical Society launched the journal in September 2014 to serve the Society's Mission of "*improving people's lives through the transforming power of chemistry*" along with the Society's vision "*to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people.*"

As you know, the Ebola virus outbreak in Africa has caused alarm worldwide. However, not many understand the science, or the mechanism of infection, as evidenced by the lack of available therapeutic when it is urgently needed. As such, I would like to ask if you would be interested in writing a Viewpoint on vaccination against Ebola virus, and/or the virus life cycle, and possibly use this forum as **a call for action to researchers**. Given the desire of our Editors to increase awareness on the actual infection mechanism, especially at this time when the disease is being highlighted by media, the *ACS Infectious Diseases* Editors would like to highlight this topic on the first Viewpoint for the journal. We collectively agreed that you are the most suited author for this piece.

Should you accept our invitation, we will plan to publish your Viewpoint in the **January 2015** inaugural Issue. This is our sample issue, and will be **available to read for free** to anyone interested. The deadline for the manuscript would be December 4, 2014. We prefer Viewpoint pieces of no more than 1,800 words. Figures and diagrams can be used freely to explain the points made and are highly encouraged. We can usually accommodate up to 2 figures per Viewpoint. If you accept, kindly submit your Viewpoint via our manuscript tracking system <https://acs.manuscriptcentral.com/acs>.

Given the time sensitivity of this matter, can you please let me know by Friday, October 17, if you will be able to help us with the Viewpoint? If you decline, I would be grateful if you could provide suggestions as to other suitable authors for this urgent and important Viewpoint.

Thank you so much!

Kind regards,

Janice Elaine Y. Silverman, Ph.D.
Acquisitions Editor,
Editorial Development | Journals Publishing Group

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:17 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Unpublished

Unpublished

d.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:54 AM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:13 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: **Personal Info**
Subject: FW: Phone call w/ Lisa - FW: **Pers** and **Personal** Travel to Liberia for Ebola Outbreak Participation

Hi Heinz,

Lisa is asking for written justification for the denial for **Perso** and **Personal** and also requesting from you some information/wording that she can use with Lockheed and Kelly in regards to the importance of **Pers** and **Personal I** participation in this mission. I'm pasting from Lisa here (or you can scroll down): "I am currently seeking specific, written, information from LM and Kelly as to why the denial of **Pers** and **Personal** travel. There needs to be a bona fide reason. Hoping to understand their position so that we can petition reasonably.

While I await this information from the contractors, would you please **inquire with Dr. Feldmann and confirm that each **Perso** and **Personal I** participation is critical to the success of the mission.** If yes, would he please draft some text for me to use in my petition for reconsideration?

I am also checking to see what the Department of Defense might be doing re permitting contractor travel for this activity."

Do you think you can give them something? I can try as well, but it may be more significant actually coming from you. I've rescheduled my phone call with her to later this afternoon to see if we can get some more info from the contractors.

Dawn

Dawn R. Clifton, Ph.D.
Scientific Operations Manager
Laboratory of Virology
Rocky Mountain Laboratories
903 S. 4th St.
Hamilton, MT 59840
406-375-9762
dawn.clifton@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Mills, Desta (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:02 PM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: Phone call w/ Lisa - FW: Ricki and Cynthia's Travel to Liberia for Ebola Outbreak Participation

Hi Dawn,

Can we wait until 2:30 or 3 p.m. our time?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Margalit, Ruth <Ruth_Margalit@newyorker.com>
Sent: Tuesday, October 14, 2014 12:01 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Query from The New Yorker
Attachments: prestonEbola.pdf

Dear Dr. Feldmann,

I'm a fact checker at The New Yorker magazine working with reporter Richard Preston on an upcoming long article on the Ebola outbreak. In the course of fact checking I will be contacting many of the experts whom Richard has interviewed for the piece but, given the sensitivity of the issue at hand and given your all-round expertise and knowledge of the subject, we wondered whether you would be so kind as to read the entire article—in strict confidentiality—before we go to press and let us know if you find any inaccuracies or areas of contention. Since this is still a work in progress and isn't to be circulated in any way, we want to make sure that you will not show it to anybody.

I have no doubt that you're extremely busy. If you do find the time and the inclination to read this, we would be extremely grateful—the piece is attached. I'm also happy to discuss the details over the phone, if you prefer, and am available at 212-286-2941.

Our deadline is Thursday.

Many thanks in advance, and I hope this finds you well,

Ruth Margalit

--

Ruth Margalit
The New Yorker
4 Times Square
NY, NY 10036
212.286.2941 (work)
Personal Info (mobile)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kathleen Caulderwood <k.caulderwood@ibtimes.com>
Sent: Tuesday, October 14, 2014 12:01 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Quick comments on Canada Ebola research
Attachments: IBT Logo.png

Hi,

I'm a reporter at International Business Times in New York. I've been doing a lot of coverage of Ebola research and today I'm working on a short story about how Canada has emerged as one of the leading sources in the industry, and was hoping to get a few comments from you about your work in Winnipeg.

I realize you're abroad right now and a phone call might be hard to arrange. So if you have a few minutes to write back on any of the questions below I would greatly appreciate it.

Thanks!

- Why you decided to join the National Microbiology Laboratory in Winnipeg
- How you managed to get funding for Ebola research, which, as I understand it, wasn't especially popular before this year
- What is the place of Canadian research among other Ebola researchers today? Are they are the forefront?

Kathleen Caulderwood
k.caulderwood@ibtimes.com

INTERNATIONAL BUSINESS TIMES

7 Hanover Square, Fl 5
New York, NY 10004
<http://www.ibt.com/>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Tuesday, October 14, 2014 11:46 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

That's great, thank you very much!

All the best, Thomas

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 11:17 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola trVLP system

Ricki,
Can you please go on my computer and open a folder from the desktop entitled 'collaborations' or something similar. This folder should include recent examples for 'Letters of collaboration'. Take one for **Pers** or **Pers** from 2014 and send it to Thomas.

Thomas, please modify the letter accordingly and send the draft to me. Once we have a final draft - Kay can use the stamp to sign.

Let me know if you need my help.

Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Tuesday, October 14, 2014 01:10 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I just got off the phone with **Pers** and asked Kay to prepare the SLA. **Pers** has asked me if we could provide her with a letter of collaboration regarding the trVLP system for an R01 application - basically affirming our help in getting the system up and running. I told her that I don't think I can sign such a letter, but that I would talk to you about this and find out whether you would be willing to do that in my stead. The application is due on Oct 28th.

Hope all is well!

All the best, Thomas

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mire, Chad <chmire@UTMB.EDU>
Sent: Tuesday, October 14, 2014 11:42 AM
To: Geisbert, Thomas W.; Safronetz, David (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]; Haddock, Elaine (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Unpublished
Attachments: Unpublished

Hi Dave,

Unpublished

Chad

-----Original Message-----

From: Geisbert, Thomas W.
Sent: Tuesday, October 14, 2014 8:49 AM
To: Safronetz, David (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]; Haddock, Elaine (NIH/NIAID) [E]; Mire, Chad
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished

Dave,

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 11:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI - Kelly will not make exception to **Personal Info** travel

If we can get **Perso** permission, her and Bob make two out of three, which is pretty good. Lisa's calling me in a few minutes, so I will check to see what the real issues are and see if we can figure out a way.

Dawn

Dawn R. Clifton, Ph.D.
Scientific Operations Manager
Laboratory of Virology
Rocky Mountain Laboratories
903 S. 4th St.
Hamilton, MT 59840
406-375-9762
dawn.clifton@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:52 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: FYI - Kelly will not make exception to **Personal Info** travel

Everyone is well.

Please make sure that the gloveboxes get ordered - we will need them.

We also need the contract workers - someone needs to look into this.

Thanks, Heinz

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:43 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: FYI - Kelly will not make exception to **Personal Info** travel

Hi Heinz,
FYI--It appears as though Kelly is not allowing **Personal** to travel to Liberia at all (see email below). Desta (Lisa's assistant) is following up with Lisa, but she's not sure Lisa can do anything.

Person permission is still up in the air. Lisa texted me late on Friday to say that a waiver may be necessary, and I have communicated with Desta this morning to follow up. I will let you know what happens.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Stephen Maher Personal Info
Sent: Tuesday, October 14, 2014 11:13 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: ebola vaccine story for Canadian newspapers

Sir,

I know you're busy but I would very much like a quick chat about this.

<http://www.niaid.nih.gov/labsandresources/labs/aboutlabs/lv/diseasemodeling/Pages/default.aspx>

This has not been covered properly in Canada and it should be.

Yours,

Stephen Maher
Postmedia News
613 238 8325

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Tuesday, October 14, 2014 11:11 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I just got off the phone with **Pers** and asked Kay to prepare the SLA. **Per** has asked me if we could provide her with a letter of collaboration regarding the trVLP system for an R01 application - basically affirming our help in getting the system up and running. I told her that I don't think I can sign such a letter, but that I would talk to you about this and find out whether you would be willing to do that in my stead. The application is due on Oct 28th.

Hope all is well!

All the best, Thomas

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 4:55 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

If you want to collaborate with her please go ahead. On the other hand, she can have the system without collaboration.

Heinz

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 06:53 PM Eastern Standard Time
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

Please go ahead.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 06:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola trVLP system

Hi Heinz,

Are you OK if I contact **Person** regarding sharing the trVLP system (of course with an SLA)?

All the best, Thomas

From: **Personal Info, Unpublished**
Sent: Sunday, October 12, 2014 12:22 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koita, Ousmane
Sent: Tuesday, October 14, 2014 10:47 AM
To: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Amadou Kone; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu
Subject: RE: Redacted by agreement

Thanks Dave,
Ok I will do this tomorrow.

Ousmane

From: Safronetz, David (NIH/NIAID) [E] [mailto:safronetzd@niaid.nih.gov]
Sent: Tuesday, October 14, 2014 3:19 PM
To: Richard Sakai; Amadou Kone; Ousmane Koita; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Sophia_ Siddiqui; ssow@medicine.umaryland.edu
Subject: RE: Redacted by agreement

Come to think of it there are most likely more SmartCycler reagents in the blue lab as well. I agree with Dick, we need a complete inventory done so that we can send the correct materials. We have everything on hand at RML, but we need to be careful as to how much we're sending out as the burn rate in Liberia is significantly higher than at Point G. We cannot afford to run out in Monrovia.

Dave

From: Sakai, Richard
Sent: Tuesday, October 14, 2014 9:16 AM
To: Safronetz, David (NIH/NIAID) [E]; Amadou Kone; Koita, Ousmane; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu
Subject: RE: Redacted by agreement

Why not do an inventory of the reagents in the blue lab including the concentrations (e.g. 5 ml of 10X reagent A).

Dick.

From: Safronetz, David (NIH/NIAID) [E] [mailto:safronetzd@niaid.nih.gov]
Sent: Tuesday, October 14, 2014 2:58 PM
To: Amadou Kone; Ousmane Koita; Richard Sakai; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Sophia_ Siddiqui; ssow@medicine.umaryland.edu
Subject: RE: Redacted by agreement

Dear Amadou,

Does this inventory include back-up supplies in the blue lab? For example, there is most likely a couple hundred extraction columns in our lab as well as the associated buffers. In any case, 154 extractions will last you for a long while at the current rate. Also, there should be more primers somewhere. As I previously mentioned we originally brought

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:43 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: FYI - Kelly will not make exception to [Personal Info] travel

Hi Heinz,
FYI--It appears as though Kelly is not allowing [Personal] to travel to Liberia at all (see email below). Desta (Lisa's assistant) is following up with Lisa, but she's not sure Lisa can do anything.

[Persona] permission is still up in the air. Lisa texted me late on Friday to say that a waiver may be necessary, and I have communicated with Desta this morning to follow up. I will let you know what happens.

I have asked for a quote from Coy for 3 glove boxes on a 28 day turnaround, but have not yet heard back. We still have one coming that Andrea should be able to take with her.

I hope you, Kyle and Kristin are doing well.

Dawn

From: Mills, Desta (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 9:41 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: FYI - Kelly will not make exception to [Personal Info] travel

Were you aware of this one too?

I am not sure there is much we can do, but again I will follow-up with Lisa.

From: Birdsong, George (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:34 AM
To: Mills, Desta (NIH/NIAID) [E]; Coronado, Lisa (NIH/NIAID) [E]
Subject: Kelly will not make exception to [Personal Info] travel

Good Morning Lisa and Desta,

Kelly is unable to provide an exception for their contractors to participate in travel arrangements in support of Ebola even if DIR or the lab picks up the cost. They are going to notify [Personal Info] today.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 9:19 AM
To: Sakai, Richard; Amadou Kone; Koita, Ousmane; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Come to think of it there are most likely more SmartCycler reagents in the blue lab as well. I agree with Dick, we need a complete inventory done so that we can send the correct materials. We have everything on hand at RML, but we need to be careful as to how much we're sending out as the burn rate in Liberia is significantly higher than at Point G. We cannot afford to run out in Monrovia.

Dave

From: Sakai, Richard
Sent: Tuesday, October 14, 2014 9:16 AM
To: Safronetz, David (NIH/NIAID) [E]; Amadou Kone; Koita, Ousmane; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Why not do an inventory of the reagents in the blue lab including the concentrations (e.g. 5 ml of 10X reagent A).

Dick.

From: Safronetz, David (NIH/NIAID) [E] [<mailto:safronetzd@niaid.nih.gov>]
Sent: Tuesday, October 14, 2014 2:58 PM
To: Amadou Kone; Ousmane Koita; Richard Sakai; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Sophia_ Siddiqui; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Dear Amadou,

Does this inventory include back-up supplies in the blue lab? For example, there is most likely a couple hundred extraction columns in our lab as well as the associated buffers. In any case, 154 extractions will last you for a long while at the current rate. Also, there should be more primers somewhere. As I previously mentioned we originally brought enough primer / probes for 1000+ reactions. I suspect there are more concentrated stocks of in the freezer in the blue lab. If you can find these then it would appear all that you need are more RT-PCR reagents for the SmartCycler, correct?

Dave

From: Amadou Kone [<mailto:amadoukone@icermali.org>]
Sent: Sunday, October 12, 2014 4:27 AM
To: Koita, Ousmane; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sakai, Richard
Sent: Tuesday, October 14, 2014 9:16 AM
To: Safronetz, David (NIH/NIAID) [E]; Amadou Kone; Koita, Ousmane; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Why not do an inventory of the reagents in the blue lab including the concentrations (e.g. 5 ml of 10X reagent A).

Dick.

From: Safronetz, David (NIH/NIAID) [E] [<mailto:safronetzd@niaid.nih.gov>]
Sent: Tuesday, October 14, 2014 2:58 PM
To: Amadou Kone; Ousmane Koita; Richard Sakai; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Sophia_ Siddiqui; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Dear Amadou,

Does this inventory include back-up supplies in the blue lab? For example, there is most likely a couple hundred extraction columns in our lab as well as the associated buffers. In any case, 154 extractions will last you for a long while at the current rate. Also, there should be more primers somewhere. As I previously mentioned we originally brought enough primer / probes for 1000+ reactions. I suspect there are more concentrated stocks of in the freezer in the blue lab. If you can find these then it would appear all that you need are more RT-PCR reagents for the SmartCycler, correct?

Dave

From: Amadou Kone [<mailto:amadoukone@icermali.org>]
Sent: Sunday, October 12, 2014 4:27 AM
To: Koita, Ousmane; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu; Amadou Kone
Subject: RE : New suspected case to be tested

Dears,

On behalf of Professor Koita, please find in attachment the inventory sheet of materials needed and in use for EBOLA screening and confirmatory. This sheet includes only EBOLA RNA extraction and Amplification/Detection, not equipments (PPE, Gloves, etc.) in use in Level-3 lab. Also, it not includes Positive controles stocked in the Blue Lab.

Cheers,
Amadou KONE

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 8:58 AM
To: 'Amadou Kone'; Koita, Ousmane; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Dear Amadou,

Does this inventory include back-up supplies in the blue lab? For example, there is most likely a couple hundred extraction columns in our lab as well as the associated buffers. In any case, 154 extractions will last you for a long while at the current rate. Also, there should be more primers somewhere. As I previously mentioned we originally brought enough primer / probes for 1000+ reactions. I suspect there are more concentrated stocks of in the freezer in the blue lab. If you can find these then it would appear all that you need are more RT-PCR reagents for the SmartCycler, correct?

Dave

From: Amadou Kone [mailto:amadoukone@icermali.org]
Sent: Sunday, October 12, 2014 4:27 AM
To: Koita, Ousmane; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu; Amadou Kone
Subject: RE : New suspected case to be tested

Dears,

On behalf of Professor Koita, please find in attachment the inventory sheet of materials needed and in use for EBOLA screening and confirmatory. This sheet includes only EBOLA RNA extraction and Amplification/Detection, not equipments (PPE, Gloves, etc.) in use in Level-3 lab. Also, it not includes Positive controles stocked in the Blue Lab.

Cheers,
Amadou KONE

----- Message d'origine-----

De: Ousmane Koita
Date: ven. 10/10/2014 15:47
À: Richard Sakai; 'Feldmann, Heinrich (NIH/NIAID) [E]'; 'Polis, Michael (NIH/NIAID) [E]'; Bassirou Diarra; 'Murphy, Robert'
Cc: 'Safronetz, David (NIH/NIAID) [E]'; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Objet : RE: New suspected case to be tested

Dear Dick,

I think you are right, I am planning to have an inventory of the stock may be tomorrow morning or Monday.

Best regards,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Randy Cron, M.D. <rcron@peds.uab.edu>
Sent: Tuesday, October 14, 2014 8:06 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Will do

Randy Q. Cron, MD, PhD

Professor of Pediatrics & Medicine
Arthritis Foundation, Alabama Chapter, Endowed Chair
Director, Division of Pediatric Rheumatology
Children's Hospital of Alabama/
University of Alabama at Birmingham
Children's Park Place, Ste. 210
1601 4th Avenue South
Birmingham, AL 35233

Tel.: (205) 996-9191
Email: rcron@peds.uab.edu
FAX: (205) 996-9545

lab webpages:

<http://www.uab.edu/medicine/immunology/faculty?id=81:cron&catid=39:faculty>
http://138.26.61.118/depts/MEB/SOMResearchFaculty/currentfacultydata.asp?s_iname=cron&s_keyword=&s_fname=&s_department_name=&s_researchtitle=&ID=RCRON
<https://services.medicine.uab.edu/facultydirectory/FacultyData.asp?FID=30608>

division webpages:

<https://www.uab.edu/medicine/peds/rheum>
<http://www.uab.edu/medicine/rheumatology/faculty/62-randy-q-cron-md-phd>

PLEASE REMOVE ANY NON-BUSINESS PICTURES AND QUOTES FROM YOUR EMAIL SIGNATURE. WE WANT TO PROJECT A PROFESSIONAL IMAGE IN ALL ASPECTS OF OUR WORK.

Confidentiality Notice: The information transmitted is intended only for the person or company to which it is addressed and may contain confidential or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action of any reliance upon, this information by person or company other than the intended recipient is prohibited. If you receive this in error, please contact the sender and delete the material from any computer.

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Tuesday, October 14, 2014 8:59 AM
To: Randy Cron, M.D.
Subject: Re: Ebola

Please contact me early November as I am afraid I will forget after 4 weeks of absence.

From: Randy Cron, M.D. [mailto:rcron@peds.uab.edu]
Sent: Tuesday, October 14, 2014 09:50 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

OK, hopefully this can help with future epidemics.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Christina Sartori <info@christina-sartori.de>
Sent: Tuesday, October 14, 2014 8:11 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: DANKE! Alles Gute!

"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> hat am 14. Oktober 2014 um 15:59 geschrieben:

Foto ist OK - habe keine weiteren Fotos hier in Monrovia.

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Tuesday, October 14, 2014 09:52 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz
super, vielen Dank, hoffe es geht Ihnen gut. Ich übernehme die Änderungen.
Dürfen wir auch das Foto von Ihnen verwenden, das auch auf der Website zu sehen ist? Haben Sie noch ein Ebola Foto?
Viele Grüße, Christina

"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> hat am 14. Oktober 2014 um 15:44 geschrieben:

Christina,

Habe gerade erst das Attachment oeffnen koennen. Das Interview ist gut - wenn noch moeglich zwei Verbesserungen:

- (1) Ich bin nur einer der Chairman der Zoonoses-Konferenz.
- (2) Es ist nicht ELSA3 sondern ELWA3.

Viele Gruesse, Heinz

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Friday, October 10, 2014 05:14 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Christina Sartori <info@christina-sartori.de>
Sent: Tuesday, October 14, 2014 7:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz

super, vielen Dank, hoffe es geht Ihnen gut. Ich übernehme die Änderungen.

Dürfen wir auch das Foto von Ihnen verwenden, das auch auf der Website zu sehen ist? Haben Sie noch ein Ebola Foto?

Viele Grüße, Christina

"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> hat am 14. Oktober 2014 um 15:44 geschrieben:

Christina,

Habe gerade erst das Attachment oeffnen koennen. Das Interview ist gut - wenn noch moeglich zwei Verbesserungen:

- (1) Ich bin nur einer der Chairman der Zoonoses-Konferenz.
- (2) Es ist nicht ELSA3 sondern ELWA3.

Viele Gruesse, Heinz

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Friday, October 10, 2014 05:14 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz,

ich hoffe Sie sind wohlbehalten aus Liberia zurückgekehrt.

Anbei die endgültige Version für das Interview, das begleitend zum German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses im Internet veröffentlicht werden soll. Können Sie es bis Montag durchsehen, Ihre Änderungswünsche eintragen und freigeben? Das wäre sehr hilfreich, um es noch rechtzeitig zur Konferenz einzustellen.

Haben Sie ein Foto von sich das wir verwenden können? Auf der Website ist eins

<http://www.zoonoses2014.com/#!welcome/c23yr>

wenn Sie einverstanden sind, nehmen wir das. Und haben Sie eventuell ein Foto vom Ebola Virus, dass wir mit dem Interview verwenden könnten?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Randy Cron, M.D. <rcron@peds.uab.edu>
Sent: Tuesday, October 14, 2014 7:51 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

OK, hopefully this can help with future epidemics.

I look forward to your call when you return.

Safe travels,

Randy

Randy C. Cron, MD, PhD
Professor of Pediatrics & Medicine
Arthritis Foundation, Alabama Chapter, Endowed Chair
Director, Division of Pediatric Rheumatology
Children's Hospital of Alabama/
University of Alabama at Birmingham
Children's Park Place, Ste. 210
1601 4th Avenue South
Birmingham, AL 35233

Tel.: (205) 996-9191
Email: rcron@peds.uab.edu
FAX: (205) 996-9545

lab webpages:

<http://www.uab.edu/medicine/immunology/faculty?id=81:cron&catid=39:faculty>
http://138.26.61.118/depts/MEB/SOMResearchFaculty/currentfacultydata.asp?s_iname=cron&s_keyword=&s_fname=&s_Department_Name=&s_ResearchTitle=&ID=RCRON
<https://services.medicine.uab.edu/facultydirectory/FacultyData.asp?FID=30608>

division webpages:

<https://www.uab.edu/medicine/peds/rheum>
<http://www.uab.edu/medicine/rheumatology/faculty/62-randy-q-cron-md-phd>

PLEASE REMOVE ANY NON-BUSINESS PICTURES AND QUOTES FROM YOUR EMAIL SIGNATURE. WE WANT TO PROJECT A PROFESSIONAL IMAGE IN ALL ASPECTS OF OUR WORK.

Confidentiality Notice: The information transmitted is intended only for the person or company to which it is addressed and may contain confidential or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action of any reliance upon, this information by person or company other than the intended recipient is prohibited. If you receive this in error, please contact the sender and delete the material from any computer.

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Tuesday, October 14, 2014 8:48 AM
To: Randy Cron, M.D.
Subject: Re: Ebola

I am in Monrovia until early November. We can discuss when I get back, but given our workload at RML in regards to Ebola additional animal experiments cannot happen before spring 2015.


Best wishes, Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Tuesday, October 14, 2014 7:49 AM
To: Safronetz, David (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]; Haddock, Elaine (NIH/NIAID) [E]; Mire, Chad
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Unpublished

Dave,

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Randy Cron, M.D. <rcron@peds.uab.edu>
Sent: Tuesday, October 14, 2014 7:40 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola
Attachments: Proposal for the use of anakinra in the treatment of Ebola hemorrhagic fever2.docx

Dear Dr. Feldmann,

I would love to speak you to some time by phone to discuss the potential role of IL-1 blockade in treating Ebola and whether this would be of interest to your laboratory research using animal models.

Please let me know times you might be available to speak by phone if you are interested. I've attached a proposal with some rationale for why this will help those infected with Ebola.

Thank you much,

Randy

Randy Q. Cron, MD, PhD
Professor of Pediatrics & Medicine
Arthritis Foundation, Alabama Chapter, Endowed Chair
Director, Division of Pediatric Rheumatology
Children's Hospital of Alabama/
University of Alabama at Birmingham
Children's Park Place, Ste. 210
1601 4th Avenue South
Birmingham, AL 35233

Tel.: (205) 996-9191
Email: rcron@peds.uab.edu
FAX: (205) 996-9545

lab webpages:

<http://www.uab.edu/medicine/immunology/faculty?id=81:cron&catid=39:faculty>
http://138.26.61.118/depts/MEB/SOMResearchFaculty/currentfacultydata.asp?s_iname=cron&s_keyword=&s_fname=&s_Department_Name=&s_ResearchTitle=&ID=RCRON
<https://services.medicine.uab.edu/facultydirectory/FacultyData.asp?FID=30608>

division webpages:

<https://www.uab.edu/medicine/peds/rheum>
<http://www.uab.edu/medicine/rheumatology/faculty/62-randy-q-cron-md-phd>

PLEASE REMOVE ANY NON-BUSINESS PICTURES AND QUOTES FROM YOUR EMAIL SIGNATURE. WE WANT TO PROJECT A PROFESSIONAL IMAGE IN ALL ASPECTS OF OUR WORK.

Confidentiality Notice: The information transmitted is intended only for the person or company to which it is addressed and may contain confidential or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action of any reliance upon, this information by person or company other than the intended recipient is prohibited. If you receive this in error, please contact the sender and delete the material from any computer.

From: Auchincloss, Hugh (NIH/NIAID) [E] [mailto:auchincloss@niaid.nih.gov]
Sent: Tuesday, October 14, 2014 8:33 AM
To: Randy Cron, M.D.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kratochvil, Christopher J <ckratoch@unmc.edu>
Sent: Tuesday, October 14, 2014 7:26 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Liberia Ebola case

Will do, thanks.
Take care,
Chris

Christopher J. Kratochvil, M.D.
Associate Vice Chancellor for Clinical Research
Vice President for Research
Chief Medical Officer, UNeHealth
University of Nebraska Medical Center
402-559-8490

The information in this e-mail is privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Tuesday, October 14, 2014 7:37 AM
To: Kratochvil, Christopher J; Iwen, Peter C; Hinrichs, Steven H
Cc: Smith, Philip W; Khan, Ali S
Subject: Re: Liberia Ebola case

Let me know what you need from our end. I would have to involve one of my colleagues as I am currently in Monrovia.

Thanks, Heinz

From: Kratochvil, Christopher J [mailto:ckratoch@unmc.edu]
Sent: Tuesday, October 14, 2014 07:52 AM Eastern Standard Time
To: Iwen, Peter C <piwen@unmc.edu>; Hinrichs, Steven H <shinrich@unmc.edu>; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W <pwsmith@unmc.edu>; Khan, Ali S <ali.khan@unmc.edu>
Subject: RE: Liberia Ebola case

Good Morning,

As I have been thinking through the potential for significant research opportunities with the samples we have available from the patients admitted to the biocontainment unit, I have decided we need to develop an IRB protocol to allow for as broad of research as appropriate with these samples, thereby limiting the need for repeated individual IRBs.

Phil, if ok with you, I think this would be a good approach. I can contact Bruce Gordon & Ernie Prentice to get the IRB's take on how broad of scope we could include. If the folks on this e-mail can provide me with a listing of potential use cases we would want to consider that will help me to make sure we are considering the breadth of opportunities.

Chris

Christopher J. Kratochvil, M.D.
Associate Vice Chancellor for Clinical Research
Vice President for Research
Chief Medical Officer, UNeHealth
University of Nebraska Medical Center
402-559-8490

Feldmann, Heinrich (NIH/NIAID) [E]

From: Eyler, Allison (NIH) [C]
Sent: Tuesday, October 14, 2014 7:22 AM
To: Pineda, Mark (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Imes, Jen (NIH) [C]; Koogler, Steven (NIH/NCI) [C]
Subject: RE: 2014 Biennial Inventory - National Institute Communicable Diseases

Hi Mark,

We were thinking that was the case. Thanks for your response – we will wait to hear from someone.

Allison

Allison Eyler
Secretary III
Clinical Monitoring Research Program
Frederick National Laboratory for Cancer Research
Leidos Biomedical Research, Inc.
Support to National Institute of Allergy and Infectious Diseases
5705 Industry Lane, Suite J
Frederick, MD 21704
Phone: (301) 846-5707
Fax: (301) 846-7514
Email: Allison.Eyler@fnlcr.nih.gov

This e-mail and any attachments to it are intended only for the identified recipient. It may contain proprietary or otherwise legally protected information for Leidos Biomedical Research, Inc. Any unauthorized use or disclosure of this communication is strictly prohibited. If you have received this communication in error, please notify the sender and delete or otherwise destroy the e-mail and all attachments immediately.

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 12:33 AM
To: Eyler, Allison (NIH) [C]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: 2014 Biennial Inventory - National Institute Communicable Diseases

Dear Allison:

Heinz is tied up at the moment in Monrovia contributing to the Ebola response. To the best of my understanding Dr. Paweska's team is also supporting the Ebola outbreak in west Africa.

We will try to address this as soon as practical.

Sincerely,

Mark

From: Eyler, Allison (NIH) [C]
Sent: Friday, October 10, 2014 04:01 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Janusz Paweska <januszp@nicd.ac.za>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:59 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); 'woodd@who.int'
Subject: RE: Collaborative study

We will make sure that we contact you before we start this process.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 8:56 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); 'woodd@who.int'
Subject: Re: Collaborative study

Let me know when you need my input as I am still in Monrovia.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 08:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); David John WOOD (woodd@who.int) <woodd@who.int>
Subject: RE: Collaborative study

OK. Thank you Heinz.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 8:45 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

I can do that. I know it is a high priority for WHO - I am slightly less convinced about the approach but it needs to be tested. My reservation is based on the difficulties to get sufficient amount, difficulties with blood safety, and timing as high affinity neutralizing antibodies will likely not show up before months after survival.



Anyhow - I am in.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 06:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Collaborative study

Redacted by
agreement

Yes. It is. I don't know what  is doing but it seems reasonable for us to participate if WHO and CBER are eager for us to do so. 

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:48 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); David John WOOD (woodd@who.int)
Subject: RE: Collaborative study

OK. Thank you Heinz.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 8:45 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

I can do that. I know it is a high priority for WHO - I am slightly less convinced about the approach but it needs to be tested. My reservation is based on the difficulties to get sufficient amount, difficulties with blood safety, and timing as high affinity neutralizing antibodies will likely not show up before months after survival.

Anyhow - I am in.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 06:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Collaborative study

Redacted by
agreement

Yes. It is. I don't know what [REDACTED] is doing but it seems reasonable for us to participate if WHO and CBER are eager for us to do so. [REDACTED]

[REDACTED] We will have follow up discussions with CBER which I hope that you can take the lead in for DIR. Any help you can provide would be greatly appreciated. Apparently this is a top priority for WHO.

Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:17 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

Is this convalescence plasma/serum? [REDACTED]

It might be helpful if done at more than one place. From where do we get the material?

We can help.

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kratochvil, Christopher J <ckratoch@unmc.edu>
Sent: Tuesday, October 14, 2014 5:53 AM
To: Iwen, Peter C; Hinrichs, Steven H; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W; Khan, Ali S
Subject: RE: Liberia Ebola case

Good Morning,

As I have been thinking through the potential for significant research opportunities with the samples we have available from the patients admitted to the biocontainment unit, I have decided we need to develop an IRB protocol to allow for as broad of research as appropriate with these samples, thereby limiting the need for repeated individual IRBs.

Phil, if ok with you, I think this would be a good approach. I can contact Bruce Gordon & Ernie Prentice to get the IRB's take on how broad of scope we could include. If the folks on this e-mail can provide me with a listing of potential use cases we would want to consider that will help me to make sure we are considering the breadth of opportunities.

Chris

Christopher J. Kratochvil, M.D.
Associate Vice Chancellor for Clinical Research
Vice President for Research
Chief Medical Officer, UNeHealth
University of Nebraska Medical Center
402-559-8490

The information in this e-mail is privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Iwen, Peter C
Sent: Monday, October 13, 2014 12:48 PM
To: Hinrichs, Steven H; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W; Khan, Ali S; Kratochvil, Christopher J
Subject: RE: Liberia Ebola case

Steve,

I have been in contact with the CDC and they have assured me by e-mail that they will not culture our specimens. Redacted by agreement This would seem to me an alternative that could be done. We would still need to look at the patient consent issue. Pete

Peter C. Iwen, MS, PhD, D(ABMM)
Professor, Pathology and Microbiology
Director, NE Public Health Laboratory
Biosafety Officer
Univer. Nebraska Med. Ctr.
985900 Nebraska Medical Center
Omaha, Nebraska 68198-5900

PH: 402.559.7774, FAX: 402.559.7799
e-mail: piwen@unmc.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 4:26 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Collaborative study

Redacted by
agreement

Yes. It is. I don't know what [REDACTED] is doing but it seems reasonable for us to participate if WHO and CBER are eager for us to do so. [REDACTED]

[REDACTED] We will have follow up discussions with CBER which I hope that you can take the lead in for DIR. Any help you can provide would be greatly appreciated. Apparently this is a top priority for WHO.

Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:17 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

Is this convalescence plasma/serum? [REDACTED]

It might be helpful if done at more than one place. From where do we get the material?

We can help.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 04:53 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Collaborative study

Heinz

Would you be willing to participate in a collaborative study with CBER and WHO to test ebola immune serum with the appropriate controls in NHP ebola challenge studies? I think this would provide some very important data on which future clinical studies may be considered.

Regards
Kathy
Kathy

Sent from my BlackBerry Wireless Handheld

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Jarvis <michael.jarvis@plymouth.ac.uk>
Sent: Tuesday, October 14, 2014 4:05 AM
To: Marzi, Andrea (NIH/NIAID) [E]; Ilhem Messaoudi Powers; Aisling Murphy
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: memory lapses
Attachments: Unpublished

Andrea, Ilhem and Aisling,

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 2:53 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Collaborative study

Heinz

Would you be willing to participate in a collaborative study with CBER and WHO to test ebola immune serum with the appropriate controls in NHP ebola challenge studies? I think this would provide some very important data on which future clinical studies may be considered.

Regards

Kathy

Kathy

Sent from my BlackBerry Wireless Handheld

Feldmann, Heinrich (NIH/NIAID) [E]

From: Achenbach, Joel <Joel.Achenbach@washpost.com>
Sent: Monday, October 13, 2014 7:11 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: doing another science story on Ebola, need your help Dr. Feldmann

Dear Heinz:

Hi, we need to do another piece on what is and isn't known about Ebola. We're seeing some contradictory information. Vox has an interview with Peter Jahrling in which he says the viral load is unusually high in the W. African Ebola patients. And he also has a comment, which is a bit enigmatic:

It turns out that in limited studies with the evacuated patients, they continued to express virus in blood and semen. What does that mean? Right now, we just don't know.

Here's the Vox article:

<http://www.vox.com/2014/10/13/6959087/ebola-outbreak-virus-mutated-airborne>

excerpt:

Julia Belluz: What concerns you most about the virus circulating now?

Peter Jahrling: I want to know if this virus is intrinsically different from the one we have seen before, if it is a more virulent strain. We are using tests now that weren't using in the past, but there seems to be a belief that the virus load is higher in these patients [today] than what we have seen before. If true, that's a very different bug.

One of the studies we're going to do here is to test the virulence of this new strain in experimentally infected primates and compare it with the reference strain, and look at whether it is hotter, extrapolating from monkeys to people. It may be that the virus burns hotter and quicker [meaning it's more contagious and easily spread].

Thanks much

Joel Achenbach
National Enterprise Reporter
The Washington Post
202-334-7261 - office

Personal Info -cell

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hinrichs, Steven H <shinrich@unmc.edu>
Sent: Monday, October 13, 2014 5:19 PM
To: Iwen, Peter C
Cc: Khan, Ali S; Smith, Philip W; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Liberia Ebola case

Peter

We need to have the IRB involved with this because when we asked to have the samples declared excess material for research purposes, they said we needed informed consent.

It never ends.

Steve

Steven Hinrichs, M.D.
Professor and Chair
Dept. of Pathology and Microbiology, UNMC
Office: 402 559 7255

On Oct 13, 2014, at 4:22 PM, "Iwen, Peter C" <piwen@unmc.edu> wrote:

Dr. Khan,

I have asked our SA certificate manager and others in the DSAT program for advice on this issue of Ebola positive specimen storage and changes to our registration certificate. My concern is that if we were to register for storage of Ebola virus positive specimens in our Certificate of Registration, would this then eliminate our ability to use these specimens for validation testing of new molecular assays? Storage to me means no research.

We are proposing to do these validation studies (we have already had requests on this) with these positive specimens (we are awaiting IRB approval to do this testing) under the guidance that these are not select agents (never been cultured).

Culture of the specimens would also make shipment of these samples a much harder process if they get classified as select agents as you know. Of course we do not know what DSAT will do in the future. They may make all PCR positive specimens select agents which certainly will change how these specimens can be used. It is hard enough to send Ebola positive specimens....we do have stories to tell about this process....

Thanks for your thoughts on this as well. Pete

Peter C. Iwen, MS, PhD, D(ABMM)
Professor, Pathology and Microbiology
Director, NE Public Health Laboratory
Biosafety Officer
Univer. Nebraska Med. Ctr.
985900 Nebraska Medical Center
Omaha, Nebraska 68198-5900

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Monday, October 13, 2014 5:05 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hinrichs, Steven H; Iwen, Peter C; Smith, Philip W
Subject: RE: Redacted by agree

Excellent. Not select agents; still diagnostic specimens. No form 2.

Ali

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 6:03 PM
To: Khan, Ali S
Cc: Hinrichs, Steven H; Iwen, Peter C; Smith, Philip W
Subject: Re: Redacted by agree

This is strange. I don't want to get anyone into trouble over this. If samples can be shipped, please let me know and we will make necessary arrangements. I think we (RML) need a form 2 to receive the samples.

I am not upset - just do not want to get anyone into trouble.

Heinz

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Monday, October 13, 2014 06:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hinrichs, Steven H <shinrich@unmc.edu>; Iwen, Peter C <piwen@unmc.edu>; Smith, Philip W <pwsmith@unmc.edu>
Subject: RE: Redacted by agree

Thanks Heinz. Keep reading. Peter has a solution.

These are NOT BSL-4 by the regs until cultured.

Ali

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 5:47 PM
To: Iwen, Peter C; Smith, Philip W; Khan, Ali S
Cc: Hinrichs, Steven H
Subject: Re: Redacted by

Just forget it. You should not be allowed to keep the samples anyway as the patients are confirmed cases. This makes the samples BSL4 and you should not have them if you are not certified. Thanks for your consideration. We will find a different way.

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Monday, October 13, 2014 4:58 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hinrichs, Steven H; Iwen, Peter C; Smith, Philip W
Subject: RE: Redacted by agreeme

Thanks Heinz. Keep reading. Peter has a solution.
These are NOT BSL-4 by the regs until cultured.
Ali

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 5:47 PM
To: Iwen, Peter C; Smith, Philip W; Khan, Ali S
Cc: Hinrichs, Steven H
Subject: Re: Redacted by

Just forget it. You should not be allowed to keep the samples anyway as the patients are conformed cases. This makes the samples BSL4 and you should not have them if you are not certified. Thanks for your consideration. We will find a different way.

Heinz

From: Iwen, Peter C [mailto:piwen@unmc.edu]
Sent: Monday, October 13, 2014 01:45 PM Eastern Standard Time
To: Smith, Philip W <pwsmith@unmc.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Cc: Hinrichs, Steven H <shinrich@unmc.edu>
Subject: RE: Redacted by agreemen

Hi Phil and Heinrich,

Redacted by agreement. There are a number of issues about sharing these specimens that would make this a large hurdle to accomplish.

1. Once the blood has been cultured, then all specimens in our possession will become select agents if I interpret the DSAT rules correctly. This means that we would no longer be able to have these Ebola positive specimens (at least ones from any patient who has been cultured) in our possession since our laboratory is not approved for Ebola virus on our certificate of registration with the select agent program (we also would not be able to get this certification since we do not have a BSL-4 laboratory, which would most likely be a requirement).
2. We would need to destroy or ship all of our specimens to an approved laboratory (once cultured). This would essentially would not allow for us to do any molecular diagnostic research on these specimens.
3. Shipment of the specimens would require a large cost (we now know that it costs \$1900 for one shipment of Ebola-positive specimens) and also would require that we file the paperwork and get approval by DSAT to be able to ship these specimens, not an insignificant task.
4. Patient consent according to our in-house IRB is required to do research on these specimens.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Monday, October 13, 2014 4:57 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Redacted by agreem

The samples are not BSL-4 by the regs until they are cultured.
They have offered you a solution that will give you sequence data.
Ali

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 5:47 PM
To: Iwen, Peter C; Smith, Philip W; Khan, Ali S
Cc: Hinrichs, Steven H
Subject: Re: Redacted by agreeme

Just forget it. You should not be allowed to keep the samples anyway as the patients are conformed cases. This makes the samples BSL4 and you should not have them if you are not certified. Thanks for your consideration. We will find a different way.

Heinz

From: Iwen, Peter C [mailto:piwen@unmc.edu]
Sent: Monday, October 13, 2014 01:45 PM Eastern Standard Time
To: Smith, Philip W <pwsmith@unmc.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Cc: Hinrichs, Steven H <shinrich@unmc.edu>
Subject: RE: Redacted by agreem

Hi Phil and Heinrich,

Redacted by agreement There are a number of issues about sharing these specimens that would make this a large hurdle to accomplish.

1. Once the blood has been cultured, then all specimens in our possession will become select agents if I interpret the DSAT rules correctly. This means that we would no longer be able to have these Ebola positive specimens (at least ones from any patient who has been cultured) in our possession since our laboratory is not approved for Ebola virus on our certificate of registration with the select agent program (we also would not be able to get this certification since we do not have a BSL-4 laboratory, which would most likely be a requirement).
2. We would need to destroy or ship all of our specimens to an approved laboratory (once cultured). This would essentially would not allow for us to do any molecular diagnostic research on these specimens.
3. Shipment of the specimens would require a large cost (we now know that it costs \$1900 for one shipment of Ebola-positive specimens) and also would require that we file the paperwork and get approval by DSAT to be able to ship these specimens, not an insignificant task.
4. Patient consent according to our in-house IRB is required to do research on these specimens.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zarembo, Alan <Alan.Zarembo@latimes.com>
Sent: Monday, October 13, 2014 3:43 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: l.a. times writer on deadline

Dear Dr. Feldmann,

This is Alan Zarembo, a science writer at the L.A. Times.

I'm working on deadline on a story about the protective suits used by health care workers treating patients with ebola, and I'm looking for experts who can discuss in detail the suits, how they are tested, the steps for taking them on and off and the places where breaches could possibly occur. Hoping you can help.

(Dupont has provided me with this info sheet: http://www.dupont.com/content/dam/assets/products-and-services/personal-protective-equipment/assets/DPP14_20240_Ebola_Tech_Bulletin_%2091114b.pdf Are there other makers of protective gear, or is the Tychem C the most common suit for these situations?)

I understand you may be in Africa, but on the off-chance you get this, I'd be happy call or continue e-mailing.

Sincerely,
Alan

Alan Zarembo
Staff Writer
The Los Angeles Times
213-237-7009
Toll free 1-800-LATIMES ext. 77009
alan.zarembo@latimes.com
Twitter @AlanZarembo

Feldmann, Heinrich (NIH/NIAID) [E]

From: Iwen, Peter C <piwen@unmc.edu>
Sent: Monday, October 13, 2014 3:22 PM
To: Khan, Ali S
Cc: Hinrichs, Steven H; Smith, Philip W; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Redacted by agree

Dr. Khan,

I have asked our SA certificate manager and others in the DSAT program for advice on this issue of Ebola positive specimen storage and changes to our registration certificate. My concern is that if we were to register for storage of Ebola virus positive specimens in our Certificate of Registration, would this then eliminate our ability to use these specimens for validation testing of new molecular assays? Storage to me means no research.

We are proposing to do these validation studies (we have already had requests on this) with these positive specimens (we are awaiting IRB approval to do this testing) under the guidance that these are not select agents (never been cultured).

Culture of the specimens would also make shipment of these samples a much harder process if they get classified as select agents as you know. Of course we do not know what DSAT will do in the future. They may make all PCR positive specimens select agents which certainly will change how these specimens can be used. It is hard enough to send Ebola positive specimens....we do have stories to tell about his process....

Thanks for your thoughts on this as well. Pete

Peter C. Iwen, MS, PhD, D(ABMM)
Professor, Pathology and Microbiology
Director, NE Public Health Laboratory
Biosafety Officer
Univer. Nebraska Med. Ctr.
985900 Nebraska Medical Center
Omaha, Nebraska 68198-5900

PH: 402.559.7774, FAX: 402.559.7799
e-mail: piwen@unmc.edu

The information contained in this email is privileged, confidential and intended only for the use of the addressee(s) listed above

From: Khan, Ali S
Sent: Monday, October 13, 2014 3:44 PM
To: Iwen, Peter C
Cc: Hinrichs, Steven H; Smith, Philip W; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Redacted by agree

Dear Peter:

I saw the proposed plan to send specimens for direct sequencing without culture – thank you.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Monday, October 13, 2014 2:44 PM
To: Iwen, Peter C
Cc: Hinrichs, Steven H; Smith, Philip W; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Redacted by agreement

Dear Peter:

I saw the proposed plan to send specimens for direct sequencing without culture – thank you.

Please submit an amended Form 1 to the select agent program. Asking for approval for storage ONLY of Ebola in appropriate secure location. This will protect your specimens even after a virus is cultured or if new rules are promulgated that include clinical specimens of confirmed patients regardless of virus isolation.

Thanks

ask

From: Iwen, Peter C
Sent: Monday, October 13, 2014 12:46 PM
To: Smith, Philip W; Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S
Cc: Hinrichs, Steven H
Subject: RE: Redacted by agreement

Hi Phil and Heinrich,

Redacted by agreement There are a number of issues about sharing these specimens that would make this a large hurdle to accomplish.

1. Once the blood has been cultured, then all specimens in our possession will become select agents if I interpret the DSAT rules correctly. This means that we would no longer be able to have these Ebola positive specimens (at least ones from any patient who has been cultured) in our possession since our laboratory is not approved for Ebola virus on our certificate of registration with the select agent program (we also would not be able to get this certification since we do not have a BSL-4 laboratory, which would most likely be a requirement).
2. We would need to destroy or ship all of our specimens to an approved laboratory (once cultured). This would essentially would not allow for us to do any molecular diagnostic research on these specimens.
3. Shipment of the specimens would require a large cost (we now know that it costs \$1900 for one shipment of Ebola-positive specimens) and also would require that we file the paperwork and get approval by DSAT to be able to ship these specimens, not an insignificant task.
4. Patient consent according to our in-house IRB is required to do research on these specimens.

So unless I am missing something, it would appear that the DSAT rules would make this a very difficult exercise and thus essentially leave us with no specimens. I will be interested to see if there are other thoughts on how this might be accomplished. Maybe DSAT has an exception? Pete

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]@gmail.com>
Sent: Monday, October 13, 2014 2:01 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola cure

I would like to volunteer to be injected with this horrible virus, on terms that you use any and all information gained to further and quite possibly finalize a cure for it. I understand that one of the main difficulties is that in order to fully understand it's effect inside our bodies, you'd need to monitor the exact process of events that take place from the initial infection. If I can be of service, please get back to me. I would be honored to potentially risk my health, to be able to end this thing from having the impact it will have on perhaps thousands if not more other people in our country, in the world. My direct number that you can reach me at is [Personal I] [Perso] My name is [Personal Info]. I am a 25 year old male, from Wayne County, Michigan. On top of that, I'd like to personally thank you for all that you are doing in your line of work. Have a great day.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 1:49 PM
To: Chil-Yong Kang
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; sklee@curocom.com; Menk, Kay (NIH/NIAID) [E]
Subject: Re: 회신: Re: 회신: RE: Re: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Will probably ship next Monday.
Thanks, A.

From: Chil-Yong Kang <cykang@uwo.ca>
Date: Monday, October 13, 2014 12:58 PM
To: Andrea Marzi <marzia@niaid.nih.gov>
Cc: Heinz Feldmann <feldmannh@niaid.nih.gov>, "sklee@curocom.com" <sklee@curocom.com>, "Menk, Kay (NIH/NIAID) [E]" <menkk@niaid.nih.gov>
Subject: 회신: Re: 회신: RE: Re: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Dear Andrea,

Good to hear from you.

Thank you for arranging the shipment of ZEBOV Mayinga NP, VP40, GP and ZEBOV Kikwit GP plasmids.
Please send me the restriction maps and sequences of each plasmid along with plasmid DNAs.

My FedEx Account number is: Redacted by ag

and the shipping address is;

Dr. C. Yong Kang
Siebens-Drake Medical Research Institute, Room 129
The University of Western Ontario
1400 Western Road, London, Ontario Canada N6G 2V4
Tel. 519-661-3226, or 519-871-3991
Email address; cykang@uwo.ca

Please contact me should you need additional information.

With best regards and thanks,

Yong

10.13.14 에 "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov> 작성:

Dear Yong,

I can send the plasmids for ZEBOV Mayinga NP, VP40, GP and ZEBOV Kikwit GP anytime.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Chil-Yong Kang <cykang@uwo.ca>
Sent: Monday, October 13, 2014 12:59 PM
To: Marzi, Andrea (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; sklee@curocom.com; Menk, Kay (NIH/NIAID) [E]
Subject: 회신: Re: 회신: RE: Re: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Dear Andrea,

Good to hear from you.

Thank you for arranging the shipment of ZEBOV Mayinga NP, VP40, GP and ZEBOV Kikwit GP plasmids.

Please send me the restriction maps and sequences of each plasmid along with plasmid DNAs.

My FedEx Account number is: Redacted by

and the shipping address is;

Dr. C. Yong Kang
Siebens-Drake Medical Research Institute, Room 129
The University of Western Ontario
1400 Western Road, London, Ontario Canada N6G 2V4
Tel. 519-661-3226, or 519-871-3991
Email address: cykang@uwo.ca

Please contact me should you need additional information.

With best regards and thanks,

Yong

10.13.14 에 "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov> 작성:

Dear Yong,

I can send the plasmids for ZEBOV Mayinga NP, VP40, GP and ZEBOV Kikwit GP anytime.

Would be great if you could provide your address and FedEx account number so we can set up the shipment.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 12:05 PM
To: Chil-Yong Kang
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; sklee@curocom.com; Menk, Kay (NIH/NIAID) [E]
Subject: Re: 회신: RE: Re: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Dear Yong,

I can send the plasmids for ZEBOV Mayinga NP, VP40, GP and ZEBOV Kikwit GP anytime.
Would be great if you could provide your address and FedEx account number so we can set up the shipment.

Thanks,
Andrea

From: Chil-Yong Kang <cykang@uwo.ca>
Date: Friday, October 10, 2014 11:34 AM
To: "Menk, Kay (NIH/NIAID) [E]" <menkk@niaid.nih.gov>, Andrea Marzi <marzia@niaid.nih.gov>
Cc: Heinz Feldmann <feldmannh@niaid.nih.gov>, "sklee@curocom.com" <sklee@curocom.com>
Subject: 회신: RE: Re: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Thank you Kay.
We look forward to receiving the clones.
Have a nice weekend.
Yong

10.10.14 에 "Menk, Kay (NIH/NIAID) [E]" <menkk@niaid.nih.gov> 작성:

Good morning,

Attached is the fully executed SLA. Please arrange shipment with Dr. Andrea Marzi.

Contact us with any questions.

Thank you.

Kay

Kay R. Menk, Laboratory Operations Specialist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-9624
Fax: (406) 375-9620
Email: menkk@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Chizhikov Eduard <euchizhikov@rttv.ru>
Sent: Monday, October 13, 2014 11:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RT interview request

Dear Mr. Heinz Feldmann

My name is Eduard Chizhikov and I am a producer at RT International, a global 24/7 news network.

I am writing you regarding the Ebola and it's mutation possibility, we've been reading your comments here:

<http://news.sciencemag.org/africa/2014/09/confronting-ebola-virologist-liberias-hot-zone>

RT is interested in interviewing you on this matter to gain your full professional opinion on it. It would be an honor having you on air.

The interview will not last longer than 5-7 minutes.

Thank you in advance for considering our request.

About RT:

RT is a global multilingual television news network, broadcasting around-the-clock from Moscow across five continents to more than 100 countries in English, Arabic and Spanish. The RT network also includes RT America, broadcasting from RT's Washington, DC studios, the documentary channel RTDoc, and a brand new video agency, Ruptly. With a global reach of over 630 million people – or 28% of all paid cable networks' subscribers – and more than 2.7 million hotel rooms worldwide, RT covers the major political, economic and cultural issues of the time for viewers wanting to question more. The best news reports, stories and programmes can be found on RT's YouTube channel, where the number of views has already exceeded 1 billion, making RT the first TV news channel to break this record in YouTube's history and also making the network the largest provider of news video footage on this world's most popular video platform.

According to official ratings by the UK's Broadcasters' Audience Research Board, RT is the third most popular TV news channel in Great Britain after BBC News and Sky News, and scores higher viewership than other foreign news channels measured by BARB, including Al Jazeera English, Fox News and Euronews (BARB ratings for the 3rd quarter 2012). In the U.S. more than 85 million viewers receive RT around the clock. Nielsen has found RT's audience in key U.S. cities to be bigger than that of other major international news channels including Euronews, France 24, Deutsche Welle, Al Jazeera English, NHK World and CCTV News. According to Nielsen, the average RT viewer in America is a male aged between 35 and 49, and either a business owner, self-employed, or employed in a management role; over 20 percent of RT viewers hold a Master's degree or a Ph.D. RT is the only Russian TV news channel to garner two nominations for the prestigious Emmy International Award.

Chizhikov Eduard,
Producer

Feldmann, Heinrich (NIH/NIAID) [E]

From: Iwen, Peter C <piwen@unmc.edu>
Sent: Monday, October 13, 2014 11:48 AM
To: Hinrichs, Steven H; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W; Khan, Ali S; Kratochvil, Christopher J
Subject: RE: Redacted by agreement

Steve,

I have been in contact with the CDC and they have assured me by e-mail that they will not culture our specimens. Redacted by agreement This would seem to me an alternative that could be done. We would still need to look at the patient consent issue. Pete

Peter C. Iwen, MS, PhD, D(ABMM)
Professor, Pathology and Microbiology
Director, NE Public Health Laboratory
Biosafety Officer
Univer. Nebraska Med. Ctr.
985900 Nebraska Medical Center
Omaha, Nebraska 68198-5900

PH: 402.559.7774, FAX: 402.559.7799
e-mail: piwen@unmc.edu

The information contained in this email is privileged, confidential and intended only for the use of the addressee(s) listed above

From: Hinrichs, Steven H
Sent: Monday, October 13, 2014 12:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W; Khan, Ali S; Iwen, Peter C
Subject: Re: Redacted by agreement

Heinrich

We believe CDC is doing this. Have you talked to Tim?
Steve.

Steven Hinrichs, M.D.
Professor and Chair
Dept. of Pathology and Microbiology, UNMC
Office: 402 559 7255

On Oct 13, 2014, at 12:22 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Thanks.

From: Smith, Philip W [<mailto:pwsmith@unmc.edu>]
Sent: Monday, October 13, 2014 01:20 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Cc: Hinrichs, Steven H <shinrich@unmc.edu>; Iwen, Peter C <piwen@unmc.edu>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Iwen, Peter C <piwen@unmc.edu>
Sent: Monday, October 13, 2014 11:46 AM
To: Smith, Philip W; Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S
Cc: Hinrichs, Steven H
Subject: RE: Redacted by agreement

Hi Phil and Heinrich,

Redacted by agreement

There are a number of issues about sharing these specimens that would make this a large hurdle to accomplish.

1. Once the blood has been cultured, then all specimens in our possession will become select agents if I interpret the DSAT rules correctly. This means that we would no longer be able to have these Ebola positive specimens (at least ones from any patient who has been cultured) in our possession since our laboratory is not approved for Ebola virus on our certificate of registration with the select agent program (we also would not be able to get this certification since we do not have a BSL-4 laboratory, which would most likely be a requirement).
2. We would need to destroy or ship all of our specimens to an approved laboratory (once cultured). This would essentially would not allow for us to do any molecular diagnostic research on these specimens.
3. Shipment of the specimens would require a large cost (we now know that it costs \$1900 for one shipment of Ebola-positive specimens) and also would require that we file the paperwork and get approval by DSAT to be able to ship these specimens, not an insignificant task.
4. Patient consent according to our in-house IRB is required to do research on these specimens.

So unless I am missing something, it would appear that the DSAT rules would make this a very difficult exercise and thus essentially leave us with no specimens. I will be interested to see if there are other thoughts on how this might be accomplished. Maybe DSAT has an exception? Pete

Peter C. Iwen, MS, PhD, D(ABMM)
Professor, Pathology and Microbiology
Director, NE Public Health Laboratory
Biosafety Officer
Univer. Nebraska Med. Ctr.
985900 Nebraska Medical Center
Omaha, Nebraska 68198-5900

PH: 402.559.7774, FAX: 402.559.7799
e-mail: piwen@unmc.edu

The information contained in this email is privileged, confidential and intended only for the use of the addressee(s) listed above

From: Smith, Philip W
Sent: Monday, October 13, 2014 12:20 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hinrichs, Steven H <shinrich@unmc.edu>
Sent: Monday, October 13, 2014 11:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W; Khan, Ali S; Iwen, Peter C
Subject: Re: Redacted by agree

Heinrich
We believe CDC is doing this. Have you talked to Tim?
Steve.

Steven Hinrichs, M.D.
Professor and Chair
Dept. of Pathology and Microbiology, UNMC
Office: 402 559 7255

On Oct 13, 2014, at 12:22 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Thanks.

From: Smith, Philip W [<mailto:pwsmith@unmc.edu>]
Sent: Monday, October 13, 2014 01:20 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Cc: Hinrichs, Steven H <shinrich@unmc.edu>; Iwen, Peter C <piwen@unmc.edu>
Subject: RE: Redacted by agree

Now I am tracking. I will forward this to our Micro staff. Thanks

Philip W Smith MD
Professor, Division of Infectious Diseases
985400 Nebraska Medical Center
Omaha, NE 68198-5400
Phone: 402-559-8650
Fax: 402-559-5581

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Monday, October 13, 2014 12:00 PM
To: Smith, Philip W; Khan, Ali S
Subject: Re: Redacted by agree

No blood samples left at your facility?

From: Smith, Philip W [<mailto:pwsmith@unmc.edu>]
Sent: Monday, October 13, 2014 11:21 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Subject: RE: Redacted by agree

Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Chow, Joanna <Joanna.Chow@foxbusiness.com>
Sent: Monday, October 13, 2014 11:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Fox Business

Ok, thanks!

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Monday, October 13, 2014 1:21 PM
To: Chow, Joanna
Subject: Re: Fox Business

No - contact the communication office of NIH.

From: Chow, Joanna [<mailto:Joanna.Chow@foxbusiness.com>]
Sent: Monday, October 13, 2014 01:19 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Fox Business

Ok, is there anyone else you can suggest?

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Monday, October 13, 2014 1:19 PM
To: Chow, Joanna
Subject: Re: Fox Business

No I am not - currently in the field until November 1.

From: Chow, Joanna [<mailto:Joanna.Chow@foxbusiness.com>]
Sent: Monday, October 13, 2014 01:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fox Business

Hi Dr. Feldmann,

I'm a producer at Fox Business and wanted to see if you're available for a live 4-6 minute interview at 5pm ET tonight regarding Ebola. Please let me know if possible. Thanks

Joanna Chow
The Willis Report
Fox Business Network
Office: 212 601 1320
joanna.chow@foxnews.com



Feldmann, Heinrich (NIH/NIAID) [E]

From: Smith, Philip W <pwsmith@unmc.edu>
Sent: Monday, October 13, 2014 11:20 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S
Cc: Hinrichs, Steven H; Iwen, Peter C
Subject: RE: [Redacted by agree]

Now I am tracking. I will forward this to our Micro staff. Thanks

Philip W Smith MD
Professor, Division of Infectious Diseases
985400 Nebraska Medical Center
Omaha, NE 68198-5400
Phone: 402-559-8650
Fax: 402-559-5581

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 12:00 PM
To: Smith, Philip W; Khan, Ali S
Subject: Re: [Redacted by agreem]

No blood samples left at your facility?

From: Smith, Philip W [mailto:pwsmith@unmc.edu]
Sent: Monday, October 13, 2014 11:21 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Subject: RE: [Redacted by]

Heinz,

I agree with your comments, [Redacted by agreement] They are at the CDC. Is this what you were asking?

Philip W Smith MD
Professor, Division of Infectious Diseases
985400 Nebraska Medical Center
Omaha, NE 68198-5400
Phone: 402-559-8650
Fax: 402-559-5581

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 5:00 AM
To: Khan, Ali S
Cc: Smith, Philip W
Subject: Re: [Redacted by agreeme]

Dear Philip,

[Redacted by agreement] We urgently need sequence data from Monrovia to potentially update and adapt diagnostics. We also would like to [Redacted by agreement]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Chow, Joanna <Joanna.Chow@foxbusiness.com>
Sent: Monday, October 13, 2014 11:20 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Fox Business

Ok, is there anyone else you can suggest?

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 1:19 PM
To: Chow, Joanna
Subject: Re: Fox Business

No I am not - currently in the field until November 1.

From: Chow, Joanna [mailto:Joanna.Chow@foxbusiness.com]
Sent: Monday, October 13, 2014 01:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fox Business

Hi Dr. Feldmann,

I'm a producer at Fox Business and wanted to see if you're available for a live 4-6 minute interview at 5pm ET tonight regarding Ebola. Please let me know if possible. Thanks

Joanna Chow
The Willis Report
Fox Business Network
Office: 212 601 1320
joanna.chow@foxnews.com



Feldmann, Heinrich (NIH/NIAID) [E]

From: Chow, Joanna <Joanna.Chow@foxbusiness.com>
Sent: Monday, October 13, 2014 11:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fox Business

Hi Dr. Feldmann,

I'm a producer at Fox Business and wanted to see if you're available for a live 4-6 minute interview at 5pm ET tonight regarding Ebola. Please let me know if possible. Thanks

Joanna Chow
The Willis Report
Fox Business Network
Office: 212 601 1320
joanna.chow@foxnews.com



Feldmann, Heinrich (NIH/NIAID) [E]

From: Beth Macdonell <Beth.Macdonell@bellmedia.ca>
Sent: Monday, October 13, 2014 10:15 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CTV Winnipeg news request - Today

Hi Dr. Fledmann,

Happy (Canadian) Thanksgiving!

Redacted by agreement

Hoping we can connect with you about this exciting news, and get some of your thoughts.

Please let me know the best way to reach you!

I am at 204 775 8016 in the newsroom.

Cheers and thanks,
Beth

Beth Macdonell | Producer & Reporter

CTV Winnipeg | t 204.788.3330 | c 204.619.1867 | f 204.943.3112

beth.macdonell@bellmedia.ca | Twitter: @bethmacdonell

400-345 Graham Avenue

Winnipeg, MB R3C 5S6

<http://winnipeg.ctvnews.ca/>



Feldmann, Heinrich (NIH/NIAID) [E]

From: Smith, Philip W <pwsmith@unmc.edu>
Sent: Monday, October 13, 2014 9:21 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S
Subject: RE: [Redacted by agreement]

Heinz,

I agree with your comments, [Redacted by agreement] They are at the CDC. Is this what you were asking?

Philip W Smith MD
Professor, Division of Infectious Diseases
985400 Nebraska Medical Center
Omaha, NE 68198-5400
Phone: 402-559-8650
Fax: 402-559-5581

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 5:00 AM
To: Khan, Ali S
Cc: Smith, Philip W
Subject: Re: [Redacted by agreement]

Dear Philip,

[Redacted by agreement] We urgently need sequence data from Monrovia to potentially update and adapt diagnostics. We also would like to compare [Redacted by agreement] [Redacted] in the nonhuman primate model.

We need to do it right - ethics and safety paperwork. RML can take care for all the DSAT (safety) paperwork - [Redacted] [Redacted by agreement]

Any help would be highly appreciated.

Best wishes,
Heinz

PS: thanks Ali.

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 12, 2014 10:02 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W <pwsmith@unmc.edu>
Subject: [Redacted by agreement]

Dear Phil :

Could you please see how we can be of assistance. Dr. Heinz Feldmann (head of Rocky Mountain labs) is a great collaborator and will be invaluable for any future Ebola efforts and has helped us with great consultation on

Feldmann, Heinrich (NIH/NIAID) [E]

From: Moresky, Rachel T. <rtm2102@cumc.columbia.edu>
Sent: Monday, October 13, 2014 9:17 AM
To: Lipkin, W. Ian; Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Cathy Roth; Spiropoulou, Christina (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Kahn, Eleanor J.
Subject: RE: Ebola Engineering Challenge

Ian,
Thanks for this. I am happy to be included in the process and story.
Best,
Rachel

Rachel T. Moresky, MD, MPH
Director, International Emergency Medicine Fellowship & sidHARTE Program
Assistant Professor of Medicine and Population & Family Health
Columbia University Mailman School of Public Health and College of Physicians & Surgeons

http://www.iemfellowships.com/prog_main.php?id=91
www.sidharte.org

From: W. Ian Lipkin [mailto:wil2001@columbia.edu]
Sent: Monday, October 13, 2014 10:32 AM
To: Sprecher Armand; Cathy Roth; Spiropoulou, Christina (CDC/OID/NCEZID); Heinz Feldmann; Lisa Hensley; Moresky, Rachel T.; Nichol Stuart T.
Cc: Kahn, Eleanor J.
Subject: Ebola Engineering Challenge

Dear Armand, Cathy, Christina, Heinz, Lisa, Rachel and Stuart,

Attached please find brief proposals that address needs that one or more of you have suggested might be amenable to low cost engineering solutions including improvements in decontamination of electronic equipment, disinfectant solutions, body bags, patient transport, and data collection and management. I will be vetting these proposals with the engineering faculty on Wednesday 15 October btw 11 AM and 3 PM EST. It would be helpful if you would fill in the attached score sheet by Tues evening. Please dont spend more than 30 minutes in total reading and scoring the proposals. What we want to know is whether you think the teams are meeting a need and whether a course correction or additional information is needed.

Thanks,

Ian

ps. The New Yorker Magazine will be writing this up as a feature story. Please tell me whether you do or dont want us to include your name.

W. Ian Lipkin, MD
John Snow Professor of Epidemiology,
Mailman School of Public Health

Professor of Neurology and Pathology,
College of Physicians and Surgeons

Director, Center for Infection and Immunity

Columbia University

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael G. Katze <honey@uw.edu>
Sent: Monday, October 13, 2014 8:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Status of Guinea Ebola Study?

All cool?

Michael G. Katze
Professor of Microbiology
University of Washington
KATZE LAB WEB PAGE
<http://viromics.washington.edu>

Feldmann, Heinrich (NIH/NIAID) [E]

From: W. Ian Lipkin <wil2001@columbia.edu>
Sent: Monday, October 13, 2014 8:32 AM
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Cathy Roth; Spiropoulou, Christina (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Rachel T. Moresky; Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Kahn Eleanor J.
Subject: Ebola Engineering Challenge
Attachments: CU_DesignChallenge_ProposalAbstracts_13Oct.pdf;
CU_DesignChallenge_Evaluations.docx

Dear Armand, Cathy, Christina, Heinz, Lisa, Rachel and Stuart,

Attached please find brief proposals that address needs that one or more of you have suggested might be amenable to low cost engineering solutions including improvements in decontamination of electronic equipment, disinfectant solutions, body bags, patient transport, and data collection and management. I will be vetting these proposals with the engineering faculty on Wednesday 15 October btw 11 AM and 3 PM EST. It would be helpful if you would fill in the attached score sheet by Tues evening. Please dont spend more than 30 minutes in total reading and scoring the proposals. What we want to know is whether you think the teams are meeting a need and whether a course correction or additional information is needed.

Thanks,

Ian

ps. The New Yorker Magazine will be writing this up as a feature story. Please tell me whether you do or dont want us to include your name.

W. Ian Lipkin, MD
John Snow Professor of Epidemiology,
Mailman School of Public Health

Professor of Neurology and Pathology,
College of Physicians and Surgeons

Director, Center for Infection and Immunity

Columbia University
www.cii.columbia.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Sunday, October 12, 2014 9:21 PM
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Clinical trials - Ebola

Dear Armand:

What a delight to hear from you. It has been a long time but I am glad for your leadership role in the current outbreak. And it is a small world if you worked in Omaha!

I am relishing my role as Dean to help educate the next generation of public health practitioners and discovery of new interventions. Also helping consult on the Ebola patients and help with communications.

We would like to participate in the clinical trial of possible and are in the process of writing one here to be a resource for others.

All my best and good luck.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

Begin forwarded message:

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
Date: October 9, 2014 at 9:03:36 AM CDT
To: "'ali.khan@unmc.edu'" <ali.khan@unmc.edu>
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
<armand.sprecher@brussels.msf.org>
Subject: Fw: Fw: CMX-001 or T705

Ali,

I talked to MSF - first Armand Sprecher and then the Monrovia Medical Lead Coordinator. He confirmed what Armand says in his response below. As you know Armand, please feel free to contact him directly - I did copy him on this email.

Let me know if I can be of further help.

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Sunday, October 12, 2014 8:03 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W
Subject: Liberia Ebola case

Dear Phil :

Could you please see how we can be of assistance. Dr. Heinz Feldmann (head of Rocky Mountain labs) is a great collaborator and will be invaluable for any future Ebola efforts and has helped us with great consultation on experimental therapeutics. He is my go to person. There are public health reasons to assure people no dramatic change in the virus.

Heinz: Dr. Phil Smith is head of our preparedness group and the lead clinician for the clinical cases. Very collaborative.

Thanks

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

On Oct 12, 2014, at 7:22 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Did you get the email from Armand Sprecher, MSF Belgium, which I forwarded to you? The email explained what needs to be done.

Redacted by agreement If so, could RML obtain it for virus isolation, sequencing and in vitro/in vivo studies? This would be important as we Redacted by agreement - we could compare to a later outbreak isolate. We still cannot get any samples out of Liberia - this may be a chance. If so, what do need to do to obtain the sample in terms of ethics. We can easily do the rest. Redacted by agreement Redacted b

Let me know as soon as possible.

Thanks and best wishes, Heinz

From: Khan, Ali S [<mailto:ali.khan@unmc.edu>]
Sent: Tuesday, October 07, 2014 07:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Study site

How go the conversations with MSF?
With so many patients and a 50% mortality we can assess the value of a drug very quickly.

Feldmann, Heinrich (NIH/NIAID) [E]

From:

Unpublished

Sent:

Sunday, October 12, 2014 6:02 PM

To:

Feldmann, Heinrich (NIH/NIAID) [E]

Subject:

Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Redacted by agreement
Sent: Sunday, October 12, 2014 5:38 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola trVLP system

Thanks for you quick reply. Could I call you at noon, east coast time, on Tuesday? If so, please let me know best #.

Please relay my best wishes for heinz' safety and gratitude for his service.

Sent from my iPad

> On Oct 12, 2014, at 7:03 PM, Hoenen, Thomas (NIH/NIAID) [F] <thomas.hoenen@nih.gov> wrote:

>

> Hi Redacted by agreement

>

> Thank you very much for contacting us regarding the tetracistronic trVLP system! Heinz is currently in Liberia as team-lead of LV's diagnostic lab in Monrovia, but he has given me the go-ahead to get the necessary arrangements in place. I would be happy to talk to you on the phone one of the next days to discuss the details, please let me know when is a good time for you. As you have probably already heard from Dan, we are in principal very happy to share the system!

>

> All the best, Thomas

>

> -----

> ----

>

> Thomas Hoenen, PhD

> Disease Modelling and Transmission - Laboratory of Virology, NIAID,

> NIH RML - Rocky Mountain Laboratories, 2A120A

> 903 S 4th St

> Hamilton, MT

> Phone: +1.406.375.7408

> Email: thomas.hoenen@nih.gov

> LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

>

> From Redacted by agreement

> Sent: Sunday, October 12, 2014 12:22 PM

> To: Hoenen, Thomas (NIH/NIAID) [F]

> Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Dan Engel

> Subject: Ebola trVLP system

>

> Dear Drs. hoenen and Feldmann,

>

> I met you most recently at the Filo mtg. In Galveston in March. As you

> may recall, I have been pursuing FDA approved drugs for Filovirus

> infections. We would like to use your marvelous trVLP system, as a

> collaboration, in our continuing studies. I would be happy to lay out

> our general plans in a phone call. And of course, we would abide by

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]@hotmail.com>
Sent: Sunday, October 12, 2014 5:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: theories and questions

Dear Dr. Feldmann,

No doubt since there is so much media hype and hysteria about the Ebola outbreak in western Africa, which unfortunately did not receive the needed attention, funding and resources when it was still in the more containable stages, you may have received a number of correspondences from a number of crackpots. I hope this email does not number among them, but I do have some questions for you.

I am a physician who has had international experience in resource poor areas, most recently with MSF in South Sudan, as well as military and public health experience. Therefore, I am well aware that using PPE in a tropical, resource poor environment is very different than in a well controlled technology and resource rich lab situation, and am familiar with how uncomfortable and unwieldy PPE such as the army's MOPP gear is, under even the best of circumstances. I have been selected to be a Global Health Innovations Fellow with Massachusetts General Hospital beginning in December 2014.

Given the high numbers of health care workers who have become infected with Ebola despite the use of PPE, I question whether such equipment may actually be contributing to the risk of infections. If Ebola does not penetrate unbroken skin, is it necessary to cover the skin entirely? In a high heat environment, does heat stress from wearing these garments contribute to lapses in infection control vigilance, and does the awkward nature of the garments and visual impairment increase the likelihood of sharps injuries? Are people more apt to contaminate their mucus membranes while removing these garments rather than washing exposed unbroken contaminated skin? Without these garments, a worker can feel a splash event and be especially vigilant about immediately cleaning the area, but with the garment, the worker does not necessarily know if splash or contact with body fluids contamination has occurred, and during the wash down process, the situation exists for additional personnel to be splashed. How was it determined these full body coverings are necessary? Would it be sufficient to cover the head and hands only? I do not have the numbers to know the infection rates of health care workers who have been presumably taking every currently advised precaution, as compared to the infection rates of family members who did not use such precautions, but the number of health care workers who have been infected seems too high to be explained by lapses in protocol or poor training. Rather than increasing the layers and complexity of PPE, I wonder if it might be prudent to at least investigate the possibility of minimizing the reliance on PPE and paying more attention to a wash down procedure and increased vigilance toward avoiding contamination of face/hands/mucus membranes? Also, I wonder if it might be prudent to investigate the use of the two things known to deactivate the virus, which are readily available in the field, ie, UV light and dessiccation.

I know there have been unusual demands on your valuable time recently, but your thoughts on these questions would be much appreciated.

Thank you,

[Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 5:04 PM
To: Redacted by
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Redacted by
agreement

Thank you very much for contacting us regarding the tetracistronic trVLP system! Heinz is currently in Liberia as team-lead of LV's diagnostic lab in Monrovia, but he has given me the go-ahead to get the necessary arrangements in place. I would be happy to talk to you on the phone one of the next days to discuss the details, please let me know when is a good time for you. As you have probably already heard from Dan, we are in principal very happy to share the system!

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

From: Redacted by agreement
Sent: Sunday, October 12, 2014 12:22 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Dan Engel
Subject: Ebola trVLP system

Dear Drs. hoenen and Feldmann,

I met you most recently at the Filo mtg. In Galveston in March. As you may recall, I have been pursuing FDA approved drugs for Filovirus infections. We would like to use your marvelous trVLP system, as a collaboration, in our continuing studies. I would be happy to lay out our general plans in a phone call. And of course, we would abide by any conditions of use and be happy to sign an MTA if needed. (I interact with Dan Engel at my university (U of Virginia, UVA) and he has informed me that he already has an MTA in place for the system.)

Please let me know at your earliest convenience whether you would be willing to work with us on this. I am anxious to propose using your system in an RO1 revision that I must have ready at UVA by oct. 28.

Thank you very much for considering my request,

Redacted by agreeme

Prof.
Univ, Virginia

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 4:58 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

The way I have been handling this so far is that I help people getting the system up and running in a collaborative fashion, i.e. with troubleshooting and detailed protocols as needed, asking in return for a coauthorship on the first paper published with the system. After that they are on their own and can do whatever they like (within the boundaries of the SLA, obviously), unless there is a real mutual interest.

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 4:54 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

If you want to collaborate with her please go ahead. On the other hand, she can have the system without collaboration.

Heinz

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 06:53 PM Eastern Standard Time
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system


Please go ahead.

----- Original Message -----


From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 06:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola trVLP system

Hi Heinz,

Redacted by
agreement

Are you OK if I contact  regarding sharing the trVLP system (of course with an SLA)?

All the best, Thomas

From: 
Sent: Sunday, October 12, 2014 12:22 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Dan Engel
Subject: Ebola trVLP system

Dear Drs. Hoenen and Feldmann,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 4:41 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola trVLP system

Hi Heinz,

Are you OK if I contact Judith regarding sharing the trVLP system (of course with an SLA)?

All the best, Thomas

From: Redacted by agreement
Sent: Sunday, October 12, 2014 12:22 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Dan Engel
Subject: Ebola trVLP system

Dear Drs. Hoenen and Feldmann,

I met you most recently at the Filo mtg. in Galveston in March. As you may recall, I have been pursuing FDA approved drugs for Filovirus infections. We would like to use your marvelous trVLP system, as a collaboration, in our continuing studies. I would be happy to lay out our general plans in a phone call. And of course, we would abide by any conditions of use and be happy to sign an MTA if needed. (I interact with Dan Engel at my university (U of Virginia, UVA) and he has informed me that he already has an MTA in place for the system.)

Please let me know at your earliest convenience whether you would be willing to work with us on this. I am anxious to propose using your system in an RO1 revision that I must have ready at UVA by Oct. 28.

Thank you very much for considering my request,

Redacted by
Prof.
Univ, Virginia

Sent from my iPad

Feldmann, Heinrich (NIH/NIAID) [E]

From: Karl Johnson [Personal Info]
Sent: Sunday, October 12, 2014 3:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola!

Just make sure they are PROVEN survivors, positive according to Dr. HF! Should be done everywhere in all 3 countries when specific Dx is available. I lost a Bolivian lab worker decades ago who had story of BHF in hospital that did not keep records and worked with us in epidemic area for many months. In our CZ lab as immune he sickened one day and died at Gorgas hospital. In fairness he had a solid CF titer against the virus when we brought him to Panama, so we did not do the neut test that had just been developed. One never forgets such history.

KMJ

K

On Sun, Oct 12, 2014 at 6:19 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
Great thought. I will bring it up in your name. Some survivors already work in the ward here, but I do not think that they are going actively after survivors.

Heinz

From: Karl Johnson [mailto:Personal Info]
Sent: Sunday, October 12, 2014 01:49 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola!

Thanks Heinz for your note during insane heavy days. I do wonder whether you are able to help get proven survivors lined up to become workers doing the risky stuff. If survival is 48% there should be a significant pool from which to recruit. And such a program if internationally known would be a significant positive for the world during a tremendous downer.


Please take care and bring back data that eventually might help in future outbreaks.

On Sun, Oct 12, 2014 at 10:08 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
Karl,
Good to hear from you - hope all is well. Yes I am in Monrovia, Liberia for the second time. We run a diagnostic lab for MSF just outside the capital - 400 patient tent hospital.

We are limited in what we can do here and are busy just diagnosing Ebola with the huge amount of patients.

MSF here does not use any injectable therapies as they are not set up for it. No beds only matrizes on the floor. [Redacted by agreement] There also isn't any institution to collect plasma.

Redacted by agreement



Feldmann, Heinrich (NIH/NIAID) [E]

From: Redacted by agreement
Sent: Sunday, October 12, 2014 12:22 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Dan Engel
Subject: Ebola trVLP system

Dear Drs. hoenen and Feldmann,

I met you most recently at the Filo mtg. In Galveston in March. As you may recall, I have been pursuing FDA approved drugs for Filovirus infections. We would like to use your marvelous trVLP system, as a collaboration, in our continuing studies. I would be happy to lay out our general plans in a phone call. And of course, we would abide by any conditions of use and be happy to sign an MTA if needed. (I interact with Dan Engel at my university (U of Virginia, UVA) and he has informed me that he already has an MTA in place for the system.)

Please let me know at your earliest convenience whether you would be willing to work with us on this. I am anxious to propose using your system in an RO1 revision that I must have ready at UVA by oct. 28.

Thank you very much for considering my request,

Redacted by

Prof.
Univ, Virginia

Sent from my iPad

Feldmann, Heinrich (NIH/NIAID) [E]

From: Karl Johnson Personal Info
Sent: Sunday, October 12, 2014 11:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola!

Thanks Heinz for your note during insane heavy days. I do wonder whether you are able to help get proven survivors lined up to become workers doing the risky stuff. If survival is 48% there should be a significant pool from which to recruit. And such a program if internationally known would be a significant positive for the world during a tremendous downer.

Please take care and bring back data that eventually might help in future outbreaks.

On Sun, Oct 12, 2014 at 10:08 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
Karl,

Good to hear from you - hope all is well. Yes I am in Monrovia, Liberia for the second time. We run a diagnostic lab for MSF just outside the capital - 400 patient tent hospital.

We are limited in what we can do here and are busy just diagnosing Ebola with the huge amount of patients.

MSF here does not use any injectable therapies as they are not set up for it. No beds only matrazes on the floor.

Redacted by agreement There also isn't any institution to collect plasma.

The survival rate here in the hospital is 48 percent - just under oral hydration, antibiotics, antimalaria, etc. Only oral treatments are considered at the moment.

All clinical trials have to be approved by a board funded by Wellcome Trust. It is not easy to just start treatment.

In my view treatment will be helpful but won't have a big short-term impact on the outbreak - what we need are vaccines. Hopefully they get started on that.

Stuart Nichol's email is: stn1@cdc.gov

Best wishes,

Heinz

-----Original Message-----

From: Karl M. Johnson
To: Heinrich (NIH/NIAID) [E] Feldmann
Subject: Ebola!
Sent: Oct 6, 2014 11:40 AM

Hi, Hope you are in WA with equipment to do quantitative viremia and abys. Former is to do daily viremia levels before and after use of convalescent plasma and to find immune persons to recruit for many of the riskiest procedures in this horrific outbreak. If you are not there do you know if anyone at CDC is doing any of that stuff. Science DURING an epidemic is tough but it needs doing for good reasons. Only Ebola case

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 11:39 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: Update

Thanks Heinz
Wish the staff well for me
Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 12:32 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Update

I apologize for not sending an update earlier. On the other hand, there is not much exciting stuff to report.

The new joint CDC/NIH team operates well. We have now split the NIH team into two members and the lead. The lead will come in a week after to work two weeks with the team and stays one more week with the incoming team. This seems to work well and provides continuous operation.

We replaced the glovebox as the bleach had started to change the color of the plastic material which made it more difficult to work. We are planing to replace the gloveboxes every 6 weeks. The cost is approx. 2500 US.

Sample numbers are about the same maybe slightly less. MSF has built the 400 bed capacity but currently only operates 250 beds due to staffing issues.

Survival rate at ELWA3 is currently 48 percent under oral hydration, antimalaria, antibiotics, antypyretics, antinausea and anti-diarrhoel therapy. All therapies are oral as they do not do IV infusion or injectables.

Positivity among new submissions has gone down to 70 percent.

We have been asked to provide testing for malaria, to do blood chemistry and to do viral load. LV staff back home is working on all three requests but we are not exactly sure what we will do. For malaria we are looking into PCR - we are trying to multiplex with one of the Ebola targets. We have ordered the Picollo machine for doing blood chemistry using the portable BSL3 lab from Nairobi. Not sure yet what we will do about viral loads.

All staff is healthy and in good spirit.

Best wishes,
Heinz
CDC/NIH Lab
ELWA3

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dr. Larry Schoonover <gntldntl@frontier.com>
Sent: Sunday, October 12, 2014 11:03 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Doctors' Donations to your research

Dear Dr. Feldmann,

I would like to institute a fund-raising campaign to assist you in your work to discover an Ebola vaccine or treatment. Please have one of your staff provide an address to which funds may be correctly conveyed.
Thank you for your work!

Dr. Larry Schoonover
Master, Academy of General Dentistry
3M Mini Dental Implant Instructor
Clendenin and Elkins, WV
Ofc: 304.548.7227
Personal Mobile: Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: John Butters <johnb@nativis.com>
Sent: Sunday, October 12, 2014 10:26 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Nativis- Knockdown of VP40

Thank you Heinz; please suggest a couple dates in November that work for you.

Best,

John

Sent from my iPhone

> On Oct 12, 2014, at 9:11 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>
> John,
> I am currently in Monrovia for the rest of the month. We could look into November for you to visit.
>
> Heinz

>
> ----- Original Message -----
> From: John Butters [mailto:johnb@nativis.com]
> Sent: Sunday, October 12, 2014 10:57 AM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: Nativis- Knockdown of VP40

>
> Heinz,
>
> I would very much like to meet with you at your location in Montana, or at our labs in Seattle, to discuss our technology; specifically the knockdown of key Ebola targets by specific inducement of specific charge pathways. The underlying technology is not uncomplicated, but the application is very straightforward. GSK is working on a similar approach (bio electronics) but they're several years behind us. I would like to meet with you to discuss a demonstration study at your labs. Our earlier email chain is below.

>
> Best,
>
> John Butters, CEO
> Nativis, Inc.
> Seattle
>
> Sent from my iPhone

>
>> On Aug 5, 2014, at 5:33 PM, "John Butters" <johnb@nativis.com> wrote:

>>
>> Heinz,
>>

Redacted by agreement

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: John Butters <johnb@nativis.com>
Sent: Sunday, October 12, 2014 8:58 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Nativis- Knockdown of VP40

Heinz,

I would very much like to meet with you at your location in Montana, or at our labs in Seattle, to discuss our technology; specifically the knockdown of key Ebola targets by specific inducement of specific charge pathways. The underlying technology is not uncomplicated, but the application is very straightforward. GSK is working on a similar approach (bio electronics) but they're several years behind us. I would like to meet with you to discuss a demonstration study at your labs. Our earlier email chain is below.

Best,

John Butters, CEO
Nativis, Inc.
Seattle

Sent from my iPhone

> On Aug 5, 2014, at 5:33 PM, "John Butters" <johnb@nativis.com> wrote:

>

> Heinz,

>

Redacted by agreement

Redacted by agreement

>

> John

>

> John Butters

> Chairman, President and CEO

> Nativis

> 219 Terry Avenue North

> Seattle, WA 98109

> 206.708.2288

> johnb@nativis.com

>

>> On Aug 5, 2014, at 5:11 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>>

>> Are you talking about an antiviral approach or what specifically do you refer to? Nevertheless, we are supposed to leave for West Africa in the next few days. Thus, I won't have any time in the near future. We can discuss when I am back if you are still interested.

>>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 8:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hoenen, Thomas (NIH/NIAID) [F]; Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: Oxford Nanopore Wen Inquiry

The machine will be free. I believe we may have to pay for the runs, there is a disposable part. I believe they are \$900.

Sent from my iPhone

On Oct 12, 2014, at 3:51 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

What does the machine cost? Let Dawn work on the purchase.

Heinz

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 07:47 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

Agreed... the big problem is a lot of the company is away a some big conference next week - the main cause for the delay. I did make it clear that we would need an answer and the equipment the next week. They are already by-passing their normal proposal route so I have the suspicion that unless they really do not think that it will work we will have one in two weeks.

As I said, if we have the money we should simultaneously pursue another machine. But I have no suggestions. Traditional Sanger probably makes the most sense except that it is quite a large setup (as far as I know). Everything else is extremely expensive. Dave thinks Steve P. may be able to provide equipment and expertise, but I guess you (Heinz) would have to make the request.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 4:03 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

I am all for it but time is important.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 05:40 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

It sounded like they will make a decision within two weeks. How fast they move after that is uncertain, but I think I made the timeliness of it pretty clear. Based on Allison's recent comments I think you can forget about the miSEQ, its sounds like any problem, vibration, etc. causes problems with the machine. The other one should easily have the capacity to sequence Ebola no problem - the guy we talked to seemed to think that Thomas's strategy was perfectly suited to the machine. Sample prep would be no

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vikki Hyman <vikki@target-conferences.com>
Sent: Sunday, October 12, 2014 7:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Geisbert, Thomas W.; Juergen Richt; YOSHIHIROKAWAOKA
Cc: Lynn Lipschitz; filovirus@target-conferences.com
Subject: Sponsorship

Dear All

Regarding sponsorship - I will prepare a brochure that includes different sponsor packages and send to you for your consideration.

I would appreciate it if you could forward me the companies that have taken part in the previous Filovirus conferences and any contact people you may have.

Many thanks
Vikki

Vikki Hyman | Project Manager
Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818
Tel: +972 3 517 5150 ext 611 | Fax: +972 73 2067718
www.target-conferences.com

On Sun, Oct 12, 2014 at 1:43 PM, Vikki Hyman <vikki@target-conferences.com> wrote:
Dear All

Further to Lynns summary, I have asked the designer to prepare a design for the conference and as soon as I receive that I will forward to you all for approval.

In addition, in order to set up the symposium website I will need from you the following:

- A welcome note - similar to the one we had for the Zoonoses conference this year (attached).
- List of committee/s members
- any specific scientific information - such as topics, block program etc.

As I understand there will be abstract submission for both orals and posters for which I will set up the online link. I suggest we have an abstract submission deadline of late January (January 29, 2015?). Please let me know your thoughts. Any time earlier will be around the Christmas break and if we do it before December it is too soon...

I think that's all for now.

Many thanks and I look forward to working with you all on this conference.

regards

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vikki Hyman <vikki@target-conferences.com>
Sent: Sunday, October 12, 2014 6:22 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: twgeisbe@utmb.edu; Jricht@ksu.edu; YOSHIHIROKAWAOKA; lynn@target-conferences.com; filovirus@target-conferences.com
Subject: Re: summary of telephone call

Do you anticipate that there will be many abstracts submitted? Will the program consist of mainly free papers or invited speakers?

If there will not be many abstracts we could go later, however if there will be a lot we need to keep it on the date I suggest - which is already less than 2 months prior to the conference.

Please advise

thanks

Vikki Hyman | Project Manager

Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818
Tel: +972 3 517 5150 ext 611 | Fax: +972 73 2067718
www.target-conferences.com

On Sun, Oct 12, 2014 at 3:15 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
Abstract deadline as late as possible to get the newest (latest) information.

From: Vikki Hyman [mailto:vikki@target-conferences.com]
Sent: Sunday, October 12, 2014 06:43 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Geisbert, Thomas W. <twgeisbe@utmb.edu>; Juergen Richt <Jricht@ksu.edu>; YOSHIHIROKAWAOKA
Cc: Lynn Lipschitz <lynn@target-conferences.com>; filovirus@target-conferences.com <filovirus@target-conferences.com>
Subject: Re: summary of telephone call

Dear All

Further to Lynns summary, I have asked the designer to prepare a design for the conference and as soon as I receive that I will forward to you all for approval.

In addition, in order to set up the symposium website I will need from you the following:

- A welcome note - similar to the one we had for the Zoonoses conference this year (attached).
- List of committee/s members
- any specific scientific information - such as topics, block program etc.

Feldmann, Heinrich (NIH/NIAID) [E]

From: SARTON DU JONCHAY Isabelle <icharton@france24.com>
Sent: Sunday, October 12, 2014 5:03 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview request today on ebola and Europe prevention tonight at 9pm or this afternoon at 1pm or 2pm

GoodMorning Sir.
I am writing you from France 24, an international TV channel based in Paris.
We would like to ask you for an interview on Ebola in Texas and prevention tonight at 9pm (Spokane time) or theis afternoon at 1pm or 2pm
. The interview will last 4 minutes and can be done by skype or telephone.

Will you be available?

Best regards
Isabelle du Jonchay
0033 647 38 11 00

Hoping that you will be available
Isabelle du jonchay
0033 647 38 11 00

This footnote confirms that this email message has been scanned by
PineApp Mail-SeCure for the presence of malicious code, vandals & computer viruses.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vikki Hyman <vikki@target-conferences.com>
Sent: Sunday, October 12, 2014 4:43 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Geisbert, Thomas W.; Juergen Richt; YOSHIHIROKAWAOKA
Cc: Lynn Lipschitz; filovirus@target-conferences.com
Subject: Re: summary of telephone call
Attachments: WELCOME.doc

Dear All

Further to Lynns summary, I have asked the designer to prepare a design for the conference and as soon as I receive that I will forward to you all for approval.

In addition, in order to set up the symposium website I will need from you the following:

- A welcome note - similar to the one we had for the Zoonoses conference this year (attached).
- List of committee/s members
- any specific scientific information - such as topics, block program etc.

As I understand there will be abstract submission for both orals and posters for which I will set up the online link. I suggest we have an abstract submission deadline of late January (January 29, 2015?). Please let me know your thoughts. Any time earlier will be around the Christmas break and if we do it before December it is too soon...

I think that's all for now.

Many thanks and I look forward to working with you all on this conference.

regards

Vikki Hyman | Project Manager

Target Conferences Ltd.

65 Derech Menachem Begin

PO Box 51227, Tel Aviv 6713818

Tel: [+972 3 517 5150 ext 611](tel:+97235175150) | Fax: [+972 73 2067718](tel:+972732067718)

www.target-conferences.com

On Fri, Oct 10, 2014 at 3:36 PM, Lynn Lipschitz <lynn@target-conferences.com> wrote:

- Lynn to contact the Washington Marriott at Metro Center to change dates slightly:

Tuesday, March 24 - reception

Wednesday, March 25 - full day

Thursday, March 26 - full day

Friday, March 27 - half day

- Tom is to send a mailing list to Vikki asap

Feldmann, Heinrich (NIH/NIAID) [E]

From: Amadou Kone <amadoukone@icermali.org>
Sent: Sunday, October 12, 2014 4:27 AM
To: Koita, Ousmane; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu; Amadou Kone
Subject: RE : New suspected case to be tested
Attachments: EBOLA Screening Inventory of consumables needed.xlsx

Dears,

Redacted by agreement

Redacted by agreement

Cheers,
Amadou KONE

----- Message d'origine-----

De: Ousmane Koita
Date: ven. 10/10/2014 15:47
À: Richard Sakai; 'Feldmann, Heinrich (NIH/NIAID) [E]'; 'Polis, Michael (NIH/NIAID) [E]'; Bassirou Diarra; 'Murphy, Robert'
Cc: 'Safronetz, David (NIH/NIAID) [E]'; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Objet : RE: New suspected case to be tested

Dear Dick,

I think you are right, I am planning to have an inventory of the stock may be tomorrow morning or Monday.

Best regards,

Ousmane

-----Original Message-----

From: Richard Sakai
Sent: Friday, October 10, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: RE: New suspected case to be tested

It appears that the stock of some of the testing reagents have been completely used up and the stock of others may also be low. Are there any plans to re-stock the reagent inventory soon?

Dick

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Friday, October 10, 2014 2:08 PM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Great job - including the troubleshooting.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 5:48 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

Agreed... the big problem is a lot of the company is away a some big conference next week - the main cause for the delay. I did make it clear that we would need an answer and the equipment the next week. They are already by-passing their normal proposal route so I have the suspicion that unless they really do not think that it will work we will have one in two weeks.

As I said, if we have the money we should simultaneously pursue another machine. But I have no suggestions. Traditional Sanger probably makes the most sense except that it is quite a large setup (as far as I know). Everything else is extremely expensive. Dave thinks Steve P. may be able to provide equipment and expertise, but I guess you (Heinz) would have to make the request.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 4:03 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

I am all for it but time is important.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 05:40 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

It sounded like they will make a decision within two weeks. How fast they move after that is uncertain, but I think I made the timeliness of it pretty clear. Based on Allison's recent comments I think you can forget about the miSEQ, its sounds like any problem, vibration, etc. causes problems with the machine. The other one should easily have the capacity to sequence Ebola no problem - the guy we talked to seemed to think that Thomas's strategy was perfectly suited to the machine. Sample prep would be no more difficult than any other other sequencing platform. No one knows how reliably it would work until we try it out. Obviously it would tested in our lab prior to deployment.

I think simultaneously investing in an alternative sequencing approach would not be a bad idea as this one will cost us nothing except time.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:19 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

How likely is it that we will get the machine soon? If this is a new technology how simple and how reliable will it work? I am all for it but we need something that we can handle from\$ a technical point of view.

When would the machine be available?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 3:43 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: [Redacted by agreement]

So I guess we will not do anything because 48% survival is acceptable to you.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:28 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: [Redacted by agreement]

Most treatment centers do not do IV infusion and injectables. I think this is unrealistic. They want oral drugs for safety and operational reasons. [Redacted by agreement]

[Redacted by agreement] From Michael Katze we know that mice lie - maybe NHPs lie as well; there is a possibility.

[Redacted by agreement] paracetamol, antimalaria, antibiotics, anti-nausea and anti-diarrhoea. I am wondering if any of the drugs tried so far did anything good as one has to expect that survival is higher under modern intensive care.

The fact that the drug doesn't harm is not a good reason for me to use it. Anyway, on the bigger picture treatment is not going to solve the outbreak - we need vaccines.

Heinz

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 03:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: [Redacted by agreement]

I have mixed feelings on this - I both agree and disagree with Heinz. My arbitrary cutoff for success was either some survival or extension of time to death of at least 10 days. We did not meet either of these. Is it possible that some sort of treatment like this could push some people to survive, maybe, it probably does not make things worse. Supportive care obviously helps, but can anything specific help above that... unfortunately you don't know until you try. I am certain that administration of ribavirin IV and treatment with IFN in humans will work better than in NHPs. The only downside being that the doses of IFN we used are unlikely (I am guessing) to be used in people?

I have no problem with disclosing the data, as long as it is communicated appropriately.

Darryl

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:23 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: [Redacted by agreement]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 3:41 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

It sounded like they will make a decision within two weeks. How fast they move after that is uncertain, but I think I made the timeliness of it pretty clear. Based on Allison's recent comments I think you can forget about the miSEQ, its sounds like any problem, vibration, etc. causes problems with the machine. The other one should easily have the capacity to sequence Ebola no problem - the guy we talked to seemed to think that Thomas's strategy was perfectly suited to the machine. Sample prep would be no more difficult than any other other sequencing platform. No one knows how reliably it would work until we try it out. Obviously it would tested in our lab prior to deployment.

I think simultaneously investing in an alternative sequencing approach would not be a bad idea as this one will cost us nothing except time.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:19 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

How likely is it that we will get the machine soon? If this is a new technology how simple and how reliable will it work? I am all for it but we need something that we can handle from\$ a technical point of view.

When would the machine be available?

Heinz

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 09:10 PM Eastern Standard Time
To: James.Braye@nanoporetech.com <James.Braye@nanoporetech.com>
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Oxford Nanopore Wen Inquiry

Dear James,

Thank you very much for taking the time to talk to Darryl and me today. Please find, as promised, attached a brief description of the project we envision with the **Redact**. Please let us know if you have any questions.

As already mentioned during our phone call, **Redacted by agreement** in the field is for us not only extremely interesting scientifically, but also has the potential to significantly contribute to our ability to control this outbreak. Therefore, we would appreciate very much a quick decision whether **Redacted by agreement**

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Saturday, October 11, 2014 2:55 PM
To: Lynn Lipschitz
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Juergen Richt; YOSHIHIROKAWAOKA; Vikki Hyman
Subject: RE: urgent decision required please
Attachments: Participants.xlsx; FiloList-6August13.xls

The first file is the list of participants for our last meeting back in March-April of this year. The second file is a list of people that were on our first distribution indicating that they had been at a previous meeting or had published something on filoviruses. Many of the names on the first file will also be on the second file so that will need to be reconciled.

Best,

Tom

From: Lynn Lipschitz [lynn@target-conferences.com]
Sent: Friday, October 10, 2014 11:27 AM
To: Geisbert, Thomas W.
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Juergen Richt; kawaokay@svm.vetmed.wisc.edu; Vikki Hyman
Subject: Re: urgent decision required please

I take it that you all agree to the dates of Wednesday-Saturday - March 25-28, 2015, (session days Thursday, Friday & Saturday)?

Yes Tom - what you wrote is correct -

The first night was only for one hour and the rates are rather high if we want to extend it to 2 hours. But if you say that we can do food and then add drinks if affordable that's great. We don't have to decide on the food and drinks as yet.

For the dinner - we can have it on either night that you want - they are not holding space - I have to tell them which night.

Please advise.

Thanks and regards
Lynn

Lynn Lipschitz | **Managing Director**
Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael G. Katze <honey@uw.edu>
Sent: Saturday, October 11, 2014 2:46 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koita, Ousmane
Sent: Saturday, October 11, 2014 10:01 AM
To: Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Sakai, Richard; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Thanks Dave.

Ousmane

-----Original Message-----

From: Safronetz, David (NIH/NIAID) [E] [<mailto:safronetzd@niaid.nih.gov>]
Sent: Fri 10/10/2014 3:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ousmane Koita; Richard Sakai; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: RE: New suspected case to be tested

As Heinz mentioned, just send us a list of required materials and we will send a re-supply package from RML.

Dave

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:49 AM
To: Koita, Ousmane; Sakai, Richard; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; 'amadoukone@icermali.org'; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Let us know if you need anything.

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 10:47 AM Eastern Standard Time
To: Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Dear Dick,

I think you are right, I am planning to have an inventory of the stock may be tomorrow morning or Monday.

Best regards,

Ousmane


-----Original Message-----

From: Richard Sakai
Sent: Friday, October 10, 2014 2:44 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Stein, Dave <Dave.Stein@oregonstate.edu>
Sent: Saturday, October 11, 2014 9:03 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; chris.basler@mssm.edu; tom.geisbert@utmb.edu
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; muehlber@bu.edu; Moulton, Hong; YOSHIHIROKAWAOKA
Subject: from David Stein re:EBOV PPMO
Attachments: PPMO_brief_intro.pptx

Redacted by agreement



Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 8:47 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Prescott, Joseph (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]
Subject: Fwd: Ebola: Clinical Update from IDWeek

Dying

Sent from my iPhone

Begin forwarded message:

From: IDWeek <info@idweek.org>
Date: October 11, 2014 at 09:47:10 EDT
To: <munstervj@niaid.nih.gov>
Subject: Ebola: Clinical Update from IDWeek

If you have difficulty viewing this message please [click here](#).



Dear Colleagues,

We write to provide a summary of the presentation at IDWeek by Dr. Bruce Ribner on caring for Ebola patients in the US¹. Dr. Ribner led the team at Emory University that cared for two patients with Ebola virus disease (EVD) in August. In light of the recent Ebola cases in Dallas and Spain he agreed that a summary could be provided to assist ID specialists in their ongoing preparedness efforts.

Planning for the care of patients

This involves the entire institution, and needs many sections to coordinate their work. EMS services were an important coordination point for the transport of the 2 patients to Emory. On the medical staff, many types of expertise were needed for clinical management: ID, critical care, anaesthesiology and several other subspecialties. Nursing, environmental management, facilities, security and media relations were all intensively involved ahead of time so that expected roles were defined. Even so, there were times when questions arose after the patients arrived.

Clinical Care

Ebola patients in Africa have only limited clinical evaluations and essentially no laboratory testing due to the lack of any infrastructure to support this. The Emory team was able to make careful clinical evaluations over time in their 2 patients and Dr. Ribner summarized the main points as follows:

1. Despite weight gains of 15-20 kg, the patients were profoundly hypovolemic due to their low serum albumin and vascular leak with third spacing. Fluid losses in their patients were 5-10 L/day.
2. Electrolyte losses were significant and included profound hyponatremia, hypokalemia and hypocalcemia. At initial assessment at Emory the patients were one week into illness yet these were their first laboratory determinations. Arrhythmias were noted, and both intravenous and oral electrolyte repletion was necessary.
3. Nutritional depletion was evident as well.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 8:33 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Oxford Nanopore Wen Inquiry

At this point it's not 100% clear. The machine is not commercially available, so we would get a prototype (they are doing beta testing with other scientific laboratories, and what we would need doing seems to work well in other labs). After talking to James I hope that they will make the decision whether to support us in the next two weeks, and can then ship the machine immediately - Darryl and I are making as much pressure as we can. But in my view this is by far the best option: The device is the size of a USB stick, and would probably cost us around 1000\$ (that's their deposit to enroll in the advanced access program). Run times are about 30 minutes, and we can run multiple samples at the same time (we will have to try how many).

By comparison, if we get a next-gen or Sanger sequencer we are looking at a piece of equipment that will cost us 80000 to 100000\$ minimum, weighs at least 80 kg, has a size of at least 1 cubic meter, so transporting will be an issue. After talking to Ali it seems that a next-gen sequencer is probably a bad idea, sample preparation is rather involved, runs take days, we have to deal with toxic waste, and if you make the smallest mistake (as little as touching the machine while it runs) the run fails, you lose thousands of dollars in reagents and you have to start over. Sanger sequencing would be the better option, run times are hours and the technology is more robust; however, these machines tend to be more expensive than next-gen, and much bigger. On the plus side sample preparation is simpler and cheaper, but still longer than with the Minlon. In my view the Minlon is the by far best and easiest option, but nobody says we can't pursue Sanger at the same time (but it probably will take longer, be more expensive, and has less chances of success).

If you want to know more, check out their three minute video at this web site:

<https://www.nanoporetech.com/technology/the-minion-device-a-miniaturised-sensing-system/the-minion-device-a-miniaturised-sensing-system>

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:19 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

How likely is it that we will get the machine soon? If this is a new technology how simple and how reliable will it work? I am all for it but we need something that we can handle from a technical point of view.

When would the machine be available?

Heinz

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 09:10 PM Eastern Standard Time
To: James.Braye@nanoporetech.com <James.Braye@nanoporetech.com>
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Oxford Nanopore Wen Inquiry

Dear James,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 8:15 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Redacted by agreement

It will not be our decision. It is data for folks to consider. I agree that we do need an safe and effective vaccine as quickly as possible.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 5:28 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Redacted by agreement

Most treatment centers do not do IV infusion and injectables. I think this is unrealistic. They want oral drugs for safety and operational reasons. The new Nebraska case is obviously treated with a new drug as well based only on in vitro data. From Michael Katze we know that mice lie - maybe NHPs lie as well; there is a possibility.

ELWA 3 has a survival rate of 48 percent under oral dehydration, paracetamol, antimalaria, antibiotics, anti-nausea and anti-diarrhoea. I am wondering if any of the drugs tried so far did anything good as one has to expect that survival is higher under modern intensive care.

The fact that the drug doesn't harm is not a good reason for me to use it. Anyway, on the bigger picture treatment is not going to solve the outbreak - we need vaccines.

Heinz

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 03:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Redacted by agreement

I have mixed feelings on this - I both agree and disagree with Heinz. My arbitrary cutoff for success was either some survival or extension of time to death of at least 10 days. We did not meet either of these. Is it possible that some sort of treatment like this could push some people to survive, maybe, it probably does not make things worse. Supportive care obviously helps, but can anything specific help above that... unfortunately you don't know until you try. I am certain that administration of ribavirin IV and treatment with IFN in humans will work better than in NHPs. The only downside being that the doses of IFN we used are unlikely (I am guessing) to be used in people?

I have no problem with disclosing the data, as long as it is communicated appropriately.

Darryl

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:23 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pierre Formenty
Sent: Saturday, October 11, 2014 7:36 AM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Anti-reston antibodies from the Philippines as a source of convalescent plasma or Ig for the current outbreak?

Cool, super that was the paper in my memory, I'll find the PDF.
A Big Thank You to both of you, this is extremely helpful for damage control

Kind Regards

Pierre

From: Geisbert, Thomas W. [mailto:twgeisbe@utmb.edu]
Sent: 11 October 2014 15:21
To: FORMENTY, Pierre B.H.; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Anti-reston antibodies from the Philippines as a source of convalescent plasma or Ig for the current outbreak?

Pierre,

Ebola-Reston immune monkeys are not protected against Ebola-Zaire. It is in the article below by Fisher-Hoch et al. They had four cynomolgus monkeys that survived Ebola-Reston challenge and they back-challenged them with Ebola-Zaire. Three of the four died. I don't have a pdf file of this article. I have the hard copy paper reprint but am traveling and don't have access to it now.

Tom

[J Infect Dis.](#) 1992 Oct;166(4):753-63.

Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain.

[Fisher-Hoch SP](#)¹, [Brammer TL](#), [Trappier SG](#), [Hutwagner LC](#), [Farrar BB](#), [Ruo SL](#), [Brown BG](#), [Hermann LM](#), [Perez-Oronoiz GI](#), [Goldsmith CS](#), et al.

Author information

- ¹Special Pathogens Branch, Research Animal Section, Centers for Disease Control, Atlanta, Georgia.

Abstract

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Saturday, October 11, 2014 7:21 AM
To: Pierre Formenty; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Anti-reston antibodies from the Philippines as a source of convalescent plasma or Ig for the current outbreak?

Pierre,

Ebola-Reston immune monkeys are not protected against Ebola-Zaire. It is in the article below by Fisher-Hoch et al. They had four cynomolgus monkeys that survived Ebola-Reston challenge and they back-challenged them with Ebola-Zaire. Three of the four died. I don't have a pdf file of this article. I have the hard copy paper reprint but am traveling and don't have access to it now.

Tom

[J Infect Dis.](#) 1992 Oct;166(4):753-63.

Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain.

[Fisher-Hoch SP¹](#), [Brammer TL](#), [Trappier SG](#), [Hutwagner LC](#), [Farrar BB](#), [Ruo SL](#), [Brown BG](#), [Hermann LM](#), [Perez-Oronoiz GI](#), [Goldsmith CS](#), et al.

Author information

- ¹Special Pathogens Branch, Research Animal Section, Centers for Disease Control, Atlanta, Georgia.

Abstract

African filoviruses have caused outbreaks of fulminating hemorrhagic fever among humans. In 1989, related filoviruses were isolated from cynomolgus monkeys imported into the United States from the Philippines. The pathogenic potential of these new filoviruses was compared in 16 Asian monkeys (*Macaca fascicularis*-cynomolgus) and 16 African monkeys (*Cercopithecus aethiops*-African green) using African filoviruses from Zaire (Ebola virus) and Sudan or Asian filoviruses (Reston and Pennsylvania). African filovirus infections resulted in earlier death ($P = .005$), had a shorter duration of disease and median incubation period (3-4 vs. 7 days), and had earlier peak viremia (5-7 vs. 7-9 days). African green monkeys showed significantly higher survival than cynomolgus monkeys (P less than .01), and some were asymptomatic as have been humans accidentally infected with Asian filovirus. Rechallenge experiments showed that protection in survivors of filovirus infections against fatal challenge with Ebola (Zaire) virus is unpredictable. The minimal clinical disease observed in humans infected with the Reston strain is consistent with host- and virus-dependent pathogenicity.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pierre Formenty
Sent: Saturday, October 11, 2014 5:54 AM
To: Geisbert, Thomas W. (twgeisbe@UTMB.EDU) (twgeisbe@UTMB.EDU); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Anti-reston antibodies from the Philippines as a source of convalescent plasma or Ig for the current outbreak?
Attachments: PLOS Neglected Tropical Diseases Serologic Cross-Reactivity of Human IgM and IgG Antibodies to Five Species of Ebola Virus.mht
Importance: High

Dear Tom and Heinz,

The Philippine MOH is proposing to use sera from people positive for Reston, to protect against Ebolazaire in West Africa...

They based their "idea" on Pierre Rollin on cross reactivity for ELISA IgG test (see attached)

To my knowledge there does not appear to be immunity between the different Ebola species.

Non Human Primates that survive Ebola Zaire virus infection, when later re-challenged with Ebola Sudan virus were not protected.

There should be a paper describing this experiment.

Am I wrong? Do you have the paper, you were probably involved in these studies...

I would need a quick reply (if you have the paper or similar papers) as some people would like to contact the President of the country etc...

Thank you for your support

Pierre

Pierre Formenty

Team Lead - Emerging and Epidemic Zoonotic Diseases team (CED/EZD)

Control of Epidemic Diseases Unit (HSE/PED/CED)

Pandemic and Epidemic Diseases (HSE/PED) department

World Health Organization

20 Avenue Appia

CH-1211 Geneva 27 - Switzerland

Tel (direct) : +41 22 791 25 50

Mobile : Personal Info

Fax : +41 22 791 41 98

Email : formentyp@who.int

<http://www.who.int/csr/disease/ebola/en/>

Please don't print this e-mail unless you really need to. Thank you.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Flaherty, Patrick (CDC/OID/NCHHSTP)
Sent: Saturday, October 11, 2014 3:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Automatic reply: request for Chinese delegation visit to ELWA 3 lab

I am currently out of the office in Liberia for the Ebola response.

I will be checking e-mail periodically and can also be reached at Personal Info (mobile in Liberia) for anything urgent.

While I am away, please send any requests to Dr. Timothy Holtz, tkh3@cdc.gov.

I am scheduled to be back in Thailand on October 15.

Thank you,
Patrick

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mott, Joshua (CDC/OID/NCIRD)
Sent: Saturday, October 11, 2014 3:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Automatic reply: request for Chinese delegation visit to ELWA 3 lab

Hello,

I am away from the office participating in the Ebola response in Liberia. During this time I may not respond to non-Ebola-related issues in a timely manner but will do my best to monitor emails. For urgent matters I can be called at one of the two following numbers [Personal Info] or [Personal Info] While I am away Henry Njuguna (vkc7@cdc.gov)) will be the Influenza Program Director.

Thanks, Josh

Feldmann, Heinrich (NIH/NIAID) [E]

From: Walke, Henry (CDC/OID/NCEZID)
Sent: Saturday, October 11, 2014 3:24 AM
To: Flannery, Brendan (CDC/OID/NCIRD); 'MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org'; Thorne, Gregory Immel (CDC/CGH/DGHA); Flaherty, Patrick (CDC/OID/NCHHSTP); Mott, Joshua (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: request for Chinese delegation visit to ELWA 3 lab

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From:

Unpublished

Sent:

Saturday, October 11, 2014 2:47 AM

To:

Feldmann, Heinrich (NIH/NIAID) [E]

Subject:

Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:33 PM
To: Eyler, Allison (NIH) [C]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: 2014 Biennial Inventory - National Institute Communicable Diseases

Dear Allison:

Heinz is tied up at the moment in Monrovia contributing to the Ebola response. To the best of my understanding Dr. Paweska's team is also supporting the Ebola outbreak in west Africa.

We will try to address this as soon as practical.

Sincerely,

Mark

From: Eyler, Allison (NIH) [C]
Sent: Friday, October 10, 2014 04:01 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Janusz Paweska <januszp@nicd.ac.za>
Cc: Pineda, Mark (NIH/NIAID) [E]; Imes, Jen (NIH) [C]
Subject: RE: 2014 Biennial Inventory - National Institute Communicable Diseases

Hi Dr. Feldmann,

I am still in need of verification that the attached list of property is accounted for on-site at the NICD in South Africa. Is there anyone you could put me in touch with, even that has been to the NICD recently that could verify this? Is Dr. Paweska still out of the country?

Thank you and best regards,

Allison

Allison Eyler
Secretary III
Clinical Monitoring Research Program
Frederick National Laboratory for Cancer Research
Leidos Biomedical Research, Inc.
Support to National Institute of Allergy and Infectious Diseases
5705 Industry Lane, Suite J
Frederick, MD 21704
Phone: (301) 846-5707
Fax: (301) 846-7514
Email: Allison.Eyler@fnlcr.nih.gov

This e-mail and any attachments to it are intended only for the identified recipient. It may contain proprietary or otherwise legally protected information for Leidos Biomedical Research, Inc. Any unauthorized use or disclosure of this communication is strictly prohibited. If you have received this communication in error, please notify the sender and delete or otherwise destroy the e-mail and all attachments immediately.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 7:11 PM
To: James.Brayer@nanoporetech.com
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Oxford Nanopore Wen Inquiry
Attachments: project-description_LV_Liberia.docx

Dear James,

Thank you very much for taking the time to talk to Darryl and me today. Please find, as promised, attached a brief description of the project we envision with the **Redact**. Please let us know if you have any questions.

As already mentioned during our phone call, **Redacted by agreement** in the field is for us not only extremely interesting scientifically, but also has the potential to significantly contribute to our ability to control this outbreak. Therefore, we would appreciate very much a quick decision whether **Redacted by agreement**

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 12:34 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: FW: Oxford Nanopore Wen Inquiry


From: James Brayer [mailto:James.Brayer@nanoporetech.com]
Sent: Friday, October 10, 2014 10:12 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

Darryl:

How about 1 PM today? I am about to go onto a call that should be done at that time. I am happy to call you at the 406-375-7410 number

James Brayer
Market Development Manager

Redacted by agreement



Feldmann, Heinrich (NIH/NIAID) [E]

From: David Mann <davevbs@earthlink.net>
Sent: Friday, October 10, 2014 3:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Disease homing, cell penetrating peptide adjuvant to boost the effectiveness of Ebola therapies

Dear Dr. Feldmann,

I am writing to you because our company is developing a disease homing therapeutic adjuvant under contract to the [REDACTED] that may have the potential to enhance the efficacy of Ebola treatments and the urgency of the current situation for Ebola patients.

[REDACTED]
Redacted by agreement

Redacted by
agreement

[REDACTED]
Redacted by

In my limited understanding of the Ebola virus it seems that the virus also damages the glycocalyx as well as producing endothelial activation.

The initial indication for which we are developing [REDACTED] pulmonary hypertension, is also characterized by endothelial activation and dysfunction.

Redacted by
agreement

In our research, [REDACTED]

[REDACTED]
Redacted by agreement

I believe that [REDACTED] could possibly boost the performance of Ebola mAb cocktails and other Ebola treatments by homing to the areas of Ebola infection and damage and increasing the localized concentrations and effects of therapy. This could result in great therapeutic effectiveness, or in the current case of a shortage of treatments, allow for existing medicines to be effectively spread amongst a greater number of patients by co-administering [REDACTED] without compromising patient outcomes.

Redacted by
agreement

I am writing you to see if you are interested in finding out more about [REDACTED] and exploring its potential as an adjuvant to boost the performance of Ebola therapies.

I realize we are facing a crisis with the current Ebola outbreak, and my company wants to do anything we can to help.

Thank you for your consideration.

Best Regards,
David

David Mann
CEO & Chairman
Vascular BioSciences
VBS Pharmaceuticals

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

You will not be.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 4:14 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I am not supportive of use in humans - I guess I feel differently about this than others. However, I do not want to be in the way but do not like my name associated with a decision for a clinical trial based on these results.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:57 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I am not promoting the CT I am just asking to share the information. I believe the benefit may be minimal at best but it may help some folks to have a few more days to mount a response and everything is already approved by regulatory authorities so we know its safety profile.

Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:23 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I do not want to be the bad guy, but what makes one think that this has any benefit? Based on my work and experience in the filovirus field for over 25 years I would stop this here. There is no justification for a clinical trial. If we go ahead here we could have gone ahead with several other drugs and vaccine candidates before that were more promising than this one.

Sorry for being a bit harsh, but I do not understand this.

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Friday, October 10, 2014 2:28 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'lynn@target-conferences.com'; 'twgeisbe@utmb.edu'
Cc: 'Jricht@ksu.edu'; 'vikki@target-conferences.com'
Subject: Re: urgent decision required please

OK.

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Handle: Feldmann, Heinrich (NIH/NIAID) [E] Mail Address: feldmannh@niaid.nih.gov
Subject: Re: urgent decision required please
To: YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>, 'lynn@target-conferences.com' <lynn@target-conferences.com>, 'twgeisbe@utmb.edu' <twgeisbe@utmb.edu>
CC: 'Jricht@ksu.edu' <Jricht@ksu.edu>, 'vikki@target-conferences.com' <vikki@target-conferences.com>
Date: Fri, 10 Oct 2014 20:14:59 +0000
Date Local: 2014/10/11 5:14:59
Message:

> It is not the time - it is the reception. Set up a time and date and I will try my best. We are 4 hours ahead of EST US.

>

> ----- Original Message -----

> From: YOSHIHIROKAWAOKA

> Sent: Friday, October 10, 2014 03:57 PM Eastern Standard Time

> To: Feldmann, Heinrich (NIH/NIAID) [E]; 'lynn@target-conferences.com'

> <lynn@target-conferences.com>; 'twgeisbe@utmb.edu' <twgeisbe@utmb.edu>

> Cc: 'Jricht@ksu.edu' <Jricht@ksu.edu>; 'vikki@target-conferences.com'

> <vikki@target-conferences.com>

> Subject: Re: urgent decision required please

>

> Heinz,

>

> Can we discuss the contents of the meeting sometime next week?

> I am currently in Japan. So, late afternoon in the US time is good for me.

>

> When is the good time?

>

> Yoshi

> -----

> From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>

> Handle: Feldmann, Heinrich (NIH/NIAID) [E] Mail Address:

> feldmannh@niaid.nih.gov

> Subject: Re: urgent decision required please

> To: YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>,

> 'lynn@target-conferences.com' <lynn@target-conferences.com>,

> 'twgeisbe@utmb.edu' <twgeisbe@utmb.edu>

> CC: 'Jricht@ksu.edu' <Jricht@ksu.edu>, 'vikki@target-conferences.com'

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Friday, October 10, 2014 2:00 PM
To: Juergen Richt; Lynn Lipschitz; Geisbert, Thomas W.
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jricht@ksu.edu; vikki@target-conferences.com
Subject: RE: urgent decision required please

I do not care much about the location.

Yoshi

From: Juergen Richt <jricht@vet.k-state.edu>
Handle: Juergen Richt
Mail Address: jricht@vet.k-state.edu
Subject: RE: urgent decision required please
To: Kawaoka <kawaokay@svm.vetmed.wisc.edu>, Lynn Lipschitz <lynn@target-conferences.com>, Geisbert, Thomas W. <twgeisbe@utmb.edu>
CC: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>, Jricht@ksu.edu <Jricht@ksu.edu>, vikki@target-conferences.com <vikki@target-conferences.com>
Date: Fri, 10 Oct 2014 19:55:10 +0000
Date Local: 2014/10/11 4:55:10
Message:

> I believe we can wait with this if we plan it at the hotel until the next conference call. Most likely not when we want to book the National Press club.

> Best,

> Juergen

>

> -----Original Message-----

> From: Kawaoka [mailto:kawaokay@svm.vetmed.wisc.edu]

> Sent: Friday, October 10, 2014 2:29 PM

> To: Lynn Lipschitz; Geisbert, Thomas W.

> Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jricht@ksu.edu;

> vikki@target-conferences.com

> Subject: Re: urgent decision required please

>

> I just woke up.

>

> Tom, Heinz, and Jürgen,

>

> Don't you want one night of dinner secured either at the hotel or the Press Club??

>

> If we can wait until next conf call, that is fine, however.

>

> Yoshi

> -----

> From: Lynn Lipschitz <lynn@target-conferences.com>

> Handle: Lynn Lipschitz

> Mail Address: lynn@target-conferences.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Friday, October 10, 2014 1:58 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'lynn@target-conferences.com'; 'twgeisbe@utmb.edu'
Cc: 'Jricht@ksu.edu'; 'vikki@target-conferences.com'
Subject: Re: urgent decision required please

Heinz,

Can we discuss the contents of the meeting sometime next week?
I am currently in Japan. So, late afternoon in the US time is good for me.

When is the good time?

Yoshi

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Handle: Feldmann, Heinrich (NIH/NIAID) [E] Mail Address: feldmannh@niaid.nih.gov
Subject: Re: urgent decision required please
To: YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>, 'lynn@target-conferences.com' <lynn@target-conferences.com>, 'twgeisbe@utmb.edu' <twgeisbe@utmb.edu>
CC: 'Jricht@ksu.edu' <Jricht@ksu.edu>, 'vikki@target-conferences.com' <vikki@target-conferences.com>
Date: Fri, 10 Oct 2014 19:39:24 +0000
Date Local: 2014/10/11 4:39:24
Message:

> Dinner is fine with me if we can afford it. If we need to save money that dinner is what we should drop in my view.
>
> I go with the majority on this. Not a big dinner fan - the reception would be more important to me - beut that is me.
>
> ----- Original Message -----
> From: YOSHIHIROKAWAOKA
> Sent: Friday, October 10, 2014 03:28 PM Eastern Standard Time
> To: Lynn Lipschitz <lynn@target-conferences.com>; Geisbert, Thomas W.
> <twgeisbe@utmb.edu>
> Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jricht@ksu.edu
> <Jricht@ksu.edu>; vikki@target-conferences.com
> <vikki@target-conferences.com>
> Subject: Re: urgent decision required please
>
> I just woke up.
>
> Tom, Heinz, and Jürgen,
>
> Don't you want one night of dinner secured either at the hotel or the Press Club??
>
> If we can wait until next conf call, that is fine, however.
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:58 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I am not promoting the CT I am just asking to share the information. I believe the benefit may be minimal at best but it may help some folks to have a few more days to mount a response and everything is already approved by regulatory authorities so we know its safety profile.

Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:23 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I do not want to be the bad guy, but what makes one think that this has any benefit? Based on my work and experience in the filovirus field for over 25 years I would stop this here. There is no justification for a clinical trial. If we go ahead here we could have gone ahead with several other drugs and vaccine candidates before that were more promising than this one.

Sorry for being a bit harsh, but I do not understand this.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:14 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Any concerns?

Darren and I discussed whether we should do a study with pegylated Avonex. What do you think?

Kathy

-----Original Message-----

From: Darren Baker [mailto:darren.baker@biogenidec.com]
Sent: Friday, October 10, 2014 3:08 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Cc: Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Disclosure of ebola-infected NHP data

Dear all

Feldmann, Heinrich (NIH/NIAID) [E]

From: Juergen Richt <jricht@vet.k-state.edu>
Sent: Friday, October 10, 2014 1:55 PM
To: YOSHIHIROKAWAOKA; Lynn Lipschitz; Geisbert, Thomas W.
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jricht@ksu.edu; vikki@target-conferences.com
Subject: RE: urgent decision required please

I believe we can wait with this if we plan it at the hotel until the next conference call. Most likely not when we want to book the National Press club.

Best,
Juergen

-----Original Message-----

From: Kawaoka [mailto:kawaokay@svm.vetmed.wisc.edu]
Sent: Friday, October 10, 2014 2:29 PM
To: Lynn Lipschitz; Geisbert, Thomas W.
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jricht@ksu.edu; vikki@target-conferences.com
Subject: Re: urgent decision required please

I just woke up.

Tom, Heinz, and Jürgen,

Don't you want one night of dinner secured either at the hotel or the Press Club??

If we can wait until next conf call, that is fine, however.

Yoshi

From: Lynn Lipschitz <lynn@target-conferences.com>
Handle: Lynn Lipschitz
Mail Address: lynn@target-conferences.com
Subject: Re: urgent decision required please
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>
CC: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>, Jricht@ksu.edu <Jricht@ksu.edu>, YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>, vikki@target-conferences.com <vikki@target-conferences.com>
Date: Fri, 10 Oct 2014 20:01:11 +0300
Date Local: 2014/10/11 2:01:11
Message:

> Hi all and Heinz hope that you are well!
> Thanks for the decision. We will book the hotel and the get-together
> reception so that they hold the space.
> As to the food/drink content - we will decide closer to the time
> according to our budget allowance. I will not hold any space for the
> gala dinner - that will follow pending budget allowance.
> During our next phone call then we need to discuss the registration
> fees (if we will take money in advance assuming that there will be a

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 1:41 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I have mixed feelings on this - I both agree and disagree with Heinz. My arbitrary cutoff for success was either some survival or extension of time to death of at least 10 days. We did not meet either of these. Is it possible that some sort of treatment like this could push some people to survive, maybe, it probably does not make things worse. Supportive care obviously helps, but can anything specific help above that... unfortunately you don't know until you try. Redacted by agree

Redacted by agreement The only downside being that the doses of IFN we used are unlikely (I am guessing) to be used in people?

I have no problem with disclosing the data, as long as it is communicated appropriately.

Darryl

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:23 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I do not want to be the bad guy, but what makes one think that this has any benefit? Based on my work and experience in the filovirus field for over 25 years I would stop this here. There is no justification for a clinical trial. If we go ahead here we could have gone ahead with several other drugs and vaccine candidates before that were more promising than this one.

Sorry for being a bit harsh, but I do not understand this.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:14 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Any concerns?

Darren and I discussed whether we should do a study with pegylated Avonex. What do you think?

Kathy

-----Original Message-----

From: Darren Baker [mailto:darren.baker@biogenidec.com]
Sent: Friday, October 10, 2014 3:08 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Cc: Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Disclosure of ebola-infected NHP data

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:37 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI..

Yes. Anton from NML.

d.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:18 AM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Re: FYI..

Anton from Winnipeg?

From: Safronetz, David (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:17 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FYI..

Anton may give you a call / send you an email in the near future. He wants to discuss some ideas with you about Ebola treatments. I gave him your cell number, but told him email would be best.

Dave

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Friday, October 10, 2014 1:29 PM
To: Lynn Lipschitz; Geisbert, Thomas W.
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jricht@ksu.edu; vikki@target-conferences.com
Subject: Re: urgent decision required please

I just woke up.

Tom, Heinz, and Jürgen,

Don't you want one night of dinner secured either at the hotel or the Press Club??

If we can wait until next conf call, that is fine, however.

Yoshi

From: Lynn Lipschitz <lynn@target-conferences.com>
Handle: Lynn Lipschitz
Mail Address: lynn@target-conferences.com
Subject: Re: urgent decision required please
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>
CC: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>, Jricht@ksu.edu <Jricht@ksu.edu>, YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>, vikki@target-conferences.com <vikki@target-conferences.com>
Date: Fri, 10 Oct 2014 20:01:11 +0300
Date Local: 2014/10/11 2:01:11
Message:

> Hi all and Heinz hope that you are well!
> Thanks for the decision. We will book the hotel and the get-together
> reception so that they hold the space.
> As to the food/drink content - we will decide closer to the time
> according to our budget allowance. I will not hold any space for the
> gala dinner - that will follow pending budget allowance.
> During our next phone call then we need to discuss the registration
> fees (if we will take money in advance assuming that there will be a
> dinner or not).
> Thanks again
> Regards
> Lynn
>
>
> *Lynn Lipschitz * | *Managing Director*
>
> *Target Conferences Ltd.*
>
> *65 Derech Menachem Begin*
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Harvey <harvey.artsob@videotron.ca>
Sent: Friday, October 10, 2014 1:15 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola - general information

Thomas,

Thank you so much. These copies are great and will not be passed on.

Harvey

From: [Hoenen, Thomas \(NIH/NIAID\) \[F\]](#)
Sent: Friday, October 10, 2014 1:48 PM
To: <mailto:harvey.artsob@videotron.ca>
Cc: [Feldmann, Heinrich \(NIH/NIAID\) \[E\]](#)
Subject: RE: Ebola - general information

Dear Harvey,

Please find attached as requested by Heinz some recent reviews as well as one older one, but which still might be relevant, on EBOV. I have also attached a recent book chapter, please note I only have the author's proof in an electronic format, so I would ask you to not further distribute that file.

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 5:06 AM
To: 'harvey.artsob@videotron.ca'; 'twgeisbe@UTMB.EDU'; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola - general information

Dear ALL,

Harvey needs some information but I do not have access to it here in Monrovia.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:15 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Mowatt, Michael (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Kathy & Heinz,

I'll follow your lead on this decision. It's your work, and I want to be sure that your needs and interests are addressed.

I assume you'll want to publish your results, so we'll want to preserve your right to do that, but I don't know what other interests you have.

Under the agreement we have the right to file patent applications on inventions we make (not sure if we have anything not already covered by Biogen patents), but we are under no obligation to do so.

We may want to set a teleconference to discuss. Please let me know.

Mike

-----Original Message-----

From: Darren Baker [mailto:darren.baker@biogenidec.com]
Sent: Friday, October 10, 2014 3:08 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Cc: Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Disclosure of ebola-infected NHP data

Dear all

Following receipt of the first data from Kathy yesterday regarding the comparison of **Redacted by agreement** ebola-infected rhesus monkeys, I wanted to check what your thoughts were about disclosing the data to a third party who I have been in discussion with regarding a potential clinical trial in ebola-infected patients. The data may be useful in selecting the type of interferon that would be used. I want to ensure that any disclosure to third parties is in keeping with the MTA between BiogenIdec and NIH/NIAID (Michael - please comment), as well as with any desire by the investigators at the NIH/NIAID **Redacted by agreement**

Please advise

Cheers ... Darren

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:14 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Any concerns?

Darren and I discussed whether we should do a study with [Redacted by agree] What do you think?

Kathy

-----Original Message-----

From: Darren Baker [mailto:darren.baker@biogenidec.com]
Sent: Friday, October 10, 2014 3:08 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Cc: Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Disclosure of ebola-infected NHP data

Dear all

Following receipt of the first data from Kathy yesterday [Redacted by agreement] ebola-infected rhesus monkeys, I wanted to check what your thoughts were about disclosing the data to a third party who I have been in discussion with regarding a potential clinical trial in ebola-infected patients. The data may be useful in selecting the type of interferon that would be used. I want to ensure that any disclosure to third parties is in keeping with the MTA between BiogenIdec and NIH/NIAID (Michael - please comment), as well as with any desire by the

[Redacted by agreement]

Please advise

Cheers ... Darren

Feldmann, Heinrich (NIH/NIAID) [E]

From: Darren Baker <darren.baker@biogenidec.com>
Sent: Friday, October 10, 2014 1:08 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Cc: Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Disclosure of ebola-infected NHP data

Dear all

Following receipt of the first data from Kathy yesterday regarding the comparison of Redacted by agreement in ebola-infected rhesus monkeys, I wanted to check what your thoughts were about disclosing the data to a third party who I have been in discussion with regarding a potential clinical trial in ebola-infected patients. The data may be useful in selecting the type of interferon that would be used. I want to ensure that any disclosure to third parties is in keeping with the MTA between BiogenIdec and NIH/NIAID (Michael - please comment), as well as with any desire by the

Redacted by agreement

Please advise

Cheers ... Darren

Feldmann, Heinrich (NIH/NIAID) [E]

From: Anja.WOLZ@geneva.msf.org
Sent: Friday, October 10, 2014 12:25 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Berlin

Sorry I was the last days in Bo back now in Monrovia
if you around let us meet

Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: Anja WOLZ/GVA/U/MSF
To: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
Date: 06.10.2014 10:38
Subject: Re: Berlin

When will you be in Monrovia? Call me my number is Personal Info
Anja

Sent from IBM Notes Traveler

Feldmann, Heinrich (NIH/NIAID) [E] --- Re: Berlin ---

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher,Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "Ilia.Semmler@tmf-ev.de'" <Ilia.Semmler@tmf-ev.de>, "jricht@vet.k-state.edu" <jricht@vet.k-state.edu>
Date: Sun, Oct 5, 2014 11:09
Subject: Re: Berlin

I guess we have to move on.

Ilia and Juergen, please make necessary changes.

Anja - I may see you in Monrovia. I am on my way.

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:12 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: talk for Berlin
Attachments: Haddock Berlin 2014.pptx

Heinz, I practiced at the Friday meeting. The talk runs about 11.5 minutes, slides have been updated to streamline and highlight some points.

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 11:49 AM
To: 'harvey.artsob@videotron.ca'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola - general information
Attachments: 2011_Hoenen_Antivir_Res_Minigenome_review.pdf; 2012_Hoenen_Vaccine_review_b.pdf; 2014_Hoenen_Reverse_Genetics_EBOV_review.pdf; 2014_Falzarano_Antivir_Res_Reporter_viruses.pdf; 2014_Hoenen_EBOV_experimental_therapies.pdf; 2006_Hoenen_EBOV_pathogenesis_review.pdf; 2012_Hoenen_Vaccine_bookchapter.pdf

Dear Harvey,

Please find attached as requested by Heinz some recent reviews as well as one older one, but which still might be relevant, on EBOV. I have also attached a recent book chapter, please note I only have the author's proof in an electronic format, so I would ask you to not further distribute that file.

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 5:06 AM
To: 'harvey.artsob@videotron.ca'; 'twgeisbe@UTMB.EDU'; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola - general information

Dear ALL,
Harvey needs some information but I do not have access to it here in Monrovia.

Tom - can you please send him the pdf of the latest Fields chapter?


Andrea, Darryl and Thomas, please send him pdfs of your latest review articles.

Please copy me if you do not mind.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Saindon, John M. (CDC/OPHSS/OD)
Sent: Friday, October 10, 2014 11:39 AM
To: Flynn, Jesse M CTR OSD OUSD ATL (US); Towner, Jonathan (Jon) (CDC/OID/NCEZID); Bird, Brian (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Nichol, Stuart T. (CDC/OID/NCEZID); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Smith, Michael A CIV (US); Stroehler, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); guillermo.pimentel@med.navy.mil
Cc: Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US)
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call

Records Originating Outside of NIAID



-----Original Appointment-----

From: Flynn, Jesse M CTR OSD OUSD ATL (US) [mailto:jesse.m.flynn.ctr@mail.mil]

Sent: Friday, September 05, 2014 5:59 PM

To: Flynn, Jesse M CTR OSD OUSD ATL (US); Towner, Jonathan (Jon) (CDC/OID/NCEZID); Bird, Brian

Feldmann, Heinrich (NIH/NIAID) [E]

From: Chil-Yong Kang <cykang@uwo.ca>
Sent: Friday, October 10, 2014 11:35 AM
To: Menk, Kay (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; sklee@curocom.com
Subject: 회신: RE: Re: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Thank you Kay.
We look forward to receiving the clones.
Have a nice weekend.
Yong

10.10.14 에 "Menk, Kay (NIH/NIAID) [E]" <menkk@niaid.nih.gov> 작성:

Good morning,

Attached is the fully executed SLA. Please arrange shipment with Dr. Andrea Marzi.

Contact us with any questions.

Thank you.

Kay

Kay R. Menk, Laboratory Operations Specialist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-9624
Fax: (406) 375-9620
Email: menkk@niaid.nih.gov

The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this email in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Friday, October 10, 2014 10:42 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'lynn@target-conferences.com'
Cc: 'Jricht@ksu.edu'; YOSHIHIROKAWAOKA; 'vikki@target-conferences.com'
Subject: RE: urgent decision required please

I think the first thing we need to do as I think Heinz is saying is lock in a reception somewhere either at the Hotel or at the Press Club. If can't afford open bar then we have to have cash bar. I am wondering though if we can decide later if we have open bar or cash bar?

On the dinner what are the options in terms of the Press Clube versus the Hotel? Also, I am wondering if we can postpone a decision on the dinner and if it turns out later that we can afford it then we have it even if it is at some other venue in the area.

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 11:38 AM
To: 'lynn@target-conferences.com'; Geisbert, Thomas W.
Cc: 'Jricht@ksu.edu'; YOSHIHIROKAWAOKA; 'vikki@target-conferences.com'
Subject: Re: urgent decision required please

I don't have a problem with the dates.

A reception would be good. If we need to save money I would drop the dinner.

Heinz

From: Lynn Lipschitz [mailto:lynn@target-conferences.com]
Sent: Friday, October 10, 2014 12:27 PM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Juergen Richt <Jricht@ksu.edu>; YOSHIHIROKAWAOKA; Vikki Hyman <vikki@target-conferences.com>
Subject: Re: urgent decision required please

I take it that you all agree to the dates of Wednesday-Saturday - March 25-28, 2015, (session days Thursday, Friday & Saturday)?

Yes Tom - what you wrote is correct -

The first night was only for one hour and the rates are rather high if we want to extend it to 2 hours. But if you say that we can do food and then add drinks if affordable that's great. We don't have to decide on the food and drinks as yet.

For the dinner - we can have it on either night that you want - they are not holding space - I have to tell them which night.

Feldmann, Heinrich (NIH/NIAID) [E]


From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:37 AM
To: NIAID RML LV Staff
Subject: FW: What You Need To Know About Ebola / The Onion

From America's Finest News Source, The Onion.

(satire)

What You Need To Know About Ebola

Oct 9, 2014



Following the death of the first person diagnosed with Ebola in the United States, concerns about the deadly hemorrhagic virus are running high throughout the country. Here is everything you need to know about Ebola:

What is Ebola?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:32 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Wilson, Deborah (NIH/OD/ORS) [E]; Schmitt, James (NIH/OD/ORS) [E]; Hoe, Nancy (NIH/OD/ORS) [E]; Morgan, Megan (NIH/OD/ORS) [E]; Anderson, Rebecca (NIH/OD/ORS) [C]; Caldwell, Marcie (NIH/OD/ORS) [C]; Feldmann, Heinrich (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Risi, George (George.Risi@providence.org)
Cc: Bloom, Marshall (NIH/NIAID) [E]
Subject: testing in State lab

The attached article notes that the Montana State Lab is now qualified to do testing for ebola as part of the CDC's Laboratory Response Network (LRN). <http://www.medpagetoday.com/InfectiousDisease/Ebola/47980>

I confirmed this in a phone call with Lab Director Suzie Zanto yesterday.

The state lab would only perform the testing at the direction of CDC. Duplicate blood samples would be collected; one would go to Helena, the other directly to CDC. This will certainly expedite results.

Thanks to those in Bethesda who pushed for Montana to be added to the LRN for this test. Hopefully, we will never have to use it!

Marshall

Marshall E. Bloom, M.D.
Associate Director
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: 406-375-9707
FAX: 406-375-9661
email: mbloom@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Harvey <harvey.artsob@videotron.ca>
Sent: Friday, October 10, 2014 10:23 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola - general information

Darryl,

Thus is greatly appreciated.

Thank you!

Harvey

From: [Falzarano, Darryl \(NIH/NIAID\) \[F\]](#)
Sent: Friday, October 10, 2014 12:03 PM
To: [Feldmann, Heinrich \(NIH/NIAID\) \[E\]](#) ; <mailto:harvey.artsob@videotron.ca>
Subject: RE: Ebola - general information

Hi Harvey,

Please find attached one recent and one slightly more dated review on Ebola.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 5:06 AM
To: 'harvey.artsob@videotron.ca'; 'twgeisbe@UTMB.EDU'; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola - general information

Dear ALL,

Harvey needs some information but I do not have access to it here in Monrovia.

Tom - can you please send him the pdf of the latest Fields chapter?

Andrea, Darryl and Thomas, please send him pdfs of your latest review articles.

Please copy me if you do not mind.

Many thanks,
Heinz

From: Harvey [<mailto:harvey.artsob@videotron.ca>]
Sent: Thursday, October 09, 2014 01:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - general information

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:17 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FYI..

Anton may give you a call / send you an email in the near future. He wants to discuss some ideas with you about Ebola treatments. I gave him your cell number, but told him email would be best.

Dave

Feldmann, Heinrich (NIH/NIAID) [E]

From: Theodora Tsoli <thtsoli@tovima.gr>
Sent: Friday, October 10, 2014 10:15 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: VIMA NEWSPAPER-GREECE-INTERVIEW REQUEST

Dear dr Feldmann

my name is Theodora Tsoli and I am a journalist for the greek newspaper TO VIMA, one of the biggest Sunday papers in my country. We are preparing an article on Ebola for our next Sunday's paper (19th October) and I was wondering if you could find some time in the beginning of next week to speak to me about the virus (has it mutated? is it easy to become airborne? how much does it survive on surfaces? are the measures in airports against it enough? could the patients take a painkiller against fever and pass from the checkpoints in the airports?)

Hope to hear from you soon
Thank you in advance
Theodora Tsoli

Theodora Tsoli
Newspaper «TO VIMA»
11526, Athens - Greece
Tel. : +30 211 365 8204
Mobile: + Personal Info
email: thtsoli@tovima.gr

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Friday, October 10, 2014 10:15 AM
To: Lynn Lipschitz; Feldmann, Heinrich (NIH/NIAID) [E]; Juergen Richt; YOSHIHIROKAWAOKA; Vikki Hyman
Subject: RE: urgent decision required please

So I am confused. Would this be a formal sit down Gala dinner at the Press Club or would this be something else.

I think we are looking to do is:

1. Have at least a 2-3 hour reception on the night before the meeting starts, i.e., the night everyone arrives. What we normally do is have a buffet and then maybe some people walking around with appetizers on plates. Then we try to have open bar (beer and wine only) if we can afford it. We have stand up tables for this.
2. Either on the first or second night of the meeting we have a formal sit down Gala dinner with podium and microphone and projector capability.

Many thanks!

Tom

From: Lynn Lipschitz [mailto:lynn@target-conferences.com]
Sent: Friday, October 10, 2014 10:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Geisbert, Thomas W.; Juergen Richt; kawaokay@svm.vetmed.wisc.edu; Vikki Hyman
Subject: Re: urgent decision required please

March 27 is free at the Press Club. Which date is better - March 26 or March 27 ??? There will be supplements for bartender and for a sound system (in case you want to make speeches). Let me know if you want a program too .. but the decision about the program is really the least urgent item we have. It can wait till the very very end
Thanks
Lynn

Lynn Lipschitz | **Managing Director**
Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818
Tel: +972 3 5175150 ext 601, Fax: +972 3 5175155
www.target-conferences.com

On Fri, Oct 10, 2014 at 6:15 PM, Lynn Lipschitz <lynn@target-conferences.com> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 10:04 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'harvey.artsob@videotron.ca'
Subject: RE: Ebola - general information
Attachments: 1-s2.0-S187962571300062X-main.pdf; erv.10.pdf

Hi Harvey,

Please find attached one recent and one slightly more dated review on Ebola.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 5:06 AM
To: 'harvey.artsob@videotron.ca'; 'twgeisbe@UTMB.EDU'; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola - general information

Dear ALL,

Harvey needs some information but I do not have access to it here in Monrovia.

Tom - can you please send him the pdf of the latest Fields chapter?

Andrea, Darryl and Thomas, please send him pdfs of your latest review articles.

Please copy me if you do not mind.

Many thanks,
Heinz

From: Harvey [mailto:harvey.artsob@videotron.ca]
Sent: Thursday, October 09, 2014 01:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - general information

Heinz,

I hope this e-mail finds you well.

I have been asked to write about Ebola for an online news source.

By way of introduction, I would like to give a brief background on Ebola including history, different strains, outbreaks since 1976 and geographic distribution. I am not looking for any great detail.

Would you happen to have any information that you could share with me?

Harvey

Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 9:55 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: New Guinea primer/probe sets

Hi Heinz,

I will not be able to make it today, as I'm flying out to Philadelphia. But go ahead and schedule a meeting with the group and you can fill me in later

You might want to compare the CT values from the beginning with those later on, and also check with MSF if they think that the admissions they now get are earlier (less time between onset and admission) from the first batch. Generally, we only get samples from the admission, and not from late state of disease, which might explain the relatively higher values.

Vincent

From: <Feldmann>, Heinrich Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 10, 2014 8:30 AM
To: "De wit, Emmie (NIH/NIAID) [E]" <Emmie.deWit@nih.gov>, Vincent Munster <munstervj@niaid.nih.gov>, "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov>, "Falzarano, Darryl (NIH/NIAID) [F]" <darryl.falzarano@nih.gov>, "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov>, "Hoenen, Thomas (NIH/NIAID) [F]" <thomas.hoenen@nih.gov>
Subject: Re: New Guinea primer/probe sets

Can we talk about this today? If the viral load estimation is correct we would have ridiculously low viral loads in most patients. There is something wrong as many more should survive. I know we have talked about this before but in my view it doesn't make any sense. The CDC Ct values make more sense to me - not saying that there assay is better.

I will try to ask Allen about their Ct values.

We need to talk about multiplex assays as well (malaria and Ebola and eventual Lassa). When is a good time for all of you?

Heinz

From: De wit, Emmie (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:08 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: New Guinea primer/probe sets

Hi Heinz,

I think the CDC Ct values might be off and not ours. First of all, Redacted by agreement

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 9:55 AM
To: Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; De wit, Emmie (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola primers and probes

This is the GP assay of the Kenian CDC,

Perhaps we should orders these and see if we get it to work on our platforms and do a comparison.


I know this has been tried in Liberia, Redacted by agreement

They were ordered by them through IDT as well,

Vincent

On 9/12/14 7:02 AM, "Fields, Barry (CDC/CGH/DGHP)" <bsf2@CDC.GOV> wrote:

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 9:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Koita, Ousmane; Sakai, Richard; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Siddiqui, Sophia (NIH/NIAID) [E]; 'amadoukone@icermali.org'; 'ssow@medicine.umaryland.edu'
Subject: RE: New suspected case to be tested

As Heinz mentioned, just send us a list of required materials and we will send a re-supply package from RML.

Dave

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:49 AM
To: Koita, Ousmane; Sakai, Richard; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; 'amadoukone@icermali.org'; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Let us know if you need anything.

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 10:47 AM Eastern Standard Time
To: Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Dear Dick,

I think you are right, I am planning to have an inventory of the stock may be tomorrow morning or Monday.

Best regards,

Ousmane

-----Original Message-----

From: Richard Sakai
Sent: Friday, October 10, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: RE: New suspected case to be tested

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koita, Ousmane
Sent: Friday, October 10, 2014 8:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Sakai, Richard; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Thanks Heinz,

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 2:49 PM
To: Ousmane Koita; Richard Sakai; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Let us know if you need anything.

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 10:47 AM Eastern Standard Time
To: Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Dear Dick,

I think you are right, I am planning to have an inventory of the stock may be tomorrow morning or Monday.

Best regards,

Ousmane

-----Original Message-----

From: Richard Sakai
Sent: Friday, October 10, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: RE: New suspected case to be tested

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koita, Ousmane
Sent: Friday, October 10, 2014 8:47 AM
To: Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Dear Dick,

I think you are right, I am planning to have an inventory of the stock may be tomorrow morning or Monday.

Best regards,

Ousmane

-----Original Message-----

From: Richard Sakai
Sent: Friday, October 10, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: RE: New suspected case to be tested

It appears that the stock of some of the testing reagents have been completely used up and the stock of others may also be low. Are there any plans to re-stock the reagent inventory soon?

Dick

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 2:08 PM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Great job - including the troubleshooting.

Heinz

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 09:47 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sakai, Richard
Sent: Friday, October 10, 2014 8:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Koita, Ousmane; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

It appears that the stock of some of the testing reagents have been completely used up and the stock of others may also be low. Are there any plans to re-stock the reagent inventory soon?

Dick

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 2:08 PM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Great job - including the troubleshooting.

Heinz

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 09:47 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Dear Heinz,

The test came negative, we did twice. For the first test, the positive control Zaire didn't show any amplification (the two other did). The second test was well done, all the positive controls were positive (Zaire Sudan and Cote d'Ivoire), the negative control (water) and the 2 samples of the specimen 027 were negative. The picture of the screen is attached for your review. The confirmatory test is underway.

So far there is no case of Ebola. We hope it continues that way.

Best regards,

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 10:05 AM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Saskia.Gerhard@zeit.de
Sent: Friday, October 10, 2014 8:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview-Inquiry: Ebola-"flight routes"

Dear Dr. Feldmann,

my name is Saskia Gerhard, I am working for the german ZEIT ONLINE and I am currently working on an article about the possible spread of Ebola via plane flight routes.

I just read your interview on Science News about your stay in Monrovia and I am especially interested in the processes you witnessed at the airport, concerning passenger control and fever measurements.

I would be very happy if we managed to do a short interview. I can send you my questions beforehand if you like.

Thank you and best regards,
Saskia Gerhard

--

Saskia Gerhard | Volontärin Wissen

ZEIT ONLINE, Askanischer Platz 1, 10963 Berlin | www.zeit.de<<http://www.zeit.de>>
saskia.gerhard@zeit.de<<mailto:alina.schadwinkel@zeit.de>>
+49(0)30-322950-165

www.twitter.com/zeitonline_wis<http://www.twitter.com/zeitonline_wis> |
www.facebook.com/zeitonline<<http://www.facebook.com/zeitonline>>

DIE ZEIT jetzt am Kiosk.
www.zeit.de/diesewoche

ZEIT ONLINE - Durchschauen Sie jeden Tag.
www.zeit.de

Zeitverlag Gerd Bucerius GmbH & Co. KG, 20079 Hamburg
Geschäftsführer: Dr. Rainer Esser
Handelsregister Hamburg HRA 91123
Amtsgericht Hamburg

Feldmann, Heinrich (NIH/NIAID) [E]

From: Samba Sow <ssow@medicine.umaryland.edu>
Sent: Friday, October 10, 2014 8:31 AM
To: Koita, Ousmane
Cc: amadoukone@icermali.org; Diarra, Bassirou; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; Murphy, Robert
Subject: Re: New suspected case to be tested

Merci
S

Sent from my iPhone

> On Oct 10, 2014, at 10:09 AM, "Ousmane Koita" <okoita@icermali.org> wrote:

>

> Thanks Heinz.

>

> Ousmane

>

> -----Original Message-----

> From: Feldmann, Heinrich (NIH/NIAID) [E]

> [mailto:feldmannh@niaid.nih.gov]

> Sent: Friday, October 10, 2014 2:08 PM

> To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra;

> Murphy, Robert

> Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui;

> Amadou Kone; 'ssow@medicine.umaryland.edu'

> Subject: Re: New suspected case to be tested

>

> Great job - including the troubleshooting.

>

> Heinz

>

> ----- Original Message -----

> From: Koita, Ousmane

> Sent: Friday, October 10, 2014 09:47 AM Eastern Standard Time

> To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID)

> [E]; Diarra, Bassirou; Murphy, Robert

> Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia

> (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>;

> ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>

> Subject: RE: New suspected case to be tested

>

> Dear Heinz,

>

> The test came negative, we did twice. For the first test, the positive

> control Zaire didn't show any amplification (the two other did). The

> second test was well done, all the positive controls were positive

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koita, Ousmane
Sent: Friday, October 10, 2014 8:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested

Thanks Heinz.

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 2:08 PM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Great job - including the troubleshooting.

Heinz

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 09:47 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Dear Heinz,

The test came negative, we did twice. For the first test, the positive control Zaire didn't show any amplification (the two other did). The second test was well done, all the positive controls were positive (Zaire Sudan and Cote d'Ivoire), the negative control (water) and the 2 samples of the specimen 027 were negative. The picture of the screen is attached for your review. The confirmatory test is underway.

So far there is no case of Ebola. We hope it continues that way.

Best regards,

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 10:05 AM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koita, Ousmane
Sent: Friday, October 10, 2014 7:47 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested
Attachments: Screening test for the patient 027 of October 10, 2014.jpg

Dear Heinz,

The test came negative, we did twice. For the first test, the positive control Zaire didn't show any amplification (the two other did). The second test was well done, all the positive controls were positive (Zaire Sudan and Cote d'Ivoire), the negative control (water) and the 2 samples of the specimen 027 were negative. The picture of the screen is attached for your review. The confirmatory test is underway.

So far there is no case of Ebola. We hope it continues that way.

Best regards,

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 10:05 AM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Sounds good.

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 05:01 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Dear Dr Heinz,

Redacted by agreement I don't know yet the specifics about the symptoms. The blood has been collected last night by the team of Dr Sow. We will process the specimen and will update you as soon as the results are available.

Best regards,

Ousmane

Feldmann, Heinrich (NIH/NIAID) [E]

From: Harvey <harvey.artsob@videotron.ca>
Sent: Friday, October 10, 2014 6:21 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola - general information

Heinz,

Thank you for your response and effort to get me references.

I should have realized you would be playing a role in the outbreak.! It would be shame if your Ebola expertise was not properly accessed. I wish I had something useful to offer myself.

Personal Info

Harvey

From: [Feldmann, Heinrich \(NIH/NIAID\) \[E\]](#)
Sent: Friday, October 10, 2014 7:02 AM
To: <mailto:harvey.artsob@videotron.ca>
Subject: Re: Ebola - general information

Harvey,

Good to hear from you. I am currently in Monrovia for the Ebola outbreak - supposed to return on November 1. I do not have much with me here but I will ask Tom to send you the latest Fields chapter and Darryl, Andrea and Thomas to send you more recent review articles. Regarding outbreaks and numbers you may want to go on the CDC and WHO websites - they usually keep track.

Personal Info However, I am not sure any longer if this would be a good choice. Any suggestion from your end? Anything to read up for me on the Personal Info in preparation
Personal Info If I go
to Personal Info maybe we can meet.

Best wishes,
Heinz

From: Harvey [<mailto:harvey.artsob@videotron.ca>]
Sent: Thursday, October 09, 2014 01:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - general information

Heinz,

I hope this e-mail finds you well.

I have been asked to write about Ebola for an online news source.

Feldmann, Heinrich (NIH/NIAID) [E]

From: ZOO <zoo@target-conferences.com>
Sent: Friday, October 10, 2014 3:50 AM
To: Semmler, Ilia
Cc: Juergen Richt; Feldmann, Heinrich (NIH/NIAID) [E]; Wieler, Lothar H.; Semler, Sebastian; Ludwig, Stephan; Groschup, Martin H.; Nikolaus Osterrieder; no.34@fu-berlin.de; Niedrig, Matthias
Subject: Re: Zoonoses Conference - Berlin - Update Ebola Talk

great news!

thanks
Vikki

On Fri, Oct 10, 2014 at 9:47 AM, Semmler, Ilia <Ilia.Semmler@tmf-ev.de> wrote:

Dear all,

to update you all: we finally have Max Gertler (MSF) for the Ebola-Talk. He made some huge efforts to make it possible.

The session at a glance:

Thursday, Oct 16

- 16:00 - Award from the AfT to Fabian Leendertz
- Ca. 16:10 - Talk Fabian Leendertz. He will split his talk into three parts: 1) thanks for the award (5min), 2) about his research, he got the award (main part), 3) about the animal reservoir of Ebola, and hopefully, of his insights into the reservoir and first transmission resulting in this outbreak, which came from a small village in Guinea.
- 16:45 - 17:30 (incl. discussion) - The Current Ebola Virus Outbreak in West Africa, Maximilian Gertler (Médecins sans Frontières)

By the way: we still **don't have a chairman** for this session. Would someone of you make it? It would be great, if it is mentioned, that it was hard to get someone to talk, because all capacities regarding Ebola (diagnosis or treatment) of Germany, Europe and USA seem to be in West Africa at the moment. I think, this

Feldmann, Heinrich (NIH/NIAID) [E]

From: Christina Sartori <info@christina-sartori.de>
Sent: Friday, October 10, 2014 3:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses
Attachments: Prof Feldmann Interview 06 10 14_en_angenommen.docx

Heinz,

ich hoffe Sie sind wohlbehalten aus Liberia zurückgekehrt.

Anbei die endgültige Version für das Interview, das begleitend zum German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses im Internet veröffentlicht werden soll. Können Sie es bis Montag durchsehen, Ihre Änderungswünsche eintragen und freigeben? Das wäre sehr hilfreich, um es noch rechtzeitig zur Konferenz einzustellen.

Haben Sie ein Foto von sich das wir verwenden können? Auf der Website ist eins

<http://www.zoonoses2014.com/#!welcome/c23yr>

wenn Sie einverstanden sind, nehmen wir das. Und haben Sie eventuell ein Foto vom Ebola Virus, dass wir mit dem Interview verwenden könnten?

Freundliche Grüße
Christina Sartori

Dipl.-Biol. Christina Sartori

Wissenschafts-Journalistin
info@christina-sartori.de
Mobil: Personal Info
Telefon: 030 - 89391473

Feldmann, Heinrich (NIH/NIAID) [E]

From: Wieler, Lothar Heinz <Lothar.Wieler@fu-berlin.de>
Sent: Friday, October 10, 2014 2:57 AM
To: Semmler, Ilia; 'Juergen Richt'; Feldmann, Heinrich (NIH/NIAID) [E]; ZOO (zoo@target-conferences.com); Semler, Sebastian; Ludwig, Stephan; Groschup, Martin H.; 'Nikolaus Osterrieder'; 'no.34@fu-berlin.de'; Niedrig, Matthias
Subject: AW: Zoonoses Conference - Berlin - Update Ebola Talk

Mach ich – kein Problem!

Univ.-Prof. Dr. Lothar H. Wieler, Director
Centre for Infection Medicine
Institute of Microbiology and Epizootics
Freie Universität Berlin
Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany
Phone: ++49 30 838 51796
Fax: ++49 30 838 451851
lothar.wieler@fu-berlin.de



Von: Semmler, Ilia [mailto:Ilia.Semmler@tmf-ev.de]
Gesendet: Freitag, 10. Oktober 2014 10:47
An: 'Juergen Richt'; Feldmann, Heinrich (NIH/NIAID) [E]; ZOO (zoo@target-conferences.com); Wieler, Lothar Heinz; Semler, Sebastian; Ludwig, Stephan; Groschup, Martin H.; 'Nikolaus Osterrieder'; 'no.34@fu-berlin.de'; Niedrig, Matthias
Betreff: Zoonoses Conference - Berlin - Update Ebola Talk

Dear all,

to update you all: we finally have Max Gertler (MSF) for the Ebola-Talk. He made some huge efforts to make it possible.

The session at a glance:

Thursday, Oct 16

- 16:00 - Award from the AfT to Fabian Leendertz
- Ca. 16:10 - Talk Fabian Leendertz. He will split his talk into three parts: 1) thanks for the award (5min), 2) about his research, he got the award (main part), 3) about the animal reservoir of Ebola, and hopefully, of his insights into the reservoir and first transmission resulting in this outbreak, which came from a small village in Guinea.
- 16:45 - 17:30 (incl. discussion) - The Current Ebola Virus Outbreak in West Africa, Maximilian Gertler (Médecins sans Frontières)

By the way: we still **don't have a chairman** for this session. Would someone of you make it? It would be great, if it is mentioned, that it was hard to get someone to talk, because all capacities regarding Ebola (diagnosis or treatment) of Germany, Europe and USA seem to be in West Africa at the moment. I think, this would show, who deep researchers and doctors are involved in this outbreak (I am sure, there will be some journalists in the room during this session).

We will prepare a sheet with the updated program and the names of the speakers as a hand out onsite.

Best regards
Ilia

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]@hotmail.com>
Sent: Thursday, October 09, 2014 11:10 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: theories and questions

Dear Dr. Feldmann,

No doubt since there is so much media hype and hysteria about the Ebola outbreak in western Africa, which unfortunately did not receive the needed attention, funding and resources when it was still in the more containable stages, you may have received a number of correspondences from a number of crackpots. I hope this email does not number among them, but I do have some questions for you.

I am a physician who has had international experience in resource poor areas, most recently with MSF in South Sudan, as well as military and public health experience. Therefore, I am well aware that using PPE in a tropical, resource poor environment is very different than in a well controlled technology and resource rich lab situation, and am familiar with how uncomfortable and unwieldy PPE such as the army's MOPP gear is, under even the best of circumstances. I have been selected to be a Global Health Innovations Fellow with Massachusetts General Hospital beginning in December 2014.

Given the high numbers of health care workers who have become infected with Ebola despite the use of PPE, I question whether such equipment may actually be contributing to the risk of infections. If Ebola does not penetrate unbroken skin, is it necessary to cover the skin entirely? In a high heat environment, does heat stress from wearing these garments contribute to lapses in infection control vigilance, and does the awkward nature of the garments and visual impairment increase the likelihood of sharps injuries? Are people more apt to contaminate their mucus membranes while removing these garments rather than washing exposed unbroken contaminated skin? Without these garments, a worker can feel a splash event and be especially vigilant about immediately cleaning the area, but with the garment, the worker does not necessarily know if splash or contact with body fluids contamination has occurred, and during the wash down process, the situation exists for additional personnel to be splashed. How was it determined these full body coverings are necessary? Would it be sufficient to cover the head and hands only? I do not have the numbers to know the infection rates of health care workers who have been presumably taking every currently advised precaution, as compared to the infection rates of family members who did not use such precautions, but the number of health care workers who have been infected seems too high to be explained by lapses in protocol or poor training. Rather than increasing the layers and complexity of PPE, I wonder if it might be prudent to at least investigate the possibility of minimizing the reliance on PPE and paying more attention to a wash down procedure and increased vigilance toward avoiding contamination of face/hands/mucus membranes? Also, I wonder if it might be prudent to investigate the use of the two things known to deactivate the virus, which are readily available in the field, ie, UV light and dessiccation.

I know there have been unusual demands on your valuable time recently, but your thoughts on these questions would be much appreciated.

Thank you,

[Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]


From: Safronetz, David (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:32 PM
To: Rosenke, Kyle (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]; Haddock, Elaine (NIH/NIAID) [E]; twgeisbe@UTMB.EDU; chmire@UTMB.EDU
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished
Attachments: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jensen, Victoria M. (CTR) <Victoria.Jensen@NBACC.DHS.GOV>
Sent: Thursday, October 09, 2014 4:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Endothelial activation by VP40/GP
Attachments: Brown_Lin_et_al_2014.pdf

Records Originating Outside of NIAID



From: Lin, Charles [mailto:Charles_Lin@DFCI.HARVARD.EDU]
Sent: Thursday, October 09, 2014 5:49 PM
To: Jensen, Victoria M. (CTR)
Subject: Endothelial activation by VP40/GP

Dr. Wahl-Jensen,

Our laboratory, the Bradner lab, at the Dana-Farber Cancer Institute <http://bradner.dfc.harvard.edu> has a focus on chemical modulation of chromatin structure. Recently we have used models of endothelial cell activation to study cell state changes phenotypically and at the level of genome-wide chromatin structure. We had a paper this week in Molecular Cell on how chromatin active agents can abrogate cell state transitions (attached). With the outbreak of Ebola we are motivated to test our molecules and hypotheses in relevant models of Ebola activation of endothelium.

We therefore read your work with great interest and in particular your 2005 study with Dr. Feldmann on VP40/GP pro-inflammatory activation of endothelium. As a chromatin/chemistry/cancer laboratory, we are highly motivated to work collaboratively. We would like to test a panel of epigenetic molecules from my laboratory on this system to determine whether we can intercept VP40/GP mediated signal transduction in endothelium. We have established relevant endothelial functional assays in lab and only require the plasmids and protocols for VP40/GP expression, purification and administration.

Would you be willing to provide these reagents for us? We can assist in any way possible to expedite shipping.

We would also be happy to discuss more over the phone.

Regards,

Charles Lin
617-276-4723

Charles Y. Lin, Ph.D.
Dana-Farber Cancer Institute
Department of Medical Oncology
charles_lin@dfci.harvard.edu<mailto:charles_lin@dfci.harvard.edu>
<http://bradnerlab.com>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 3:01 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: IFN/ribavirin data for ebola
Attachments: Layout 1.jpg; IFN riba NHP.pzfx

Tony

Here is the data the Darryl sent from our IFN ribavirin study. The [Redacted by agreement]
[Redacted by agreement] Other information can be shared since we purchased the intron A
peg-IntronA and ribavirin. [Redacted by agreement]
I would be happy to discuss with you tomorrow.
Kathy

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Thursday, October 09, 2014 2:32 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Bekisz, Joseph (NIH/NIAID) [E]
Subject: IFN/ribavirin data

Please find data on survival and viral loads in blood and swabs attached. [Redacted by agreement]
[Redacted by agreement]

Sorry for the delay.
Darryl

Darryl Falzarano, Ph.D.
Visiting Fellow
Disease Modeling and Transmission
Laboratory of Virology
Rocky Mountain Laboratories
DIR, NIAID, NIH
903 South 4th Street
Hamilton, MT
59840 USA

Tel +1 406 375-7417
Fax +1 406 375-9620
Email Darryl.Falzarano@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Thursday, October 09, 2014 2:36 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Barcelona?

Heinz,

Do you want me to go ahead and cancel Barcelona? I have received a couple of e-mails from them today and so far I have put them off, but told them I could not give them a definitive time regarding your travel due to the continuing Ebola crisis.

Thanks.

Joyce Walczynski
Logistics Technician, LV (Contractor)
Rocky Mountain Laboratories
903 South 4th St.
Hamilton, MT 59840
Phone: 406.375.9600
Fax: 406.375.9620
Email: walczynskij@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: McFadden, Diane C. <dc2120@cumc.columbia.edu>
Sent: Thursday, October 09, 2014 1:43 PM
To: Baric, Ralph; MichaelKatze; David A. Relman; Shepard, Kenneth L.; William B. Karesh; Christina Egan; Jay Varma; Lipkin, W. Ian; Angela L. Rasmussen; Amy C. Sims; Catherine Machalaba; Eleanor (Ellie) Kahn; Baric, Toni C; Heise, Mark T; Randell, Scott H; Feldmann, Heinrich (NIH/NIAID) [E]; Rose M. Howard; Jennifer Rakeman-Cagno
Subject: Cancelled: Oct 15th CRDD teleconference

Dear Group,

We unfortunately need to cancel next week's teleconference call. Ian has been involved in a number of ebola-related meetings of late and one of them regrettably conflicts with our call. Our next call will be Wednesday November 19th at the new time of 2:30 pm Eastern time.

The major agenda item was going to be about the yearly progress report. I will send more detailed information out hopefully next week. In a nut shell, at least for the science part, each project must provide a progress report up to 5 pages in length that does not exceed 6MB in size. The report must cover the following 6 sections: Accomplishments, Products, Participants, Impact, Changes, Special Reporting Requirements. More detailed instructions can be found under Sections 6.2-6.7 of the RPPR instruction guide (starting at page 51) (http://grants.nih.gov/grants/rppr/rppr_instruction_guide.pdf). Some additional information is being requested by program in regards to BSL3 and 4 usage, product development activities, changes in specific aims etc. I will explain more in the near future but it does not seem too cumbersome.

Please feel free to contact me if you have any questions or need more information.

Regards,
Diane

--

Diane C. McFadden, Ph.D.
Center for Infection & Immunity
Mailman School of Public Health
Columbia University
MSPH Box 20
722 West 168th Street, 17th floor
New York, NY 10032
212-342-0007 (phone)
212-342-9044 (fax)
dc2120@columbia.edu (email)

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Thursday, October 09, 2014 1:37 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Fw: Influenza researcher Yoshihiro Kawaoka wins Breakthrough Award

Yes

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Handle: Feldmann, Heinrich (NIH/NIAID) [E] Mail Address: feldmannh@niaid.nih.gov
Subject: Fw: Influenza researcher Yoshihiro Kawaoka wins Breakthrough Award
To: YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>
CC: --
Date: Thu, 9 Oct 2014 16:49:45 +0000
Date Local: 2014/10/10 1:49:45
Message:

> Congratulations - wee deserved.

>

> From: Pekoc, Ken (NIH/NIAID) [E]

> Sent: Thursday, October 09, 2014 10:50 AM Eastern Standard Time

> To: Feldmann, Heinrich (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID)

> [E]; Ebihara, Hideki (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]

> Subject: Influenza researcher Yoshihiro Kawaoka wins Breakthrough

> Award

>

> This is nice.

> Influenza researcher Yoshihiro Kawaoka wins Breakthrough Award Oct. 7,

> 2014 by Kelly April

> Tyrrell<mailto:%6b%74%79%72%72%65%6c%6c%32@%77%69%73%63.%65%64%75>

> The University of Wisconsin-Madison's Yoshihiro Kawaoka<<http://www.vetmed.wisc.edu/people/kawaokay/>> has been recognized as a 2014 Popular Mechanics Breakthrough Award recipient for his efforts to understand and prevent pandemic influenza.

> He joins a list of prominent innovators, scientists and engineers selected for the award over the past decade for their world-changing contributions, including: SpaceX and Tesla Motors CEO Elon Musk; XPRIZE Foundation founder Peter Diamandis; and humanitarian engineer Amy Smith.

> "I am just so happy," says Kawaoka, a UW-Madison professor of veterinary medicine who studies influenza and Ebola viruses. "I think I don't believe it."

> In recent years, Kawaoka has found himself at the center of controversy surrounding research on highly pathogenic influenza and other sensitive pathogens known as select agents. His studies to understand, monitor, treat and potentially prevent pandemic influenza have often been misrepresented and misunderstood.

> However, according to Popular Mechanics — a science and technology-focused magazine published by Hearst Magazines — Kawaoka was chosen despite the controversy because his work studying mutations in viruses that are currently found in nature and carry pandemic potential could "help protect humanity."

> "We know Ebola is a big issue in Africa right now, but Kawaoka's investigations into influenza — which is in fact a constant and greater threat to public health in the United States — could help us avoid or beat back the type of flu viruses that have erupted into deadly pandemics in the past," says Ryan D'Agostino, Popular Mechanics editor-in-chief.

> Other Popular Mechanics award winners this year include the robotics company Boston Dynamics for its rescue robot, Atlas; NASA, for a lunar orbiter named Ladee; and the National Audubon Society for a study on the impact of climate

Feldmann, Heinrich (NIH/NIAID) [E]

From: Scott Wycherly, Elizabeth (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 1:13 PM
To: NIAID Announcements
Subject: Inside NIAID Newsletter—October 2014

insideNIAID NEWSLETTER

October 2014

Welcome to *Inside NIAID*, a newsletter about events and policies affecting NIAID staff.

If you're having trouble viewing this page, visit

<http://inside.niaid.nih.gov/topic/communications/publications/newsletters/insideNIAID/2014/Pages/oct.aspx#>.

Looking for back issues? Check out our [archive](#).

News and Events

- [Save the Date for the NIAID Merit Awards Ceremony](#)
- [2014 CFC Has Begun](#)
- [New Video Highlights NIH's Investment in Older Workers](#)
- [Learn How Prize Competitions Can Benefit Your Program](#)

Policies and Procedures

- [Federal Teleworkers Must Maintain Telework Agreements](#)
- [Retirement: Meet With NIH Benefits Personnel](#)
- [IRS Keeps You Aware of Scams](#)

Training

- [OWER Announces NIAID Fourth Quarter Training Opportunities](#)

Staff Activities

- [DIR Scientists Receive Early Career Funding](#)
- [Learn More About NIAID Science](#)
- [Annual Leave: Use It or Donate It To Help Someone in Need](#)

Q&A

- [Click Submit To Save Your NED Updates](#)

News and Events

Save the Date for the NIAID Merit Awards Ceremony

Feldmann, Heinrich (NIH/NIAID) [E]

From: Harvey <harvey.artsob@videotron.ca>
Sent: Thursday, October 09, 2014 11:59 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - general information

Heinz,

I hope this e-mail finds you well.

I have been asked to write about Ebola for an online news source.

By way of introduction, I would like to give a brief background on Ebola including history, different strains, outbreaks since 1976 and geographic distribution. I am not looking for any great detail.

Would you happen to have any information that you could share with me?

Harvey

Feldmann, Heinrich (NIH/NIAID) [E]

From: WPambianch [Personal Info]
Sent: Thursday, October 09, 2014 11:06 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: jricht@vet.k-state.edu
Subject: Re: Request to Speak

Speaking with your LIBR colleagues would be helpful.

FYI <http://www.liberianobserver.com/news/dr-logan-wants-support-his-ebola-treatment-protocol%E2%80%99-which-he-has-used-%E2%80%98cure%E2%80%99-10-ebola-patients>

In a message dated 10/9/2014 1:01:19 P.M. Eastern Daylight Time, feldmannh@niaid.nih.gov writes:



I do not know any Dr. Logan. I don't have any contact to clinical treatment centers others than MSF. I can talk to the LIBR colleagues when I meet them.

From: WPambianch [Personal Info]
Sent: Thursday, October 09, 2014 12:38 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: jricht@vet.k-state.edu <jricht@vet.k-state.edu>
Subject: Re: Request to Speak

Hi Heinz,

I hope all is going well there with you.

In addition to contacting MSF and WHO, Hemispherx is trying to get into direct contact with Dr. Gorbee Logan, the Liberian physician who successfully treated Ebola patients with a nucleoside reverse transcriptase inhibitor. Although he is located in Bomi county, he is reported to have sent samples to the Liberian Institute of Biological Research (LIBR) which I gather from news reports is one of if not the main center for testing samples for suspected Ebola patients. Dr. Carter assumes that you have some connection with with LIBR and perhaps with Dr. Logan himself. Dr. Carter would like your assistance in simply trying to find out how we can reach Dr. Logan directly either by phone or email. After several hours of searching, I was unable to find either. Nor was I able to find a phone number at the Bomi County health Department which Dr. Logan heads. By email to their sites, I have contacted the Monrovia Observer and one of its writers who interviewed Dr. Logan as well as the Liberian Minister of Health and Social Welfare but I have heard from neither.

Dr. Carter understands the limits of what you can do and is asking only for your assistance in helping identify how we can connect directly with Dr. Logan.

Thank you very much.

Wayne

In a message dated 10/7/2014 6:51:37 P.M. Eastern Daylight Time, WPambianch [Personal I] writes:



Okay. Thanks for the guidance.

Best regards,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Chil-Yong Kang <cykang@uwo.ca>
Sent: Thursday, October 09, 2014 10:56 AM
To: Marzi, Andrea (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; sklee@curocom.com
Subject: 회신: Re: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Dear Andrea,

Thank you for your reply.

Redacted by agreement

I look forward to working with your group.

With best regards,

Yong

10.09.14에 "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov> 작성:

The MTA covers all Zaire ebolaviruses, so Mayinga and Kikwit are fine. However, we do not have all the genes cloned from Kikwit, only GP to my knowledge since all our in vitro systems are based on Mayinga.

Best, Andrea

From: Chil-Yong Kang <cykang@uwo.ca<<mailto:cykang@uwo.ca>>>
Date: Thursday, October 9, 2014 10:16 AM
To: "Menk, Kay (NIH/NIAID) [E]" <menkk@niaid.nih.gov<<mailto:menkk@niaid.nih.gov>>>
Cc: Heinz Feldmann <feldmannh@niaid.nih.gov<<mailto:feldmannh@niaid.nih.gov>>>, Andrea Marzi <marzia@niaid.nih.gov<<mailto:marzia@niaid.nih.gov>>>, "sklee@curocom.com<<mailto:sklee@curocom.com>>" <sklee@curocom.com<<mailto:sklee@curocom.com>>>
Subject: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Dear Kay,

I trust this email finds you well.

Attached please find the MTA signed by our Provost and Vice President (Academic), Dr. Janice Deakin, and myself.

I asked Dr. Heinz Feldmann to send us appropriate clones of Zaire ebolavirus Mayinga 1976 strain. I wonder whether or not we can also receive the Kikwit 1995 strain as well.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Thursday, October 09, 2014 10:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: jricht@vet.k-state.edu
Subject: Re: Request to Speak

Hi Heinz,

I hope all is going well there with you.

In addition to contacting MSF and WHO, Hemispherx is trying to get into direct contact with Dr. Gorbee Logan, the Liberian physician who successfully treated Ebola patients with a nucleoside reverse transcriptase inhibitor. Although he is located in Bomi county, he is reported to have sent samples to the Liberian Institute of Biological Research (LIBR) which I gather from news reports is one of if not the main center for testing samples for suspected Ebola patients. Dr. Carter assumes that you have some connection with with LIBR and perhaps with Dr. Logan himself. Dr. Carter would like your assistance in simply trying to find out how we can reach Dr. Logan directly either by phone or email. After several hours of searching, I was unable to find either. Nor was I able to find a phone number at the Bomi County health Department which Dr. Logan heads. By email to their sites, I have contacted the Monrovia Observer and one of its writers who interviewed Dr. Logan as well as the Liberian Minister of Health and Social Welfare but I have heard from neither.

Dr. Carter understands the limits of what you can do and is asking only for your assistance in helping identify how we can connect directly with Dr. Logan.

Thank you very much.

Wayne

In a message dated 10/7/2014 6:51:37 P.M. Eastern Daylight Time, WPambianch Personal I writes:



Okay. Thanks for the guidance.

Best regards,

Wayne

In a message dated 10/7/2014 6:27:16 P.M. Eastern Daylight Time, feldmannh@niaid.nih.gov writes:



As mentioned before you need to contact the groups and agencies that are responsible for patient care. You should contact MSF (doctors without borders) and WHO (World Health Organization). They do coordinate treatment and vaccines. I cannot get involved in this in my position. I also do not propose any treatment or vaccine that I do not know in terms of animal efficacy data against Ebola. In vitro efficacy is a needed start but does not mean much to me at all.

Heinz

From: Personal Info
Sent: Tuesday, October 07, 2014 06:05 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 10:31 AM
To: Chil-Yong Kang; Menk, Kay (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; sklee@curocom.com
Subject: Re: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

The MTA covers all Zaire ebolaviruses, so Mayinga and Kikwit are fine. However, we do not have all the genes cloned from Kikwit, only GP to my knowledge since all our in vitro systems are based on Mayinga.

Best, Andrea

From: Chil-Yong Kang <cykang@uwo.ca>
Date: Thursday, October 9, 2014 10:16 AM
To: "Menk, Kay (NIH/NIAID) [E]" <menkk@niaid.nih.gov>
Cc: Heinz Feldmann <feldmannh@niaid.nih.gov>, Andrea Marzi <marzia@niaid.nih.gov>, "sklee@curocom.com" <sklee@curocom.com>
Subject: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Dear Kay,

I trust this email finds you well.

Attached please find the MTA signed by our Provost and Vice President (Academic), Dr. Janice Deakin, and myself.

I asked Dr. Heinz Feldmann to send us appropriate clones of Zaire ebolavirus Mayinga 1976 strain. I wonder whether or not we can also receive the Kikwit 1995 strain as well.

Please let me know should you require any additional information.

With best regards and thanks,

Yong

Dr. C. Yong Kang, FRSC

Professor of Virology

Department of Microbiology and Immunology

Schulich School of Medicine and Dentistry

Siebens-Drake Medical Research Institute

Western University

Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 10:20 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Walczynski, Joyce (NIH/NIAID) [C]
Subject: Re: tentative team schedule
Attachments: Planning Ebola laboratory teams.xlsx

Hi Heinz,

We agree and have come up with the following schedule,

Cheers,

Vincent Munster
Chief, Virus Ecology Unit
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH
903 South 4th street
Hamilton, MT 59840
[406-375-7489](tel:406-375-7489)

From: <Feldmann>, Heinrich Feldmann <feldmannh@niaid.nih.gov>
Date: Thursday, October 9, 2014 7:49 AM
To: Vincent Munster <munstervj@niaid.nih.gov>
Cc: "De wit, Emmie (NIH/NIAID) [E]" <Emmie.deWit@nih.gov>, "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov>, Kay Menk <menkk@niaid.nih.gov>, "Walczynski, Joyce (NIH/NIAID) [C]" <walczynskij@niaid.nih.gov>
Subject: Re: tentative team schedule

I think Emmie and Darryl are set as Team 4. I can stay longer (November 1) - that should not be a problem if it helps.

Team 5 should be Ricki and Joe - Andrea should come later if I have to stay longer.

In regards to December (over Christmas) why don't you take Emmie (not much time for Emmie between Team 4 and 6) and Cynthia. Andrea would be better as a team lead in January or later depending on who is going.

Best wishes, Heinz

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 12:04 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: tentative team schedule

Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Chil-Yong Kang <cykang@uwo.ca>
Sent: Thursday, October 09, 2014 10:17 AM
To: Menk, Kay (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; sklee@curocom.com
Subject: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc
Attachments: MTA from NIAID, NIH 10092014.PDF

Dear Kay,

I trust this email finds you well.

Attached please find the MTA signed by our Provost and Vice President (Academic), Dr. Janice Deakin, and myself.

I asked Dr. Heinz Feldmann to send us appropriate clones of Zaire ebolavirus Mayinga 1976 strain. I wonder whether or not we can also receive the Kikwit 1995 strain as well.

Please let me know should you require any additional information.

With best regards and thanks,

Yong

Dr. C. Yong Kang, FRSC

Professor of Virology

Department of Microbiology and Immunology

Schulich School of Medicine and Dentistry

Siebens-Drake Medical Research Institute

Western University

London, Ontario N6G 2V4, Canada

Phone: (519) 661-3226, Fax: (519) 661-3359

Mobile Phone: (519) 871-3991

Feldmann, Heinrich (NIH/NIAID) [E]

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Thursday, October 09, 2014 9:04 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Barcelona, Spain

Hi Heinz,

Would you like me to give apologies to the Institute in Barcelona. I can let them know that with the Ebola crisis, you are regrettably unable to make it to the celebration due to the crisis in West Africa.

Also, it appears that your return date from Monrovia may have changed. If you know for sure, then we need to get your return flight changed. So, please let me know if it is a for sure change.

Thank you, Heinz. All of you please take care!

Joyce Walczynski

Logistics Technician, LV (Contractor)

Rocky Mountain Laboratories

903 South 4th St.

Hamilton, MT 59840

Phone: 406.375.9600

Fax: 406.375.9620

Email: walczynskij@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Thursday, October 09, 2014 8:55 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

Redacted by agreement
Redacted by agreement

I am not sure what you mean about IFN/ribavirin. All the animals are gone. I am just preparing a summary of survival and PCR data for Kathy. I will also send to you.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:30 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Fw: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

They are asking about doxycyclin. I thought you did that in hamsters, did you?

What's the deal with the ribavirin/interferon study? I don't think we should continue.

Heinz

----- Original Message -----

From: Mielke, Martin [mailto:MielkeM@rki.de]
Sent: Thursday, October 09, 2014 03:50 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Kuhn, Jens (NIH/NIAID) [C]
Cc: Sekretariat Abt1 <SekretariatAbt1@rki.de>; Kurth, Andreas <KurthA@rki.de>; Burger, Reinhard <BurgerR@rki.de>; Schaade, Lars <SchaadeL@rki.de>
Subject: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

Sehr geehrter Herr Feldmann, sehr geehrter Herr Kuhn,

ich bin Kollege von Herrn Kurth am Robert Koch-Institut in Berlin und wende mich an Sie mit der Bitte um Ihre Einschätzung eines frühzeitigen Einsatzes von Doxycyclin im Rahmen des aktuellen Ebolaausbruchs in Westafrika im Hinblick auf den Versuch, die Letalität im Rahmen des Geschehens zu senken.

Zur Begründung führe ich an:

- 1) Die von Ihnen gut untersuchte Cytokin-vermittelte Pathogenese der EBOV Infektion (s. Anlagen)
- 2) Die Effekte von Doxycyclin auf die Cytokinausschüttung (s. Anlagen)
- 3) Die Wirkung von Doxycyclin auf die Malaria (s. Anlage)

Ich würde mich freuen, Ihre Einschätzung zu einem möglichst frühzeitigen Einsatz bei Patienten mit Verdacht auf eine EBOV-Infektion (DD Malaria) zu kennen.

Mit den besten Grüßen und Dank,
Martin Mielke

Feldmann, Heinrich (NIH/NIAID) [E]

From: Jason Niehaus <jason@addgene.org>
Sent: Thursday, October 09, 2014 7:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Distributing your iVLP assay plasmids with Addgene

Dear Drs. Feldmann and Hoenen,

My name is Jason Niehaus and I am a Senior Scientist at Addgene, a non-profit organization dedicated to promoting the sharing of published plasmids within the research community. A scientist recently contacted us looking for the pCAGGS-NP, pCAGGS-VP35, pCAGGS-VP30, pCAGGS-L, p4cis-vRNA-RLuc, pCAGGS-T7 and pCAGGS-Tim1 plasmids mentioned in your recent [JoVE article](#), but which appear to have been originally described in your 2006 Journal of Virology article. Due to the nature of these plasmids, I am not sure whether depositing them with Addgene would be advisable. We normally accept viral plasmids if the plasmid itself is considered BSL1 and a scientist would have to perform at least one additional step after a transfection into a target cell to create infectious viral particles. I would greatly appreciate your expertise on whether it would be sensible to contribute these plasmids to Addgene's repository, if you were interested in doing so.

More than 1900 scientists are currently using Addgene to archive their plasmids and handle their distribution requests, including MTAs. You can learn more about the benefits of depositing on our website at www.addgene.org/deposit/benefits/.

Thank you for your time. I look forward to hearing from you.

Best,
Jason

Jason L. Niehaus, Ph.D.
Senior Scientist
Addgene
1 Kendall Sq., Ste B7102
Cambridge, MA 02139-1669
Phone: 617-225-9000 x116
Email: jason@addgene.org

Webpage: www.addgene.org



Feldmann, Heinrich (NIH/NIAID) [E]

From: Baric, Ralph
Sent: Thursday, October 09, 2014 7:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: EBOLA RO1
Attachments: CV_2.2.docx

Hi Heinz, Hope you are doing well. We have been thinking about a "Pete Halfman" like UNC person to work at the RML. I realize that these types of positions are difficult to fill, but if you were serious, I could recommend **Personal Info** for such a position. She has a lot of experience with select agents (SARS, VEE) and 1918 flu (very soon as we have approval and will be receiving the virus shortly). I have appended her CV. She has about 2+ years of experience working with the CC mice and a fair amount of other animal experience, so should could help out our collaborations on multiple fronts, especially in terms of developing other improved animal models of human disease. Let me know if you'd like to continue these discussions. Hope your surviving the Ebola outbreak. Ralph

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Thursday, October 02, 2014 2:28 PM
To: 'Michael G. Katze'; mtferris; ANGELA L. RASMUSSEN
Cc: Marcus J. Korth; SEAN PROLL; Heise, Mark T; Baric, Ralph S; Okumura, Atsushi (NIH/NIAID) [V]
Subject: RE: EBOLA RO1

Congrats – fantastic.

From: Michael G. Katze [mailto:honey@uw.edu]
Sent: Thursday, October 02, 2014 7:43 AM
To: mtferris@email.unc.edu; ANGELA L. RASMUSSEN
Cc: Marcus J. Korth; SEAN PROLL; Mark Heise; Baric, Ralph; Okumura, Atsushi (NIH/NIAID) [V]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: EBOLA RO1

Dear Angela and Marty

Congratulations on your grant! **Critique** Thank you for all your patience and now you can get back to work (sorry!). Lets do a post mortem after some time passes. There are so many cool directions to go in. Thanks to Heinz and Atsu at RML without whom we could not do anything.

Cheers
Michael

Michael G. Katze
Professor of Microbiology
University of Washington
KATZE LAB WEB PAGE
<http://viromics.washington.edu>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bradner, James E.,M.D. <James_Bradner@DFCI.HARVARD.EDU>
Sent: Thursday, October 09, 2014 3:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Brown, Jonathan David,M.D.; Charles Lin Lin
Subject: Ebola concept (confidential)
Attachments: Brown_Lin_et_al_2014.pdf

Dr. Feldmann.

My laboratory at the Dana-Farber Cancer Institute has recently become very interested in endothelial cell activation. We published last week a fine study on EC activation in atherosclerosis (attached). Owing to the present crisis of the Ebola pandemic, we are motivated to assess BET bromodomain inhibition in Ebola-mediated EC activation and in vivo pathogenesis.

As a chromatin/chemistry/cancer laboratory, we are highly motivated to work collaboratively. Immediately, Jon and Charles (postdocs, cc'd) would like to Redacted by agr

Redacted by agreement

in 2005 (Wahl-Jensen et.al.).

Could you kindly provide plasmids and simple protocols for their experimental use (expression/purification/administration)?

I would gladly speak by phone, if desired.

Best.

Jay Bradner

James Bradner, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

james_bradner@dfci.harvard.edu
<http://bradner.dfc.harvard.edu/>
@jaybradner

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mielke, Martin <MielkeM@rki.de>
Sent: Thursday, October 09, 2014 1:51 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Kuhn, Jens (NIH/NIAID) [C]
Cc: Sekretariat Abt1; Kurth, Andreas; Burger, Reinhard; Schaade, Lars
Subject: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?
Attachments: Feldmann EBOV Cytokines.pdf; Ebola Pathogenese 1.pdf; EBOV Pathogenese.pdf; Tetracycline Cytokines.pdf; Tetracyclines human monocytes.pdf; Malaria Tetracycline.pdf

Sehr geehrter Herr Feldmann, sehr geehrter Herr Kuhn,

ich bin Kollege von Herrn Kurth am Robert Koch-Institut in Berlin und wende mich an Sie mit der Bitte um Ihre Einschätzung eines frühzeitigen Einsatzes von Doxycyclin im Rahmen des aktuellen Ebolaausbruchs in Westafrika im Hinblick auf den Versuch, die Letalität im Rahmen des Geschehens zu senken.

Zur Begründung führe ich an:

- 1) Die von Ihnen gut untersuchte Cytokin-vermittelte Pathogenese der EBOV Infektion (s. Anlagen)
- 2) Die Effekte von Doxycyclin auf die Cytokinausschüttung (s. Anlagen)
- 3) Die Wirkung von Doxycyclin auf die Malaria (s. Anlage)

Ich würde mich freuen, Ihre Einschätzung zu einem möglichst frühzeitigen Einsatz bei Patienten mit Verdacht auf eine EBOV-Infektion (DD Malaria) zu kennen.

Mit den besten Grüßen und Dank,
Martin Mielke

PS: Lieber Herr Kuhn, vielleicht erinnern Sie sich noch an die gemeinsame Reise zum Treffen der Nobelpreisträger am Bodensee und die Zeit bei Herrn Hahn. Ich hatte dort vor vielen Jahren über den Einfluss von Antibiotika auf die Cytokinantwort promoviert.

Prof. Dr. med. Martin Mielke

Robert Koch-Institut
Leiter der Abteilung 1, Abteilung für Infektionskrankheiten

Nordufer 20
13353 Berlin

Tel. 030 18754-2233
E-Mail: MielkeM@rki.de

Das Robert Koch-Institut ist ein Bundesinstitut im Geschäftsbereich des Bundesministeriums für Gesundheit

Feldmann, Heinrich (NIH/NIAID) [E]

From: Miles Davenport <z9801119@unsw.edu.au>
Sent: Wednesday, October 08, 2014 10:38 PM
To: Ilhem Messaoudi Powers
Cc: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Adeshina Adekunle
Subject: Re: Modelling Ebola infection

Dear Ilhem,

Thanks very much for your e-mail. I am looking forward to receiving the data and working with you and Andrea and Heinz to better understand Ebola infection dynamics. I have also cc'd Adeshina Adekunle, the PhD student who will work on the modelling.

Thanks again,

Miles

Professor Miles Davenport
Head, Complex Systems in Biology Group
Centre for Vascular Research
UNSW Australia
Sydney, NSW 2052
Australia
Ph: +61 2 9385 2762
Fax: +61 2 9385 1797
m.davenport@unsw.edu.au

On 09/10/2014, at 2:06 PM, Ilhem Messaoudi Powers <Ilhem.messaoudi@ucr.edu> wrote:

Hi Miles

Nice to hear from you! I think this is a fabulous idea and a good use of already available data set. We would love to collaborate with you.

The other key individuals to include are Drs. Heinz Feldmann and Andrea Marzi (copied on this email)
Andrea and I will be able to send you the data you need in excel sheet format:

1. Viral loads (Andrea)
2. Complete blood counts (Andrea)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ilhem Messaoudi Powers <Ilhem.messaoudi@ucr.edu>
Sent: Wednesday, October 08, 2014 9:07 PM
To: Miles Davenport
Cc: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Modelling Ebola infection

Hi Miles

Nice to hear from you! I think this is a fabulous idea and a good use of already available data set. We would love to collaborate with you.

The other key individuals to include are Drs. Heinz Feldmann and Andrea Marzi (copied on this email)
Andrea and I will be able to send you the data you need in excel sheet format:

1. Viral loads (Andrea)
2. Complete blood counts (Andrea)
3. Blood chemistry: liver panels (Andrea)
4. Antibody titers (Ilhem)
5. Cytokine levels (Ilhem)

Did I cover everything?

Looking forward to getting this started

Ilhem

Ilhem Messaoudi
Associate Professor
Division of Biomedical Sciences
School of Medicine
University of California Riverside
311 School of Medicine Research Building
900 University Ave
Riverside, CA 92521
phone: 951-827-7774
Email: messaoud@ucr.edu

From: Miles Davenport <z9801119@unsw.edu.au>
Date: Monday, October 6, 2014 10:16 PM
To: Ilhem Messaoudi <Ilhem.messaoudi@ucr.edu>
Subject: Modelling Ebola infection

Hi Ilhem,

It is now a few years since we met at VGTI to discuss modelling in immunology (and at the time your work on monkey pox). I am still working on modelling SIV infection kinetics and pathogenesis quite a bit, and now more and more on malaria. I have recently begun to look at Ebola infection and pathogenesis, with a view to whether our modelling may help understand this virus better. I read with interest your PNAS paper last year on Ebola vaccination in macaques, and wondered if it would be possible to get access to this published data for our modelling? In particular, the time courses of individual animals after challenge for virus, blood counts and biochemistry, antibody levels, and cytokines [largely the data that make up figure 5 and the supplementary figures]. Although there are no guarantees of success, I am optimistic that we might be able to analyse

Feldmann, Heinrich (NIH/NIAID) [E]

From: Brieese, Thomas <tb2047@cumc.columbia.edu>
Sent: Wednesday, October 08, 2014 7:29 PM
To: Marzi, Andrea (NIH/NIAID) [E]
Cc: ANGELA L. RASMUSSEN; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Follow up

Hi Andrea,

Can I call you tomorrow ([Personal Info] when?) to discuss? See below.

Best, Thomas

From: "ANGELA L. RASMUSSEN" <arasmus@uw.edu>
Date: Saturday, October 4, 2014 6:58 PM
To: Thomas Brieese <tb2047@cumc.columbia.edu>
Subject: Re: Follow up

Great, thanks, Thomas. Heinz Feldmann asked me to tell you to contact him or Andrea Marzi directly about sera from other RML studies. Do you know them? If not, I'd be happy to set up an email introduction. You might want to contact Andrea since Heinz is leaving for Liberia first thing tomorrow.

From: <Brieese>, Thomas <tb2047@cumc.columbia.edu>
Date: Thursday, October 2, 2014 at 2:55 PM
To: Angela Rasmussen <arasmus@uw.edu>
Subject: Re: Follow up

Hi Angela,

Yes, transfer will be covered by MTA throughr the CRDD grant. We would need a short description of samples to fill in the sheet: Sera samples from rodents (collaborative cross mice; bled days 14 and 21) and non-human primates (...) experimentally infected with Ebola virus? Something like that- please fill-in what else you like for 'Materials transferred'.

Best, Thomas

From: "ANGELA L. RASMUSSEN" <arasmus@uw.edu>
Date: Wednesday, October 1, 2014 7:04 PM
To: Thomas Brieese <tb2047@cumc.columbia.edu>
Subject: Re: Follow up

Hi Thomas,

I have a call with Heinz on Friday morning and I will ask about the primate sera. Otherwise, Heinz has suggested pulling all the day 21 serum samples collected at the time of euthanasia in the mice—I didn't realize they collected these automatically. These are likely even better than the day 14 samples (for Ebola). Atsu is taking some samples out of the BSL-

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 6:22 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

Ok Heinz

It would be helpful to know their plans

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 07:44 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

Not yet but he did not answer my last two emails either. I asked the CDC people here in Monrovia and they did not know anything.

I will send a few emails to try to find out.

Heinz

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 07:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

We can check

What is CDC doing about this for their teams? We should be held to the same standards. Have you checked with Stuart?

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 06:45 PM Eastern Standard Time
To: Pekoc, Ken (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

Thanks. Can NIH do something for us to get through easier. We are under the control of OMS - would that help?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 5:15 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

We can check

What is CDC doing about this for their teams? We should be held to the same standards. Have you checked with Stuart?

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 06:45 PM Eastern Standard Time
To: Pekoc, Ken (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

Thanks. Can NIH do something for us to get through easier. We are under the control of OMS - would that help?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 03:56 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]
Subject: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

FYI

From: MMWR Media List [<mailto:MMWR-MEDIA@LISTSERV.CDC.GOV>] On Behalf Of Media@cdc.gov (CDC)
Sent: Wednesday, October 08, 2014 3:31 PM
To: MMWR-MEDIA@LISTSERV.CDC.GOV
Subject: Press Release: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES



Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 5:12 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: IFN/ribavirin NHP update

Thank you

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 06:48 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: IFN/ribavirin NHP update

Tom largely does the Profectus work. We still do some work together with Tom, but we are focusing on the construct. Redacted by

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 04:31 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update

Heinz
Are you working with Tom Geisbert on the VSV ebola vaccine or just LV?
Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 11:14 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update

Redacted by agreement

These are the current plans for the near future. Other study may follow.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: IFN/ribavirin NHP update

Feldmann, Heinrich (NIH/NIAID) [E]

From: Caroline Kim <caroline.kim@axonadvisors.com>
Sent: Wednesday, October 08, 2014 5:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Paid Conference Call RE: Ebola Virus

Dr. Feldmann,

Thank you for letting me know. Do you have anybody you can recommend for this call?

Best,
Caroline

Caroline Kim
Research Project Manager
+1 646 502 5065 (Direct)

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 8, 2014 6:58 PM
To: Caroline Kim
Subject: Re: Paid Conference Call RE: Ebola Virus

I am not available for the rest of this month.

From: Caroline Kim [mailto:caroline.kim@axonadvisors.com]
Sent: Wednesday, October 08, 2014 05:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Paid Conference Call RE: Ebola Virus

Dr. Feldmann,

We talked on the phone briefly last week about this request for a conference call. I know you said you would be away from the office, but wanted to see if you might have any 1 hour slots next week (as the deadline of this project has been extended). Our clients have requested you by name as the top expert in this area and so would very much appreciate the opportunity to speak to you, if at all possible. We have an advised topics to be discussed from the below.

- A brief summary of Ebola Virus, what it does, where it comes from and what is happening in Africa.
- Why is this outbreak so much worse than prior outbreaks? What is different and why?
- How much is known and certain and inevitable about the epidemic and how much is still "up in the air"?
- Is the situation under control in Africa? What are the continuing risks in Africa and the likely outcome?
- What are the medical and economic risks to the US, to Europe and to other countries?
- What public health measures are being taken in Africa? What measures are being taken outside Africa? What others might be contemplated or considered?
- What are the risks from the case in Dallas? What measures should businesses take with respect to those risks today?
- What should investors look for as signals that things are improving? In Africa? In the US? What are the first signs that things are deteriorating?
- How predictable are the outcomes from this situation? What could go right and better than expected? What could go wrong and worse than expected?

Please let me know!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dan Zimmerman <dzimmerman@cel-sci.com>
Sent: Wednesday, October 08, 2014 5:08 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; hfeldmann@niaid.nih.gov
Subject: As suggested by Dr. Subbarao FW: Wild idea of using LEAPS for Ebola
Attachments: Summary of LEAPS studies 10 7 14.pdf; Boonnak et al 2013 Influenza LEAPS JCI167... Supplemental material.pdf; Boonnak et al 2013 Influenza LEAPS JCI67550.pdf
Importance: High

Dear Dr Feldmann

As suggested in her email below Dr Subbarao suggested I contact you regarding an idea we had which is along the lines of an approach we successfully used for a immune-therapeutic for influenza. The suggestion to Dr Subbarao is below her reply to me in my email to her. I also am attaching a copy of the published study done in Dr Subbarao's lab using LEAPS immunotherapeutic agents and a summary document on the LEAPS immunotherapeutic vaccines / agents.

Dan

Daniel H Zimmerman, Ph.D.
Senior Vice President Research and Development, Cellular Immunology CEL-SCI Corporation
8229 Boone Blvd, Suite 802 Vienna VA 22182
Office 703-506-9460 Fax 703-506-9471 Lab 410-358-6866 Lab Fax 410-358-1647
dzimmerman@cel-sci.com

This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by reply e-mail and delete the message and any attachments from your system.

-----Original Message-----

From: Subbarao, Kanta (NIH/NIAID) [E] [mailto:KSUBBARAO@niaid.nih.gov]
Sent: Wednesday, October 08, 2014 3:09 PM
To: Dan Zimmerman
Subject: Re: Wild idea of using LEAPS for Ebola

Dear Dan-

I suggest you contact Heinz Feldmann at the Laboratory of Virology, Rocky Mountain Labs, NIAID about this idea.

Best wishes-
Kanta

--

Kanta Subbarao, MD, MPH
Chief, Emerging Respiratory Viruses Section Laboratory of Infectious Diseases, NIAID, NIH Bldg 33, Room 3E13C.1,
33 North Drive, MSC 3203
Bethesda, MD 20892-3203
Phone: 301-451-3839
Fax: 301-480-4749
Email: ksubbarao@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dorian Bevec, PhD <dorian.bevec@therametrics.com>
Sent: Wednesday, October 08, 2014 3:55 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: testing
Attachments: therametrics rocky mountain press release 1st Draft .docx

Hello Ken,
please find enclosed the draft of the press release; please be so kind to improve and advise. The overall message is hopefully clear.
Best greetings,
Dorian

From: Pekoc, Ken (NIH/NIAID) [E] <kpekoc@niaid.nih.gov>
Sent: Wednesday, October 8, 2014 2:17 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Dorian Bevec, PhD; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: testing

Sure. If THERAMetrics wants to create and distribute a news item, I'll be happy to help with the writing and reviewing. It can include references to any NIAID investigators who are involved, but cannot directly quote them.

> On Oct 7, 2014, at 5:28 PM, "Hoenen, Thomas (NIH/NIAID) [F]" <thomas.hoenen@nih.gov> wrote:
>
> Hi Ken,
>
> Could you work together with Dorian Bevec (cc'ed) from THERAMetrics, with whom Heinz and I have started collaborating with respect to novel treatment options for EVD, on a press release regarding that collaboration? I am more than happy to answer any questions you might have.
>
> All the best, Thomas
>
> -----Original Message-----
> From: Hoenen, Thomas (NIH/NIAID) [F]
> Sent: Tuesday, October 07, 2014 5:10 PM
> To: Feldmann, Heinrich (NIH/NIAID) [E]; 'dorian.bevec@therametrics.com'
> Subject: RE: testing
>
> Most definitely.
>
> -----Original Message-----
> From: Feldmann, Heinrich (NIH/NIAID) [E]
> Sent: Tuesday, October 07, 2014 5:05 PM
> To: 'dorian.bevec@therametrics.com'; Hoenen, Thomas (NIH/NIAID) [F]
> Subject: Re: testing
>
> This is fine but we need to work with Ken Pekoc on this. Thomas - can you please help?
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Caroline Kim <caroline.kim@axonadvisors.com>
Sent: Wednesday, October 08, 2014 3:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Paid Conference Call RE: Ebola Virus

Dr. Feldmann,

We talked on the phone briefly last week about this request for a conference call. I know you said you would be away from the office, but wanted to see if you might have any 1 hour slots next week (as the deadline of this project has been extended). Our clients have requested you by name as the top expert in this area and so would very much appreciate the opportunity to speak to you, if at all possible. We have advised topics to be discussed from the below.

- A brief summary of Ebola Virus, what it does, where it comes from and what is happening in Africa.
- Why is this outbreak so much worse than prior outbreaks? What is different and why?
- How much is known and certain and inevitable about the epidemic and how much is still “up in the air”?
- Is the situation under control in Africa? What are the continuing risks in Africa and the likely outcome?
- What are the medical and economic risks to the US, to Europe and to other countries?
- What public health measures are being taken in Africa? What measures are being taken outside Africa? What others might be contemplated or considered?
- What are the risks from the case in Dallas? What measures should businesses take with respect to those risks today?
- What should investors look for as signals that things are improving? In Africa? In the US? What are the first signs that things are deteriorating?
- How predictable are the outcomes from this situation? What could go right and better than expected? What could go wrong and worse than expected?

Please let me know!

Best,
Caroline

Caroline Kim
Research Project Manager
+1 646 502 5065 (Direct)

From: Caroline Kim
Sent: Friday, October 3, 2014 12:47 PM
To: 'feldmannh@niaid.nih.gov'
Subject: Paid Conference Call RE: Ebola Virus

Dear Dr. Feldmann,

I represent Axon Advisors, a leading healthcare fieldwork company. We connect research analysts to industry professionals for research projects.

One of our clients, a healthcare analyst (no relation to any healthcare company), has engaged us to schedule a conference call with you to discuss the following topics.

- A brief summary of Ebola Virus, what it does, where it comes from and what is happening in Africa.
- Why is this outbreak so much worse than prior outbreaks? What is different and why?
- How much is known and certain and inevitable about the epidemic and how much is still “up in the air”?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Philipps, David <david.philipps@nytimes.com>
Sent: Wednesday, October 08, 2014 3:12 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: need a quick answer about ebola for the new york times

Hi Dr Feldmann,

I need someone to briefly explain to me why early treatment improves survival rates in ebola patients. Can you give me a call if you get this email before about 6 your time?

Dave Philipps

The New York Times
620 Eighth Avenue
New York, NY 10018
david.philipps@nytimes.com

c: Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 2:52 PM
To: Fischer, Robert (NIH/NIAID) [F]; Bushmaker, Trenton (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Walczynski, Joyce (NIH/NIAID) [C]; Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Prescott, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Hoenen, Thomas (NIH/NIAID) [F]; Groseth, Allison (NIH/NIAID) [E]; Martellaro, Cynthia (NIH/NIAID) [C]; Safronetz, David (NIH/NIAID) [E]
Subject: FW: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES
Attachments: image001.jpg; image002.jpg

Of note,

This would indicate that everybody needs sufficient between flights time to clear passport control (at least two hours) and make it to their connecting flight.

Kay and Joyce, can you take this into account when booking travel back from Liberia?

Regards,

Vincent Munster
Chief, Virus Ecology Unit
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH
903 South 4th street
Hamilton, MT 59840
[406-375-7489](tel:406-375-7489)

From: <Pekoc>, "Ken [E] (NIH/NIAID)" <kpekoc@niaid.nih.gov>
Date: Wednesday, October 8, 2014 1:56 PM
To: Heinrich Feldmann <feldmannh@niaid.nih.gov>, "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov>, "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov>, Vincent Munster <munstervj@niaid.nih.gov>
Subject: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

FYI

From: MMWR Media List [<mailto:MMWR-MEDIA@LISTSERV.CDC.GOV>] On Behalf Of Media@cdc.gov (CDC)
Sent: Wednesday, October 08, 2014 3:31 PM
To: MMWR-MEDIA@LISTSERV.CDC.GOV
Subject: Press Release: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 2:34 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola - Does NIH...?

Do you have any data?

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 2:30 PM
To: Glowinski, Irene (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Mays, Gary (NIH/NIAID) [E]; Moore, Melissa (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [C]; NIAID BUGS
Subject: RE: Ebola - Does NIH...?

OK _ I'll respond. "No New."

"NIAID did not propose similar research in its request for new money in 2015. NIAID may have (or had) research with aims similar to the below , that examines(d) different aspects of survival/viability of the virus outside the host. But, although some NIAID projects may address survivability of the virus outside of the host, there **are** currently no **new** FY 2015 projects addressing this specific issue in NIAID's portfolio."

Martin S. Johnson
Chief – Resource Planning and Mission Integration Branch (RPMIB) – NIAID
NIH Bldg. 31 Room 7A47
Bethesda, MD 20892–2520
Tel: 301–594–6359
Fax: 301–402–0492

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Glowinski, Irene (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 2:11 PM
To: Kurilla, Michael (NIH/NIAID) [E]; Johnson, Martin S. (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Mays, Gary (NIH/NIAID) [E]; Moore, Melissa (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [C]; NIAID BUGS
Subject: RE: Ebola - Does NIH...?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 2:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update


Heinz

Are you working with Tom Geisbert on the VSV ebola vaccine or just LV?

Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 11:14 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update

Redacted by agreement



These are the current plans for the near future. Other study may follow.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: IFN/ribavirin NHP update

Heinz

Niaid wants have a meeting to coordinate the ebola work. Please send me a list of all the ongoing and planned studies we are going to do at RML.

Thank you

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 07:45 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update

This looks not too bad. The question is – can the drugs keep the virus load down (high Ct values) for long enough to pull through.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, September 28, 2014 5:09 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 08, 2014 2:29 PM
To: s.mccarthy@mail.utoronto.ca
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Request for plasmids

Dear Stephen,

Heinz forwarded me your request regarding the tetracistronic trVLP system. Are you available for a quick phone call either sometime after 3:30pm MDT (I believe that's 5:30 EDT), or later this week?

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 12:08 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Request for plasmids

Thomas - can you please communicate? If you agree we would need a SLA.

Thanks, Heinz

From: Stephen McCarthy [mailto:s.mccarthy@mail.utoronto.ca]
Sent: Wednesday, October 08, 2014 01:51 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request for plasmids

Hello Dr. Feldmann,

I recently read your article on modeling the lifecycle of Ebola virus under biosafety level 2 conditions, and am very impressed by your approach. My research interests are in viral transcription and I would very much like to try your tetracistronic minigenome system in my lab. Would it be possible to request the 7 plasmids outlined in your paper? They are pCAGGS-NP, pCAGGS-VP35, pCAGGS-VP30, pCAGGS-L, p4cis-vRNA-RLuc, pCAGGS-T7 and pCAGGS-T7. Our lab can pay for the shipment of the plasmids (Fed Ex number: Redacted by

R. This is our mailing address:

Attn: Darinka Sakac

Feldmann, Heinrich (NIH/NIAID) [E]

From: Teresa Demel <TeresaD@vulcan.com>
Sent: Wednesday, October 08, 2014 2:11 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'arasmus@uw.edu'; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Andy Hickl
Subject: Re: Introduction and Ebola questions

Heinz,

Thanks for the feedback. We will continue to speak with our contacts from other NGOs, and identify contacts at MOH.

We appreciate the great work you are doing in West Africa. Thank you.

Teresa and Andy

On 10/8/14, 11:11 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>We do not have that information. You need to ask the hospitals not us.
>We also would not be allowed to share that information. You need to
>talk to the country lead people -most likely the MOH.

>

>Heinz

>

>----- Original Message -----

>From: Teresa Demel [mailto:TeresaD@vulcan.com]
>Sent: Wednesday, October 08, 2014 01:51 PM Eastern Standard Time
>To: ANGELA L. RASMUSSEN <arasmus@uw.edu>; Marzi, Andrea (NIH/NIAID)
>[E]; Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID)
>[E]; Andy Hickl <AndyH@vulcan.com>
>Subject: Re: Introduction and Ebola questions

>

>Andrea, Dave, and Heinz,

>

>I know that your work on the ground is incredibly important, but if you
>can spare 30 minutes to talk on the phone, we would love to discuss
>this project with you. I'll include questions in here in case email is easier.

>

>Vulcan Innovation Labs is working on a data sharing platform to improve
>the accuracy of information reported back to WHO, CDC, USAID, as well
>as basic researchers and epidemiologists. Right now, stats on Ebola are
>shared in a weekly phone call between WHO, CDC, etc. The stats are the
>bare minimum: cases vs deaths and confirmed/probable/suspected. Angela
>told us that research and action could progress faster if clinicians
>were able to collect and share the following information in real time:

>

- > * Patient symptoms
- > * Survival
- > * Viral strain

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sabrina Boyer <sabrina.boyer@phac-aspc.gc.ca>
Sent: Wednesday, October 08, 2014 1:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Chris Peterson; Dorothea Blandford
Subject: RE: VSV-vaccine protocol
Attachments: 01014 NIH-RML 10-02-14 .doc

Hi Heinz,

I've prepared the collaboration agreement for review and consideration of NIH-RML. I would ask that you "track your changes", if there are any, and return your comments to Chris Peterson; he has been cc'd on this email.

With thanks
Sabrina

Sabrina Boyer
Manager, Technology Transfer
Office of the Chief Science Officer/Bureau du Conseiller scientifique principal
Public Health Agency of Canada/ Agence de la santé publique du Canada
1015 Arlington Street
Winnipeg, MB R3E 3R2
Phone: (204) 789-2120
Fax: (204) 789-2097
Email: sabrina.boyer@phac-aspc.gc.ca



Public Health
Agency of Canada

Agence de la santé
publique du Canada

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: 'Sabrina Boyer' <sabrina.boyer@phac-aspc.gc.ca>, Jim Strong <Jim.Strong@phac-aspc.gc.ca>
Date: 2014-09-30 06:07 PM
Subject: RE: VSV-vaccine protocol

Sabrina,

Please send the document to me and I will forward it to the appropriate people.

Hope things are going well for you.

Heinz

From: Sabrina Boyer [<mailto:sabrina.boyer@phac-aspc.gc.ca>]
Sent: Tuesday, September 30, 2014 9:47 AM
To: Jim Strong
Cc: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: David McKie <david.mckie@cbc.ca>
Sent: Wednesday, October 08, 2014 1:15 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CBC News request

Good afternoon, Dr. Feldmann. My name is David McKie. I'm a producer working out of the CBC Parliamentary bureau for the show Power & Politics. Would you be available to chat about the Ebola virus vaccine?

I can be reached at this email address, or my desk at 613-288-6523.

I look forward to hearing from you.

Thanks.

David

Feldmann, Heinrich (NIH/NIAID) [E]

From: Richard Besserman <Richard.Besserman@asu.edu>
Sent: Wednesday, October 08, 2014 12:25 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Neal Woodbury; Stephen Johnston
Subject: Re: Immunosignature strategy to safeguard immunologically naive healthcare personnel
Attachments: image001.png

Heinrich

I have talked with Neal Woodbury and Stephen Johnston at our Center for Innovations in Medicine and wish to thank you for your kind offer and recommendation about animal studies.

In the interim, we are looking for a small amount of inactivated primate blood to validate the hypothesis that like other viral disease we can obtain a unique immune signature for Ebola, days 1, 2, 3, 4, 5, 6 post exposure/infection from experiments you may or others may have done. We have a source for human blood but as you know the samples would be from people already diagnosed with the disease.

Our goal would be to use immunosignatures as a baseline and then periodically to identify a signature in healthcare workers to facilitate early treatment with antivirals. I have asked Neal or Stephen at Biodesign to introduce themselves to you and to send you a few papers on their work.

Thanks.

Best

Richard

From: <Feldmann>, "Heinrich [E] (NIH/NIAID)" <feldmannh@niaid.nih.gov>
Date: Saturday, October 4, 2014 at 10:41 AM
To: Richard Besserman <rbesserm@exchange.asu.edu>
Subject: RE: Immunosignature strategy to safeguard immunologically naive healthcare personnel

I agree with you but as mentioned before we are unable to provide human samples for your studies. Once the MOU with the Liberian government is in place for sample transfer, the best would be to contact CDC as they have the US lead in the country on the Ebola outbreak. They would have to release the samples for you. I would not be able to make that decision. The contact would be the Viral Special Pathogens Branch at CDC in Atlanta.

We and others could do the necessary animal studies with you if you are interested. Unfortunately, my group is currently unable to take on more studies as we have many of our staff in the field. Once this outbreak gets under control animal studies might be possible. In order to get this done sooner you may want to contact the containment lab at UTMB Galveston.

Best wishes,
Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kenneth Gorelick, MD [Personal Info]
Sent: Wednesday, October 08, 2014 12:01 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: twgeisbe@utmb.edu
Subject: Re: [Redacted by agreement]

Thanks,

Honestly the idea that this could be useful in ebola struck me when I saw a paper on [Redacted by agr] so I thought that I would offer a look at the compound. We are fully focused elsewhere, but wanted to see if an expert thought there would be some value in this approach.

Will write back in November.

Good luck in Monrovia!

Ken
Kenneth Gorelick, MD, FCCP

[Personal Info]

On Oct 8, 2014, at 1:54 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

I am in Monrovia until the end of the month. Please contact me again early November. We are pretty busy with Monrovia and work back home. Unlikely to do any work on this until spring 2015 if I can interest one of my postdocs. If you don't want to wait that long and take the risk, please contact other BSL4 labs.

Heinz

From: Kenneth Gorelick [<mailto:>[Personal Info]]
Sent: Wednesday, October 08, 2014 01:21 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: twgeisbe@utmd.edu <twgeisbe@utmd.edu>
Subject: [Redacted by agreement]

Dear Heinz,

Tom Geisbert suggested that I contact you about an agent I am developing as an immunotherapeutic for cancer.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mail Delivery System <MAILER-DAEMON@nihcesxway5.hub.nih.gov>
To: twgeisbe@utmd.edu
Sent: Wednesday, October 08, 2014 11:54 AM
Subject: Undeliverable: Redacted by agreement

Delivery has failed to these recipients or groups:

twgeisbe@utmd.edu

A problem occurred during the delivery of this message to this e-mail address. Try sending this message again. If the problem continues, please contact your helpdesk.

Diagnostic information for administrators:

Generating server: nihcesxway5.hub.nih.gov

twgeisbe@utmd.edu

#< #5.0.0 smtp; 5.1.2 - Bad destination host 'DNS Hard Error looking up utmd.edu (MX): NXDomain' (delivery attempts: 0)> #SMTP#

Original message headers:

X-IronPort-Anti-Spam-Filtered: true

X-IronPort-Anti-Spam-Result:

Ag8FAI15NVScKEem/2dsb2JhbABcA4JJRoErBIMAz1kCGXEWAQN4hAMBAAQEEhFWegEIBAkEBAEBCx0DAgQdAhEUCQgCB
A4FCBqICAMRphiKKo1pDYZrAReOEoIBFgsQBgERgmY2gR4FkXcDiTkBgZ+DRYMahH6CLoZUg2NsgUiBAgEBAQ

X-IPAS-Result:

Ag8FAI15NVScKEem/2dsb2JhbABcA4JJRoErBIMAz1kCGXEWAQN4hAMBAAQEEhFWegEIBAkEBAEBCx0DAgQdAhEUCQgCB
A4FCBqICAMRphiKKo1pDYZrAReOEoIBFgsQBgERgmY2gR4FkXcDiTkBgZ+DRYMahH6CLoZUg2NsgUiBAgEBAQ

Received: from unknown (HELO CASHTv02.nih.gov) ([156.40.71.166]) by
nihxway5out.hub.nih.gov with ESMTP/TLS/AES128-SHA; 08 Oct 2014 13:54:28 -0400

Received: from MLBXV11.nih.gov ([169.254.1.124]) by CASHTv02.nih.gov
([156.40.71.166]) with mapi id 14.03.0174.001; Wed, 8 Oct 2014 13:54:28 -0400

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>

To: "kgorelick@gmail.com" <kgorelick@gmail.com>

CC: "twgeisbe@utmd.edu" <twgeisbe@utmd.edu>

Subject: Re: Dendritic cell therapy

Thread-Topic: Dendritic cell therapy

Thread-Index: AQHP4xxQ8OYUa3cMK0G5zywKBxxt7pwme5aB

Date: Wed, 8 Oct 2014 17:54:28 +0000

Feldmann, Heinrich (NIH/NIAID) [E]

From: Stephen McCarthy <s.mccarthy@mail.utoronto.ca>
Sent: Wednesday, October 08, 2014 11:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request for plasmids

Hello Dr. Feldmann,

I recently read your article on modeling the lifecycle of Ebola virus under biosafety level 2 conditions, and am very impressed by your approach. My research interests are in viral transcription and I would very much like to try your tetracistronic minigenome system in my lab. Would it be possible to request the 7 plasmids outlined in your paper? They are pCAGGS-NP, pCAGGS-VP35, pCAGGS-VP30, pCAGGS-L, p4cis-vRNA-RLuc, pCAGGS-T7 and pCAGGS-T7. Our lab can pay for the shipment of the plasmids (Fed Ex number: Redacted by ag 1). This is our mailing address:

Attn: Darinka Sakac

Dr. Donald R. Branch
Canadian Blood Services
4th Floor Room 453
67 College St.
Toronto, Ontario
Canada M5G 2M1

Kind Regards,

Stephen McCarthy
Canadian Blood Services

Feldmann, Heinrich (NIH/NIAID) [E]

From: Teresa Demel <TeresaD@vulcan.com>
Sent: Wednesday, October 08, 2014 11:51 AM
To: ANGELA L. RASMUSSEN; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Andy Hickl
Subject: Re: Introduction and Ebola questions

Andrea, Dave, and Heinz,

I know that your work on the ground is incredibly important, but if you can spare 30 minutes to talk on the phone, we would love to discuss this project with you. I'll include questions in here in case email is easier.

Vulcan Innovation Labs is working on a data sharing platform to improve the accuracy of information reported back to WHO, CDC, USAID, as well as basic researchers and epidemiologists. Right now, stats on Ebola are shared in a weekly phone call between WHO, CDC, etc. The stats are the bare minimum: cases vs deaths and confirmed/probable/suspected. Angela told us that research and action could progress faster if clinicians were able to collect and share the following information in real time:

- * Patient symptoms
- * Survival
- * Viral strain
- * Genetic profile of virus
- * Genetic profile of patient (?)
- * Demographics (age, sex)
- * What else?

We know that clinicians are incredibly busy and want to expedite data collection. As an example, we could use a mix of text message photos and object recognition to deliver Bioanalyzer data to a centralized database. This would allow virologists to study the evolution of Ebola in real time. In addition, epidemiologists could understand which strains of the virus are in which regions, and the clinical data associated with each patient (anonymized).

I worked in a genetics lab about 18 years ago, so I'm mostly layperson with some basic knowledge of viruses, PCR, etc. We would love to hear what your team (and the wider Ebola containment community) needs in order to make this work. While we want to help the basic research side, we also want to provide any data that will help stop this epidemic as soon as possible.

Questions for you. Answer the relevant ones. Feel free to elaborate.

- * What data do you want/need to collect about each patient? How is that data currently collected? What resources would you need to make that data more accurate or easier to collect?
- * What data do you want / need to collect about the community? How is that collected? What resources would you need to make it more accurate/easier to collect?
- * What are the limitations in sending information (photo or text) via text message? (not everybody has cell phones, charging phones, photo text messages don't work...)
- * What are the barriers to collecting information from blood samples? (running PCR - time, electricity, PCR machines, space)

Please put us in contact with anyone else who is interested in collecting and aggregating better data. Send them our email addresses (teresad@vulcan.com, andyh@vulcan.com) if they have ideas or input. As Angela said, the Paul G. Allen

Feldmann, Heinrich (NIH/NIAID) [E]

From: Unpublished
Sent: Wednesday, October 08, 2014 11:25 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished Manuscript Received

Dear Dr. Feldmann,

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kenneth Gorelick [Personal Info]
Sent: Wednesday, October 08, 2014 11:22 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: twgeisbe@utmd.edu
Subject: [Redacted by agreement]

Dear Heinz,

Tom Geisbert suggested that I contact you about an agent I am developing as an immunotherapeutic for cancer.

This is a [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

We have considerable in vitro and in vivo cancer data, and are planning to begin human studies in mid-2015. Please let me know a) that you have received this and b) if you are interested in the compound. We would be happy to supply you with product under a MTA.

Best regards,

Kenneth Gorelick, MD
mobile: [Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

Subject: Ebola: West Africa Field Lab Coordination Call

Location: Conference call Intl Conference call PC Conferenc

Start: Wed 10/8/2014 2:00 PM

End: Wed 10/8/2014 3:00 PM

Show Time As: Tentative

Recurrence: Weekly

Recurrence Pattern: every Wednesday from 4:00 PM to 5:00 PM

Meeting Status: Not yet responded

Organizer: Saindon, John M. (CDC/OPHSS/OD)

Required Attendees: Towner, Jonathan (Jon) (CDC/OID/NCEZID); 'jesse.m.flynn.ctr@mail.mil'; Bartee, Maureen S. (CDC/CGH/DGHP); 'maureen.s.bartee.civ@mail.mil'; 'guillermo.pimentel@med.navy.mil'; 'ian.watson@dtra.mil'; 'carl.newman@dtra.mil'; Stroehrer, Ute (CDC/OID/NCEZID); Nichol, Stuart T. (CDC/OID/NCEZID); 'david.a.norwood.civ@mail.mil'; Munster, Vincent (NIH/NIAID) [E]; 'andrew.dorau@dtra.mil'; 'michael.a.smith215.civ@mail.mil'; 'gabriel@bni-hamburg.de'; 'antonino.dicaro@inmi.i'; 'Christopher.Logue@phe.gov.uk'; 'gary.w.carter4.civ@mail.mil'; 'david.a.norwood@us.army.mil'; 'gary.kobinger@phac-aspc.gc.ca'; 'jennifer.b.smith48.civ@mail.mil'; Feldmann, Heinrich (NIH/NIAID) [E]; Fields, Barry (CDC/CGH/DGHP); 'januszp@nicd.ac.za'; Jahrling, Peter (NIH/NIAID) [E]; Geibe, Jesse R. (CDC/OPHPR/OD); Lane, Cliff (NIH/NIAID) [E]; 'neal.e.woollen.mil@mail.mil'; 'guenther@bni.uni-hamburg.de'; Hensley, Lisa (NIH/NIAID) [E]; Bird, Brian (CDC/OID/NCEZID); CDC IMS Logistics Section Chief (CDC); 'anthony.r.jones14.mil@mail.mil'; 'Espinosa, Benjamin LCDR NMRC'; 'McCoy, Andrea J LT NMRC'; 'asall@pasteur.sn'; Giuseppe Ippolito; 'wangxq@chinacdc.cn'; 'Nidx@chinacdc.cn'; Klena, John (CDC); 'kendrachuk.kenneth@nih.gov'; 'Christina.farris@med.navy.mil'; 'Vishwesh.mokashi@med.navy.mil'; Safronetz, David (NIH/NIAID) [E]; Cindi Corbett (Cindi.Corbett@phac-aspc.gc.ca); 'Anders.leung@phac-aspc.gc.ca'; 'usamriid.lib.ops@gmail.com'

Optional Attendees: CDC IMS Laboratory; CDC IMS Epidemiology; Sheridan, Reed (CDC/OPHPR/DEO); Mead, Paul (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Montgomery, Joel M. (CDC/CGH/DGHP); 'Ksiazek, Thomas G.'; Rouse, Edward N. (CDC/OPHPR/DEO); 'Moudy, Robin CTR OSD OUSD ATL (US'; 'Antonino Di Caro'; Jones, Franca R CDR USN OSD OUSD ATL (US); Honko, Anna (NIH/NIAID) [E]; Gajewski, Kimberly N CIV (US); Galloway, Summer E CTR OSD OUSD ATL (US); Kilmarx, Peter (CDC/CGH/DGHA); DeVos, Joshua R. (CDC/CGH/DGHA); Demby, Austin (HHS/OS/OGA); Nkengasong, John (CDC/CGH/DGHA); Alan Kemp

Gentle Reminder.

This call is at 2000 West Africa Time.

Bridgeline: Conference call p

International: Conference call

Passcode: Conferenc

Feldmann, Heinrich (NIH/NIAID) [E]

From: Natasha Leeson <n.leeson@futuremedicine.com>
Sent: Wednesday, October 08, 2014 10:06 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interest in your work

Dear Dr Feldmann,

I hope this email finds you well. I would like to introduce myself as the Commissioning Editor of the journal *Future Microbiology* published by *Future Medicine* (<http://www.futuremedicine.com/loi/fmb>).

Future Microbiology publishes reviews, comment and original research in bacteriology, virology, mycology and parasitology. The journal is indexed by Medline, EMBASE, Chemical Abstracts and Journal Citation Reports/Science Edition®, amongst others, and has an **Impact Factor of 3.819 (2013)**. You can find out more about the journal, including the Aims and Scope and list of Editorial Board members, on our [webpage](#).

Having read of your recent work and considering that you are an expert in the field, I would like to invite you to contribute an **Editorial** on the topic '**Ebola virus vaccines: are we close approval?**' for an upcoming issue of the journal. As commissioning has only just begun, there is plenty of flexibility regarding the title of the Editorial. I am happy for you to work with any co-authors you feel necessary.

Editorial articles provide authors with the opportunity to express their opinions, present criticism or address controversy; the intention is very much that authors offer a personal perspective.

The article should be **1500 words maximum** and would be provisionally scheduled for publication in the **April** issue of *Future Microbiology*, presenting a provisional copy deadline of **Monday 5th January 2015**; however, I am more than happy to extend the deadline should you be interested in writing for the journal.

Three months free personal online subscription is offered to eligible lead authors upon publication of the article as well as a **complimentary copy** of the issue to which they contribute.

If you or your colleagues are unable to prepare this Editorial, I would be very grateful if you could recommend a suitable alternative author.

I look forward to your reply.

Kindest regards,

Natasha

Natasha Leeson
Commissioning Editor
Future Medicine

part of **future science group**
Unitec House, 2 Albert Place, London, N3 1QB, UK
+44 (0)20 8371 6090 | www.futuremedicine.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 10:05 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: tentative team schedule
Attachments: Planning Ebola laboratory teams.xlsx

Hi Heinz,

Please have a look at the schedule and provide us with feedback,

Of note, this schedule has you staying until first of November,

Hope all is well,

Vincent Munster
Chief, Virus Ecology Unit
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH
903 South 4th street
Hamilton, MT 59840
[406-375-7489](tel:406-375-7489)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 08, 2014 10:03 AM
To: 'Caroline Kim'
Subject: RE: 1-on-1 Paid Call RE: Ebola Virus

Dear Caroline,

Thank you very much for your email and for the offer to serve as an expert on Ebola virus. Unfortunately, I have to decline this offer – both my status at the NIH and my **Personal In** make it impossible for me to work with you on this. Thank you for your understanding!

Yours sincerely, Thomas Hoenen

From: Caroline Kim [mailto:caroline.kim@axonadvisors.com]
Sent: Wednesday, October 08, 2014 9:50 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: FW: 1-on-1 Paid Call RE: Ebola Virus

Dr. Hoenen,

I want to follow up: were you able to take a look at the below e-mail?

Please let me know if you would be available for this phone consultation sometime this week or next!

Best,
Caroline

Caroline Kim
Research Project Manager
+1 646 502 5065 (Direct)

From: Caroline Kim
Sent: Tuesday, October 7, 2014 5:05 PM
To: 'thomas.hoenen@nih.gov'
Subject: 1-on-1 Paid Call RE: Ebola Virus

Dear Dr. Hoenen,

I represent Axon Advisors, a leading healthcare fieldwork company. We connect research analysts to industry professionals for research projects.

One of our clients, a healthcare analyst (no relation to any healthcare company), has engaged us to schedule 1-on-1 calls with experts who meet the following criteria and can knowledgeably discuss the following topics.

1. Expert Profile Criteria:
 - Virologist who is an expert on Ebola/Filovirus.
2. Topics to be discussed:
 - Transmission data
 - Replication locations and duration in humans

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vadim Tsvetnitsky <VTsvetnitsky@iavi.org>
Sent: Wednesday, October 08, 2014 9:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Looking for copy of poster presented at 2006 CRTI Summer Symposium - "Therapeutic antibodies to Ebola and Marburg viruses"
Attachments: Ebola CRTI 2006.pdf

Hi Heinz,
Don somehow missed you in his email but perhaps you can help?
Best,
Vadim

Vadim Tsvetnitsky, Ph.D.
Director, Vaccine Development & Manufacturing
International AIDS Vaccine Initiative (IAVI)
125 Broad St, New York, NY 10004
+1.212.847.1070 (office) - Personal Info (Mobile)

Imagine a World Without AIDS



From: Don Stewart [mailto:don.stewart@plantformcorp.com]
Sent: Wednesday, October 08, 2014 5:33 PM
To: Erik Wiersma; Vadim Tsvetnitsky; Jones Steven; msuresh@pharmacy.ualberta.ca
Cc: jcopps@inspection.gc.ca
Subject: FW: Looking for copy of poster presented at 2006 CRTI Summer Symposium - "Therapeutic antibodies to Ebola and Marburg viruses"

Hi to all:

This is a long shot but can anyone help with this, see below.

Don

From: Judy Inglis [mailto:Judy.Inglis@phac-aspc.gc.ca]
Sent: 08 October, 2014 10:55 AM
To: Judy Inglis
Subject: Looking for copy of poster presented at 2006 CRTI Summer Symposium - "Therapeutic antibodies to Ebola and Marburg viruses"

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kim, Lewis (NIH/NIAID) [C]
Sent: Wednesday, October 08, 2014 9:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Xirasagar, Sandhya (NIH/NIAID) [E]; Whalen, Christopher (NIH/NIAID) [C]
Subject: Discussing ideas for HFV Informatics Approaches
Attachments: OCICB Potential collaboration idea discussion 10.08.2014.pptx

Dear Dr. Feldmann:

I am Lewis Kim, project manager at the [Bioinformatics and Computational Biosciences Branch \(BCBB\)](#), NIAID, NIH which provides informatics expertise to infectious disease researchers in computational biology data analysis including genomics and structural biology and in developing bioinformatics analysis tools and databases.

We are interested in applying our informatics expertise to address unmet needs of the Viral Hemorrhagic fevers (VHFs) research community, with emphasis on the current Ebola outbreak. We would like to collaborating with your laboratory to pursue potential collaborations in areas including, developing Point of Care diagnostics; addressing challenges to real-time data collection in remote areas; creating a viral bioinformatics web portal to collect, store, and share genomics data, medical information, and spatiotemporal metadata to facilitate communication between field agents, healthcare providers, and researchers and enable improved biosurveillance. The attached document provides more in depth explanation of these ideas.

We are excited to meet with you to discuss this proposal and to discussing other short term and long-term informatics strategies that you perceive will be helpful to the community.

Look forward to hearing from you,
Sincerely,

Lewis Kim, MPH, PHI
Public Health Informatics Specialist
Contractor, Medical Science and Computing, Inc.
Bioinformatics and Computational Biosciences Branch (BCBB)
Office of Cyber Infrastructure and Computational Biology
Office of Science Management and Operations
Office of the Director, National Institute of Allergy and Infectious Diseases
National Institutes of Health

5601 Fisher Lane, 4A38
Rockville, MD 20852
Phone: 240-669-2744
Mobile: Personal Info
<http://bioinformatics.niaid.nih.gov> (Within NIH)
<http://exon.niaid.nih.gov> (Public)
<https://twitter.com/niaidbioit> (Twitter)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Rota, Paul (CDC/OID/NCIRD)
Sent: Wednesday, October 08, 2014 8:57 AM
To: Martha Mulks
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Contact for virologist working with Ebola?

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: b.nyaku@elsevier.com
Sent: Wednesday, October 08, 2014 8:53 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Article tracking [EBIOM_5] - Expected dispatch of proofs

Article title: Ebola conquers West Africa - more to come?

Reference: Pending Publication

Journal title: EBioMedicine

Corresponding author: Dr. Heinz Feldmann First author: Dr. Peter Halfmann Expected dispatch of proofs: 13-OCT-2014

Dear Dr. Feldmann,

The proof of your article will be sent to you for checking soon. This will be your last opportunity for incorporating minor corrections before final publication of your article. We expect the proof to be sent to you on 13-OCT-2014. Please note that this date is subject to change due to variations in the production process. We will e-mail you with more information about your proof as it becomes available.

To track the status of your article throughout the publication process, please use our article tracking service:

Pending Publication

For more information on proofs: Pending Publication

Yours sincerely,
Mr. Basil Nyaku
E-mail: b.nyaku@elsevier.com

HAVE A QUERY?

We have 24/7 support to answer all of your queries quickly.
<http://help.elsevier.com>

For help with article tracking: <http://Pending Publication>

CONTENT INNOVATION – Enrich your article and make your research stand out

With the rapid advance of technology in scientific research, Elsevier has developed new ways for authors to present their research. Spearheaded by Elsevier's Article of the Future project, our content innovations enable scientists to add new levels of digital information and interaction to your published research articles.

See our innovations at: www.elsevier.com/about/content-innovation

PRIVACY POLICY

Please read our privacy policy.

<http://www.elsevier.com/privacypolicy>

Pending Publication

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pilar Pérez Personal Info
Sent: Wednesday, October 08, 2014 8:43 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: URGENT!! REPORT EBOLA SPANISH PAPER

Dear dr. Feldmann,

This is Pilar Perez, from a Spanish daily national newspaper called LA RAZON<<http://www.larazon.es/>>, in specially a weekly magazine called in English FOR YOUR HEALTH (A TU SALUD)<<http://www.larazon.es/secciones/a-tu-salud>>, it has a paper version, that publish every Sunday. We prepare an special issue with the main clues about the possibilities of surveillance with ebola.

I wonder if you could answer some questions that I need to explain our readers.

- In some scientific papers suggest that the progression of infectious disease is an evolution in which after a time you know if the patient is going to save or not, is it true? Is it a 15 days or week?
- What other diseases or infections determine a favorable outcome?
- What stops the infection in patients? Immunity ?
- From which irreversible damage is the situation?
- What should be an effective treatment, even experimental?

Thanks so much, I expect you could talk me something as soon as possible, because my deadline is tomorrow.

Regards,

Pilar

--

It receives a warm greeting,
Pilar Perez Jiménez
LA RAZÓN

Personal Info
pperez@larazon.es

Feldmann, Heinrich (NIH/NIAID) [E]

From: DeSiloJ@ReedElsevier.com
Sent: Wednesday, October 08, 2014 8:27 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Your paper [EBIOM_5] submitted to EBioMedicine

Dr. Heinz Feldmann
National Institutes of Health
Laboratory of Virology, Division of Intramural Research
903 South 4th Street
Hamilton, Montana 59840
United States
Phone: not available
Fax: not available
E-mail: feldmannh@niaid.nih.gov

Our reference: Pending Publication
Editorial reference:
To be published in: EBioMedicine

Re: Ebola conquers West Africa - more to come?

Dear Dr. Feldmann,

Thank you for choosing to publish in EBioMedicine.

Please read this e-mail carefully and check that your details are correct so we can contact you if needed. Please also note your article's reference number Pending Publication and quote it in all future correspondence so we can provide you with the best service. We will do everything possible to publish your article quickly and efficiently. In order to start the publication process we will ask you to fill out a number of forms which can be accessed using the below URL.

<http://Pending Publication>

If this link does not work, please copy the entire URL (noting that it may run on to a second line in this message) into your browser.

For further assistance, please visit our customer support site at <http://support.elsevier.com>. Here you can search for solutions on a range of topics. You will also find our 24/7 support contact details should you need any help from one of our customer support representatives.

Yours sincerely,

Jermalyn De Silos
Data Administrator
Elsevier
E-Mail: DeSiloJ@ReedElsevier.com
Fax:

Feldmann, Heinrich (NIH/NIAID) [E]

From: NIAID-DIRLLAlerts@nih.gov
Sent: Wednesday, October 08, 2014 7:56 AM
To: Walczynski, Joyce (NIH/NIAID) [C]; Vervick, Jason (NIH/NIAID) [E]; Taggart, Brian (NIH/NIAID) [E]; Schmitt, Kristine (NIH/NIAID) [E]; Richichi, Irene (NIH/NIAID) [E]; Miller, Colleen (NIH/NIAID) [E]; Meuchel, Tammy (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Barr, Leona (NIH/NIAID) [E]; Alkula, Glynis (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Clifton, Dawn (NIH/NIAID) [E]
Cc: Sullivan, Kevin (NIH/NIAID) [E]; Ser Voss, Rita (NIH/NIAID) [E]; Jones, Kim (NIH/NIAID) [C]; Hickman, Cathy (NIH/NIAID) [E]; Gehlhaus, Kristie (NIH/NIAID) [E]; Birdsong, George (NIH/NIAID) [E]; Altman, Edward (NIH/NIAID) [C]; Schmidt, Beth (NIH/NIAID) [E]; Mitchell, Jennifer (NIH/NIAID) [E]; Mays, Gary (NIH/NIAID) [E]; Coronado, Lisa (NIH/NIAID) [E]; Blaney, Joe (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: Approved with Conditions: CHG-LV-FY15-0064-00 - 1YR-MOD-SUP - SUPPLIES/SERVICES

[CHG-LV-FY15-0064-00 - 1YR-MOD-SUP - SUPPLIES/SERVICES](#)

DESCRIPTION:

Section: DMT
PI: Heinz Feldmann

Purpose: I request a CAN to be assigned specifically for the Ebola outbreak response. There are several excellent reasons in support of this: (1) allows efficient tracking of orders/travel since everything on that CAN is for the response; (2) financial reporting is available as needed; (3) eliminates the need and potential errors in tracking DMT and Ebola costs in separate spreadsheets; and (4) reduces the likelihood of exceeding the CR limit on the DMT CAN. I would suggest seeding it with \$250,000 to start since Lynne said there is already approximately \$95,000 in pending travel and AMBIS orders this FY on the DMT CAN for the response. Additionally, we will be placing orders shortly to replace supplies taken by Team 1 when we deployed in August. Dawn and Lynne can update Gary when more needs to be added (if necessary). Overall, given the urgency of this mission, I anticipate the orders/dollars to be significant.

Request has been Approved with Conditions by Kathryn Zoon on 2014-10-08.

DIR COMMENTS:

Approved with Conditions: DIR OSD CAN 8015724 - EMERGING VIRUS PROGRAM is available for use. Current allocation is \$250,000. Added to LV SOFIE View.

This is an automatically generated e-mail. Please do not reply.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ryan Kohls <Ryan.Kohls@aljazeera.net>
Sent: Wednesday, October 08, 2014 7:40 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: MEDIA REQUEST: The Stream // Al Jazeera English

Hello Dr. Feldmann,

My name is Ryan Kohls. I'm a producer with Al Jazeera English's "The Stream" - Al Jazeera English's award-winning, social media based show. Our show, which has recently won an Emmy nomination, is a 45 minute, live, interactive, daily talk show. (stream.aljazeera.com). We're based in Washington, D.C.

This Thursday, October 9th, between 1900 and 2015 PM EST, we are doing a show on Ebola. We want to have a well-rounded panel of people who can discuss the latest information on the fight to stop this outbreak. I would love to connect with an expert like yourself who understands the big picture questions and has some experience on the ground dealing with this.

Would love to chat if that might interest you. All the best,



Ryan Kohls
Interview Producer – The Stream
Al Jazeera English

O: 202 496 4622 | M: Personal Inf

[@ryankohls](https://twitter.com/ryankohls)
Washington, D.C | UTC/GMT -4

stream.aljazeera.com | www.aljazeera.com

Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 7:12 AM
To: NIAID RML BSL-4 Logistics Group
Subject: FW: 20140911 Logistics meeting tasks.xlsx
Attachments: 20140911 Logistics meeting tasks.xlsx

Since so many people are going to be out of town, I would like to cancel tomorrow's meeting.
Please email me any updates or new issues. I will compile and distribute.
Thanks
Marshall

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 12:17 PM
To: NIAID RML BSL-4 Logistics Group
Subject: 20140911 Logistics meeting tasks.xlsx

Please use this version. Kristi corrected me about the new cameras.
Thanks
Marshall

Feldmann, Heinrich (NIH/NIAID) [E]

From: Schultz-Cherry, Stacey <Stacey.Schultz-Cherry@STJUDE.ORG>
Sent: Wednesday, October 08, 2014 6:39 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: ASV 2015 Lunch Topic Table

Hey. Another favor to ask. Would you be willing/interested to write a Gems article on the current Ebola situation for JV? If you haven't seen the Gems section these are short articles (3 pages max) highlighting cool new research, methodologies, careers, just about anything that are by invite only. I am one of the Gems editors and think your take on the current situation would be of great interest. You can write from any aspect, invite people from your lab to author/co-author, and the deadline is open. Please let me know if this might be of interest.

Please tell Vincent and Emmie hello from me
Best,
Stacey

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 08, 2014 4:32 AM
To: Schultz-Cherry, Stacey
Cc: 'Judy.Gaza@utoledo.edu'; 'Dorothea.Sawicki@utoledo.edu'; 'vrr1@columbia.edu'
Subject: Re: ASV 2015 Lunch Topic Table

Sure - would be my pleasure.

Heinz

From: Schultz-Cherry, Stacey [mailto:Stacey.Schultz-Cherry@STJUDE.ORG]
Sent: Tuesday, October 07, 2014 08:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Gaza, Judy (Judy.Gaza@utoledo.edu) <Judy.Gaza@utoledo.edu>; Sawicki, Dorothea (Dorothea.Sawicki@utoledo.edu) <Dorothea.Sawicki@utoledo.edu>; Vincent Racaniello (vrr1@columbia.edu) <vrr1@columbia.edu>
Subject: ASV 2015 Lunch Topic Table

Dear Dr. Feldmann,
Good evening. My name is Stacey Schultz-Cherry and I am the Chair of the ASV Education and Career Development Committee. One function of the committee is to organize the very popular lunch time topic tables; including the "Meet the Speakers" tables. This is an opportunity for grad students/postdocs to meet with plenary speakers and discuss research, careers in science, whatever. This year, the London, Ontario hosts will try to provide each table with their own room and each table will likely have up to 20 students that will be required to sign up in advance. Would you be willing to host one of these tables on Monday July 13th at the lunch following your session? I know the young investigators would be very excited to meet with you. Please let me know if you are able to accept this opportunity or if you have any questions. I look forward to hearing from you in the near future.
Best,

Stacey Schultz-Cherry, PhD
Member, Department of Infectious Diseases

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Wednesday, October 08, 2014 6:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: CMX-001 or T705

Yea. We will coordinate with WHO since we will need all the help we can get.
But let's lock down a treatment facility.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

> On Oct 8, 2014, at 4:40 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
>
> Give me one more day as I have just arrived yesterday.
> Should this be coordinated with WHO?
> Heinz
>
>
> ----- Original Message -----
> From: Khan, Ali S [mailto:ali.khan@unmc.edu]
> Sent: Tuesday, October 07, 2014 11:46 PM Eastern Standard Time
> To: Uyeki, Timothy M. (CDC/OID/NCIRD)
> Cc: Feldmann, Heinrich (NIH/NIAID) [E]; De Alba, Armando <armando.dealba@unmc.edu>
> Subject: Re: CMX-001 or T705
>
> Thanks Tim for these ideas. Very helpful. With 50% case fatality, the power calculations are simple. We can do this.
> Chatted with Lu today.
> Waiting for Heinz to check with MSF.
> Best and thank you for the great info going out and the individual clinician consultation.
>
> Ali
>
> * UNMC College of Public Health
> Bringing innovative solutions to
> healthier communities in Nebraska
> and worldwide
>
>> On Oct 7, 2014, at 10:26 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Wednesday, October 08, 2014 5:24 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Fw: CMX-001 or T705

Hi Heinz,

I remember Ali, and I even worked in the emergency room at UNMC for a while.

The short answer is that all MSF involvement in clinical trials is being organized through a research consortium set up via a Wellcome Trust grant that has MSF, ISARIC, WHO, some drug companies, and a host of other people. CDC is even nominally onboard (I think in the form of Tim Uyeki). Any trial would need to be organized through this group. The short list of candidate agents is being organized by WHO, and these two may well be on the list.

Redacted by agreement

Redacted by a

Our lead on this is Annick Antierens. I can put Ali in touch with her if he is interested.

Hope Monrovia is treating you well - Armand

Armand Sprecher MD MPH
Public Health Specialist
Médecins Sans Frontières
Operational Center of Brussels

-----"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote: -----

To: "Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)"
<armand.sprecher@brussels.msf.org>
From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
Date: 10/08/2014 05:39AM
Subject: Fw: CMX-001 or T705

Armand,

Redacted by agreement

I can talk to Ruggiero but wanted to ask you first. You may remember Ali - he was former CDC, now Dean of the Omaha Medical School. Please let me know as soon as possible.

I can also call if you prefer.

Best wishes, Heinz

----- Original Message -----

From: Khan, Ali S [<mailto:ali.khan@unmc.edu>]
Sent: Tuesday, October 07, 2014 11:46 PM Eastern Standard Time
To: Uyeki, Timothy M. (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; De Alba, Armando
<armando.dealba@unmc.edu>
Subject: Re: CMX-001 or T705

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koita, Ousmane
Sent: Wednesday, October 08, 2014 5:13 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone; ssow@medicine.umaryland.edu
Subject: RE: New suspected case to be tested
Attachments: EBOLA screening test suspect 26.jpg; EBOLA Confirmatory test of suspect 26.jpg

Dear Dr Heinz,

Redacted by agreement

Redacted by agreement

Best regards,

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 06, 2014 4:45 AM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Great work - have a good weekend.

----- Original Message -----

From: Koita, Ousmane
Sent: Sunday, October 05, 2014 05:30 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Dear Heinz,

Redacted by agreement

We will take the picture when we return at work on Tuesday.

Best regards,

Ousmane

-----Original Message-----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Barry Rockx <barry.rockx@rivm.nl>
Sent: Wednesday, October 08, 2014 12:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: ebola risk

Hi Heinz,

How are things at RML? I hear your teams have been very busy with the field diagnostics, I hope things are going well. I have started my new job and am already getting a lot of questions regarding transmission risk of Ebola.

I wanted to get your opinion on the following questions if you have some time:

1. Can you tell me if you know culture attempts have been made on feces and if they were successful: ie was EBOV isolated by culture techniques?
2. Role of feces in transmission?
3. Do you have an indication of viral titers (presumably on RNA/PCR) in feces?
4. other than bats and apes, are there any other species believed to be involved in transmission? Duikers: involved in transmission? Easily Infected? Shedding, Porcupines, Pangolins, Rodents, Reptiles, Other?

thanks!

Barry

[Proclaimer RIVM http://www.rivm.nl/Proclaimer](http://www.rivm.nl/Proclaimer)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Tuesday, October 07, 2014 9:46 PM
To: Uyeki, Timothy M. (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; De Alba, Armando
Subject: Re: CMX-001 or T705


Thanks Tim for these ideas. Very helpful. With 50% case fatality, the power calculations are simple. We can do this. Chatted with Lu today.
Waiting for Heinz to check with MSF.
Best and thank you for the great info going out and the individual clinician consultation.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

> On Oct 7, 2014, at 10:26 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

Records Originating Outside of NIAID



> -----Original Message-----

> From: Khan, Ali S [mailto:ali.khan@unmc.edu]
> Sent: Monday, October 06, 2014 11:40 PM
> To: Uyeki, Timothy M. (CDC/OID/NCIRD)
> Cc: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: CMX-001 or T705

>

> Thanks Tim

> I think we may try to launch a trial. Hopefully Heinz can find a clinical site. And provide lab backup.

>

> Please share thoughts

>

> Ali

>

> * UNMC College of Public Health
> Bringing innovative solutions to
> healthier communities in Nebraska
> and worldwide

>

>> On Oct 6, 2014, at 10:34 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 7:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Attachments: Berlin 2014.pptx

Heinz,

Here is my talk for Berlin. It's about 12 minutes long if I don't get too nervous and talk too quickly. I'll practice with people from the lab later in the week.

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Felipe Restrepo Acosta <FRestrepoA@semana.com>
Sent: Tuesday, October 07, 2014 6:26 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: From the Colombian weekly magazine 'Semana' - Request of information about the Ebola outbreak spread in Western countries

Dear Professor Feldmann:

My name is Felipe Restrepo-Acosta, journalist at *Semana* ([last printed issue](#)), a weekly magazine published in Colombia. It provides in-depth articles about current events, politics, technology and culture.

It's as well one of the most important magazines in Latin America and a widely cited publication in leading English-speaking, media as The Economist ([link to Google results](#)), CNN ([link](#)) or The New York Times ([link](#)).

Currently I'm working on an article about the Ebola outbreak spread in the United States and Europe. I would like to know your viewpoint and ideas on the following issues:

1. It was well known that that the virus could appear in the First World, but a contagion inside a hospital (like in Spain) is quiet distressing. How seriously is Europe taking the current outbreak?
2. How likely are we to see Ebola appearing in Asian and Latin-American countries?
3. Do you think the emergence of cases in the United States and Europe would have an impact on world commerce and travels?

Best regards,

Felipe Restrepo-Acosta

Cell phone Personal Info

Office (571) 6 46 84 00 ext. 5058

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ilhem Messaoudi Powers <Ilhem.messaoudi@ucr.edu>
Sent: Tuesday, October 07, 2014 5:49 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]
Subject: Re: Modelling Ebola infection

Cool!

Sent from my iPhone

On Oct 7, 2014, at 5:27 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Fine with me.

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 06:08 PM Eastern Standard Time
To: Ilhem Messaoudi Powers <Ilhem.messaoudi@ucr.edu>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Modelling Ebola infection

Sounds good to me.
Let me know if you need anything.
Thanks, Andrea

From: Ilhem Messaoudi <ilhem.messaoudi@ucr.edu>
Date: Tuesday, October 7, 2014 6:38 AM
To: Heinz Feldmann <feldmannh@niaid.nih.gov>, Andrea Marzi <marzia@niaid.nih.gov>
Subject: FW: Modelling Ebola infection

Hi Heinz and Andrea

Miles is a world leader in mathematical modeling of immunity. He is a wonderful person (he works closely with several of my colleagues) and a collaborator with integrity. He is requesting to our already published data from the PNAS paper and I think this is a great opportunity for us to get a second manuscript out of this data set.

I hope that you will agree to collaborate and I would like to send him an email confirming our willingness to collaborate later today.

Thank you
Ilhem

From: Miles Davenport <z9801119@unsw.edu.au>
Date: Monday, October 6, 2014 10:16 PM
To: Ilhem Messaoudi <Ilhem.messaoudi@ucr.edu>
Subject: Modelling Ebola infection

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Tuesday, October 07, 2014 5:10 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: 1-on-1 Paid Call RE: Ebola Virus

Hi Heinz,

Sorry to bother you with this, but any idea what I should do with the attached email? Even if I wanted to do it (which I'm not sure I am) I don't think I could for legal reasons (working for the NIH & **Personal Info**). Have you ever dealt with something like this before?

All the best, Thomas

From: Caroline Kim [mailto:caroline.kim@axonadvisors.com]
Sent: Tuesday, October 07, 2014 3:05 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: 1-on-1 Paid Call RE: Ebola Virus

Dear Dr. Hoenen,

I represent Axon Advisors, a leading healthcare fieldwork company. We connect research analysts to industry professionals for research projects.

One of our clients, a healthcare analyst (no relation to any healthcare company), has engaged us to schedule 1-on-1 calls with experts who meet the following criteria and can knowledgeably discuss the following topics.

1. Expert Profile Criteria:
 - Virologist who is an expert on Ebola/Filovirus.
2. Topics to be discussed:
 - Transmission data
 - Replication locations and duration in humans
 - Typical course and variability in duration of asymptomatic incubation period, duration of illness, time to loss of viremia and to loss of infectivity
 - Organs and tissues affected by virus
 - Efficacy of supportive care to prevent fatalities
 - Potential of different antivirals in development
 - Suitability for vaccine strategies...effect of natural exposure

Would you be willing to discuss this topic on a 1-on-1 phone call? The call should last about 45 minutes. We will compensate you **\$400 per hour** for your participation.

If you are interested:

1. Please affirm that you meet all of the criteria and can knowledgeably discuss all of the topics. If you do not meet some of the criteria or cannot discuss some of the topics, please clarify.
2. Prior to engaging in any consultation engagement, we require disclosure of any conflicts related to the subject matter to be discussed, so as to avoid discussion of inappropriate consultants on this basis. Please list any conflicts. If you do not disclose any conflicts of interest we will assume that you have none.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Tuesday, October 07, 2014 4:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Okay. Thanks for the guidance.

Best regards,

Wayne

In a message dated 10/7/2014 6:27:16 P.M. Eastern Daylight Time, feldmannh@niaid.nih.gov writes:



As mentioned before you need to contact the groups and agencies that are responsible for patient care. You should contact MSF (doctors without borders) and WHO (World Health Organization). They do coordinate treatment and vaccines. I cannot get involved in this in my position. I also do not propose any treatment or vaccine that I do not know in terms of animal efficacy data against Ebola. In vitro efficacy is a needed start but does not mean much to me at all.

Heinz

From: Personal Info
Sent: Tuesday, October 07, 2014 06:05 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Hi Heinz,

Attached are two small but very relevant documents that Dr. Carter would like you to have so you are prepared to inform physicians who are treating Ebola patients about the availability and possibilities of Ampligen. I am told that once a physician requests a product for emergency use to treat Ebola, there is a call with the physician, FDA and the supplier and if OK'ed, product can then be used.

FYI, Dr. Zoon and Dr. Carter are well acquainted with each other and have met and spoken. Based on those discussion Hemispherx plans additional testing of Ampligen (VP35 binding assays) but meanwhile physicians on the front line with you should know of Ampligen and its MoA.

Hemispherx appreciates any assistance you can provide in this regard.

Wayne

In a message dated 10/7/2014 4:58:06 P.M. Eastern Daylight Time, Personal Info writes:



Heinz,

Yes I know that. I was more interested in Contacts you must have with physicians. Who or what is MSF?

Wayne
Sent from my iPhone

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kristen Moulton <kmoulton@mail.SLTrib.com>
Sent: Tuesday, October 07, 2014 4:25 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: University of Utah and Ebola

Hello Dr. Feldmann,

I'm working on a story about some Ebola-related research at the University of Utah, and wonder if one of your researchers is available and willing to be interviewed about the significance of the discovery. The Utah research is reported today in Science Daily, <http://www.sciencedaily.com/releases/2014/10/141007152603.htm>

If possible, could we speak today?

If not, I may still be working on the story tomorrow...

Best regards,

Kristen Moulton
Reporter
The Salt Lake Tribune
801-831-0467
kmoulton@sltrib.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 4:15 PM
To: Kelly Keith
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: VSV Ebola vaccine
Attachments: graycol.gif; Protocol Addendum Marzi 2014-066.1E.pdf; Protocol Marzi 2014-066E
Efficacy of the rVSV_ZEBOV-GP vaccine against a ZEBOV Guinea isolate in nonhuman primates August 2014.pdf

Kelly,

Here are the approved ASP and addendum requesting the use of the GMP-produced vaccine against ZEBOV Guinea in NHPs.

Please let me know if you have any questions.

Thanks, Andrea

Andrea Marzi, Ph.D.
Staff Scientist
Laboratory of Virology
Rocky Mountain Laboratories, NIAID, NIH
903 South 4th Street
Hamilton, MT 59840

Phone: 406-375-7421
Fax: 406-375-9620
email: marzia@niaid.nih.gov

From: Kelly Keith <kelly.keith@phac-aspc.gc.ca>
Date: Sunday, October 5, 2014 1:54 PM
To: Heinz Feldmann <feldmannh@niaid.nih.gov>
Cc: Andrea Marzi <marzia@niaid.nih.gov>
Subject: RE: VSV Ebola vaccine

Thank you! I look forward to hearing from Andrea.

(Ms.) G. Kelly Keith

Community Liaison Program Manager / National Microbiology Laboratory / Infectious Disease Prevention and Control Branch
Canadian Science Centre for Human and Animal Health
Public Health Agency of Canada / Government of Canada
kelly.keith@phac-aspc.gc.ca / Tel: 204-789-5028 / Cell: Personal Info

Gestionnaire de programme, Liaison avec la collectivité / Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses
Centre scientifique canadien de la santé humaine et animale
Agence de la santé publique du Canada / Gouvernement du Canada

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 4:08 PM
To: Ilhem Messaoudi Powers
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Modelling Ebola infection

Sounds good to me.
Let me know if you need anything.
Thanks, Andrea

From: Ilhem Messaoudi <ilhem.messaoudi@ucr.edu>
Date: Tuesday, October 7, 2014 6:38 AM
To: Heinz Feldmann <feldmannh@niaid.nih.gov>, Andrea Marzi <marzia@niaid.nih.gov>
Subject: FW: Modelling Ebola infection

Hi Heinz and Andrea

Miles is a world leader in mathematical modeling of immunity. He is a wonderful person (he works closely with several of my colleagues) and a collaborator with integrity. He is requesting to our already published data from the PNAS paper and I think this is a great opportunity for us to get a second manuscript out of this data set. I hope that you will agree to collaborate and I would like to send him an email confirming our willingness to collaborate later today.

Thank you
Ilhem

From: Miles Davenport <z9801119@unsw.edu.au>
Date: Monday, October 6, 2014 10:16 PM
To: Ilhem Messaoudi <ilhem.messaoudi@ucr.edu>
Subject: Modelling Ebola infection

Hi Ilhem,

It is now a few years since we met at VGTI to discuss modelling in immunology (and at the time your work on monkey pox). I am still working on modelling SIV infection kinetics and pathogenesis quite a bit, and now more and more on malaria. I have recently begun to look at Ebola infection and pathogenesis, with a view to whether our modelling may help understand this virus better. I read with interest your PNAS paper last year on Ebola vaccination in macaques, and wondered if it would be possible to get access to this published data for our modelling? In particular, the time courses of individual animals after challenge for virus, blood counts and biochemistry, antibody levels, and cytokines [largely the data that make up figure 5 and the supplementary figures]. Although there are no guarantees of success, I am optimistic that we might be able to analyse infection dynamics and provide some additional insights into Ebola infection. I would of course be pleased to include you and other key members of the original team as co-authors on any publications that may use the data.

I hope you will be willing to collaborate to analyse this published data. Please let me know if you need more information or want to discuss by Skype or e-mail. I look forward to hearing from you.

Thanks

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]
Sent: Tuesday, October 07, 2014 4:05 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak
Attachments: CorrectedNPGLE_Edited_GQZ6ZVII_EMI2014092.pdf; EINDdocument.pdf

Hi Heinz,

Attached are two small but very relevant documents that Dr. Carter would like you to have so you are prepared to inform physicians who are treating Ebola patients about the availability and possibilities of Ampligen. I am told that once a physician requests a product for emergency use to treat Ebola, there is a call with the physician, FDA and the supplier and if OK'ed, product can then be used.

FYI, Dr. Zoon and Dr. Carter are well acquainted with each other and have met and spoken. Based on those discussion Hemispherx plans additional testing of Ampligen (VP35 binding assays) but meanwhile physicians on the front line with you should know of Ampligen and its MoA.

Hemispherx appreciates any assistance you can provide in this regard.

Wayne

In a message dated 10/7/2014 4:58:06 P.M. Eastern Daylight Time, [Personal Info] writes:



Heinz,

Yes I know that. I was more interested in Contacts you must have with physicians. Who or what is MSF?

Wayne
Sent from my iPhone

On Oct 7, 2014, at 4:33 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

I have nothing to do with patients. You need to contact MSF.

From: [Personal Info]
Sent: Tuesday, October 07, 2014 03:33 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Hi Heinz,

I knew you were going but I didn't think it was until next week.

The purpose of my wanting to speak is that Dr Carter has learned that an emergency IND can be obtained if a physician treating Ebola patients makes such a request. Having been in Liberia before and being there now, you are in an excellent position to suggest to physicians that they consider the use of Ampligen for certain patients. I think you have the relevant information but I will send you a small packet which you can use to discuss the concept of Ampligen with certain physicians. Would you do that for Hemispherx ?

Best regards

Feldmann, Heinrich (NIH/NIAID) [E]

From: Doug Grosenbach <DGrosenbach@sigat.com>
Sent: Tuesday, October 07, 2014 4:00 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request for information - SIGA Technologies

Dr Feldman,

I was uncertain who would be an appropriate contact at RML for my request and chose you based on your stated research interests at the RML-NIAID website.

Redacted by agreement

Redacted by agreement

Are you willing to discuss this with me or do you have a suggestion for an appropriate contact for such work? We are also contacting other ABSL-4 capable facilities but are always open to suggestions as well.

Thank you in advance for your assistance.

Regards,

Doug Grosenbach, PhD
Associate Director, Poxvirology
SIGA Technologies
541-766-3751

CONFIDENTIALITY NOTICE: This e-mail transmission contains confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please reply to the sender, so that SIGA Technologies, Inc. can arrange for proper delivery, and then please delete the message from your inbox. Thank you

CONFIDENTIALITY NOTICE: This e-mail transmission contains confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please reply to the sender, so that SIGA Technologies, Inc. can arrange for proper delivery, and then please delete the message from your inbox. Thank you

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Tuesday, October 07, 2014 2:58 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Heinz,

Yes I know that. I was more interested in Contacts you must have with physicians. Who or what is MSF?

Wayne
Sent from my iPhone

On Oct 7, 2014, at 4:33 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

I have nothing to do with patients. You need to contact MSF.

From: Personal Info
Sent: Tuesday, October 07, 2014 03:33 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Hi Heinz,

I knew you were going but I didn't think it was until next week.

The purpose of my wanting to speak is that Dr Carter has learned that an emergency IND can be obtained if a physician treating Ebola patients makes such a request. Having been in Liberia before and being there now, you are in an excellent position to suggest to physicians that they consider the use of Ampligen for certain patients. I think you have the relevant information but I will send you a small packet which you can use to discuss the concept of Ampligen with certain physicians. Would you do that for Hemispherx ?

Best regards

Wayne

PS... Please be careful!

Sent from my iPhone

On Oct 7, 2014, at 3:04 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Most likely not possible as I am in Monrovia for the next three weeks.

From: Personal Info
Sent: Tuesday, October 07, 2014 02:19 PM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]

From: De wit, Emmie (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Munster, Vincent (NIH/NIAID) [E]
Subject: standard curve smartcycler
Attachments: Ebola PCR comparison 10072014.xlsx

All,

I ran a fresh dilution series of

Redacted by agreement

Redacted by agreement

Emmie

Emmie de Wit, PhD
Disease Modeling and Transmission
Laboratory of Virology
Rocky Mountain Laboratories
NIAID, NIH
903 South 4th Street
Hamilton, MT59840
Phone: 406-375-7490

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 1:54 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Sullivan, Kevin (NIH/NIAID) [E]
Subject: RE: lodging liberia

Heinz:

While the Embassy in Brazzaville has indeed be willing to do this, the Embassy in Monrovia is almost surely way too busy with the Ebola crisis to take this on at the moment.

I think we will need to come up with an arrangement on our own.

Sincerely,

MARK

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 2:53 PM
To: Munster, Vincent (NIH/NIAID) [E]; Sullivan, Kevin (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Gehlhaus, Kristie (NIH/NIAID) [E]; Barr, Leona (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: lodging liberia

The embassy would be the best choice. If they don't want to cover the expenses, we would have to transfer money.

Mark, we have done that in RC, haven't we?

Heinz

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 01:16 PM Eastern Standard Time
To: Sullivan, Kevin (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Barron, Karyl (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Gehlhaus, Kristie (NIH/NIAID) [E]; Barr, Leona (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: lodging liberia

Hi Kevin,

Thanks for your email. It looks like going outside the travel system might have the highest chance of success.

The 100% advance would be the 2nd (or 3rd) best option, although that would not be available for the next team,

Let me know if there is anything we need to do from our end,

Kind regards,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vandenburg, Marnie <Marnie.Vandenburg@oup.com>

Sent: Tuesday, October 07, 2014 1:30 PM

To: Feldmann, Heinrich (NIH/NIAID) [E]; Vickie Groth

Subject: RE: Unpublished

Attachments: Manuscripts Unpublished

Importance: High

Dear Dr. Feldmann,

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Tuesday, October 07, 2014 1:36 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: 20th Anniversary Celebration

Thank you. I just spoke with Ricki, and hopefully we will have some answers from her contractors by Friday.

If she goes in November, then you will have to cancel DZIF, too.

Take care!

Joyce Walczynski

Logistics Technician, LV (Contractor)
Rocky Mountain Laboratories
903 South 4th St.
Hamilton, MT 59840
Phone: 406.375.9600
Fax: 406.375.9620
Email: walczynskij@niaid.nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 12:55 PM
To: Walczynski, Joyce (NIH/NIAID) [C]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Fw: 20th Anniversary Celebration

Did Ricki talk to you about this travel? If she goes on the November team I cannot travel. She is trying to find out this week. Don't put too much effort into this as I may have to cancel.

Heinz

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Tuesday, October 07, 2014 01:17 PM Eastern Standard Time
To: Fran Garcia <fran.garcia@vhir.org>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: 20th Anniversary Celebration

Good Afternoon Fran:

With the new time change to 4 p.m. on November 21, I believe Dr. Feldmann may fly into Barcelona the morning of November 21, and then depart the morning of November 22 for Amsterdam.

I am attaching the Sponsor Acceptance Letter from us, and an LOI Form. The letter is from us to you and the LOI Form I will need to have filled out, signed, and returned to me. If you would please place the LOI Form on your letterhead before returning, that would be great. One of the things we have problems with when I send out this form is that on the form it asks for the sponsor to specifically give where the funds are coming from to provide the sponsorship. When I receive the form back from the sponsor, then I forward it to our Ethics

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]
Sent: Tuesday, October 07, 2014 1:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Hi Heinz,

I knew you were going but I didn't think it was until next week.

The purpose of my wanting to speak is that Dr Carter has learned that an emergency IND can be obtained if a physician treating Ebola patients makes such a request. Having been in Liberia before and being there now, you are in an excellent position to suggest to physicians that they consider the use of Ampligen for certain patients. I think you have the relevant information but I will send you a small packet which you can use to discuss the concept of Ampligen with certain physicians. Would you do that for Hemispherx ?

Best regards

Wayne

PS... Please be careful!

Sent from my iPhone

On Oct 7, 2014, at 3:04 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Most likely not possible as I am in Monrovia for the next three weeks.

From: [Personal Info]
Sent: Tuesday, October 07, 2014 02:19 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request to Speak

Hi Heinz,

I just spoke with Dr Carter and he'd like me to speak with you...not about the testing but rather treating Ebola patients in West Africa. Can we chat for 10 minutes sometime today convenient for you.

Thanks.

Best regards,

Wayne Pambianchi
Senior Adviser to the Chairman
Hemispherx Biopharma, Inc.
1617 JFK Boulevard
Suite 500
Philadelphia, PA 19013
Cell [Personal Info]
Office 215-988-0080

[Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: [Personal Info]
Sent: Tuesday, October 07, 2014 12:19 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request to Speak

Hi Heinz,

I just spoke with Dr Carter and he'd like me to speak with you...not about the testing but rather treating Ebola patients in West Africa. Can we chat for 10 minutes sometime today convenient for you.

Thanks.

Best regards,

Wayne Pambianchi
Senior Adviser to the Chairman
Hemispherx Biopharma, Inc.
1617 JFK Boulevard
Suite 500
Philadelphia, PA 19013
Cel [Personal Info]
Office 215-988-0080
[Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fran Garcia Morales <fran.garcia@vhir.org>
Sent: Tuesday, October 07, 2014 11:57 AM
To: Walczynski, Joyce (NIH/NIAID) [C]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: 20th Anniversary Celebration

Dear Joyce,

We will fill the letter and return to you.

Of course he can arrive on November 21 during the morning but I think it maybe better if he arrives on November 20 because we will have a dinner the night before and also maybe we can arrange some interviews with media.

Thanks in advance,

Enviado desde m

> El 07/10/2014, a las 19:19, "Walczynski, Joyce (NIH/NIAID) [C]" <walczynskij@niaid.nih.gov> escribió:

>

> Good Afternoon Fran:

>

> With the new time change to 4 p.m. on November 21, I believe Dr. Feldmann may fly into Barcelona the morning of November 21, and then depart the morning of November 22 for Amsterdam.

>

> I am attaching the Sponsor Acceptance Letter from us, and an LOI Form. The letter is from us to you and the LOI Form I will need to have filled out, signed, and returned to me. If you would please place the LOI Form on your letterhead before returning, that would be great. One of the things we have problems with when I send out this form is that on the form it asks for the sponsor to specifically give where the funds are coming from to provide the sponsorship. When I receive the form back from the sponsor, then I forward it to our Ethics Department for their approval. Quite frequently, Ethics will contact me and ask for the sponsor to provide specifically where the sponsorship is coming from. Ethics has given examples of where the funding could be coming from—following are a couple of examples: “funding is coming from registration fees” or “funding is from an unrestricted grant from XYZ organization”. So, if you can list specifically where the funds are coming from to sponsor Dr. Feldmann’s travel, I would appreciate it.

>

> Are you able to sponsor his flight from Missoula, Montana to Barcelona and from Barcelona to Amsterdam rather than back to the U.S.? Dr. Feldmann has a previous commitment in Europe and not enough time to travel from Barcelona back to Missoula, Montana and then back to Amsterdam and on to Germany. Dr. Feldmann is currently in Monrovia, Liberia; but hopefully, he will be able to respond to e-mails that I send to him with questions regarding his travel to Barcelona, etc.

>

> Please contact me with any questions.

>

> Thank you very much for your assistance with this sponsored travel.

>

> Joyce Walczynski

> Logistics Technician, LV (Contractor)

> Rocky Mountain Laboratories

> 903 South 4th St.

> Hamilton, MT 59840

> Phone: 406.375.9600

Feldmann, Heinrich (NIH/NIAID) [E]

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Tuesday, October 07, 2014 11:18 AM
To: Fran Garcia
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: 20th Anniversary Celebration
Attachments: Sponsor Acceptance Letter - signed - 10-6-14.pdf; Sponsor LOI Template.doc

Good Afternoon Fran:

With the new time change to 4 p.m. on November 21, I believe Dr. Feldmann may fly into Barcelona the morning of November 21, and then depart the morning of November 22 for Amsterdam.

I am attaching the Sponsor Acceptance Letter from us, and an LOI Form. The letter is from us to you and the LOI Form I will need to have filled out, signed, and returned to me. If you would please place the LOI Form on your letterhead before returning, that would be great. One of the things we have problems with when I send out this form is that on the form it asks for the sponsor to specifically give where the funds are coming from to provide the sponsorship. When I receive the form back from the sponsor, then I forward it to our Ethics Department for their approval. Quite frequently, Ethics will contact me and ask for the sponsor to provide specifically where the sponsorship is coming from. Ethics has given examples of where the funding could be coming from—following are a couple of examples: “funding is coming from registration fees” or “funding is from an unrestricted grant from XYZ organization”. So, if you can list specifically where the funds are coming from to sponsor Dr. Feldmann’s travel, I would appreciate it.

Are you able to sponsor his flight from Missoula, Montana to Barcelona and from Barcelona to Amsterdam rather than back to the U.S.? Dr. Feldmann has a previous commitment in Europe and not enough time to travel from Barcelona back to Missoula, Montana and then back to Amsterdam and on to Germany. Dr. Feldmann is currently in Monrovia, Liberia; but hopefully, he will be able to respond to e-mails that I send to him with questions regarding his travel to Barcelona, etc.

Please contact me with any questions.

Thank you very much for your assistance with this sponsored travel.

Joyce Walczynski
Logistics Technician, LV (Contractor)
Rocky Mountain Laboratories
903 South 4th St.
Hamilton, MT 59840
Phone: 406.375.9600
Fax: 406.375.9620
Email: walczynskij@niaid.nih.gov

From: Fran Garcia [mailto:fran.garcia@vhir.org]
Sent: Monday, October 06, 2014 10:01 AM
To: Walczynski, Joyce (NIH/NIAID) [C]
Subject: RV: 20th Anniversary Celebration

Feldmann, Heinrich (NIH/NIAID) [E]

From: McFadden, Douglas Grant <grantmcf@ufl.edu>
Sent: Tuesday, October 07, 2014 10:47 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola L-protein domain boundaries

Stay protected! Too many infections are occurring in health care workers....

g

On Oct 7, 2014, at 12:44 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

I am in Monrovia for the rest of the month - Ebola outbreak response.

From: McFadden, Douglas Grant [<mailto:grantmcf@ufl.edu>]
Sent: Tuesday, October 07, 2014 12:23 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola L-protein domain boundaries

Hi Heinz:

Perfect, thanks!

Grant

PS: I gather things are busy at your end.....

On Oct 7, 2014, at 12:12 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Grant,
You can try Elke Muehlberger (Boston), Hideki Ebihara (NIAID), Chris Basler (Mount Sinai) or Thomas Hoenen (my lab). Erica Ollman- Saphire (Scripps) may have structural knowledge.

Hope this will help. I may have mis-spelled some names).

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marston, Hilary (NIH/NIAID) [C]
Sent: Tuesday, October 07, 2014 10:46 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: Re: quick question

Oh of course - thank you!

On Oct 7, 2014, at 12:00 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

When the G is deleted you have no projections on the surface. The VSV vaccine has projection as the G is replaced by the Ebola glycoprotein which is then displayed on the surface.

From: Marston, Hilary (NIH/NIAID) [C]
Sent: Monday, October 06, 2014 06:25 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: quick question

Hello again – sorry to bother you with this, but we are doing a schematic of the VSV delta G vector, and wanted to use an image like this, but were wondering: is it a smooth membrane (without the glycoprotein spikes) once the g protein gene is deleted?

<image001.jpg>

http://www.virology.ws/wp-content/uploads/2010/02/vsv_virion-300x223.jpg

Feldmann, Heinrich (NIH/NIAID) [E]

From: McFadden, Douglas Grant <grantmcf@ufl.edu>
Sent: Tuesday, October 07, 2014 10:24 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola L-protein domain boundaries

Hi Heinz:

Perfect, thanks!

Grant

PS: I gather things are busy at your end.....

On Oct 7, 2014, at 12:12 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Grant,
You can try Elke Muehlberger (Boston), Hideki Ebihara (NIAID), Chris Basler (Mount Sinai) or Thomas Hoenen (my lab). Erica Ollman-Saphire (Scripps) may have structural knowledge.

Hope this will help. I may have mis-spelled some names).

Best wishes, Heinz

From: McFadden, Douglas Grant [<mailto:grantmcf@ufl.edu>]
Sent: Tuesday, October 07, 2014 10:47 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fwd: Ebola L-protein domain boundaries

Heinz:

I am on the SAB of a pathogen protein structure consortium, and I have received the request below about the Ebola RNA polymerase.

Do you know who I could contact who might be knowledgeable about the ebola virus polymerase protein?

Thanks,

Grant

Feldmann, Heinrich (NIH/NIAID) [E]

From: Shupert, W. Lesley (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 9:56 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: agent list
Attachments: MCLagentlist(1).xls

List for October.

Les

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 9:54 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]
Subject: Fw: Special Ebola PPE meeting on Thursday, Oct 9th at 1030AM
Attachments: (CUI) BDRD-SOSCBRNE Meeting - Ebola Personal Protective Equipment 10-9-2014.docx; Directions to White House Conference Center.docx

Fyi

Sent from my BlackBerry Wireless Handheld

From: Kurilla, Michael (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 11:23 AM Eastern Standard Time
To: Lane, Cliff (NIH/NIAID) [E]
Cc: Heilman, Carole (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: FW: Special Ebola PPE meeting on Thursday, Oct 9th at 1030AM

Cliff,

Not only won't I be in town (IDweek), but if I were to be in town it would be for something else.

This is well outside our swimlane. Unless you feel that with either current rotation of NIAID personnel into West Africa, or the eventual Phase II/III you intend to manage there, are sufficient reasons to pay attention or provide input, I'm going to pass on this.

Carole and I both sit on the NSTC Biological Defense Research and Development Subcommittee which is how it came my way (Hebbeler is the OSTP staff who manage the subcommittee).

If you do want to send someone let me know, I'm sure they are flexible.

Michael G Kurilla, MD-PhD
Director, Office of BioDefense, Research Resources, and Translational Research
Associate Director for BioDefense Product Development
DMID, NIAID, NIH, DHHS
5601 Fishers Lane 8G61
Rockville, MD 20852
301-402-4197

*You can get the monkey off your back,
But the circus never leaves town.
- Anne Lamont*

From: Hebbeler, Andrew [mailto:Andrew_M_Hebbeler@ostp.eop.gov]
Sent: Tuesday, October 07, 2014 10:58 AM
To: 'Dabisch, Jennifer C CIV (US)'; Aaron Firoved; Muldoon, Anna (HHS/ASPR/OPP); Anthony Lewis; Petro, James B CIV OSD OUSD ATL (US); Bradley Smith; Brendan Doyle; Spencer, Carmen J SES USARMY DOD JPEOCBD (US); Linden, Carol (HHS/ASPR/BARDA); Charles Onwulata; Christian Hassell; Holloway, Carl C (Clay) CIV OSD OUSD ATL (US); David

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Tuesday, October 07, 2014 9:32 AM
To: 'Alaaeldin Saad'
Subject: RE: important

Dear Alaa eldin,

Thank you very much for your email! Unfortunately, I'm not really the right person to talk to about this – I myself am only a trainee at the NIH, and don't have my own group. The person you would probably want to talk to is my supervisor Heinz Feldmann (<http://www.niaid.nih.gov/labsandresources/labs/aboutlabs/lv/Pages/default.aspx>). He is on an outbreak mission in Monrovia, Liberia, right now, and supposed to be back in three weeks.

Also, just to make sure you are aware of this, I no longer work in Germany, but am now at the NIH in the U.S., so I'm not sure if the DAAD would fund you coming here. If you are interested in working on EBOV in Germany, I would suggest talking to Stephan Becker, who is my former supervisor in Marburg (<https://www.uni-marburg.de/fb20/virologie/forschung/beckerfold>).

Sorry I can't be of more help!

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov

From: Alaaeldin Saad [mailto:Personal Info]
Sent: Tuesday, October 07, 2014 6:04 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: important

Dear Prof. Dr. Thomas Hoenen

Greeting from Egypt. My name is Alaa Eldin Mohamed Saad, I am an assistant lecturer at Zoonoses Department, Faculty of Veterinary Medicine, Zagazig University. I have read many of your papers and I am highly interested to do my research in Ebola virus. The Egyptian Government and DAAD organization offer a Long Term Training Grant called (GERLS) and it is completely funded (Travelling, Living expenses, Salary, Health insurance) from both ministry of higher education and scientific research in Egypt and DAAD. And so, you will offer me only your Supervision.

I hope this request will be met with a positive response from your side. I attached my CV with this mail.

Feldmann, Heinrich (NIH/NIAID) [E]

From: McFadden, Douglas Grant <grantmcf@ufl.edu>
Sent: Tuesday, October 07, 2014 8:48 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fwd: Ebola L-protein domain boundaries

Heinz:

I am on the SAB of a pathogen protein structure consortium, and I have received the request below about the Ebola RNA polymerase.

Do you know who I could contact who might be knowledgeable about the ebola virus polymerase protein?

Thanks,

Grant

Begin forwarded message:

From: Bart Staker <bart.staker@seattlebiomed.org>
Subject: Ebola L-protein domain boundaries
Date: October 6, 2014 at 1:34:19 PM EDT
To: "grantmcf@ufl.edu" <grantmcf@ufl.edu>

Hi Grant,

Thanks for your service on the SSGCID advisory board. NIAID has asked us to apply extra effort on structure determination efforts of Ebola viral proteins due to current events. They are especially interested in the RNA dependent RNA polymerase (RdRp) domain of the L-protein.

The L-protein is a ~2200 amino acid long protein which contains several domains. There are no experimental descriptions of the domain boundaries of the L-protein, so we are looking for anybody who may have experience or knowledge about the RdRp domain boundaries of the Ebola virus L-protein. We appreciate any suggestions or introductions you may be able to make.

Thanks,
Bart

Bart Staker, Ph.D.
Outreach Manager
Seattle Structural Genomics Center for Infectious Disease
Seattle Biomed
Phone: (206)256-7190

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ilhem Messaoudi Powers <Ilhem.messaoudi@ucr.edu>
Sent: Tuesday, October 07, 2014 6:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: FW: Modelling Ebola infection

Hi Heinz and Andrea

Miles is a world leader in mathematical modeling of immunity. He is a wonderful person (he works closely with several of my colleagues) and a collaborator with integrity. He is requesting to our already published data from the PNAS paper and I think this is a great opportunity for us to get a second manuscript out of this data set.

I hope that you will agree to collaborate and I would like to send him an email confirming our willingness to collaborate later today.

Thank you
Ilhem

From: Miles Davenport <z9801119@unsw.edu.au>
Date: Monday, October 6, 2014 10:16 PM
To: Ilhem Messaoudi <Ilhem.messaoudi@ucr.edu>
Subject: Modelling Ebola infection

Hi Ilhem,

It is now a few years since we met at VGTI to discuss modelling in immunology (and at the time your work on monkey pox). I am still working on modelling SIV infection kinetics and pathogenesis quite a bit, and now more and more on malaria. I have recently begun to look at Ebola infection and pathogenesis, with a view to whether our modelling may help understand this virus better. I read with interest your PNAS paper last year on Ebola vaccination in macaques, and wondered if it would be possible to get access to this published data for our modelling? In particular, the time courses of individual animals after challenge for virus, blood counts and biochemistry, antibody levels, and cytokines [largely the data that make up figure 5 and the supplementary figures]. Although there are no guarantees of success, I am optimistic that we might be able to analyse infection dynamics and provide some additional insights into Ebola infection. I would of course be pleased to include you and other key members of the original team as co-authors on any publications that may use the data.

I hope you will be willing to collaborate to analyse this published data. Please let me know if you need more information or want to discuss by Skype or e-mail. I look forward to hearing from you.

Thanks

Miles

Professor Miles Davenport
Head, Complex Systems in Biology Group
Centre for Vascular Research
UNSW Australia
Sydney, NSW 2052

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dr. R. K. Dixit <chiefauthor@journalofscience.org>
Sent: Tuesday, October 07, 2014 4:45 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Regarding Ebolavirus in West Africa, and the use of experimental therapies or vaccines



07 - October - 2014

Dear Dr. Heinz Feldmann,

I came across to your research paper titled "Ebola virus in West Africa, and the use of experimental therapies or vaccines" and feel that your research is having a very good impact.

With a view to begin a long-term fruitful association with you, I invite you to submit your upcoming research articles / papers for publication in Global Journal of Science Frontier Research (GJSFR), an international double blind peer reviewed research journal.

This may be noted that due date of forthcoming issue GJSFR is 15 November, 2014.

The process of publication is expected to be completed within three to five weeks. Our processes follow rigid quality control measures and comply with international standards in journal publishing.

For more details please refer to websites <https://GlobalJournals.org> (Core Website) and <http://JournalofScience.org>

Brief Introduction:

Global Journals Inc. (US) is well known, fastest growing and leading research publishing organization in the world. We encourage research activities all around the globe with Online, 3D and Print versions. We also follow open journal system.

We publish various journals covering all streams (UDC/DDC/LCC etc.) of Computer Science, Engineering, Medical, Management, Natural Science and Human Science.

The Publication of Science Frontier Research stream is diversified as:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Howe, Jessica (Sky News) <Jessica.Howe@bskyb.com>
Sent: Tuesday, October 07, 2014 4:08 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Sky News interview

Dear Heinz

We are really keen to set up an interview with you this evening, about the spread of Ebola given that it has now been contracted by the Spanish nurse. We're also keen to look at the possible model for infection and how it could spread outside of Africa.

We would love to set up an interview today – either live or pre-recorded. It would be for our new flagship evening programme Sky News Tonight - which is to be an in-depth, serious and intelligent exposition of the day's news. It would set the agenda on Sky News that night and throughout the following days. The presenter is Sky News Editor at Large, Adam Boulton.

Do let me know if this is an option – my direct line is 0044 207 032 0424

Many thanks

Jessica

Information in this email including any attachments may be privileged, confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received it in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. SKY and the SKY marks are trademarks of British Sky Broadcasting Group plc and Sky International AG and are used under licence. British Sky Broadcasting Limited (Registration No. 2906991), Sky-In-Home Service Limited (Registration No. 2067075) and Sky Subscribers Services Limited (Registration No. 2340150) are direct or indirect subsidiaries of British Sky Broadcasting Group plc (Registration No. 2247735). All of the companies mentioned in this paragraph are incorporated in England and Wales and share the same registered office at Grant Way, Isleworth, Middlesex TW7 5QD.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Monday, October 06, 2014 9:40 PM
To: Uyeki, Timothy M. (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: CMX-001 or Redacted by

Thanks Tim

I think we may try to launch a trial. Hopefully Heinz can find a clinical site. And provide lab backup.

Please share thoughts

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

> On Oct 6, 2014, at 10:34 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

>

Redacted by agreement

> Tim

> -----Original Message-----

> From: Khan, Ali S [mailto:ali.khan@unmc.edu]

> Sent: Monday, October 06, 2014 11:02 AM

> To: Feldmann, Heinrich (NIH/NIAID) [E]

> Cc: Uyeki, Timothy M. (CDC/OID/NCIRD)

> Subject: RE: CMX-001 or Redacted

>

Redacted by agreement

> I am still disturbed that we are not using these drugs in Africa for the primary people who are infected and bearing the
brunt of the outbreak!

>

>

> Thanks,

>

> Ali

>

> -----Original Message-----

> From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]

> Sent: Monday, October 6, 2014 12:53 AM

> To: Khan, Ali S

Feldmann, Heinrich (NIH/NIAID) [E]

From: Uyeki, Timothy M. (CDC/OID/NCIRD)
Sent: Monday, October 06, 2014 9:34 PM
To: 'Khan, Ali S'; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: CMX-001 or [REDACTED] Redacted by agreement

[REDACTED]

Tim

-----Original Message-----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Monday, October 06, 2014 11:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Uyeki, Timothy M. (CDC/OID/NCIRD)
Subject: RE: CMX-001 or [REDACTED] Redacted by agreement

[REDACTED]

[REDACTED]

I am still disturbed that we are not using these drugs in Africa for the primary people who are infected and bearing the brunt of the outbreak!

Thanks,

Ali

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 6, 2014 12:53 AM
To: Khan, Ali S
Subject: Re: CMX-001

We can do [REDACTED]

[REDACTED]

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 05, 2014 03:21 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: CMX-001

CDC is suggesting we try based on in vitro data.
Let's reconsider a therapeutic trial when you get in Monrovia.
Be safe,
Ali

Feldmann, Heinrich (NIH/NIAID) [E]

From: Callison, Julie (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 2:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: question from our high school student

Importance: High

Hi Heinz,

Personal Info

I forgot to tell you in my last email that I told [REDACTED] no, that I cannot speak with his parents and that's why I wanted to talk to you first. I told him this would have to come from you.

I hope that was okay.

Thanks!
Julie

From: <Callison>, Julie Callison <callisonj@niaid.nih.gov>
Date: Monday, October 6, 2014 at 2:41 PM
To: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
Subject: question from our high school student

Hi Heinz,

I know you are traveling, and I'm not sure if you have access to email, but one of our high school kids has a question and I wanted to run it by you.

He said his parents are concerned about him working in the lab, especially with the Ebola outbreak in Africa. He said they are concerned about people from the lab going over to Africa, and then coming back to the lab right away. It sounds like they are considering asking him to quit working here.

Personal Info [REDACTED] asked me to speak to them, or email them, and explain that he should be safe. I told him I wanted to speak with you first. I'm not sure it's my place to talk to them about this. Would you like to send them an email, or is this something better handled with a phone call when you get back in the country? I wasn't sure what to do.

I know this is hard to take care of when you are traveling to Africa, but he was hoping someone could talk to them this week. I did explain to him that you are out of the country for at least three weeks.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Callison, Julie (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 2:42 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: question from our high school student

Importance: High

Hi Heinz,

I know you are traveling, and I'm not sure if you have access to email, but one of our high school kids has a question and I wanted to run it by you.

He said his parents are concerned about him working in the lab, especially with the Ebola outbreak in Africa. He said they are concerned about people from the lab going over to Africa, and then coming back to the lab right away. It sounds like they are considering asking him to quit working here.

Personal Info asked me to speak to them, or email them, and explain that he should be safe. I told him I wanted to speak with you first. I'm not sure it's my place to talk to them about this. Would you like to send them an email, or is this something better handled with a phone call when you get back in the country? I wasn't sure what to do.

I know this is hard to take care of when you are traveling to Africa, but he was hoping someone could talk to them this week. I did explain to him that you are out of the country for at least three weeks.

Thanks for your help, and I hope your travels are going smoothly so far!
Julie

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Egan <eganm@profectusbiosciences.net>
Sent: Monday, October 06, 2014 1:37 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jeffrey Meshulam; John Eldridge; Geisbert, Thomas W. (twgeisbe@UTMB.EDU);
Demetrius Matassov; David Clarke
Subject: RE: back from Liberia?

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Egan <eganm@profectusbiosciences.net>
Sent: Monday, October 06, 2014 1:23 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jeffrey Meshulam; John Eldridge; Geisbert, Thomas W. (twgeisbe@UTMB.EDU);
Demetrius Matassov; David Clarke
Subject: RE: back from Liberia?

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Casey, Erin D <CaseyED@state.gov>
Sent: Monday, October 06, 2014 1:17 PM
To: Koita, Ousmane; Feldmann, Heinrich (NIH/NIAID) [E]; Seydou Doumbia
Cc: Sangare, Djibril; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]
Subject: RE: Laboratory questions

Records Originating Outside of NIAID



From: Ousmane Koita [<mailto:okoita@icermali.org>]
Sent: Saturday, October 04, 2014 7:24 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Casey, Erin D; Seydou Doumbia
Cc: Djibril Sangare; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]
Subject: RE: Laboratory questions

Thanks Prof Heinz, so far we have tested 22 suspected cases using the screening assay and the confirmatory RT-PCR. All were negative

Erin, I hope to see you during your coming visit here in Mali.

Best regards,

Ousmane

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Friday, October 03, 2014 9:03 PM
To: 'Casey, Erin D'; Seydou Doumbia
Cc: Djibril Sangare; Ousmane Koita; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]
Subject: RE: Laboratory questions

The assays are the same that the NHI/CDC team uses in Monrovia to support ELWA3 (MSF ward). They target L, NP and GP.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 12:29 PM
To: Michael Egan; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jeffrey Meshulam; John Eldridge; Geisbert, Thomas W. (twgeisbe@UTMB.EDU);
Demetrius Matassov; David Clarke
Subject: Re: back from Liberia?

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Egan <eganm@profectusbiosciences.net>
Sent: Monday, October 06, 2014 11:52 AM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jeffrey Meshulam; John Eldridge; Geisbert, Thomas W. (twgeisbe@UTMB.EDU);
Demetrius Matassov; David Clarke
Subject: RE: back from Liberia?

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Egan <eganm@profectusbiosciences.net>
Sent: Monday, October 06, 2014 11:46 AM
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jeffrey Meshulam; John Eldridge; Geisbert, Thomas W. (twgeisbe@UTMB.EDU);
Demetrius Matassov; David Clarke
Subject: RE: back from Liberia?

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Karl Johnson [Personal Info]
Sent: Monday, October 06, 2014 11:40 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola!

Hi,

Hope you are in WA with equipment to do quantitative viremia and abys. Former is to do daily viremia levels before and after use of convalescent plasma and to find immune persons to recruit for many of the riskiest procedures in this horrific outbreak. If you are not there do you know if anyone at CDC is doing any of that stuff. Science DURING an epidemic is tough but it needs doing for good reasons. [Redacted by agreement]

[Redacted by agreement]

Do you have contact info for Stuart Nichol? Please send if yes or any other number I could use to reach Special Pathogens.

Is your vaccine the one finally being pushed by Tony? If not, why the hell not. If yes then perhaps you are still in country and pushing.


Any news appreciated. Almost wish I was still in loop.

KMJ

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 11:36 AM
To: Michael Egan; Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jeffrey Meshulam; John Eldridge; Geisbert, Thomas W. (twgeisbe@UTMB.EDU);
Demetrius Matassov; David Clarke
Subject: Re: back from Liberia?

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Karl Johnson Personal Info
Sent: Monday, October 06, 2014 11:28 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Robert Frenck
Sent: Monday, October 06, 2014 10:26 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Expert Review Vaccine Article

Dear Dr Feldmann,

My name is Bob Frenck. I am a Ped ID physician at Cincinnati Children's Hospital. I was wondering if you would have an electronic copy of your article entitled "Ebola virus vaccines: an overview of current approaches" that was published in Expert Rev Vaccines earlier this year? If so, would you be so kind as to send me a copy. I was asked to participate in a local meeting discussing Ebola including prevention and treatment. Your article would be very helpful in my preparation for the meeting.

Thank you in advance,

Bob Frenck

Robert W. Frenck, Jr M.D.
Professor of Pediatrics
Division of Infectious Diseases
Cincinnati Children's Hospital Medical Center

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 06, 2014 10:22 AM
To: 'Marlovits,Thomas'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Question related to cDNAs
Attachments: 2010__Hoenen__J_Virol__VP40_oligomerization.pdf; 2010__Hoenen__Virology__VP40_and_VP24_inhibit_EBOV_replication_and_transcription.pdf; 2011__Hoenen__Antivir_Res__Minigenome_review.pdf; 2012__Hoenen__J_Virol__Inclusion_Bodies.pdf; 2014__Watt__J_Virol__Tetracistronic_trVLP_system.pdf

Dear Thomas,

From what you tell me, I believe what you will need is a minigenome system. This system consists of expression plasmids for the polymerase L, its cofactor VP35, the transcriptional activator VP30 and the nucleoprotein NP, as well as an expression plasmid for a minigenome, which is recognized as a legitimate template by the viral polymerase complex (plus some accessory proteins to make the system work). I have attached a review which gives an overview over these systems (Hoenen Antivir. Res. 2011). I would be very happy to help you get this system running in your lab – if that is what you need (please note that I have been trying to look by EM at sites of genome replication as described in Hoenen J Virol. 2012, but at least with regular TEM we see very little discernible structures – EM reports of EBOV inclusion bodies in the literature, which I have shown to be sites of genome replication, look at very late forms of these inclusion bodies, and I'm not sure if those are at all relevant for genome replication).

It should be no problem to send also expression plasmids for the other viral proteins VP40, VP24 and GP; as you can see from attached publications (Hoenen J. Virol. 2010, Hoenen Virology 2010, Watt J. Virol. 2014) I have shown functional interactions between VP40 and VP24 on the one hand and the replication/transcription machinery on the other hand, and at least for VP24 and NP there is biochemical evidence for interactions as well.

I'm also very interested in host factors involved in replication and transcription – in fact I am working on a genome-wide siRNA screen to identify those factors, and we have screened about 68,000 siRNAs now, and are validating hits. However, I'm not sure whether the type of screen described in the Nature paper would work for anything other than entry factors (at least in BSL2) – the VSV-EBOV-GP they used had the advantage that it is a reasonable (albeit not perfect) model of EBOV-entry that can be used under BSL2 conditions, and at the same time the virus VSV is very cytotoxic (much more so than EBOV).

I have attached all the literature that I referred to, this might be a good primer for EBOV genome replication and transcription. If you want we can always discuss things some more by phone – otherwise I would propose to send expression plasmids for all viral structural proteins, a monocistronic minigenome and necessary accessory plasmids. Please let me know what you think.

All the best, Thomas

From: Marlovits,Thomas [mailto:Thomas.Marlovits@imba.oeaw.ac.at]
Sent: Sunday, October 05, 2014 5:30 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Question related to cDNAs

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Jarvis <michael.jarvis@plymouth.ac.uk>
Sent: Monday, October 06, 2014 9:54 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Unpublished

Dr Michael A. Jarvis, PhD.

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Monday, October 06, 2014 9:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Uyeki, Timothy M. (CDC/OID/NCIRD)
Subject: RE: CMX-001 o [Redacted by agree]

[Redacted by agreement]

I am still disturbed that we are not using these drugs in Africa for the primary people who are infected and bearing the brunt of the outbreak!

Thanks,

Ali

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 6, 2014 12:53 AM
To: Khan, Ali S
Subject: Re: CMX-001

We can do [Redacted by agreement]

[Redacted by agreement]

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 05, 2014 03:21 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: CMX-001

CDC is suggesting we try based on in vitro data.
Let's reconsider a therapeutic trial when you get in Monrovia.
Be safe,
Ali

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Sunday, October 5, 2014 1:56 PM
To: Khan, Ali S
Subject: Re: CMX-001

I do not know. I am on my way to Monrovia. I heard you will receive the [Redacted by agreement]

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Helen Branswell <Helen.Branswell@thecanadianpress.com>
Sent: Monday, October 06, 2014 8:19 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: my latest story

just fyi.
Hope it's nice in Brussels. Not my favorite town.
Helen

Forwarded from The Canadian Press Staff by user HB

Experts starting to admit it may take vaccine to stop Ebola in West Africa (Ebola-Vaccine) Oct 06 01:36 - CP - The Canadian Press

By Helen Branswell

THE CANADIAN PRESS

TORONTO _ As West Africa's Ebola outbreak continues to rage, some experts are coming to the conclusion that it may take large amounts of vaccines and maybe even drugs _ all still experimental and in short supply _ to bring the outbreak under control.

Embedded in that notion is the reality that the catastrophic epidemic may remain unchecked for months, given that these products haven't yet been proven to be safe or effective in people, and won't be available in significant amounts any time soon. Experimental Ebola drugs in particular will remain in scarce supply for a considerable time.

"It is conceivable that this epidemic will not turn around even if we pour resources into it. It may just keep going and going and it might require a vaccine," Dr. Anthony Fauci, director of the U.S. National Institute for Allergy and Infectious Diseases, told The Canadian Press in an interview.

"As the epidemic gets more and more formidable and in some cases out of control it is quite conceivable, if not likely, that we may need to deploy the vaccine to the entire country to be able to shut the epidemic down. That is clearly a possibility."

Earlier in the outbreak many experts insisted experimental vaccines could not be tested and produced in large enough amounts in time to have an impact on the outcome. They stressed _ publicly, some still do _ that the "tried and true" measures used to contain Ebola outbreaks in the past would eventually control this one.

Those measures are aimed at breaking the chains of transmission.

The sick are housed in isolation units, where the only people they have contact with are garbed head-to-toe in protective apparel.

Those who don't survive are buried in thick body bags, without the cultural rituals that often spread the disease.

Contacts of the sick are monitored for 21 days and are whisked into isolation if they start to get ill. People with Ebola are believed to be contagious only when they have symptoms, which is when you need to ensure they don't come into contact with others.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Sent: Monday, October 06, 2014 7:39 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Side effects

No, I have not asked her but I imagine that GSK would object for sure. I do agree though that it may be worth a try as if they object then they should not publish.

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Sunday, October 05, 2014 1:38 PM
To: Kobinger, Gary (Public Health Agency of Canada); Geisbert, Thomas W.
Subject: Re: Side effects

We don't have the vector either. Sharing might be difficult during phase I - I guess GSK would object. Otherwise, I agree with Gary.

On my way to Monrovia.

Heinz

From: Kobinger, Gary (Public Health Agency of Canada)
Sent: Sunday, October 05, 2014 02:06 PM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Side effects

I don't, I have several simian Ads-ZGP but it would need to be the same to be meaningful. Ask Nancy or is she not sharing? I never asked her any reagents so I don't know.

If she is not sharing then that would be breaking publication agreements, and then she shouldn't publish. Old stuff but never too late to do good (enforce).

Take care

Gary

-----Original Message-----

From: Geisbert, Thomas W.
To: Heinz Feldmann
To: Gary Kobinger
Subject: RE: Side effects
Sent: Oct 2, 2014 20:09

It is hard to say right now with N being so small. Gary, on the ChAd do you know of anyone that has the ChAd3 Ebola GP vectors other than VRC. Someone needs to test that against a 7U virus.

Tom
From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov] **Sent:** Wednesday, October 01, 2014 1:06 PM **To:** Geisbert, Thomas W.; Kobinger, Gary (Public Health Agency of Canada) **Subject:** RE: Side effects Gary – could it be

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Gardner, Don (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 7:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Clark, Terri (NIH/OD) [E]
Subject: FW: domestic animals and Ebola virus

Hello, Heinz,

Please see Terri Clark's email below. Terri is the Chief Professional Officer for Commissioned Corps veterinarians, director of the NIH Office of Animal Care and Use and an advisor to the U.S. Surgeon General. Would you be able to provide her with some information which she can relay to the Surgeon General's office in regard to reservoir species and Ebola?

Thanks,

Don

Don Gardner, DVM, DACLAM, DACVP // Attending Veterinarian, Rocky Mountain Veterinary Branch, RML, NIAID // CAPT, US Public Health Service // 406-363-9467 // dgardner@niaid.nih.gov

From: Clark, Terri (NIH/OD) [E]
Sent: Friday, October 03, 2014 2:51 PM
To: Gardner, Don (NIH/NIAID) [E]
Subject: FW: domestic animals and Ebola virus

Hi Don – do you know the answer to these questions? I haven't heard from Heinz or Vince, but know they are probably quite busy. Thanks - Terri

Dr. Terri R. Clark, DVM, DACLAM // Director, Office of Animal Care & Use // Chief Veterinary Officer, CAPT, USPHS
301-496-5424/7236 // clarkte@od.nih.gov // <http://oacu.od.nih.gov>

From: Clark, Terri (NIH/OD) [E]
Sent: Wednesday, October 01, 2014 12:12 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]
Cc: Elkins, Randy (NIH/NIAID) [E]
Subject: domestic animals and Ebola virus

Good morning gentlemen – in addition to my role here at NIH, I'm currently serving as an advisor the US Surgeon General. The SG and staff asked a couple of questions about domestic animals and their potential role with the Ebola virus and so I would appreciate your expertise and input.

Can domestic animals serve as 'carriers' of the virus? I assume there is a concern that individuals diagnosed with the disease may have pets and so would the pets then be a source of concern for further spread of the virus.

This question is for my education:

Do we definitively know which animal species are the reservoir hosts for this virus?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 7:21 AM
To: Safronetz, David (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: MOH letter
Attachments: Lettre n° 2055 - MSHP_Request MoH.pdf; English version NIAID - MSPH.doc

David:

Can you please give me a call when you have a chance. In brief, as you can see, we have been asked officially by the GOM to assist with Ebola preparedness. While we obviously want to be helpful, we also need to be sure to delimit what we can do (given our mission as a research entity). I want to discuss this with you given Heinz is away.

Sincerely,

MARK

-----Original Message-----

From: Sow, Ydrissa (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 8:10 AM
To: Handley, Gray (NIH/NIAID) [E]
Cc: Pineda, Mark (NIH/NIAID) [E]; Meegan, James (NIH/NIAID) [E]
Subject: FW: MOH letter

Gray,

Attached is a letter we received from Dick. It is from the Malian Ministry of Health and addressed to Dr. Fauci. The original is in French, but I made an English version.

Mark, I am not sure if the embassy has an other way to send it out, maybe Gray can advise on the next step.

Best

-----Original Message-----

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:33 PM
To: Sow, Ydrissa (NIH/NIAID) [E]
Subject: FW: MOH letter

Drissa:

This must be the letter the DCM handed to Dick.

We need this translated ASAP.

MARK

-----Original Message-----

From: Sakai, Richard
Sent: Thursday, October 02, 2014 12:27 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US) <mark.j.wolcott.civ@mail.mil>
Sent: Monday, October 06, 2014 6:53 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Kobinger, Gary (Public Health Agency of Canada); Allen.Grolla@phac-aspc.gc.ca
Subject: RE: Primers (UNCLASSIFIED)

Classification: UNCLASSIFIED
Caveats: NONE

Thanks

Mark
301-619-4738
mark.j.wolcott.civ@mail.mil

PRISM KEYWORDS: bioterrorism; anthrax; plague


-----Original Message-----

From: Falzarano, Darryl (NIH/NIAID) [F] [mailto:darryl.falzarano@nih.gov]
Sent: Monday, October 06, 2014 2:29 AM
To: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US); Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Kobinger, Gary (Public Health Agency of Canada); Allen.Grolla@phac-aspc.gc.ca
Subject: RE: Primers (UNCLASSIFIED)

Hi Mark,

Sorry for the slow response. I am not sure what you mean by what is the ZEBOV L assay target? The target is the L (polymerase) gene. I will assume you actually want the sequences?

Redacted by agreement



These primers were designed by the National Microbiology Laboratory in Winnipeg, Canada. I have copied Gary Kobinger and Allen Grolla. I would be best to contact them with any design and validation questions.

I will have to get back to you to confirm the sequences for the VSV-N assay.

Best regards,
Darryl

Feldmann, Heinrich (NIH/NIAID) [E]

From: James Glynn <james.glynn@bbc.co.uk>
Sent: Monday, October 06, 2014 6:42 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: BBC Interview Request

Hello Heinz,

I work for a radio programme called World Update on BBC World Service (international radio). We are on air between 10-11am UK time.

We would like to arrange a pre-recorded interview with you for later today to talk about Ebola and airport screening measures. We want to ask how successful airport screening is, we would like to clarify how Ebola is transmitted and your personal experience of the airport measures.

We can pre-record around 7pm UK time that's 12pm MT – we can speak to you via Skype/FaceTime or from a local radio studio.

It's off the back of a new report that says Ebola there is a 50% chance that Ebola will reach the UK and 75% chance it will France within a few weeks. So we are looking to discuss how effective screening is at major transit points.

Would be able to talk to us about this? We would like to do the interview in the next couple of days.

Best Wishes

James

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 6:25 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Sorry Heinz
What is the VS? I can look into it.
Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:20 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Yes - even though Darryl seems to have better data with the other type of drugs.

We need the vaccine for the outbreak. I heard that NIH is getting involved in the VS? trial - true? If so, is there a role for us?

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:17 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Also some anti-inflammatory drugs might be helpful.

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:12 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Sounds good. There are some candidate drugs that interfere with coagulation and/or seal the endothelium. One of those might be interesting.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Cornelia Ceianu <ceianu@CANTACUZINO.RO>
Sent: Monday, October 06, 2014 4:58 AM
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation

unfortunately, if a screening would not be possible fast, we will meet problems in correctly diagnosing malaria patients

Cornelia Ceianu
Bucharest

> Hi Anders,
> Herewith a recent WHO recommendation that Ebola testing and
> malaria/leptospirosis testing on Ebola suspected cases can be done at
> bsl3. The EC based on recommendations of the quandhip consortium has
> just decided that it must be done at bsl4. Which is a bit weird of
> course to ask bsl4 labs whether it should be done at bsl4 without
> consulting a consortium like ENIVD specialized in clinical diagnostic
> procedures of these kind of viruses. So safest is to ask your ministry
> of health to confirm that your working procedure, which you need to
> carefully describe, is safe on basis of the WHO recommendation. We
> have also made sure before getting approval of the ministry that our
> national working procedure were agreed upon by all experts in the
> Netherlands. In addition we asked our biological safety manager and
> the board of our institute to sign a letter stating that our lab and the procedures around our lab are safe.
> Yours Martin
>
>
> Martin Schutten PhD
> Head unit clinical virology
> Erasmus University hospital Rotterdam
>
>
> ----- Oorspronkelijk bericht -----
> Van: Anders Fomsgaard
> Datum:05-10-2014 10:55 (GMT+01:00)
> Aan: ENIVD-L@LISTSERV.DFN.DE
> Onderwerp: Re: Ebola standard preparation
>
> Dear Martin Schutten, Herve Zeller, Mathias others?
> I completely agree with Martin's comments below, BUT ... The issue of
> diagnostic PCR testing of obs Ebola patients in a non-BSL4 lab has
> occurred again in from our safety authorities in Denmark.
> They simply do not graduate "targeted and non-targeted testings") and
> require that diagnostic work of an BSL4 organism MUST be in BSL4 lab
> (which we don't have in DK) – they don't seem to understand bedside
> inactivation either!?

Feldmann, Heinrich (NIH/NIAID) [E]

From: FREEMAN DELINE, Nancy <delinen@who.int>
Sent: Monday, October 06, 2014 3:58 AM
To: UMALI DALANGIN, Khristeen; WAI, Lokky; WERTSCHNIG, Brian Adam
Cc: goarn; mwanamwenge@who.int; GASASIRA, Alex Ntale; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; NYONPLUE, Richard G.; MWANAMWENG, Abrahams
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Yes he will be picked up. Richard and Abraham please take note. He will be arriving on SN Brussels.

Regards,
Nancy

From: UMALI DALANGIN, Khristeen
Sent: Monday, October 06, 2014 7:14 AM
To: WAI, Lokky; WERTSCHNIG, Brian Adam
Cc: FREEMAN DELINE, Nancy; goarn; mwanamwenge@who.int; GASASIRA, Alex Ntale; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Lokky, Brian,

Dr Heinz Feldmann is arriving tonight in Monrovia. Could you kindly confirm airport transfer tonight to pick him up? He will arrive with four pieces of luggage including one oversize piece (not too big). As previously requested, the driver needs to bring him to the Kendeja Hotel. Dr Feldmann has already a room at that hotel.

Thanks,

Khristeen

From: WAI, Lokky
Sent: 28 September 2014 22:00
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: FREEMAN DELINE, Nancy; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Well noted. Even if you want to stay in the Royal 'whatever' hotel it is not possible as they are all full. The drivers will take the passengers to Kendeja Hotel from the airport as requested. Thank you
Lokky

Sent from my iPhone

On 28 Sep 2014, at 18:37, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Please be advised that our team members are not staying at the Royal 'whatever' hotel! This is important and happened to the last team (team 2). Our team stays at the Kendeja hotel and the driver should transport them to the Kendeja as we have rooms booked for Kyle Rosenke, Kristin McNally and myself at the Kendeja.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Anja.WOLZ@geneva.msf.org
Sent: Monday, October 06, 2014 2:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Berlin

When will you be in Monrovia? Call me my number is Personal Info
Anja

Sent from IBM Notes Traveler

Feldmann, Heinrich (NIH/NIAID) [E] --- Re: Berlin ---

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher,Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "Ilia.Semmler@tmf-ev.de" <Ilia.Semmler@tmf-ev.de>, "jricht@vet.k-state.edu" <jricht@vet.k-state.edu>
Date: Sun, Oct 5, 2014 11:09
Subject: Re: Berlin

I guess we have to move on.

Ilia and Juergen, please make necessary changes.

Anja - I may see you in Monrovia. I am on my way.

Heinz

From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
Sent: Sunday, October 05, 2014 03:15 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de) <Ilia.Semmler@tmf-ev.de>; Juergen Richt <jricht@vet.k-state.edu>
Subject: RE: Berlin

Dear Heinz, I'm sorry but I have to cancel my participation.
Again I have to stay longer in West Africa and I will not be back in time for the meeting.
I'm really sorry for this,
But maybe Armand you know someone else?
Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher,Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "Semmler, Ilia" (Ilia.Semmler@tmf-ev.de) <Ilia.Semmler@tmf-ev.de>, Juergen Richt <jricht@vet.k-state.edu>


Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Monday, October 06, 2014 12:29 AM
To: 'Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US)'; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Kobinger, Gary (Public Health Agency of Canada); Allen.Grolla@phac-aspc.gc.ca
Subject: RE: Primers (UNCLASSIFIED)

Hi Mark,

Sorry for the slow response. I am not sure what you mean by what is the ZEBOV L assay target? The target is the L (polymerase) gene. I will assume you actually want the sequences?

Redacted by agreement



These primers were designed by the National Microbiology Laboratory in Winnipeg, Canada. I have copied Gary Kobinger and Allen Grolla. I would be best to contact them with any design and validation questions.


I will have to get back to you to confirm the sequences for the VSV-N assay.

Best regards,
Darryl

-----Original Message-----

From: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US) [mailto:mark.j.wolcott.civ@mail.mil]
Sent: Thursday, October 02, 2014 1:33 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
Subject: RE: Primers (UNCLASSIFIED)

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: WAI, Lokky <wail@who.int>
Sent: Monday, October 06, 2014 12:17 AM
To: UMALI DALANGIN, Khristeen
Cc: WERTSCHNIG, Brian Adam; FREEMAN DELINE, Nancy; goarn; mwanamwenge@who.int; GASASIRA, Alex Ntale; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Khristeen,
No problem. The passenger will be picked up and dropped at the Kendeja Hotel as per your request. Thank you Lokky

Sent from my iPhone

On 6 Oct, 2014, at 6:13 am, "UMALI DALANGIN, Khristeen" <umalik@who.int> wrote:

Dear Lokky, Brian,

Dr Heinz Feldmann is arriving tonight in Monrovia. Could you kindly confirm airport transfer tonight to pick him up? He will arrive with four pieces of luggage including one oversize piece (not too big). As previously requested, the driver needs to bring him to the Kendeja Hotel. Dr Feldmann has already a room at that hotel.

Thanks,

Khristeen

From: WAI, Lokky
Sent: 28 September 2014 22:00
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: FREEMAN DELINE, Nancy; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Well noted. Even if you want to stay in the Royal 'whatever' hotel it is not possible as they are all full. The drivers will take the passengers to Kendeja Hotel from the airport as requested. Thank you
Lokky

Sent from my iPhone

On 28 Sep 2014, at 18:37, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Please be advised that our team members are not staying at the Royal 'whatever' hotel! This is important and happened to the last team (team 2). Our team stays at the Kendeja hotel and the driver should transport them to the Kendeja as we have rooms booked for Kyle Rosenke, Kristin McNally and myself at the Kendeja.

Feldmann, Heinrich (NIH/NIAID) [E]

From: WAI, Lokky <wail@who.int>
Sent: Monday, October 06, 2014 12:16 AM
To: UMALI DALANGIN, Khristeen
Cc: WERTSCHNIG, Brian Adam; FREEMAN DELINE, Nancy; goarn; mwanamwenge@who.int; GASASIRA, Alex Ntale; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Sent from my iPhone

On 6 Oct, 2014, at 6:13 am, "UMALI DALANGIN, Khristeen" <umalik@who.int> wrote:

Dear Lokky, Brian,

Dr Heinz Feldmann is arriving tonight in Monrovia. Could you kindly confirm airport transfer tonight to pick him up? He will arrive with four pieces of luggage including one oversize piece (not too big). As previously requested, the driver needs to bring him to the Kendeja Hotel. Dr Feldmann has already a room at that hotel.

Thanks,

Khristeen

From: WAI, Lokky
Sent: 28 September 2014 22:00
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: FREEMAN DELINE, Nancy; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Well noted. Even if you want to stay in the Royal 'whatever' hotel it is not possible as they are all full. The drivers will take the passengers to Kendeja Hotel from the airport as requested. Thank you
Lokky

Sent from my iPhone

On 28 Sep 2014, at 18:37, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Please be advised that our team members are not staying at the Royal 'whatever' hotel! This is important and happened to the last team (team 2). Our team stays at the Kendeja hotel and the driver should transport them to the Kendeja as we have rooms booked for Kyle Rosenke, Kristin McNally and myself at the Kendeja.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Diarra, Bassirou
Sent: Sunday, October 05, 2014 2:54 PM
To: Nwakanma Davis
Cc: Secka Ousman; Feldmann, Heinrich (NIH/NIAID) [E]; Koita, Ousmane
Subject: Testing for suspected Ebola samples

Dear Dr. Davis,
Hope you are fine,

Please with regards to your request, here is Dr. Heinz Feldmann at the Rocky Mountain Laboratory who helped us for our Ebola platform testing.
Dr. Heinz, please meet by e-mail Dr. Davis from the MRC unit The Gambia who is interested to test Ebola suspected cases in the Gambia.

Dr. Davis, you also may know Pr. Ousmane Koita the actual Director of SEREFO laboratories, he may help you for your set up.

Best regards and happy Tobaski in the Gambia

Bassirou

.....
Bassirou DIARRA, MD, MSc Tropical Medicine
SEREFO (HIV/TB Research and Training Center)
FMOS, University of STT, Bamako; Mali
Office: 00223 20 22 67 86
Fax: 00223 20 22 75 13
cell: Personal Info

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kelly Keith <kelly.keith@phac-aspc.gc.ca>
Sent: Sunday, October 05, 2014 1:55 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: VSV Ebola vaccine

Thank you! I look forward to hearing from Andrea.

(Ms.) G. Kelly Keith

Community Liaison Program Manager / National Microbiology Laboratory / Infectious Disease Prevention and Control Branch
Canadian Science Centre for Human and Animal Health
Public Health Agency of Canada / Government of Canada
kelly.keith@phac-aspc.gc.ca / Tel: 204-789-5028 / Cell: Personal Info

Gestionnaire de programme, Liaison avec la collectivité / Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses
Centre scientifique canadien de la santé humaine et animale
Agence de la santé publique du Canada / Gouvernement du Canada
kelly.keith@phac-aspc.gc.ca / Tél. : 204-789-5028 / Tél Cell. Personal Info

▼ "Feldmann, Heinrich (NIH---2014-10-03 05:49:14 PM---Kelly, We just submitted an addendum - as soon as approved Andrea will provide you with the original

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: 'Kelly Keith' <kelly.keith@phac-aspc.gc.ca>, "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov>
Cc: "Pekoc, Ken (NIH/NIAID) [E]" <kpekoc@niaid.nih.gov>, "jim.strong@phac-aspc.gc.ca" <jim.strong@phac-aspc.gc.ca>, "Kobinger, Gary (Public Health Agency of Canada)" <gary.kobinger@phac-aspc.gc.ca>
Date: 2014-10-03 05:49 PM
Subject: RE: VSV Ebola vaccine

Kelly,

We just submitted an addendum – as soon as approved Andrea will provide you with the original protocol and the addendum. Please use the documents for internal use only.

Hope things are going well.

Best wishes,
Heinz

From: Kelly Keith [<mailto:kelly.keith@phac-aspc.gc.ca>]
Sent: Friday, October 03, 2014 12:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Sunday, October 05, 2014 1:21 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: CMX-001

CDC is suggesting we try based on in vitro data.
Let's reconsider a therapeutic trial when you get in Monrovia.
Be safe,
Ali

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Sunday, October 5, 2014 1:56 PM
To: Khan, Ali S
Subject: Re: CMX-001

I do not know. I am on my way to Monrovia. I heard you will receive the

Redacted by agreement

Heinz

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 05, 2014 10:51 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CMX-001

Being used for Ebola?
Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 1:18 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Also some anti-inflammatory drugs might be helpful.

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:12 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Sounds good. There are some candidate drugs that interfere with coagulation and/or seal the endothelium. One of those might be interesting.

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:06 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Thanks Heinz. We can see how they fair and decide what if any might be the best combination.
K

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 02:42 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 1:07 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10


Thanks Heinz. We can see how they fair and decide what if any might be the best combination.
K

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 02:42 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Redacted by agreement



Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 01:46 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

This is pretty interesting. We know that different IFNs can have different virus specificity. I wonder how much, if any, delay in virus replication might be useful.
Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 12:40 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kobinger, Gary (Public Health Agency of Canada)
Sent: Sunday, October 05, 2014 12:08 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'Hayden, Frederick G *HS'; Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]
Subject: Re: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Not us

-----Original Message-----

From: Heinz Feldmann
To: 'Hayden, Frederick G *HS'
To: Lisa Hensley
To: Olinger, Gene (NIH/NIAID) [C]
To: Gary Kobinger
Subject: RE: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic
Sent: Oct 3, 2014 19:13

Let those people speak to it who actually did the mouse studies.

-----Original Message-----

From: Hayden, Frederick G *HS [<mailto:FGH@hscmail.mcc.virginia.edu>]
Sent: Friday, October 03, 2014 8:14 AM
To: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic
Importance: High

Help - any knowledge (data) on this remarkable formulation of repurposed drugs? Who has done the murine model work? As a Stanford graduate myself, I know it must be good. Please feel free to call me directly Personal Info. Thanks in advance for any insights, fgh

From: Shalabh Gupta, MD, MPA [shalabh.gupta@globavir.com]
Sent: 03 October 2014 02:59
To: Hayden, Frederick G *HS; fgh@virginia.edu
Cc: friedem@who.int; kienym@who.int
Subject: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Dear Dr. Hayden.

I am taking this opportunity to follow up with you regarding the email chain between you and Dr. John Ryan. Dr. John Ryan is on our Board of Directors as well as has been a mentor to our team to develop our drugs.

I wanted to provide you some details on our company and our drugs.

* Our lead drug, which was licensed from Stanford University, has shown potent efficacy in cellular models of Ebola infection, and further yielded 100% survival in an Ebola mouse model. What sets our therapy apart from other developmental therapies is that our candidate is a combination of two previously approved drugs, and thus safety and manufacturing hurdles are largely mitigated. In the mouse study, for example, the dose given to mice was equivalent to the dosage approved in humans for chronic use. Additionally, our drug targets host pathways hijacked by the virus rather than targeting the virus itself, which provides 2 benefits: 1) Proven b

Feldmann, Heinrich (NIH/NIAID) [E]

From: Kobinger, Gary (Public Health Agency of Canada)
Sent: Sunday, October 05, 2014 12:07 PM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Side effects

I don't, I have several simian Ads-ZGP but it would need to be the same to be meaningful. Ask Nancy or is she not sharing? I never asked her any reagents so I don't know.

If she is not sharing then that would be breaking publication agreements, and then she shouldn't publish. Old stuff but never too late to do good (enforce).

Take care

Gary

-----Original Message-----

From: Geisbert, Thomas W.
To: Heinz Feldmann
To: Gary Kobinger
Subject: RE: Side effects
Sent: Oct 2, 2014 20:09

It is hard to say right now with N being so small. Gary, on the ChAd do you know of anyone that has the ChAd3 Ebola GP vectors other than VRC. Someone needs to test that against a 7U virus.

Tom
From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov] Sent: Wednesday, October 01, 2014 1:06 PM To: Geisbert, Thomas W.; Kobinger, Gary (Public Health Agency of Canada) Subject: RE: Side effects Gary – could it be related to the higher dose (1×10^8)? [Redacted by agreement] The Profectus backbone vector obviously did not show any adverse effects if you look at the HIV phase I trial – why do you think there is such a difference? Tom?

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU] Sent: Wednesday, October 01, 2014 6:42 AM To: Kobinger, Gary (Public Health Agency of Canada); Feldmann, Heinrich (NIH/NIAID) [E] Subject: RE: Side effects

Gary,

Do you mean the German case?

Tom
From: Gary Kobinger [gary.kobinger@phac-aspc.gc.ca] Sent: Wednesday, October 01, 2014 3:55 AM To: Heinz Feldmann; Geisbert, Thomas W. Subject: Side effects

[Redacted by agreement]

[Redacted by agreement]

This may be supporting your profectus VSV even more. I still think that Ad won't reach 90% protection, I speculate 30-40 range.
CheersGary

Feldmann, Heinrich (NIH/NIAID) [E]

From: Heinz Feldmann <heinz_feldmann@yahoo.ca>
Sent: Sunday, October 05, 2014 12:00 PM
To: koch.eva_maria@yahoo.at
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Fw: Frage ad Ebola und PS

Die Uebertragung von Ebola geschieht normalerweise durch Kontakt mit Infizierten und Verstorbenen entweder durch direkten Kontakt oder ueber Koerperfluessigkeiten. Es gibt keinerlei Hinweis das Aerosoluebertragung eine Rolle spielt bei der natuerlichen Mensch-zu-Mensch-Uebertragung. Wenn man in engen Kontakt mit Infizierten ist sollte man jedoch sicherstellen, dass Schleimhaeute oder ander moeglichen Eintrittswege geschuetzt sind (z.B.: Munschutzhandschuhe oder besser N95-Maske; Augenschutz; Handschuhe). Dies hat nichts mit Aerosoluebertragung zu tun, aber es verhindert direkten Kontakt von Schleimhaeuten mit Virus in Troefchen, die durch verschiedene Manipulationen oder Verhaltensweisen des Patienten entstehen koennen.

Die meisten Infektionen in Westafrika entstehen durch direkten Kontakt mit Infizierten und Verstorbenen. Die Bevoelkerung hat keine entsprechenden Schutzartikel, die sie vor Uebertragung schuetzen wuerden. In Sachen Infektionen von medizinischem Personal spielt die unsachgemaesse Handhabung von Schutzartikeln sowie Ueberarbeitung unter unguenstigen Bedingungen eine grosse Rolle.

Die Ausbreitung in Westafrika ist unter anderem eine Konsequenz von fehlendem 'contact tracing' in der Bevoelkerung und der Tatsache, dass nicht genugend Behandlungszentren vorhanden sind. Dies ist natuerlich anders in den USA oder den europaeischen Laendern, wo 'contract tracing' entsprechend durchgefuehrt werden kann und man natuerlich extrem vorsichtig ist. Ich habe wenig Bedenken in diesen Laendern und glaube, dass die nationalen Gesundheitssysteme eine Verbreitung des Virus schnell unterbinden. Dies heisst nicht, dass es keine Sekundaerinfektionen geben kann, aber wahrscheinlich nur sehr bedingt und sie wuerden schnell unter Kontrolle gebracht.

Ich hoffe, dass beantwortet einige Ihrer Fragen.

Ich bin jetzt in Monrovia und werde nur sehr selten auf Email antworten koennen.

Viele Gruesse,
Heinz Feldmann

PS: Bitte entschuldigen Sie eventuelle Sprachfehler in dieser Nachricht.

On Sun, 10/5/14, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Subject: Fw: Frage ad Ebola und PS
To: "'Heinz_Feldmann@yahoo.ca'" <Heinz_Feldmann@yahoo.ca>
Received: Sunday, October 5, 2014, 5:34 AM

----- Original Message -----

From: Koch Eva maria [mailto:koch.eva_maria@yahoo.at]
Sent: Sunday, October 05, 2014 04:44 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 11:46 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

This is pretty interesting. We know that different IFNs can have different virus specificity. I wonder how much, if any, delay in virus replication might be useful.

Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 12:40 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: RE: NHP update - day 10

Redacted by agreement

Darryl

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 6:30 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Thanks for the update Darryl

Redacted by agreement

Kathy

Sent from my BlackBerry Wireless Handheld

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 02:22 AM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: NHP update - day 10

Redacted by agreement

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 10:41 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: RE: NHP update - day 10

Redacted by agreement

Darryl

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 6:30 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Thanks for the update Darryl

Redacted by agreement

Kathy

Sent from my BlackBerry Wireless Handheld

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 02:22 AM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: NHP update - day 10

Redacted by agreement

Thanks,
Darryl

Feldmann, Heinrich (NIH/NIAID) [E]

From: Juergen Richt <jricht@vet.k-state.edu>
Sent: Sunday, October 05, 2014 9:47 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Anja.WOLZ@geneva.msf.org; Ilia.Semmler@tmf-ev.de
Subject: Re: Berlin

I have to refer to Ilia on this.
Safe travels ,
Juergen

> On Oct 5, 2014, at 9:35 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>

> It looks like they are fine now - Ilia and Juergen?

>

> ----- Original Message -----

> From: Sprecher, Armand (Médecins Sans Frontières Operational Center of
> Brussels)

> Sent: Sunday, October 05, 2014 08:04 AM Eastern Standard Time

> To: Feldmann, Heinrich (NIH/NIAID) [E]

> Cc: Anja WOLZ <Anja.WOLZ@geneva.msf.org>; Ilia.Semmler@tmf-ev.de

> <Ilia.Semmler@tmf-ev.de>; jricht@vet.k-state.edu

> <jricht@vet.k-state.edu>

> Subject: Re: Berlin

>

>

> Heinz,

>

> Do you need someone back from the field, or someone who can speak for MSF?

> I can put you in contact with MSF-Germany, who may well have returned

> expats who may fit your needs.

>

> Sent from my iPhone

>

>>> On Oct 5, 2014, at 1:09 PM, "Feldmann, Heinrich (NIH/NIAID) [E]"

>> <feldmannh@niaid.nih.gov> wrote:

>>

>> I guess we have to move on.

>>

>> Ilia and Juergen, please make necessary changes.

>>

>> Anja - I may see you in Monrovia. I am on my way.

>>

>> Heinz

>>

>> From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]

>> Sent: Sunday, October 05, 2014 03:15 AM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]

From: Khan, Ali S <ali.khan@unmc.edu>
Sent: Sunday, October 05, 2014 8:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CMX-001

Being used for Ebola?

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Herve Zeller <Herve.Zeller@ECDC.EUROPA.EU>
Sent: Sunday, October 05, 2014 8:15 AM
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation
Attachments: ACDP HPE VHF guidance 12.08.2014[1].pdf; WHO_EVD_GUIDANCE_LAB_14_1_eng.pdf; Guidelines lab diag safe work practice CDC 2012.pdf; ATT00001.txt

Dear Anders,

The ECDC algorithm http://ecdc.europa.eu/en/healthtopics/ebola_marburg_fevers/algorithm-evd-diagnosis/Pages/default.aspx

indicates that EVD testing should be performed in BSL 3 or BSL4. For other testing, there is no specific mention.

- Quandhip mentions that other testing should be done in BSL4 which is not feasible in most of the cases.
- The HPE (UK) guidance provides some indications cf pages 58-60
- The WHO EVD guidance reported by Martin is the last updated document to my knowledge.
- I added also the CDC 2012 guidelines and the referenced link in the algorithm:
<http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-specimen-collection-submission-patients-suspected-infection-ebola.html>

Best
Herve

From: Europäischen Netzwerkes zur Diagnostik von "importierten" Virusinfektionen [mailto:ENIVD-L@LISTSERV.DFN.DE]
On Behalf Of Anders Fomsgaard
Sent: 05 October 2014 10:55
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation

Dear Martin Schutten, Herve Zeller, Mathias others?

I completely agree with Martin's comments below, BUT ...

The issue of diagnostic PCR testing of obs Ebola patients in a non-BSL4 lab has occurred again in from our safety authorities in Denmark.

They simply do not graduate "targeted and non-targeted testings") and require that diagnostic work of an BSL4 organism MUST be in BSL4 lab (which we don't have in DK) – they don't seem to understand bedside inactivation either!?

Can somebody help with approved (preferentially EU, ENIVD, eCDC) approved guidelines to show them and explain that it is OK to test in a BSL3 lab by diagnostic ebola etc PCR on bedside inactivated blood samples from suspected cases?

It could be a general problem?

Yours

Anders Fomsgaard, Professor MD DMSc
Chief of Virus R&D Laboratory (ViFU)
BSL3 laboratory build.87

Feldmann, Heinrich (NIH/NIAID) [E]

From: M.P.G. Koopmans <m.koopmans@ERASMUSMC.NL>
Sent: Sunday, October 05, 2014 8:04 AM
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation

Hi Anders

This discrepancy between BSL3/4 assessment, comes from the different approaches in the biosecurity/ personnel protection guidelines versus the clinical/microbiological guidelines. This is a continuous issue that we have dealt with as Martin described. The question of combining with clinical chemistry is also something that comes up a lot. We have decided to do essential clin chem in th BSLIII lab, because of issues around reliability / evidence of inactivation protocols. For the guanidine based buffers, that is one thing, but for the other inactivation protocols (heat, triton, a.o.) there either is not conclusive evidence of inactivation of Ebola, or the clin chemistry does not work properly anymore.

Based on these observations, we are putting together a validation experiment, so will keep you informed of protocols.

Another question: what are views about paralel testing: we split our diagnostic requests and run them in paralel in a BSL4. This of course delays things, even if our colleagues do a terrific job at fast confirmation. Does everyone do that?

Marion

As martin explained, the real issue here is that the European Commission and WHO have seemingly differing guidance.

On 05 Oct 2014, at 15:34, Silvia Bino Personal Info > wrote:

here there are WHO EVD lab recommendations, they help a lot even it is not easy.

Biosafety recommendations for laboratories conducting diagnostic testing for EVD with appropriate biosafety level 4 (BSL4)/BSL3 facilities

- Virus isolation should be done only in a maximum containment BSL4 laboratory. Ensure safe and secure handling and storage of the virus isolates and other specimens from accidental or deliberate release.
- The inactivation of specimens, depending on the detection protocol used, should be performed under BSL3 conditions.
- For non-inactivated samples, RT PCR and enzyme-linked immunosorbent assay

Feldmann, Heinrich (NIH/NIAID) [E]

From: Meyer Institut für Mikrobiologie der Bundeswehr
<Hermann1Meyer@BUNDESWEHR.ORG>
Sent: Sunday, October 05, 2014 8:01 AM
To: ENIVD-L@LISTSERV.DFN.DE
Subject: AUTO: Dr. Hermann 1 Meyer/ZSanDBw/BMVg/DE ist außer Haus.

Ich werde ab 25.09.2014 nicht im Büro sein. Ich kehre zurück am 06.10.2014.

Hinweis: Dies ist eine automatische Antwort auf Ihre Nachricht "Re: Ebola standard preparation" gesendet am 05.10.2014 15:34:00.

Diese ist die einzige Benachrichtigung, die Sie empfangen werden, während diese Person abwesend ist.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Silvia Bino [Personal Info]
Sent: Sunday, October 05, 2014 7:34 AM
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation

here there are WHO EVD lab recommendations, they help a lot even it is not easy.

Biosafety recommendations for laboratories conducting diagnostic testing for EVD with appropriate biosafety level 4 (BSL4)/BSL3 facilities

- Virus isolation should be done only in a maximum containment BSL4 laboratory. Ensure safe and secure handling and storage of the virus isolates and other specimens from accidental or deliberate release.
- The inactivation of specimens, depending on the detection protocol used, should be performed under BSL3 conditions.
- For non-inactivated samples, RT PCR and enzyme-linked immunosorbent assay (ELISA) testing can be performed at a BSL3 laboratory.
- If samples have been inactivated (i.e. cell lysis) RT PCR and ELISA testing can be performed at a BSL2 laboratory

Biosafety recommendations for laboratories conducting diagnostic testing for EVD without appropriate BSL3/BSL4 facilities

- Specimens for either PCR or ELISA testing should be processed inside a Class III biosafety cabinet (glovebox) with current certification in a separate laboratory area.
- Following inactivation, specimens can be removed from the glovebox and all other procedures performed under BSL2 conditions.
- Use appropriate Personal Protective Equipment (PPE) when handling the specimens before inactivation: gloves, fit-tested masks such as N95 Respirators and Filtering Face Piece (FFP) 3, Powered Air Purifying Respirators (PAPR) if fit-testing fails, full face shields, and disposable impermeable gowns.

On Sun, Oct 5, 2014 at 11:35 AM, Brown, Caroline Sarah (DCE-IRP) <cbr@euro.who.int> wrote:

Dear Anders,

The WHO EDV lab testing guidelines recommend testing at BSL3 for non-inactivated and BSL2 for inactivated samples. The guidelines do not address bioch or haem testing labs.

Hope this helps.

Kind regards

Caroline

From: Anders Fomsgaard [mailto:AFO@SSI.DK]
Sent: Sunday, October 05, 2014 10:50 AM
To: ENIVD-L@LISTSERV.DFN.DE <ENIVD-L@LISTSERV.DFN.DE>
Subject: Re: Ebola standard preparation

Feldmann, Heinrich (NIH/NIAID) [E]

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 6:30 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Thanks for the update Darryl

Redacted by agreement

Kathy

Sent from my BlackBerry Wireless Handheld

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 02:22 AM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: NHP update - day 10

Redacted by agreement

Thanks,
Darryl

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Sunday, October 05, 2014 6:05 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Anja WOLZ; Ilia.Semmler@tmf-ev.de; jricht@vet.k-state.edu
Subject: Re: Berlin

Heinz,

Do you need someone back from the field, or someone who can speak for MSF?
I can put you in contact with MSF-Germany, who may well have returned expats who may fit your needs.

Sent from my iPhone

> On Oct 5, 2014, at 1:09 PM, "Feldmann, Heinrich (NIH/NIAID) [E]"
<feldmannh@niaid.nih.gov> wrote:
>
> I guess we have to move on.
>
> Ilia and Juergen, please make necessary changes.
>
> Anja - I may see you in Monrovia. I am on my way.
>
> Heinz
>
> From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
> Sent: Sunday, October 05, 2014 03:15 AM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of
Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de) <Ilia.Semmler@tmf-ev.de>; Juergen Richt <jricht@vet.k-state.edu>
> Subject: RE: Berlin
>
> Dear Heinz, I'm sorry but I have to cancel my participation.
> Again I have to stay longer in West Africa and I will not be back in
> time
for the meeting.
> I'm really sorry for this,
> But maybe Armand you know someone else?
> Anja Wolz
> Operational Adviser Ebola
> MSF-Switzerland
> +41 796186933
>
>
>
> From: "Feldmann, Heinrich (NIH/NIAID) [E]"
<feldmannh@niaid.nih.gov>
> To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Marlovits,Thomas <Thomas.Marlovits@imba.oeaw.ac.at>
Sent: Sunday, October 05, 2014 5:30 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Question related to cDNAs

Dear Thomas,

thank you very much for getting back so quickly.

We would be interested in understanding more about replication processes - so everything that is needed to initiate and continue RNA polymerization would be required. RNA-dep RNA polym L plus additional factors. In case you would be interested in a joint effort, please let me know - I'd highly appreciate.

Looking at the small number of genes present on the entire genome, it may be just helpful if you would be willing to share cDNAs for all the components (after all, there are not so many, and we would also then try to do biochemical interaction studies).

Would you be also interested in pursuing any studies to identify novel host-factors for pathogenic interactions? I am sure you are aware of the work published in nature 2011 using haploid cells to identify such factors for ebola (<http://www.ncbi.nlm.nih.gov/pubmed/218661030>). We might be able to so similar experiments here as well (provided that we do not need more than a BS2 level laboratory) also for other pathogens.

Let me know, what you think ...

-T.

On Oct 4, 2014, at 7:32 AM, "Hoenen, Thomas (NIH/NIAID) [F]" <thomas.hoenen@nih.gov> wrote:

Dear Thomas,

Can you provide a little more detail, so that I know what constructs you will need? Looking at your publications I assume you are coming from a more structural perspective? I myself have been studying genome replication and transcription of Ebola viruses for almost 10 years now, so I might be able to help...

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408

Feldmann, Heinrich (NIH/NIAID) [E]

From: Brown, Caroline Sarah (DCE-IRP) <cbr@EURO.WHO.INT>
Sent: Sunday, October 05, 2014 3:35 AM
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation

Dear Anders,

The WHO EDV lab testing guidelines recommend testing at BSL3 for non-inactivated and BSL2 for inactivated samples. The guidelines do not address bioch or haem testing labs.

Hope this helps.

Kind regards

Caroline

From: Anders Fomsgaard [mailto:AFO@SSI.DK]
Sent: Sunday, October 05, 2014 10:50 AM
To: ENIVD-L@LISTSERV.DFN.DE <ENIVD-L@LISTSERV.DFN.DE>
Subject: Re: Ebola standard preparation

Dear Martin Schutten, Herve Zeller, Mathias others?

I completely agree with Martin's comments below, BUT ...

The issue of diagnostic PCR testing of obs Ebola patients in a non-BSL4 lab has occurred again in from our safety authorities in Denmark.

They simply do not graduate "targeted and non-targeted testings") and require that diagnostic work of an BSL4 organism MUST be in BSL4 lab (which we don't have in DK) – they don't seem to understand bedside inactivation either!?

Can somebody help with approved (preferentially EU, ENIVD, eCDC) approved guidelines to show them and explain that it is OK to test in a BSL3 lab by diagnostic ebola etc PCR on bedside inactivated blood samples from suspected cases?

It could be a general problem?

Yours

Anders Fomsgaard, Professor MD DMSc
Chief of Virus R&D Laboratory (ViFU)
BSL3 laboratory build.87
Departments og Microbiologic Diagnostic & Virology
Statens Serum Institut
5 Artillerivej
DK-2300 Copenhagen, Denmark
Tel: +45-3268 3460 / +45-4063 4638; fax: +45-3268 3148
e-mail: afo@ssi.dk

From: Europäischen Netzwerkes zur Diagnostik von "importierten" Virusinfektionen [mailto:ENIVD-L@LISTSERV.DFN.DE]
On Behalf Of M. Schutten
Sent: 11. august 2014 11:39
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation

Feldmann, Heinrich (NIH/NIAID) [E]

From: M. Schutten <m.schutten@ERASMUSMC.NL>
Sent: Sunday, October 05, 2014 3:29 AM
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation
Attachments: WHO_EVD_GUIDANCE_LAB_14.1_eng.pdf

Hi Anders,

Herewith a recent WHO recommendation that Ebola testing and malaria/leptospirosis testing on Ebola suspected cases can be done at bsl3. The EC based on recommendations of the quandhip consortium has just decided that it must be done at bsl4. Which is a bit weird of course to ask bsl4 labs whether it should be done at bsl4 without consulting a consortium like ENIVD specialized in clinical diagnostic procedures of these kind of viruses. So safest is to ask your ministry of health to confirm that your working procedure, which you need to carefully describe, is safe on basis of the WHO recommendation. We have also made sure before getting approval of the ministry that our national working procedure were agreed upon by all experts in the Netherlands. In addition we asked our biological safety manager and the board of our institute to sign a letter stating that our lab and the procedures around our lab are safe.

Yours Martin

Martin Schutten PhD
Head unit clinical virology
Erasmus University hospital Rotterdam

----- Oorspronkelijk bericht -----

Van: Anders Fomsgaard
Datum: 05-10-2014 10:55 (GMT+01:00)
Aan: ENIVD-L@LISTSERV.DFN.DE
Onderwerp: Re: Ebola standard preparation

Dear Martin Schutten, Herve Zeller, Mathias others?

I completely agree with Martin's comments below, BUT ...

The issue of diagnostic PCR testing of obs Ebola patients in a non-BSL4 lab has occurred again in from our safety authorities in Denmark.

They simply do not graduate "targeted and non-targeted testings") and require that diagnostic work of an BSL4 organism MUST be in BSL4 lab (which we don't have in DK) – they don't seem to understand bedside inactivation either!?

Can somebody help with approved (preferentially EU, ENIVD, eCDC) approved guidelines to show them and explain that it is OK to test in a BSL3 lab by diagnostic ebola etc PCR on bedside inactivated blood samples from suspected cases?

It could be a general problem?

Yours

Anders Fomsgaard, Professor MD DMSc
Chief of Virus R&D Laboratory (ViFU)
BSL3 laboratory build.87
Departments og Microbiologic Diagnostic & Virology
Statens Serum Institut

Feldmann, Heinrich (NIH/NIAID) [E]

From: Anders Fomsgaard <AFO@SSI.DK>
Sent: Sunday, October 05, 2014 2:50 AM
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation

Dear Martin Schutten, Herve Zeller, Mathias others?

I completely agree with Martin's comments below, BUT ...

The issue of diagnostic PCR testing of obs Ebola patients in a non-BSL4 lab has occurred again in from our safety authorities in Denmark.

They simply do not graduate "targeted and non-targeted testings") and require that diagnostic work of an BSL4 organism MUST be in BSL4 lab (which we don't have in DK) – they don't seem to understand bedside inactivation either!?

Can somebody help with approved (preferentially EU, ENIVD, eCDC) approved guidelines to show them and explain that it is OK to test in a BSL3 lab by diagnostic ebola etc PCR on bedside inactivated blood samples from suspected cases?

It could be a general problem?

Yours

Anders Fomsgaard, Professor MD DMSc
Chief of Virus R&D Laboratory (ViFU)
BSL3 laboratory build.87
Departments og Microbiologic Diagnostic & Virology
Statens Serum Institut
5 Artillerivej
DK-2300 Copenhagen, Denmark
Tel: +45-3268 3460 / +45-4063 4638; fax: +45-3268 3148
e-mail: afo@ssi.dk

From: Europäischen Netzwerkes zur Diagnostik von "importierten" Virusinfektionen [mailto:ENIVD-L@LISTSERV.DFN.DE]
On Behalf Of M. Schutten
Sent: 11. august 2014 11:39
To: ENIVD-L@LISTSERV.DFN.DE
Subject: Re: Ebola standard preparation

I do not agree. A Biosafety level-4 (BSL-4) lab is not required for diagnosing VHF patients. In diagnostics labs all over the world it is very common to down-grade one or even two levels as long as you do not use virus culture as diagnostic assay. For both molecular assays and serology first step is/can be inactivation (either heat or lysis buffer or dilution with a soap containing buffer) after which down-grading one level or even two is possible. We have in diagnostic laboratories similar situations for HIV/HBV/HCV which are BSL-3 pathogens but handled for MDX/serology diagnostics in virtually all diagnostic laboratories over the whole world at level 2 (often even level 1!). It is of course good to liaise with a lab with lots of expertise (which is in general one of the BSL-4 labs) for confirmation testing.

A potentially bigger problem is other diagnostics then viral diagnostics and transport of patients. One of the first questions in the clinic is what blood type the patient has (even before virus diagnosis is needed). Samples are then sent to a lab that does diagnostics in a lab that doesn't even know what biosafety is in systems that are open and

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koch Eva maria Personal Info
Sent: Sunday, October 05, 2014 2:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Frage ad Ebola und PS

Sehr geehrter Herr Prof.Feldmann,

bitte verzeihen Sie die Belästigung, ich las in den Medien von Ihnen zu Ebola, und wollte Sie nun als Experten fragen, wie konkret der Ansteckungsweg ist ?

Denn irgendetwas stimmt doch hier bei der Berichterstattung nicht, auch seitens Virologen, einerseits heißt es, es ist nicht so hoch ansteckend, wie z B Influenza, weil nur über Körperflüssigkeiten ansteckend, aber auf der anderen Seite, ist die Ansteckungsrate doch extrem hoch, und die Warnungen (siehe aktuell bei dem USA Patienten, der evtl. mit über 100 Pers. Kontakt hatte) obwohl kein Kontakt zu Körperflüssigkeiten bestand und besteht.

Es aber dennoch ständig zu Ansteckungen kommt.

Was stimmt hier nicht ?

Wieso kommt es ständig zu Ansteckungen auch bei Ärzten und Pflegern ?

Welche Handschuhe sind Ebola sicher ?

Ich machte die Erfahrung, daß zB Latex- Handschuhe Clostridium Difficile durchlässig ist !

Dennoch sieht man sowohl in Österr. Spitälern als auch in den Ebola Gebieten überall auch Latex- Handschuhe.

Wäre Ihnen sehr dankbar für Ihre Antwort.

Mit besten Grüßen

Eva Koch

PS:

bezüglich allg. Statements nun, daß Ebola nur über Blut und Körperflüssigkeiten übertragen wird, und nicht, wie Gerüchte meinten, evtl. auch über Tröpfcheninfektion, wenn diese Ihre Meinung stimmt, wie erklären Sie dann die so extrem hohe Durchseuchungsrate, Ansteckungsrate, diese extremen Vorsichtsmaßnahmen und Warnungen und der Ansteckungen trotzdem ?!

Stimmt dies, dann gleicht ja HIV, Hepatitis C, etc. und diese Ansteckungen und Warnungen und Vorsichtsmaßnahmen sehen ja -zum Glück- ganz anders aus. Wenn auch tragische genug.

Da stimmt doch etwas nicht !

Mit freundlichen Grüßen

Feldmann, Heinrich (NIH/NIAID) [E]

From: Anja.WOLZ@geneva.msf.org
Sent: Sunday, October 05, 2014 1:15 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt
Subject: RE: Berlin

Dear Heinz, I'm sorry but I have to cancel my participation.
Again I have to stay longer in West Africa and I will not be back in time for the meeting.
I'm really sorry for this,
But maybe Armand you know someone else?
Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de)" <Ilia.Semmler@tmf-ev.de>, Juergen Richt <jricht@vet.k-state.edu>
Date: 23.09.2014 02:17
Subject: RE: Berlin

Anja,
We would like to invite you to present a talk on the Ebola outbreak in West Africa. The presentation is scheduled for Thursday, October 16 in the time from 16:30-17:30h.

Please let us know as soon as possible if you will accept our invitation.

Best wishes and stay safe,
Heinz

-----Original Message-----

From: Anja.WOLZ@geneva.msf.org [<mailto:Anja.WOLZ@geneva.msf.org>]
Sent: Saturday, September 20, 2014 12:54 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt
Subject: RE: Berlin


Dear Heinz for me it would be no problem to do an presentation but I don't know what is your timing I will be minimum 2 weeks in Liberia (maybe longer depend on the situation) Tell me what you think

Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 12:23 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: NHP update - day 10

Redacted by agreement



Thanks,
Darryl

Feldmann, Heinrich (NIH/NIAID) [E]

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 1:56 PM
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID)
Subject: Re: Expat sample

Great work,

Talk to the Libr guys for more gloves if needed. I can also reach out to the navy lab and see if they have supplies Which would be available for you guys. It is crazy that they can't get your stuff till after the weekend, did Kyle talk to the Brussels airline rep?

Might want to talk to darlington as well as he is moh, or talk to dawn Arlotta and see if she can do anything for you.

Currently stuck in Atlanta, new protocol for people traveling from Ebola countries. I hope I can still make my flight.

Sent from my iPhone

> On Oct 4, 2014, at 12:45, "McNally, Kristin (NIH/NIAID) [E]" <mcnallyk@niaid.nih.gov> wrote:

>

> Heavy sample load today with 56 already. ELWA 3 stopped bringing samples in the evening the last 2 days, which makes for busy mornings. We talked with them and they will bring us samples in the evening again. Our cutoff is 6:00 - this allows us to process them and get the pcrs running so we can give them results in the morning and that gets us out around 8 pm if we're lucky! Long days but we are working well as a team. Kyle is struggling without his personal bag and I don't blame him. It looks like the office won't be open until Monday to get them.

>

> Salomon said he's had no contact with his sister or brother.

>

> We are down to 2 boxes of long cuffed medium gloves and a few bags of smart cycled tubes so our bags would be helpful!

>

> Kristin

>

>

> Sent from my iPhone

>

>> On Oct 4, 2014, at 4:29 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>>

>> Kristin & Kyle,

>>

>> I just talked to Dawn - she is working on the case with absolute priority. She told me that she had talked to Kyle on the phone. I think this will be resolved soon. Please let me know immediately when you hear from them. Please contact me in any case.

>>

>> Hope things are well otherwise. How is the sample load today?

>>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dr P.D. Walsh <pdw36@cam.ac.uk>
Sent: Saturday, October 04, 2014 8:16 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CMV

Hi Heniz

I forgot to mention that I am also interested in the CMV vaccine, as a self-disseminating vaccine is something that I have always thought is the long term solution for Ebola and many other pathogens. I think that this is the kind of bold research that Paul Allen might like to fund.

But getting the people in Africa to accept the use of a self-disseminating vaccine in the wild will take some confidence building. As a step in that direction have you thought of doing captive trials in group housed NHP's (perhaps Chimps) to see how well the CMV vaccine spreads? Some work on the host specificity of CMV would also be useful in predicting spillover potential, while development of non-invasive fecal or urinary assays would allow for assessment of spillover rates in the field.

--

Peter D Walsh, PhD
Division of Biological Anthropology
University of Cambridge
(0)1223 764701
ApesInc.org
http://www.bioanth.cam.ac.uk/s_pwalsh.html

Feldmann, Heinrich (NIH/NIAID) [E]

From: Koch Eva maria Personal Info
Sent: Saturday, October 04, 2014 6:45 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Frage ad Ebola

Sehr geehrter Herr Prof.Feldmann,

bitte verzeihen Sie die Belästigung, ich las in den Medien von Ihnen zu Ebola, und wollte Sie nun als Experten fragen, wie konkret der Ansteckungsweg ist ?

Denn irgendetwas stimmt doch hier bei der Berichterstattung nicht, auch seitens Virologen, einerseits heißt es, es ist nicht so hoch ansteckend, wie z B Influenza, weil nur über Körperflüssigkeiten ansteckend, aber auf der anderen Seite, ist die Ansteckungsrate doch extrem hoch, und die Warnungen (siehe aktuell bei dem USA Patienten, der evtl. mit über 100 Pers. Kontakt hatte) obwohl kein Kontakt zu Körperflüssigkeiten bestand und besteht.

Es aber dennoch ständig zu Ansteckungen kommt.

Was stimmt hier nicht ?

Wieso kommt es ständig zu Ansteckungen auch bei Ärzten und Pflegern ?

Welche Handschuhe sind Ebola sicher ?

Ich machte die Erfahrung, daß zB Latex- Handschuhe Clostridium Difficile durchlässig ist !

Dennoch sieht man sowohl in Österr. Spitälern als auch in den Ebola Gebieten überall auch Latex- Handschuhe.

Wäre Ihnen sehr dankbar für Ihre Antwort.

Mit besten Grüßen
Eva Koch

Feldmann, Heinrich (NIH/NIAID) [E]

From: Miller, Katherine (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 6:41 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Clifton, Dawn (NIH/NIAID) [E]; Hartley, Maggie (NIH/NIAID) [E]
Subject: Due Monday - Action Item: Info on Biocontainment Labs

Importance: High

Hi Dr. Feldmann

NIAID needs 5 examples of truly significant research/research findings that would not have been made possible without the use of high containment laboratories to respond to House request.

Could you let me know what you consider the top 3 research contributions from the RML IRF?

Alternatively, we could use a more general description, such as:

Development of animal models to study pathogenesis, new drugs and vaccines for BSL 3 and 4 agents, e.g. Hanta virus, Nipah Virus, Ebola virus, Marburg, yersinia pestis, tularemia, influenza high path avian and 1918

Again, your thoughts are requested and appreciated.

The final list is due Monday.

Thanks so much!
Katherine

From: Haskins, Melinda (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 9:23 AM
To: NIAID BUGS; NIAID DIR-OCGR; NIAID VRC-OPA; NIAID DAIDS WOCRB; NIAID DAIT-OPA
Cc: Kurilla, Michael (NIH/NIAID) [E]; Dixon, Dennis M. (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; NIAID OCGR
Leg: Stover, Kathy (NIH/NIAID) [E]
Subject: Action Item: Info on Biocontainment Labs

Colleagues –

We have received a House oversight inquiry about the benefits and risks of BSL-3 and BSL-4 labs. By COB, Monday, October 6th, please provide me **up to 5 bulleted examples of truly significant research/research findings** that would not have been made possible **without the use of high containment laboratories**.

NOTE: On October 16th, Dr. will testify before the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations, about NIAID's Ebola activities. CDC, FDA, BARDA, and DHS also will participate.

Thanks,
Melinda

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dr P.D. Walsh <pdw36@cam.ac.uk>
Sent: Saturday, October 04, 2014 4:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Personal Info
Subject: Gorilla vaccination

Hi Heinz

I hope you are safe, sound, and not exhausted with work on the West African Ebola outbreak. I am writing because the outbreak has rekindled Paul Allen's interest in ape vaccination. He funded our VLP vaccine trial in chimps and his foundation (the Paul G. Allen Family Foundation) has recently contacted me to ask for a proposal for further Ebola vaccination work.

I have not given up on VLP's and am looking into the possibility of oral delivery. Even though they are not a natural for oral vaccination, VLPs are attractive because the folks in Africa are exceptionally wary about the idea of putting live virus baits out in area where there is serious spillover potential into endangered species. However, for obvious reasons, VLP's are not a good solution for emergency situations such as those I think we may be facing shortly with bonobos (ask me sometime whether wave spread is indeed dead).

Because of the rapid, robust immune response, VSV is clearly the best option For emergency situations. Therefore, i want to explore the possibility of getting Allen to pay for a gorilla field trial using a VSV vaccine. I understand that lots of people and institutions are involved with VSV vaccines. But I know and trust you so I figured I would start there. Please pass me off or pull in others as appropriate.

In that vein, we don't really need GMP for a gorilla trial. Thus, if it is necessary to work through your commercial partners, that is fine with me. However, it seems like it would be simpler and quicker to do something with lab grade vaccine that you or Health Canada produce on a small scale.

Finally, I am copying the vet I have worked with previously on gorilla vaccination, Chris Whittier. He has been talking with the World Wildlife Fund about doing further vaccination work at the Central African site where we did a measles vaccine trial. I think they have recently contacted Mike Jarvis about Ebola vaccines and copied you. It would be good if we pulled the strands together.

Thanks
Peter

--

Peter D Walsh, PhD
Division of Biological Anthropology
University of Cambridge
(0)1223 764701
ApesInc.org
http://www.bioanth.cam.ac.uk/s_pwalsh.html

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bradner, James E.,M.D. <James_Bradner@DFCI.HARVARD.EDU>
Sent: Saturday, October 04, 2014 4:16 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Charles Lin; Brown, Jonathan David,M.D.; Qi, Jun
Subject: request for reagents (urgent)

Dr. Feldmann.

My laboratory at the Dana-Farber Cancer Institute has a focus on chemical modulation of chromatin structure. Two postdocs in the group ccd have used models of endothelial cell activation to study cell state changes phenotypically and at the level of genome-wide chromatin structure. We had a paper this week in Molecular Cell on how chromatin active agents can abrogate cell state transitions. With the outbreak of Ebola we are motivated to test our molecules and hypotheses in relevant models of Ebola activation of endothelium.

We therefore read your work with great interest and in particular your 2005 study (Wahl-Jensen et al.,) on VP40/GP pro-inflammatory activation of endothelium. We would like to test a panel of epigenetic molecules from my laboratory on this system to determine whether we can intercept VP40/GP mediated signal transduction in endothelium. We have established relevant endothelial functional assays in lab and only require the plasmids and protocols for VP40/GP expression, purification and administration.

Would you be willing to provide these reagents for us? We can assist in any way possible to expedite shipping.

Thank you for this consideration.

Jay Bradner

James E. Bradner, M.D.

Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
james_bradner@dfci.harvard.edu
<http://bradnerlab.com>
@jaybradner

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at <http://www.partners.org/complianceline> . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Unpublished
Sent: Friday, October 03, 2014 11:41 AM
To: vgroth@svm.vetmed.wisc.edu; YOSHIHIROKAWAOKA; cary.kimpton@oup.com;
Feldmann, Heinrich (NIH/NIAID) [E]; twgeisbe@UTMB.edu;
Marnie.Vandenburg@oup.com
Subject: FW: Unpublished
Attachments: Manuscripts Unpublished

Here is the e-mail I previously received stating this information.

--
Unpublished

----- Forwarded message from "Vandenburg, Marnie" <Marnie.Vandenburg@oup.com> -----

Date: Fri, 26 Sep 2014 09:41:29 -0400
From: "Vandenburg, Marnie" <Marnie.Vandenburg@oup.com>
Reply-To: "Vandenburg, Marnie" <Marnie.Vandenburg@oup.com>
Subject: FW: Filovirus Supplement to JID
To: "Hirsch, Martin S., M.D. (Hirsch.Martin@mgh.harvard.edu)" <Hirsch.Martin@mgh.harvard.edu>,
Unpublished
Cc: "Kimpton, Cary" <cary.kimpton@oup.com>

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Folkers, Greg (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 3:40 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [C]
Subject: RE: PCR positivity

Heinz,

Thanks very much.

The genesis of our question was is that someone asked us about this guidance from CDC

When Specimens Should Be Collected for Ebola Testing at CDC

Ebola virus is detected in blood only after the onset of symptoms, usually fever. It may take up to 3 days after symptoms appear for the virus to reach detectable levels. Virus is generally detectable by real-time RT-PCR from 3-10 days after symptoms appear. Specimens ideally should be taken when a symptomatic patient reports to a healthcare facility and is suspected of having an Ebola exposure. However, if the onset of symptoms is <3 days, a later specimen may be needed to completely rule-out Ebola virus, if the first specimen tests negative.

This does not seem to be consonant with what you tell us below (which makes more sense to me).

In the past we have say we have read and said that asymptomatic patients may test positive, eg [J Virol. 2004 Apr;78\(8\):4330-41](#), "The RT-PCR and antigen-capture diagnostic assays proved very effective for detecting ebolavirus in patient serum, plasma, and whole blood. In samples collected very early in the course of infection, the RT-PCR assay could detect ebolavirus 24 to 48 h prior to detection by antigen capture." (Sudan ebolavirus)

Is there common algorithm and test that one would use for testing an exposed asymptomatic patient with, say, a moderate exposure?

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 4:55 PM
To: Marston, Hilary (NIH/NIAID) [C]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: PCR positivity

In my view it makes no sense to make recommendations on this issue as assay outcome will depend on several things such as sensitivity, target region etc. It is quite difficult to catch early onset of clinical signs in NHPs and thus hard to say when PCR turns out positive – before or after onset of signs. When we infect cynomolgus macaques with 1000 TCID₅₀ we can detect viremia by RT-PCR on day 2 post infection in the majority of the animals (some animals are still negative at this time) – never before that meaning day 1 post infection. This is around the time clinical signs become obvious.

For humans my recommendation is to use well established, well-defined and sensitive RT-PCR assays and use a proper diagnostic algorithm. There is no such thing that humans do not become positive before day 3 after onset as there will always the exception and determination of onset of clinical symptoms in humans is highly subjective. If diagnostics are done or at least interpreted by people who have proper education and training you will be fine.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Thursday, October 02, 2014 3:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Collaboration
Attachments: DOX_results.xlsx

FYI – nothing I would put much hope on...

All the best, Thomas

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Thursday, October 02, 2014 3:05 PM
To: 'Jacob, Joshy'
Subject: RE: Collaboration

Hi Joshy,

I already started the experiment on the weekend, and got the results yesterday afternoon.

Redacted by agreement

Redacted by agreement

All the best, Thomas

From: Jacob, Joshy [<mailto:jjacob3@emory.edu>]
Sent: Tuesday, September 30, 2014 8:03 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Collaboration

Dear Thomas:

Good luck with the experiment tomorrow.

I am so excited to know how it turns out.

Best wishes
Joshy


Joshy Jacob PhD
Associate Professor
Emory University
954 Gatewood Rd
Atlanta, GA 30329

Tel: 404 727 7919
Fax: 404 727 8199
Web: http://www.vaccines.emory.edu/faculty/jacob_joshy.html

Feldmann, Heinrich (NIH/NIAID) [E]

From: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US) <mark.j.wolcott.civ@mail.mil>
Sent: Thursday, October 02, 2014 1:33 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
Subject: RE: Primers (UNCLASSIFIED)

Records Originating Outside of NIAID



-----Original Message-----

From: Falzarano, Darryl (NIH/NIAID) [F] [mailto:darryl.falzarano@nih.gov]
Sent: Tuesday, September 30, 2014 8:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US)
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
Subject: RE: Primers (UNCLASSIFIED)

I assume it should work. I also assume you are talking about the SuperScript III One Step RT-PCR system with platinum Taq.

I do not see why it wouldn't but of course without having tested it ourselves I don't know.

Best regards,
Darryl

Feldmann, Heinrich (NIH/NIAID) [E]

From: Glenn Goldstein <glenn.goldstein@ki.se>
Sent: Thursday, October 02, 2014 12:41 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Svante Norgren
Subject: Karolinska anti-viral research
Attachments: NIH CDA 09 2014.pdf

Hello Dr. Feldmann

I am writing to continue to our brief discussion of new anti-viral research@ Karolinska. We are working with a new ,highly bioavailable, non-toxic (in animals) compound which has demonstrated anti-transcription actions and a significant decrease in virions in HIV and EBV.

Since the compound is a thiol , it may also have a Zinc ejection mechanism in the Zinc finger. I have discussed our research with Dr. Daniel Appella at NIH-NIDDK and he suggested that your lab could possibly test our compound for anti-Ebola virus activity

.As you will see attached , the NIDDK has signed a Confidential Disclosure Agreement and I am informed that this CDA should also be active with your lab. If this is not the case can you please have your lab prepare one.

Svante Norgren M.D. Divisionschef Astrid Lindgrens Barnsjukhus vid Karolinska is supervising this continuing research and will be available to discuss this work in detail.

Sincerely

Glenn Goldstein M.D.

Research Scientist

Karolinska Institutet

US mobile # Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Anja.WOLZ@geneva.msf.org
Sent: Thursday, October 02, 2014 12:06 PM
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada); Stephan Gunther; michel.van.herp@brussels.msf.org; Rosa.CRESTANI@brussels.msf.org; Esther.STERK@geneva.msf.org; MSFCH-Liberia-ECoordo@geneva.msf.org; Hugues.ROBERT@geneva.msf.org
Subject: Re: The mysterious re-positive patients
Attachments: P.Z.2Page2.JPG; P.Z.2Page3.JPG; P.Z.2Page4.JPG; P.Z.2Page5.JPG; P.Z.2Page6.JPG; P.Z.2Page7.JPG; P.Z.2Page8.JPG; P.Z1-Page1.JPG; P.Z1-Page2.JPG; P.Z1Page3.JPG; P.Z1Page4.JPG; P.Z1Page5.JPG; P.Z1Page6.jpg; P.Z2Page1.JPG

Sorry for the delay

Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: Armand SPRECHER/BRU/U/MSF
To: MSFOCB-Monrovia-Emed/BRU/U/MSF@MSF, Anja WOLZ/GVA/U/MSF@MSF
Cc: gary.kobinger@phac-aspc.gc.ca, feldmannh@niaid.nih.gov, Rosa CRESTANI/BRU/U/MSF, Michel VAN HERP/BRU/U/MSF@MSF, "Stephan Gunther" <guenther@bni.uni-hamburg.de>
Date: 02.10.2014 09:59
Subject: The mysterious re-positive patients

Hi Ruggero & Anja,

So, you each have a patient who

Redacted by agreement

Redacted by agreement

Could you both, please:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fischer, Robert (NIH/NIAID) [F]
Sent: Thursday, October 02, 2014 9:35 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: feces collection protocol
Attachments: Feces collection protocol.docx

Heinz

Attached is a protocol for working with Ebola infected NHP feces. We discussed writing this as a protocol rather than as an SOP. Vincent has looked it over and I was hoping that you could find time to look it over to see if it looks OK or if there are things that need to be added. Once approved I will get with Ricki to work out the specifics on where to do the work etc. I understand that I will need her supervision to carry out any of this work until I am approved to perform the tasks on my own.

Bob

From: Fischer, Robert (NIH/NIAID) [F]
Sent: Tuesday, July 29, 2014 11:12 AM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: feces collection protocol

Vincent

Attached is the protocol for the collection of feces from infected monkeys. I also have it as an SOP but Heinz thought that it would be better as a protocol rather than as an SOP. Let me know what you think and I will send it off to Heinz to get his take on it.

Bob

Bob Fischer PhD
Contractor (MSC Inc.)
Viral Ecology Unit
Laboratory of Virology
NIAID/NIH
903 S 4th St
Hamilton, MT 59840
(406) 363-9477

Feldmann, Heinrich (NIH/NIAID) [E]

From: Fischer, Robert (NIH/NIAID) [F]
Sent: Thursday, October 02, 2014 9:18 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Wildlife ASP
Attachments: GlobalHemoragicFeverSurveillanceASPJuly2014.docx;
SupplementalSpeciesTableWildlife.docx

Heinz,
Attached is the ASP for collecting wildlife samples for whenever you can get to it.
Thanks
Bob

Bob Fischer PhD
Contractor (MSC Inc.)
Viral Ecology Unit
Laboratory of Virology
NIAID/NIH
903 S 4th St
Hamilton, MT 59840
(406) 363-9477

Feldmann, Heinrich (NIH/NIAID) [E]

From: Warren Marcus <warrenmarcus@altorbioscience.com>
Sent: Thursday, October 02, 2014 8:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert

Dr. Feldmann,

Could you please give me an estimate of the costs associated with the study? I was thinking that 8 rhesus macaques (3 controls, 5 treated) would be sufficient to draw conclusions from?

Although this study is not a priority of the company

Redacted by agreement

Redacted by agreement

as someone who is a

descendant of West Africans, this outbreak has affected me more personally than others in the company. Therefore, I am going to try to raise private funds to cover the expenses.

Regards,
Warren

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, September 29, 2014 1:00 PM
To: Warren Marcus
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert

OK – we will have to use either cynomolgus or rhesus macaques. Will this work according to your data? NHP work is expensive and we may have to discuss how to perform a potential study and who will cover what expenses. Let me know if you are still interested.

Best wishes,
Heinz

From: Warren Marcus [mailto:warrenmarcus@altorbioscience.com]
Sent: Sunday, September 28, 2014 8:10 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: Re: Seeking research help from Ebola expert

Dr. Wong (our CEO) and I discussed this today. Unfortunately, this will not work in a rodent model. That is why all of the preclinical studies that led to the IND's for ALT-836 were all performed in NHPs (chimpanzees, baboons, and cynomolgus monkey's).

The safety studies were predominantly performed in the monkey and was not published. But here are two publications involving a baboon model and a chimpanzee model:


<http://ajplung.physiology.org/content/ajplung/290/1/L21.full.pdf>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vickie Groth <vgroth@svm.vetmed.wisc.edu>
Sent: Thursday, October 02, 2014 7:37 AM
To: YOSHIHIROKAWAOKA; Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Unpublis
Attachments: Manuscripts Unpublished

Yoshi, Tom and Heinz,

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 2:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Clearance
Attachments: Unpublished

Just in case, I am sending the manuscript as electronic version by email.

Please let me know if you also need filled clearance form.

Thank you in advance for your trouble.

Hideki

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mark Roth <mroth@fhcrc.org>
Sent: Wednesday, October 01, 2014 1:07 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: influenza

Hi Heinz, Thank you for your response. I will reach out to David. Is there any chance of testing our agents in your Ebola model?

Good luck with your work.

Best regards,

Mark

On Oct 1, 2014, at 1:02 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Dear Mark,

Sorry for the long delay in getting back to you. Yes I am back from Monrovia but will go back on Sunday for the rest of October. All our efforts are currently devoted to Ebola research and outbreak response. I have copied David on this email who works with HPS in hamsters.

Perhaps the two of you can discuss if it would be possible to do the work in the Andes virus hamster model.

Best wishes,
Heinz

From: Mark Roth [mailto:mroth@fhcrc.org]
Sent: Wednesday, September 24, 2014 11:19 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: influenza

Hi Heinz, Are you back yet? I am very interested to do the study we had planned. Are you able to talk on the phone?

Best regards,

Mark

On Aug 28, 2014, at 3:21 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 12:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Manuscript (Newsworthy) RML LV - SAFRONETZ Sequential immunization with Vesicular stomatitis virus based vaccines against Lassa and Ebola viruses does not affect the protective efficacy in non-human primates.
Attachments: VSV LASV Ebola (HF DS).docx; Figure 1 2014-09-26.pdf; pubclear - Safronetz Oct 2014.pdf; NIH cover sheet.pdf

FYI..

Unpublished

ut

d.

From: Mellinger, Mary (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 12:48 PM
To: Safronetz, David (NIH/NIAID) [E]
Cc: Hartley, Maggie (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Williams, Paul (NIH/NIAID) [E]; Mellinger, Mary (NIH/NIAID) [E]; Mellinger, Mary (NIH/NIAID) [E]
Subject: FW: Manuscript (Newsworthy) RML LV - SAFRONETZ Sequential immunization with Vesicular stomatitis virus based vaccines against Lassa and Ebola viruses does not affect the protective efficacy in non-human primates.

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 2:38 PM
To: Mellinger, Mary (NIH/NIAID) [E]
Subject: FW: Manuscript (Newsworthy) RML LV - SAFRONETZ Sequential immunization with Vesicular stomatitis virus based vaccines against Lassa and Ebola viruses does not affect the protective efficacy in non-human primates.

Newsworthy

Select Agents – Ebola virus, Lassa virus

Cleared

Joe

From: Mellinger, Mary (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 2:16 PM
To: Shott, Joseph (NIH/NIAID) [E]
Subject: manuscript RML LV - SAFRONETZ

Feldmann, Heinrich (NIH/NIAID) [E]

From: John Moody [Personal Info]
Sent: Wednesday, October 01, 2014 12:39 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Friederike Feldmann
Subject: [Personal Info]

Dear Heinz and Ricki,

[Personal Info]

Sincerely,
John Moody

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vickie Groth <vgroth@svm.vetmed.wisc.edu>
Sent: Wednesday, October 01, 2014 11:07 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished
Attachments: Copy of Manuscript; Unpublished

Hi Heinz,

Unpublished

Thanks,
Vickie L Groth
Influenza Research Institute
University of Wisconsin - Madison
575 Science Drive
Madison, WI 53711
608-262-2019
vgroth@svm.vetmed.wisc.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Clark, Terri (NIH/OD) [E]
Sent: Wednesday, October 01, 2014 10:12 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]
Cc: Elkins, Randy (NIH/NIAID) [E]
Subject: domestic animals and Ebola virus

Good morning gentlemen – in addition to my role here at NIH, I'm currently serving as an advisor the US Surgeon General. The SG and staff asked a couple of questions about domestic animals and their potential role with the Ebola virus and so I would appreciate your expertise and input.

Can domestic animals serve as 'carriers' of the virus? I assume there is a concern that individuals diagnosed with the disease may have pets and so would the pets then be a source of concern for further spread of the virus.

This question is for my education:

Do we definitively know which animal species are the reservoir hosts for this virus?

Thanks very much for your help - Terri

Dr. Terri R. Clark, DVM, DACLAM // Director, Office of Animal Care & Use // Chief Veterinary Officer, CAPT, USPHS
301-496-5424/7236 // clarkte@od.nih.gov // <http://oacu.od.nih.gov>

The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014

More than 16 million Americans suffer from a disease caused by smoking.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Smith, Marcia (NIH/FIC) [E] on behalf of FIC Cable (NIH/FIC)
Sent: Tuesday, September 30, 2014 2:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: country clearance - Liberia
Attachments: Travel Information for LIBERIA

Based upon the Notification of Foreign Travel (NFT) submitted by your IC, the Fogarty International Center (FIC) has requested country clearance from the US Embassy. This is a requirement for USG agencies when their staff is traveling abroad on official business. Here is a copy of the [approval](#) from the Embassy (Request Summary, below) - for your information. (It is not a visa, nor does it need to be presented upon arrival.) Also attached is general travel information for the country you will be visiting.

Please take a moment to review the following security information:
http://www.fic.nih.gov/About/International/Pages/security_briefing.aspx

Questions about official passports or visas? Please contact your [FIC International Travel Program Specialist](#).

Questions about vaccinations? Please consult with the [Occupational Medical Service](#) for individualized recommendations based on your itinerary, immunization history and current CDC recommendations.

Safe travels.

Marcia Smith
Management Analyst
Office of Administrative Management
and International Services
Fogarty International Center, NIH
TEL: 301-402-9046
FAX: 301-402-1135
VISA/PASSPORT OFFICE: 301-827-5555
E-MAIL: marcia.smith@nih.gov

Request Summary

Itinerary #:1279195

Date Requested:9/24/2014

Request Summary

Travel Itinerary				
Destination Country	Destination Cities	Start Date	End Date	Status
LIBERIA	Monrovia	10/20/2014	11/10/2014	APPROVED

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Tuesday, September 30, 2014 1:37 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: vgroth@svm.vetmed.wisc.edu; Thomas W.
Subject: Unpublish
Attachments: Manuscripts Unpublished

Heinz,

Unpublished

Yoshi

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 12:58 PM
To: NIAID RML Users
Subject: RML E-News: Missoulain story about St Patrick hospital's care and isolation unit
Attachments: St. Patrick Hospital 1 of 4 sites in U.S.pdf; 20140919 MSO article about Risi.pdf

As part of the lawsuit settlement agreement that NIH signed in 2004 to proceed with construction of the IRF, we agreed to establish patient isolation services at a hospital within 75 miles of RML in the unlikely event that one of our employees suffered an exposure to a BSL4 agent. St Pat Hospital won the contract to provide these services to RML, and constructed a Care and Isolation Unit (CIU) to NIH standards. The CIU is now listed as one of the 4 sites in the US specifically designed to care for patients with ebola and other serious infectious diseases.

The accompanying article describes the CIU and how it might be put into use to care for patients in the current ebolavirus outbreak. George Risi, RML's infectious disease adviser, is featured in the article. I am also attaching a recent article about Dr Risi's experiences as a volunteer treating patients in Sierra Leone.

Many of us have had friends and community members ask about RML's role in this serious outbreak. Everyone I have spoken with takes pride in the fact that RML is able to assist in this dire situation and is working on countermeasures.

Thanks to Heinz Feldmann's leadership, RML has been able to dispatch several teams to Liberia to assist in diagnosis. I am hoping to arrange a presentation for the RML staff sometime in October by one of those team leaders.

Marshall

Marshall E. Bloom, M.D.
Associate Director
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: 406-375-9707
FAX: 406-375-9661
email: mbloom@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Michael Jarvis <michael.jarvis@plymouth.ac.uk>
Sent: Tuesday, September 30, 2014 10:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished
Attachments: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Mehedi, Masfique (NIH/NIAID) [F]
Sent: Tuesday, September 30, 2014 8:46 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Announcement: [Viruses] IF 3.279 - Special Issue "Advances in Ebolavirus, Marburgvirus, and Cuevavirus Research 2014-2015"

Dear Heinz,

Good morning! I hope you are fine and well. I have read your interview on ScienceInsider. I liked the interview very much. I hope and wish your safety, as you one of the constant partners for the lab and on-site Ebola diagnosis, treatment and research. I do understand you are very busy, it is really a very busy time for the Ebola researchers. Recently, I got an e-mail from the Journal Viruses regarding special issue on Ebola virus (forwarded here). I wonder

Unpublished

Sincerely,
Masfique

P.S. We are doing well, our **Perso** is gaining weight, laughing, screaming, and demanding. We wish you and Ricky to visit us whenever possible.

On 9/26/14 6:45 AM, "Viruses Editorial Office" <viruses@mdpi.com> wrote:

>Dear Dr. Mehedi,
>
>The journal Viruses is dedicating a special issue entitled "Advances in
>Ebolavirus, Marburgvirus, and Cuevavirus Research 2014-2015" edited by
>Dr. Jens H.
>Kuhn
>(NIH/NIAID/IRF-Frederick). Based on your expertise in this field, we
>think you could make an excellent contribution to this themed issue.
>
>The final submission deadline is 31 December 2015, but articles will be
>published immediately after acceptance (four articles are already
>published at this point in time). Upon completion of the special issue,
>there may be a printed edition you could order (see previous special
>issue on filovirus research at
>http://www.mdpi.com/journal/viruses/special_issues/Filovirus). For
>further information please visit the website of the special issue:
>http://www.mdpi.com/si/viruses/filovirus_2014_2015.
>
>Please read the Viruses Resource on Ebola virus and other filoviruses
>published in recent years at
><http://blog.mdpi.com/2014/09/24/resources-on-ebola-virus/>.
>
>Viruses (ISSN 1999-4915) is a fully open access journal, with an Impact

Feldmann, Heinrich (NIH/NIAID) [E]

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 7:17 AM
To: Pekoc, Ken (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Schmitt, James (NIH/OD/ORS) [E]; Wilson, Deborah (NIH/OD/ORS) [E]; Hoe, Nancy (NIH/OD/ORS) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Davey, Richard (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Seth Bloom (seth.m.bloom@gmail.com); Jesse Bloom
Subject: Story about Dr Risi

There was also an extended and very moving interview with him on the local NPR affiliate yesterday afternoon. George now probably has as much experience actually treating ebola patients as anyone in the US.
http://missoulain.com/news/local/st-patrick-hospital-of-sites-in-u-s-ready-for/article_da521772-4839-11e4-b266-4342d105e33f.html

Marshall E. Bloom, M.D.
Associate Director
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: 406-375-9707
FAX: 406-375-9661
email: mbloom@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Isaac, Freeda E - APHIS <Freeda.E.Isaac@aphis.usda.gov>
Sent: Tuesday, September 30, 2014 7:07 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Permit application 14268054

Records Originating Outside of NIAID

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, September 29, 2014 11:57 AM
To: Isaac, Freeda E - APHIS
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Permit application 14268054

Dear Dr. Isaac,

I would highly appreciate if this permit request could be addressed as soon as possible. I hate to ask you for this special treatment, but the material is needed for a vaccine trial regarding the current Ebola virus strain causing the disastrous outbreak in West Africa. WHO and other organization are very keen to learn if the vaccine, which is based on a different strain, will also protect against this new strain. As sooner as we can start the experiment as better it would be for outbreak response and the beginning human clinical trial with the vaccine candidate. We have an approved animal study protocol and the animals are already sitting ready to go. Winnipeg is ready to ship immediately we are just awaiting the USDA import permit (we do have the CDC import permit).

If you have any questions, please feel free to contact me any time by email (see above) or phone (office: 406-375-7410; BB phone Personal Info)

Many thanks for your cooperation - best wishes,
Heinz Feldmann

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416

Feldmann, Heinrich (NIH/NIAID) [E]

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Monday, September 29, 2014 3:03 PM
To: Clifton, Dawn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]
Subject: FW: Virus related kits forecast

From: Savannah Liu - QIAGEN [mailto:Savannah.Liu2@qiagen.com]
Sent: Monday, September 29, 2014 2:40 PM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Virus related kits forecast

Hello Darryl,

With the upgrading of Ebola situation, and other virus infection showing up at the same time, we see increased demand of QIAamp Viral RNA mini kit and detection PCR kits.

We want to make sure we can meet the demand from all sides.

Would you let me know if you might need large amounts of them? I need to give production a forecast, so they can produce sufficient reagents.

With warm regards,

Savannah Liu,
Account Manager
(Former PCR Array Application Scientist)

QIAGEN - Sample & Assay Technologies

Office: 6617023143

Mobile: Personal Info

savannah.liu2@qiagen.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Warren Marcus <warrenmarcus@altorbioscience.com>
Sent: Monday, September 29, 2014 11:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert

It is probably best to stick to rhesus macaques so that a comparison can be done between this study and the previous one with rNAPc2.

All of our funding (we are venture-backed with no approved drugs yet) has been earmarked for our oncology drugs. I was hoping that as a federally-funded lab that the costs for this study would be minimal, or perhaps you can point us to a rapid funding mechanism now that Ebola has been given special consideration by the government?

Nonetheless, I recently reconnected with a friend from my MIT days (she was at Harvard then) who currently works at the Gates Foundation and she is going to look into a potential funding mechanism through them. So I am crossing my fingers for that to come through asap..

Cheers,
Warren

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, September 29, 2014 1:00 PM
To: Warren Marcus
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert

OK – we will have to use either cynomolgus or rhesus macaques. Will this work according to your data? NHP work is expensive and we may have to discuss how to perform a potential study and who will cover what expenses. Let me know if you are still interested.

Best wishes,
Heinz

From: Warren Marcus [mailto:warrenmarcus@altorbioscience.com]
Sent: Sunday, September 28, 2014 8:10 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: Re: Seeking research help from Ebola expert

Dr. Wong (our CEO) and I discussed this today. Unfortunately, this will not work in a rodent model. That is why all of the preclinical studies that led to the IND's for ALT-836 were all performed in NHPs (chimpanzees, baboons, and cynomolgus monkey's).

The safety studies were predominantly performed in the monkey and was not published. But here are two publications involving a baboon model and a chimpanzee model:

<http://ajplung.physiology.org/content/ajplung/290/1/L21.full.pdf>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 10:04 AM
To: 'asall@pasteur.sn'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: News from Senegal
Attachments: journal.pntd.0002582[1].pdf; Zivcec et al. 2014.pdf; Safronetz et al 2010.pdf

Hello Amadou,

Attached are a few manuscripts from our work in Mali. I'll contact our people in Mali and discuss joining the consortium. I'm sure they would be excited to. Depending on the results of our upcoming fever study we may be able to provide some preliminary data for your grant application since we plan on testing the human samples from the Malian YFV project for all the pathogens you list below.

Dave

-----Original Message-----

From: asall@pasteur.sn [mailto:asall@pasteur.sn]
Sent: Sunday, September 28, 2014 5:41 PM
To: Safronetz, David (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: News from Senegal

Dear David,

Thanks for your message and information about the great work you are doing in Mali. We have been in contact with some collaborators from Fondation Mérieux for an EU project and also for the dengue emergence in Sadiola in 2008.

I'll be more than happy to welcome you in Dakar and discuss collaborations; We have set up a program on Fever of unknown origin in Kédougou at the bordering area with Mali for the last 5 years and we have interesting results. Our project was funded by NIH as an R01...

Please let me know for your colleague and I'll be happy to receive your manuscripts. The framework I designed for the grant will focus on Ebola, Dengue, YF, RVF, CCHF and Lassa. I'll send it to you tomorrow. Best,

Amadou

> I will discuss with Nafomon and Seydou, but I think it's a great idea
> and I'm sure they'll agree.
>
> Amadou, we've been working in Mali for the last 5 years. We've
> focused primarily on field studies aimed at determining the
> geographic distribution of Lassa virus but we've recently expanded
> to include CCHFV. We are currently expanding once again and next
> week will begin testing human samples collected from patients with

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sylvain Baize <sylvain.baize@inserm.fr>
Sent: Monday, September 29, 2014 1:50 AM
To: Ali Mirazimi; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Roger.Hewson@phe.gov.uk; Di Caro Antonino; herve; Klas Ola Blixt; mats.nilsson@scilifelab.se; pascal.mertens@corisbio.com; amasall@hotmail.com; muyembejj@gmail.com; xavier.de-lamballerie@univ-amu.fr; Anna BOITARD; anna.boitard@gmail.com; AFO@ssi.dk
Subject: Re: urgent
Attachments: Wp Matrix-Pasteur Lyon.docx

Dear Ali,
Please find enclosed the doc for French NRC for VHF.
Regards,
Sylvain

Sylvain Baize

Unité de Biologie des Infections Virales Emergentes
CNR des Fièvres Hémorragiques Virales
INSTITUT PASTEUR
CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE (CIRI)

21, av. Tony Garnier
69365 Lyon cedex 07

Tél. 04 37 28 24 43 (40) / 07 87 94 76 47

Fax. 04 37 28 24 41

sylvain.baize@inserm.fr

sylvain.baize@pasteur.fr

Institut Pasteur



Centre
International
de Recherche
en Infectiologie

Le 26/09/2014 19:49, Ali Mirazimi a écrit :

Dear All,

I send you a WP-Matrix; In this document you will find the suggested WP and also tasks in each action, Please just mark (X) in which WP are you interested to participate.

You will also find in this document that I have put even one WP on the Antivirals (as I get this as a suggestion today)– However, I am not sure if this WP is fitting in the general concept of our project, however, I let it stay in the document but may be we take it out ...!

Instruction;

- 1- Put X in the WP you will participate
- 2- suggest tasks that you find is lacking

I see forward to get this information at latest Tomorrow (it takes 5 minutes).

Best

Ali

Feldmann, Heinrich (NIH/NIAID) [E]

From: Warren Marcus <warrenmarcus@altorbioscience.com>
Sent: Sunday, September 28, 2014 8:10 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: Re: Seeking research help from Ebola expert

Dr. Wong (our CEO) and I discussed this today. Unfortunately, this will not work in a rodent model. That is why all of the preclinical studies that led to the IND's for ALT-836 were all performed in NHPs (chimpanzees, baboons, and cynomolgus monkey's).

The safety studies were predominantly performed in the monkey and was not published. But here are two publications involving a baboon model and a chimpanzee model:

<http://ajplung.physiology.org/content/ajplung/290/1/L21.full.pdf>

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927860/pdf/nihms162815.pdf>

Both of these studies demonstrate the efficacy of ALT-836s blocking of tissue factor-initiated downstream events. If you look at the sepsis model performed in the baboon, there is a significant decrease in many of the hallmark characteristics of inflammation, including proinflammatory cytokines. The cytokine storm has been linked to the mortality caused by Ebola.

Therefore, since the increased expression of TF was the primary premise behind using rNAPc2 in the rhesus macaque model by Geisbert, then a proven inhibitor of the downstream events caused by the over expression of TF should also validate the use of ALT-836 in a NHP model.

Thanks,
Warren

Sent from my iPad

On Sep 27, 2014, at 4:35 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Would this work in rodent models – we have mouse, hamster and guinea pig for Ebola. It would be great to test it first in a rodent model prior to going into a nonhuman primate model. We would prefer the hamster.

I have attached a Simple Letter Agreement (SLA) from the NIH. You may not agree with this but it would have the advantage that I can sign on our end as the authoritative person. If we take a different MTA I will have to give it to Bethesda for their approval. This usually takes about two weeks. In case you go for the attached SLA please work with Kay (copied here) – she will prepare the SLA from our end.

Best wishes,
Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Dhillon, Ranvir Singh,M.D. <RSDHILLON@PARTNERS.ORG>
Sent: Sunday, September 28, 2014 3:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: sri.devabhaktuni@gmail.com
Subject: Ebola
Attachments: Unpublished

Dear Dr. Feldmann,

I am a physician in the Division of Global Health Equity at Brigham and Women's Hospital and a Senior Health Advisor at the Earth Institute at Columbia University. I previously worked as an advisor to the Ministry of Health in Liberia on health systems development and am currently helping the office of President Alpha Conde in Guinea frame its Ebola control strategy.

My colleague, Devabhaktuni Srikrishna, and I read your article about Ebola in NEJM with great interest and saw that you recently returned from the field (<http://www.foxnews.com/world/2014/09/28/ebola-clinics-fill-up-as-death-toll-hits-3000/>).

Unpublished

Thanks,
Ranu Dhillon

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at <http://www.partners.org/complianceline> . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Personal Info
Sent: Sunday, September 28, 2014 3:34 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: questions

Dr Feldmann:

I am a physician from Olympia, WA, going to volunteer to do training/education for clinics around Monrovia with Medical Teams International on PPE, etc for Ebola. I am looking for folks I can ask questions of when the providers on the ground ask me questions. I am wondering if this email still works for you (from 2011 Lancet article) and if you might help me when I get stuck.

Thank you in advance.

Personal Info MD, FACP
Internal Medicine

Feldmann, Heinrich (NIH/NIAID) [E]

From: Okumura, Atsushi (NIH/NIAID) [V]
Sent: Sunday, September 28, 2014 11:40 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished
Attachments:

Hi Heinz,

Unpublished

Thanks,

Atsu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Ali Mirazimi <Ali.Mirazimi@folkhalsomyndigheten.se>
Sent: Friday, September 26, 2014 11:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Roger.Hewson@phe.gov.uk; Di Caro Antonino; herve; Klas Ola Blixt; mats.nilsson@scilifelab.se; pascal.mertens@corisbio.com; amasall@hotmail.com; muyembejj@gmail.com; sylvain.baize@inserm.fr; xavier.de-lamballerie@univ-amu.fr; Anna BOITARD; anna.boitard@gmail.com; AFO@ssi.dk
Subject: urgent
Attachments: Wp Matrix.docx

Dear All,

I send you a WP-Matrix; In this document you will find the suggested WP and also tasks in each action, Please just mark (X) in which WP are you interested to participate.

You will also find in this document that I have put even one WP on the Antivirals (as I get this as a suggestion today)- However, I am not sure if this WP is fitting in the general concept of our project, however, I let it stay in the document but may be we take it out ...!

Instruction;

- 1- Put X in the WP you will participate
- 2- suggest tasks that you find is lacking

I see forward to get this information at latest Tomorrow (it takes 5 minutes).

Best

Ali

Feldmann, Heinrich (NIH/NIAID) [E]

From: McFadden, Diane C. <dc2120@columbia.edu>
Sent: Wednesday, September 24, 2014 10:57 AM
To: Baric, Ralph; MichaelKatze; David A. Relman; Shepard, Kenneth L.; William B. Karesh; Christina Egan; Jay Varma; Lipkin, W. Ian; Angela L. Rasmussen; Amy C. Sims; Catherine Machalaba; Eleanor (Ellie) Kahn; Baric, Toni C; Heise, Mark T; Randell, Scott H; Feldmann, Heinrich (NIH/NIAID) [E]; Rose M. Howard; Jennifer Rakeman-Cagno
Subject: September 17th CRDD telecon minutes
Attachments: Minutes Telecon 091714.doc

Dear Group,

Attached are minutes from last week's CRDD teleconference call. If you wish to make any changes, please let me know.

Our next conference call is scheduled for October 15th at 2:00 pm EDT. Please feel free to send me any agenda items between now and then.

Regards,

Diane

--

Diane C. McFadden, Ph.D.
Center for Infection & Immunity
Mailman School of Public Health
Columbia University
MSPH Box 20
722 West 168th Street, 17th floor
New York, NY 10032
212-342-0007 (phone)
212-342-9044 (fax)
dc2120@columbia.edu (email)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Tuesday, September 23, 2014 4:15 AM
To: Hensley, Lisa (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada); 'guenther@bni.uni-hamburg.de'; Jahrling, Peter (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); 'asall@pasteur.sn'
Cc: Michel VAN HERP; Rosa CRESTANI; MIO-VHFever
Subject: Re: A research proposal

Hello all,

After a rather charged week, I am able to come back to you all on this. So far, there has been general support for the idea of a study, with the caveat that we (MSF) will need to provide adequate support for the field teams to assure that any increase in their workload does not disrupt normal activities and communicate well to them that this study is one that MSF is leading (and so our involvement is necessary).

I think this is the kind of study that we can get exemption from ethical review by the ERB, as this is a matter of immediate operational practice. I will take care of this.

To get the exemption and to prepare matters for the field, it would help if we had the rough outlines of a study protocol - some pieces of which have already been put forward.

1) What specimens should be collected from patients upon arrival, and continued with what frequency, up until what point?

- I imagine that skin swabs, saliva, and blood at least
- Is daily more than we need?
- I assume we would do this until discharge, but would we want to consider continuing after?

2) What additional data do we need from these patients?

- Date of onset of illness
- Do we need date of likely exposure?
- Do we need the type of likely exposure?

3) What sort of sample size would we need?

4) Which specimens would need to be shipped to a BSL-4 lab for viral isolation? What sort of administrative procedures does this entail?

5) What have I forgotten?

Armand Sprecher MD MPH
Public Health Specialist
Médecins Sans Frontières
Operational Center of Brussels

armand.sprecher@brussels.msf.org
Tel: +32 2 474 7543

Feldmann, Heinrich (NIH/NIAID) [E]

From: YOSHIHIROKAWAOKA
Sent: Tuesday, September 23, 2014 3:32 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; HALFMANP@SVM.VETMED.WISC.EDU;
neumannng@vetmed.wisc.edu
Subject: RE: Re: short commentary on Ebola

Heiz,

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Yulia Kotliarenko **Personal Info**
Sent: Monday, September 22, 2014 11:22 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview request

Dear Mr Feldmann,

On behalf of Radio VR from Moscow, I would like to invite you for a brief telephone interview to talk about Ebola, its cure strategy and findings. One of the key issues our program discusses as well is the ethical issue related to the Sierra Leone lockdown. And most certainly your findings at the 4level lab would be an asset to our coverage of the ebola outbreak. These and other related issues are expressed in the following questions, that we would love to discuss with you. Here they are:

Qs

1. The initiative to impose a lockdown sparked controversy in the society. In your opinion, was the measure relevant? Local authorities described it as a successful step, so what results did they achieve due to the Ebola curfew?
2. How do you estimate the current situation in West Africa? Can we expect the epidemic to subside in the near future?
3. The largest international health organizations are involved in the fighting against the Ebola outbreak, European authorities have repeatedly allotted money and dispatched the medical staff to the contaminated areas. In your opinion, why did the international community fail to contain the Ebola epidemic so far?
4. According to the UN estimation, the spread of the disease poses a serious threat for the African economy. How could you evaluate the damage caused by the epidemic? How much time will it take to restore the infrastructure of the region?

Interviews take about 7 minutes and are conducted in English in a LIVE q&a format.

Hope you can find few minutes to talk to us over the telephone today, September 23, 2014.

Our slots are every hour from an early morning to 1:30 pm Manitoba time.

Please let me know what time is most convenient for you. It will be a pleasure to arrange.

Most kindly,

Yulia

Yulia Kotliarenko-Shukhman
Head of Producing and Monitoring Unit
Radio VR
English World Service
Moscow Bureau
www.voiceofrussia.com
mob. **Personal Info**
outlook: kotlyarenko@ruvr.ru

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vickie Groth <vgroth@svm.vetmed.wisc.edu>
Sent: Monday, September 22, 2014 12:48 PM
To: YOSHIHIROKAWAOKA; Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished
Attachments: Copy of Manuscripts Unpublished

Yoshi,

Unpublished

Vickie

-----Original Message-----

From: Kawaoka [mailto:kawaokay@svm.vetmed.wisc.edu]
Sent: Monday, September 22, 2014 8:21 AM
To: Geisbert, Thomas W.; Feldmann, Heinrich (NIH/NIAID) [E]; vgroth@svm.vetmed.wisc.edu
Subject: RE: Unpublished

Tom,

Yes.

Vickie,

Unpublished

Yoshi

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Handle: Geisbert, Thomas W.
Mail Address: twgeisbe@UTMB.EDU
Subject: RE: Filovirus supplement to JID
To: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>, YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>
CC: --
Date: Mon, 22 Sep 2014 12:32:00 +0000
Date Local: 2014/09/22 21:32:00
Message:

> Do you want to do this tomorrow?

>

> -----Original Message-----

> **From:** Feldmann, Heinrich (NIH/NIAID) [E]

> [mailto:feldmannh@niaid.nih.gov]

> **Sent:** Thursday, September 18, 2014 11:51 AM

> **To:** Geisbert, Thomas W.; YOSHIHIROKAWAOKA

Feldmann, Heinrich (NIH/NIAID) [E]

From: Haifeng Song <Hsong@Novavax.com>
Sent: Monday, September 22, 2014 10:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Touch base for Ebola challenge study

Dear Dr. Feldmann,

This is Haifeng Song, an immunologist from Novavax Inc. in Maryland. I'm writing you for the possibility to collaborate to test our Ebola-nanoparticle vaccine candidate in your virus challenge model (starting from rodents to NHPs). Novavax develops vaccine candidates in insect cell expression system. We have influenza vaccines including pandemic and seasonal Flu vaccines, and RSV vaccines at different stages of clinical trials. In addition, we also develop CoV-MERS vaccine and Ebola vaccine candidates and now try to find collaborator to test our Ebola vaccine in animal model. We would appreciate very much for an opportunity to work together with your team. We can discuss more if you think it is possible.

By the way, we are a frequent collaborator with NIAID for vaccine development.

Thank you very much,

Haifeng

*Haifeng Song, PhD
Senior Manager, Immunology department
Novavax Inc.
20 Firstfield Road
Gaithersburg, MD20878
Phone 240-268-2083*

Confidentiality Notice: This email message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential, proprietary, or privileged information. Any unauthorized review, use, disclosure, or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and you are hereby notified that the copying, use, disclosure, or distribution of any information or materials transmitted in or with this message is strictly prohibited.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Vincent Racaniello <vrr1@columbia.edu>
Sent: Sunday, September 21, 2014 3:47 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: American Society for Virology

Redacted by agreement

Vincent

On Sep 21, 2014, at 12:45 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

> Vincent,
>
> Looking forward to the meeting. I really enjoyed your commentary on the potential aerosol transmissibility of Ebola. This was much needed and coming from someone like you will weigh much more. The field really appreciates your comment and insight. People like Osterholm sometimes do more harm than good.
>
> Best wishes, Heinz
>
> -----Original Message-----
> From: Vincent Racaniello [mailto:vrr1@columbia.edu]
> Sent: Thursday, September 18, 2014 7:45 PM
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: American Society for Virology
>
> Dear Heinz,
>
> I'm so glad you can make it. I'll have more information about the meeting next year.
>
> No problem missing me at RML, I fully understand. I had a great visit.
>
> Vincent
>
>
>
> On Sep 18, 2014, at 9:00 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
>
>> Dear Vincent,
>>
>> Got back a few days ago from Monrovia - sorry for not responding but I hadn't gone through all my emails.
>>
>> I feel delighted and honored by the invitation and it is my great pleasure to accept.
>>
>> I also wanted to let you know that I felt terrible for missing you when you came to RML. I
>>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 6:16 PM
To: Redacted by agreement
Subject: Re: Hallo

Redacted by agreement

From: Redacted by agreement
Sent: Monday, October 20, 2014 01:23 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Hallo

Redacted by agreement

2014-10-16 1:15 GMT+02:00 Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>:

Redacted by agreement

From: Redacted by agreement
Sent: Wednesday, October 15, 2014 04:21 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Hallo

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 5:51 PM
To: Pekoc, Ken (NIH/NIAID) [E]; 'George.Risi@providence.org'; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]
Subject: Re: explain PCR / blood handling at St. Patrick?

Can this wait until I am back?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 06:41 PM Eastern Standard Time
To: 'Risi, George' <George.Risi@providence.org>; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

Paul, can you meet with Dave and Andrea to fill them in on what Joyce requested ... to make sure it's relevant to the staff there.

George, can you offer some thoughts to Dave, Andrea and Heinz about why a presentation to the St. Pat's staff might be good given the background of last week?

From: Risi, George [mailto:George.Risi@providence.org]
Sent: Monday, October 20, 2014 4:11 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

Would be great. We will buy them lunch

From: Pekoc, Ken (NIH/NIAID) [E] [mailto:kpekoc@niaid.nih.gov]
Sent: Monday, October 20, 2014 4:09 PM
To: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Risi, George; Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: explain PCR / blood handling at St. Patrick?

Dave / Andrea ... I can provide details later, but would either or both of you be interested / available in going to St. Patrick Hospital (soon) and presenting to their staff on how you handle a blood sample from a suspected Ebola case? If yes, please let me know some ideal days / times and I'll work back with the hospital.

If this comes together Paul and I would like to accompany you to observe.

George, looping you in on this request that just came today via conversations with Joyce / Paul. This would be a good-will gesture the way I see it.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 5:50 PM
To: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: Re: explain PCR / blood handling at St. Patrick?

I do not know anything about it. If you don't feel comfortable - don't do it. I can talk to George about it.

----- Original Message -----

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 06:36 PM Eastern Standard Time
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: explain PCR / blood handling at St. Patrick?

Ken explained this differently on the phone.

Redacted by agreement

Personally, I'm not sure if us talking with them will do any good especially since our role and their role is so different. We cannot give them advice on blood collection, PPE, etc; that should come from the CDC.

What is your thoughts on this request? I guess it's too late and we have essentially committed to going unless you tell us not to.

Dave

-----Original Message-----

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:29 PM
To: Marzi, Andrea (NIH/NIAID) [E]; Risi, George; Safronetz, David (NIH/NIAID) [E]
Cc: Carlson, Paul (NIH/OD/ORS) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: explain PCR / blood handling at St. Patrick?

I've spoken to Dave ... am going to try and set this up with the hospital for Friday before lunch. I think it will be good for both Dave and Andrea to present from both the lab / blood handling perspective and the field / diagnostic perspective in Liberia.

George / Paul, can you fill Dave and Andrea in on some of the background from last week on why the hospital would like this presentation?

-----Original Message-----

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 4:24 PM
To: Risi, George; Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]


Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 5:45 PM
To: 'Matthias.Borchert@charite.de'; 'Nora.Love@rescue.org'
Subject: Re: Introductions

Matthias,
No-one told us yet, but we will do what we can.
Heinz

From: Borchert, Matthias [mailto:Matthias.Borchert@charite.de]
Sent: Monday, October 20, 2014 06:11 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'Nora Love (Nora.Love@rescue.org)' <Nora.Love@rescue.org>
Subject: Introductions

Redacted by agreement



Cheers,

Matthias

Matthias Borchert
International Rescue Committee - Liberia
Ebola Treatment Unit
Senior Health Coordinator
Cell: Personal Info
Email: matthias.borchert@charite.de
Skype: matthias.borchert

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 5:34 PM
To: Caldwell, Harlan (NIH/NIAID) [E]
Subject: Re: question

Harlan,

We do not know. But we know that if we infect NHPs with a virus that does not produce sGP, the virus reverts immediately back to a virus expressing sGP.

Heinz

From: Caldwell, Harlan (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 05:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: question

Hello Heinz,

Redacted by agreement

Redacted by a

Harlan

Harlan D. Caldwell, Ph.D
Chief and Senior Investigator
Laboratory of Intracellular Parasites
Rocky Mountain Laboratory
National Institute of Allergy and Infectious Diseases
903 South 4th Street
Hamilton, MT 59840

Email: hcaldwell@niaid.nih.gov
Phone: 406-363-9333
FAX: 406-363-9355

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 2:27 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

If it is important to you - please go ahead with the letter. I never really had anything to do with her.


Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 04:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I understand where you are coming from - I guess one can argue both ways whether or not it is a reasonable collaboration or not (particularly if we include the establishment of an improved protocol for 96-well format screening which we would do in the letter). There is a strong mutual interest and benefit, but the actual wet-work is certainly mostly in their hands.

Moving forward, you will have to make a definitive decision whether or not we are willing uphold our agreement to provide a letter of collaboration or not - I get the impression that you rather would not want to do that. I certainly hate to disappoint  but I can also appreciate your position, so I will see how we can back out of our agreement to provide such a letter without causing too many damage to our relationship with her. I'll start working on an email to her, and send you the draft.

Personal Info

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:50 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

Every letter will be evaluated carefully. If it is a reasonable collaboration - no problem. If not - I would rather not write a letter.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 12:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 2:25 PM
To: Pierre Formenty; 'twgeisbe@utmb.edu'; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

We haven't done that.

From: Pierre Formenty
Sent: Monday, October 20, 2014 03:58 PM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

And are you aware of NHP surviving Zaire rechallenged with Zaire?

From: Geisbert, Thomas W. [mailto:twgeisbe@utmb.edu]
Sent: 20 October 2014 21:56
To: Feldmann, Heinrich (NIH/NIAID) [E]; FORMENTY, Pierre B.H.; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Are Ebola survivors all immune against a re-infection?

I agree with Heinz. Even for survivors I think you would still want some form of PPE.

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 20, 2014 11:19 AM
To: Pierre Formenty; Geisbert, Thomas W.; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

I don't think there is a guaranty that they will be all immune. I would at least wait a month which would also be good in regards to their full recovery. Overall, I would assume that survivors are immune to immediate reinfection with the same species.

MSF is using survivors here in Monrovia on the ward. They still wear PPE but less than other health care workers. I would think a low grade PPE should be used.

Heinz

From: Pierre Formenty
Sent: Monday, October 20, 2014 04:06 AM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

Dear Tom, Gary and Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:50 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

Every letter will be evaluated carefully. If it is a reasonable collaboration - no problem. If not - I would rather not write a letter.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 12:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

What we would do is to help her get the system up and running, as I initially wrote you. In addition, I am thinking of developing protocols to downscale the system for HTS screening (probably using reverse transfection) - this would be something that would be very applicable to **Perso** work, and might also be good for us in the future. What we get in return is basically that they validate the usefulness of our system as an actual screening system prior to BSL4 screening of antivirals - something I would love to do myself, but just don't have the time / manpower to do. So I do think in this case there is a mutual interest, even though my own contributions are relatively small.

For your information, **Personal Inf** also had asked for a letter of collaboration to support a grant application, but I did not agree to this because a) I don't think his proposal makes any sense, at least not for that particular call, and b) I didn't think there was a real mutual interest.

That being said, if you prefer not to provide the letter, please let me know, and I will communicate that to **Pers**

All the best, Thomas

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:27 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola trVLP system

I am fine with the letter but what does she need us for? If she collaborates with Gene and we give her the system why does she need a collaboration?

I am saying this as we may want to save letters for future collaborations. I do not want to provide a letter to just help her get a grant.

Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:43 AM
To: Safronetz, David (NIH/NIAID) [E]; 'petra.wuelfroth@accella-advisors.com'
Cc: 'thomas.steiner@mche.at'
Subject: Re: FX06

Thanks.

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 12:28 PM Eastern Standard Time
To: 'Petra Wülfroth' <petra.wuelfroth@accella-advisors.com>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; 'Thomas Thomas Steiner' <thomas.steiner@mche.at>
Subject: RE: FX06

Dear all,

Redacted by agreement

Dave

From: Safronetz, David (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:52 PM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; 'Thomas Thomas Steiner'
Subject: RE: FX06

Hi Petra,

Redacted by agreement

Thanks in advance,
Dave

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:42 AM
To: Lane, Cliff (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: MOU

Dear Cliff,

Here is a request for sample shipment from the CDC/NIH Lab to the US. We urgently need sequence information on currently circulating strains/variants to improve diagnostics. We are already seeing false-negatives with our GP-based assay which is likely due to mutations. We also need virus isolates for diagnostics and urgently needed pathogenesis studies. It would also be good to test the vaccine candidates against currently circulating strains which has not been done yet. The outbreak response is severely hampered by the lack of information.

We also need a quick answer on a possible shipment in order to make decisions on already collected material here at the lab. If sample shipments are not going to happen we will be forced to destroy the material as security and safety could become problems at certain locations. We are waiting for those decisions now since mid-August.

I am looking forward to hearing from your office as soon as possible.

Thanks and best wishes, Heinz

----- Original Message -----

From: Lane, Cliff (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 04:56 PM Eastern Standard Time
To: Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: MOU

Colleagues,

Dr. Jahrling has pulled me into this discussion.

Letters exchanged between the Liberian Minister of Health, Walter Gwenigale and the HHS Secretary of Health and Human Services, Sylvia Burwell have identified me as the point of contact for the development of a clinical research program between our two countries. In this regard anything having to do with NIH investigators seeking permission to work with clinical material must be coordinated through my office and the take into account the relationships we are developing with the Liberian Ministry. These have been greatly facilitated by Dr. Frank Mahoney who is on this string as well.

To be clear, if someone from NIAID has a request of this type it should go to me. From there I will discuss with Frank whether or not it seems appropriate and whether or not it is of sufficient critical priority to take forward. It is likely that

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:27 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola trVLP system

I am fine with the letter but what does she need us for? If she collaborates with Gene and we give her the system why does she need a collaboration?

I am saying this as we may want to save letters for future collaborations. I do not want to provide a letter to just help her get a grant.

Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 19, 2014 05:02 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I have used the letter we sent to **Personal Info** in 2014 as a template, and worked in the draft that **Pers** sent. It would be great if you could have a look and make any changes you would like/think are necessary, and then send the final draft to Kay/me for signing - I can then take it from there.

Thank you very much for doing this!

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 11:16 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola trVLP system

Ricki,
Can you please go on my computer and open a folder from the desktop entitled 'collaborations' or something similar. This folder should include recent examples for 'Letters of collaboration'. Take one for **Pers** or **Perso** from 2014 and send it to Thomas.

Thomas, please modify the letter accordingly and send the draft to me. Once we have a final draft - Kay can use the stamp to sign.

Let me know if you need my help.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:21 AM
To: 'millersi@uw.edu'; Bloom, Marshall (NIH/NIAID) [E]
Cc: 'stapl@uw.edu'; George Risi
Subject: Re: Redacted by agreement

I am still in Monrovia until the end of the month. If wished we can talk after my return. Otherwise, I agree with Marshall's remarks. We can talk about therapy.

George Risi is the contact in Missoula.

Best wishes, Heinz

----- Original Message -----

From: Samuel Miller [mailto:millersi@uw.edu]
Sent: Monday, October 20, 2014 11:04 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Cc: Ann Stapleton <stapl@uw.edu>
Subject: Redacted by agreement

Heinz and Marshall, My colleagues in infectious diseases and the Clinical and Translational Research Center at the UW have asked me to reach out to you to assist in the planning for the Redacted by agreement Can you help us establish contacts with the clinical facility at St. Patrick's in Missoula as well as establish good training and access to possibly experimental therapies as needed. It will be important for us to get some education that I am sure you can help us with. I am sure you are very busy at this time but would appreciate a response. If there are experimental therapies that we can access together we can apply for IND in case they become necessary. In any event at a recent meeting it was felt to be important for us regionally to reach out to you at this time. I or my colleagues would be happy to discuss with you as necessary. best and thanks for considering this request, Sam Miller

Samuel I. Miller M.D.
Professor of Medicine, Microbiology, and Genome Sciences U of Washington

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:19 AM
To: Pierre Formenty; 'twgeisbe@utmb.edu'; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

I don't think there is a guaranty that they will be all immune. I would at least wait a month which would also be good in regards to their full recovery. Overall, I would assume that survivors are immune to immediate reinfection with the same species.

MSF is using survivors here in Monrovia on the ward. They still wear PPE but less than other health care workers. I would think a low grade PPE should be used.

Heinz

From: Pierre Formenty
Sent: Monday, October 20, 2014 04:06 AM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Are Ebola survivors all immune against a re-infection?

Dear Tom, Gary and Heinz,

Over the week-end UNICEF supported a conference on Ebola Survivors in Sierra Leone. Their assumption n°1 was "all recovered Ebola patients are immune" and will not be reinfected. Assumption n°2 was that "Survivors could take care of Ebola patients without PPE".

Do we have solid evidence for this?

As NHP surviving Reston infection were rechallenged with Sudan or Zaire, I wonder if someone rechallenge NHP surviving Zaire with Zaire, and which findings? May be rechallenges studies were conducted in BLS4 and not published? I would happy to read any anecdotal report or grey litterature on rechallenges with Zaire.

Thank you for you support.

Kind regards,

Pierre

Pierre Formenty
World Health Organization

Mobile in Geneva : Personal Info

Envoyé de mon iPad

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:15 AM
To: 'jdkettner@icloud.com'
Subject: Re: Greetings from an old colleague from Winnipeg

I can call now or in a few hours - otherwise tomorrow.

What is a good number to call?

Heinz

----- Original Message -----

From: Joel Kettner [mailto:Personal Info]
Sent: Sunday, October 19, 2014 08:53 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Greetings from an old colleague from Winnipeg

Well I can't wait till then to get your thoughts on the situation! Do you have adequate internet access for a Skype call? If so, is there a best time for you?

On Oct 19, 2014, at 6:32 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

> Until November 3.

>

> ----- Original Message -----

> From: Joel Kettner [mailto:Personal Info]
> Sent: Sunday, October 19, 2014 07:06 PM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: Greetings from an old colleague from Winnipeg

>

> Thank you for your quick reply, Heinz. How long are you planning to be there?

> Joel.

>

> Joel Kettner.

>

>> On Oct 19, 2014, at 8:50 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>>

>> Joel,

>> Long time no see or whatever people say. Glad to hear from you after all those years. I hope you and the family are well. I am currently in Monrovia until early November running an Ebola lab that supports what is known as ELWA Hospital. I would love to discuss things - let me know when. We can do it when I get back or while I am here.

>>

>> Best wishes,

>> Heinz

>>

>>

>> ----- Original Message -----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:11 AM
To: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: Re: Unpublished

Unpublished

----- Original Message -----

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 11:27 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: FW: Unpublished

Unpublished

Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 10:09 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Plasmids request (Would you do me a favor)

Sounds good - many thanks.

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 10:57 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Plasmids request (Would you do me a favor)

We do. I will contact them and get the process started. Also, I found the pDisplay-GP1,2 Michael Gunn requested; Darryl suggested for him to contact Winnipeg about the antibodies Michael asked for. Unless I hear different from you, I'll pass this recommendation along.

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:55 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Plasmids request (Would you do me a favor)

Do we have those plasmids? We need an SLA.

From: Wei Wei [<mailto:wwei6@jhu.edu>]
Sent: Sunday, October 19, 2014 11:07 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Plasmids request (Would you do me a favor)

Dear Dr. Feldmann,

I am sorry to disturb you. After read your interesting paper titled "**The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence *In Vivo***", I would like to request :
(1)pCAGGS empty vector, (2)pCAGGS-NP, (3) pCAGGS-VP35, (4)pCAGGS-VP30 and
(5)pCAGGS-L mentioned in your important paper. You would be very appreciated for your great help.

We promise that:

The research materials you provide and their derivatives will only be used in our lab for non-commercial research and educational purpose.

The research materials you provide and their derivatives will not be transferred to other investigators without your permission.

We will cite the origin of the plasmids in any future publications using them.

My Fedex account is Personal Info
Thank you very much for your consideration!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:56 AM
To: 'mombouliv@gmail.com'
Subject: Re: Conakry bound

I agree with you but have no influence on this.

Heinz

From: Jean-Vivien MOMBOULI [mailto:mombouliv@gmail.com]
Sent: Sunday, October 19, 2014 09:23 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Conakry bound

Hi Heinz,

It is a pity, because those guys are being hit too hard, it would be key to kill two birds with one stone. Also, the prophylactic benefit of rVSV can be best tested in newly infected aid workers! I have just heard that a thousand doses have been transferred to WHO for a trial in Geneva! I hope this is not the case, I wish those trials could focus on the affected countries, since that is where we urgently need some solid answers!

JV M

2014-10-19 11:02 GMT+01:00 Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>:

Dear Jean-Vivien,

Good to hear from you. It will be tough to get the vaccine. They are doing a trial in Monrovia not including aid workers as far as I know.

Heinz

From: Jean-Vivien MOMBOULI [mailto:Personal Info]
Sent: Sunday, October 19, 2014 12:30 AM Eastern Standard Time
To: Munster, Vincent (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Conakry bound

Dear Vincent,

I'm willing to fly into Conakry on Thursday. With such a huge outbreak on hand, one can imagine that ebolavirus spillovers may be happening in some mammal or insect species? Wouldn't you think that there maybe some opportunity for investigation of that novel question?

Also, Redacted by agreement

JV M

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:55 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Plasmids request (Would you do me a favor)

Do we have those plasmids? We need an SLA.

From: Wei Wei [mailto:wwei6@jhu.edu]
Sent: Sunday, October 19, 2014 11:07 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Plasmids request (Would you do me a favor)

Dear Dr. Feldmann,

I am sorry to disturb you. After read your interesting paper titled "**The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence *In Vivo***", I would like to request :
(1)pCAGGS empty vector, (2)pCAGGS-NP, (3) pCAGGS-VP35, (4)pCAGGS-VP30 and
(5)pCAGGS-L mentioned in your important paper. You would be very appreciated for your great help.

We promise that:

The research materials you provide and their derivatives will only be used in our lab for non-commercial research and educational purpose.

The research materials you provide and their derivatives will not be transferred to other investigators without your permission.

We will cite the origin of the plasmids in any future publications using them.

My Fedex account is # Personal Info
Thank you very much for your consideration!

Sincerely yours

Wei Wei, PhD

Xiao-Fang Yu Lab.
Department of Molecular Microbiology and Immunology
Johns Hopkins University Bloomberg School of Public Health
E2202 Room, 615 N. Wolfe St.
Baltimore, MD 21205
Phone (410) 614-4273 Fax (410) 955-0105
E-mail: wwei@jhsph.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:21 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: Spreadsheets
Attachments: CDC_NIH_lab_data_CTs_new version_oct11.xlsx

From: Rosenke, Kyle (NIH/NIAID) [F]
Sent: Monday, October 20, 2014 10:18 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Spreadsheets

Heinz,
Here is the lab spread sheet. Complete with the Cts. Sorry I forgot to do this before we left.
Kyle

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 8:13 AM
To: 'MHoffmann@dpz.eu'
Subject: Re: AW: Reston ebolavirus

I do not know any lab that would be able to do that. Honestly, I would not work with Reston in BSL2 or BSL3.

Heinz

From: Hoffmann, Markus [<mailto:MHoffmann@dpz.eu>]
Sent: Monday, October 20, 2014 10:07 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: Reston ebolavirus

Dear Dr. Feldmann,

First of all thank you for your quick reply. Indeed, the big problem I am facing is that all people I asked have (store) Reston Ebolavirus under BSL-4 conditions. In Germany, REBOV is belongs to the risk group 2 but I understand that you can only send the virus to BSL-4 laboratories. Can you suggest me anyone who might be able to send me the virus?

Thanks for your help,
Markus

Von: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Gesendet: Montag, 20. Oktober 2014 15:39
An: Hoffmann, Markus
Betreff: Re: Reston ebolavirus

Markus,

Unfortunately not from us and you might have problems in general. In many countries all filoviruses are BSL4 pathogens including Reston ebolavirus. I can only send Reston to a certified BSL4 facility.

The general problem you might be facing is that most Reston stocks are stored in BSL4 labs and can only be shipped to BSL4 facilities.

Best wishes, Heinz

From: Hoffmann, Markus [<mailto:MHoffmann@dpz.eu>]
Sent: Monday, October 20, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Reston ebolavirus

Dear Dr. Feldmann,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 7:39 AM
To: 'MHoffmann@dpz.eu'
Subject: Re: Reston ebolavirus

Markus,

Unfortunately not from us and you might have problems in general. In many countries all filoviruses are BSL4 pathogens including Reston ebolavirus. I can only send Reston to a certified BSL4 facility.

The general problem you might be facing is that most Reston stocks are stored in BSL4 labs and can only be shipped to BSL4 facilities.

Best wishes, Heinz

From: Hoffmann, Markus [mailto:MHoffmann@dpz.eu]
Sent: Monday, October 20, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Reston ebolavirus

Dear Dr. Feldmann,

My name is Markus Hoffmann and I am a Post-Doc at the German Primate Center in Goettingen, Germany. I write to you since we are trying to find a laboratory that can provide us with a Reston ebolavirus (REBOV) isolate like that one you have used in some of your published studies (Marzi et al., 2011, J Inf Dis; de Wit et al., 2011, J Inf Dis).

Our plan is to assess the ability of certain chemical compounds to interfere with filovirus replication, first in cell culture and later (long term goal) in macaques. At our institute we have the possibility to work under BSL-3 conditions (so we have to rely on REBOV rather than the African filoviruses) and trained staff for the animal experiments is available. Furthermore, our institute has a proven history on the work with pathogenic viruses (e.g. monkeypox virus, herpes B virus, SIV).

My question to you is, if it would be (generally) possible to obtain a REBOV isolate from you (your lab)?

Sincerely,
Markus Hoffmann

Dr. Markus Hoffmann
German Primate Center (DPZ)
Leibniz Institute for Primate Research
Kellnerweg 4
37077 Göttingen

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 7:11 AM
To: 'meyer@mpiib-berlin.mpg.de'
Subject: Re: RNAi screen Ebola

Dear Thomas,

I am currently in Monrovia until early November. We can try a phone call from here if urgent but the connection is not always the best. Otherwise, we would have to wait for my return.

Best wishes, Heinz

From: Thomas F. Meyer [mailto:meyer@mpiib-berlin.mpg.de]
Sent: Monday, October 20, 2014 05:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RNAi screen Ebola

Dear Heinz,

Greeting from the Max Planck Institute in Berlin! We haven't met since quite some time and I hope you are doing well!

I am contacting you since we consider to perform a genome-wide RNAi screen with the intention to not only identify essential host cell targets but to also determine putative drugs that might be of immediate use in the fight against Ebola. As you may be aware, we have accumulated substantial experience with this fast-track strategy in the past (and current) in the context of e.g. Influenza, Chikungunya, and Chlamydia. We are currently forming a leadership team here in Berlin involving several key players in the field and I would be delighted if you would also be prepared to support us with advice and support to the extent possible.

I am aware that you must be very busy in these times but I wonder if you had time for a brief telephone conversation. I am sure you could provide us with valuable information and your personal opinion on our plans. Thus, I would be delighted if you give me a telephone number and a time slot at which I could reach you.

With best wishes!

Thomas

Professor Dr. Thomas F. Meyer
Director
Max Planck Institute for Infection Biology
Department of Molecular Biology
Charitéplatz 1
D-10117 Berlin, Germany
Phone: ++49/30-28460-400/-402
Fax: ++49/30-28460-401

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 7:08 AM
To: 'rothc@who.int'
Subject: Re: WHO Science Working Group on Ebola - Teleconference on 22 October @ 15:00 GVA Time

Cathy,

I am currently in Monrovia but will try to make the phone call. At this, however, I am not sure if I can make the face-to-face meeting.

Best wishes, Heinz

From: ROTH, Cathy Ellen [mailto:rothc@who.int]
Sent: Monday, October 20, 2014 03:43 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: WHO Science Working Group on Ebola - Teleconference on 22 October @ 15:00 GVA Time

Hi Heinz,

I hope you will be able to join this week for the teleconference. It will be followed by a face-to-face meeting in Geneva on 13-14 November.

Best wishes,

Cathy

Sent from my iPad

On 20 Oct 2014, at 09:39, "KINCAID, Janet" <kincaidj@who.int> wrote:

Dear Dr Feldmann,

On behalf of the Director-General of the World Health Organization, I wish to invite you to participate as an independent expert in a WHO consultation on how science can inform our response to the Ebola virus disease (EVD) epidemic in west Africa.

The objective of the consultation is to obtain perspectives from the review of the science in relation to the diagnostic and virological findings, clinical features, epidemiology, and the impact (including the behavioural aspects) of the disease control measures on the evolution of the outbreak. These observations could be used by WHO to:

- Consider if any changes in any aspect of our control strategy are warranted, whether immediately or later after further observation generates stronger or clearer data (if required).
- Facilitate or coordinate the gathering of important data not currently available, but needed to achieve a more profound understanding of the situation for decision-making.

The group convened its first teleconference on 7 October 2014. A follow-up teleconference will take place on Wednesday, 22 October 2014 at 15:00 Geneva Time. This teleconference will our review of the constantly changing

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 20, 2014 7:04 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Request from Matter

From: Kate Yandell Personal Info
Sent: Monday, October 20, 2014 01:15 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request from Matter

Dear Dr. Feldmann,

I am a freelance science journalist who mostly writes about biology. I have been asked by the editors of the online magazine [Matter](#) to write a description of what contracting Ebola virus involves, from initial infection through recovery or death.

I was wondering if you might be able to answer a few questions about Ebola for me Monday, Tuesday, or perhaps Wednesday.

I've read some very helpful review articles on Ebola's clinical presentation and pathobiology, but I have a few lingering questions. Primarily, I'm still trying to connect what I've learned about its symptoms to what I've learned about its pathology. For instance, what is happening during the incubation period of the virus? What events cause the onset of fever?

Please let me know if you think you might be able to help or if you can think of anyone who you think may be able to answer my questions.

Thanks,

Kate Yandell

--
Kate Yandell
www.kateyandell.com
Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 5:33 PM
To: 'jdkettner@icloud.com'
Subject: Re: Greetings from an old colleague from Winnipeg

Until November 3.

----- Original Message -----

From: Joel Kettner [mailto:[Personal Info](#)]
Sent: Sunday, October 19, 2014 07:06 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Greetings from an old colleague from Winnipeg

Thank you for your quick reply, Heinz. How long are you planning to be there?
Joel.

Joel Kettner.

> On Oct 19, 2014, at 8:50 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>

> Joel,

> Long time no see or whatever people say. Glad to hear from you after all those years. I hope you and the family are well. I am currently in Monrovia until early November running an Ebola lab that supports what is known as ELWA Hospital. I would love to discuss things - let me know when. We can do it when I get back or while I am here.

>

> Best wishes,

> Heinz

>

>

> ----- Original Message -----

> From: Joel Kettner [mailto:[Personal Info](#)]
> Sent: Saturday, October 18, 2014 04:29 PM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Greetings from an old colleague from Winnipeg

>

> Hello Heinz:

>

> I am Joel Kettner, previous chief medical officer of health of Manitoba - do you remember me?

>

> You are probably too busy for emails these days, but I have been meaning to tell you that you were excellent on CBC radio a few weeks ago, discussing the situation in West Africa. I liked your mix of science and cultural sensitivity and understanding.

>

> I would be interested in your view of the present situation and what needs to be done. I am considering volunteering for public health work in West Africa, but am not sure how useful that would be.

>

> Keep up the good work.

>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 5:28 PM
To: Pineda, Mark (NIH/NIAID) [E]
Subject: Re: MOU

Yes it does.

----- Original Message -----

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 03:04 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: MOU

Hienz: I presume these are clinical samples. I also presume the bit about a separate agreement is motivated by their sharing concerns and desire to get first. Dibs. Does it make sense in your mind to have one agreement to cover both agencies?

Mark

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 02:24 PM
To: Pineda, Mark (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

If CDC does not want the samples they should go to RML.

----- Original Message -----

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 01:12 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

Heinz: will coordinate with Gray

First, what role will Rafael play in this? If he is from NIAMS, how will he have access to an appropriate containment facility to use samples (IRF Fred?) or will these all be inactivated?

In terms of the agreement, if I am correct (Gray: Fatoumata noted an agreement with Liberia was in review when I was inquiring about the Mali ICER agreement), the CDC agreement has not yet been approved formally on the US side. While I see get why CDC would want us to have our own agreement, in this case it would likely be more efficient to have the agreement between HHS and the MOH to cover both opdivs. If I am correct about the status, that should not be difficult.

While I do not know how the GOL review process works, I think it would be easier for an already overextended government to sign one agreement as opposed to two.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 12:26 PM
To: 'michael.jarvis@plymouth.ac.uk'
Subject: Re: various

Redacted by
agreement

----- Original Message -----

From: Michael Jarvis [mailto:michael.jarvis@plymouth.ac.uk]
Sent: Sunday, October 19, 2014 02:11 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: various

Heinz,

One last question before we talk. Is there detectable viremia with the 7A in VSV-GP vaccinees?

Michael

Dr Michael A. Jarvis, PhD.
Reader in Virology & Immunology,
Director of Graduate Studies,
School of Biomedicine & Healthcare Science, University of Plymouth

E-Mail:
michael.jarvis@plymouth.ac.uk<mailto:michael.jarvis@plymouth.ac.uk>
michael.jarvis@plymouth.ac.uk

On Oct 19, 2014, at 4:08 PM, Feldmann, Heinrich (NIH/NIAID) [E]
<feldmannh@niaid.nih.gov<mailto:feldmannh@niaid.nih.gov>> wrote:

The 7A versus 8A story is complicated. We should discuss over the phone. 7A is wildtype meaning what we see in humans and apes. Tom Geisbert and I think that protection needs to be shown against 7A challenges. Many of the previous studies have used 8A challenges. This is a big thing in the field but others like to ignore this.

Redacted by agreement

Heinz

----- Original Message -----

From: Michael Jarvis [mailto:michael.jarvis@plymouth.ac.uk]
Sent: Friday, October 17, 2014 12:50 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: various

Heinz,

The meeting is now over, but was good. I introduced myself to Jürgen, and we got talking about the African Swine Fever Virus. I like him. I was also good to see Elaine, Cynthia, and Alison (who I have never really spoken to before today), and Elaine gave an excellent, and very clear presentation - probably as expected.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 12:24 PM
To: Pineda, Mark (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

If CDC does not want the samples they should go to RML.

----- Original Message -----

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 01:12 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

Heinz: will coordinate with Gray

First, what role will Rafael play in this? If he is from NIAMS, how will he have access to an appropriate containment facility to use samples (IRF Fred?) or will these all be inactivated?

In terms of the agreement, if I am correct (Gray: Fatoumata noted an agreement with Liberia was in review when I was inquiring about the Mali ICER agreement), the CDC agreement has not yet been approved formally on the US side. While I see get why CDC would want us to have our own agreement, in this case it would likely be more efficient to have the agreement between HHS and the MOH to cover both opdivs. If I am correct about the status, that should not be difficult.

While I do not know how the GOL review process works, I think it would be easier for an already overextended government to sign one agreement as opposed to two.

Of course, this approach is predicated on the idea that the provisions in the current draft would suit our needs as well. If this is principally about sample access, I would be surprised if that were not the case.

Gray: your thought on this.

Sincerely,

Mark

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 12:24 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

Mark and Gray - can you please help here - it is urgent.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 10:24 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

Mark and Gray - can you please help here - it is urgent.

Thanks, Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 11:37 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID); Pineda, Mark (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: Re: MOU

This will involve Mark Pineda and Gray Handley.
Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 11:12 AM Eastern Standard Time
To: Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)
Subject: Re: MOU

Kathy and/or Peter - can you please weigh in?

Thanks Stuart.

Heinz

----- Original Message -----

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Sunday, October 19, 2014 10:59 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 10:23 AM
To: 'pdw36@cam.ac.uk'
Cc: 'chris_whittier@hotmail.com'
Subject: Re: Gorilla vaccination

Sounds good.

----- Original Message -----

From: Dr P.D. Walsh [mailto:pdw36@cam.ac.uk]
Sent: Sunday, October 19, 2014 11:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: 'chris_whittier@hotmail.com' <chris_whittier@hotmail.com>
Subject: Re: Gorilla vaccination

Hi Heinz

I figured you were over there so did not want to pester you.

Great. I need to get back to the Allen Foundation with a proposal. Is it OK if I say something vague like

"in discussions with the developers of the VSV vaccine about its use in wild gorillas"?

Stay safe.

Peter

Peter D Walsh, PhD
Division of Biological Anthropology
University of Cambridge
(0)1223 764701
ApesInc.org
http://www.bioanth.cam.ac.uk/s_pwalsh.html

On 2014-10-19 15:47, Feldmann, Heinrich (NIH/NIAID) [E] wrote:

> Peter,
> We would certainly be interested in a project using VSV in apes. We
> may want to discuss this further some day soon. I am still in Monrovia
> until early November. Please contact me then again if you are
> interested. I am afraid I might forget otherwise when I get back.
>
> Best wishes, Heinz
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 9:12 AM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)
Subject: Re: MOU

Kathy and/or Peter - can you please weigh in?

Thanks Stuart.

Heinz

----- Original Message -----

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Sunday, October 19, 2014 10:59 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Casellas, Rafael (NIH/NIAMS) [E]
Cc: Damon, Inger K. (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)
Subject: Fw: MOU

Records Originating Outside of NIAID

a is

Original Message

From: Casellas, Rafael (NIH/NIAMS) [E] <casellar@mail.nih.gov>
Sent: Sunday, October 19, 2014 10:22 AM
To: Nichol, Stuart T. (CDC/OID/NCEZID)
Subject: Re: MOU

Will do, thank you for your quick reply

R

Rafael Casellas, Ph.D.
National Institutes of Health
10 Center Drive, MSC 1930
10/13C103-D, Bethesda,
MD. 20892, 301-402-7858
<http://casellaslab.github.io/index.html>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:47 AM
To: 'pdw36@cam.ac.uk'
Cc: 'chris_whittier@hotmail.com'
Subject: Re: Gorilla vaccination

Peter,

We would certainly be interested in a project using VSV in apes. We may want to discuss this further some day soon. I am still in Monrovia until early November. Please contact me then again if you are interested. I am afraid I might forget otherwise when I get back.

Best wishes, Heinz

----- Original Message -----

From: Dr P.D. Walsh [mailto:pdw36@cam.ac.uk]
Sent: Saturday, October 04, 2014 06:49 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: chris_whittier@hotmail.com <chris_whittier@hotmail.com>
Subject: Gorilla vaccination

Hi Heinz

I hope you are safe, sound, and not exhausted with work on the West African Ebola outbreak. I am writing because the outbreak has rekindled Paul Allen's interest in ape vaccination. He funded our VLP vaccine trial in chimps and his foundation (the Paul G. Allen Family Foundation) has recently contacted me to ask for a proposal for further Ebola vaccination work.

I have not given up on VLP's and am looking into the possibility of oral delivery. Even though they are not a natural for oral vaccination, VLPs are attractive because the folks in Africa are exceptionally wary about the idea of putting live virus baits out in area where there is serious spillover potential into endangered species. However, for obvious reasons, VLP's are not a good solution for emergency situations such as those I think we may be facing shortly with bonobos (ask me sometime whether wave spread is indeed dead).

Because of the rapid, robust immune response, VSV is clearly the best option For emergency situations. Therefore, i want to explore the possibility of getting Allen to pay for a gorilla field trial using a VSV vaccine. I understand that lots of people and institutions are involved with VSV vaccines. But I know and trust you so I figured I would start there. Please pass me off or pull in others as appropriate.

In that vein, we don't really need GMP for a gorilla trial. Thus, if it is necessary to work through your commercial partners, that is fine with me. However, it seems like it would be simpler and quicker to do something with lab grade vaccine that you or Health Canada produce on a small scale.

Finally, I am copying the vet I have worked with previously on gorilla vaccination, Chris Whittier. He has been talking with the World Wildlife Fund about doing further vaccination work at the Central African site where we did a measles vaccine trial. I think they have recently contacted Mike Jarvis about Ebola vaccines and copied you. It would be good if we pulled the strands together.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:44 AM
To: 'pdw36@cam.ac.uk'
Cc: 'michael.jarvis@plymouth.ac.uk'
Subject: Re: CMV

Peter,

Sorry for the long delay in getting back to you. I copied Michael Jarvis on my response. You may want to discuss the CMV approach with him as he is the one who got us involved. He also makes the vaccine vectors.

Heinz

----- Original Message -----

From: Dr P.D. Walsh [mailto:pdw36@cam.ac.uk]
Sent: Saturday, October 04, 2014 10:15 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CMV

Hi Heinz

I forgot to mention that I am also interested in the CMV vaccine, as a self-disseminating vaccine is something that I have always thought is the long term solution for Ebola and many other pathogens. I think that this is the kind of bold research that Paul Allen might like to fund.

But getting the people in Africa to accept the use of a self-disseminating vaccine in the wild will take some confidence building. As a step in that direction have you thought of doing captive trials in group housed NHP's (perhaps Chimps) to see how well the CMV vaccine spreads? Some work on the host specificity of CMV would also be useful in predicting spillover potential, while development of non-invasive fecal or urinary assays would allow for assessment of spillover rates in the field.

--

Peter D Walsh, PhD
Division of Biological Anthropology
University of Cambridge
(0)1223 764701
ApesInc.org
http://www.bioanth.cam.ac.uk/s_pwalsh.html

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:39 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

You cannot but I can. Ask Dawn for the stamp unless you can wait until my return.

Heinz

----- Original Message -----

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 10:34 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

Thanks

I also thought about it.
I can tell him about Gary.

Another question: can you sign simple letter agreement with noncommercial institute?

From now, I have to sign SLA to receive the virus from CDC Fort Collins. If I can sign by myself, I will do, but I guess that I cannot so it.

Hideki

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 08:28 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

I thought Gary had done similar this work. Best might be to refer them to Winnipeg.

Heinz

----- Original Message -----

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 10:26 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fw: Collaboration to test DEF201 in hamster Ebola model

Are you interested?

Unfortunately, my group does not have any manpower and time to do this kind of things for now. I have not responded, yet, but I can guide him to you and/or someone in DMT.

Have a safe travel.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:29 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Subject: Re: Collaboration to test DEF201 in hamster Ebola model

I thought Gary had done similar this work. Best might be to refer them to Winnipeg.

Heinz

----- Original Message -----

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 10:26 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fw: Collaboration to test DEF201 in hamster Ebola model

Are you interested?

Unfortunately, my group does not have any manpower and time to do this kind of things for now. I have not responded, yet, but I can guide him to you and/or someone in DMT.

Have a safe travel.

Hideki

----- Original Message -----

From: K Peri [mailto:Personal Info]
Sent: Sunday, October 19, 2014 08:12 AM
To: Ebihara, Hideki (NIH/NIAID) [E]
Cc: K Peri <kperi@hnplabs.com>
Subject: Collaboration to test DEF201 in hamster Ebola model

Redacted by agreement

I look forward to hearing from you.

Regards
Krishna

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:08 AM
To: 'michael.jarvis@plymouth.ac.uk'
Subject: Re: various

The 7A versus 8A story is complicated. We should discuss over the phone. 7A is wildtype meaning what we see in humans and apes. Tom Geisbert and I think that protection needs to be shown against 7A challenges. Many of the previous studies have used 8A challenges. This is a big thing in the field but others like to ignore this. Redacted by agr

Redacted by agreement

Heinz

----- Original Message -----

From: Michael Jarvis [mailto:michael.jarvis@plymouth.ac.uk]
Sent: Friday, October 17, 2014 12:50 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: various

Heinz,

The meeting is now over, but was good. I introduced myself to Jürgen, and we got talking about the African Swine Fever Virus. I like him. I was also good to see Elaine, Cynthia, and Alison (who I have never really spoken to before today), and Elaine gave an excellent, and very clear presentation - probably as expected.

On other fronts, I am starting to put together the RhCMV Ebola paper. I am trying to get to terms with efficacy of 7A versus 8A challenge. Other than a Profectus talk back in Aug 23, where only protection and disease was discussed (no viremia data), there seems to be very little on the state of vaccine trials using this low passage virus. I did find a link which discusses the issue:

<http://www.biosciencetechnology.com/articles/2014/09/two-anti-ebola-vaccines-historic-race> wherein citing Tom, Gary Kobinger and John Eldridge indicate that the Ad vaccines may not hold up to 7A challenge.

Can you shed any further light? I asked Andrea, but received a somewhat nebulous answer.

I hope everything is going well.

Michael

ps. Although probably too early along my select agent training, but if you are needing help with the analysis in Monrovia let me know.

Dr Michael A. Jarvis, PhD.
Reader in Virology & Immunology,
Director of Graduate Studies,
School of Biomedicine & Healthcare Science, University of Plymouth

E-Mail:
michael.jarvis@plymouth.ac.uk<mailto:michael.jarvis@plymouth.ac.uk>
michael.jarvis Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:03 AM
To: 'wil2001@columbia.edu'
Subject: Re: Ebola Engineering Challenge

Personal Info

Best wishes, Heinz

From: W. Ian Lipkin [mailto:wil2001@columbia.edu]
Sent: Friday, October 17, 2014 02:10 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola Engineering Challenge

Personal Info

On Oct 17, 2014, at 11:42 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Whenand how did this happen?

From: W. Ian Lipkin [mailto:wil2001@columbia.edu]
Sent: Tuesday, October 14, 2014 02:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Kahn Ellie <ejk2162@columbia.edu>
Subject: Re: Ebola Engineering Challenge

Ok.

Personal Info

On Oct 14, 2014, at 2:48 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Ian - having a hard time to get on interne to download the attachment. Currently in Monrovia until early November. I am sure the proposals are fine. I am happy to support. Exclude me from the article as this would need approval from Bethesda.

Sorry and best wishes, Heinz

From: W. Ian Lipkin [mailto:wil2001@columbia.edu]
Sent: Monday, October 13, 2014 10:32 AM Eastern Standard Time
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Cathy Roth <rothc@who.int>; Spiropoulou, Christina (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Rachel T. Moresky <rtm2102@cumc.columbia.edu>; Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Kahn Eleanor J. <ejk2162@cumc.columbia.edu>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:02 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Ebola diagnostic reagents?

Thomas,

Can you please help here? If we have the plasmid, please contact them on my behalf. Sorry for all the extre work.

Thanks, Heinz

From: Michael Gunn, M.D. [mailto:michael.gunn@duke.edu]
Sent: Friday, October 17, 2014 02:32 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola diagnostic reagents?

Dr. Feldmann,

I am part of a group at Duke University that develops diagnostics for infectious diseases. The engineering part of our group has recently developed a novel point-of-care assay platform that is essentially a miniaturized sandwich ELISA on a small portable cassette. The key advantages of this platform are 1) that no mixing of reagents is required (the assay goes to completion with just a drop of blood) and 2) that we can achieve limits of detection in the 1 pg/ml range.

Given the pressing need for an Ebola diagnostic, I am trying to determine if we can use existing reagents to develop a point of care assay to detect ebola sGP in the blood that would actually work in the field. From what I can tell, the POC assays currently being tested have an LOD in the 100 ng/ml range, which I do not think will provide sufficient sensitivity. I have three questions for you.

First, we will need to use recombinant sGP to develop our assay. Would it be possible to obtain the pDisplay-sGP plasmid that you described in your 2005 *J. Virology* paper (Wahl-Jensen et al)? We have a lot of experience with protein expression and could construct an expression plasmid ourselves, but having one already shown to work well would save us significant time. If it is possible to obtain this plasmid, please let me know what I would need to do.

Second, I would like to test three monoclonal Abs that were described by Mavanur Suresh in a 2007 *J. Virological Methods* paper (Shahhosseini et al) on which you were a co-author. These would be the three mAbs that reacted to sGP per his data. However, when I tried to track Dr. Suresh down, it appears that he is no longer at the University of Alberta and his name does not pop up anywhere else. Would you by any chance know what became of Dr. Suresh or who should be contacted about any of the mAbs that he developed?

Third, I am in no way a virologist and have zero background knowledge of Ebola. In looking at the biology of Ebola, sGP seems like the clear choice for a diagnostic target, yet most of the assays described seem to target other viral proteins. Is this just based on the Abs that people have come up with or am I missing something important?

Thank you very much for any information that you can provide. Also, best of luck with your work in what is undoubtedly a very hectic time.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 8:01 AM
To: 'mclauss@iupui.edu'
Subject: Re: TNF expression in HUVEC

Matthias,


We have considered it but not much on it. I am currently in Monrovia until early November. We should talk anyway after all those years and several attempts from your end. If you are still interested, please contact me early November. I am afraid that things get lost when I get back.

Best wishes, Heinz

From: Clauss, Matthias A [mailto:mclauss@iupui.edu]
Sent: Friday, October 17, 2014 02:34 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: TNF expression in HUVEC

Hallo Heinz,

Redacted by agreement



Thanks

Matthias Clauss
[Associate Research Professor of Cellular and Integrative Physiology](#)
Indiana Center for Vascular Biology and Medicine
RLR-VA Medical Center - C 3108
1481 West 10th Street
Indianapolis, IN 46202
Phone: (317) 988-4076
MClauss@iupui.edu

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Thursday, May 26, 2011 11:26 AM
To: Clauss, Matthias A
Subject: RE: Meeting

Cell: Personal Info
Office: 406-375-7410

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 7:57 AM
To: 'rafael.delgado@salud.madrid.org'
Subject: Re: Request of advice for lab facility

Dear Rafael,

I am currently in Monrovia until early November. My expertise is Ebola in general. Lab diagnostics and high containment but not patient management. I would be more than happy to discuss things with you when I get back. If you wish to talk, please contact me again at the beginning of November.

Best wishes, Heinz

----- Original Message -----

From: Delgado Vazquez.Rafael [mailto:rafael.delgado@salud.madrid.org]
Sent: Saturday, October 18, 2014 03:45 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request of advice for lab facility

Dear Dr Feldmann

My name is Rafael Delgado, I'm a physician researcher in Madrid, Spain. Since my postdoctoral training in Gary Nabel's Lab, I began working in the Ebola field and once back in Spain, where I (try to) combine clinics and lab, I have continued active on Ebola and our group has made some contribution specifically on the interaction of Ebola GP with C-type lectins working with pseudotypes.

I'm contacting you due to your expertise in the field, your condition of scientist and doctor, and also on your recent activity on the affected area in Africa. You probably are aware that we have

Redacted by agreement

Redacted by agreement

The Spanish Government has designed a Scientific Advisory Committee, of which I'm a member, to deal with the Ebola outbreak both at the national level and also is considering to increase its participation on the affected area through the deploy of 1-2 units for treatment of patients (25-50 beds each) as some other countries are already doing. As you probably may know Spain has a relatively advanced National Health System with experienced professional in areas such as Infectious and Tropical Diseases and a good network of diagnostic microbiology laboratories with wide experience in molecular biology techniques. This effort is planned to be implemented with the help of one of the agencies already active in the zone that would be most probably the International Red Cross.

At the present moment I'm trying, in collaboration with other colleagues in different clinical areas, to organize all the logistics related to this project and specifically on the requirements of laboratory facilities to serve one of this projected units. I would very much appreciate your advice in this particular matter or the indication of a reference source of information to have an estimation of equipment, organization, biosafety issues and whatever information could be useful to be helpful as soon as possible.

Even though this is a primarily humanitarian project scientific and research issues will also be incorporated so any suggestions in this area will specially be welcome.

Thank you very much for attention and I look forward to having your comments or references and hopefully the opportunity of scientific collaboration in the near future related to this unprecedented situation.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 7:51 AM
To: 'jdkettner@icloud.com'
Subject: Re: Greetings from an old colleague from Winnipeg

Joel,
Long time no see or whatever people say. Glad to hear from you after all those years. I hope you and the family are well. I am currently in Monrovia until early November running an Ebola lab that supports what is known as ELWA Hospital. I would love to discuss things - let me know when. We can do it when I get back or while I am here.

Best wishes,
Heinz

----- Original Message -----

From: Joel Kettner [mailto:Personal Info]
Sent: Saturday, October 18, 2014 04:29 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Greetings from an old colleague from Winnipeg

Hello Heinz:

I am Joel Kettner, previous chief medical officer of health of Manitoba - do you remember me?

You are probably too busy for emails these days, but I have been meaning to tell you that you were excellent on CBC radio a few weeks ago, discussing the situation in West Africa. I liked your mix of science and cultural sensitivity and understanding.

I would be interested in your view of the present situation and what needs to be done. I am considering volunteering for public health work in West Africa, but am not sure how useful that would be.

Keep up the good work.

Best regards,

Joel Kettner.
Medical director, International Centre for Infectious Diseases, Winnipeg.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 19, 2014 4:03 AM
To: [Personal Info]; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Conakry bound

Dear Jean-Vivien,

Good to hear from you. It will be tough to get the vaccine. They are doing a trial in Monrovia not including aid workers as far as I know.

Heinz

From: Jean-Vivien MOMBOULI [Personal Info]
Sent: Sunday, October 19, 2014 12:30 AM Eastern Standard Time
To: Munster, Vincent (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Conakry bound

Dear Vincent,

I will be flying into Conakry on Thursday. With such a huge outbreak on hand, one can imagine that ebolavirus spillovers may be happening in some mammal or insect species? Wouldn't you think that there maybe some opportunity for investigation of that novel question?

Also, [Redacted by agreement]

JV M

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:32 PM
To: 'honey@uw.edu'
Subject: Re: Unpublished manuscript

No internet since days - cannot download anything. Also extremely busy the last few days. I will try.

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:31 PM
To: Sanderson, Philip (NIH/NCATS) [E]
Cc: Zheng, Wei (NIH/NCATS) [E]; Michael, Sam (NIH/NCATS) [E]
Subject: Re: repurposing screen for ebola

I am currently in Monrovia until early November.

From: Sanderson, Philip (NIH/NCATS) [E]
Sent: Friday, October 17, 2014 04:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Zheng, Wei (NIH/NCATS) [E]; Michael, Sam (NIH/NCATS) [E]
Subject: repurposing screen for ebola

Dear Dr. Feldmann,

I am with NCATS and am contacting you concerning the use of our small molecule libraries of approved and investigational drugs for the identification of treatments for ebola infection. Sarah Anzick passed on your name to us.

Wei Zheng's group in our laboratories (BSL2) is performing a screen for inhibitors of viral entry. However, ideally, we want to have the compound set screened in a BSL4 facility against viable virus to try to hit the full range of targets. We do not want to miss a drug in our compound collection which could be an effective treatment.

We have a number of libraries, the most useful for this purpose being the approved drug library (2,800 compounds) and a library of clinical investigational drugs (2,000 compounds).

I am cc'ing Sam Michael, director of our automation and compound management group.

We are happy to discuss at your earliest convenience.

Best regards

Phil

Philip Sanderson, PhD
Therapeutics for Rare and Neglected Diseases
National Center for Advancing Translational Sciences
9800 Medical Center Drive
Rockville, MD 20850
philip.sanderson@nih.gov
office: 301 217 5818

NOTICE: This e-mail and any attachments to it are intended only for the identified recipients. It may contain proprietary or otherwise legally protected information for the National Center for Advancing Translational Sciences (NCATS). Any unauthorized use or disclosure of this communication is strictly prohibited. If you have received this communication in error, please notify the sender and delete or otherwise destroy the e-mail and all attachments immediately.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:30 PM
To: 'muehlber@bu.edu'
Subject: Re: diagnostics

I am currently in Monrovia. We are using slightly adapted assays from Winnipeg. You would have to ask Gary Kobinger, Jim Strong or Allen Grolla for the assay conditions.

In terms of testing US citizens you may want to be more careful. As far as I know you need to use a FDA pre-approved assay. I would contact CDC or the State Public Health Lab to get advise on the assays. We were told that our current assays here in Monrovia are OK for the outbreak mission but not for testing US citizens. I guess they are different when it comes to Ebola.

Don't ask me why - same stupidity as with all the other things in the US regarding Ebola. Decisions are being largely made by people who do not know anything and on top of it are not the smartest cookies.

Best wishes, Heinz

From: Muhlberger, Elke [mailto:muehlber@bu.edu]
Sent: Friday, October 17, 2014 05:03 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: diagnostics

Hi Heinz,

Hope you are doing well. I was wondering if you would be willing to share your Ebola virus diagnostic PCR protocol with us. More and more people, including humanitarian organizations, are asking us for advice and it would be helpful if we knew what is used in the field. Also, there is so much panic about EBOV that it would be nice for the ID guys to have at least a preliminary screen that a patient with fever coming from Haiti is not infected with EBOV.

Thank you so much,

Elke

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:23 PM
To: 'barrenas@uw.edu'; 'ilhem.messaoudi@ucr.edu'; Marzi, Andrea (NIH/NIAID) [E]; YOSHIHIROKAWAOKA
Cc: 'greener@uw.edu'; 'mnkyboy@uw.edu'; 'gllaw@uw.edu'; 'honey@uw.edu'
Subject: Re: Unpublished manuscript

I need more than two days for this. I am not even sure if I can access the file.

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:22 PM
To: Personal Info
Subject: FW: Unpublished manuscript
Attachments: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:20 PM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: Re: Ebola antibody

Yes we do - SLA.

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:51 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola antibody

Do we need an MTA in place for this?

From: <Marzi>, Andrea Marzi <marzia@niaid.nih.gov>
Date: Saturday, October 18, 2014 10:51 AM
To: "<malik@hku.hk>" <malik@hku.hk>
Cc: Heinz Feldmann <feldmannh@niaid.nih.gov>
Subject: RE: Ebola antibody

Dear Malik,

Heinz forwarded me your request for antibodies.
We can provide a few inactivated NHP serum samples from animals that survived challenge. But only up to 0.5ml.
Would that be enough?

Please let me know.

Thanks,
Andrea

Andrea Marzi, Ph.D.
Staff Scientist
Laboratory of Virology
Rocky Mountain Laboratories, NIAID, NIH
903 South 4th Street
Hamilton, MT 59840

Phone: 406-375-7421
Fax: 406-375-9620
email: marzia@niaid.nih.gov

From: Malik [<mailto:malik@hku.hk>]
Sent: Wednesday, October 15, 2014 09:46 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola antibody

Dear Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:18 PM
To: 'vherrera@bu.edu'
Subject: Re: question re **Unfunded** for Ebola non-medical research

I am away until early November - we can discuss when I get back. If this takes too long you may want to contact Tom Geisbert.

From: Herrera, Victoria L M [mailto:vherrera@bu.edu]
Sent: Saturday, October 18, 2014 01:47 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: question **Unfunded** for Ebola non-medical research

Hi Dr. Feldmann

Allow me to introduce myself - Victoria Herrera, MD, Professor of Medicine at the Whitaker Cardiovascular Institute at Boston University School of Medicine. One aspect of my research is the microvasculature in cardiovascular disease. I am considering submitting a **Unfunded** for Ebola non-medical research - based on an observation of published histology images of Ebola infected patients.

I have been thinking about studying the endothelium and the endothelial glycocalyx integrity since Ebola hit the news this year. I know papers have been published reporting that the endothelial cells do not harbor the virus in the pre-symptomatic stage and only exhibit viral presence after symptoms are present.

However, upon looking at the histology presented in those papers, (and based on my visual picture of what a normal endothelium looks from my animal model research in vascular disease), I strongly suspect that something has happened to the vascular endothelium earlier and therefore, I propose to study this to gain insight into potential mechanism(s) for earlier potential contagion (not 100% 'penetrance') prior to symptom presence, and to gain insight into figuring out a potential test that could be informative earlier for exposed individuals prior to symptoms for the detection of EBOLA using existing clinical technologies. This would help in containment which does not seem to be working when based on the concept that contagious phase begins when symptoms begin. I think this concept is not watertight.

I was wondering if you have, or know where I can get histology slides of Ebola animal model tissues at different time points from infection with Ebola --ie, especially early stages before symptoms appear in the animal models. I would like to propose to study them.

May I invite you as collaborator or consultant, depending on your availability, for this **Unfunded** understand if it is not possible. We do have the NEIDL here at BUSM, and I can avail of their microscopes.

My naïve question: if paraffin embedded sections from fixed tissues are on slides which are stained and mounted and coverslipped, are they still considered infectious or can they be viewed in a regular lab microscope?

I can imagine you are very busy. I appreciate your consideration and feedback - hope this is not a crazy idea. I am thinking that this work can be done within a year or shorter once I get the slides. Meticulous proper documentation is necessary - and will be tedious but can be done.

Question: does animal model research qualify for "non-medical" research according to NSF request for RAPID proposals for Ebola?

Best
Victoria

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 10:56 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: Re: glycoprotein cDNA clone request

Thanks.

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 12:00 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: glycoprotein cDNA clone request

I'll reply and copy you.
A.

From: <Feldmann>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Date: Saturday, October 18, 2014 9:19 AM
To: Andrea Marzi <marzia@niaid.nih.gov>
Subject: Fw: glycoprotein cDNA clone request

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 11:19 AM Eastern Standard Time
To: 'marzia@niaid.nih.gov' <marzia@niaid.nih.gov>
Subject: Fw: glycoprotein cDNA clone request

Can you please look into this request. I may have asked you before.

From: Ethan Bier [<mailto:ebier@ucsd.edu>]
Sent: Friday, October 17, 2014 05:30 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Personal Info

Thanks and best regards,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 9:20 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: Fw: glycoprotein cDNA clone request

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 11:19 AM Eastern Standard Time
To: 'marzia@niaid.nih.gov' <marzia@niaid.nih.gov>
Subject: Fw: glycoprotein cDNA clone request

Can you please look into this request. I may have asked you before.

From: Ethan Bier [mailto:ebier@ucsd.edu]
Sent: Friday, October 17, 2014 05:30 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Personal Info

Thanks and best regards,

Ethan

--

Ethan Bier
Section of Cell and Developmental Biology
Bonner Hall, Room 4218
University of California, San Diego
9500 Gilman Drive
La Jolla, CA 92093-0349

Tel. (858) 534-8792

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 9:19 AM
To: 'marzia@niaid.nih.gov'
Subject: Fw: glycoprotein cDNA clone request

Can you please look into this request. I may have asked you before.

From: Ethan Bier [mailto:ebier@ucsd.edu]
Sent: Friday, October 17, 2014 05:30 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Personal Info

Thanks and best regards,

Ethan

--

Ethan Bier
Section of Cell and Developmental Biology
Bonner Hall, Room 4218
University of California, San Diego
9500 Gilman Drive
La Jolla, CA 92093-0349

Tel. (858) 534-8792
Fax. (858) 822-2044
Email: ebier@ucsd.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 18, 2014 3:26 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Understanding Ebola

Good luck for the game.

From: Jeremy Walker Personal Info
Sent: Friday, October 17, 2014 08:48 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Understanding Ebola

Hello Mr. Feldmann, I am Jeremy Walker, a citizen journalist and have been pouring through your research and science articles.

I would be most honored to interview you on Skype video in my effort to assist in educating the public on this, now, most sensitive national matter.

For example, specifically, what are the most notable methods of preventing infection? I read in a separate science journal apoptosis of bystander lymphocytes and loss of NK cells is the most notable mode of progression or maturation of the virus. Also, what are the role of monocytes transmuting to macrophages or dendritic cells if monocytes have an inhibitory effect on the progression of this apoptosis? Is there a correlation between a high production of monocytes and increased survival rate based on more dendritic cells or more macrophage cells?

Thank you for your time.

Best wishes,

Jeremy Robert Walker
Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:01 PM
To: Marzi, Andrea (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]; Walczynski, Joyce (NIH/NIAID) [C]
Subject: Fw: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation
Attachments: Itinerary Liberia AMarzi OctNov2014.pdf; ItineraryKV7B7W_26SEP.PDF; itinerary_E de Wit.pdf
Importance: High

Andrea,

Why are you scheduled to arrive on October 26 (see below)? Please clarify - this makes no sense as I leave on October 31.

Heinz

From: goarn [mailto:goarn@who.int]
Sent: Friday, October 17, 2014 12:21 PM Eastern Standard Time
To: GRAAFF, Peter Jan <graaffp@who.int>; GASASIRA, Alex Ntale <gasasiraa@who.int>; WERTSCHNIG, Brian Adam <wertschnigb@who.int>; WAI, Lokky <wail@who.int>
Cc: DAVIS, Raphael <davisr@who.int>; KOLLIE, Robert K. <kollier@who.int>; FREEMAN DELINE, Nancy <delinen@who.int>; UMALI DALANGIN, Khristeen <umalik@who.int>; SEOCC <afrgoseocc@who.int>; goarn <goarn@who.int>; SHOC <shoc@who.int>; KASHYAP, Sanjeev <kashyaps@who.int>; Pierre Formenty; NAIDOO, Dhamari <naidood@who.int>; DRURY, Patrick Anthony <druryp@who.int>; SAIKAT, Sohel <saikats@who.int>; NORTON, Ian <nortoni@who.int>; NYONPLUE, Richard G. <nyonpluer@who.int>; MWANAMWENGGE, Abrahams <mwanamwengea@who.int>; mwanamwenge@who.int <mwanamwenge@who.int>; Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: Arrival of GOARN experts : NIH lab team #4: Drs Emmie de Wit, Darryl Falzarano & Andrea Marzi, Ebola response, Liberia / request for airport pick-up & accommodation

Dear WR, Dr Gasasira and Colleagues,

We wish to inform you of the flight details of the GOARN lab experts (team#4) from the National Institute for Health (NIH), USA:

Team#4 consists of:

1. **Dr Emmie de Wit** will arrive in Monrovia on **Monday, 20 October 2014 at 19h20** on flight SN1247 from Brussels. She will depart Monrovia on 14 November 2014 at 21:35 via the same flight SN1247.
2. **Dr Darryl Falzarano** is traveling on the same flight as Dr Emmie de Wit arriving on **Monday, 20 October 2014 at 19h20** on flight SN1247 from Brussels. She will depart Monrovia on 14 November 2014 at 21:35 via the same flight SN1247.
3. **Dr Andrea Marzi (Team leader)** will arrive in Monrovia on **26 October 2014 at 20h15** on flight SN1247 from Brussels. She will depart Monrovia on 21 November 2014 at 21h35 via the same flight SN1247.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 5:33 PM
To: Clifton, Dawn (NIH/NIAID) [E]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Re: Request for Lockheed Martin Reconsideration: Travel to Liberia for [Personal Info]

Thanks Dawn. Our weekends are good as every day - no difference.

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 06:29 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: FW: Request for Lockheed Martin Reconsideration: Travel to Liberia for [Personal Info]

Hi Heinz,
Lisa has submitted the petition to Lockheed for [Perso] to travel. She sends her thanks and appreciation for the information you sent which she felt was extremely helpful. You can read it below if you wish.

Also, since Ricki has [Personal Info] MSC states that it is not a problem to pick up her contract—they had not done so previously since Lockheed had initially [Personal Info] and no one had updated or pursued a move once her [Personal Inf] was obtained. I'm sure this was in part due to the fact that [Perso] was/is not an LV employee and there was no impetus to do so. We are only pushing the situation now for our purposes, which lead us to this determination. We should probably bring in Randy as a courtesy too, since she is now part in his group. Lisa also suggests moving [Personal] to MSC, which I will discuss with her upon her return from Germany to see if she wants to do this. There will be no gap in employment benefits or health insurance for either one—MSC is working hard to accomplish this with us.

I will be discussing this further with Lisa and [Pers] on Monday, and I will notify Randy and Colleen (RMVB's AO) as needed.

I hope you have a good weekend, and I will update you further on Monday.

Dawn

From: Coronado, Lisa (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 5:13 PM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: FW: Request for Lockheed Martin Reconsideration: Travel to Liberia for [Personal Info]

Hi Dawn,

Petition submitted. Let's keep our fingers crossed.

Lisa

From: Coronado, Lisa (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 7:11 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]
Cc: Mays, Gary (NIH/NIAID) [E]; Blaney, Joe (NIH/NIAID) [E]; Sullivan, Kevin (NIH/NIAID) [E];

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 3:30 PM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: Re: glycoprotein cDNA clone request

Please set it up.

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 12:42 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: glycoprotein cDNA clone request

Yes, we can and yes, MTA.
Do you want to reply or want me to setup the thing?

From: <Feldmann>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 17, 2014 9:41 AM
To: Andrea Marzi <marzia@niaid.nih.gov>
Subject: Fw: glycoprotein cDNA clone request

Can we do this? We need MTA.

From: Ethan Bier [<mailto:ebier@ucsd.edu>]
Sent: Tuesday, October 14, 2014 05:42 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Personal Info

Thanks and best regards,

Ethan

--

Ethan Bier
Section of Cell and Developmental Biology
Bonner Hall, Room 4218
University of California, San Diego

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:44 PM
To: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Re: anything??

AAA batteries for Jonathan the driver. I cannot think of anything else.

Will call you later.

Love you.

----- Original Message -----

From: Feldmann, Ricki (NIH/NIAID) [C]
Sent: Friday, October 17, 2014 01:26 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: anything??

Is there anything you want Emmie and Darryl to bring?
Everything is fine here.
Love you,
Ricki

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:51 AM
To: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Fw: conference call re hyperthermia treatment for Ebola virus

If you have time, can you make a quick listing of what was tested so that I can forward it? Please do it in the email text rather in an attachment.

Here is everything is fine. How about you and David?

Love you - miss you.

----- Original Message -----

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 03:27 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz, Ricki says all the [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

Elaine Haddock, Ph.D.
Biologist, LV

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:37 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Bats in Austin, Texas

From: John Savage [mailto:[Personal Info](#)]
Sent: Friday, October 17, 2014 04:08 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Bats in Austin, Texas

Hi Dr. Feldmann,

I'm a reporter working on a piece that involves bats and Ebola, and I came across your study on the subject. Could I ask you a few questions? Give me a call anytime today if you get a chance, my numbers are below. Thanks!

Best,
John

[Personal Info](#)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:36 PM
To: 'gdavis@chimerix.com'
Subject: Re: Ebola - BCV

I did forward your email to the POC in Missoula.

----- Original Message -----

From: Gray Davis [mailto:gdavis@chimerix.com]
Sent: Friday, October 17, 2014 04:29 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - BCV

Dr. Feldmann,

Fred Hayden gave me your name as a potential source of information. My name is Gray Davis and I am working with Chimerix as part of their Ebola response. As you know BCV is one of the therapeutic products being studied for the treatment of Ebola. We are trying to streamline our response times in case we get requests from the various crisis centers. To that end we are trying to get all of the regulatory paperwork and approvals completed prior to the need for drug shipments. Having the appropriate approvals and procedures established early can significantly improve response times.

Do you have a contact name at St. Patrick Hospital in Missoula, Montana? We are trying to get to this hospital so that we can work out the logistics for a rapid response. We appreciate any help that you could provide.

Gray

Gray Davis , Ph.D.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 2:36 PM
To: 'George.Risi@providence.org'
Subject: Fw: Ebola - BCV

Did not want to give him your email. Please contact him if you wish.

Heinz

----- Original Message -----

From: Gray Davis [mailto:gdavis@chimerix.com]
Sent: Friday, October 17, 2014 04:29 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - BCV

Dr. Feldmann,

Fred Hayden gave me your name as a potential source of information. My name is Gray Davis and I am working with Chimerix as part of their Ebola response. As you know BCV is one of the therapeutic products being studied for the treatment of Ebola. We are trying to streamline our response times in case we get requests from the various crisis centers. To that end we are trying to get all of the regulatory paperwork and approvals completed prior to the need for drug shipments. Having the appropriate approvals and procedures established early can significantly improve response times.

Do you have a contact name at St. Patrick Hospital in Missoula, Montana? We are trying to get to this hospital so that we can work out the logistics for a rapid response. We appreciate any help that you could provide.

Gray

Gray Davis , Ph.D.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 10:07 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: EBOV material request

SLA is fine unless it is a request from and industrial firm.

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 17, 2014 11:14 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: EBOV material request

Hi Heinz,

Another request for the trVLP system, this time from Spain. Can I go ahead as usual (i.e. we can share with an SLA)?

All the best, Thomas

From: PEREZ VILARO, GEMMA [mailto:gemma.perez@upf.edu]
Sent: Friday, October 17, 2014 7:58 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: JUANA MARÍA DÍEZ ANTÓN
Subject: EBOV material request

Dear Dr. Hoenen,

My name is Gemma, I am working as a PostDoc in the laboratory of Molecular Virology under the supervision of Dr. Juana Díez. Currently we are investigating the involvement of different host factors in viral RNA replication and we would like to expand to other viruses. In this context, we would be very grateful if you could provide us the plasmids detailed below to work with Ebola virus-like particles containing tetracistronic minigenomes described in your publication: "Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes, published in JOVE, 2014". The paper was extremely informative and nicely written!

The plasmids that we would need are:

pCAGGS-NP

pCAGGS-VP35

pCAGGS-VP30

pCAGGS-L

pCAGGS-T7

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:54 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Press Inquiry: Ebola transmission, for Wired?

From: nadia drake [Personal Info]
Sent: Friday, October 17, 2014 10:44 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Press Inquiry: Ebola transmission, for Wired?

Hi Dr. Feldmann --

I'm a science reporter and am working on a story for Wired about Ebola transmission. We'd like to address concerns about the virus mutating and becoming airborne by explaining as much as we know about how it gains entry to host cells, where those cells are in the body, and what would need to change for it to become respiratory.

Is there any chance you might be able to help me out with this? I've seen a few studies suggesting that Ebola can affect the lungs and congregate in alveoli ([here's a review with some of that](#)) but I don't know what that all means and if it's significant. Are you aware of any studies in rodents or primates that might be informative here?

I'm trying to collect all my information today, so if you're available for a phone call, that would be great! My day is free after about 12:30pm EDT.

Cheers,
Nadia

--

Nadia Drake
Science Reporter
San Francisco, CA
nadiadrake1@gmail.com
[Personal Info] (mobile)
Twitter: [Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:51 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: Re: Ebola antibody

Thanks for the update - can you contact Malik and let him know what we have?

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 10:36 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola antibody

We have some serum from immunized or immunized/challenged animals that we can share. Not a whole lot though.

I think the talk went ok. Received several emails already thanking for the info we provided and helping answer a lot of questions that are obviously posed by the community.

The seminar room was packed, have never seen it that full and I was a bit scared.

The 3 main things we got across were:

1. RML is providing a service doing diagnostics, no research
2. We don't have patient contact – so yes, we are welcome home and the OMS surveillance program was well received (people were worried we would just walk into a physicians office if we would get sick, but that is just not going to happen)
3. We volunteer for this work are not sent/deployed to do this

Think the talks were well received. It was certainly interesting to see George's pictures and hear his stories.

I decided to keep the background and science to a minimum, not wanting to give the expression that we do research over there.

Focused on our setups instead, what a day over there is like, the samples we processed etc. Pretty much very similar to what I showed at WIP when we got back and added the OMS slide in the end.

Hope all is well over there with you guys.

Andrea

From: <Feldmann>, Heinz Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 17, 2014 6:57 AM
To: Andrea Marzi <marzia@niaid.nih.gov>
Subject: Fw: Ebola antibody

Have you looked into this? Can we provide antibodies? Please let me know or contact Malik directly (please copy me).

How was your seminar? I heard very good things about it? Are we still welcome back home?

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:47 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Interview for University of Zurich

From: susan.kamal@ethik.uzh.ch [mailto:susan.kamal@ethik.uzh.ch]
Sent: Friday, October 17, 2014 09:51 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview for University of Zurich

Dear Dr.Feldmann,

I hope you are well. I am Susan a researcher at the institute of Biomedical ethics at the university of Zurich. I am currently working on a case study on Ebola, and I would like to ask you for a telephone interview for about 20 minutes. Would this be possible?

I look forward to hearing from you.

Best wishes,
Susan

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:46 AM
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Re: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

Thanks -

From: Auchincloss, Hugh (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 10:10 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

Fyi. No response necessary.

Hugh

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:24 PM
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

Please handle.

Begin forwarded message:

From: "Sengupta, Tapas K." <Tapas.Sengupta@inova.org>
Date: October 16, 2014, 2:35:20 PM EDT
To: "anthony.fauci@nih.gov" <anthony.fauci@nih.gov>
Subject: FW: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

Dr. Fauci,

Thank you for your leadership role in fighting Ebola. Thank you again for letting your colleague answer my question in my previous e-mail. I sent you the e-mail below in August and your colleague wrote me back saying that the hydrolase inhibitor would not work and was found too toxic in humans. May be, but I also found in another article that the antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from *Trypanosoma cruzi* ([Bioorg Med Chem](#). 2007 Dec 1;15(23):7281-7). Is there a way that the same principle may be researched further and customized to fight Ebola? This might be even body's natural mechanism to fight viruses, as some people have shown higher levels of S-adenosyl homocysteine (SAH) in blood without low levels of vitamin B12 and Folate (may be they just fought off a viral infection when blood was sampled?). It seems that the antiviral function of hydrolase inhibitor may come from

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:44 AM
To: 'WillisD@ebsi.com'
Subject: Re: Rabies virus seed materials

We do not have rabies in my lab. You may want to ask Matthias Schnell.

From: Willis, David [mailto:WillisD@ebsi.com]
Sent: Friday, October 17, 2014 10:27 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Rabies virus seed materials

Dear Dr. Feldmann,

I am writing in search of rabies seed stock sources. Emergent BioDefense has a product license (BLA) for a human Rabies Vaccine (Rabies Vaccine Adsorbed). Our original Kissling derived seed stock is no longer available and we are looking at other possible sources. One option would be to obtain the same Kissling line originally received from CDC. We are making requests at CDC in this regard, however they are somewhat preoccupied at the moment with Ebola. Given that your facility's involvement in both areas (Rabies and Ebola), we thought you might have access to original Kissling strain Rabies seed materials.

I would appreciate hearing from you at your convenience,

Sincerely,

David Willis, PhD
Senior Manager, Regulatory Affairs
Biodefense Division

Emergent BioSolutions
3500 N. Martin Luther King Jr. Blvd.
Lansing, MI 48906-9910

t 517 327 7295
f 517 327 6895
i 107295
e willisd@ebsi.com
www.emergentbiosolutions.com
www.linkedin.com/companies/emergent-biosolutions
@emergentbiosolu

This e-mail communication (including any attachments) contains information from Emergent BioSolutions or its affiliates that is confidential and may be privileged. The information contained herein is intended only for the use of the addressee(s) named above. If you are not the intended recipient (or the agent responsible to deliver it to the intended recipient), you are hereby notified that any dissemination, distribution, use, or copying of this communication is strictly prohibited. If you have received this e-mail in error, please immediately reply to sender, delete the message and destroy all copies of it. If you have questions, please email netops@ebsi.com. Thank you.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:42 AM
To: 'wil2001@columbia.edu'
Cc: 'ejk2162@columbia.edu'
Subject: Re: Ebola Engineering Challenge

When and how did this happen?

From: W. Ian Lipkin [mailto:wil2001@columbia.edu]
Sent: Tuesday, October 14, 2014 02:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Kahn Ellie <ejk2162@columbia.edu>
Subject: Re: Ebola Engineering Challenge

Ok. Wish I were there. Stuck in U.S. Personal Info

On Oct 14, 2014, at 2:48 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Ian - having a hard time to get on internet to download the attachment. Currently in Monrovia until early November. I am sure the proposals are fine. I am happy to support. Exclude me from the article as this would need approval from Bethesda.

Sorry and best wishes, Heinz

From: W. Ian Lipkin [mailto:wil2001@columbia.edu]
Sent: Monday, October 13, 2014 10:32 AM Eastern Standard Time
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Cathy Roth <rothc@who.int>; Spiropoulou, Christina (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Rachel T. Moresky <rjm2102@cumc.columbia.edu>; Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Kahn Eleanor J. <ejk2162@cumc.columbia.edu>
Subject: Ebola Engineering Challenge

Dear Armand, Cathy, Christina, Heinz, Lisa, Rachel and Stuart,

Attached please find brief proposals that address needs that one or more of you have suggested might be amenable to low cost engineering solutions including improvements in decontamination of electronic equipment, disinfectant solutions, body bags, patient transport, and data collection and management. I will be vetting these proposals with the engineering faculty on Wednesday 15 October btw 11 AM and 3 PM EST. It would be helpful if you would fill in the attached score sheet by Tuesday evening. Please don't spend more than 30 minutes in total reading and scoring the proposals. What we want to know is whether you think the teams are meeting a need and whether a course correction or additional information is needed.

Thanks,

Ian

ps. The New Yorker Magazine will be writing this up as a feature story. Please tell me whether you do or don't want us to include your name.

W. Ian Lipkin, MD
John Snow Professor of Epidemiology,
Mailman School of Public Health

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 9:41 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: Fw: glycoprotein cDNA clone request

Can we do this? We need MTA.

From: Ethan Bier [mailto:ebier@ucsd.edu]
Sent: Tuesday, October 14, 2014 05:42 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: glycoprotein cDNA clone request

Dear Dr. Feldmann,

My lab has been studying the cellular effects of bacterial and viral virulence factors using fruit flies as a discovery system (e.g., anthrax toxins: <http://www.ncbi.nlm.nih.gov/pubmed/20944747> and cholera toxin: <http://www.ncbi.nlm.nih.gov/pubmed/24034615>).

We are interested in using similar approaches to identify potential new functions of ebola glycoproteins in *Drosophila*. I contacted Dr. Richard Copans for cDNA clones encoding the sGP and full length GP1,2 for these studies. He replied that he could send us a clone for the secreted glycoprotein but that he did not have one for the full length form GP1,2. He suggested that you might have such a GP1,2 full length clone. If so, could you send it to us?

Our FedEx number is Redacted by

Thanks and best regards,

Ethan

--

Ethan Bier
Section of Cell and Developmental Biology
Bonner Hall, Room 4218
University of California, San Diego
9500 Gilman Drive
La Jolla, CA 92093-0349

Tel. (858) 534-8792
Fax. (858) 822-2044
Email: ebier@ucsd.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 7:15 AM
To: Moss, Bernard (NIH/NIAID) [E]
Subject: Re: Ebola

Bernie,

Sorry for the late response. I am currently in Monrovia for the rest of the month. In general we would be interested but didn't Nancy Sullivan include an MVA vector in her last paper with no protectivity in NHPs? Tom Geisbert also told me that something went terribly wrong with MVA in MHP. Not sure if he refers to the same paper or an own study. Do we need to consider this?

Best wishes, Heinz

From: Moss, Bernard (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 09:56 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola

Heinz

Would your group have an interest in working with us on developing an Ebola vaccine based on attenuated vaccinia virus? We made a preliminary construct in 2003 that was tested in mice in collaboration with the VRC. Paper is attached. We would make new constructs if you are interested and think it worthwhile.

Regards

Bernie

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:57 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: Fw: Ebola antibody

Have you looked into this? Can we provide antibodies? Please let me know or contact Malik directly (please copy me).

How was your seminar? I heard very good things about it? Are we still welcome back home?

Heinz

From: Malik [mailto:malik@hku.hk]
Sent: Wednesday, October 15, 2014 09:46 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola antibody

Dear Heinz

Given our success with H5N1 and MERS-CoV pseudotypes for sero-diagnosis, we have developed ebolavirus pseudotypes for use in serodiagnosis purposes, just to be prepared for the future.

Would you be able to provide us with a bit of ebolavirus antibody, either from immunized animals or other sources to allow us to optimize our assays?

Best wishes

Malik Peiris
The University of Hong Kong

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:51 AM
To: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Fw: conference call re hyperthermia treatment for Ebola virus

If you have time, can you make a quick listing of what was tested so that I can forward it? Please do it in the email text rather in an attachment.

Here is everything is fine. How about you and David?

Love you - miss you.

----- Original Message -----

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 03:27 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz, Ricki says all the [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:41 AM
To: 'roger@verthermia.com'
Cc: [Personal Info]; 'jan@verthermia.com'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: conference call re hyperthermia treatment for Ebola virus

I am currently in Monrovia until early November.

Elaine will do the testing when she will get back from Europe. Hopefully we can get this done by mid- or end-November.

Heinz

From: Roger Vertrees [mailto:roger@verthermia.com]
Sent: Thursday, October 16, 2014 10:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:49 AM
To: Casellas, Rafael (NIH/NIAMS) [E]
Subject: Re: Intramural Ebola project

Dear Rafael,

You should address CDC or MSF with your request. Work on clinical specimens needs an MOU with the ministry here in Liberia and ethics approval. We have samples but not under proper storage. We cannot do anything with the samples as proper paperwork is not in place for us. I heard that CDC has an MOU in place now. You might want to contact Stuart Nichol or Pierre Rollin from CDC.

Good luck and best wishes Heinz

From: Casellas, Rafael (NIH/NIAMS) [E]
Sent: Thursday, October 16, 2014 05:57 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Intramural Ebola project

Dear Heinz

Please see email below. if there is interest in pursuing that project we would love to help out

Best regards

Rafael

Rafael Casellas, Ph.D.
Senior Investigator
Genomics & Immunity
NIAMS-NCI, NIH, 10/13C103-D
10 Center Drive MSC 1930
Bethesda, MD. 20892, 301-402-7858
<http://casellaslab.github.io/index.html>

From: <Auchincloss>, "Hugh [E] (NIH/NIAID)" <auchinclossh@niaid.nih.gov>
Date: Tuesday, October 14, 2014 at 9:17 AM
To: Rafael Casellas <casellar@mail.nih.gov>
Subject: FW: Intramural Ebola project

Dear Dr. Casellas, Your idea is certainly interesting although given the chaos that exists in West Africa I think it probably unlikely that you would be able to come up with sufficient samples with well documented clinical histories to make this work. However, you might want to talk with NIAID scientists Lisa Hensley or Heinz Feldmann, both of who have spent time on the ground. In addition you might want to contact CDC directly or Doctors Without Borders.

Sincerely,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:24 AM
To: 'rrelich@iupui.edu'
Subject: Re: Question about disinfection

Thanks for the update. We get the news from back home and are sort of informed. The situation in Monrovia is bad but the lab work goes well.

Talk to you when I get back. Always up for a visit, talk, beer and food.

Heinz

From: Relich, Ryan Ford [mailto:rrelich@iupui.edu]
Sent: Thursday, October 16, 2014 04:08 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Question about disinfection

Oh, wow...

How's the situation there? Our clinical research group (who you met during your visit) had a lot of contacts in Liberia: most of whom have contracted Ebola and died. From the sounds of it, things are not really getting any better. Also, if you haven't heard, two nurses from Texas Presbyterian Hospital (Dallas) have contracted Ebola from the patient who they cared for (Thomas Eric Duncan). One of the nurses travelled to Cleveland, OH during the incubation period.

Thanks very much for the information regarding disinfection: we're preparing protocols for dealing with suspected Ebola patients and their specimens. We will only be doing point-of-care testing (e.g., urinalysis by dipstick, iStat testing device for electrolytes and basic biochemical analytes), blood films for malaria diagnosis, and blood cultures. The malaria smears and blood cultures will be performed by me and a few other folks in our BSL-3 laboratory. We just ordered Tyvek suits, more PAPRs, etc.

I certainly will buy you beer the next time I see you. Also, I owe you a steak (as in a Porterhouse)! I'll try to touch base with you in November about another speaking opportunity in April, if you're still interested. There's probably not much I can do, but please let me know if there's anything that you need.

Stay safe, my friend!!!!
Ryan

Ryan F. Relich, Ph.D., MLS(ASCP)^{CM}

Visiting Assistant Professor & Fellow
Division of Clinical Microbiology
Department of Pathology and Laboratory Medicine
Indiana University School of Medicine
Room 6027E, IUH Pathology Laboratory
350 W. 11th Street
Indianapolis, IN 46202

E: rrelich@iupui.edu
F: (317) 491-6649

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 17, 2014 6:12 AM
To: 'dwodarz@uci.edu'
Subject: Re: mathematical modeling of virus dynamics

I am currently in Monrovia until early November. If you are still interested please contact me again after my return.

Heinz

From: Dominik Wodarz [mailto:dwodarz@uci.edu]
Sent: Friday, October 17, 2014 02:56 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: mathematical modeling of virus dynamics

Dear Dr Feldmann,

I'm a professor at University of California Irvine, and my area of research is mathematical modeling of the in vivo dynamics of viruses, and the interactions between viruses and immune responses. Much of my work has concentrated on HIV/SIV, as well as murine virus infections. We use mathematical equations to describe the dynamics of virus growth within hosts, to interpret experimental data, and to measure crucial kinetic parameters, such as the basic reproductive ratio of the virus, the rates of viral replication, cell death, etc. More info on my web page: wodarz.bio.uci.edu.

Out of curiosity, I have been reading about ebola growth in animal models and I realized that there could be a lot of potential to apply those types of mathematical approaches to data and to quantitatively characterize the infection kinetics. One interesting aspect might be to calculate and compare parameters in different animal models to see how they differ, although there are probably quite a few other questions where the interaction between math models and experimental data could provide interesting insights. So I wondered whether you would perhaps be interested in exploring a possible collaboration in this respect.

With best regards,

Dominik

=====
Dominik Wodarz
Professor
Department of Ecology and Evolutionary Biology
University of California
Irvine, CA 92697
wodarz.bio.uci.edu


Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 4:51 PM
To: Self, Joshua S. (CDC/OID/NCEZID)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Nichol, Stuart T. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP); Rayfield, Mark (CDC/CGH/DGHP); Zemtsova, Galina E. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Sounds good.

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 03:33 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Nichol, Stuart T. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP); Rayfield, Mark (CDC/CGH/DGHP); Zemtsova, Galina E. (CDC/OID/NCEZID)
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID



From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:00 PM
To: Self, Joshua S. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: De wit, Emmie (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Dear ALL,

I just found out that Viktor and Collins from Nairobi both stay until October 28. I am satying until October 31. Emmie and Darryl are arriving on Monday October 20 to stay for almost 4 weeks.

This means if the two colleagues from Atlanta will come on Monday, October 20 we will have 7 people here for almost 10 days. There is no work for 7 people - we hardly find work for 5 people. I would highly recommend that the CDC people postpone their trip by a full week.

Please respond immediately so that we can plan. It makes no sense to have 7 people here for more than a week.

Heinz

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:34 AM Eastern Standard Time
To: Self, Joshua S. (CDC/OID/NCEZID)

Feldmann, Heinrich (NIH/NIAID) [E]


From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 4:50 PM
To: Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

I think if the CDC Atlanta folks come a week later we are fine.

Heinz

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Thursday, October 16, 2014 03:21 PM Eastern Standard Time
To: Nichol, Stuart T. (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Self, Joshua S. (CDC/OID/NCEZID); Rayfield, Mark (CDC/CGH/DGHP)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Rayfield, Mark (CDC/CGH/DGHP)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 2:04 PM
To: Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: conference call re hyperthermia treatment for Ebola virus

Thanks.

----- Original Message -----

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 03:27 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz, Ricki says all the [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:41 AM
To: 'roger@verthermia.com'
Cc: [Personal Info]; 'jan@verthermia.com'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: conference call re hyperthermia treatment for Ebola virus

I am currently in Monrovia until early November.

Elaine will do the testing when she will get back from Europe. Hopefully we can get this done by mid- or end-November.

Heinz

From: Roger Vertrees [mailto:roger@verthermia.com]
Sent: Thursday, October 16, 2014 10:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Z Forwarding Account for JW [Personal Info] Jan Winetz <jan@verthermia.com>
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Morning Dr. Feldman,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 1:00 PM
To: Self, Joshua S. (CDC/OID/NCEZID); Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Dear ALL,

I just found out that Viktor and Collins from Nairobi both stay until October 28. I am staying until October 31. Emmie and Darryl are arriving on Monday October 20 to stay for almost 4 weeks.

This means if the two colleagues from Atlanta will come on Monday, October 20 we will have 7 people here for almost 10 days. There is no work for 7 people - we hardly find work for 5 people. I would highly recommend that the CDC people postpone their trip by a full week.

Please respond immediately so that we can plan. It makes no sense to have 7 people here for more than a week.

Heinz

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:34 AM Eastern Standard Time
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Safe travels.

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 4:12 PM
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Joshua,

We just heard that the next team members are coming from Atlanta. We are currently doing the sample inactivation in a glovebox using minimal PPE (N95, Tyvek and face shield). This is largely worn for the support work of the glovebox not for the actual glovebox work. For RNA extraction we are using the QIAGEN Viral RNA kits - the first two steps (buffer and ethanol) are done in the glovebox. The rest is done on the bench with face shield protection to avoid splashes. We are running an L gene-specific screening assay on SmartCyclers and the Nairobi team runs a GP gene-specific assay on JBAIDS. We have a third NP gene-specific assay on SmartCycler which we use in problematic cases. We have also started

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 12:12 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Interview request from The Scientist magazine

From: Molly Sharlach [mailto:msharlach@the-scientist.com]
Sent: Thursday, October 16, 2014 02:05 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview request from The Scientist magazine

Dear Dr. Feldmann:

In light of the recent announcement about the start of clinical trials for NewLink's VSV Ebola vaccine, I'm writing an online news piece about fast-tracking clinical trials for Ebola vaccines and therapies. I found your opinion piece in BMC Biology very informative, and I'm interested in your thoughts on how the process is unfolding, both in terms of regulatory issues and potential plans for funding/distributing vaccines and therapies to affected areas.

Are you available for a ~15-minute phone interview early next week?

Here are some times when I'm available (all MDT):

Monday, Oct. 20, before 10 am or after 1 pm

Tuesday, Oct. 21, before 1 pm or after 4 pm

Thanks so much for your help.

--

Molly Sharlach, PhD

[The Scientist](#)

Phone: 203-858-2594

Skype: molly.thescientist

E-mail: msharlach@the-scientist.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 12:10 PM
To: Schmidt, Beth (NIH/NIAID) [E]
Subject: Re: Update on Ebola activities in Mali

Great - many thanks.

From: Schmidt, Beth (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 01:32 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

Yes. I will send you a reminder the morning of the Mali call.

Beth

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 12:25 PM
To: Schmidt, Beth (NIH/NIAID) [E]
Subject: Re: Update on Ebola activities in Mali

Beth, if you could send me another reminder on Thursday morning that would help.

Thanks, Heinz

From: Schmidt, Beth (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:56 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

Yes, Dr. Feldmann. We can do the Mali call from 2:00 – 3:00 PM (Maryland time) on Thursday, October 23rd. I'll forward the call-in information to you as soon as I get it.

Beth

Beth Schmidt
Special Assistant to the Director (Scientific Program Specialist)
Division of Intramural Research
National Institute of Allergy and Infectious Diseases, NIH, DHHS

33 North Drive, Rm 2N09G.1
Bethesda, MD 20892-3207
Direct Office Phone: (301) 435-6528
Cell Phone: Personal Info
Main Office: (301) 496-3006
Fax: (301) 402-0166
bschmidt@niaid.nih.gov

Disclaimer:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 12:05 PM
To: Clifton, Dawn (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]
Subject: Re: Heinz's comment on evacuation to incorporate into the letter RE: DRAFT for Review: Request for Reconsideration: Travel for **Pers** to Liberia

OK - we need a decision soon.

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 01:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]
Subject: FW: Heinz's comment on evacuation to incorporate into the letter RE: DRAFT for Review: Request for Reconsideration: Travel for **Pers** to Liberia

Hi Heinz,
Quick update: Lisa intends to submit the petition Friday, and states below that if it is not successful, Dr. Barron is ready to escalate the matter further since Dr. Zoon is out of town.

Dawn

From: Coronado, Lisa (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:03 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Cc: Mahyera, Anna; Barron, Karyl (NIH/NIAID) [E]; Mills, Desta (NIH/NIAID) [E]
Subject: RE: Heinz's comment on evacuation to incorporate into the letter RE: DRAFT for Review: Request for Reconsideration: Travel for **Pers** to Liberia

You are most welcome, Dawn.

I have Dr. Barron on stand-by. She will escalate this matter to NIAID and NIH management, if the petitions to LM and Kelly are not successful.

Lisa

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 1:01 PM
To: Coronado, Lisa (NIH/NIAID) [E]
Cc: Mahyera, Anna; Barron, Karyl (NIH/NIAID) [E]; Mills, Desta (NIH/NIAID) [E]
Subject: RE: Heinz's comment on evacuation to incorporate into the letter RE: DRAFT for Review: Request for Reconsideration: Travel for **Pers** to Liberia

Thank you, Lisa. I will pass along the info about submitting the letter, I know Heinz and **Pers** (and others) are anxious to hear the outcome.

Many thanks to you, Anna, Karyl, and Desta for keeping this on track and supporting this critical effort.

Dawn

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 12:00 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: F.A.S.-Anfrage Ebola

From: Fritzen, Florentine [mailto:f.fritzen@faz.de]
Sent: Thursday, October 16, 2014 11:54 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: F.A.S.-Anfrage Ebola

Sehr geehrter Herr Feldmann,

für die nächste Ausgabe der Frankfurter Allgemeinen Sonntagszeitung, also für diesen Sonntag, planen wir einen größeren Artikel über Ebola. Und zwar unter der Fragestellung, ob der Kampf gegen die Ausbreitung zu gewinnen ist. Der UN-Ebola-Beauftragte Anthony Banbury hat am Dienstag vor dem Sicherheitsrat gesagt: „Wir sind dabei, das Rennen zu verlieren.“ Als denjenigen, der den VSV-Impfstoff in Marburg entwickelt und in Kanada weiterentwickelt hat, würde ich Sie gern fragen, wie Sie das sehen, und zwar mit Blick auf die rechtzeitige Entwicklung eines Impfstoffs: Ist es aus Ihrer Sicht zu schaffen, das Rennen zu gewinnen? Und: Was ist jetzt das Wichtigste? Über eine kurze Antwort bis zum morgigen Freitag würde ich mich sehr freuen.

Mit herzlichen Grüßen aus Frankfurt
Florentine Fritzen

Dr. Florentine Fritzen
Politikredakteurin
Frankfurter Allgemeine Sonntagszeitung

Hellerhofstraße 2-4
60327 Frankfurt am Main

Tel. (069) 7591-2412
www.faz.net

Frankfurter Allgemeine Zeitung GmbH
Hellerhofstraße 2-4 · 60327 Frankfurt am Main
HRB 7344 · Amtsgericht Frankfurt am Main
Vorsitzender des Aufsichtsrats: Karl Dietrich Seikel
Geschäftsführung: Thomas Lindner (Vorsitzender), Burkhard Petzold

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 12:00 PM
To: Haddock, Elaine (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]
Subject: Re: conference call re hyperthermia treatment for Ebola virus

Thanks.

----- Original Message -----

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 12:02 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Heinz, I set up the samples for [Redacted by agreement] [Redacted by agreement]

Ricki, is there any sign of CPE in the flasks yet?

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:41 AM
To: 'roger@verthermia.com'
Cc: [Personal Info] 'jan@verthermia.com'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: conference call re hyperthermia treatment for Ebola virus

I am currently in Monrovia until early November.

Elaine will do the testing when she will get back from Europe. Hopefully we can get this done by mid- or end-November.

Heinz

From: Roger Vertrees [mailto:roger@verthermia.com]
Sent: Thursday, October 16, 2014 10:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Z Forwarding Account for JW [Personal Info]; Jan Winetz <jan@verthermia.com>
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Morning Dr. Feldman,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:25 AM
To: Schmidt, Beth (NIH/NIAID) [E]
Subject: Re: Update on Ebola activities in Mali

Beth, if you could send me another reminder on Thursday morning that would help.

Thanks, Heinz

From: Schmidt, Beth (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:56 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

Yes, Dr. Feldmann. We can do the Mali call from 2:00 – 3:00 PM (Maryland time) on Thursday, October 23rd. I'll forward the call-in information to you as soon as I get it.

Beth

Beth Schmidt
Special Assistant to the Director (Scientific Program Specialist)
Division of Intramural Research
National Institute of Allergy and Infectious Diseases, NIH, DHHS

33 North Drive, Rm 2N09G.1
Bethesda, MD 20892-3207
Direct Office Phone: (301) 435-6528
Cell Phone: Personal Inf
Main Office: (301) 496-3006
Fax: (301) 402-0166
bschmidt@niaid.nih.gov

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:54 AM
To: Schmidt, Beth (NIH/NIAID) [E]
Subject: Re: Update on Ebola activities in Mali

Can we do 2:00 - 3:00 PM?

From: Schmidt, Beth (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:51 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

Dr. Feldmann,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:18 AM
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

We could need:

Gloves (medium)
Duct tape (several rolls)
Hand sanitizers (big bottles)
Tips (1000) LTS (3 cases)
Tips 200 LTS (3 cases)
Tips 20 LTS (3 cases)
Zipp lock bags (large - slider close)

You may need different tips if you wish to bring your own pippters.

Heinz

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 11:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 11:34 AM
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Safe travels.

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 4:12 PM
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Joshua,

We just heard that the next team members are coming from Atlanta. We are currently doing the sample inactivation in a

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 9:38 AM
To: 'halfmanp@svm.vetmed.wisc.edu'; YOSHIHIROKAWAOKA
Subject: Re: Conflicts of Interest

No.

From: Pete Halfmann [mailto:halfmanp@svm.vetmed.wisc.edu]
Sent: Thursday, October 16, 2014 11:13 AM Eastern Standard Time
To: YOSHIHIROKAWAOKA
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Conflicts of Interest

Yoshi and Heinz,
Do you have any Conflicts of Interests to declare with the Ebola virus commentary in EBioMedicine?

Thanks

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 9:36 AM
To: Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: Ebola

Sounds good.

----- Original Message -----

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 09:44 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

She spoke this morning, so I can find her, or be found, fairly easily.

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:57 AM
To: 'm.koopmans@erasmusmc.nl'
Cc: 'j.vankampen@erasmusmc.nl'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: Ebola

I cannot do much from here. Will be back early November. Please talk to Elaine Haddock. Elaine will present the data at the meeting.

Heinz

From: Archief Marion [mailto:m.koopmans@erasmusmc.nl]
Sent: Thursday, October 16, 2014 05:42 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: J.J.A. van Kampen <j.vankampen@erasmusmc.nl>
Subject: Ebola

Dear Heinz,

Had - against odds - hoped to run into you in Berlin. I saw the validation of inactivation protocols for Ebola. We have a group of IC specialists that have listed what they consider essential info, and want to validate the available or potential inactivation protocols for compatibility with other lab parameters for high care patients. Would it be possible to get the

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 9:34 AM
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Safe travels.

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Thursday, October 16, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 4:12 PM
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Joshua,

We just heard that the next team members are coming from Atlanta. We are currently doing the sample inactivation in a glovebox using minimal PPE (N95, Tyvek and face shield). This is largely worn for the support work of the glovebox not for the actual glovebox work. For RNA extraction we are using the QIAGEN Viral RNA kits - the first two steps (buffer and ethanol) are done in the glovebox. The rest is done on the bench with face shield protection to avoid splashes. We are running an L gene-specific screening assay on SmartCyclers and the Nairobi team runs a GP gene-specific assay on JBAIDS. We have a third NP gene-specific assay on SmartCycler which we use in problematic cases. We have also started to run malaria PCR.

If you want to bring PPE we would recommend to bring the gloves that you wish to use, N95 masks, face shields (disposable), and Tyveks. We wear scrubs in the lab. We have quite a few here, but you may want to bring your own ones. Bring foot wear - most of us wear crocs in the lab and rubber boots when we go to the ward. Don't bring rubber boots - you can get them here or use whatever is here already.

Just so that you know we stay at the Kendeja Hotel, which is about 10 minutes or less away from the lab. The Nairobi people also stayed here. Otherwise, the CDC stays at Mamba Point in Downtown. The ride to the lab would be longer - no idea how long.

Who is the second person from Atlanta? Please share this email. Let me know if you have further questions.

Best wishes, Heinz

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 11:58 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 9:34 AM
To: 'lynn@target-conferences.com'
Subject: Re: all good, hope you are well

Certainly not.

From: Lynn Lipschitz [mailto:lynn@target-conferences.com]
Sent: Thursday, October 16, 2014 08:58 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: all good, hope you are well

Oh ...so very sad. People are saying that it was induced (an experiment that went wrong)!
I hope not.
Warm regards
Lynn

Lynn Lipschitz | [Managing Director](#)
Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818
Tel: +972 3 5175150 ext 601, Fax: +972 3 5175155
www.target-conferences.com

On Thu, Oct 16, 2014 at 3:44 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Fantastic - too bad that I am not in Berlin.

All fine here in sunny Monrovia. But the sunshine does not reflect the sad situation in this country.

Best wishes, Heinz

From: Lynn Lipschitz [mailto:lynn@target-conferences.com]
Sent: Thursday, October 16, 2014 06:01 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: all good, hope you are well

Hello Heinz

Just a short note to let you know that all is going well here in Germany at the conference.

In his opening speech Juergen thanked you and mentioned that you are busy fighting Ebola in Africa and wished you good health and a speedy return.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:54 AM
To: Schmidt, Beth (NIH/NIAID) [E]
Subject: Re: Update on Ebola activities in Mali

Can we do 2:00 - 3:00 PM?

From: Schmidt, Beth (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:51 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

Dr. Feldmann,

Do you think you could call in to this meeting if we scheduled it for 1pm-2pm our time on Thursday, October 23rd? If not, we can try another time.

Beth

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:50 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Shott, Joseph (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Cc: Schmidt, Beth (NIH/NIAID) [E]
Subject: Re: Update on Ebola activities in Mali

I will try to call in.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 07:49 AM Eastern Standard Time
To: Shott, Joseph (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Cc: Schmidt, Beth (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

I would like to have a conference call on this, maybe next week if possible

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 7:21 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Subject: Update on Ebola activities in Mali

Good morning,

I just met with Ousmane Koita and wanted to provide you with a brief update on the Ebola diagnostic activities in the BSL3 lab at USTTB.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:53 AM
To: Mowatt, Michael (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Disclosure of ebola-infected NHP data

Mike,

Sorry for the delay in the response. Personally I think the interferon studies in NHPs do not make much sense after the outcome of the last experiment. If certain people planning to go into humans anyway independent of outcome of NHP studies - why doing NHP studies?

Putting my personal thoughts aside, the studies could most likely not run before January or February. Darryl will be in Monrovia until mid-November and is leaving RML by the end of November. The most logical person to take over would be Andrea Marzi but she will be in Monrovia for all November and January.

If Kathy and Darryl think we should do the study we will work it in somehow, but the pathogenesis and vaccine studies using the new West African virus should have have priority at the moment.

Finally, we are losing 60 percent of the animal BSL4 capacity for the period of mid-December to at least mid-January due to re-certification.

I know this is no answer - I wait until Darryl and Kathy weigh in.

Heinz

----- Original Message -----

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 10:00 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Heinz and Darryl,

Redacted by
agreement

I'm sure you are swamped, but I need to close the loop with [Redacted] today about NIAID's interest in obtaining [Redacted] by agreement

I've prepared a draft amendment in which I've added a second research plan (Exhibit B), in which I've substituted [Redacted by agreement]

Please let me know asap:

1. Do you want to obtain the [Redacted by agreement]
2. If so, is Exhibit B an accurate description of the work you intend?

Thanks,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:42 AM
To: 'roger@verthermia.com'
Cc: [Personal Info]@hotmail.com'; 'jan@verthermia.com'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: conference call re hyperthermia treatment for Ebola virus

I am currently in Monrovia until early November.

Elaine will do the testing when she will get back from Europe. Hopefully we can get this done by mid- or end-November.

Heinz

From: Roger Vertrees [mailto:roger@verthermia.com]
Sent: Thursday, October 16, 2014 10:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Z Forwarding Account for JW [Personal Info]; Jan Winetz <jan@verthermia.com>
Subject: RE: conference call re hyperthermia treatment for Ebola virus

Morning Dr. Feldman,

I am sure you are being overwhelmed with the Ebola situation but was wondering if you had a chance to run the below pilot in vitro study? If not when do you think you would be able to do so? Sorry, just anxious to know what you come up with.

Thanks
Roger and Jan

From: Roger Vertrees
Sent: Wednesday, September 24, 2014 7:17 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Z Forwarding Account for JW; Jan Winetz
Subject: Re: conference call re hyperthermia treatment for ebola virus

It was our pleasure. Tlx

Sent from my iPhone

On Sep 24, 2014, at 6:18 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Dr. Jim Strong (Jim.Strong@phac-aspc.gc.ca)

I will try to arrange for the pilot in vitro study.

Best wishes,
Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 8:38 AM
To: Shott, Joseph (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Subject: Re: Update on Ebola activities in Mali

I think they are doing a good job. It might be helpful to prepare a panel of 5-10 specimens (inactivated) to test the proficiency of the lab testing. For example, we could spike human blood with RNA or gamma-irradiated virus (won't affect PCRs on small targets); ENIVD does this all the time.

Heinz

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 07:21 AM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Subject: Update on Ebola activities in Mali

Good morning,

I just met with Ousmane Koita and wanted to provide you with a brief update on the Ebola diagnostic activities in the BSL3 lab at USTTB.

1. 26 potential cases have been screened in the BSL3 and all were negative for EBOV.
2. Consumption of traditional medicine causing GI toxicity and fever has been identified as the likely causes in most of these 26.
3. The MOH and the WHO AFRO Regional Director visited the lab on Monday this week for a tour.
4. They wish to see continued engagement between all parties for screening potential positives, and have offered \$ to assist. (We should talk to Ousmane further).
5. MOH and WHO AFRO hope we (NIAID/USTTB) can provide a wider array of diagnostics for other HFV etc., but I have advised Ousmane to hold off on responding until further instruction.
6. SEREFO staff have been training regional units of the MOH on phlebotomy and PPE (We should talk to Ousmane further about this).
7. I have asked the lab to do a thorough inventory today of reagents, consumables and PPE since they are not busy.
8. We have an estimate for repairing the broken pass-through autoclave which Ousmane is going to ask all programs to contribute to. \$10K total. (Need to discuss sharing the purchase of a new autoclave possibly). The back-up benchtop autoclave is being used while the primary unit is inoperable.
9. Ousmane is asking if NIAID plans to respond to the letter from the Minister, sent to NIAID through the Embassy.

Please let me know if you have any questions.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 6:50 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Shott, Joseph (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Cc: Schmidt, Beth (NIH/NIAID) [E]
Subject: Re: Update on Ebola activities in Mali

I will try to call in.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 07:49 AM Eastern Standard Time
To: Shott, Joseph (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Cc: Schmidt, Beth (NIH/NIAID) [E]
Subject: RE: Update on Ebola activities in Mali

I would like to have a conference call on this, maybe next week if possible

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 7:21 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]
Subject: Update on Ebola activities in Mali

Good morning,

I just met with Ousmane Koita and wanted to provide you with a brief update on the Ebola diagnostic activities in the BSL3 lab at USTTB.

1. 26 potential cases have been screened in the BSL3 and all were negative for EBOV.
2. Consumption of traditional medicine causing GI toxicity and fever has been identified as the likely causes in most of these 26.
3. The MOH and the WHO AFRO Regional Director visited the lab on Monday this week for a tour.
4. They wish to see continued engagement between all parties for screening potential positives, and have offered \$ to assist. (We should talk to Ousmane further).
5. MOH and WHO AFRO hope we (NIAID/USTTB) can provide a wider array of diagnostics for other HFV etc., but I have advised Ousmane to hold off on responding until further instruction.
6. SEREFO staff have been training regional units of the MOH on phlebotomy and PPE (We should talk to Ousmane further about this).
7. I have asked the lab to do a thorough inventory today of reagents, consumables and PPE since they are not busy.
8. We have an estimate for repairing the broken pass-through autoclave which Ousmane is going to ask all programs to contribute to. \$10K total. (Need to discuss sharing the purchase of a new autoclave possibly). The back-up benchtop autoclave is being used while the primary unit is inoperable.
9. Ousmane is asking if NIAID plans to respond to the letter from the Minister, sent to NIAID through the Embassy.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 6:47 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Interview for Scidev.net

From: Aamna Mohdin Personal Info
Sent: Thursday, October 16, 2014 08:00 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview for Scidev.net

Dear Heinz Feldmann,

I'm writing a feature for Scidev.net on promising Ebola research we've covered over the past 12 years. [In 2007, we covered a study](#) you were involved with, on the development of a rapid, cheap and reliable field test to detect two strains of the Ebola virus.

I've been reading your papers, and am interested in interviewing you for your opinion on the development of that study, you work and what it means for Ebola research today. I'm also interested in talking about the media's recent hype of Ebola becoming a health crisis within Europe and America.

Would you be available for a quick phone interview or Skype? If it's easier, I'm happy to send over my questions and conduct the interview via email.

Kind regards,

Aamna Mohdin

<http://www.scidev.net/global/author.aamna-mohdin.html>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 6:45 AM
To: 'lynn@target-conferences.com'
Subject: Re: all good, hope you are well

Fantastic - too bad that I am not in Berlin.

All fine here in sunny Monrovia. But the sunshine does not reflect the sad situation in this country.

Best wishes, Heinz

From: Lynn Lipschitz [mailto:lynn@target-conferences.com]
Sent: Thursday, October 16, 2014 06:01 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: all good, hope you are well

Hello Heinz

Just a short note to let you know that all is going well here in Germany at the conference.

In his opening speech Juergen thanked you and mentioned that you are busy fighting Ebola in Africa and wished you good health and a speedy return.

We have a full house, with 380 participants (and a waitlist of over 60).

At the moment 65 (of the 380) haven't yet registered but they are trickling in slowly.

Heinz - we have people from 35 countries - rather an achievement.

So - besides the fact that you're not here - all is good (and no worries about our friend)!

With best regards and much respect
Lynn

Lynn Lipschitz | **Managing Director**
Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818
Tel: +972 3 5175150 ext 601, Fax: +972 3 5175155
www.target-conferences.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:58 AM
To: 'm.koopmans@erasmusmc.nl'
Cc: 'j.vankampen@erasmusmc.nl'; Haddock, Elaine (NIH/NIAID) [E]
Subject: Re: Ebola

I cannot do much from here. Will be back early November. Please talk to Elaine Haddock. Elaine will present the data at the meeting.

Heinz

From: Archief Marion [mailto:m.koopmans@erasmusmc.nl]
Sent: Thursday, October 16, 2014 05:42 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: J.J.A. van Kampen <j.vankampen@erasmusmc.nl>
Subject: Ebola

Dear Heinz,


Had - against odds - hoped to run into you in Berlin. I saw the validation of inactivation protocols for Ebola. We have a group of IC specialists that have listed what they consider essential info, and want to validate the available or potential inactivation protocols for compatibility with other lab parameters for high care patients. Would it be possible to get the specifics of your protocols so we can reverse validate them for the other parameters (we were planning this with a p4 lab in Europe, but no need to repeat things).

I understand you are in Monrovia, but if you can link me to someone, I'll follow-up.

Kind regards,

Marion

Professor Marion Koopmans, DVM PhD
Head of Department
Viroscience



P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
Visiting address: office Ee-1726, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
Email m.koopmans@erasmusmc.nl | Telephone +31 031 10 70 44 | Fax +31 031 10 70 44
www.erasmusmc.nl | www.erasmusmc.nl/www.viroscience.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:56 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]
Subject: Re: Ebola Animal Work

Not really needed - perhaps under certain circumstances. Increased holding space would be key.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 05:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

We are working on modifying ARMCO 1 for more holding space. If we could hold more animals, that reduces the delay in conducting experiments. The 30 days for quarantine of the animals is to ensure they have adapted and there are no health issues. We can check with Don and Randy if this time frame can be reduced.
Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 5:35 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: Re: Ebola Animal Work

I agree with Kathy - no real problems with RML. Having said that things with NHPs could run better if we could have more holding space at RML. Shipping of animals from the East Coast is time-consuming and expensive. We then have a quarantine period of at least 30 days. This occasionally delays animal studies by 1-2 months, in particular at outbreak times.

Thanks,
Heinz

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 02:52 AM Eastern Standard Time
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

For RML, there are no issues I am aware of. Of course there are more things to test than we have capacity to do so we have to prioritize. Our ACUC is working well as is our IBC. No problem with supply of Rhesus. I would be happy to look into further if there is something specific. I suspect this relates to IRF Fred.
Kathy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 11:06 PM
To: Trevor Mundel

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:40 AM
To: Personal Info
Subject: Re: Questions from a Johns Hopkins Student

(1) Yes

(2) Yes but we likely need more for this outbreak (more of everything)

(3) Cannot comment on this.

From: Personal Info
Sent: Wednesday, October 15, 2014 07:10 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Questions from a Johns Hopkins Student

I understand. Would you be willing to answer a few questions over email? I would just like to know:

1) Can you confirm that this outbreak is Ebola Zaire?

2) In your 2011 article you say, "we urgently need strategies, financial support, and political will to bring these developments to the populations of endemic areas in equatorial." Do you think the US is doing its job in that regard, and if not, what kind of efforts are needed beyond this point to quell the outbreak?

3) Dr. Peter Jarhling said in an interview that his findings from Liberian patients show a higher concentration of the virus in the blood than ever seen before. Is this consistent with your findings? Do you think this is why the virus seems to be more contagious?

Thank you so much. I appreciate the work you are doing and will keep you in my thoughts.

Personal I

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: Wednesday, October 15, 2014 6:39 PM
To: Personal Info
Subject: Re: Questions from a Johns Hopkins Student

Sorry but I am not. I am currently in Monrovia until November 2.

From: Personal Info
Sent: Wednesday, October 15, 2014 03:35 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Questions from a Johns Hopkins Student

Hi, Dr. Feldmann. I am a student at Johns Hopkins University, writing an essay on the current Ebola outbreak, and I was wondering if I could ask you a few questions about the virus and how we are handling it. I am currently reading through your 2011 study in the Lancet.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:38 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: Fw: Ebola antibody

Do we have antibodies to share?

From: Malik [mailto:malik@hku.hk]
Sent: Wednesday, October 15, 2014 09:46 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola antibody

Dear Heinz

Given our success with H5N1 and MERS-CoV pseudotypes for sero-diagnosis, we have developed ebolavirus pseudotypes for use in serodiagnosis purposes, just to be prepared for the future.

Would you be able to provide us with a bit of ebolavirus antibody, either from immunized animals or other sources to allow us to optimize our assays?

Best wishes

Malik Peiris
The University of Hong Kong

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 3:35 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Cc: Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: Re: Ebola Animal Work

I agree with Kathy - no real problems with RML. Having said that things with NHPs could run better if we could have more holding space at RML. Shipping of animals from the East Coast is time-consuming and expensive. We then have a quarantine period of at least 30 days. This occasionally delays animal studies by 1-2 months, in particular at outbreak times.

Thanks,
Heinz

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Thursday, October 16, 2014 02:52 AM Eastern Standard Time
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work

For RML, there are no issues I am aware of. Of course there are more things to test than we have capacity to do so we have to prioritize. Our ACUC is working well as is our IBC. No problem with supply of Rhesus. I would be happy to look into further if there is something specific. I suspect this relates to IRF Fred.
Kathy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 11:06 PM
To: Trevor Mundel
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Ebola Animal Work


Trevor:
I am not aware of this problem, but I will check further.
Tony

From: Trevor Mundel [mailto:Trevor.Mundel@gatesfoundation.org]
Sent: Wednesday, October 15, 2014 8:47 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Ebola Animal Work


Hi Tony,

I heard some rumblings from the NIAID / BSL4 unit around some delays they were experiencing in initiating animal studies. Mostly the usual areas of legal, animal committees convening and transfers from other agencies. Do you have any sense whether there is any substance to this? The South Africans had offered to establish some Ebola animal capabilities in their BSL4 if there was a real constraint on this resource, but this would take a while to set up and would be costly.


Redacted by agreement




Redacted by agreement




Redacted by agreement



Redacted by agreement



Redacted by agreement



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 4:40 PM
To: 'Jerry.N.Yang@pjc.com'
Subject: Re: Consultation on ebola virus

I am currently away and won't be available until early November.

From: Yang, Jerry [mailto:Jerry.N.Yang@pjc.com]
Sent: Wednesday, October 15, 2014 03:05 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Consultation on ebola virus

Dear Dr. Feldmann,

My name is Jerry Yang, and I am on a biotech team with Josh Schimmer, MD at Piper Jaffray in New York. We are interested in having a discussion with you on ebola this Friday. The format of discussion is through a conference call, which is open to investors. We won't discuss any material non-public information, but will rather focus on the disease mechanism, emerging epidemic and implications.

Let me know if you are willing to speak with us for an hour on Friday (morning preferred). Piper Jaffray typically provides an honorarium of \$500/hour – let me know if this is acceptable to you.

Thank you and I look forward to hearing from you soon.

Jerry

Jerry N. Yang, Ph.D. | Biotech Equity Research Analyst
Piper Jaffray & Co | 345 Park Ave, Suite 1200 | New York, NY 10154
O: 212-284-9331 | M: Personal Info
Jerry.n.yang@pjc.com

Piper Jaffray & Co. Since 1895. Member SIPC and NYSE. Learn more at www.piperjaffray.com. Piper Jaffray corporate headquarters is located at 800 Nicollet Mall, Minneapolis, MN 55402.

Piper Jaffray outgoing and incoming e-mail is electronically archived and recorded and is subject to review, monitoring and/or disclosure to someone other than the recipient. This e-mail may be considered an advertisement or solicitation for purposes of regulation of commercial electronic mail messages. If you do not wish to receive commercial e-mail communications from Piper Jaffray, go to: www.piperjaffray.com/do_not_email to review the details and submit your request to be added to the Piper Jaffray "Do Not E-mail Registry." For additional disclosure information see www.piperjaffray.com/disclosures

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 4:39 PM
To: 'mzinn@nmff.org'
Subject: Re: Ebola

I do not do patient care. You may want to contact MSF or WHO. I cannot answer your question.

From: Personal Info
Sent: Wednesday, October 15, 2014 03:09 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola

Hi Dr. Feldmann,

As a practicing intensivist in the Chicagoland area, it has been difficult to find statistics on the survival rate of Ebola patients who suffer a cardiopulmonary arrest. I am hoping you may know the answer or that you can find the answer to this question. I understand that, for the most part, West Africa does not have the resources to care for these patients that we have in the US.

As experts in Ebola are guiding our leaders, it seems prudent to assess this question. If the survival rate of a person who has Ebola & has suffered a cardiopulmonary arrest is ZERO, I would endorse not providing ACLS support. Undoubtedly, I sound cruel & heartless. I am not cruel & heartless. In an attempt to save one life in a CODE, a situation which is often hectic and in which things are done very fast, many others are likely to be exposed. From a benefit / risk analysis, this is a question that must be asked and answered.

These are "no ordinary" times. The American healthcare workers are looking for guidance. The guidance comes top down. Our non-medical leaders are looking for expertise from those who have insight into the disease. It is imperative that we safeguard the nation immediately. I am hoping that I can gain insight into whether or not Ebola victims benefit from ACLS support.

Thanks for your consideration,

Personal Info

This message and any included attachments are intended only for the addressee. The information contained in this message is confidential and may constitute proprietary or non-public information under international, federal, or state laws. Unauthorized forwarding, printing, copying, distribution, or use of such information is strictly prohibited and may be unlawful. If you are not the addressee, please promptly delete this message and notify the sender of the delivery error by e-mail.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 4:39 PM
To: Personal Info
Subject: Re: Questions from a Johns Hopkins Student

Sorry but I am not. I am currently in Monrovia until November 2.

From: Personal Info
Sent: Wednesday, October 15, 2014 03:35 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Questions from a Johns Hopkins Student

Hi, Dr. Feldmann. I am a student at Johns Hopkins University, writing an essay on the current Ebola outbreak, and I was wondering if I could ask you a few questions about the virus and how we are handling it. I am currently reading through your 2011 study in the Lancet.

Are you available for a call sometime this week/weekend?

Thank you very much,

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 4:30 PM
To: Personal Info
Subject: Re: ebola Reston and Zaire, Cody Wyoming

Highly unlikely from all we know. Susan Fisher-Hoch did some of this work. Unfortunately, I do not have the access to the papers - I am currently in Monrovia.

From: Pamela Clegg Personal Info
Sent: Wednesday, October 15, 2014 05:17 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: ebola Reston and Zaire, Cody Wyoming

Hello Dr. Feldmann

I am a pathologist in Cody Wyoming, conducting a review of scientific literature about Ebola for in-service. I keep wondering if antibodies formed against Reston confer immunity for Zaire? Cannot find anything about this in the literature. I am sure this has been considered and ruled out, but I would like to have a reference.

Thank you.

Pamela Clegg, MD
Cody WY

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 2:19 PM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: review statement for Ricki's travel to Liberia FW: DRAFT for Review: Request for Reconsideration: Travel for **Pers** to Liberia

Sounds good to me. The only thing I don't like is the statement about travel restrictions. I would take this out. Instead I would use a separate bullet stating that should an exposure or infection occur she will be medevaced to one of the designated treatment centers in the US on US chartered air service providers.

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 03:32 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: review statement for **Perso** travel to Liberia FW: DRAFT for Review: Request for Reconsideration: Travel for **Pers** to Liberia

Hi Heinz,
Lisa said that the information regarding the participation of **Pers** and **Personal** from your email was very helpful, and wanted to thank you. Additionally, as part of the justification to allow **Pers** (and **Persona**) to travel, Lisa wanted to indicate briefly what plans are in place for an evacuation in the case of an exposure or active infection. I spoke with Vincent to get an idea of what might you all might have discussed and I wrote a revised statement. Both I have included Lisa's draft and my correction below. Would you please let me know if my statement is accurate? Or what might need to be corrected?

Lisa's draft statement: She will be traveling with select NIH federal staff. If travel restrictions prevent her from traveling on commercial flights (due to Ebola exposure), she will either wait to travel until after the 21-day incubation period for Ebola, or travel on charter flights (arranged and funded by US government).

My revision: She will be traveling with select NIH federal staff. If travel restrictions prevent her from traveling on commercial flights (due to Ebola exposure), evacuation arrangements would be made to return her to the US via travel on charter or military flights (arranged and funded by US government).

If you scroll down you can see the entirety of the draft letter. We are also moving forward with obtaining her visa and making travel plans for her as Lisa has indicated she believes that we will obtain approval. Maybe I told you that already??

Thanks,
Dawn

Dawn R. Clifton, Ph.D.
Scientific Operations Manager
Laboratory of Virology
Rocky Mountain Laboratories
903 S. 4th St.
Hamilton, MT 59840
406-375-9762
dawn.clifton@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 2:12 PM
To: Self, Joshua S. (CDC/OID/NCEZID)
Subject: Re: Ebola Outbreak Response Monrovia Liberia

Joshua,

We just heard that the next team members are coming from Atlanta. We are currently doing the sample inactivation in a glovebox using minimal PPE (N95, Tyvek and face shield). This is largely worn for the support work of the glovebox not for the actual glovebox work. For RNA extraction we are using the QIAGEN Viral RNA kits - the first two steps (buffer and ethanol) are done in the glovebox. The rest is done on the bench with face shield protection to avoid splashes. We are running an L gene-specific screening assay on SmartCyclers and the Nairobi team runs a GP gene-specific assay on JBAIDS. We have a third NP gene-specific assay on SmartCycler which we use in problematic cases. We have also started to run malaria PCR.

If you want to bring PPE we would recommend to bring the gloves that you wish to use, N95 masks, face shields (disposable), and Tyveks. We wear scrubs in the lab. We have quite a few here, but you may want to bring your own ones. Bring foot wear - most of us wear crocs in the lab and rubber boots when we go to the ward. Don't bring rubber boots - you can get them here or use whatever is here already.


Just so that you know we stay at the Kendeja Hotel, which is about 10 minutes or less away from the lab. The Nairobi people also stayed here. Otherwise, the CDC stays at Mamba Point in Downtown. The ride to the lab would be longer - no idea how long.

Who is the second person from Atlanta? Please share this email. Let me know if you have further questions.

Best wishes, Heinz

From: Self, Joshua S. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 11:58 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola Outbreak Response Monrovia Liberia

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 1:04 PM
To: Hoenen, Thomas (NIH/NIAID) [F]; 'Victoria.Jensen@NBACC.DHS.GOV'
Subject: Re: Endothelial activation by VP40/GP

We can send the plasmid under an SLA.

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 02:57 PM Eastern Standard Time
To: 'Jensen, Victoria M. (CTR)' <Victoria.Jensen@NBACC.DHS.GOV>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Endothelial activation by VP40/GP

Hi Vic,


We have expression plasmids for VP40 and GP1,2, so from my end it would be no problem to send those if Heinz is OK with this (but if I get it right he was the person who contacted you in the first place). We get tons of requests for plasmids right now anyway, mostly for the tetracistronic trVLP system.

I'm not 100% sure what they mean with expression / purification protocols, do they want to produce VLPs? If that's the case, a simple transfection in 293T cells followed by purification over a sucrose cushion should do them – but you are the one who did the endothelial work, so you probably know best...

All the best, Thomas

From: Jensen, Victoria M. (CTR) [mailto:Victoria.Jensen@NBACC.DHS.GOV]
Sent: Wednesday, October 15, 2014 10:39 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: FW: Endothelial activation by VP40/GP

Records Originating Outside of NIAID



From: Lin, Charles [mailto:Charles.Lin@DFCI.HARVARD.EDU]
Sent: Thursday, October 09, 2014 5:49 PM
To: Jensen, Victoria M. (CTR)
Subject: Endothelial activation by VP40/GP

Dr. Wahl-Jensen,

Our laboratory, the Bradner lab, at the Dana-Farber Cancer Institute <http://bradner.dfci.harvard.edu> has a focus on chemical modulation of chromatin structure. Recently we have used models of endothelial cell activation to study cell

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:38 PM
To: 'map2028@med.cornell.edu'; Hoenen, Thomas (NIH/NIAID) [F]
Cc: 'anm2047@med.cornell.edu'
Subject: Re: Tetracistronic minigenome for Ebola

Please communicate with Thomas Hoenen on this. I am currently in Monrovia for the rest of the month.

Best wishes, Heinz

----- Original Message -----

From: Matteo Porotto [mailto:map2028@med.cornell.edu]
Sent: Wednesday, October 15, 2014 02:31 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Anne Moscona <anm2047@med.cornell.edu>
Subject: Tetracistronic minigenome for Ebola

Dear Heinz,

I hope this e-mail finds you well. We have just seen your recent article using the tetracistronic minigenomes for mimicking Ebola infection. We have been working with Barry (and now with Dennis Bente) to develop fusion inhibitors for Ebola as we did for Nipah. It would be great to have your system if you are willing to share, to test our peptide inhibitors in BSL2. We would be of course be happy to do this as a collaboration.

Take care,

Matteo

Matteo Porotto, Ph.D.
Associate Professor
Pediatrics Department
Weill Medical College
12 floor 413E 69 street
New York, NY, 10021
646-962-6250 (office)
646-962-6254 (lab)
646-962-0574 (fax)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:37 PM
To: 'meichberg@berkeley.edu'
Subject: Re: UC Berkeley Invitation: Symposium Speaker/Panelist

Tom Geisbert from UTMB Galveston would be my first choice. Gary Kobinger from Winnipeg would be equally good.

From: Michael J Eichberg [mailto:meichberg@berkeley.edu]
Sent: Wednesday, October 15, 2014 02:28 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: UC Berkeley Invitation: Symposium Speaker/Panelist

Dr. Feldmann,

Thanks for your rapid response. Do you have any other suggestions for possible speaker? Perhaps Mathias Schnell from Thomas Jefferson, Maria Croyle from UT, Myron Levine from Maryland?

Best wishes on your important and ongoing work in Liberia.

Best,
Mike

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 15, 2014 11:26 AM
To: 'meichberg@berkeley.edu'
Subject: Re: UC Berkeley Invitation: Symposium Speaker/Panelist

Thanks for the invitation, but I may be in Monrovia at that time.

Best wishes,
Heinz

From: Michael J Eichberg [mailto:meichberg@berkeley.edu]
Sent: Wednesday, October 15, 2014 01:35 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: UC Berkeley Invitation: Symposium Speaker/Panelist

Dear Dr. Feldmann,

I am the Executive Director of the Berkeley Center for Emerging and Neglected Diseases (CEND) and each year we organize a high profile and very well attended symposium on areas related to our mission in infectious diseases (see the website, <http://cend.globalhealth.berkeley.edu>). This year's theme is Vaccines and Therapeutics: From Science to Solutions. Please see below for our current speaker line-up.

This year we are inviting speakers in the areas of vaccine and therapeutic development, and are planning a special panel to discuss the status of the Ebola vaccines and therapeutics pipeline, and their potential use in the current epidemic. We are interested in inviting and hosting you as a panel member to discuss the vaccine pipeline.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:36 PM
To: 'Helen.Branswell@thecanadianpress.com'
Subject: Re: FYI

Thanks.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Wednesday, October 15, 2014 02:26 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FYI

You told me awhile back that other organizations had seen my story about NML and wanted to do similar pieces.
Here is one: <http://www.ibtimes.com/canada-leads-way-ebola-experimental-drugs-zmapp-tkm-ebola-vsv-ebov-1704995>

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-14-14 8:35 AM
To: Branswell, Helen
Subject: Re: How are you doing?

Not really as we have been using different Zaire ebolavirus challenge strains in the NHP studies. It won't protect against another species - for example Sudan ebolavirus. More nervous about the overall performance in humans. and potential adverse effects (live-attenuated vaccine). This is exciting but also a little worrisome.

We started the experiment in NHPs using a Guinea isolate as the challenge virus - should know in a month.

Heinz

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Tuesday, October 14, 2014 08:24 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: How are you doing?

Have I asked you: are you at all concerned that the efficacy of the VSV vax might be lower because the outbreak virus is drifted or at least somewhat difference from the vaccine reference strain?

Best,
Helen

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: October-14-14 6:12 AM
To: Branswell, Helen
Subject: Re: How are you doing?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:35 PM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: FYI

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Wednesday, October 15, 2014 02:26 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FYI

You told me awhile back that other organizations had seen my story about NML and wanted to do similar pieces.
Here is one: <http://www.ibtimes.com/canada-leads-way-ebola-experimental-drugs-zmapp-tkm-ebola-vsv-ebov-1704995>

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-14-14 8:35 AM
To: Branswell, Helen
Subject: Re: How are you doing?

Not really as we have been using different Zaire ebolavirus challenge strains in the NHP studies. It won't protect against another species - for example Sudan ebolavirus. More nervous about the overall performance in humans. and potential adverse effects (live-attenuated vaccine). This is exciting but also a little worrisome.

We started the experiment in NHPs using a Guinea isolate as the challenge virus - should know in a month.

Heinz

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Tuesday, October 14, 2014 08:24 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: How are you doing?

Have I asked you: are you at all concerned that the efficacy of the VSV vax might be lower because the outbreak virus is drifted or at least somewhat difference from the vaccine reference strain?

Best,
Helen

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: October-14-14 6:12 AM
To: Branswell, Helen
Subject: Re: How are you doing?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:30 PM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

When do you have time to talk?

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 12:20 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Have you seen the request to evaluate Redacted by agre

Unless there is a compelling argument otherwise I think that Redacte has a pretty good half-life without being Redacted b so that the only advantage would be less frequent administration - which is not a big advantage in my opinion for what would be a short course of treatment.

-----Original Message-----

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:58 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Thanks, Kathy.

I'll begin preparing an amendment to the MTA to address data sharing with third parties, but I will await word from Darryl and Heinz regarding our request for Redacted by agreemen

-----Original Message-----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:39 AM
To: Mowatt, Michael (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I agree with Darren. I am at WHO in Geneva, so I am not sure we will be able to touch base. I can try. I think we need to see if Darryl and Heinz are willing to try the pegylated form of IFN beta in a NHP study.

Kathy

From: Mowatt, Michael (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 9:06 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Mellinger, Mary (NIH/NIAID) [E]; Schmidt, Beth (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:26 PM
To: 'meichberg@berkeley.edu'
Subject: Re: UC Berkeley Invitation: Symposium Speaker/Panelist

Thanks for the invitation, but I may be in Monrovia at that time.

Best wishes,
Heinz

From: Michael J Eichberg [mailto:meichberg@berkeley.edu]
Sent: Wednesday, October 15, 2014 01:35 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: UC Berkeley Invitation: Symposium Speaker/Panelist

Dear Dr. Feldmann,

I am the Executive Director of the Berkeley Center for Emerging and Neglected Diseases (CEND) and each year we organize a high profile and very well attended symposium on areas related to our mission in infectious diseases (see the website, <http://cend.globalhealth.berkeley.edu>). This year's theme is Vaccines and Therapeutics: From Science to Solutions. Please see below for our current speaker line-up.

This year we are inviting speakers in the areas of vaccine and therapeutic development, and are planning a special panel to discuss the status of the Ebola vaccines and therapeutics pipeline, and their potential use in the current epidemic. We are interested in inviting and hosting you as a panel member to discuss the vaccine pipeline.

The symposium is all day on January 9th, 2015 with a dinner to follow. Please let me know if you would be interested in attending.

Best,
Mike Eichberg

Michael J. Eichberg, Ph.D.
Executive Director
Center for Emerging and Neglected Diseases
University of California, Berkeley
444A Li Ka Shing Center
Berkeley, CA 94720-3370
510-664-4867 (t)
510-643-4966 (f)
Personal Inf (c)
meichberg@berkeley.edu
<http://globalhealth.berkeley.edu/cend>

David Russell, Professor, Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University

Speaking Topic: "How host physiology impacts the drug susceptibility of *Mycobacterium tuberculosis*"

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 11:10 AM
To: Damon, Inger K. (CDC/OID/NCEZID); Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD)
Cc: George Risi
Subject: Re: Montana

I just talked to Dr. George Risi - feel free to call him at Personal Info This is mobile - he is not in the office.

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 12:52 PM Eastern Standard Time
To: Damon, Inger K. (CDC/OID/NCEZID); Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD)
Cc: George Risi
Subject: Re: Montana

Inger,
Please contact George Risi - I copied George on this email.

Heinz

----- Original Message -----

From: Damon, Inger K. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 12:41 PM Eastern Standard Time
To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Montana

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 11:03 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Miller, Katherine (NIH/NIAID) [E]
Subject: Re: ASPA_0682: ASPR press release "HHS accelerates development of third Ebola vaccine"

This the Profectus VSV vaccine platform which still has the VSV G in a mutated form. We have done one preliminary pilot study in guinea pigs and one in NHPs (two animals only). Profectus is no working with UTMB Galveston - we do not have a role others than providing input in some of the scientific discussions. LV still works with serivatives of the Winnipeg VSV v accine (delta VSV G).

Overall, not our vaccine.

Heinz

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 10:23 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Miller, Katherine (NIH/NIAID) [E]
Subject: FW: ASPA_0682: ASPR press release "HHS accelerates development of third Ebola vaccine"

Heinz, is this the platform that LV developed / studies here ... if so please confirm asap, and if you can review the release let me know of edits / suggestions.

Under a one-year contract with Profectus BioSciences, Inc. of Tarrytown, New York, the ASPR's Biomedical Advanced Research and Development Authority (**BARDA**) will provide approximately \$5.8 million funding, subject matter expertise and technical assistance to further develop an experimental Ebola vaccine **called rVSVN4CT1 EBOV**, manufacture vaccine for use in animal studies and Phase 1 clinical studies, and conduct animal studies to test safety and efficacy.

Thanks.

From: OS HHSPress (HHS/ASPA) [<mailto:HHSPress@hhs.gov>]
Sent: Tuesday, October 14, 2014 6:25 PM
To: OS - ASPA - Clearance; DPAID (CDC) (dpaid@cdc.gov); Hoskins, Sharon (K.D.) (CDC/OD/OADC); NIH News Clearance (NIH/OD); OC OPA-PRESS (OCOPA-PRESS@OC.FDA.GOV)
Cc: Michael, Gretchen (HHS/ASPR/COO); Kane, Elleen (HHS/ASPR/COO)
Subject: ASPA_0682: ASPR press release "HHS accelerates development of third Ebola vaccine"

CLOSE HOLD – EXPEDITED

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 10:53 AM
To: Damon, Inger K. (CDC/OID/NCEZID); Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD)
Cc: George Risi
Subject: Re: Montana


Inger,
Please contact George Risi - I copied George on this email.

Heinz

----- Original Message -----

From: Damon, Inger K. (CDC/OID/NCEZID)
Sent: Wednesday, October 15, 2014 12:41 PM Eastern Standard Time
To: Brooks, John T. (CDC/OID/NCHHSTP); Redd, Stephen (CDC/OID/OD); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Montana

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 10:50 AM
To: 'joe@acacia-advisors.com'
Subject: Re: Paul Farmer Recommendation

I am away until early November.

From: Joe Cashion [mailto:joe@acacia-advisors.com]
Sent: Wednesday, October 15, 2014 12:37 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Paul Farmer Recommendation

Dear Dr. Feldmann,

Dr. Farmer's office gave me your contact information and suggested you might be able to connect at some point. I've known Paul for many years through my work with the Clinton Foundation on HIV/AIDS issues, and am currently doing some research on possible impacts of Ebola in West Africa, with a particular focus on Cote d'Ivoire.

I currently run a small consulting company with a range of non profit and investment companies. I am trying to better understand the public health and economic to West Africa as a result of the Ebola crisis, and as part of this, I am looking into whether Cote d'Ivoire, should the virus spread, might follow the path of Liberia, or more hopeful examples like Nigeria, in terms of virus containment.

Given your work, I was wondering if you might have a few moments to connect with myself and a couple of colleagues. A bit out of the blue, I realize, but given your background, you were a natural port of call. And of course, we are happy to compensate for your time, if that's appropriate. Also, I realize you are certainly very busy these days, so either way, appreciate it very much.

Many thanks,

Joe Cashion

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 10:47 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: VP24

Sure - we may need a letter from the quarantine office as this goes abroad. Ask Nancy about it.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 15, 2014 11:33 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: VP24

Hi Heinz,

I got a request from the ETH Zurich for an expression plasmid for VP24. Are you OK with me getting an SLA in place and sharing that plasmid?

All the best, Thomas

-----Original Message-----

From: Chi Celestine [mailto:chi.celestine@phys.chem.ethz.ch]
Sent: Wednesday, October 15, 2014 1:33 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: VP24

Hi Thomas,

I was wondering if it will be possible for you to lend me the gene for Vp24? I mean we could open up future collaborative works if you prefer this. My aim at the moment is to express the protein and carry out some preliminary works prior to my start in Sweden later next year. This will likely help me secure more funding

Kind Regards

Chi

Celestine Chi, PhD
ETH Zürich
Laboratory for Physical Chemistry
Vladimir-Prelog-Weg 2 HCI F 222
CH-8093 Zürich
Email: chi.celestine@phys.chem.ethz.ch<mailto:chi.celestine@phys.chem.ethz.ch>
tele: 004144 63 37510

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 10:10 AM
To: Young, Howard (NIH/NCI) [E]
Subject: Re: experiment?

Haven't done the experiment. Currently in Monrovia.

From: Young, Howard (NIH/NCI) [E]
Sent: Wednesday, October 15, 2014 09:36 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: experiment?

Dear Heinz,

I am certainly you are overwhelmed with inquiries but I wanted to know if you know the answer to this question. Did you ever try to infect interferon-gamma treated monocytes with Ebola? Sina said HeLa cells are resistant but neither he, Gene or Lisa knew if it applied to monocytes. Given that gamma is approved for human use, my naïve rationale is that maybe a low dose might offer some protection to health care workers.

Regards,
Howard

Howard A. Young, Ph.D.
Deputy Chief & Principal Investigator
Laboratory of Experimental Immunology
Cancer & Inflammation Program
Center for Cancer Research
National Cancer Institute at Frederick
Frederick, MD 21702
Tel: 301-846-5743
Email: younghow@mail.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 10:08 AM
To: 'emily.ragobeer@aljazeera.net'
Subject: Re: Urgent - Al Jazeera English Interview

Just send me an email.

From: Emily Ragobeer [mailto:emily.ragobeer@aljazeera.net]
Sent: Wednesday, October 15, 2014 09:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Urgent - Al Jazeera English Interview

Thank you – stay safe.
Is there a number where I may reach you for future?

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 15, 2014 2:41 PM
To: Emily Ragobeer
Subject: Re: Urgent - Al Jazeera English Interview

I am away in Monrovia and not available until early November.

From: Emily Ragobeer [mailto:emily.ragobeer@aljazeera.net]
Sent: Wednesday, October 15, 2014 06:30 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Urgent - Al Jazeera English Interview

Hello Dr. Feldman,
Any word on this request please?
Many thanks
Emily

From: Emily Ragobeer
Sent: Wednesday, October 15, 2014 11:48 AM
To: 'feldmannh@niaid.nih.gov'
Subject: Urgent - Al Jazeera English Interview
Importance: High

Dear Dr. Feldman,

I hope this email finds you well.

I am a producer with Al Jazeera English based in Doha Qatar and I would like to request you for an interview today on our flagship discussion program 'Inside Story' at 930 am ET (130 pm GMT) in-studio.

Today we're doing a in-depth show on Ebola and primarily containing and finding out the root cause of it and how the its host travels.

I've been reading your comments on this and I would like to have your expertise on this program.

This would be a paid appearance and would be pre-recorded between 930-10 am ET.

Please let me know if you would be available and the best number to reach you on.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 5:42 AM
To: 'KaiKupferschmidt@gmx.de'
Subject: Re: vaccine story

Kannst Du jetzt - sagen wir 14:00 Uhr MEZ? Was ist Deine Nummer?

From: Kai Kupferschmidt [mailto:KaiKupferschmidt@gmx.de]
Sent: Wednesday, October 15, 2014 05:52 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: vaccine story

Kein Problem. Wollte dich ein paar Sachen für eine Geschichte zu der Testung der Impfstoffe fragen und noch ein paar andere Sachen.
Sag einfach, wann es dir passt.

Gruß
Kai

On 15.10.2014, at 00:53, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Ich bin zur Zeit in Monrovia. Wann passt es fuer Dich? Dies muss inoffiziell sein, da ich keine offiziellen Interviews gebe waehrend meines Monrovia-Aufenthalts.

Heinz

From: Kai Kupferschmidt [mailto:KaiKupferschmidt@gmx.de]
Sent: Tuesday, October 14, 2014 03:50 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: vaccine story

Hallo Heinz,

hoffe, dir gehts gut. Hast du morgen mal 15 Minuten, um mit mir zu sprechen?

Gruß
Kai

On 30.09.2014, at 17:50, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Danke fuer den Artikel. Wir fangen naechste Woche an.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 5:41 AM
To: 'emily.ragobeer@aljazeera.net'
Subject: Re: Urgent - Al Jazeera English Interview

I am away in Monrovia and not available until early November.

From: Emily Ragobeer [mailto:emily.ragobeer@aljazeera.net]
Sent: Wednesday, October 15, 2014 06:30 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Urgent - Al Jazeera English Interview

Hello Dr. Feldman,
Any word on this request please?
Many thanks
Emily

From: Emily Ragobeer
Sent: Wednesday, October 15, 2014 11:48 AM
To: 'feldmannh@niaid.nih.gov'
Subject: Urgent - Al Jazeera English Interview
Importance: High

Dear Dr. Feldman,

I hope this email finds you well.

I am a producer with Al Jazeera English based in Doha Qatar and I would like to request you for an interview today on our flagship discussion program 'Inside Story' at 930 am ET (130 pm GMT) in-studio.

Today we're doing a in-depth show on Ebola and primarily containing and finding out the root cause of it and how the its host travels.

I've been reading your comments on this and I would like to have your expertise on this program.

This would be a paid appearance and would be pre-recorded between 930-10 am ET.

Please let me know if you would be available and the best number to reach you on.

Many thanks

Emily Ragobeer
Al Jazeera English
Doha Qatar
+974-4489-2497

Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 5:41 AM
To: 'Ilia.Semmler@tmf-ev.de'
Subject: Re: AW: AW: Text für die Pressemitteilung zur Freigabe und Presseanfrage

Viel Spass.

----- Original Message -----

From: Semmler, Ilia [mailto:Ilia.Semmler@tmf-ev.de]
Sent: Wednesday, October 15, 2014 06:46 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: AW: Text für die Pressemitteilung zur Freigabe und Presseanfrage

Lieber Heinz,

danke für die Anmerkung - das können wir noch einbauen, kein Problem! Die PM geht morgen raus!

Wir werden versuchen, dich würdig beim Symposium zu vertreten. :)

Viele Grüße
Ilia

-----Ursprüngliche Nachricht-----

Von: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Gesendet: Dienstag, 14. Oktober 2014 15:03
An: Semmler, Ilia
Betreff: Re: AW: Text für die Pressemitteilung zur Freigabe und Presseanfrage

Ilia,

Es tut mir leid, aber ich hatte grosse Probleme das Attachment zu oeffnen.

Sehr gute Pressemitteilung. Nur eine Anmerkung - die 'Internal Conference on Zoonoses' ist eigentlich nicht US-amerikanisch sondern international. Kein Problem, wenn das nun zu spaet kommt.

Viel Spass und Erfolg mit der Tagung. Ich waere sehr gern gekommen.

Gruss, Heinz

-----Original Message-----

From: Semmler, Ilia
To: Heinrich (NIH/NIAID) [E] Feldmann
Subject: AW: Text für die Pressemitteilung zur Freigabe und Presseanfrage
Sent: Oct 14, 2014 1:54 AM

Anbei meine Mail von Donnerstag noch einmal, damit sie bei dir wieder obenauf ist.
Mit der Bitte um Freigabe.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 5:40 AM
To: 'Helen.Branswell@thecanadianpress.com'
Subject: Re: How are you doing?

OK - you most likely know more than I do.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Wednesday, October 15, 2014 06:47 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: How are you doing?

That isn't what they have been talking about, Heinz. Are talking about dosing work.

Helen Branswell
Medical reporter
The Canadian Press

iPhone. iTypos. iApologize.
(iCribbedThis)

On Oct 15, 2014, at 5:36 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

I am not sure if they will include a dose trial - they most likely will give a single dose.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Tuesday, October 14, 2014 07:09 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: How are you doing?

Thanks.

If they find the Goldilocks dose - I know, not a scientific term - shouldn't that help with the reactogenicity issue?

I have been thinking this whole experience must be thrilling and scary for people who have devised Ebola vaccines and therapeutics. You will finally see them in use, and finally get an idea if they work. But the flip side of that coin is you never know until you know, huh?

Best,
Helen

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-14-14 8:35 AM
To: Branswell, Helen
Subject: Re: How are you doing?

Not really as we have been using different Zaire ebolavirus challenge strains in the NHP studies. It won't protect against another species - for example Sudan ebolavirus. More nervous about the overall

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 3:37 AM
To: 'Helen.Branswell@thecanadianpress.com'
Subject: Re: How are you doing?

I am not sure if they will include a dose trial - they most likely will give a single dose.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Tuesday, October 14, 2014 07:09 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: How are you doing?

Thanks.

If they find the Goldilocks dose – I know, not a scientific term – shouldn't that help with the reactogenicity issue?

I have been thinking this whole experience must be thrilling and scary for people who have devised Ebola vaccines and therapeutics. You will finally see them in use, and finally get an idea if they work. But the flip side of that coin is you never know until you know, huh?

Best,
Helen

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-14-14 8:35 AM
To: Branswell, Helen
Subject: Re: How are you doing?

Not really as we have been using different Zaire ebolavirus challenge strains in the NHP studies. It won't protect against another species - for example Sudan ebolavirus. More nervous about the overall performance in humans. and potential adverse effects (live-attenuated vaccine). This is exciting but also a little worrisome.

We started the experiment in NHPs using a Guinea isolate as the challenge virus - should know in a month.

Heinz

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Tuesday, October 14, 2014 08:24 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: How are you doing?

Have I asked you: are you at all concerned that the efficacy of the VSV vax might be lower because the outbreak virus is drifted or at least somewhat difference from the vaccine reference strain?

Best,
Helen

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: October-14-14 6:12 AM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 3:36 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Al Jazeera INSIDE STORY

From: Aliena Haig [mailto:aliena.haig@aljazeera.net]
Sent: Wednesday, October 15, 2014 05:22 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Al Jazeera INSIDE STORY

Dear Mr. Feldmann,

Al Jazeera's flagship current affairs show Inside Story is discussing the latest developments regarding ebola on today's show and we would very much like to invite you to join our guest panel and partake in the discussion, particularly since you have recently returned from Monrovia.

It is scheduled to take place at 9:30 (DC local time) this morning and would last half an hour.

I realize it is very short notice, but please do let me know if you would be at all interested and/or available.

I very much look forward to hearing from you.

Many thanks and kind regards,
Aliena



ALIENA HAIG
ALJAZEERA CHANNEL, NETWORK
PRODUCER | INSIDE STORY | NEWS DEPT
T +974 4489 2680 / 2494 |
M **Personal Info**
E aliena.haig@aljazeera.net |

www.aljazeera.net/english | www.aljazeera.com

Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 3:35 AM
To: YOSHIHIROKAWAOKA; 'twgeisbe@UTMB.EDU'
Subject: Re: Scientific Program for Filovirus meeting

They plan all kind of trials but no-one seems to coordinate them. If they want to do trials at MSF sites they need to go through a board including WHO and others.

I do not think there are specific modeling people for Ebola. UK people do modeling - don't they? Perhaps Peter Walsh knows someone.

Heinz

----- Original Message -----

From: YOSHIHIROKAWAOKA
Sent: Tuesday, October 14, 2014 10:03 PM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Scientific Program for Filovirus meeting

At a tel conf, Peter Hoby stated that they are planning to do clinical trials with drugs (not specified).

Redacted by agreement

So, clinical trials of potential drugs would be another topic.

Inviting Margret Chan is an option too. She or Keiji Fukuda will likely come.

For modeling, who would be the one. I can think of flu epidemic modeling person. But, not shure they are doing one for Ebola.

From: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>
Handle: Geisbert, Thomas W.
Mail Address: twgeisbe@UTMB.EDU
Subject: RE: Scientific Program for Filovirus meeting
To: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>, YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>
CC: --
Date: Tue, 14 Oct 2014 16:39:02 +0000
Date Local: 2014/10/15 1:39:02
Message:

> Got it. Outbreak modeling would be interesting.

>

> -----Original Message-----

> From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]

> Sent: Tuesday, October 14, 2014 11:38 AM

> To: Geisbert, Thomas W.; YOSHIHIROKAWAOKA

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 3:18 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Urgent - Al Jazeera English Interview

Importance: High

From: Emily Ragobeer [mailto:emily.ragobeer@aljazeera.net]
Sent: Wednesday, October 15, 2014 04:46 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Urgent - Al Jazeera English Interview

Dear Dr. Feldman,

I hope this email finds you well.

I am a producer with Al Jazeera English based in Doha Qatar and I would like to request you for an interview today on our flagship discussion program 'Inside Story' at 930 am ET (130 pm GMT) in-studio.

Today we're doing a in-depth show on Ebola and primarily containing and finding out the root cause of it and how the its host travels.

I've been reading your comments on this and I would like to have your expertise on this program.

This would be a paid appearance and would be pre-recorded between 930-10 am ET.

Please let me know if you would be available and the best number to reach you on.

Many thanks

Emily Ragobeer
Al Jazeera English
Doha Qatar
+974-4489-2497

Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 15, 2014 3:16 AM
To: 'dhorn@mid-atlanticbio.com'
Subject: Re: Studying IMT504 in an Ebola mouse model

I am currently in Monrovia and Darryl is leaving us. We can talk about this when I get back in November.

Heinz

From: David Horn [mailto:dhorn@mid-atlanticbio.com]
Sent: Tuesday, October 14, 2014 11:00 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Studying IMT504 in an Ebola mouse model

Dear Heinz,

As you may recall, we have been developing IMT504 as an anti-infective agent for a number of years, and have shown very robust survival results against a number of different intractable viral and bacterial pathogens, including in highly lethal *Pseudomonas aeruginosa* and rabies models (see Chahin et al., 2014 - attached).

When we first spoke to you about IMT504, we had not thoroughly investigated whether IMT504 would signal in a mouse model, but recently, we have found evidence to suggest that it has broad utility in various mouse models (Bianchi et al., 2014; Zhao et al., 2009 – also attached).

Given the severity of the ongoing Ebola epidemic, and the scarcity of effective treatments, we would like to propose a study to evaluate the efficacy of IMT504 in a mouse Ebola model. We currently have IMT504 drug supply available to undertake such a study, and can advise on the best strategy to dose IMT504 to ensure maximum probability of success.

Please let us know the best way to proceed if you are interested in moving forward.

Regards,

David

David Horn, MD
CEO
Mid-Atlantic BioTherapeutics, Inc.
3805 Old Easton Road
Doylestown, PA 18902
dhorn@mid-atlanticbio.com
www.mid-atlanticbio.com
215-266-2301

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 5:37 PM
To: Clifton, Dawn (NIH/NIAID) [E]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Re: Phone call w/ Lisa - FW: [Pers] and [Personal] Travel to Liberia for Ebola Outbreak Participation

LV currently operates a diagnostic laboratory in Monrovia in support of the Ebola virus outbreak in West Africa. The service is an extremely important part of the international public health response to the worldwide infectious disease crisis. In order to perform our duties in Monrovia we need well trained personnel experienced in high containment and biosafety. [Personal Info] and [Personal Info] are extremely important assets for this response duty due to their extensive experience and expertise. Their participation is absolutely critical for a successful response.

Will this be OK? Please feel free to make changes if necessary.

Heinz

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 02:12 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: FW: Phone call w/ Lisa - FW: [Pers] and [Personal] Travel to Liberia for Ebola Outbreak Participation

Hi Heinz,

Lisa is asking for written justification for the denial for [Pers] and [Personal], and also requesting from you some information/wording that she can use with Lockheed and Kelly in regards to the importance of [Perso] and [Personal In] participation in this mission. I'm pasting from Lisa here (or you can scroll down): "I am currently seeking specific, written, information from LM and Kelly as to why the denial of [Pers] and [Personal I] travel. There needs to be a bona fide reason. Hoping to understand their position so that we can petition reasonably.

While I await this information from the contractors, would you please **inquire with Dr. Feldmann and confirm that each [Pers] and [Personal I] participation is critical to the success of the mission.** If yes, would he please draft some text for me to use in my petition for reconsideration?

I am also checking to see what the Department of Defense might be doing re permitting contractor travel for this activity."

Do you think you can give them something? I can try as well, but it may be more significant actually coming from you. I've rescheduled my phone call with her to later this afternoon to see if we can get some more info from the contractors.

Dawn


Dawn R. Clifton, Ph.D.
Scientific Operations Manager
Laboratory of Virology
Rocky Mountain Laboratories
903 S. 4th St.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 5:22 PM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Re: Unpublished

Sounds good.

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 4:53 PM
To: 'KaiKupferschmidt@gmx.de'
Subject: Re: vaccine story

Ich bin zur Zeit in Monrovia. Wann passt es fuer Dich? Dies muss inoffiziell sein, da ich keine offiziellen Interviews gebe waehrend meines Monrovia-Aufenthalts.

Heinz

From: Kai Kupferschmidt [<mailto:KaiKupferschmidt@gmx.de>]
Sent: Tuesday, October 14, 2014 03:50 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: vaccine story

Hallo Heinz,

hoffe, dir gehts gut. Hast du morgen mal 15 Minuten, um mit mir zu sprechen?

Gruß
Kai

On 30.09.2014, at 17:50, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Danke fuer den Artikel. Wir fangen naechste Woche an.

From: Kai Kupferschmidt [<mailto:KaiKupferschmidt@gmx.de>]
Sent: Tuesday, September 30, 2014 5:00 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: vaccine story

Hallo Heinz,

war dann gestern schon im Bett als die story online gegangen
ist: <http://news.sciencemag.org/africa/2014/09/ebola-vaccine-tests-needlessly-delayed-researchers-claim>

Hast du anfangen können, den Impfstoff gegen den Guinea strain zu testen?

Gruß und viel Erfolg!
Kai

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 4:51 PM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Re: Unpublished

Fine with me.

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 4:47 PM
To: 'meshulam@profectusbiosciences.net'; 'twgeisbe@UTMB.EDU'
Cc: 'eldridge@profectusbiosciences.net'
Subject: Re: Comments on Ebola research funding

ZMapp, VSV and Tekmira come to a certain degree from Canada. This might be the background for the question.

Things are OK in Monrovia.

Best wishes, Heinz

From: Jeffrey Meshulam [mailto:meshulam@profectusbiosciences.net]
Sent: Tuesday, October 14, 2014 06:16 PM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: John Eldridge <eldridge@profectusbiosciences.net>
Subject: FW: Comments on Ebola research funding

This reporter has been good.. she ran a story about our ebola funding. I am so not the person to get into this with her. I am not sure where she is going but would one of you want to talk to her?

Heinz stay safe!

Thank you

From: Kathleen Caulderwood [mailto:k.caulderwood@ibtimes.com]
Sent: Tuesday, October 14, 2014 3:48 PM
To: Jeffrey Meshulam
Subject: Re: Comments on Ebola research funding

Hi,

Thanks again for your help with my other stories, I'm still covering Ebola research and now I have a new query.

It seems to me that many of the most prominent experimental drugs are coming from Canadian research firms. Not sure if I'm getting all the information here. Can you tell me anything about Canada's reputation in the industry? Are they particularly known for Ebola funding or something?

Let me know!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 2:27 PM
To: 'Jana.Schluetter@tagesspiegel.de'
Subject: Re: Press request: vaccines against ebola

I won't be at the meeting - I am currently in Monrovia.

Best wishes, Heinz

From: Jana Schluetter [mailto:Jana.Schluetter@tagesspiegel.de]
Sent: Tuesday, October 14, 2014 04:12 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Press request: vaccines against ebola

Dear Dr. Feldmann,

According to the program of the Annual Meeting of the National Zoonosis Platform Germany, you will be in Berlin on Thursday. I would be very interested in meeting you at the conference venue - if at all possible. I am preparing a longer article about ebola vaccine research for the science page of a Berlin daily newspaper called "Tagesspiegel".

Thank you ever so much!

Jana Schlütter

--

Jana Schlütter
Der Tagesspiegel
Ressort Wissen & Forschen
Askanischer Platz 3
10963 Berlin

Tel.: +49 (0)30 / 29021-14408
E-Mail: jana.schluetter@tagesspiegel.de

Verlag Der Tagesspiegel GmbH

Askanischer Platz 3, 10963 Berlin

Geschäftsführung: Florian Kranefuß

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 2:25 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: TheBlazeTV interview request

From: Decker, Jonathan [mailto:jdecker@theblaze.com]
Sent: Tuesday, October 14, 2014 03:04 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: TheBlazeTV interview request

Good afternoon,
My name is Jonathan Decker
I am a TV Producer for the Glenn Beck TV Show.
Glenn would like to speak with you or someone else who can talk to us about the possibilities of EBOLA being an Airborne Disease.
Also, about what people can do to stop this and on the numbers that WHO released about how there could be up to 10 thousand EBOLA cases weekly by December.

Glenn would like to speak with you today between 5-6 ET
We can set a remote up and transportation to and from as well.
Thanks again and I look forward to hearing from you soon,

Jonathan Decker
jdecker@theblaze.com

Jonathan Decker
Associate Producer
The Glenn Beck Program
TheBlazeTV

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:49 PM
To: 'wil2001@columbia.edu'
Subject: Re: Ebola Engineering Challenge

Ian - having a hard time to get on interne to download the attachment. Currently in Monrovia until early November. I am sure the proposals are fine. I am happy to support. Exclude me from the article as this would need approval from Bethesda.

Sorry and best wishes, Heinz

From: W. Ian Lipkin [mailto:wil2001@columbia.edu]
Sent: Monday, October 13, 2014 10:32 AM Eastern Standard Time
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Cathy Roth <rothc@who.int>; Spiropoulou, Christina (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Rachel T. Moresky <rtm2102@cumc.columbia.edu>; Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Kahn Eleanor J. <ejk2162@cumc.columbia.edu>
Subject: Ebola Engineering Challenge

Dear Armand, Cathy, Christina, Heinz, Lisa, Rachel and Stuart,

Attached please find brief proposals that address needs that one or more of you have suggested might be amenable to low cost engineering solutions including improvements in decontamination of electronic equipment, disinfectant solutions, body bags, patient transport, and data collection and management. I will be vetting these proposals with the engineering faculty on Wednesday 15 October btw 11 AM and 3 PM EST. It would be helpful if you would fill in the attached score sheet by Tues evening. Please dont spend more than 30 minutes in total reading and scoring the proposals. What we want to know is whether you think the teams are meeting a need and whether a course correction or additional information is needed.

Thanks,

Ian

ps. The New Yorker Magazine will be writing this up as a feature story. Please tell me whether you do or dont want us to include your name.

W. Ian Lipkin, MD
John Snow Professor of Epidemiology,
Mailman School of Public Health

Professor of Neurology and Pathology,
College of Physicians and Surgeons

Director, Center for Infection and Immunity

Columbia University
www.cii.columbia.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:44 PM
To: 'Ruth_Margalit@newyorker.com'
Subject: Re: Query from The New Yorker

Sorry but I cannot do this. I am currently in Monrovia until early November with little to no internet access.

Best wishes, Heinz

From: Margalit, Ruth [mailto:Ruth_Margalit@newyorker.com]
Sent: Tuesday, October 14, 2014 02:01 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Query from The New Yorker

Dear Dr. Feldmann,

I'm a fact checker at The New Yorker magazine working with reporter Richard Preston on an upcoming long article on the Ebola outbreak. In the course of fact checking I will be contacting many of the experts whom Richard has interviewed for the piece but, given the sensitivity of the issue at hand and given your all-round expertise and knowledge of the subject, we wondered whether you would be so kind as to read the entire article—in strict confidentiality—before we go to press and let us know if you find any inaccuracies or areas of contention. Since this is still a work in progress and isn't to be circulated in any way, we want to make sure that you will not show it to anybody.

I have no doubt that you're extremely busy. If you do find the time and the inclination to read this, we would be extremely grateful—the piece is attached. I'm also happy to discuss the details over the phone, if you prefer, and am available at 212-286-2941.

Our deadline is Thursday.

Many thanks in advance, and I hope this finds you well,

Ruth Margalit


--

Ruth Margalit
The New Yorker
4 Times Square
NY, NY 10036
212.286.2941 (work)
Personal Info (mobile)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:39 PM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Re: Unpublished

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:37 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Quick comments on Canada Ebola research
Attachments: IBT Logo.png

From: Kathleen Caulderwood [mailto:k.caulderwood@ibtimes.com]
Sent: Tuesday, October 14, 2014 02:01 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Quick comments on Canada Ebola research

Hi,

I'm a reporter at International Business Times in New York. I've been doing a lot of coverage of Ebola research and today I'm working on a short story about how Canada has emerged as one of the leading sources in the industry, and was hoping to get a few comments from you about your work in Winnipeg.

I realize you're abroad right now and a phone call might be hard to arrange. So if you have a few minutes to write back on any of the questions below I would greatly appreciate it.

Thanks!

- Why you decided to join the National Microbiology Laboratory in Winnipeg
- How you managed to get funding for Ebola research, which, as I understand it, wasn't especially popular before this year
- What is the place of Canadian research among other Ebola researchers today? Are they are the forefront?

Kathleen Caulderwood
k.caulderwood@ibtimes.com

INTERNATIONAL BUSINESS TIMES

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:36 PM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Fw: Unpublished
Attachments: Unpublished

Please send me the updated manuscript as I have not even started on this one.

Thanks, Heinz

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:35 PM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: FYI - Kelly will not make exception to **Personal Info** travel

Persona was one of a few who had agreed to cover the holiday season. We will have trouble to replace her over Christmas and New Year.

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 01:37 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI - Kelly will not make exception to **Personal Info** travel

If we can get **Perso** permission, her and Bob make two out of three, which is pretty good. Lisa's calling me in a few minutes, so I will check to see what the real issues are and see if we can figure out a way.

Dawn

Dawn R. Clifton, Ph.D.
Scientific Operations Manager
Laboratory of Virology
Rocky Mountain Laboratories
903 S. 4th St.
Hamilton, MT 59840
406-375-9762
dawn.clifton@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:52 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: FYI - Kelly will not make exception to Cynthia Martellaro travel

Everyone is well.

Please make sure that the gloveboxes get ordered - we will need them.

We also need the contract workers - someone needs to look into this.

Thanks, Heinz

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:43 PM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:32 PM
To: 'J_Silverman@acs.org'
Subject: Re: Invitation to write a Viewpoint for ACS Infectious Diseases

Thanks for the invitation but I would not be able to do that in the next six months or even longer.

Heinz

From: Janice E. Silverman [mailto:J_Silverman@acs.org]
Sent: Tuesday, October 14, 2014 02:28 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Invitation to write a Viewpoint for ACS Infectious Diseases



Dear Dr. Feldmann:

I hope you are doing well. I recently read your articles "**Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates**" published in **PNAS** with great interest. I know you are very busy, but I wanted to ask if you would be willing to write a Viewpoint article on Ebola vaccine/treatment for our new journal, [ACS Infectious Diseases](#). The American Chemical Society launched the journal in September 2014 to serve the Society's Mission of "*improving people's lives through the transforming power of chemistry*" along with the Society's vision "*to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people.*"

As you know, the Ebola virus outbreak in Africa has caused alarm worldwide. However, not many understand the science, or the mechanism of infection, as evidenced by the lack of available therapeutic when it is urgently needed. As such, I would like to ask if you would be interested in writing a Viewpoint on vaccination against Ebola virus, and/or the virus life cycle, and possibly use this forum as **a call for action to researchers**. Given the desire of our Editors to increase awareness on the actual infection mechanism, especially at this time when the disease is being highlighted by media, the *ACS Infectious Diseases* Editors would like to highlight this topic on the first Viewpoint for the journal. We collectively agreed that you are the most suited author for this piece.

Should you accept our invitation, we will plan to publish your Viewpoint in the **January 2015** inaugural Issue. This is our sample issue, and will be **available to read for free** to anyone interested. The deadline for the manuscript would be **December 4, 2014**. We prefer Viewpoint pieces of no more than 1,800 words. Figures and diagrams can be used freely to explain the points made and are highly encouraged. We can usually accommodate up to 2 figures per Viewpoint. If you accept, kindly submit your Viewpoint via our manuscript tracking system <https://acs.manuscriptcentral.com/acs>.

Given the time sensitivity of this matter, can you please let me know by Friday, October 17, if you will be able to help us with the Viewpoint? If you decline, I would be grateful if you could provide suggestions as to other suitable authors for this urgent and important Viewpoint.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:00 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: letter of collaboration
Attachments: Kawaoka Collaboration 2013.doc

Hi Thomas,
Let me know if this ok, there is more if you need.
Ricki

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416
Email: feldmannh@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 11:20 AM
To: 'gary_kobinger@phac-aspc.gc.ca'
Subject: Fw: VSV-vaccine protocol
Attachments: 01014 NIH-RML 10-02-14 .doc

Gary,

One question regarding the vaccine doses. Sabrina mentions in the agreement 10 doses. Is that what you wish to have listed? We did receive more.

Let me know as soon as possible so that I can send this on to Bethesda.

Heinz

From: Sabrina Boyer [mailto:sabrina.boyer@phac-aspc.gc.ca]
Sent: Wednesday, October 08, 2014 03:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Chris Peterson <chris.peterson@phac-aspc.gc.ca>; Dorothea Blandford <Dorothea.Blandford@phac-aspc.gc.ca>
Subject: RE: VSV-vaccine protocol

Hi Heinz,

I've prepared the collaboration agreement for review and consideration of NIH-RML. I would ask that you "track your changes", if there are any, and return your comments to Chris Peterson; he has been cc'd on this email.

With thanks
Sabrina

Sabrina Boyer
Manager, Technology Transfer
Office of the Chief Science Officer/Bureau du Conseiller scientifique principal
Public Health Agency of Canada/ Agence de la santé publique du Canada
1015 Arlington Street
Winnipeg, MB R3E 3R2
Phone: (204) 789-2120
Fax: (204) 789-2097
Email: sabrina.boyer@phac-aspc.gc.ca



Public Health
Agency of Canada

Agence de la santé
publique du Canada

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: 'Sabrina Boyer' <sabrina.boyer@phac-aspc.gc.ca>, Jim Strong <Jim.Strong@phac-aspc.gc.ca>
Date: 2014-09-30 06:07 PM
Subject: RE: VSV-vaccine protocol

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 11:17 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: ebola vaccine story for Canadian newspapers

From: Stephen Maher [mailto:Personal Info]
Sent: Tuesday, October 14, 2014 01:12 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: ebola vaccine story for Canadian newspapers

Sir,

I know you're busy but I would very much like a quick chat about this.

<http://www.niaid.nih.gov/labsandresources/labs/aboutlabs/lv/diseasemodeling/Pages/default.aspx>

This has not been covered properly in Canada and it should be.

Yours,

Stephen Maher
Postmedia News

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 11:17 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: Ebola trVLP system

Ricki,
Can you please go on my computer and open a folder from the desktop entitled 'collaborations' or something similar. This folder should include recent examples for 'Letters of collaboration'. Take one for **Pers** or **Pers** from 2014 and send it to Thomas.

Thomas, please modify the letter accordingly and send the draft to me. Once we have a final draft - Kay can use the stamp to sign.

Let me know if you need my help.

Heinz

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Tuesday, October 14, 2014 01:10 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola trVLP system

Hi Heinz,

I just got off the phone with **Pers** and asked Kay to prepare the SLA. **Per** has asked me if we could provide her with a letter of collaboration regarding the trVLP system for an R01 application - basically affirming our help in getting the system up and running. I told her that I don't think I can sign such a letter, but that I would talk to you about this and find out whether you would be willing to do that in my stead. The application is due on Oct 28th.

Hope all is well!

All the best, Thomas

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 4:55 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

If you want to collaborate with her please go ahead. On the other hand, she can have the system without collaboration.

Heinz

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:54 AM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Unpublished

Did you submit the Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:52 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: FYI - Kelly will not make exception to **Personal Info** travel

Everyone is well.

Please make sure that the gloveboxes get ordered - we will need them.

We also need the contract workers - someone needs to look into this.

Thanks, Heinz

From: Clifton, Dawn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 12:43 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: FYI - Kelly will not make exception to **Personal Info** travel

Hi Heinz,
FYI--It appears as though Kelly is not allowing **Personal** to travel to Liberia at all (see email below). Desta (Lisa's assistant) is following up with Lisa, but she's not sure Lisa can do anything.

Ricki's permission is still up in the air. Lisa texted me late on Friday to say that a waiver may be necessary, and I have communicated with Desta this morning to follow up. I will let you know what happens.

I have asked for a quote from Coy for 3 glove boxes on a 28 day turnaround, but have not yet heard back. We still have one coming that Andrea should be able to take with her.

I hope you, Kyle and Kristin are doing well.

Dawn

From: Mills, Desta (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 9:41 AM
To: Clifton, Dawn (NIH/NIAID) [E]
Subject: FYI - Kelly will not make exception to **Personal Info** travel

Were you aware of this one too?

I am not sure there is much we can do, but again I will follow-up with Lisa.

From: Birdsong, George (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 10:34 AM
To: Mills, Desta (NIH/NIAID) [E]; Coronado, Lisa (NIH/NIAID) [E]
Subject: Kelly will not make exception to **Personal Info** travel

Good Morning Lisa and Desta,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 8:00 AM
To: 'info@christina-sartori.de'
Subject: Re: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Foto ist OK - habe keine weiteren Fotos hier in Monrovia.

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Tuesday, October 14, 2014 09:52 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz

super, vielen Dank, hoffe es geht Ihnen gut. Ich übernehme die Änderungen.

Dürfen wir auch das Foto von Ihnen verwenden, das auch auf der Website zu sehen ist? Haben Sie noch ein Ebola Foto?

Viele Grüße, Christina

"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> hat am 14. Oktober 2014 um 15:44 geschrieben:

Christina,

Habe gerade erst das Attachment oeffnen koennen. Das Interview ist gut - wenn noch moeglich zwei Verbesserungen:

- (1) Ich bin nur einer der Chairman der Zoonoses-Konferenz.
- (2) Es ist nicht ELSA3 sondern ELWA3.

Viele Gruesse, Heinz

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Friday, October 10, 2014 05:14 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz,

ich hoffe Sie sind wohlbehalten aus Liberia zurückgekehrt.

Anbei die endgültige Version für das Interview, das begleitend zum German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses im Internet veröffentlicht werden soll.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:59 AM
To: 'rcron@peds.uab.edu'
Subject: Re: Ebola

Please contact me early November as I am afraid I will forget after 4 weeks of absence.

From: Randy Cron, M.D. [mailto:rcron@peds.uab.edu]
Sent: Tuesday, October 14, 2014 09:50 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

OK, hopefully this can help with future epidemics.

I look forward to your call when you return.

Safe travels,

Randy

Randy Q. Cron, MD, PhD
Professor of Pediatrics & Medicine
Arthritis Foundation, Alabama Chapter, Endowed Chair
Director, Division of Pediatric Rheumatology
Children's Hospital of Alabama/
University of Alabama at Birmingham
Children's Park Place, Ste. 210
1601 4th Avenue South
Birmingham, AL 35233

Tel.: (205) 996-9191
Email: rcron@peds.uab.edu
FAX: (205) 996-9545

lab webpages:

<http://www.uab.edu/medicine/immunology/faculty?id=81:cron&catid=39:faculty>
http://138.26.61.118/depts/MEB/SOMResearchFaculty/currentfacultydata.asp?s_iname=cron&s_keyword=&s_fname=&s_Department_Name=&s_ResearchTitle=&ID=RCRON
<https://services.medicine.uab.edu/facultydirectory/FacultyData.asp?FID=30608>

division webpages:

<https://www.uab.edu/medicine/peds/rheum>
<http://www.uab.edu/medicine/rheumatology/faculty/62-randy-q-cron-md-phd>

PLEASE REMOVE ANY NON-BUSINESS PICTURES AND QUOTES FROM YOUR EMAIL SIGNATURE. WE WANT TO PROJECT A PROFESSIONAL IMAGE IN ALL ASPECTS OF OUR WORK.

Confidentiality Notice: The information transmitted is intended only for the person or company to which it is addressed and may contain confidential or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action of any reliance upon, this information by person or company other than the intended recipient is prohibited. If you receive this in error, please contact the sender and delete the material from any computer.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:57 AM
To: Baric, Ralph
Subject: Re: EBOLA RO1

Ralph,

I am currently in Monrovia supposed to come back early November. We can discuss the option when I get back if it can wait that long. We now have slots for Special Volunteer and Guest Researchers that we cannot exceed. I need to talk to admin as there was nothing open when I asked last time.

The person would have to commit for a longer period as training for BSL4 is quite time-consuming. They also need to go through re-training when they haven't been in BSL4 for three months. On top we need all the select agent and biosurveillance paperwork and screening including an annual psychological test in person either at RML or in Bethesda.

Best wishes, Heinz

-----Original Message-----

From: Baric, Ralph
To: Heinrich (NIH/NIAID) [E] Feldmann
Subject: RE: EBOLA RO1
Sent: Oct 9, 2014 7:49 AM

Hi Heinz, Hope you are doing well. We have been thinking about a "Pete Halfman" like UNC person to work at the RML. I realize that these types of positions are difficult to fill, but if you were serious, I could recommend **Personal Info** for such a position. She has a lot of experience with select agents (SARS, VEE) and 1918 flu (very soon as we have approval and will be receiving the virus shortly). I have appended her CV. She has about 2+ years of experience working with the CC mice and a fair amount of other animal experience, so should be able to help out our collaborations on multiple fronts, especially in terms of developing other improved animal models of human disease. Let me know if you'd like to continue these discussions. Hope you're surviving the Ebola outbreak. Ralph

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov] Sent: Thursday, October 02, 2014 2:28 PM
To: 'Michael G. Katze'; mtferris; ANGELA L. RASMUSSEN Cc: Marcus J. Korth; SEAN PROLL; Heise, Mark T; Baric, Ralph S; Okumura, Atsushi (NIH/NIAID) [V] Subject: RE: EBOLA RO1

Congrats – fantastic.

From: Michael G. Katze [mailto:honey@uw.edu] Sent: Thursday, October 02, 2014 7:43 AM To: mtferris@email.unc.edu; ANGELA L. RASMUSSEN Cc: Marcus J. Korth; SEAN PROLL; Mark Heise; Baric, Ralph; Okumura, Atsushi (NIH/NIAID) [V]; Feldmann, Heinrich (NIH/NIAID) [E] Subject: EBOLA RO1

Dear Angela and Marty

Personal Info Thank you for all your patience and now you can get back to work (sorry!). Let's do a post mortem after some time passes. There are so many cool directions to go in. Thanks to Heinz and Atsu at RML without whom we could not do anything.

Cheers

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:48 AM
To: 'rcron@peds.uab.edu'
Subject: Re: Ebola

I am in Monrovia until early November. We can discuss when I get back, but given our workload at RML in regards to Ebola additional animal experiments cannot happen before spring 2015.

Best wishes, Heinz

From: Randy Cron, M.D. [mailto:rcron@peds.uab.edu]
Sent: Tuesday, October 14, 2014 09:40 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola

Dear Dr. Feldmann,

I would love to speak you to some time by phone to discuss the potential role of IL-1 blockade in treating Ebola and whether this would be of interest to your laboratory research using animal models.

Please let me know times you might be available to speak by phone if you are interested. I've attached a proposal with some rationale for why this will help those infected with Ebola.

Thank you much,

Randy

Randy C. Cron, MD, PhD

Professor of Pediatrics & Medicine
Arthritis Foundation, Alabama Chapter, Endowed Chair
Director, Division of Pediatric Rheumatology
Children's Hospital of Alabama/
University of Alabama at Birmingham
Children's Park Place, Ste. 210
1601 4th Avenue South
Birmingham, AL 35233

Tel.: (205) 996-9191
Email: rcron@peds.uab.edu
FAX: (205) 996-9545

lab webpages:

<http://www.uab.edu/medicine/immunology/faculty?id=81:cron&catid=39:faculty>
http://138.26.61.118/depts/MEB/SOMResearchFaculty/currentfacultydata.asp?s_iname=cron&s_keyword=&s_fname=&s_Department_Name=&s_ResearchTitle=&ID=RCRON
<https://services.medicine.uab.edu/facultydirectory/FacultyData.asp?FID=30608>

division webpages:

<https://www.uab.edu/medicine/peds/rheum>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:44 AM
To: 'info@christina-sartori.de'
Subject: Re: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Christina,

Habe gerade erst das Attachment oeffnen koennen. Das Interview ist gut - wenn noch moeglich zwei Verbesserungen:

- (1) Ich bin nur einer der Chairman der Zoonoses-Konferenz.
- (2) Es ist nicht ELSA3 sondern ELWA3.

Viele Gruesse, Heinz

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Friday, October 10, 2014 05:14 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz,

ich hoffe Sie sind wohlbehalten aus Liberia zurückgekehrt.

Anbei die endgültige Version für das Interview, das begleitend zum German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses im Internet veröffentlicht werden soll. Können Sie es bis Montag durchsehen, Ihre Änderungswünsche eintragen und freigeben? Das wäre sehr hilfreich, um es noch rechtzeitig zur Konferenz einzustellen.

Haben Sie ein Foto von sich das wir verwenden können? Auf der Website ist eins

<http://www.zoonoses2014.com/#!welcome/c23yr>

wenn Sie einverstanden sind, nehmen wir das. Und haben Sie eventuell ein Foto vom Ebola Virus, dass wir mit dem Interview verwenden könnten?

Freundliche Grüße
Christina Sartori

Dipl.-Biol. Christina Sartori

Wissenschafts-Journalistin
info@christina-sartori.de
Mobil: Personal Info
Telefon: 030 - 89391473

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:33 AM
To: Jahrling, Peter (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Re: Update

We are doing in average about 51 samples per day ranging from 23 - 72.

I met with Cliff when he was here and we briefly discussed the vaccine trial. The lab support for that trial will most likely have to be covered by a different group. I do not think we can run this aside of the diagnostics.

Heinz

----- Original Message -----

From: Jahrling, Peter (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 12:50 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: Update

Heinz,

Thank you for this comprehensive update. Can I assume your normal throughput is in the range of 60-80/day? 70% positive is a bit higher then LIBR for whatever that means. Has Cliff talked to you about a proposed clinical trial of the two front running vaccines in Liberia? If that initiative materializes we will certainly have to increase our operational tempos and augment staff.

Peter

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 12:33 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Update

I apologize for not sending an update earlier. On the other hand, there is not much exciting stuff to report.

The new joint CDC/NIH team operates well. We have now split the NIH team into two members and the lead. The lead will come in a week after to work two weeks with the team and stays one more week with the incoming team. This seems to work well and provides continuous operation.

We replaced the glovebox as the bleach had started to change the color of the plastic material which made it more difficult to work. We are planing to replace the gloveboxes every 6 weeks. The cost is approx. 2500 US.

Sample numbers are about the same maybe slightly less. MSF has built the 400 bed capacity but currently only operates 250 beds due to staffing issues.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:28 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: Ebola Engineering Challenge
Attachments: CU_DesignChallenge_ProposalAbstracts _13Oct.pdf;
CU_DesignChallenge_Evaluations.docx

From: W. Ian Lipkin [mailto:wil2001@columbia.edu]
Sent: Monday, October 13, 2014 10:32 AM Eastern Standard Time
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Cathy Roth <rothc@who.int>; Spiropoulou, Christina (CDC/OID/NCEZID); Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Rachel T. Moresky <rtm2102@cumc.columbia.edu>; Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Kahn Eleanor J. <ejk2162@cumc.columbia.edu>
Subject: Ebola Engineering Challenge

Dear Armand, Cathy, Christina, Heinz, Lisa, Rachel and Stuart,

Attached please find brief proposals that address needs that one or more of you have suggested might be amenable to low cost engineering solutions including improvements in decontamination of electronic equipment, disinfectant solutions, body bags, patient transport, and data collection and management. I will be vetting these proposals with the engineering faculty on Wednesday 15 October btw 11 AM and 3 PM EST. It would be helpful if you would fill in the attached score sheet by Tues evening. Please dont spend more than 30 minutes in total reading and scoring the proposals. What we want to know is whether you think the teams are meeting a need and whether a course correction or additional information is needed.

Thanks,

Ian

ps. The New Yorker Magazine will be writing this up as a feature story. Please tell me whether you do or dont want us to include your name.

W. Ian Lipkin, MD
John Snow Professor of Epidemiology,
Mailman School of Public Health

Professor of Neurology and Pathology,
College of Physicians and Surgeons

Director, Center for Infection and Immunity

Columbia University
www.cii.columbia.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:25 AM
To: 'halfmanp@svm.vetmed.wisc.edu'
Subject: Fw: Article tracking [EBIOM_5] - Accepted manuscript available online (unedited version)

----- Original Message -----

From: Elsevier - Article Status [mailto:Article_Status@elsevier.com]
Sent: Monday, October 13, 2014 03:17 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA
Subject: Article tracking [EBIOM_5] - Accepted manuscript available online (unedited version)

Article title: Ebola conquers West Africa - more to come?

Reference:: Pending Publ

Journal title: EBIOMedicine

Corresponding author: Dr. Heinz Feldmann First author: Dr. Peter Halfmann Accepted manuscript (unedited version)
available online: Pending Publication

Dear Dr. Feldmann,

We are pleased to inform you that your accepted manuscript (unformatted and unedited PDF) is now available online at:

<http://Pending Publication>

You might like to bookmark this permanent URL to your article.

This version of your article has already been made available at this early stage to provide the fastest access to your article. It is not intended to be the final version of your article. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note changes to the article should not be requested at this stage.

Your article can already be cited using the year of online availability and the DOI as follows: Author(s), Article Title, Journal (Year), DOI.

Once the full bibliographic details (including volume and page numbering) for citation purposes are available, you will be alerted by e-mail.

To track the status of your article throughout the publication process, please use our article tracking service:

Pending Publication

Yours sincerely,
Elsevier Author Support

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:25 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: Article tracking [EBIOM_5] - Accepted manuscript available online (unedited version)

----- Original Message -----

From: Elsevier - Article Status [mailto:Article_Status@elsevier.com]
Sent: Monday, October 13, 2014 03:17 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA
Subject: Article tracking [EBIOM_5] - Accepted manuscript available online (unedited version)

Article title: Ebola conquers West Africa - more to come?

Reference:: Pending

Journal title: EBioMedicine

Corresponding author: Dr. Heinz Feldmann First author: Dr. Peter Halfmann Accepted manuscript (unedited version)
available online: Pending Publication

Dear Dr. Feldmann,

We are pleased to inform you that your accepted manuscript (unformatted and unedited PDF) is now available online at:

<http://Pending Publication>

You might like to bookmark this permanent URL to your article.

This version of your article has already been made available at this early stage to provide the fastest access to your article. It is not intended to be the final version of your article. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note changes to the article should not be requested at this stage.

Your article can already be cited using the year of online availability and the DOI as follows: Author(s), Article Title, Journal (Year), DOI.

Once the full bibliographic details (including volume and page numbering) for citation purposes are available, you will be alerted by e-mail.

To track the status of your article throughout the publication process, please use our article tracking service:

<http://Pending Publication>

Yours sincerely,
Elsevier Author Support

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:15 AM
To: 'pathogengh@imperial.ac.uk'
Subject: Re: PGH - Ebola diagnosis article

Thanks for the invitation. My group support laboratory diagnosis in Monrovia and we are unable to contribute at the moment. You may want to contact Stephan Guenther from Hamburg or Allen Grolla from Winnipeg.

Best wishes, Heinz

From: PathogenGH [mailto:pathogengh@imperial.ac.uk]
Sent: Tuesday, October 14, 2014 05:07 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: PGH - Ebola diagnosis article

Dear Dr Feldmann,

I am putting together copy to be featured in an issue that will be published before the end of this year on the Ebola virus. One of the items that I would like to explore is the challenge of diagnosis, particularly within remote areas of the affected countries. And some context behind why rapid detection is so important in an outbreak of this stature. Perhaps this could be an opportunity to engage with new technologies that may equip better and quicker diagnosis too. I wonder whether you or a colleague of yours would be interested in writing such an article? I am open to hear your suggestions for the topic. Obviously timing is important so if you are interested please do let me know when you think you could have something written by.

Best wishes

Prof Andrea Crisanti
Editor-in-Chief
[Pathogens and Global Health](#)
Imperial College London

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:04 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); 'woodd@who.int'
Subject: Re: Collaborative study

Thanks.

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 08:58 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); 'woodd@who.int' <woodd@who.int>
Subject: RE: Collaborative study

We will make sure that we contact you before we start this process.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 8:56 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); 'woodd@who.int'
Subject: Re: Collaborative study

Let me know when you need my input as I am still in Monrovia.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 08:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); David John WOOD (woodd@who.int) <woodd@who.int>
Subject: RE: Collaborative study

OK. Thank you Heinz.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 8:45 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

I can do that. I know it is a high priority for WHO - I am slightly less convinced about the approach but it needs to be tested. My reservation is based on the difficulties to get sufficient amount, difficulties with blood safety, and timing as high affinity neutralizing antibodies will likely not show up before months after survival.

Anyhow - I am in.

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 7:03 AM
To: 'Ilia.Semmler@tmf-ev.de'
Subject: Re: AW: Text für die Pressemitteilung zur Freigabe und Presseanfrage

Ilia,

Es tut mir leid, aber ich hatte grosse Probleme das Attachment zu oeffnen.

Sehr gute Pressemitteilung. Nur eine Anmerkung - die 'Internal Conference on Zoonoses' ist eigentlich nicht US-amerikanisch sondern international. Kein Problem, wenn das nun zu spaet kommt.

Viel Spass und Erfolg mit der Tagung. Ich waere sehr gern gekommen.

Gruss, Heinz

-----Original Message-----

From: Semmler, Ilia
To: Heinrich (NIH/NIAID) [E] Feldmann
Subject: AW: Text für die Pressemitteilung zur Freigabe und Presseanfrage
Sent: Oct 14, 2014 1:54 AM

Anbei meine Mail von Donnerstag noch einmal, damit sie bei dir wieder obenauf ist.
Mit der Bitte um Freigabe.

Grüße
Ilia

Von: Semmler, Ilia Gesendet: Donnerstag, 9. Oktober 2014 21:33 An: 'Feldmann, Heinrich (NIH/NIAID) [E]' Betreff: Text für die Pressemitteilung zur Freigabe und Presseanfrage

Lieber Heinz,

ich hoffe, du bist wohlauf. Die Vorbereitungen für das Symposium sind hier im vollen Gange. Auch der Ebola-Talk kann wohl gehalten werden: von Maximilian Gertler, MSF (jetzt so gut wie sicher). Wir werden dazu aus Zeitgründen lediglich die Preisverleihung und den Ebola-Talk tauschen müssen. Ich werde dazu, wenn es morgen hoffentlich tatsächlich fix, ist noch eine Info-Mail an dich, Juergen und Vikki/Lynn schicken.

Ich habe noch zwei Fragen bzw. Bitten an dich.

Im Anhang sende ich dir den Text für die Pressemitteilung, die wir am Donnertag zum Symposium versenden wollen. Darin haben wir Ausschnitte aus dem Interview, das du Frau Sartori gegeben hast verwendet (auf deutsch übersetzt – in die gleichzeitig erscheinende englische Pressemitteilung kommen natürlich die Originalzitate, die du von Frau Sartori noch zur Freigabe bekommen wirst). Wir möchten nur sicher gehen, dass sie dir in dem Kontext recht sind.

Außerdem hat sich bei mir Volkart Wildermuth vom Deutschlandfunk (Forschung aktuell; Radio) gemeldet. Er ist ein absolut seriöser Journalist, mit dem ich schon öfter zu tun hatte und von dem ich sehr viel halte. Er wollte dich eigentlich gerne am Rande des Symposiums interviewen. Ich habe ihm nun gesagt, dass du leider gar nicht dort sein wirst.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:57 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); 'woodd@who.int'
Subject: Re: Collaborative study

Let me know when you need my input as I am still in Monrovia.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 08:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Epstein, Jay (FDA/CBER); David John WOOD (woodd@who.int) <woodd@who.int>
Subject: RE: Collaborative study

OK. Thank you Heinz.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 8:45 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

I can do that. I know it is a high priority for WHO - I am slightly less convinced about the approach but it needs to be tested. My reservation is based on the difficulties to get sufficient amount, difficulties with blood safety, and timing as high affinity neutralizing antibodies will likely not show up before months after survival.

Anyhow - I am in.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 06:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Collaborative study

Yes. It is. I don't know what Tom is doing but it seems reasonable for us to participate if WHO and CBER are eager for us to do so. Dr. Jay Epstein(CBER, Director of Office of Blood, CBER) will look into identifying source (s) of convalescence plasma/serum and work with us on drafting the study. We will have follow up discussions with CBER which I hope that you can take the lead in for DIR. Any help you can provide would be greatly appreciated. Apparently this is a top priority for WHO.

Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:17 AM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:46 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

I can do that. I know it is a high priority for WHO - I am slightly less convinced about the approach but it needs to be tested. My reservation is based on the difficulties to get sufficient amount, difficulties with blood safety, and timing as high affinity neutralizing antibodies will likely not show up before months after survival.

Anyhow - I am in.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 06:25 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Collaborative study

Yes. It is. I don't know what Tom is doing but it seems reasonable for us to participate if WHO and CBER are eager for us to do so. Dr. Jay Epstein(CBER, Director of Office of Blood, CBER) will look into identifying source (s) of convalescence plasma/serum and work with us on drafting the study. We will have follow up discussions with CBER which I hope that you can take the lead in for DIR. Any help you can provide would be greatly appreciated. Apparently this is a top priority for WHO.

Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:17 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

Is this convalescence plasma/serum? I thought Tom Geisbert is doing that for WHO.

It might be helpful if done at more than one place. From where do we get the material?

We can help.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 04:53 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Collaborative study

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:42 AM
To: Personal Info
Subject: Re: in Liberia?

I came last Monday to Monrovia - I was not at the dinner. I am staying until the end of the month.

If the question on dead bodies is Ebola or not - swabs are fine (oral (in particular gums) or nasal). The cardiac stick is time-consuming, more dangerous for the investigator and not well accepted in the communities. I would vote for swab. Special Pathogens in Atlanta would most likely argue as they seem to like the cardiac stick for serology- at least they did in the past.

Best wishes, Heinz

----- Original Message -----

From: Jeffrey Gilbert [mailto:Personal Info]
Sent: Tuesday, October 14, 2014 07:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: in Liberia?

Hi, I was at Kendeja last Sunday for dinner - shame I didn't know you were there. I stay central area - Sinkor - but generally come to MoH - at least for some of the day. How long are you around for? Likely to be heading out at weekend. What's your thoughts on sampling dead bodies - swabs v cardiac puncture (bio hazard aside) Jeff

On 14 Oct 2014, at 10:15, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

> Jeff,
> Yes, I am at ELWS3 with the lab team.
> We stay at the Kendeja Hotel.
> Heinz

>
> ----- Original Message -----

> From: Jeffrey Gilbert [mailto:Personal Info]
> Sent: Tuesday, October 14, 2014 03:42 AM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: in Liberia?

>
> Dear Heinz,
>
> are you in Liberia? I saw your name on the WHO deployed list. Recall WHO China SARS 2003/4 .. we were on a mission together in Guangdong. I'm in Monrovia for 7 weeks on epi-surv stuff.
>
> Rgds Jeff

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:37 AM
To: 'ckratoch@unmc.edu'; 'piwen@unmc.edu'; 'shinrich@unmc.edu'
Cc: 'pwsmith@unmc.edu'; 'ali.khan@unmc.edu'
Subject: Re: Liberia Ebola case

Let me know what you need from our end. I would have to involve one of my colleagues as I am currently in Monrovia.

Thanks, Heinz

From: Kratochvil, Christopher J [mailto:ckratoch@unmc.edu]
Sent: Tuesday, October 14, 2014 07:52 AM Eastern Standard Time
To: Iwen, Peter C <piwen@unmc.edu>; Hinrichs, Steven H <shinrich@unmc.edu>; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W <pwsmith@unmc.edu>; Khan, Ali S <ali.khan@unmc.edu>
Subject: RE: Liberia Ebola case

Good Morning,

As I have been thinking through the potential for significant research opportunities with the samples we have available from the patients admitted to the biocontainment unit, I have decided we need to develop an IRB protocol to allow for as broad of research as appropriate with these samples, thereby limiting the need for repeated individual IRBs.

Phil, if ok with you, I think this would be a good approach. I can contact Bruce Gordon & Ernie Prentice to get the IRB's take on how broad of scope we could include. If the folks on this e-mail can provide me with a listing of potential use cases we would want to consider that will help me to make sure we are considering the breadth of opportunities.

Chris

Christopher J. Kratochvil, M.D.
Associate Vice Chancellor for Clinical Research
Vice President for Research
Chief Medical Officer, UNeHealth
University of Nebraska Medical Center
402-559-8490

The information in this e-mail is privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Iwen, Peter C
Sent: Monday, October 13, 2014 12:48 PM
To: Hinrichs, Steven H; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W; Khan, Ali S; Kratochvil, Christopher J
Subject: RE: Liberia Ebola case

Steve,

I have been in contact with the CDC and they have assured me by e-mail that they will not culture our specimens. Is it possible to do sequencing directly from the positive whole blood. This would seem to me an alternative that could be done. We would still need to look at the patient consent issue. Pete

Peter C. Iwen, MS, PhD, D(ABMM)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 6:35 AM
To: 'Helen.Branswell@thecanadianpress.com'
Subject: Re: How are you doing?

Not really as we have been using different Zaire ebolavirus challenge strains in the NHP studies. It won't protect against another species - for example Sudan ebolavirus. More nervous about the overall performance in humans. and potential adverse effects (live-attenuated vaccine). This is exciting but also a little worrisome.

We started the experiment in NHPs using a Guinea isolate as the challenge virus - should know in a month.

Heinz

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Tuesday, October 14, 2014 08:24 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: How are you doing?

Have I asked you: are you at all concerned that the efficacy of the VSV vax might be lower because the outbreak virus is drifted or at least somewhat difference from the vaccine reference strain?

Best,
Helen

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: October-14-14 6:12 AM
To: Branswell, Helen
Subject: Re: How are you doing?

Fine - working as usual.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Monday, October 13, 2014 10:22 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: How are you doing?

You OK?

Helen

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 4:18 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Collaborative study

Is this convalescence plasma/serum? I thought Tom Geisbert is doing that for WHO.

It might be helpful if done at more than one place. From where do we get the material?

We can help.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 04:53 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Collaborative study

Heinz

Would you be willing to participate in a collaborative study with CBER and WHO to test ebola immune serum with the appropriate controls in NHP ebola challenge studies? I think this would provide some very important data on which future clinical studies may be considered.

Regards

Kathy

Kathy

Sent from my BlackBerry Wireless Handheld

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 14, 2014 4:12 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: doing another science story on Ebola, need your help Dr. Feldmann

OK.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 09:26 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: doing another science story on Ebola, need your help Dr. Feldmann

Heinz, FYI below ... let me see how Bethesda wants this handled. This seems to be awkward. I doubt they'd want you (or anyone at NIH) doing a counter point with a colleague.

Just so I know in case Dr. Fauci's staff asks, what is your answer / opinion on the question asked?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 7:23 PM
To: Achenbach, Joel
Subject: RE: doing another science story on Ebola, need your help Dr. Feldmann

Hi Joel ... Dr. Feldmann is deployed overseas again for an undetermined number of days and I am not sure of his email access. If I can track him down for this I'll let you know.

Ken Pekoc
Public Affairs Officer
Rocky Mountain Laboratories
NIAID Office of Communications and Government Relations
406-375-9690

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

Dear Heinz:

Hi, we need to do another piece on what is and isn't known about Ebola. We're seeing some contradictory information. Vox has an interview with Peter Jahrling in which he says the viral load is unusually high in the W. African Ebola patients. And he also has a comment, which is a bit enigmatic:

It turns out that in limited studies with the evacuated patients, they continued to express virus in blood and semen. What does that mean? Right now, we just don't know.

Here's the Vox article:

<http://www.vox.com/2014/10/13/6959087/ebola-outbreak-virus-mutated-airborne>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 5:15 PM
To: 'ali.khan@unmc.edu'
Cc: 'shinrich@unmc.edu'; 'piwen@unmc.edu'; 'pwsmith@unmc.edu'
Subject: Re: Liberia Ebola case

OK. Let me know if you can ship. We can pay for shipment if that is a problem.
What about ethics?
Best wishes, Heinz

From: Khan, Ali S [<mailto:ali.khan@unmc.edu>]
Sent: Monday, October 13, 2014 07:04 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hinrichs, Steven H <shinrich@unmc.edu>; Iwen, Peter C <piwen@unmc.edu>; Smith, Philip W <pwsmith@unmc.edu>
Subject: RE: Liberia Ebola case

Excellent. Not select agents; still diagnostic specimens. No form 2.

Ali

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Monday, October 13, 2014 6:03 PM
To: Khan, Ali S
Cc: Hinrichs, Steven H; Iwen, Peter C; Smith, Philip W
Subject: Re: Liberia Ebola case

This is strange. I don't want to get anyone into trouble over this. If samples can be shipped, please let me know and we will make necessary arrangements. I think we (RML) need a form 2 to receive the samples.

I am not upset - just do not want to get anyone into trouble.

Heinz

From: Khan, Ali S [<mailto:ali.khan@unmc.edu>]
Sent: Monday, October 13, 2014 06:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hinrichs, Steven H <shinrich@unmc.edu>; Iwen, Peter C <piwen@unmc.edu>; Smith, Philip W <pwsmith@unmc.edu>
Subject: RE: Liberia Ebola case

Thanks Heinz. Keep reading. Peter has a solution.
These are NOT BSL-4 by the regs until cultured.
Ali

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 5:03 PM
To: 'ali.khan@unmc.edu'
Cc: 'shinrich@unmc.edu'; 'piwen@unmc.edu'; 'pwsmith@unmc.edu'
Subject: Re: Liberia Ebola case

This is strange. I don't want to get anyone into trouble over this. If samples can be shipped, please let me know and we will make necessary arrangements. I think we (RML) need a form 2 to receive the samples.

I am not upset - just do not want to get anyone into trouble.

Heinz

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Monday, October 13, 2014 06:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hinrichs, Steven H <shinrich@unmc.edu>; Iwen, Peter C <piwen@unmc.edu>; Smith, Philip W <pwsmith@unmc.edu>
Subject: RE: Liberia Ebola case

Thanks Heinz. Keep reading. Peter has a solution.
These are NOT BSL-4 by the regs until cultured.
Ali

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 5:47 PM
To: Iwen, Peter C; Smith, Philip W; Khan, Ali S
Cc: Hinrichs, Steven H
Subject: Re: Liberia Ebola case

Just forget it. You should not be allowed to keep the samples anyway as the patients are conformed cases. This makes the samples BSL4 and you should not have them if you are not certified. Thanks for your consideration. We will find a different way.

Heinz

From: Iwen, Peter C [mailto:piwen@unmc.edu]
Sent: Monday, October 13, 2014 01:45 PM Eastern Standard Time
To: Smith, Philip W <pwsmith@unmc.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Cc: Hinrichs, Steven H <shinrich@unmc.edu>
Subject: RE: Liberia Ebola case

Hi Phil and Heinrich,
We do have whole blood and plasma frozen on both of our patients. There are a number of issues about sharing these specimens that would make this a large hurdle to accomplish.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 4:59 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: l.a. times writer on deadline

From: Zarembo, Alan [mailto:Alan.Zarembo@latimes.com]
Sent: Monday, October 13, 2014 05:42 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: l.a. times writer on deadline

Dear Dr. Feldmann,

This is Alan Zarembo, a science writer at the L.A. Times.

I'm working on deadline on a story about the protective suits used by health care workers treating patients with ebola, and I'm looking for experts who can discuss in detail the suits, how they are tested, the steps for taking them on and off and the places where breaches could possibly occur. Hoping you can help.

(Dupont has provided me with this info sheet: http://www.dupont.com/content/dam/assets/products-and-services/personal-protective-equipment/assets/DPP14_20240_Ebola_Tech_Bulletin_%2091114b.pdf Are there other makers of protective gear, or is the Tychem C the most common suit for these situations?)

I understand you may be in Africa, but on the off-chance you get this, I'd be happy call or continue e-mailing.

Sincerely,
Alan

Alan Zarembo
Staff Writer
The Los Angeles Times
213-237-7009
Toll free 1-800-LATIMES ext. 77009
alan.zarembo@latimes.com
Twitter @AlanZarembo

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 4:59 PM
To: 'halfmanp@svm.vetmed.wisc.edu'
Subject: Re: Article tracking [EBIOM_5] - Accepted manuscript available online (unedited version)

Great - I haven't gotten anything else.

----- Original Message -----

From: Pete Halfmann [mailto:halfmanp@svm.vetmed.wisc.edu]
Sent: Monday, October 13, 2014 05:28 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Article tracking [EBIOM_5] - Accepted manuscript available online (unedited version)

Heinz,
We have been trying to handle things on our end here with the manuscript.

Let me know if you get anything else; they seem to be cc: Yoshi now.

The link they mention below seems broken, but maybe it takes some time to update.

Best,
Peter

-----Original Message-----

From: Kawaoka [mailto:kawaokay@svm.vetmed.wisc.edu]
Sent: Monday, October 13, 2014 4:20 PM
To: halfmanp@svm.vetmed.wisc.edu; neumannng@svm.vetmed.wisc.edu
Subject: Fwd: Article tracking [EBIOM_5] - Accepted manuscript available online (unedited version)

Can you access to the link?

From: Elsevier - Article Status <Article_Status@elsevier.com>
Handle: Elsevier - Article Status
Mail Address: Article_Status@elsevier.com
Subject: Article tracking [EBIOM_5] - Accepted manuscript available online (unedited version)
To: feldmannh@niaid.nih.gov, kawaokay@svm.vetmed.wisc.edu
CC: --
Date: Mon, 13 Oct 2014 20:17:20 +0100
Date Local: 2014/10/14 4:17:20
Message:

Article title: Ebola conquers West Africa - more to come?
Reference:: EBIOM5
Journal title: EBioMedicine

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 4:48 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: RT interview request

From: Chizhikov Eduard [mailto:euchizhikov@rttv.ru]
Sent: Monday, October 13, 2014 01:50 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RT interview request

Dear Mr. Heinz Feldmann

My name is Eduard Chizhikov and I am a producer at RT International, a global 24/7 news network.

I am writing you regarding the Ebola and it's mutation possibility, we've been reading your comments here:

<http://news.sciencemag.org/africa/2014/09/confronting-ebola-virologist-liberias-hot-zone>

RT is interested in interviewing you on this matter to gain your full professional opinion on it. It would be an honor having you on air.

The interview will not last longer than 5-7 minutes.

Thank you in advance for considering our request.

About RT:

RT is a global multilingual television news network, broadcasting around-the-clock from Moscow across five continents to more than 100 countries in English, Arabic and Spanish. The RT network also includes RT America, broadcasting from RT's Washington, DC studios, the documentary channel RTDoc, and a brand new video agency, Ruptly. With a global reach of over 630 million people – or 28% of all paid cable networks' subscribers – and more than 2.7 million hotel rooms worldwide, RT covers the major political, economic and cultural issues of the time for viewers wanting to question more. The best news reports, stories and programmes can be found on RT's YouTube channel, where the number of views has already exceeded 1 billion, making RT the first TV news channel to break this record in YouTube's history and also making the network the largest provider of news video footage on this world's most popular video platform.

According to official ratings by the UK's Broadcasters' Audience Research Board, RT is the third most popular TV news channel in Great Britain after BBC News and Sky News, and scores higher viewership than other foreign news channels measured by BARB, including Al Jazeera English, Fox News and Euronews (BARB ratings for the 3rd quarter 2012). In the U.S. more than 85 million viewers receive RT around the clock. Nielsen has found RT's audience in key U.S. cities to be bigger than that of other major international news channels including Euronews, France 24, Deutsche Welle, Al Jazeera English, NHK World and CCTV News. According to Nielsen, the average RT viewer in America

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 4:47 PM
To: 'piwen@unmc.edu'; 'pwsmith@unmc.edu'; 'ali.khan@unmc.edu'
Cc: 'shinrich@unmc.edu'
Subject: Re: Liberia Ebola case

Just forget it. You should not be allowed to keep the samples anyway as the patients are conformed cases. This makes the samples BSL4 and you should not have them if you are not certified. Thanks for your consideration. We will find a different way.

Heinz

From: Iwen, Peter C [mailto:piwen@unmc.edu]
Sent: Monday, October 13, 2014 01:45 PM Eastern Standard Time
To: Smith, Philip W <pwsmith@unmc.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Cc: Hinrichs, Steven H <shinrich@unmc.edu>
Subject: RE: Liberia Ebola case

Hi Phil and Heinrich,

We do have whole blood and plasma frozen on both of our patients. There are a number of issues about sharing these specimens that would make this a large hurdle to accomplish.

1. Once the blood has been cultured, then all specimens in our possession will become select agents if I interpret the DSAT rules correctly. This means that we would no longer be able to have these Ebola positive specimens (at least ones from any patient who has been cultured) in our possession since our laboratory is not approved for Ebola virus on our certificate of registration with the select agent program (we also would not be able to get this certification since we do not have a BSL-4 laboratory, which would most likely be a requirement).
2. We would need to destroy or ship all of our specimens to an approved laboratory (once cultured). This would essentially would not allow for us to do any molecular diagnostic research on these specimens.
3. Shipment of the specimens would require a large cost (we now know that it costs \$1900 for one shipment of Ebola-positive specimens) and also would require that we file the paperwork and get approval by DSAT to be able to ship these specimens, not an insignificant task.
4. Patient consent according to our in-house IRB is required to do research on these specimens.

So unless I am missing something, it would appear that the DSAT rules would make this a very difficult exercise and thus essentially leave us with no specimens. I will be interested to see if there are other thoughts on how this might be accomplished. Maybe DSAT has an exception? Pete

Peter C. Iwen, MS, PhD, D(ABMM)
Professor, Pathology and Microbiology
Director, NE Public Health Laboratory
Biosafety Officer
Univer. Nebraska Med. Ctr.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 11:21 AM
To: 'pwsmith@unmc.edu'; 'ali.khan@unmc.edu'
Cc: 'shinrich@unmc.edu'; 'piwen@unmc.edu'
Subject: Re: Liberia Ebola case

Thanks.

From: Smith, Philip W [mailto:pwsmith@unmc.edu]
Sent: Monday, October 13, 2014 01:20 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Cc: Hinrichs, Steven H <shinrich@unmc.edu>; Iwen, Peter C <piwen@unmc.edu>
Subject: RE: Liberia Ebola case

Now I am tracking. I will forward this to our Micro staff. Thanks

Philip W Smith MD
Professor, Division of Infectious Diseases
985400 Nebraska Medical Center
Omaha, NE 68198-5400
Phone: 402-559-8650
Fax: 402-559-5581

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 12:00 PM
To: Smith, Philip W; Khan, Ali S
Subject: Re: Liberia Ebola case

No blood samples left at your facility?

From: Smith, Philip W [mailto:pwsmith@unmc.edu]
Sent: Monday, October 13, 2014 11:21 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Subject: RE: Liberia Ebola case

Heinz,

I agree with your comments, but we do not have any of our patient's viral isolates. They are at the CDC. Is this what you were asking?

Philip W Smith MD
Professor, Division of Infectious Diseases
985400 Nebraska Medical Center
Omaha, NE 68198-5400
Phone: 402-559-8650
Fax: 402-559-5581

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 11:21 AM
To: 'Joanna.Chow@foxbusiness.com'
Subject: Re: Fox Business

No - contact the communication office of NIH.

From: Chow, Joanna [mailto:Joanna.Chow@foxbusiness.com]
Sent: Monday, October 13, 2014 01:19 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Fox Business

Ok, is there anyone else you can suggest?

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 1:19 PM
To: Chow, Joanna
Subject: Re: Fox Business

No I am not - currently in the field until November 1.

From: Chow, Joanna [mailto:Joanna.Chow@foxbusiness.com]
Sent: Monday, October 13, 2014 01:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fox Business

Hi Dr. Feldmann,

I'm a producer at Fox Business and wanted to see if you're available for a live 4-6 minute interview at 5pm ET tonight regarding Ebola. Please let me know if possible. Thanks

Joanna Chow
The Willis Report
Fox Business Network
Office: 212 601 1320
joanna.chow@foxnews.com



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 11:20 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Fox Business

From: Chow, Joanna [mailto:Joanna.Chow@foxbusiness.com]
Sent: Monday, October 13, 2014 01:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fox Business

Hi Dr. Feldmann,

I'm a producer at Fox Business and wanted to see if you're available for a live 4-6 minute interview at 5pm ET tonight regarding Ebola. Please let me know if possible. Thanks

Joanna Chow
The Willis Report
Fox Business Network
Office: 212 601 1320
joanna.chow@foxnews.com



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 11:19 AM
To: 'Joanna.Chow@foxbusiness.com'
Subject: Re: Fox Business

No I am not - currently in the field until November 1.

From: Chow, Joanna [mailto:Joanna.Chow@foxbusiness.com]
Sent: Monday, October 13, 2014 01:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fox Business

Hi Dr. Feldmann,

I'm a producer at Fox Business and wanted to see if you're available for a live 4-6 minute interview at 5pm ET tonight regarding Ebola. Please let me know if possible. Thanks

Joanna Chow
The Willis Report
Fox Business Network
Office: 212 601 1320
joanna.chow@foxnews.com



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 11:00 AM
To: 'pwsmith@unmc.edu'; 'ali.khan@unmc.edu'
Subject: Re: Liberia Ebola case

No blood samples left at your facility?

From: Smith, Philip W [mailto:pwsmith@unmc.edu]
Sent: Monday, October 13, 2014 11:21 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Khan, Ali S <ali.khan@unmc.edu>
Subject: RE: Liberia Ebola case

Heinz,

I agree with your comments, but we do not have any of our patient's viral isolates. They are at the CDC. Is this what you were asking?

Philip W Smith MD
Professor, Division of Infectious Diseases
985400 Nebraska Medical Center
Omaha, NE 68198-5400
Phone: 402-559-8650
Fax: 402-559-5581

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, October 13, 2014 5:00 AM
To: Khan, Ali S
Cc: Smith, Philip W
Subject: Re: Liberia Ebola case

Dear Philip,

This would be the first isolate from Liberia that I know about. We urgently need sequence data from Monrovia to potentially update and adapt diagnostics. We also would like to compare a more recent isolate with the early Guinea isolate in the nonhuman primate model.

We need to do it right - ethics and safety paperwork. RML can take care for all the DSAT (safety) paperwork - we need assistance with ethics as this would clearly be an identifiable source.

Any help would be highly appreciated.

Best wishes,
Heinz

PS: thanks Ali.

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 12, 2014 10:02 PM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 10:58 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: CTV Winnipeg news request - Today

From: Beth Macdonell [mailto:Beth.Macdonell@bellmedia.ca]
Sent: Monday, October 13, 2014 12:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CTV Winnipeg news request - Today

Hi Dr. Fledmann,

Happy (Canadian) Thanksgiving!

Big news today about the Ebola vaccine developed here in Winnipeg, that it will now be tested on humans this year.

Hoping we can connect with you about this exciting news, and get some of your thoughts.

Please let me know the best way to reach you!

I am at 204 775 8016 in the newsroom.


Cheers and thanks,
Beth

Beth Macdonell | Producer & Reporter

CTV Winnipeg | t 204.788.3330 | c 204.619.1867 | f 204.943.3112
beth.macdonell@bellmedia.ca | Twitter: @bethmacdonell
400-345 Graham Avenue
Winnipeg, MB R3C 5S6
<http://winnipeg.ctvnews.ca/>



Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 13, 2014 4:00 AM
To: 'ali.khan@unmc.edu'
Cc: 'pwsmith@unmc.edu'
Subject: Re: Liberia Ebola case

Dear Philip,

This would be the first isolate from Liberia that I know about. We urgently need sequence data from Monrovia to potentially update and adapt diagnostics. We also would like to compare a more recent isolate with the early Guinea isolate in the nonhuman primate model.

We need to do it right - ethics and safety paperwork. RML can take care for all the DSAT (safety) paperwork - we need assistance with ethics as this would clearly be an identifiable source.

Any help would be highly appreciated.

Best wishes,
Heinz

PS: thanks Ali.

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 12, 2014 10:02 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Smith, Philip W <pwsmith@unmc.edu>
Subject: Liberia Ebola case

Dear Phil :

Could you please see how we can be of assistance. Dr. Heinz Feldmann (head of Rocky Mountain labs) is a great collaborator and will be invaluable for any future Ebola efforts and has helped us with great consultation on experimental therapeutics. He is my go to person. There are public health reasons to assure people no dramatic change in the virus.

Heinz: Dr. Phil Smith is head of our preparedness group and the lead clinician for the clinical cases. Very collaborative.

Thanks

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

On Oct 12, 2014, at 7:22 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 4:55 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

If you want to collaborate with her please go ahead. On the other hand, she can have the system without collaboration.

Heinz

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 06:53 PM Eastern Standard Time
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

Please go ahead.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 06:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola trVLP system

Hi Heinz, Personal Info

Are you OK if I contact [redacted] regarding sharing the trVLP system (of course with an SLA)?

All the best, Thomas

From: Personal Info
Sent: Sunday, October 12, 2014 12:22 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Dan Engel
Subject: Ebola trVLP system

Dear Drs. hoenen and Feldmann,

I met you most recently at the Filo mtg. In Galveston in March. As you may recall, I have been pursuing FDA approved drugs for Filovirus infections. We would like to use your marvelous trVLP system, as a collaboration, in our continuing studies. I would be happy to lay out our general plans in a phone call. And of course, we would abide by any conditions of use and be happy to sign an MTA if needed. (I interact with Dan Engel at my university (U of Virginia, UVA) and he has informed me that he already has an MTA in place for the system.)

Please let me know at your earliest convenience whether you would be willing to work with us on this. I am anxious to propose using your system in an RO1 revision that I must have ready at UVA by oct. 28.

Thank you very much for considering my request,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 4:54 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Ebola trVLP system

Please go ahead.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 06:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola trVLP system

Hi Heinz,

Are you OK if I contact **Perso** regarding sharing the trVLP system (of course with an SLA)?

All the best, Thomas

From: **Personal Info**
Sent: Sunday, October 12, 2014 12:22 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Dan Engel
Subject: Ebola trVLP system

Dear Drs. hoenen and Feldmann,

I met you most recently at the Filo mtg. In Galveston in March. As you may recall, I have been pursuing FDA approved drugs for Filovirus infections. We would like to use your marvelous trVLP system, as a collaboration, in our continuing studies. I would be happy to lay out our general plans in a phone call. And of course, we would abide by any conditions of use and be happy to sign an MTA if needed. (I interact with Dan Engel at my university (U of Virginia, UVA) and he has informed me that he already has an MTA in place for the system.)

Please let me know at your earliest convenience whether you would be willing to work with us on this. I am anxious to propose using your system in an RO1 revision that I must have ready at UVA by oct. 28.

Thank you very much for considering my request,

Personal Info

Prof.
Univ, Virginia

Sent from my iPad

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 4:36 PM
To: Personal Info
Subject: Re: Hallo

Personal Info

From: Personal Info
Sent: Sunday, October 12, 2014 04:02 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Hallo

Personal Info

2014-10-10 12:22 GMT+02:00 Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>:

Personal Info

From: Personal Info
Sent: Friday, October 10, 2014 03:33 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Hallo

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 12:19 PM
To: Personal Info
Subject: Re: Ebola!

Great thought. I will bring it up in your name. Some survivors already work in the ward here, but I do not think that they are going actively after survivors.

Heinz

From: Karl Johnson [mailto:Personal Info]
Sent: Sunday, October 12, 2014 01:49 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola!

Thanks Heinz for your note during insane heavy days. I do wonder whether you are able to help get proven survivors lined up to become workers doing the risky stuff. If survival is 48% there should be a significant pool from which to recruit. And such a program if internationally known would be a significant positive for the world during a tremendous downer.

Please take care and bring back data that eventually might help in future outbreaks.

On Sun, Oct 12, 2014 at 10:08 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
Karl,

Good to hear from you - hope all is well. Yes I am in Monrovia, Liberia for the second time. We run a diagnostic lab for MSF just outside the capital - 400 patient tent hospital.

We are limited in what we can do here and are busy just diagnosing Ebola with the huge amount of patients.

MSF here does not use any injectable therapies as they are not set up for it. No beds only matrizes on the floor. Convalescent plasma therapy is not considered here at the moment. There also isn't any institution to collect plasma.

The survival rate here in the hospital is 48 percent - just under oral hydration, antibiotics, antimalaria, etc. Only oral treatments are considered at the moment.

All clinical trials have to be approved by a board funded by Welcome Trust. It is not easy to just start treatment.

In my view treatment will be helpful but won't have a big short-term impact on the outbreak - what we need are vaccines. Hopefully they get started on that.

Stuart Nichol's email is: stn1@cdc.gov

Best wishes,
Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 12:16 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: Update

Will do.

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 01:38 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: Update

Thanks Heinz
Wish the staff well for me
Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 12:32 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Update

I apologize for not sending an update earlier. On the other hand, there is not much exciting stuff to report.

The new joint CDC/NIH team operates well. We have now split the NIH team into two members and the lead. The lead will come in a week after to work two weeks with the team and stays one more week with the incoming team. This seems to work well and provides continuous operation.

We replaced the glovebox as the bleach had started to change the color of the plastic material which made it more difficult to work. We are planing to replace the gloveboxes every 6 weeks. The cost is approx. 2500 US.

Sample numbers are about the same maybe slightly less. MSF has built the 400 bed capacity but currently only operates 250 beds due to staffing issues.

Survival rate at ELWA3 is currently 48 percent under oral hydration, antimalaria, antibiotics, antypyretics, antinausea and anti-diarrhoeal therapy. All therapies are oral as they do not do IV infusion or injectables.

Positivity among new submissions has gone down to 70 percent.

We have been asked to provide testing for malaria, to do blood chemistry and to do viral load. LV staff back home is working on all three requests but we are not exactly sure what we will do. For malaria we are looking into PCR - we are

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 10:35 AM
To: Fischer, Robert (NIH/NIAID) [F]; Bushmaker, Trenton (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]; Prescott, Joseph (NIH/NIAID) [E]
Cc: Clifton, Dawn (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Walczynski, Joyce (NIH/NIAID) [C]; Shupert, W. Lesley (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]
Subject: Fw: Update

FYI

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 12:32 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Update

I apologize for not sending an update earlier. On the other hand, there is not much exciting stuff to report.

The new joint CDC/NIH team operates well. We have now split the NIH team into two members and the lead. The lead will come in a week after to work two weeks with the team and stays one more week with the incoming team. This seems to work well and provides continuous operation.

We replaced the glovebox as the bleach had started to change the color of the plastic material which made it more difficult to work. We are planing to replace the gloveboxes every 6 weeks. The cost is approx. 2500 US.

Sample numbers are about the same maybe slightly less. MSF has built the 400 bed capacity but currently only operates 250 beds due to staffing issues.

Survival rate at ELWA3 is currently 48 percent under oral hydration, antimalaria, antibiotics, antipyretics, antinausea and anti-diarrhoeal therapy. All therapies are oral as they do not do IV infusion or injectables.

Positivity among new submissions has gone down to 70 percent.

We have been asked to provide testing for malaria, to do blood chemistry and to do viral load. LV staff back home is working on all three requests but we are not exactly sure what we will do. For malaria we are looking into PCR - we are trying to multiplex with one of the Ebola targets. We have ordered the Picollo machine for doing blood chemistry using the portable BSL3 lab from Nairobi. Not sure yet what we will do about viral loads.

All staff is healthy and in good spirit.

Best wishes,
Heinz
CDC/NIH Lab
ELWA3
Monrovia

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 10:33 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Update

I apologize for not sending an update earlier. On the other hand, there is not much exciting stuff to report.

The new joint CDC/NIH team operates well. We have now split the NIH team into two members and the lead. The lead will come in a week after to work two weeks with the team and stays one more week with the incoming team. This seems to work well and provides continuous operation.

We replaced the glovebox as the bleach had started to change the color of the plastic material which made it more difficult to work. We are planing to replace the gloveboxes every 6 weeks. The cost is approx. 2500 US.

Sample numbers are about the same maybe slightly less. MSF has built the 400 bed capacity but currently only operates 250 beds due to staffing issues.

Survival rate at ELWA3 is currently 48 percent under oral hydration, antimalaria, antibiotics, antypyretics, antinausea and anti-diarrhoel therapy. All therapies are oral as they do not do IV infusion or injectables.

Positivity among new submissions has gone down to 70 percent.

We have been asked to provide testing for malaria, to do blood chemistry and to do viral load. LV staff back home is working on all three requests but we are not exactly sure what we will do. For malaria we are looking into PCR - we are trying to multiplex with one of the Ebola targets. We have ordered the Picollo machine for doing blood chemistry using the portable BSL3 lab from Nairobi. Not sure yet what we will do about viral loads.

All staff is healthy and in good spirit.

Best wishes,
Heinz
CDC/NIH Lab
ELWA3
Monrovia

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 10:11 AM
To: 'johnb@nativis.com'
Subject: Re: Nativis- Knockdown of VP40

John,
I am currently in Monrovia for the rest of the month. We could look into November for you to visit.

Heinz

----- Original Message -----

From: John Butters [mailto:johnb@nativis.com]
Sent: Sunday, October 12, 2014 10:57 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Nativis- Knockdown of VP40

Heinz,

I would very much like to meet with you at your location in Montana, or at our labs in Seattle, to discuss our technology; specifically the knockdown of key Ebola targets by specific inducement of specific charge pathways. The underlying technology is not uncomplicated, but the application is very straightforward. GSK is working on a similar approach (bio electronics) but they're several years behind us. I would like to meet with you to discuss a demonstration study at your labs. Our earlier email chain is below.

Best,

John Butters, CEO
Nativis, Inc.
Seattle

Sent from my iPhone

> On Aug 5, 2014, at 5:33 PM, "John Butters" <johnb@nativis.com> wrote:

>

> Heinz,

>

> RFE inducement of a specific charge along a specific charge pathway. We've demonstrated specific mRNA and protein knockdown. We can provide sequential combinatorial RFE to knockdown Ebola VP24, VP30, VP35, VP40, L-polymerase and NP, or other targets. The specific RFE is delivered via low level EM field, unattenuated in the body. We're currently proceeding into human trials to treat recurrent GBM patients, using a specific RFE that blocks the disassembly of microtubule, resulting in disruption of mitotic spindle activity at metaphase. Safe travels to West Africa. I will remain interested to meet with you, upon your return.

>

> John

>

> John Butters

> Chairman, President and CEO

> Nativis

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 10:08 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Hoenen, Thomas (NIH/NIAID) [F]; Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: Oxford Nanopore Wen Inquiry

Sounds good.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 12, 2014 10:55 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hoenen, Thomas (NIH/NIAID) [F]; Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: Oxford Nanopore Wen Inquiry

The machine will be free. I believe we may have to pay for the runs, there is a disposable part. I believe they are \$900.

Sent from my iPhone

On Oct 12, 2014, at 3:51 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

What does the machine cost? Let Dawn work on the purchase.

Heinz

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 07:47 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

Agreed... the big problem is a lot of the company is away a some big conference next week - the main cause for the delay. I did make it clear that we would need an answer and the equipment the next week. They are already by-passing their normal proposal route so I have the suspicion that unless they really do not think that it will work we will have one in two weeks.

As I said, if we have the money we should simultaneously pursue another machine. But I have no suggestions. Traditional Sanger probably makes the most sense except that it is quite a large setup (as far as I know). Everything else is extremely expensive. Dave thinks Steve P. may be able to provide equipment and expertise, but I guess you (Heinz) would have to make the request.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 4:03 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

I am all for it but time is important.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 05:40 PM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 6:35 AM
To: 'barry.rockx@rivm.nl'
Subject: Re: ebola risk

Barry,

I am currently in Monrovia for the rest of the month. Internet access is very limited and unstable.

I have no good answers for you questions.

I know some people have done work on feces but I do not know the results. You may want to ask Gary Kobinger (Winnipeg) and/ or Stuart Nichol/Pierre Rollin (CDC Atlanta).

In regards to animals, there are no good data either. Bats are supposed to be the natural reservoir. Great apes and certain other nonhuman primate species get infected and are considered end host that can transmit. Duikers have been described but I am not sure about their role in transmission. Some people propose that Ebola could be amplified in pigs and transmitted to human but no real data from field work. Animal-to-human transmission should anyway not be a problem for non-endemic countries.

Hope this helps a little. We can talk over the phone if you like. Just give me a number and I will try to call.

Best wishes and good luck in the new job.

Heinz

-----Original Message-----

From: Barry Rockx
To: Heinrich (NIH/NIAID) [E] Feldmann
Subject: ebola risk
Sent: Oct 8, 2014 12:55 AM

Hi Heinz, How are things at RML? I hear your teams have been very busy with the field diagnostics, I hope things are going well. I have started my new job and am already getting a lot of questions regarding transmission risk of Ebola. I wanted to get your opinion on the following questions if you have some time: 1. Can you tell me if you know culture attempts have been made on feces and if they were successful: ie was EBOV isolated by culture techniques? 2. Role of feces in transmission? 3. Do you have an indication of viral titers (presumably on RNA/PCR) in feces? 4. other than bats and apes, are there any other species believed to be involved in transmission? Duikers: involved in transmission? Easily Infected? Shedding, Porcupines, Pangolins, Rodents, Reptiles, Other? thanks! Barry Proclaimer RIVM
<http://www.rivm.nl/Proclaimer>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 6:15 AM
To: 'vikki@target-conferences.com'; 'twgeisbe@utmb.edu'; 'Jricht@ksu.edu'; YOSHIHIROKAWAOKA
Cc: 'lynn@target-conferences.com'; 'filovirus@target-conferences.com'
Subject: Re: summary of telephone call

Abstract deadline as late as possible to get the newest (latest) information.

From: Vikki Hyman [mailto:vikki@target-conferences.com]
Sent: Sunday, October 12, 2014 06:43 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Geisbert, Thomas W. <twgeisbe@utmb.edu>; Juergen Richt <Jricht@ksu.edu>; YOSHIHIROKAWAOKA
Cc: Lynn Lipschitz <lynn@target-conferences.com>; filovirus@target-conferences.com <filovirus@target-conferences.com>
Subject: Re: summary of telephone call

Dear All

Further to Lynns summary, I have asked the designer to prepare a design for the conference and as soon as I receive that I will forward to you all for approval.

In addition, in order to set up the symposium website I will need from you the following:

- A welcome note - similar to the one we had for the Zoonoses conference this year (attached).
- List of committee/s members
- any specific scientific information - such as topics, block program etc.

As I understand there will be abstract submission for both orals and posters for which I will set up the online link. I suggest we have an abstract submission deadline of late January (January 29, 2015?). Please let me know your thoughts. Any time earlier will be around the Christmas break and if we do it before December it is too soon...

I think that's all for now.

Many thanks and I look forward to working with you all on this conference.

regards

Vikki Hyman | Project Manager
Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818
Tel: [+972 3 517 5150 ext 611](tel:+97235175150) | Fax: [+972 73 2067718](tel:+972732067718)
www.target-conferences.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 6:14 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Interview request today on ebola and Europe prevention tonight at 9pm or this afternoon at 1pm or 2pm

From: SARTON DU JONCHAY Isabelle [mailto:icharton@france24.com]
Sent: Sunday, October 12, 2014 07:02 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview request today on ebola and Europe prevention tonight at 9pm or this afternoon at 1pm or 2pm

GoodMorning Sir.
I am writing you from France 24, an international TV channel based in Paris.
We would like to ask you for an interview on Ebola in Texas and prevention tonight at 9pm (Spokane time) or this afternoon at 1pm or 2pm
. The interview will last 4 minutes and can be done by skype or telephone.

Will you be available?

Best regards
Isabelle du Jonchay
0033 647 38 11 00

Hoping that you will be available
Isabelle du jonchay
0033 647 38 11 00

This footnote confirms that this email message has been scanned by
PineApp Mail-SeCure for the presence of malicious code, vandals & computer viruses.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 6:13 AM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Fw: RE : New suspected case to be tested
Attachments: EBOLA Screening Inventory of consumables needed.xlsx

Dave, can you please have a look at the list?

Thanks, Heinz

From: Amadou Kone [mailto:amadoukone@icermali.org]
Sent: Sunday, October 12, 2014 06:27 AM Eastern Standard Time
To: Koita, Ousmane; Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>; Amadou Kone <amadoukone@icermali.org>
Subject: RE : New suspected case to be tested

Dears,

On behalf of Professor Koita, please find in attachment the inventory sheet of materials needed and in use for EBOLA screening and confirmatory. This sheet includes only EBOLA RNA extraction and Amplification/Detection, not equipments (PPE, Gloves, etc.) in use in Level-3 lab. Also, it not includes Positive controles stocked in the Blue Lab.

Cheers,
Amadou KONE

----- Message d'origine-----

De: Ousmane Koita
Date: ven. 10/10/2014 15:47
À: Richard Sakai; 'Feldmann, Heinrich (NIH/NIAID) [E]'; 'Polis, Michael (NIH/NIAID) [E]'; Bassirou Diarra; 'Murphy, Robert'
Cc: 'Safronetz, David (NIH/NIAID) [E]'; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Objet : RE: New suspected case to be tested

Dear Dick,

I think you are right, I am planning to have an inventory of the stock may be tomorrow morning or Monday.

Best regards,

Ousmane

-----Original Message-----

From: Richard Sakai
Sent: Friday, October 10, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: RE: New suspected case to be tested

It appears that the stock of some of the testing reagents have been completely used up and the stock of others may also be low. Are there any plans to re-stock the reagent inventory soon?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 4:08 AM
To: Personal Info
Subject: Re: Ebola!

Karl,
Good to hear from you - hope all is well. Yes I am in Monrovia, Liberia for the second time. We run a diagnostic lab for MSF just outside the capital - 400 patient tent hospital.

We are limited in what we can do here and are busy just diagnosing Ebola with the huge amount of patients.

MSF here does not use any injectable therapies as they are not set up for it. No beds only matrazes on the floor. Convalescent plasma therapy is not considered here at the moment. There also isn't any institution to collect plasma.

The survival rate here in the hospital is 48 percent - just under oral hydration, antibiotics, antimalaria, etc. Only oral treatments are considered at the moment.

All clinical trials have to be approved by a board funded by Wellcome Trust. It is not easy to just start treatment.

In my view treatment will be helpful but won't have a big short-term impact on the outbreak - what we need are vaccines. Hopefully they get started on that.

Stuart Nichol's email is: stn1@cdc.gov

Best wishes,
Heinz

-----Original Message-----

From: Karl M. Johnson
To: Heinrich (NIH/NIAID) [E] Feldmann
Subject: Ebola!
Sent: Oct 6, 2014 11:40 AM

Hi, Hope you are in WA with equipment to do quantitative viremia and abys. Former is to do daily viremia levels before and after use of convalescent plasma and to find immune persons to recruit for many of the riskiest procedures in this horrific outbreak. If you are not there do you know if anyone at CDC is doing any of that stuff. Science DURING an epidemic is tough but it needs doing for good reasons. Only Ebola case who got plasma and was monitored was the Redact

Redacted by agreement

Redacted by agreement. Do you have contact info for Stuart Nichol? Please send if yes or any other number I could use to reach Special Pathogens. Is your vaccine the one finally being pushed by Tony? If not, why the hell not. If yes then perhaps you are still in country and pushing. Any news appreciated. Almost wish I was still in loop. KMJ

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 12, 2014 3:51 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Hoenen, Thomas (NIH/NIAID) [F]
Cc: Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: Oxford Nanopore Wen Inquiry

What does the machine cost? Let Dawn work on the purchase.

Heinz

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 07:47 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

Agreed... the big problem is a lot of the company is away a some big conference next week - the main cause for the delay. I did make it clear that we would need an answer and the equipment the next week. They are already by-passing their normal proposal route so I have the suspicion that unless they really do not think that it will work we will have one in two weeks.

As I said, if we have the money we should simultaneously pursue another machine. But I have no suggestions. Traditional Sanger probably makes the most sense except that it is quite a large setup (as far as I know). Everything else is extremely expensive. Dave thinks Steve P. may be able to provide equipment and expertise, but I guess you (Heinz) would have to make the request.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 4:03 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

I am all for it but time is important.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 05:40 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

It sounded like they will make a decision within two weeks. How fast they move after that is uncertain, but I think I made the timeliness of it pretty clear. Based on Allison's recent comments I think you can forget about the miSEQ, its sounds like any problem, vibration, etc. causes problems with the machine. The other one should easily have the capacity to sequence Ebola no problem - the guy we talked to seemed to think that Thomas's strategy was perfectly suited to the machine. Sample prep would be no more difficult than any other other sequencing platform. No one knows how reliably it would work until we try it out. Obviously it would tested in our lab prior to deployment.


I think simultaneously investing in an alternative sequencing approach would not be a bad idea as this one will cost us nothing except time.

Darryl

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 4:07 PM
To: 'honey@uw.edu'
Subject: Re: EBOLA-Confidential

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 4:04 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

I am all for it but time is important.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 05:40 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Oxford Nanopore Wen Inquiry

It sounded like they will make a decision within two weeks. How fast they move after that is uncertain, but I think I made the timeliness of it pretty clear. Based on Allison's recent comments I think you can forget about the miSEQ, its sounds like any problem, vibration, etc. causes problems with the machine. The other one should easily have the capacity to sequence Ebola no problem - the guy we talked to seemed to think that Thomas's strategy was perfectly suited to the machine. Sample prep would be no more difficult than any other other sequencing platform. No one knows how reliably it would work until we try it out. Obviously it would tested in our lab prior to deployment.

I think simultaneously investing in an alternative sequencing approach would not be a bad idea as this one will cost us nothing except time.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:19 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

How likely is it that we will get the machine soon? If this is a new technology how simple and how reliable will it work? I am all for it but we need something that we can handle from\$ a technical point of view.

When would the machine be available?

Heinz

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 09:10 PM Eastern Standard Time
To: James.Bray@nanoporetech.com <James.Bray@nanoporetech.com>
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Oxford Nanopore Wen Inquiry

Dear James,

Redacted by
agreement

Thank you very much for taking the time to talk to Darryl and me today. Please find, as promised, attached a brief description of the project we envision with the [REDACTED] Please let us know if you have any questions.

As already mentioned during our phone call, the ability to test the [REDACTED] in the field is for us not only extremely interesting scientifically, but also has the potential to significantly contribute to our ability to control this outbreak. Therefore, we would appreciate very much a quick decision whether we can get access to a [REDACTED]

Redacted by
agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 4:00 PM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

It is not acceptable to me but I would not use interferon as your data do not support that. Would you seriously support the use of interferon? You could also use chicken soup.

Heinz

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 05:43 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

So I guess we will not do anything because 48% survival is acceptable to you.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:28 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Disclosure of ebola-infected NHP data

Most treatment centers do not do IV infusion and injectables. I think this is unrealistic. They want oral drugs for safety and operational reasons. The new Redacted by agreement

Reda From Michael Katze we know that mice lie - maybe NHPs lie as well; there is a possibility.

ELWA 3 has a survival rate of 48 percent under oral dehydration, paracetamol, antimalaria, antibiotics, anti-nausea and anti-diarrhoea. I am wondering if any of the drugs tried so far did anything good as one has to expect that survival is higher under modern intensive care.

The fact that the drug doesn't harm is not a good reason for me to use it. Anyway, on the bigger picture treatment is not going to solve the outbreak - we need vaccines.

Heinz

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 03:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I have mixed feelings on this - I both agree and disagree with Heinz. My arbitrary cutoff for success was either some survival or extension of time to death of at least 10 days. We did not meet either of these. Is it possible that some sort of treatment like this could push some people to survive, maybe, it probably does not make things worse. Supportive care obviously helps, but can anything specific help above that... unfortunately you don't know until you try. I am certain that

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 10:54 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

OK - let's go for it.

----- Original Message -----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Saturday, October 11, 2014 10:32 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Oxford Nanopore Wen Inquiry

At this point it's not 100% clear. The machine is not commercially available, so we would get a prototype (they are doing beta testing with other scientific laboratories, and what we would need doing seems to work well in other labs). After talking to James I hope that they will make the decision whether to support us in the next two weeks, and can then ship the machine immediately - Darryl and I are making as much pressure as we can. But in my view this is by far the best option: The device is the size of a USB stick, and would probably cost us around 1000\$ (that's their deposit to enroll in the advanced access program). Run times are about 30 minutes, and we can run multiple samples at the same time (we will have to try how many).

By comparison, if we get a next-gen or Sanger sequencer we are looking at a piece of equipment that will cost us 80000 to 100000\$ minimum, weighs at least 80 kg, has a size of at least 1 cubic meter, so transporting will be an issue. After talking to Ali it seems that a next-gen sequencer is probably a bad idea, sample preparation is rather involved, runs take days, we have to deal with toxic waste, and if you make the smallest mistake (as little as touching the machine while it runs) the run fails, you lose thousands of dollars in reagents and you have to start over. Sanger sequencing would be the better option, run times are hours and the technology is more robust; however, these machines tend to be more expensive than next-gen, and much bigger. On the plus side sample preparation is simpler and cheaper, but still longer than with the Minlon. In my view the Minlon is the by far best and easiest option, but nobody says we can't pursue Sanger at the same time (but it probably will take longer, be more expensive, and has less chances of success).

If you want to know more, check out their three minute video at this web site:

<https://www.nanoporetech.com/technology/the-minion-device-a-miniaturised-sensing-system/the-minion-device-a-miniaturised-sensing-system>

All the best, Thomas

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:19 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

How likely is it that we will get the machine soon? If this is a new technology how simple and how reliable will it work? I am all for it but we need something that we can handle from a technical point of view.

When would the machine be available?

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 10:52 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Disclosure of ebola-infected NHP data

Cliff came to Monrovia regarding a vaccine trial. I met briefly with him, but he only spent two days in country.

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 10:15 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

It will not be our decision. It is data for folks to consider. I agree that we do need a safe and effective vaccine as quickly as possible.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 5:28 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Disclosure of ebola-infected NHP data

Most treatment centers do not do IV infusion and injectables. I think this is unrealistic. They want oral drugs for safety and operational reasons. The new [Redacted by agreement]

[Redacted] From Michael Katze we know that mice lie - maybe NHPs lie as well; there is a possibility.

ELWA 3 has a survival rate of 48 percent under oral dehydration, paracetamol, antimalaria, antibiotics, anti-nausea and anti-diarrhoea. I am wondering if any of the drugs tried so far did anything good as one has to expect that survival is higher under modern intensive care.

The fact that the drug doesn't harm is not a good reason for me to use it. Anyway, on the bigger picture treatment is not going to solve the outbreak - we need vaccines.

Heinz

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 03:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I have mixed feelings on this - I both agree and disagree with Heinz. My arbitrary cutoff for success was either some survival or extension of time to death of at least 10 days. We did not meet either of these. Is it possible that some sort of treatment like this could push some people to survive, maybe, it probably does not make things worse. Supportive care obviously helps, but can anything specific help above that... unfortunately you don't know until you try. I am certain that administration of [Redacted by agreement] in humans will work better than in NHPs. The only downside being that the doses of [Redacted] we used are unlikely (I am guessing) to be used in people?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 7:09 AM
To: Pierre Formenty; 'twgeisbe@utmb.edu'
Subject: Re: Anti-reston antibodies from the Philippines as a source of convalescent plasma or Ig for the current outbreak?

I am in Monrovia and have no access to the manuscripts. Tom has done studies like this. In my view, convalescent plasma only has a chance to work if against the same Ebola species (i.e. Zaire ebolavirus would need Zaire ebolavirus). Reston convalescent serum won't work.

Heinz

From: Pierre Formenty
Sent: Saturday, October 11, 2014 07:53 AM Eastern Standard Time
To: Geisbert, Thomas W. (twgeisbe@UTMB.EDU) (twgeisbe@UTMB.EDU) <twgeisbe@utmb.edu>; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Anti-reston antibodies from the Philippines as a source of convalescent plasma or Ig for the current outbreak?

Dear Tom and Heinz,

The Philippine MOH is proposing to use sera from people positive for Reston, to protect against Ebolazaire in West Africa...
They based their "idea" on Pierre Rollin on cross reactivity for ELISA IgG test (see attached)

To my knowledge there does not appear to be immunity between the different Ebola species.

Non Human Primates that survive Ebola Zaire virus infection, when later re-challenged with Ebola Sudan virus were not protected.
There should be a paper describing this experiment.

Am I wrong? Do you have the paper, you were probably involved in these studies...

I would need a quick reply (if you have the paper or similar papers) as some people would like to contact the President of the country etc...

Thank you for your support

Pierre

Pierre Formenty

Team Lead - Emerging and Epidemic Zoonotic Diseases team (CED/EZD)
Control of Epidemic Diseases Unit (HSE/PED/CED)
Pandemic and Epidemic Diseases (HSE/PED) department
World Health Organization
20 Avenue Appia
CH-1211 Geneva 27 - Switzerland

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 4:40 AM
To: Personal Info
Subject: Re: wieder Quito

Uns geht es recht gut hier im Labor. Wir haben nicht viel Kontakt mit Patienten. Der Ausbruch ist schlimm und sicher nicht einfach unter Kontrolle zu bringen. Wir brauchen wohl einen Impfstoff um erfolgreich zu sein. Je frueher desto besser.

Kontakte auf der Strasse und im Hotel sollte man vermeiden. Man weiss nie, wen man vor sich hat.

Wie war Deine Reise? Wann gehst Du zurueck nach Deutschland?

Heinz

From: Klaus Gierhake [mailto:Personal Info]
Sent: Friday, October 10, 2014 05:40 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: wieder Quito

Hallo Heinz

ob Du wohl in Afrika emails liest - schreibst? als Ablenkung?

Letzten Sonntag war irgendwie "der Wurm drin" bei den Telefonversuchen.

Die Nachrichten in den Zeitungen werden immer dramatischer was Ebola betrifft. Vorgestern hatte ich eine Auslandsjournal über Internetfernsehn ZDF gesehen.

Wie es vor Ort aussieht? Was Du dort wohl in die Wege leiten kannst?

Einen solchen riesigen Ausbruch gab es wohl noch nie, und mit der Zahl der Infizierten werden wohl auch die Gegenmaßnahmen zur Eindämmung immer schwieriger

Die erste Ansteckung in Europa ist wohl eine neue Stufe.

Machst Du Dir um Dich selbst Sorgen? Ein unbewusster und nicht gewollten Kontakt auf der Strasse? Kann so was in dieser Krise passieren?

Hoffe, Dir geht es gut

Klaus

Feldmann, Heinrich (NIH/NIAID) [E]


From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:30 AM
To: Walke, Henry (CDC/OID/NCEZID); Flannery, Brendan (CDC/OID/NCIRD); 'MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org'; Thorne, Gregory Immel (CDC/CGH/DGHA); Flaherty, Patrick (CDC/OID/NCHHSTP); Mott, Joshua (CDC/OID/NCIRD)
Subject: Re: request for Chinese delegation visit to ELWA 3 lab

Sure - someone will have time to lead them around.

Heinz

From: Walke, Henry (CDC/OID/NCEZID)
Sent: Saturday, October 11, 2014 05:23 AM Eastern Standard Time
To: Flannery, Brendan (CDC/OID/NCIRD); 'MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org' <MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org>; Thorne, Gregory Immel (CDC/CGH/DGHA); Flaherty, Patrick (CDC/OID/NCHHSTP); Mott, Joshua (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: request for Chinese delegation visit to ELWA 3 lab

Records Originating Outside of NIAID



From: MSFOCB-Monrovia-LiaisonOfficer [mailto:MSFOCB-Monrovia-LiaisonOfficer@brussels.msf.org]
Sent: Saturday, October 11, 2014 03:34 AM Eastern Standard Time
To: Flannery, Brendan (CDC/OID/NCIRD)
Subject: request for Chinese delegation visit to ELWA 3 lab

Hi Brendan,

The Chinese have an Advanced Team of officials who are doing a fact-finding visit for possible deployment of a medical team for Ebola in Liberia. In addition to visiting ELWA, they requested to visit the CDC lab. They should be at ELWA at about 9 am tomorrow.

Would a visit to the lab be possible?

Thanks!

Kris

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:29 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Disclosure of ebola-infected NHP data

Most treatment centers do not do IV infusion and injectables. I think this is unrealistic. They want oral drugs for safety and operational reasons. The new Nebraska case is obviously treated with a new drug as well based only on in vitro data. From Michael Katze we know that mice lie - maybe NHPs lie as well; there is a possibility.

ELWA 3 has a survival rate of 48 percent under oral dehydration, paracetamol, antimalaria, antibiotics, anti-nausea and anti-diarrhoea. I am wondering if any of the drugs tried so far did anything good as one has to expect that survival is higher under modern intensive care.

The fact that the drug doesn't harm is not a good reason for me to use it. Anyway, on the bigger picture treatment is not going to solve the outbreak - we need vaccines.

Heinz

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 03:41 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

I have mixed feelings on this - I both agree and disagree with Heinz. My arbitrary cutoff for success was either some survival or extension of time to death of at least 10 days. We did not meet either of these. Is it possible that some sort of treatment like this could push some people to survive, maybe, it probably does not make things worse. Supportive care obviously helps, but can anything specific help above that... unfortunately you don't know until you try. I am certain that administration of ribavirin IV and treatment with IFN in humans will work better than in NHPs. The only downside being that the doses of IFN we used are unlikely (I am guessing) to be used in people?

I have no problem with disclosing the data, as long as it is communicated appropriately.

Darryl

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:23 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I do not want to be the bad guy, but what makes one think that this has any benefit? Based on my work and experience in the filovirus field for over 25 years I would stop this here. There is no justification for a clinical trial. If we go ahead here we could have gone ahead with several other drugs and vaccine candidates before that were more promising than this one.

Sorry for being a bit harsh, but I do not understand this.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:19 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Oxford Nanopore Wen Inquiry

How likely is it that we will get the machine soon? If this is a new technology how simple and how reliable will it work? I am all for it but we need something that we can handle from a technical point of view.

When would the machine be available?

Heinz

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 09:10 PM Eastern Standard Time
To: James.Brayer@nanoporetech.com <James.Brayer@nanoporetech.com>
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Oxford Nanopore Wen Inquiry

Dear James,

Redacted by
agreement

Thank you very much for taking the time to talk to Darryl and me today. Please find, as promised, attached a brief description of the project we envision with the [REDACTED]. Please let us know if you have any questions.

As already mentioned during our phone call, the ability to test the [REDACTED] in the field is for us not only extremely interesting scientifically, but also has the potential to significantly contribute to our ability to control this outbreak. Therefore, we would appreciate very much a quick decision whether we can get access to a [REDACTED]

Redacted by
agreement

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 12:34 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: FW: Oxford Nanopore Wen Inquiry

From: James Brayer [mailto:James.Brayer@nanoporetech.com]
Sent: Friday, October 10, 2014 10:12 AM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 11, 2014 3:15 AM
To: Unpublished
Subject:

I have to decline. I am currently in Liberia with little access to internet.

Best wishes, Heinz

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 3:16 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Disclosure of ebola-infected NHP data

Sounds good.

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 04:44 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Disclosure of ebola-infected NHP data

You will not be.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 4:14 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I am not supportive of use in humans - I guess I feel differently about this than others. However, I do not want to be in the way but do not like my name associated with a decision for a clinical trial based on these results.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:57 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I am not promoting the CT I am just asking to share the information. I believe the benefit may be minimal at best but it may help some folks to have a few more days to mount a response and everything is already approved by regulatory authorities so we know its safety profile.

Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:23 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 2:15 PM
To: YOSHIHIROKAWAOKA; 'lynn@target-conferences.com'; 'twgeisbe@utmb.edu'
Cc: 'Jricht@ksu.edu'; 'vikki@target-conferences.com'
Subject: Re: urgent decision required please

It is not the time - it is the reception. Set up a time and date and I will try my best. We are 4 hours ahead of EST US.

----- Original Message -----

From: YOSHIHIROKAWAOKA
Sent: Friday, October 10, 2014 03:57 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'lynn@target-conferences.com' <lynn@target-conferences.com>; 'twgeisbe@utmb.edu' <twgeisbe@utmb.edu>
Cc: 'Jricht@ksu.edu' <Jricht@ksu.edu>; 'vikki@target-conferences.com' <vikki@target-conferences.com>
Subject: Re: urgent decision required please

Heinz,

Can we discuss the contents of the meeting sometime next week?
I am currently in Japan. So, late afternoon in the US time is good for me.

When is the good time?

Yoshi

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Handle: Feldmann, Heinrich (NIH/NIAID) [E] Mail Address: feldmannh@niaid.nih.gov
Subject: Re: urgent decision required please
To: YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>, 'lynn@target-conferences.com' <lynn@target-conferences.com>, 'twgeisbe@utmb.edu' <twgeisbe@utmb.edu>
CC: 'Jricht@ksu.edu' <Jricht@ksu.edu>, 'vikki@target-conferences.com' <vikki@target-conferences.com>
Date: Fri, 10 Oct 2014 19:39:24 +0000
Date Local: 2014/10/11 4:39:24
Message:

> Dinner is fine with me if we can afford it. If we need to save money that dinner is what we should drop in my view.
>

> I go with the majority on this. Not a big dinner fan - the reception would be more important to me - beut that is me.
>

> ----- Original Message -----

> From: YOSHIHIROKAWAOKA
> Sent: Friday, October 10, 2014 03:28 PM Eastern Standard Time
> To: Lynn Lipschitz <lynn@target-conferences.com>; Geisbert, Thomas W.
> <twgeisbe@utmb.edu>
> Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jricht@ksu.edu
> <Jricht@ksu.edu>; vikki@target-conferences.com
> <vikki@target-conferences.com>
> Subject: Re: urgent decision required please

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 2:14 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I am not supportive of use in humans - I guess I feel differently about this than others. However, I do not want to be in the way but do not like my name associated with a decision for a clinical trial based on these results.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:57 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I am not promoting the CT I am just asking to share the information. I believe the benefit may be minimal at best but it may help some folks to have a few more days to mount a response and everything is already approved by regulatory authorities so we know its safety profile.

Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:23 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I do not want to be the bad guy, but what makes one think that this has any benefit? Based on my work and experience in the filovirus field for over 25 years I would stop this here. There is no justification for a clinical trial. If we go ahead here we could have gone ahead with several other drugs and vaccine candidates before that were more promising than this one.

Sorry for being a bit harsh, but I do not understand this.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:14 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Any concerns?

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:39 PM
To: YOSHIHIROKAWAOKA; 'lynn@target-conferences.com'; 'twgeisbe@utmb.edu'
Cc: 'Jricht@ksu.edu'; 'vikki@target-conferences.com'
Subject: Re: urgent decision required please

Dinner is fine with me if we can afford it. If we need to save money that dinner is what we should drop in my view.

I go with the majority on this. Not a big dinner fan - the reception would be more important to me - but that is me.

----- Original Message -----

From: YOSHIHIROKAWAOKA
Sent: Friday, October 10, 2014 03:28 PM Eastern Standard Time
To: Lynn Lipschitz <lynn@target-conferences.com>; Geisbert, Thomas W. <twgeisbe@utmb.edu>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jricht@ksu.edu <Jricht@ksu.edu>; vikki@target-conferences.com <vikki@target-conferences.com>
Subject: Re: urgent decision required please

I just woke up.

Tom, Heinz, and Jürgen,

Don't you want one night of dinner secured either at the hotel or the Press Club??

If we can wait until next conf call, that is fine, however.

Yoshi

From: Lynn Lipschitz <lynn@target-conferences.com>
Handle: Lynn Lipschitz
Mail Address: lynn@target-conferences.com
Subject: Re: urgent decision required please
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>
CC: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>, Jricht@ksu.edu <Jricht@ksu.edu>, YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>, vikki@target-conferences.com <vikki@target-conferences.com>
Date: Fri, 10 Oct 2014 20:01:11 +0300
Date Local: 2014/10/11 2:01:11
Message:

> Hi all and Heinz hope that you are well!
> Thanks for the decision. We will book the hotel and the get-together
> reception so that they hold the space.
> As to the food/drink content - we will decide closer to the time
> according to our budget allowance. I will not hold any space for the
> gala dinner - that will follow pending budget allowance.
> During our next phone call then we need to discuss the registration
> fees (if we will take money in advance assuming that there will be a

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:37 PM
To: 'Helen.Branswell@thecanadianpress.com'
Subject: Re: Here you go

Interesting even though they might be wrong on a few assumptions. I am also not the biggest fan of randomized control studies in this scenario but perhaps for slightly different reasons. On the other hand, a randomized control study is better than no study.

Heinz

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Friday, October 10, 2014 03:13 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Here you go

Randomised controlled trials for Ebola: practical and ethical issues

2 months ago, when the numbers known to have died from Ebola in west Africa could still be counted in hundreds, WHO made an important statement about investigational drugs and vaccines. This crisis is so acute, WHO declared, that it is ethical to offer interventions with potential benefits but unknown efficacy and side-effects, though every effort should be made to evaluate benefits and risks and share all data generated. The need for drugs and vaccines was urgent then. With cases now rising exponentially and health systems overwhelmed, it is even greater today. Vaccine safety trials are underway in the USA and the UK, and poised to roll out to Africa soon. But treatments for those with infection are required too. Besides playing a direct part in containing

the epidemic, interventions that could improve outcomes for the sick would help to rebuild the confidence of affected communities in health services, a critical step if Ebola is to be overcome.

A fast-track initiative for evaluating investigational drugs was launched in September, 2014.¹ But although the question of whether unproven treatments should be offered at all is now settled, the question of how they should be deployed and

tested is not. Still at issue is whether such treatments should be made available only in the context of randomised controlled trials (RCTs) in which patients receive either a new intervention and conventional care, or conventional care alone or with a placebo.

Advocates of this RCT approach state that as this experimental design will create the most robust evidence for the future, and is what regulators are used to, it is the only approach that should be considered. We disagree. While we concur that RCTs provide robust evidence, and support their use where this is ethical and practical, we do not believe that either consideration is likely to be satisfied in the context of this epidemic. The priority must be to generate data about effectiveness and safety as swiftly as possible, so that the most useful new treatments can be identified for rapid deployment.

Alternative trial designs have the potential to do this more quickly, and with greatest social and ethical acceptability.

The first objection to RCTs in which investigational drugs plus conventional care are compared purely with conventional care is ethical. Such randomisation is ethical when there is equipoise – when there is genuine uncertainty about whether an untested treatment has benefits or risks that exceed those of conventional care. Equipoise is a useful principle, but it can break down when conventional care offers little benefit and mortality is extremely high. This is precisely the problem with Ebola: current conventional care does not much affect clinical outcomes and mortality is as high as 70%. When

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:23 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Disclosure of ebola-infected NHP data

I do not want to be the bad guy, but what makes one think that this has any benefit? Based on my work and experience in the filovirus field for over 25 years I would stop this here. There is no justification for a clinical trial. If we go ahead here we could have gone ahead with several other drugs and vaccine candidates before that were more promising than this one.

Sorry for being a bit harsh, but I do not understand this.

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 03:14 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Disclosure of ebola-infected NHP data

Any concerns?

Darren and I discussed whether we should do Redacted by agreement

Kathy

-----Original Message-----

From: Darren Baker [mailto:darren.baker@biogenidec.com]
Sent: Friday, October 10, 2014 3:08 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Mowatt, Michael (NIH/NIAID) [E]
Cc: Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Disclosure of ebola-infected NHP data

Dear all

Following receipt of the first data from Kathy yesterday regarding the comparison of Intron-A, PEG-Intron, and Avonex in ebola-infected rhesus monkeys, I wanted to check what your thoughts were about disclosing the data to a third party who I have been in discussion with regarding a potential clinical trial in ebola-infected patients. The data may be useful in selecting the type of interferon that would be used. Redacted by agreement

Redacted by agreement

Redacted by agreement

Please advise

Cheers ... Darren

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 1:00 PM
To: 'Helen.Branswell@thecanadianpress.com'
Subject: Re: Great letter in Lancet

That would work.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Friday, October 10, 2014 02:59 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Great letter in Lancet

If you cannot I can cut and paste into an email

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-10-14 2:58 PM
To: Branswell, Helen
Subject: Re: Great letter in Lancet

I will try to access it. Thanks.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Friday, October 10, 2014 02:33 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Great letter in Lancet

...challenging the idea of requiring RCTs for Ebola therapeutics.
Can you read PDFs there? Attaching.

H.

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-10-14 5:37 AM
To: Branswell, Helen
Subject: Re: your VSV vaccine update

Thanks for the update. I hear that a team is coming out to plan for a randomized control/vaccine study here in Monrovia and/or Liberia. Not sure what vaccine.

Best wishes, Heinz

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Thursday, October 09, 2014 10:54 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: your VSV vaccine update

WHO said today that they're finalizing the legal agreement to take possession of the vials and expect the vaccine to be shipped to Geneva next week.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:58 PM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: Great letter in Lancet
Attachments: Lancet letter on RCTs.pdf

From: Branswell, Helen [<mailto:Helen.Branswell@thecanadianpress.com>]
Sent: Friday, October 10, 2014 02:33 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Great letter in Lancet

...challenging the idea of requiring RCTs for Ebola therapeutics.
Can you read PDFs there? Attaching.

H.


From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: October-10-14 5:37 AM
To: Branswell, Helen
Subject: Re: your VSV vaccine update

Thanks for the update. I hear that a team is coming out to plan for a randomized control/vaccine study here in Monrovia and/or Liberia. Not sure what vaccine.

Best wishes, Heinz

From: Branswell, Helen [<mailto:Helen.Branswell@thecanadianpress.com>]
Sent: Thursday, October 09, 2014 10:54 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: your VSV vaccine update

Redacted by agreement



Helen

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:58 PM
To: 'Helen.Branswell@thecanadianpress.com'
Subject: Re: Great letter in Lancet

I will try to access it. Thanks.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Friday, October 10, 2014 02:33 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Great letter in Lancet

...challenging the idea of requiring RCTs for Ebola therapeutics.
Can you read PDFs there? Attaching.

H.


From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-10-14 5:37 AM
To: Branswell, Helen
Subject: Re: your VSV vaccine update

Thanks for the update. I hear that a team is coming out to plan for a randomized control/vaccine study here in Monrovia and/or Liberia. Not sure what vaccine.

Best wishes, Heinz

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Thursday, October 09, 2014 10:54 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: your VSV vaccine update

Redacted by agreement



Helen

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:57 PM
To: 'Anja.WOLZ@geneva.msf.org'
Subject: Re: Berlin

If you have the time, please visit the lab. Otherwise, we need to communicate and decide on a time.

From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
Sent: Friday, October 10, 2014 02:24 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Berlin

Sorry I was the last days in Bo back now in Monrovia
if you around let us meet

Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
Personal Info

From: Anja WOLZ/GVA/U/MSF
To: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
Date: 06.10.2014 10:38
Subject: Re: Berlin

When will you be in Monrovia? Call me my number is Personal Info
Anja

Sent from IBM Notes Traveler

Feldmann, Heinrich (NIH/NIAID) [E] --- Re: Berlin ---

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "Ilia.Semmler@tmf-ev.de" <Ilia.Semmler@tmf-ev.de>, "jricht@vet.k-state.edu" <jricht@vet.k-state.edu>
Date: Sun, Oct 5, 2014 11:09
Subject: Re: Berlin

I guess we have to move on.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:57 PM
To: Personal Info
Subject: Fw: talk for Berlin
Attachments: Haddock Berlin 2014.pptx

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 02:12 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: talk for Berlin

Heinz, I practiced at the Friday meeting. The talk runs about 11.5 minutes, slides have been updated to streamline and highlight some points.

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:54 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: (thanks) FW: VIMA NEWSPAPER-GREECE-INTERVIEW REQUEST

Sounds good - thanks.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:59 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: (thanks) FW: VIMA NEWSPAPER-GREECE-INTERVIEW REQUEST

Just so you're aware, here is the standard reply I have been sending to these reporters.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:59 AM
To: 'tchtsoli@tovima.gr'
Subject: FW: VIMA NEWSPAPER-GREECE-INTERVIEW REQUEST

Greetings Theodora, I'm assisting Dr. Feldmann on replying to his media inquiries. He is deployed overseas for an undetermined number of days and will not be available for this interview, via any recording format. Thanks for asking and for your interest in his work.

Ken Pekoc
Public Affairs Officer
Rocky Mountain Laboratories
NIAID Office of Communications and Government Relations
406-375-9690

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Theodora Tsoli [<mailto:tchtsoli@tovima.gr>]
Sent: Friday, October 10, 2014 12:15 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: VIMA NEWSPAPER-GREECE-INTERVIEW REQUEST

Dear dr Feldmann

my name is Theodora Tsoli and I am a journalist for the greek newspaper TO VIMA, one of the biggest Sunday papers in my country. We are preparing an article on Ebola for our next Sunday's paper (19th October) and I was wondering if you could find some time in the beginning of next week to speak to me about the virus (has it mutated? is it easy to become airborne? how much does it survive on surfaces? are the measures in airports against it enough? could the patients take a painkiller against fever and pass from the checkpoints in the airports?)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:53 PM
To: Hoenen, Thomas (NIH/NIAID) [F]; 'harvey.artsob@videotron.ca'
Subject: Re: Ebola - general information

Thanks Thomas.

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 01:48 PM Eastern Standard Time
To: 'harvey.artsob@videotron.ca' <harvey.artsob@videotron.ca>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola - general information

Dear Harvey,

Please find attached as requested by Heinz some recent reviews as well as one older one, but which still might be relevant, on EBOV. I have also attached a recent book chapter, please note I only have the author's proof in an electronic format, so I would ask you to not further distribute that file.

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov
LinkedIn: www.linkedin.com/pub/thomas-hoenen/38/75/639/

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 5:06 AM
To: 'harvey.artsob@videotron.ca'; 'twgeisbe@UTMB.EDU'; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola - general information

Dear ALL,
Harvey needs some information but I do not have access to it here in Monrovia.

Tom - can you please send him the pdf of the latest Fields chapter?

Andrea, Darryl and Thomas, please send him pdfs of your latest review articles.

Please copy me if you do not mind.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:38 AM
To: 'lynn@target-conferences.com'; 'twgeisbe@utmb.edu'
Cc: 'Jricht@ksu.edu'; YOSHIHIROKAWAOKA; 'vikki@target-conferences.com'
Subject: Re: urgent decision required please

I don't have a problem with the dates.

A reception would be good. If we need to save money I would drop the dinner.

Heinz

From: Lynn Lipschitz [mailto:lynn@target-conferences.com]
Sent: Friday, October 10, 2014 12:27 PM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@utmb.edu>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Juergen Richt <Jricht@ksu.edu>; YOSHIHIROKAWAOKA; Vikki Hyman <vikki@target-conferences.com>
Subject: Re: urgent decision required please

I take it that you all agree to the dates of Wednesday-Saturday - March 25-28, 2015, (session days Thursday, Friday & Saturday)?

Yes Tom - what you wrote is correct -

The first night was only for one hour and the rates are rather high if we want to extend it to 2 hours. But if you say that we can do food and then add drinks if affordable that's great. We don't have to decide on the food and drinks as yet.

For the dinner - we can have it on either night that you want - they are not holding space - I have to tell them which night.

Please advise.

Thanks and regards
Lynn

Lynn Lipschitz | **Managing Director**
Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818
Tel: +972 3 5175150 ext 601, Fax: +972 3 5175155
www.target-conferences.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:18 AM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Re: FYI..

Anton from Winnipeg?

From: Safronetz, David (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:17 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FYI..

Anton may give you a call / send you an email in the near future. He wants to discuss some ideas with you about Ebola treatments. I gave him your cell number, but told him email would be best.

Dave

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:18 AM
To: Munster, Vincent (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: New Guinea primer/probe sets

You can use my office line even though you are quite a bit away from the speaker.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 12:15 PM Eastern Standard Time
To: Munster, Vincent (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: New Guinea primer/probe sets

Already tried that with little success.

When can the others call. Can we do in 15 minutes?

Heinz

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 11:55 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: New Guinea primer/probe sets

Hi Heinz,

I will not be able to make it today, as I'm flying out to Philadelphia. But go ahead and schedule a meeting with the group and you can fill me in later

You might want to compare the CT values from the beginning with those later on, and also check with MSF if they think that the admissions they now get are earlier (less time between onset and admission) from the first batch. Generally, we only get samples from the admission, and not from late state of disease, which might explain the relatively higher values.

Vincent

From: <Feldmann>, Heinrich Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 10, 2014 8:30 AM
To: "De wit, Emmie (NIH/NIAID) [E]" <Emmie.deWit@nih.gov>, Vincent Munster <munstervj@niaid.nih.gov>, "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov>, "Falzarano, Darryl (NIH/NIAID) [F]" <darryl.falzarano@nih.gov>, "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov>, "Hoenen, Thomas (NIH/NIAID) [F]" <thomas.hoenen@nih.gov>
Subject: Re: New Guinea primer/probe sets

Can we talk about this today? If the viral load estimation is correct we would have ridiculously low viral loads in most patients. There is something wrong as many more should survive. I know we have talked about this before but in my view it doesn't make any sense. The CDC Ct values make more sense to me - not saying that their assay is better.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:17 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: VIMA NEWSPAPER-GREECE-INTERVIEW REQUEST

From: Theodora Tsoli [mailto:thtsoli@tovima.gr]
Sent: Friday, October 10, 2014 12:15 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: VIMA NEWSPAPER-GREECE-INTERVIEW REQUEST

Dear dr Feldmann

my name is Theodora Tsoli and I am a journalist for the greek newspaper TO VIMA, one of the biggest Sunday papers in my country. We are preparing an article on Ebola for our next Sunday's paper (19th October) and I was wondering if you could find some time in the beginning of next week to speak to me about the virus (has it mutated? is it easy to become airborne? how much does it survive on surfaces? are the measures in airports against it enough? could the patients take a painkiller against fever and pass from the checkpoints in the airports?)

Hope to hear from you soon

Thank you in advance

Theodora Tsoli

Theodora Tsoli
Newspaper «TO VIMA»
11526, Athens - Greece
Tel. : +30 211 365 8204
Mobile: Personal Info
email: thtsoli@tovima.gr

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:16 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; 'harvey.artsob@videotron.ca'
Subject: Re: Ebola - general information

Thanks Darryl.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Friday, October 10, 2014 12:03 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'harvey.artsob@videotron.ca' <harvey.artsob@videotron.ca>
Subject: RE: Ebola - general information

Hi Harvey,

Please find attached one recent and one slightly more dated review on Ebola.

Darryl

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 5:06 AM
To: 'harvey.artsob@videotron.ca'; 'twgeisbe@UTMB.EDU'; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola - general information

Dear ALL,

Harvey needs some information but I do not have access to it here in Monrovia.

Tom - can you please send him the pdf of the latest Fields chapter?

Andrea, Darryl and Thomas, please send him pdfs of your latest review articles.

Please copy me if you do not mind.

Many thanks,
Heinz

From: Harvey [mailto:harvey.artsob@videotron.ca]
Sent: Thursday, October 09, 2014 01:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - general information

Heinz,

I hope this e-mail finds you well.

I have been asked to write about Ebola for an online news source.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:15 AM
To: Munster, Vincent (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: New Guinea primer/probe sets

Already tried that with little success.

When can the others call. Can we do in 15 minutes?

Heinz

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 11:55 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: New Guinea primer/probe sets

Hi Heinz,

I will not be able to make it today, as I'm flying out to Philadelphia. But go ahead and schedule a meeting with the group and you can fill me in later

You might want to compare the CT values from the beginning with those later on, and also check with MSF if they think that the admissions they now get are earlier (less time between onset and admission) from the first batch. Generally, we only get samples from the admission, and not from late state of disease, which might explain the relatively higher values.

Vincent

From: <Feldmann>, Heinrich Feldmann <feldmannh@niaid.nih.gov>
Date: Friday, October 10, 2014 8:30 AM
To: "De wit, Emmie (NIH/NIAID) [E]" <Emmie.deWit@nih.gov>, Vincent Munster <munstervj@niaid.nih.gov>, "Marzi, Andrea (NIH/NIAID) [E]" <marzia@niaid.nih.gov>, "Falzarano, Darryl (NIH/NIAID) [F]" <darryl.falzarano@nih.gov>, "Safronetz, David (NIH/NIAID) [E]" <safronetzd@niaid.nih.gov>, "Hoenen, Thomas (NIH/NIAID) [F]" <thomas.hoenen@nih.gov>
Subject: Re: New Guinea primer/probe sets

Can we talk about this today? If the viral load estimation is correct we would have ridiculously low viral loads in most patients. There is something wrong as many more should survive. I know we have talked about this before but in my view it doesn't make any sense. The CDC Ct values make more sense to me - not saying that there assay is better.

I will try to ask Allen about their Ct values.

We need to talk about multiplex assays as well (malaria and Ebola and eventual Lassa). When is a good time for all of you?

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:14 AM
To: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; De wit, Emmie (NIH/NIAID) [E]
Subject: Re: Ebola primers and probes

If we do that we may want to upadate the primers as there mis-matches. Of course, that wouldn't allow the comparison.

Heinz

----- Original Message -----

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 11:54 AM Eastern Standard Time
To: Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; De wit, Emmie (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola primers and probes

This is the GP assay of the Kenian CDC,

Perhaps we should orders these and see if we get it to work on our platforms and do a comparison.


I know this has been tried in Liberia, but we might have more luck at RML

They were ordered by them through IDT as well,

Vincent

On 9/12/14 7:02 AM, "Fields, Barry (CDC/CGH/DGHP)" <bsf2@CDC.GOV> wrote:

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:49 AM
To: Koita, Ousmane; Sakai, Richard; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; 'amadoukone@icermali.org'; 'ssow@medicine.umaryland.edu'
Subject: Re: Redacted by agreement

Let us know if you need anything.

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 10:47 AM Eastern Standard Time
To: Sakai, Richard; Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: Redacted by agreement

Dear Dick,

I think you are right, I am planning to have an inventory of the stock may be tomorrow morning or Monday.

Best regards,

Ousmane

-----Original Message-----

From: Richard Sakai
Sent: Friday, October 10, 2014 2:44 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: RE: Redacted by agreement

It appears that the stock of some of the testing reagents have been completely used up and the stock of others may also be low. Are there any plans to re-stock the reagent inventory soon?

Dick

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 2:08 PM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: Redacted by agreement

Great job - including the troubleshooting.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:48 AM
To: Pekoc, Ken (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]
Subject: Re: I liked this a lot ... FW: KECI TV: Hamilton scientist works on Ebola diagnosis, vaccine

Great job.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:46 AM Eastern Standard Time
To: Marzi, Andrea (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: I liked this a lot ... FW: KECI TV: Hamilton scientist works on Ebola diagnosis, vaccine

You and Dave both did great jobs with the TV interviews ... relaxed, genuine, and confident in your appearance. Great explanations and talked slowly. Perfect combinations. Thanks for doing these.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:35 AM
To: NIAID RML Users
Subject: KECI TV: Hamilton scientist works on Ebola diagnosis, vaccine

From last night's KECI news broadcast. Video runs 2:37.

<http://www.nbcmontana.com/news/hamilton-scientist-works-on-ebola-diagnosis-vaccine/29043588>

By Andrea Olson, KECI Reporter, aolson@keci.com
Oct. 9, 2014

Hamilton scientist works on Ebola diagnosis, vaccine

MISSOULA, Mont. -

A possible Ebola vaccine called VSV is being developed in Hamilton. It's been tested successfully on hamsters and monkeys.

Rocky Mountain Laboratories has all the components and just needs to run human clinical trials, which will likely happen next summer.

One of the scientists working on VSV at Rocky Mountain Laboratories recently returned from her work with Ebola patients in West Africa.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:46 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: draft THERAMetrics news release

Sounds good.

Please ask them to change to.leading experts in the field of Ebola virus animal modeling'. The way it is written it could be interpreted as Marburg is not a leader in Ebola virus biology, which they actually are.

Best wishes, Heinz

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 09:57 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hoenen, Thomas (NIH/NIAID) [F]
Subject: draft THERAMetrics news release

Hi Heinz ... can you review this and make sure it's ok with you? Afterward I'll send a copy to Kathy and Karyl.

Thomas, my boss and I all have reviewed it. This was initiated by THERAMetrics.

Thanks

Ken Pekoc
Public Affairs Officer
Rocky Mountain Laboratories
NIAID Office of Communications and Government Relations
406-375-9690

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:40 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: draft THERAMetrics news release
Attachments: therametrics rml press release kppw.docx

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 09:57 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hoenen, Thomas (NIH/NIAID) [F]
Subject: draft THERAMetrics news release

Hi Heinz ... can you review this and make sure it's ok with you? Afterward I'll send a copy to Kathy and Karyl.

Thomas, my boss and I all have reviewed it. This was initiated by THERAMetrics.

Thanks

Ken Pekoc
Public Affairs Officer
Rocky Mountain Laboratories
NIAID Office of Communications and Government Relations
406-375-9690

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:40 AM
To: 'Saskia.Gerhard@zeit.de'
Subject: Re: Interview-Inquiry: Ebola-"flight routes"

I am currently away until the end of the month.

According to my colleagues the situation at the airport has been fixed.

Heinz

----- Original Message -----

From: Saskia.Gerhard@zeit.de [mailto:Saskia.Gerhard@zeit.de]
Sent: Friday, October 10, 2014 10:37 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview-Inquiry: Ebola-"flight routes"

Dear Dr. Feldmann,

my name is Saskia Gerhard, I am working for the german ZEIT ONLINE and I am currently working on an article about the possible spread of Ebola via plane flight routes.

I just read your interview on Science News about your stay in Monrovia and I am especially interested in the processes you witnessed at the airport, concerning passenger control and fever measurements.

I would be very happy if we managed to do a short interview. I can send you my questions beforehand if you like.

Thank you and best regards,
Saskia Gerhard

--

Saskia Gerhard | Volontärin Wissen

ZEIT ONLINE, Askanischer Platz 1, 10963 Berlin | www.zeit.de<<http://www.zeit.de>>
saskia.gerhard@zeit.de<<mailto:alina.schadwinkel@zeit.de>>
+49(0)30-322950-165

www.twitter.com/zeitonline_wis<http://www.twitter.com/zeitonline_wis> |
www.facebook.com/zeitonline<<http://www.facebook.com/zeitonline>>

DIE ZEIT jetzt am Kiosk.
www.zeit.de/diesewoche

ZEIT ONLINE - Durchschauen Sie jeden Tag.
www.zeit.de

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:31 AM
To: De wit, Emmie (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: New Guinea primer/probe sets

Can we talk about this today? If the viral load estimation is correct we would have ridiculously low viral loads in most patients. There is something wrong as many more should survive. I know we have talked about this before but in my view it doesn't make any sense. The CDC Ct values make more sense to me - not saying that there assay is better.

I will try to ask Allen about their Ct values.


We need to talk about multiplex assays as well (malaria and Ebola and eventual Lassa). When is a good time for all of you?

Heinz

From: De wit, Emmie (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 10:08 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: New Guinea primer/probe sets

Hi Heinz,

Redacted by agreement



Emmie

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 5:31 PM
To: Munster, Vincent (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: New Guinea primer/probe sets

Not sure if this is true or not. The problem is that they are requesting the labs to report Ct values and I am afraid that our generally high Ct values are going to create problems. We hardly have a patient with a Ct under 20 even 20-25 is getting more rare. What would that be in virus load? Discrepancies in Ct values of up to 10 will be difficult to understand and interpret for physicians and epidemiologists. What would you think about an assay like ours if everybody else reports lower Ct values? We can handle it, but they cannot.

This is rather strange also to me as I never had that in outbreaks before.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:08 AM
To: Koita, Ousmane; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; 'amadoukone@icermali.org'; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Great job - including the troubleshooting.

Heinz

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 09:47 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Dear Heinz,

The test came negative, we did twice. For the first test, the positive control Zaire didn't show any amplification (the two other did). The second test was well done, all the positive controls were positive (Zaire Sudan and Cote d'Ivoire), the negative control (water) and the 2 samples of the specimen 027 were negative. The picture of the screen is attached for your review. The confirmatory test is underway.
So far there is no case of Ebola. We hope it continues that way.

Best regards,

Ousmane

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Friday, October 10, 2014 10:05 AM
To: Ousmane Koita; Polis, Michael (NIH/NIAID) [E]; Bassirou Diarra; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Richard Sakai; Sophia_ Siddiqui; Amadou Kone; 'ssow@medicine.umaryland.edu'
Subject: Re: New suspected case to be tested

Sounds good.

----- Original Message -----

From: Koita, Ousmane
Sent: Friday, October 10, 2014 05:01 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Polis, Michael (NIH/NIAID) [E]; Diarra, Bassirou; Murphy, Robert
Cc: Safronetz, David (NIH/NIAID) [E]; Sakai, Richard; Siddiqui, Sophia (NIH/NIAID) [E]; Amadou Kone <amadoukone@icermali.org>; ssow@medicine.umaryland.edu <ssow@medicine.umaryland.edu>
Subject: RE: New suspected case to be tested

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 8:07 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: EBOLA SPAIN

From: mricart@lavanguardia.es [mailto:mricart@lavanguardia.es]
Sent: Friday, October 10, 2014 09:58 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: EBOLA SPAIN

Hello dr

I'm MARTA RICART, journalist from LA VANGUARDIA, a leader newspaper from BARCELONA, SPAIN
I'm writting an article for our sunday MAGAZINE, a sort of who's who in EBOLA RESEARCH
I liked to know...

Are you working in the vaccine project? i

Why did you choose to work in ebola, not rellevant during lot of time until now?

THANKS

Marta Ricart
Magazine-La Vanguardia
Barcelona
00 34 934 812 397
mricart@lavanguardia.es

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 7:24 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Fw: mers update

What should I tell him? Are we proceeding with this study?

From: Dimitrov, Dimiter (NIH/NCI) [E]
Sent: Thursday, October 09, 2014 08:34 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: gogotily@gmail.com <gogotily@gmail.com>
Subject: mers update

Heinz,

any update on the mers ab? Also I have my site visit on nov13 and suppose not a problem to show one slide from the mers ab data as a preliminary indication for efficacy?

Tianlei sent me an email - below - suggesting that others are going to publish some results on structures and animal studies perhaps combined. I know you are probably overwhelmed with Ebola but still.

Dear Mitko,

I am attending a meeting at which Dr. Xinquan Wang who just gave a lecture about the Mers RBD- antibody complex structure. They got the complex structure of RBD with Linqi's MERS-27. Both heavy and light chains interact with RBD. They also found that the TRP535 of RBD interact both the antibody and the Carbohydrate moiety of asn229 of DPP4. They even compared with our antibodies, and believe that their antibody MERS-27 binds to the patch 1 of RBD, while our antibodies as well as Wayne's antibody all bind to Patch2 of RBD. Very nice work.

Unfortunately we fell behind again. I believe they already submitted the paper. I talked to him and they also finished the animal studies but did not tell me more details. I do not know whether they combined the animal data with structural or submitted separately. Anyway seems we have to catch up.

Best wishes
Tianlei

Best wishes
Mitko

Dimiter S Dimitrov
301 846 1352 office
<http://ccr.cancer.gov/staff/staff.asp?profileid=5749>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 5:06 AM
To: 'harvey.artsob@videotron.ca'; 'twgeisbe@UTMB.EDU'; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Ebola - general information

Dear ALL,
Harvey needs some information but I do not have access to it here in Monrovia.

Tom - can you please send him the pdf of the latest Fields chapter?

Andrea, Darryl and Thomas, please send him pdfs of your latest review articles.

Please copy me if you do not mind.

Many thanks,
Heinz

From: Harvey [mailto:harvey.artsob@videotron.ca]
Sent: Thursday, October 09, 2014 01:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - general information

Heinz,

I hope this e-mail finds you well.

I have been asked to write about Ebola for an online news source.

By way of introduction, I would like to give a brief background on Ebola including history, different strains, outbreaks since 1976 and geographic distribution. I am not looking for any great detail.

Would you happen to have any information that you could share with me?

Harvey


Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 5:03 AM
To: 'harvey.artsob@videotron.ca'
Subject: Re: Ebola - general information

Harvey,

Good to hear from you. I am currently in Monrovia for the Ebola outbreak - supposed to return on November 1. I do not have much with me here but I will ask Tom to send you the latest Fields chapter and Darryl, Andrea and Thomas to send you more recent review articles. Regarding outbreaks and numbers you may want to go on the CDC and WHO websites - they usually keep track.

Personal Info



Best wishes,
Heinz

From: Harvey [mailto:harvey.artsob@videotron.ca]
Sent: Thursday, October 09, 2014 01:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola - general information

Heinz,

I hope this e-mail finds you well.

I have been asked to write about Ebola for an online news source.

By way of introduction, I would like to give a brief background on Ebola including history, different strains, outbreaks since 1976 and geographic distribution. I am not looking for any great detail.

Would you happen to have any information that you could share with me?

Harvey

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 4:24 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: Text für die Pressemitteilung zur Freigabe und Presseanfrage
Attachments: PM_Zoonosensymposium-2014_16-10-2014_de_v02_IS.docx

From: Semmler, Ilia [mailto:Ilia.Semmler@tmf-ev.de]
Sent: Thursday, October 09, 2014 03:32 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Text für die Pressemitteilung zur Freigabe und Presseanfrage

Lieber Heinz,

ich hoffe, du bist wohlauf. Die Vorbereitungen für das Symposium sind hier im vollen Gange. Auch der Ebola-Talk kann wohl gehalten werden: von Maximilian Gertler, MSF (jetzt so gut wie sicher). Wir werden dazu aus Zeitgründen lediglich die Preisverleihung und den Ebola-Talk tauschen müssen. Ich werde dazu, wenn es morgen hoffentlich tatsächlich fix, ist noch eine Info-Mail an dich, Juergen und Vikki/Lynn schicken.

Ich habe noch zwei Fragen bzw. Bitten an dich.

Im Anhang sende ich dir den Text für die Pressemitteilung, die wir am Donnerstag zum Symposium versenden wollen. Darin haben wir Ausschnitte aus dem Interview, das du Frau Sartori gegeben hast verwendet (auf deutsch übersetzt – in die gleichzeitig erscheinende englische Pressemitteilung kommen natürlich die Originalzitate, die du von Frau Sartori noch zur Freigabe bekommen wirst). Wir möchten nur sicher gehen, dass sie dir in dem Kontext recht sind.

Außerdem hat sich bei mir Volkart Wildermuth vom Deutschlandfunk (Forschung aktuell; Radio) gemeldet. Er ist ein absolut seriöser Journalist, mit dem ich schon öfter zu tun hatte und von dem ich sehr viel halte. Er wollte dich eigentlich gerne am Rande des Symposiums interviewen. Ich habe ihm nun gesagt, dass du leider gar nicht dort sein wirst. Könntest du dir vorstellen, per Skype oder Telefon mit ihm zu sprechen? (Ehrliche Antwort – wir alle haben Verständnis, wenn es nicht geht.)

Viele Grüße und pass auf dich auf!

Ilia

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 4:24 AM
To: 'Victoria.Jensen@NBACC.DHS.GOV'
Subject: Re: Endothelial activation by VP40/GP

Thanks Vicki.

From: Jensen, Victoria M. (CTR) [mailto:Victoria.Jensen@NBACC.DHS.GOV]
Sent: Thursday, October 09, 2014 06:06 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Endothelial activation by VP40/GP

Records Originating Outside of NIAID

From: Lin, Charles [mailto:Charles_Lin@DFCI.HARVARD.EDU]
Sent: Thursday, October 09, 2014 5:49 PM
To: Jensen, Victoria M. (CTR)
Subject: Endothelial activation by VP40/GP

Dr. Wahl-Jensen,

Redacted by agreement

Redacted by agreement

Would you be willing to provide these reagents for us? We can assist in any way possible to expedite shipping.

We would also be happy to discuss more over the phone.

Regards,

Charles Lin
617-276-4723

Charles Y. Lin, Ph.D.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 4:23 AM
To: Redacted by agreement
Subject: Re: Hallo

Redacted by agreement

Redacted by agreement

Redacted by agree

From: Redacted by agreement
Sent: Friday, October 10, 2014 03:33 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Hallo

Redacted by agreement

2014-10-09 1:49 GMT+02:00 Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>:

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 4:06 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses
Attachments: Prof Feldmann Interview 06 10 14_en_angenommen.docx

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Friday, October 10, 2014 05:14 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Last time: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz,

ich hoffe Sie sind wohlbehalten aus Liberia zurückgekehrt.

Anbei die endgültige Version für das Interview, das begleitend zum German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses im Internet veröffentlicht werden soll. Können Sie es bis Montag durchsehen, Ihre Änderungswünsche eintragen und freigeben? Das wäre sehr hilfreich, um es noch rechtzeitig zur Konferenz einzustellen.

Haben Sie ein Foto von sich das wir verwenden können? Auf der Website ist eins

<http://www.zoonoses2014.com/#!/welcome/c23yr>

wenn Sie einverstanden sind, nehmen wir das. Und haben Sie eventuell ein Foto vom Ebola Virus, dass wir mit dem Interview verwenden könnten?

Freundliche Grüße
Christina Sartori

Dipl.-Biol. Christina Sartori

Wissenschafts-Journalistin
info@christina-sartori.de
Mobil: Personal Info
Telefon: 030 - 89391473

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 4:04 AM
To: 'Ilia.Semmler@tmf-ev.de'; 'jricht@vet.k-state.edu'; 'zoo@target-conferences.com'; 'Lothar.Wieler@fu-berlin.de'; 'Sebastian.Semler@tmf-ev.de'; 'ludwigs@uni-muenster.de'; 'martin.groschup@fli.bund.de'; 'no34@cornell.edu'; 'no.34@fu-berlin.de'; 'NiedrigM@rki.de'
Subject: Re: Zoonoses Conference - Berlin - Update Ebola Talk

Sounds good.

From: Semmler, Ilia [mailto:Ilia.Semmler@tmf-ev.de]
Sent: Friday, October 10, 2014 04:47 AM Eastern Standard Time
To: 'Juergen Richt' <jricht@vet.k-state.edu>; Feldmann, Heinrich (NIH/NIAID) [E]; ZOO (zoo@target-conferences.com) <zoo@target-conferences.com>; Wieler, Lothar H. <Lothar.Wieler@fu-berlin.de>; Semler, Sebastian <Sebastian.Semler@tmf-ev.de>; Ludwig, Stephan <ludwigs@uni-muenster.de>; Groschup, Martin H. <martin.groschup@fli.bund.de>; 'Nikolaus Osterrieder' <no34@cornell.edu>; 'no.34@fu-berlin.de' <no.34@fu-berlin.de>; Niedrig, Matthias <NiedrigM@rki.de>
Subject: Zoonoses Conference - Berlin - Update Ebola Talk

Dear all,

to update you all: we finally have Max Gertler (MSF) for the Ebola-Talk. He made some huge efforts to make it possible.

The session at a glance:

Thursday, Oct 16

- 16:00 - Award from the AfT to Fabian Leendertz
- Ca. 16:10 - Talk Fabian Leendertz. He will split his talk into three parts: 1) thanks for the award (5min), 2) about his research, he got the award (main part), 3) about the animal reservoir of Ebola, and hopefully, of his insights into the reservoir and first transmission resulting in this outbreak, which came from a small village in Guinea.
- 16:45 - 17:30 (incl. discussion) - The Current Ebola Virus Outbreak in West Africa, Maximilian Gertler (Médecins sans Frontières)

By the way: we still **don't have a chairman** for this session. Would someone of you make it? It would be great, if it is mentioned, that it was hard to get someone to talk, because all capacities regarding Ebola (diagnosis or treatment) of Germany, Europe and USA seem to be in West Africa at the moment. I think, this would show, who deep researchers and doctors are involved in this outbreak (I am sure, there will be some journalists in the room during this session).

We will prepare a sheet with the updated program and the names of the speakers as a hand out onsite.

Best regards
Ilia

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 10, 2014 3:34 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: Unpublished
Attachments: Unpublished

From: Safronetz, David (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 09:32 PM Eastern Standard Time
To: Rosenke, Kyle (NIH/NIAID) [F]; Feldmann, Ricki (NIH/NIAID) [C]; Haddock, Elaine (NIH/NIAID) [E]; twgeisbe@UTMB.EDU <twgeisbe@UTMB.EDU>; chmire@UTMB.EDU <chmire@UTMB.EDU>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished

Dear all,

Unpublished

Dave

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 11:01 AM
To: Personal Info
Cc: 'jricht@vet.k-state.edu'
Subject: Re: Request to Speak

I do not know any Dr. Logan. I don't have any contact to clinical treatment centers others than MSF. I can talk to the LIBR colleagues when I meet them.

From: Personal Info
Sent: Thursday, October 09, 2014 12:38 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: jricht@vet.k-state.edu <jricht@vet.k-state.edu>
Subject: Re: Request to Speak

Hi Heinz,

I hope all is going well there with you.


In addition to contacting MSF and WHO, Hemispherx is trying to get into direct contact with Dr. Gorbee Logan, the Liberian physician who successfully treated Ebola patients with a nucleoside reverse transcriptase inhibitor. Although he is located in Bomi county, he is reported to have sent samples to the Liberian Institute of Biological Research (LIBR) which I gather from news reports is one of if not the main center for testing samples for suspected Ebola patients. Dr. Carter assumes that you have some connection with with LIBR and perhaps with Dr. Logan himself. Dr. Carter would like your assistance in simply trying to find out how we can reach Dr. Logan directly either by phone or email. After several hours of searching, I was unable to find either. Nor was I able to find a phone number at the Bomi County health Department which Dr. Logan heads. By email to their sites, I have contacted the Monrovia Observer and one of its writers who interviewed Dr. Logan as well as the Liberian Minister of Health and Social Welfare but I have heard from neither.

Dr. Carter understands the limits of what you can do and is asking only for your assistance in helping identify how we can connect directly with Dr. Logan.

Thank you very much.

Wayne

In a message dated 10/7/2014 6:51:37 P.M. Eastern Daylight Time, Personal Info writes:




Okay. Thanks for the guidance.

Best regards,

Wayne

In a message dated 10/7/2014 6:27:16 P.M. Eastern Daylight Time, feldmannh@niaid.nih.gov writes:



As mentioned before you need to contact the groups and agencies that are responsible for patient care. You should contact MSF (doctors without borders) and WHO (World Health Organization). They do coordinate treatment and vaccines. I cannot get involved in this in my position. I also do not propose any treatment or vaccine that I do not know in terms of animal efficacy data

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 10:56 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Fw: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc
Attachments: MTA from NIAID, NIH 10092014.PDF

Do we have the Kikwit clones? Can you please communicate with him on the plasmids?

Thanks, Heinz

From: Chil-Yong Kang [mailto:cykang@uwo.ca]
Sent: Thursday, October 09, 2014 12:16 PM Eastern Standard Time
To: Menk, Kay (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; sklee@curocom.com <sklee@curocom.com>
Subject: 회신: RE: MTA_15-LV-03_AM Siebens Drake Medical Research Inst..doc

Dear Kay,

I trust this email finds you well.

Attached please find the MTA signed by our Provost and Vice President (Academic), Dr. Janice Deakin, and myself.

I asked Dr. Heinz Feldmann to send us appropriate clones of Zaire ebolavirus Mayinga 1976 strain. I wonder whether or not we can also receive the Kikwit 1995 strain as well.

Please let me know should you require any additional information.

With best regards and thanks,

Yong

Dr. C. Yong Kang, FRSC

Professor of Virology

Department of Microbiology and Immunology

Schulich School of Medicine and Dentistry

Siebens-Drake Medical Research Institute

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 10:50 AM
To: YOSHIHIROKAWAOKA
Subject: Fw: Influenza researcher Yoshihiro Kawaoka wins Breakthrough Award

Congratulations - wee deserved.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 10:50 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Ebihara, Hideki (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]
Subject: Influenza researcher Yoshihiro Kawaoka wins Breakthrough Award

This is nice.

Influenza researcher Yoshihiro Kawaoka wins Breakthrough Award

Oct. 7, 2014

by [Kelly April Tyrrell](#)

The University of Wisconsin-Madison's [Yoshihiro Kawaoka](#) has been recognized as a 2014 Popular Mechanics Breakthrough Award recipient for his efforts to understand and prevent pandemic influenza.

He joins a list of prominent innovators, scientists and engineers selected for the award over the past decade for their world-changing contributions, including: SpaceX and Tesla Motors CEO Elon Musk; XPRIZE Foundation founder Peter Diamandis; and humanitarian engineer Amy Smith.

"I am just so happy," says Kawaoka, a UW-Madison professor of veterinary medicine who studies influenza and Ebola viruses. "I think I don't believe it."

In recent years, Kawaoka has found himself at the center of controversy surrounding research on highly pathogenic influenza and other sensitive pathogens known as select agents. His studies to understand, monitor, treat and potentially prevent pandemic influenza have often been misrepresented and misunderstood.

However, according to Popular Mechanics — a science and technology-focused magazine published by Hearst Magazines — Kawaoka was chosen despite the controversy because his work studying mutations in viruses that are currently found in nature and carry pandemic potential could "help protect humanity."

"We know Ebola is a big issue in Africa right now, but Kawaoka's investigations into influenza — which is in fact a constant and greater threat to public health in the United States — could help us avoid or beat back the type of flu viruses that have erupted into deadly pandemics in the past," says Ryan D'Agostino, Popular Mechanics editor-in-chief.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 10:46 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

Thanks.

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Thursday, October 09, 2014 10:54 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

Doxycycline did NOT work in hamsters. At all. At the recommended dose. It has a little bit of an effect in vitro. Not sure what would happen if you give a huge dose in vivo.

I am not sure what you mean about IFN/ribavirin. All the animals are gone. I am just preparing a summary of survival and PCR data for Kathy. I will also send to you.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:30 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Fw: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

They are asking about doxycyclin. I thought you did that in hamsters, did you?

What's the deal with the ribavirin/interferon study? I don't think we should continue.

Heinz

----- Original Message -----

From: Mielke, Martin [mailto:MielkeM@rki.de]
Sent: Thursday, October 09, 2014 03:50 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Kuhn, Jens (NIH/NIAID) [C]
Cc: Sekretariat Abt1 <SekretariatAbt1@rki.de>; Kurth, Andreas <KurthA@rki.de>; Burger, Reinhard <BurgerR@rki.de>; Schaade, Lars <SchaadeL@rki.de>
Subject: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

Sehr geehrter Herr Feldmann, sehr geehrter Herr Kuhn,

ich bin Kollege von Herrn Kurth am Robert Koch-Institut in Berlin und wende mich an Sie mit der Bitte um Ihre Einschätzung eines frühzeitigen Einsatzes von Doxycyclin im Rahmen des aktuellen Ebolaausbruchs in Westafrika im Hinblick auf den Versuch, die Letalität im Rahmen des Geschehens zu senken.

Zur Begründung führe ich an:

1) Die von Ihnen gut untersuchte Cytokin-vermittelte Pathogenese der EBOV Infektion (s. Anlagen)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 8:04 AM
To: 'ali.khan@unmc.edu'
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Subject: Fw: Fw: CMX-001 or [REDACTED]

Redacted by
agreement

Ali,
I talked to MSF - first Armand Sprecher and then the Monrovia Medical Lead Coordinator. He confirmed what Armand says in his response below. As you know Armand, please feel free to contact him directly - I did copy him on this email.

Let me know if I can be of further help.

Heinz

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Wednesday, October 08, 2014 07:24 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Fw: CMX-001 or [REDACTED]

Redacted by
agreement

Hi Heinz,

I remember Ali, and I even worked in the emergency room at UNMC for a while.

The short answer is that all MSF involvement in clinical trials is being organized through a research consortium set up via a Wellcome Trust grant that has MSF, ISARIC, WHO, some drug companies, and a host of other people. CDC is even nominally onboard (I think in the form of Tim Uyeki). Any trial would need to be organized through this group. The short list of candidate agents is being organized by WHO, and these two may well be on the list.

I imagine that ELWA 3 will get a visit at some point by some of the ISARIC people who are scoping out trial sites.

Our lead on this is Annick Antierens. I can put Ali in touch with her if he is interested.

Hope Monrovia is treating you well - Armand

Armand Sprecher MD MPH
Public Health Specialist
Médecins Sans Frontières
Operational Center of Brussels

-----"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote: -----

To: "Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)"
<armand.sprecher@brussels.msf.org>

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>

Date: 10/08/2014 05:39AM

Subject: Fw: CMX-001 or [REDACTED]

Redacted by
agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:59 AM
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Subject: Re: Fw: CMX-001 or [REDACTED]

Redacted by
agreement

Thanks Armand - this very helpful.

Heinz

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Wednesday, October 08, 2014 07:24 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Fw: CMX-001 or [REDACTED]

Redacted by
agreement

Hi Heinz,

I remember Ali, and I even worked in the emergency room at UNMC for a while.

The short answer is that all MSF involvement in clinical trials is being organized through a research consortium set up via a Wellcome Trust grant that has MSF, ISARIC, WHO, some drug companies, and a host of other people. CDC is even nominally onboard (I think in the form of Tim Uyeki). Any trial would need to be organized through this group. The short list of candidate agents is being organized by WHO, and these two may well be on the list.

I imagine that ELWA 3 will get a visit at some point by some of the ISARIC people who are scoping out trial sites.

Our lead on this is Annick Antierens. I can put Ali in touch with her if he is interested.

Hope Monrovia is treating you well - Armand

Armand Sprecher MD MPH
Public Health Specialist
Médecins Sans Frontières
Operational Center of Brussels

-----"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote: -----

To: "Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)"
<armand.sprecher@brussels.msf.org>
From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
Date: 10/08/2014 05:39AM
Subject: Fw: CMX-001 or [REDACTED]

Redacted by
agreement

Armand,

Do you think ELWA 3 would be interested and can do this? I can talk to Ruggerio but wanted to ask you first. You may remember Ali - he was former CDC, now Dean of the Omaha Medical School. Please let me know as soon as possible.

I can also call if you prefer.

Best wishes, Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:45 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: tentative team schedule
Attachments: Planning Ebola laboratory teams.xlsx

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 12:04 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: De wit, Emmie (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: tentative team schedule

Hi Heinz,

Please have a look at the schedule and provide us with feedback,

Of note, this schedule has you staying until first of November,

Hope all is well,

Vincent Munster
Chief, Virus Ecology Unit
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH
903 South 4th street
Hamilton, MT 59840
[406-375-7489](tel:406-375-7489)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:39 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw: VSV-vaccine protocol
Attachments: 01014 NIH-RML 10-02-14 .doc

From: Sabrina Boyer [mailto:sabrina.boyer@phac-aspc.gc.ca]
Sent: Wednesday, October 08, 2014 03:58 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Chris Peterson <chris.peterson@phac-aspc.gc.ca>; Dorothea Blandford <Dorothea.Blandford@phac-aspc.gc.ca>
Subject: RE: VSV-vaccine protocol

Hi Heinz,

I've prepared the collaboration agreement for review and consideration of NIH-RML. I would ask that you "track your changes", if there are any, and return your comments to Chris Peterson; he has been cc'd on this email.

With thanks
Sabrina

Sabrina Boyer
Manager, Technology Transfer
Office of the Chief Science Officer/Bureau du Conseiller scientifique principal
Public Health Agency of Canada/ Agence de la santé publique du Canada
1015 Arlington Street
Winnipeg, MB R3E 3R2
Phone: (204) 789-2120
Fax: (204) 789-2097
Email: sabrina.boyer@phac-aspc.gc.ca



Public Health
Agency of Canada

Agence de la santé
publique du Canada

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: 'Sabrina Boyer' <sabrina.boyer@phac-aspc.gc.ca>, Jim Strong <Jim.Strong@phac-aspc.gc.ca>
Date: 2014-09-30 06:07 PM
Subject: RE: VSV-vaccine protocol

Sabrina,

Please send the document to me and I will forward it to the appropriate people.

Hope things are going well for you.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:32 AM
To: 'domsjvi@lists.upenn.edu'
Subject: Unpublished

I am currently away for the Ebola outbreak with only limited internet access. Therefore, I have decline the request.

Best wishes, Heinz

From: asm@msubmit.net [mailto:asm@msubmit.net]
Sent: Wednesday, October 08, 2014 10:00 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished

Dear Dr. Feldmann,

Unpublished

Please note that the due date for the review is 14 days after the date you accept this invitation. If you don't think you can complete the review by the due date, please decline this request via the eJP website (see link below) and if possible, suggest others who you think would be good reviewers for this study. We are doing our best to improve turnaround times at the Journal of Virology, so if you can review the paper by the due date, this will be of great help in making JVI a more attractive journal in which to publish. If you would like to have a junior member of your laboratory help review the paper, please let me know in advance. It is important to maintain confidentiality and transparency of the review process. The abstract appears at the end of this message.

If you AGREE to review this manuscript, we ask that you submit your comments within 14 days. I will be notified automatically of your response, and if you agree to do the review, the entire manuscript will be made available to you. Your prompt response will speed up the review process quite a bit and help me keep track of the papers I am responsible for. You can ACCEPT the invitation by clicking the link below:

[http://](#)Unpublished

If you are unable to review this manuscript or feel that you may have a conflict of interest, you can DECLINE by clicking the link below:

[http://](#)Unpublished

If you cannot review the manuscript, I would appreciate your suggestions for colleagues who may be able to do so. You may make your suggestions when you click the "Decline" link above.

If you accept the invitation via the ACCEPT link above, you can access the full manuscript in PDF format and

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:30 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Fw: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?
Attachments: Feldmann EBOV Cytokines.pdf; Ebola Pathogenese 1.pdf; EBOV Pathogenese.pdf; Tetracycline Cytokines.pdf; Tetracyclines human monocytes.pdf; Malaria Tetracycline.pdf

They are asking about doxycyclin. I thought you did that in hamsters, did you?

What's the deal with the ribavirin/interferon study? I don't think we should continue.

Heinz

----- Original Message -----

From: Mielke, Martin [mailto:MielkeM@rki.de]
Sent: Thursday, October 09, 2014 03:50 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Kuhn, Jens (NIH/NIAID) [C]
Cc: Sekretariat Abt1 <SekretariatAbt1@rki.de>; Kurth, Andreas <KurthA@rki.de>; Burger, Reinhard <BurgerR@rki.de>; Schaade, Lars <SchaadeL@rki.de>
Subject: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

Sehr geehrter Herr Feldmann, sehr geehrter Herr Kuhn,

ich bin Kollege von Herrn Kurth am Robert Koch-Institut in Berlin und wende mich an Sie mit der Bitte um Ihre Einschätzung eines frühzeitigen Einsatzes von Doxycyclin im Rahmen des aktuellen Ebolaausbruchs in Westafrika im Hinblick auf den Versuch, die Letalität im Rahmen des Geschehens zu senken.

Zur Begründung führe ich an:

- 1) Die von Ihnen gut untersuchte Cytokin-vermittelte Pathogenese der EBOV Infektion (s. Anlagen)
- 2) Die Effekte von Doxycyclin auf die Cytokinausschüttung (s. Anlagen)
- 3) Die Wirkung von Doxycyclin auf die Malaria (s. Anlage)

Ich würde mich freuen, Ihre Einschätzung zu einem möglichst frühzeitigen Einsatz bei Patienten mit Verdacht auf eine EBOV-Infektion (DD Malaria) zu kennen.

Mit den besten Grüßen und Dank,
Martin Mielke

PS: Lieber Herr Kuhn, vielleicht erinnern Sie sich noch an die gemeinsame Reise zum Treffen der Nobelpreisträger am Bodensee und die Zeit bei Herrn Hahn. Ich hatte dort vor vielen Jahren über den Einfluss von Antibiotika auf die Cytokinantwort promoviert.

Prof. Dr. med. Martin Mielke

Robert Koch-Institut
Leiter der Abteilung 1, Abteilung für Infektionskrankheiten

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:28 AM
To: 'MielkeM@rki.de'
Subject: Re: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

Kann ich nicht viel zu sagen. Redacted by agreement. In Sachen Ebolabehandlung muessen Sie sich an eine spezielle Kommission richten - die WHO spielt eine Hauptrolle in dieser Sache.

Heinz Feldmann

----- Original Message -----

From: Mielke, Martin [mailto:MielkeM@rki.de]
Sent: Thursday, October 09, 2014 03:50 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Kuhn, Jens (NIH/NIAID) [C]
Cc: Sekretariat Abt1 <SekretariatAbt1@rki.de>; Kurth, Andreas <KurthA@rki.de>; Burger, Reinhard <BurgerR@rki.de>; Schaade, Lars <SchaadeL@rki.de>
Subject: Einsatz von Doxycyclin im Rahmen des Ebola Ausbruchs in Westafrika ?

Sehr geehrter Herr Feldmann, sehr geehrter Herr Kuhn,

ich bin Kollege von Herrn Kurth am Robert Koch-Institut in Berlin und wende mich an Sie mit der Bitte um Ihre Einschätzung eines frühzeitigen Einsatzes von Doxycyclin im Rahmen des aktuellen Ebolaausbruchs in Westafrika im Hinblick auf den Versuch, die Letalität im Rahmen des Geschehens zu senken.

Zur Begründung führe ich an:

- 1) Die von Ihnen gut untersuchte Cytokin-vermittelte Pathogenese der EBOV Infektion (s. Anlagen)
- 2) Die Effekte von Doxycyclin auf die Cytokinausschüttung (s. Anlagen)
- 3) Die Wirkung von Doxycyclin auf die Malaria (s. Anlage)

Ich würde mich freuen, Ihre Einschätzung zu einem möglichst frühzeitigen Einsatz bei Patienten mit Verdacht auf eine EBOV-Infektion (DD Malaria) zu kennen.

Mit den besten Grüßen und Dank,
Martin Mielke

PS: Lieber Herr Kuhn, vielleicht erinnern Sie sich noch an die gemeinsame Reise zum Treffen der Nobelpreisträger am Bodensee und die Zeit bei Herrn Hahn. Ich hatte dort vor vielen vielen Jahren über den Einfluss von Antibiotika auf die Cytokinantwort promoviert.

Prof. Dr. med. Martin Mielke

Robert Koch-Institut
Leiter der Abteilung 1, Abteilung für Infektionskrankheiten

Nordufer 20
13353 Berlin

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 09, 2014 7:23 AM
To: 'Victoria.Jensen@NBACC.DHS.GOV'
Subject: Fw: Ebola concept (confidential)
Attachments: Brown_Lin_et_al_2014.pdf

Hi Vicki,

I hope things are going well. Perhaps you can help the people below as I am back in Monrovia.

Best wishes, Heinz

From: Bradner, James E.,M.D. [mailto:James_Bradner@DFCI.HARVARD.EDU]
Sent: Thursday, October 09, 2014 05:37 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Brown, Jonathan David,M.D. <JBROWN0@PARTNERS.ORG>; Charles Lin Lin
Subject: Ebola concept (confidential)

Personal Info

Dr. Feldmann.

My laboratory at the Dana-Farber Cancer Institute has recently become very interested in endothelial cell activation. We published last week a fine study on EC activation in atherosclerosis (attached). Owing to the present crisis of the Ebola pandemic, we are motivated to assess BET bromodomain inhibition in Ebola-mediated EC activation and in vivo pathogenesis.

As a chromatin/chemistry/cancer laboratory, we are highly motivated to work collaboratively. Immediately, Jon and Charles (postdocs, cc'd) would like to test a few chromatin-active drugs in the VP40/GP pro-inflammatory activation model you published in 2005 (Wahl-Jensen et.al.).

Could you kindly provide plasmids and simple protocols for their experimental use (expression/purification/administration)?

I would gladly speak by phone, if desired.

Best.

Jay Bradner

James Bradner, MD
Dana-Farber Cancer Institute

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 5:44 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

Not yet but he did not answer my last two emails either. I asked the CDC people here in Monrovia and they did not know anything.

I will send a few emails to try to find out.

Heinz

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 07:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

We can check

What is CDC doing about this for their teams? We should be held to the same standards. Have you checked with Stuart?

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 06:45 PM Eastern Standard Time
To: Pekoc, Ken (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

Thanks. Can NIH do something for us to get through easier. We are under the control of OMS - would that help?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 03:56 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]
Subject: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

FYI

From: MMWR Media List [<mailto:MMWR-MEDIA@LISTSERV.CDC.GOV>] On Behalf Of Media@cdc.gov (CDC)
Sent: Wednesday, October 08, 2014 3:31 PM
To: MMWR-MEDIA@LISTSERV.CDC.GOV

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 5:42 PM
To: 'caroline.kim@axonadvisors.com'
Subject: Re: Paid Conference Call RE: Ebola Virus

No - I don't.

From: Caroline Kim [<mailto:caroline.kim@axonadvisors.com>]
Sent: Wednesday, October 08, 2014 07:08 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Paid Conference Call RE: Ebola Virus

Dr. Feldmann,

Thank you for letting me know. Do you have anybody you can recommend for this call?

Best,
Caroline

Caroline Kim
Research Project Manager
+1 646 502 5065 (Direct)

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Wednesday, October 8, 2014 6:58 PM
To: Caroline Kim
Subject: Re: Paid Conference Call RE: Ebola Virus

I am not available for the rest of this month.

From: Caroline Kim [<mailto:caroline.kim@axonadvisors.com>]
Sent: Wednesday, October 08, 2014 05:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Paid Conference Call RE: Ebola Virus

Dr. Feldmann,

We talked on the phone briefly last week about this request for a conference call. I know you said you would be away from the office, but wanted to see if you might have any 1 hour slots next week (as the deadline of this project has been extended). Our clients have requested you by name as the top expert in this area and so would very much appreciate the opportunity to speak to you, if at all possible. We have an advised topics to be discussed from the below.

- A brief summary of Ebola Virus, what it does, where it comes from and what is happening in Africa.
- Why is this outbreak so much worse than prior outbreaks? What is different and why?
- How much is known and certain and inevitable about the epidemic and how much is still "up in the air"?
- Is the situation under control in Africa? What are the continuing risks in Africa and the likely outcome?
- What are the medical and economic risks to the US, to Europe and to other countries?
- What public health measures are being taken in Africa? What measures are being taken outside Africa? What others might be contemplated or considered?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 5:41 PM
To: 'dzimmerman@cel-sci.com'; Marzi, Andrea (NIH/NIAID) [E]; 'hfeldmann@niaid.nih.gov'
Subject: Re: As suggested by Dr. Subbarao FW: Wild idea of using LEAPS for Ebola

I am currently in Monrovia for the rest of the month. If still interested, please contact me again in November.

Heinz

From: Dan Zimmerman [mailto:dzimmerman@cel-sci.com]
Sent: Wednesday, October 08, 2014 07:08 PM Eastern Standard Time
To: Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; hfeldmann@niaid.nih.gov
<hfeldmann@niaid.nih.gov>
Subject: As suggested by Dr. Subbarao FW: Wild idea of using LEAPS for Ebola

Dear Dr Feldmann

As suggested in her email below Dr Subbarao suggested I contact you regarding an idea we had which is along the lines of an approach we successfully used for a immune-therapeutic for influenza. The suggestion to Dr Subbarao is below her reply to me in my email to her. I also am attaching a copy of the published study done in Dr Subbarao's lab using LEAPS immunotherapeutic agents and a summary document on the LEAPS immunotherapeutic vaccines / agents.

Dan

Daniel H Zimmerman, Ph.D.
Senior Vice President Research and Development, Cellular Immunology CEL-SCI Corporation
8229 Boone Blvd, Suite 802 Vienna VA 22182
Office 703-506-9460 Fax 703-506-9471 Lab 410-358-6866 Lab Fax 410-358-1647
dzimmerman@cel-sci.com

This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by reply e-mail and delete the message and any attachments from your system.

-----Original Message-----

From: Subbarao, Kanta (NIH/NIAID) [E] [mailto:KSUBBARAO@niaid.nih.gov]
Sent: Wednesday, October 08, 2014 3:09 PM
To: Dan Zimmerman
Subject: Re: Wild idea of using LEAPS for Ebola

Dear Dan-

I suggest you contact Heinz Feldmann at the Laboratory of Virology, Rocky Mountain Labs, NIAID about this idea.

Best wishes-

Kanta

--

Kanta Subbarao, MD, MPH
Chief, Emerging Respiratory Viruses Section Laboratory of Infectious Diseases, NIAID, NIH Bldg 33, Room 3E13C.1,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 4:58 PM
To: 'caroline.kim@axonadvisors.com'
Subject: Re: Paid Conference Call RE: Ebola Virus

I am not available for the rest of this month.

From: Caroline Kim [mailto:caroline.kim@axonadvisors.com]
Sent: Wednesday, October 08, 2014 05:52 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Paid Conference Call RE: Ebola Virus

Dr. Feldmann,

We talked on the phone briefly last week about this request for a conference call. I know you said you would be away from the office, but wanted to see if you might have any 1 hour slots next week (as the deadline of this project has been extended). Our clients have requested you by name as the top expert in this area and so would very much appreciate the opportunity to speak to you, if at all possible. We have an advised topics to be discussed from the below.

- A brief summary of Ebola Virus, what it does, where it comes from and what is happening in Africa.
- Why is this outbreak so much worse than prior outbreaks? What is different and why?
- How much is known and certain and inevitable about the epidemic and how much is still "up in the air"?
- Is the situation under control in Africa? What are the continuing risks in Africa and the likely outcome?
- What are the medical and economic risks to the US, to Europe and to other countries?
- What public health measures are being taken in Africa? What measures are being taken outside Africa? What others might be contemplated or considered?
- What are the risks from the case in Dallas? What measures should businesses take with respect to those risks today?
- What should investors look for as signals that things are improving? In Africa? In the US? What are the first signs that things are deteriorating?
- How predictable are the outcomes from this situation? What could go right and better than expected? What could go wrong and worse than expected?

Please let me know!

Best,
Caroline

Caroline Kim
Research Project Manager
+1 646 502 5065 (Direct)

From: Caroline Kim
Sent: Friday, October 3, 2014 12:47 PM
To: 'feldmannh@niaid.nih.gov'
Subject: Paid Conference Call RE: Ebola Virus

Dear Dr. Feldmann,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 4:48 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: IFN/ribavirin NHP update


Tom largely does the Profectus work. We still do some work together with Tom, but we are focusing on the dewltaG construct.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 04:31 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update

Heinz
Are you working with Tom Geisbert on the VSV ebola vaccine or just LV?
Kathy

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 11:14 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update

Redacted by agreement



These are the current plans for the near future. Other study may follow.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: IFN/ribavirin NHP update

Heinz
Niaid wants have a meeting to coordinate the ebola work. Please send me a list of all the ongoing and planned studies we are going to do at RML.
Thank you

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 07:45 PM Eastern Standard Time

Feldmann, Heinrich (NIH/NIAID) [E]


From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 4:45 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]
Subject: Re: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

Thanks. Can NIH do something for us to get through easier. We are under the control of OMS - would that help?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 03:56 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]
Subject: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES

FYI

From: MMWR Media List [<mailto:MMWR-MEDIA@LISTSERV.CDC.GOV>] On Behalf Of Media@cdc.gov (CDC)
Sent: Wednesday, October 08, 2014 3:31 PM
To: MMWR-MEDIA@LISTSERV.CDC.GOV
Subject: Press Release: ENHANCED EBOLA SCREENING TO START AT FIVE U.S. AIRPORTS FOR ALL PEOPLE ENTERING U.S. FROM EBOLA-AFFECTED COUNTRIES



CDC Media Relations
406-639-3286



DHS Office of Public Affairs
202-282-8010

Press Release

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 4:42 PM
To: 'halfmanp@svm.vetmed.wisc.edu'; YOSHIHIROKAWAOKA
Subject: Re: Your paper Unpublished

Thanks.

----- Original Message -----

From: Pete Halfmann [mailto:halfmanp@svm.vetmed.wisc.edu]
Sent: Wednesday, October 08, 2014 03:49 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA
Subject: RE: Your paper Unpublished

Hi Heinz, I can look it over and we'll take care of it on this end.

Peter

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, October 08, 2014 10:06 AM
To: YOSHIHIROKAWAOKA; 'halfmanp@svm.vetmed.wisc.edu'
Subject: Fw: Your paper Unpublished

Can one of you do this please?

Thanks, Heinz

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 4:41 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: CBC News request

From: David McKie [mailto:david.mckie@cbc.ca]
Sent: Wednesday, October 08, 2014 03:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CBC News request

Good afternoon, Dr. Feldmann. My name is David McKie. I'm a producer working out of the CBC Parliamentary bureau for the show Power & Politics. Would you be available to chat about the Ebola virus vaccine?

I can be reached at this email address, or my desk at 613-288-6523.

I look forward to hearing from you.

Thanks.

David

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 4:36 PM
To: 'Richard.Besserman@asu.edu'
Cc: 'NWoodbury@asu.edu'; 'Stephen.Johnston@asu.edu'
Subject: Re: Immunosignature strategy to safeguard immunologically naive healthcare personnel

I am currently in Monrovia until the end of the months. If you are interested, please contact me again in November.

Heinz

From: Richard Besserman [mailto:Richard.Besserman@asu.edu]
Sent: Wednesday, October 08, 2014 02:25 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Neal Woodbury <NWoodbury@asu.edu>; Stephen Johnston <Stephen.Johnston@asu.edu>
Subject: Re: Immunosignature strategy to safeguard immunologically naive healthcare personnel

Heinrich

I have talked with Neal Woodbury and Stephen Johnston at our Center for Innovations in Medicine and wish to thank you for your kind offer and recommendation about animal studies.

In the interim, we are looking for a small amount of inactivated primate blood to validate the hypothesis that like other viral disease we can obtain a unique immune signature for Ebola, days 1, 2, 3, 4, 5, 6 post exposure/infection from experiments you may or others may have done. We have a source for human blood but as you know the samples would be from people already diagnosed with the disease.

Our goal would be to use immunosignatures as a baseline and then periodically to identify a signature in healthcare workers to facilitate early treatment with antivirals. I have asked Neal or Stephen at Biodesign to introduce themselves to you and to send you a few papers on their work.

Thanks.

Best

Richard

From: <Feldmann>, "Heinrich [E] (NIH/NIAID)" <feldmannh@niaid.nih.gov>
Date: Saturday, October 4, 2014 at 10:41 AM
To: Richard Besserman <rbesserm@exchange.asu.edu>
Subject: RE: Immunosignature strategy to safeguard immunologically naive healthcare personnel

I agree with you but as mentioned before we are unable to provide human samples for your studies. Once the MOU with the Liberian government is in place for sample transfer, the best would be to contact CDC as they have the US lead in the country on the Ebola outbreak. They would have to release the samples for you. I would not be able to make that decision. The contact would be the Viral Special Pathogens Branch at CDC in Atlanta.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 12:12 PM
To: 'TeresaD@vulcan.com'; 'arasmus@uw.edu'; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; 'AndyH@vulcan.com'
Subject: Re: Introduction and Ebola questions

We do not have that information. You need to ask the hospitals not us. We also would not be allowed to share that information. You need to talk to the country lead people -most likely the MOH.

Heinz

----- Original Message -----

From: Teresa Demel [mailto:TeresaD@vulcan.com]
Sent: Wednesday, October 08, 2014 01:51 PM Eastern Standard Time
To: ANGELA L. RASMUSSEN <arasmus@uw.edu>; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Andy Hickl <AndyH@vulcan.com>
Subject: Re: Introduction and Ebola questions

Andrea, Dave, and Heinz,

I know that your work on the ground is incredibly important, but if you can spare 30 minutes to talk on the phone, we would love to discuss this project with you. I'll include questions in here in case email is easier.

Vulcan Innovation Labs is working on a data sharing platform to improve the accuracy of information reported back to WHO, CDC, USAID, as well as basic researchers and epidemiologists. Right now, stats on Ebola are shared in a weekly phone call between WHO, CDC, etc. The stats are the bare minimum: cases vs deaths and confirmed/probable/suspected. Angela told us that research and action could progress faster if clinicians were able to collect and share the following information in real time:

- * Patient symptoms
- * Survival
- * Viral strain
- * Genetic profile of virus
- * Genetic profile of patient (?)
- * Demographics (age, sex)
- * What else?

We know that clinicians are incredibly busy and want to expedite data collection. As an example, we could use a mix of text message photos and object recognition to deliver Bioanalyzer data to a centralized database. This would allow virologists to study the evolution of Ebola in real time. In addition, epidemiologists could understand which strains of the virus are in which regions, and the clinical data associated with each patient (anonymized).

I worked in a genetics lab about 18 years ago, so I'm mostly layperson with some basic knowledge of viruses, PCR, etc. We would love to hear what your team (and the wider Ebola containment community) needs in order to make this work. While we want to help the basic research side, we also want to provide any data that will help stop this epidemic as soon as possible.

Questions for you. Answer the relevant ones. Feel free to elaborate.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 12:09 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Fw: Request for plasmids

Thomas - can you please communicate? If you agree we would need a SLA.

Thanks, Heinz

From: Stephen McCarthy [mailto:s.mccarthy@mail.utoronto.ca]
Sent: Wednesday, October 08, 2014 01:51 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request for plasmids

Hello Dr. Feldmann,

I recently read your article on modeling the lifecycle of Ebola virus under biosafety level 2 conditions, and am very impressed by your approach. My research interests are in viral transcription and I would very much like to try your tetracistronic minigenome system in my lab. Would it be possible to request the 7 plasmids outlined in your paper? They are pCAGGS-NP, pCAGGS-VP35, pCAGGS-VP30, pCAGGS-L, p4cis-vRNA-RLuc, pCAGGS-T7 and pCAGGS-T7. Our lab can pay for the shipment of the plasmids (Fed Ex number: Personal Info)
1). This is our mailing address:

Attn: Darinka Sakac

Dr. Donald R. Branch
Canadian Blood Services
4th Floor Room 453
67 College St.
Toronto, Ontario
Canada M5G 2M1

Kind Regards,

Stephen McCarthy
Canadian Blood Services

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 11:54 AM
To: Personal Info
Cc: 'twgeisbe@utmd.edu'
Subject: Re: Dendritic cell therapy

I am in Monrovia until the end of the month. Please contact me again early November. We are pretty busy with Monrovia and work back home. Unlikely to do any work on this until spring 2015 if I can interest one of my postdocs. If you don't want to wait that long and take the risk, please contact other BSL4 labs.

Heinz

From: Kenneth Gorelick Personal Info
Sent: Wednesday, October 08, 2014 01:21 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: twgeisbe@utmd.edu <twgeisbe@utmd.edu>
Subject: Dendritic cell therapy

Dear Heinz,

Tom Geisbert suggested that I contact you about an agent I am developing as an immunotherapeutic for cancer.

This is a small injectable protein that stimulates senescent monocytes to mature into CD86/CD80 double positive dendritic cells. The focus of the company is on its use as an immunomodulator in cancer, but some recent reading suggests that there might be some potential for use in ebola.

We have considerable in vitro and in vivo cancer data, and are planning to begin human studies in mid-2015. Please let me know a) that you have received this and b) if you are interested in the compound. We would be happy to supply you with product under a MTA.

Best regards,

Kenneth Gorelick, MD
mobile: Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 11:39 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: MEDIA REQUEST: The Stream // Al Jazeera English

Thanks.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 11:06 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: MEDIA REQUEST: The Stream // Al Jazeera English

Tomorrow afternoon. I'll text you the score.

Then we play Stevensville on Saturday.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 9:00 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: MEDIA REQUEST: The Stream // Al Jazeera English

Thanks - all well here. Did you already play Loyolo (spelling)?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 10:49 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: MEDIA REQUEST: The Stream // Al Jazeera English

Thanks. I declined this and the one from Colombia. I also asked Thomas to decline the agency that wanted to pay him to speak to people in the industry; that is a new twist my branch had never before seen.

Hope all is well for you and the team.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 7:57 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: MEDIA REQUEST: The Stream // Al Jazeera English

From: Ryan Kohls [<mailto:Ryan.Kohls@aljazeera.net>]
Sent: Wednesday, October 08, 2014 09:40 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: MEDIA REQUEST: The Stream // Al Jazeera English

Hello Dr. Feldmann,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 9:06 AM
To: YOSHIHIROKAWAOKA; 'halfmanp@svm.vetmed.wisc.edu'
Subject: Fw: Your paper Unpublished

Can one of you do this please?

Thanks, Heinz

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 9:00 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: URGENT!! REPORT EBOLA SPANISH PAPER

Another one.

From: Pilar Pérez [mailto:pilarperezjimenez@gmail.com]
Sent: Wednesday, October 08, 2014 10:42 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: URGENT!! REPORT EBOLA SPANISH PAPER

Dear dr. Feldmann,

This is Pilar Perez, from a Spanish daily national newspaper called LA RAZON<<http://www.larazon.es/>>, in specially a weekly magazine called in English FOR YOUR HEALTH (A TU SALUD)<<http://www.larazon.es/secciones/a-tu-salud>>, it has a paper version, that publish every Sunday. We prepare an special issue with the main clues about the possibilities of surveillance with ebola.

I wonder if you could answer some questions that I need to explain our readers.

- In some scientific papers suggest that the progression of infectious disease is an evolution in which after a time you know if the patient is going to save or not, is it true? Is it a 15 days or week?
- What other diseases or infections determine a favorable outcome?
- What stops the infection in patients? Immunity ?
- From which irreversible damage is the situation?
- What should be an effective treatment, even experimental?

Thanks so much, I expect you could talk me something as soon as possible, because my deadline is tomorrow.

Regards,
Pilar

--

It receives a warm greeting,
Pilar Perez Jiménez
LA RAZÓN

pilarperezjimenez@gmail.com
pperez@larazon.es

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 9:00 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: MEDIA REQUEST: The Stream // Al Jazeera English

Thanks - all well here. Did you already play Loyolo (spelling)?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 10:49 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: MEDIA REQUEST: The Stream // Al Jazeera English

Thanks. I declined this and the one from Colombia. I also asked Thomas to decline the agency that wanted to pay him to speak to people in the industry; that is a new twist my branch had never before seen.

Hope all is well for you and the team.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 7:57 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: MEDIA REQUEST: The Stream // Al Jazeera English

From: Ryan Kohls [<mailto:Ryan.Kohls@aljazeera.net>]
Sent: Wednesday, October 08, 2014 09:40 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: MEDIA REQUEST: The Stream // Al Jazeera English

Hello Dr. Feldmann,

My name is Ryan Kohls. I'm a producer with Al Jazeera English's "The Stream" - Al Jazeera English's award-winning, social media based show. Our show, which has recently won an Emmy nomination, is a 45 minute, live, interactive, daily talk show. (stream.aljazeera.com). We're based in Washington, D.C.

This Thursday, October 9th, between 1900 and 2015 PM EST, we are doing a show on Ebola. We want to have a well-rounded panel of people who can discuss the latest information on the fight to stop this outbreak. I would love to connect with an expert like yourself who understands the big picture questions and has some experience on the ground dealing with this.

Would love to chat if that might interest you. All the best,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 8:58 AM
To: 'b.nyaku@elsevier.com'
Cc: YOSHIHIROKAWAOKA
Subject: Re: Article tracking **Unpublish** - Expected dispatch of proofs

Please send all communication to Dr. Kawaoka (copied here). I am in Monrovia until the end of the month with little opportunity to do internet.

Heinz

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 7:57 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: MEDIA REQUEST: The Stream // Al Jazeera English

From: Ryan Kohls [mailto:Ryan.Kohls@aljazeera.net]
Sent: Wednesday, October 08, 2014 09:40 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: MEDIA REQUEST: The Stream // Al Jazeera English

Hello Dr. Feldmann,

My name is Ryan Kohls. I'm a producer with Al Jazeera English's "The Stream" - Al Jazeera English's award-winning, social media based show. Our show, which has recently won an Emmy nomination, is a 45 minute, live, interactive, daily talk show. (stream.aljazeera.com). We're based in Washington, D.C.

This Thursday, October 9th, between 1900 and 2015 PM EST, we are doing a show on Ebola. We want to have a well-rounded panel of people who can discuss the latest information on the fight to stop this outbreak. I would love to connect with an expert like yourself who understands the big picture questions and has some experience on the ground dealing with this.

Would love to chat if that might interest you. All the best,



Ryan Kohls
Interview Producer – The Stream
Al Jazeera English

O: 202 496 4622 | M: 202 374 5970

[@ryankohls](https://twitter.com/ryankohls)

Washington, D.C | UTC/GMT -4

stream.aljazeera.com | www.aljazeera.com

Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 3:41 AM
To: 'ali.khan@unmc.edu'; Uyeki, Timothy M. (CDC/OID/NCIRD)
Cc: 'armando.dealba@unmc.edu'
Subject: Re: CMX-001 or [REDACTED]

Redacted by
agreement

Give me one more day as I have just arrived yesterday.
Should this be coordinated with WHO?
Heinz

Redacted by
agreement

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Tuesday, October 07, 2014 11:46 PM Eastern Standard Time
To: Uyeki, Timothy M. (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; De Alba, Armando <armando.dealba@unmc.edu>
Subject: Re: CMX-001 or [REDACTED]

Thanks Tim for these ideas. Very helpful. With 50% case fatality, the power calculations are simple. We can do this.
Chatted with Lu today.
Waiting for Heinz to check with MSF.
Best and thank you for the great info going out and the individual clinician consultation.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

> On Oct 7, 2014, at 10:26 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

Records Originating Outside of NIAID

> -----Original Message-----

> From: Khan, Ali S [mailto:ali.khan@unmc.edu]
> Sent: Monday, October 06, 2014 11:40 PM
> To: Uyeki, Timothy M. (CDC/OID/NCIRD)
> Cc: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: CMX-001 or [REDACTED]

Redacted by
agreement

>
> Thanks Tim

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 3:40 AM
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Subject: Fw: CMX-001 or [REDACTED] Redacted by agreement

Armand,

Do you think ELWA 3 would be interested and can do this? I can talk to Ruggerio but wanted to ask you first. You may remember Ali - he was former CDC, now Dean of the Omaha Medical School. Please let me know as soon as possible. I can also call if you prefer.

Best wishes, Heinz

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Tuesday, October 07, 2014 11:46 PM Eastern Standard Time
To: Uyeki, Timothy M. (CDC/OID/NCIRD)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; De Alba, Armando <armando.dealba@unmc.edu>
Subject: Re: CMX-001 or [REDACTED] Redacted by agreement

Thanks Tim for these ideas. Very helpful. With 50% case fatality, the power calculations are simple. We can do this. Chatted with Lu today.

Waiting for Heinz to check with MSF.

Best and thank you for the great info going out and the individual clinician consultation.

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

> On Oct 7, 2014, at 10:26 PM, Uyeki, Timothy M. (CDC/OID/NCIRD) <tmu0@cdc.gov> wrote:

Records Originating Outside of NIAID

> -----Original Message-----

> **From:** Khan, Ali S [mailto:ali.khan@unmc.edu]
> **Sent:** Monday, October 06, 2014 11:40 PM
> **To:** Uyeki, Timothy M. (CDC/OID/NCIRD)
> **Cc:** Feldmann, Heinrich (NIH/NIAID) [E]
> **Subject:** Re: CMX-001 or [REDACTED] Redacted by agreement
>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 3:35 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: 1-on-1 Paid Call RE: Ebola Virus

Talk to Ken about it to see if NIH wants to do this. If not just decline.

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Tuesday, October 07, 2014 07:09 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: 1-on-1 Paid Call RE: Ebola Virus

Hi Heinz,

Sorry to bother you with this, but any idea what I should do with the attached email? Even if I wanted to do it (which I'm not sure I am) I don't think I could for legal reasons (working for the NIH & immigration status). Have you ever dealt with something like this before?

All the best, Thomas

From: Caroline Kim [mailto:caroline.kim@axonadvisors.com]
Sent: Tuesday, October 07, 2014 3:05 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: 1-on-1 Paid Call RE: Ebola Virus

Dear Dr. Hoenen,

I represent Axon Advisors, a leading healthcare fieldwork company. We connect research analysts to industry professionals for research projects.

One of our clients, a healthcare analyst (no relation to any healthcare company), has engaged us to schedule 1-on-1 calls with experts who meet the following criteria and can knowledgeably discuss the following topics.

1. Expert Profile Criteria:
 - Virologist who is an expert on Ebola/Filovirus.
2. Topics to be discussed:
 - Transmission data
 - Replication locations and duration in humans
 - Typical course and variability in duration of asymptomatic incubation period, duration of illness, time to loss of viremia and to loss of infectivity
 - Organs and tissues affected by virus
 - Efficacy of supportive care to prevent fatalities
 - Potential of different antivirals in development
 - Suitability for vaccine strategies...effect of natural exposure

Would you be willing to discuss this topic on a 1-on-1 phone call? The call should last about 45 minutes. We will compensate you **\$400 per hour** for your participation.

If you are interested:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 3:32 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: From the Colombian weekly magazine 'Semana' - Request of information about the Ebola outbreak spread in Western countries

From: Felipe Restrepo Acosta [mailto:FRestrepoA@semana.com]
Sent: Tuesday, October 07, 2014 08:25 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: From the Colombian weekly magazine 'Semana' - Request of information about the Ebola outbreak spread in Western countries

Dear Professor Feldmann:

My name is Felipe Restrepo-Acosta, journalist at *Semana* ([last printed issue](#)), a weekly magazine published in Colombia. It provides in-depth articles about current events, politics, technology and culture.

It's as well one of the most important magazines in Latin America and a widely cited publication in leading English-speaking media as The Economist ([link to Google results](#)), CNN ([link](#)) or The New York Times ([link](#)).

Currently I'm working on an article about the Ebola outbreak spread in the United States and Europe. I would like to know your viewpoint and ideas on the following issues:

1. It was well known that that the virus could appear in the First World, but a contagion inside a hospital (like in Spain) is quiet distressing. How seriously is Europe taking the current outbreak?
2. How likely are we to see Ebola appearing in Asian and Latin-American countries?
3. Do you think the emergence of cases in the United States and Europe would have an impact on world commerce and travels?

Best regards,

Felipe Restrepo-Acosta

Cell phone Personal Info

Office (571) 6 46 84 00 ext. 5058

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 08, 2014 3:31 AM
To: 'Heinz_Feldmann@yahoo.ca'
Subject: Fw:
Attachments: Berlin 2014.pptx

From: Haddock, Elaine (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 09:31 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject:

Heinz,

Here is my talk for Berlin. It's about 12 minutes long if I don't get too nervous and talk too quickly. I'll practice with people from the lab later in the week.

Elaine Haddock, Ph.D.
Biologist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-7488
Fax: (406) 375-9620
Email: Elaine.Haddock@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 4:28 PM
To: Marzi, Andrea (NIH/NIAID) [E]; 'Ilhem.messaoudi@ucr.edu'
Subject: Re: Modelling Ebola infection

Fine with me.

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 06:08 PM Eastern Standard Time
To: Ilhem Messaoudi Powers <Ilhem.messaoudi@ucr.edu>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Modelling Ebola infection

Sounds good to me.
Let me know if you need anything.
Thanks, Andrea

From: Ilhem Messaoudi <ilhem.messaoudi@ucr.edu>
Date: Tuesday, October 7, 2014 6:38 AM
To: Heinz Feldmann <feldmannh@niaid.nih.gov>, Andrea Marzi <marzia@niaid.nih.gov>
Subject: FW: Modelling Ebola infection

Hi Heinz and Andrea

Miles is a world leader in mathematical modeling of immunity. He is a wonderful person (he works closely with several of my colleagues) and a collaborator with integrity. He is requesting to our already published data from the PNAS paper and I think this is a great opportunity for us to get a second manuscript out of this data set.
I hope that you will agree to collaborate and I would like to send him an email confirming our willingness to collaborate later today.

Thank you
Ilhem

From: Miles Davenport <z9801119@unsw.edu.au>
Date: Monday, October 6, 2014 10:16 PM
To: Ilhem Messaoudi <ilhem.messaoudi@ucr.edu>
Subject: Modelling Ebola infection

Hi Ilhem,

It is now a few years since we met at VGTI to discuss modelling in immunology (and at the time your work on monkey pox). I am still working on modelling SIV infection kinetics and pathogenesis quite a bit, and now more and more on malaria. I have recently begun to look at Ebola infection and pathogenesis, with a view to whether our modelling may help understand this virus better. I read with interest your PNAS paper last year on Ebola vaccination in macaques, and wondered if it would be possible to get access to this published data for our modelling? In particular, the time courses of individual animals after challenge for virus, blood counts and biochemistry, antibody levels, and cytokines [largely the data that make up figure 5 and the supplementary figures]. Although there are no guarantees of success, I am optimistic that we might be able to analyse

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 4:27 PM
To: Personal Info
Subject: Re: Request to Speak

As mentioned before you need to contact the groups and agencies that are responsible for patient care. You should contact MSF (doctors without borders) and WHO (World Health Organization). They do coordinate treatment and vaccines. I cannot get involved in this in my position. I also do not propose any treatment or vaccine that I do not know in terms of animal efficacy data against Ebola. In vitro efficacy is a needed start but does not mean much to me at all.

Heinz

From: Personal Info
Sent: Tuesday, October 07, 2014 06:05 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Hi Heinz,

Attached are two small but very relevant documents that Dr. Carter would like you to have so you are prepared to inform physicians who are treating Ebola patients about the availability and possibilities of Ampligen. I am told that once a physician requests a product for emergency use to treat Ebola, there is a call with the physician, FDA and the supplier and if OK'ed, product can then be used.

FYI, Dr. Zoon and Dr. Carter are well acquainted with each other and have met and spoken. Based on those discussion Hemispherx plans additional testing of Ampligen (VP35 binding assays) but meanwhile physicians on the front line with you should know of Ampligen and its MoA.

Hemispherx appreciates any assistance you can provide in this regard.

Wayne

In a message dated 10/7/2014 4:58:06 P.M. Eastern Daylight Time, Personal Info writes:



Heinz,

Yes I know that. I was more interested in Contacts you must have with physicians. Who or what is MSF?

Wayne
Sent from my iPhone

On Oct 7, 2014, at 4:33 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

I have nothing to do with patients. You need to contact MSF.

From: Personal Info
Sent: Tuesday, October 07, 2014 03:33 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 2:37 PM
To: Pineda, Mark (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Sullivan, Kevin (NIH/NIAID) [E]
Subject: Re: lodging liberia

It will be difficult as the hotel does not have that many options to receive money. A government Credit card may work.

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 03:54 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Sullivan, Kevin (NIH/NIAID) [E]
Subject: RE: lodging liberia

Heinz:

While the Embassy in Brazzaville has indeed be willing to do this, the Embassy in Monrovia is almost surely way too busy with the Ebola crisis to take this on at the moment.

I think we will need to come up with an arrangement on our own.

Sincerely,

MARK

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 2:53 PM
To: Munster, Vincent (NIH/NIAID) [E]; Sullivan, Kevin (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Barron, Karyl (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Gehlhaus, Kristie (NIH/NIAID) [E]; Barr, Leona (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: lodging liberia

The embassy would be the best choice. If they don't want to cover the expenses, we would have to transfer money.

Mark, we have done that in RC, haven't we?

Heinz

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 01:16 PM Eastern Standard Time
To: Sullivan, Kevin (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Barron, Karyl (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]; Gehlhaus, Kristie (NIH/NIAID) [E]; Barr, Leona (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]; Clifton, Dawn (NIH/NIAID) [E]
Subject: Re: lodging liberia

Hi Kevin,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 2:34 PM
To: Walczynski, Joyce (NIH/NIAID) [C]
Subject: Re: 20th Anniversary Celebration

I know.

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Tuesday, October 07, 2014 03:35 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: 20th Anniversary Celebration

Thank you. I just spoke with Ricki, and hopefully we will have some answers from her contractors by Friday.

If she goes in November, then you will have to cancel DZIF, too.

Take care!

Joyce Walczynski

Logistics Technician, LV (Contractor)
Rocky Mountain Laboratories
903 South 4th St.
Hamilton, MT 59840
Phone: 406.375.9600
Fax: 406.375.9620
Email: walczynskij@niaid.nih.gov

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 12:55 PM
To: Walczynski, Joyce (NIH/NIAID) [C]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Fw: 20th Anniversary Celebration

Did Ricki talk to you about this travel? If she goes on the November team I cannot travel. She is trying to find out this week. Don't put too much effort into this as I may have to cancel.

Heinz

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Tuesday, October 07, 2014 01:17 PM Eastern Standard Time
To: Fran Garcia <fran.garcia@vhir.org>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: 20th Anniversary Celebration

Good Afternoon Fran:

With the new time change to 4 p.m. on November 21, I believe Dr. Feldmann may fly into Barcelona the morning of November 21, and then depart the morning of November 22 for Amsterdam.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 2:33 PM
To: Personal Info
Subject: Re: Request to Speak

I have nothing to do with patients. You need to contact MSF.

From: Personal Info
Sent: Tuesday, October 07, 2014 03:33 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Request to Speak

Hi Heinz,

I knew you were going but I didn't think it was until next week.

The purpose of my wanting to speak is that Dr Carter has learned that an emergency IND can be obtained if a physician treating Ebola patients makes such a request. Having been in Liberia before and being there now, you are in an excellent position to suggest to physicians that they consider the use of Ampligen for certain patients. I think you have the relevant information but I will send you a small packet which you can use to discuss the concept of Ampligen with certain physicians. Would you do that for Hemispherx ?

Best regards

Wayne

PS... Please be careful!

Sent from my iPhone

On Oct 7, 2014, at 3:04 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Most likely not possible as I am in Monrovia for the next three weeks.

From: Personal Info
Sent: Tuesday, October 07, 2014 02:19 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request to Speak

Hi Heinz,

I just spoke with Dr Carter and he'd like me to speak with you...not about the testing but rather treating Ebola patients in West Africa. Can we chat for 10 minutes sometime today convenient for you.

Thanks.

Best regards,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 1:05 PM
To: Personal Info
Subject: Re: Request to Speak

Most likely not possible as I am in Monrovia for the next three weeks.

From: Personal Info
Sent: Tuesday, October 07, 2014 02:19 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Request to Speak

Hi Heinz,

I just spoke with Dr Carter and he'd like me to speak with you...not about the testing but rather treating Ebola patients in West Africa. Can we chat for 10 minutes sometime today convenient for you.

Thanks.

Best regards,

Wayne Pambianchi
Senior Adviser to the Chairman
Hemispherx Biopharma, Inc.
1617 JFK Boulevard
Suite 500
Philadelphia, PA 19013
Cell Personal Info
Office 215-988-0080
Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 12:55 PM
To: Walczynski, Joyce (NIH/NIAID) [C]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Fw: 20th Anniversary Celebration
Attachments: Sponsor Acceptance Letter - signed - 10-6-14.pdf; Sponsor LOI Template.doc

Did Ricki talk to you about this travel? If she goes on the November team I cannot travel. She is trying to find out this week. Don't put too much effort into this as I may have to cancel.

Heinz

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Tuesday, October 07, 2014 01:17 PM Eastern Standard Time
To: Fran Garcia <fran.garcia@vhir.org>
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: 20th Anniversary Celebration

Good Afternoon Fran:

With the new time change to 4 p.m. on November 21, I believe Dr. Feldmann may fly into Barcelona the morning of November 21, and then depart the morning of November 22 for Amsterdam.

I am attaching the Sponsor Acceptance Letter from us, and an LOI Form. The letter is from us to you and the LOI Form I will need to have filled out, signed, and returned to me. If you would please place the LOI Form on your letterhead before returning, that would be great. One of the things we have problems with when I send out this form is that on the form it asks for the sponsor to specifically give where the funds are coming from to provide the sponsorship. When I receive the form back from the sponsor, then I forward it to our Ethics Department for their approval. Quite frequently, Ethics will contact me and ask for the sponsor to provide specifically where the sponsorship is coming from. Ethics has given examples of where the funding could be coming from—following are a couple of examples: “funding is coming from registration fees” or “funding is from an unrestricted grant from XYZ organization”. So, if you can list specifically where the funds are coming from to sponsor Dr. Feldmann’s travel, I would appreciate it.

Are you able to sponsor his flight from Missoula, Montana to Barcelona and from Barcelona to Amsterdam rather than back to the U.S.? Dr. Feldmann has a previous commitment in Europe and not enough time to travel from Barcelona back to Missoula, Montana and then back to Amsterdam and on to Germany. Dr. Feldmann is currently in Monrovia, Liberia; but hopefully, he will be able to respond to e-mails that I send to him with questions regarding his travel to Barcelona, etc.

Please contact me with any questions.

Thank you very much for your assistance with this sponsored travel.

Joyce Walczynski
Logistics Technician, LV (Contractor)
Rocky Mountain Laboratories
903 South 4th St.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 10:45 AM
To: 'grantmcf@ufl.edu'
Subject: Re: Ebola L-protein domain boundaries

I am in Monrovia for the rest of the month - Ebola outbreak response.

From: McFadden, Douglas Grant [mailto:grantmcf@ufl.edu]
Sent: Tuesday, October 07, 2014 12:23 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Ebola L-protein domain boundaries

Hi Heinz:

Perfect, thanks!

Grant

PS: I gather things are busy at your end.....

On Oct 7, 2014, at 12:12 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Grant,
You can try Elke Muehlberger (Boston), Hideki Ebihara (NIAID), Chris Basler (Mount Sinai) or Thomas Hoenen (my lab). Erica Ollman-Saphire (Scripps) may have structural knowledge.

Hope this will help. I may have mis-spelled some names).

Best wishes, Heinz

From: McFadden, Douglas Grant [mailto:grantmcf@ufl.edu]
Sent: Tuesday, October 07, 2014 10:47 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fwd: Ebola L-protein domain boundaries

Heinz:

I am on the SAB of a pathogen protein structure consortium, and I have received the request below about the Ebola RNA polymerase.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 10:13 AM
To: 'grantmcf@ufl.edu'
Subject: Re: Fwd: Ebola L-protein domain boundaries

Grant,

You can try Elke Muehlberger (Boston), Hideki Ebihara (NIAID), Chris Basler (Mount Sinai) or Thomas Hoenen (my lab). Erica Ollman-Saphire (Scripps) may have structural knowledge.

Hope this will help. I may have mis-spelled some names).

Best wishes, Heinz

From: McFadden, Douglas Grant [mailto:grantmcf@ufl.edu]
Sent: Tuesday, October 07, 2014 10:47 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fwd: Ebola L-protein domain boundaries

Heinz:

I am on the SAB of a pathogen protein structure consortium, and I have received the request below about the Ebola RNA polymerase.

Do you know who I could contact who might be knowledgeable about the ebola virus polymerase protein?

Thanks,

Grant

Begin forwarded message:

From: Bart Staker <bart.staker@seattlebiomed.org>
Subject: Ebola L-protein domain boundaries
Date: October 6, 2014 at 1:34:19 PM EDT
To: "grantmcf@ufl.edu" <grantmcf@ufl.edu>

Hi Grant,

Thanks for your service on the SSGCID advisory board. NIAID has asked us to apply extra effort on structure determination efforts of Ebola viral proteins due to current events. They are especially interested in the RNA dependent RNA polymerase (RdRp) domain of the L-protein.


Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 10:01 AM
To: Marston, Hilary (NIH/NIAID) [C]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: Re: quick question

When the G is deleted you have no projections on the surface. The VSV vaccine has projection as the G is replaced by the Ebola glycoprotein which is then displayed on the surface.

From: Marston, Hilary (NIH/NIAID) [C]
Sent: Monday, October 06, 2014 06:25 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject: quick question

Hello again – sorry to bother you with this, but we are doing a schematic of the VSV delta G vector, and wanted to use an image like this, but were wondering: is it a smooth membrane (without the glycoprotein spikes) once the g protein gene is deleted?



http://www.virology.ws/wp-content/uploads/2010/02/vsv_virion-300x223.jpg

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 7:51 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: Sky News interview

Thanks.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 09:48 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Sky News interview

I'll decline and suggest she speak to Peter or Tom.

On Oct 7, 2014, at 7:32 AM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

From: Howe, Jessica (Sky News) [<mailto:Jessica.Howe@bskyb.com>]
Sent: Tuesday, October 07, 2014 06:07 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Sky News interview

Dear Heinz

We are really keen to set up an interview with you this evening, about the spread of Ebola given that it has now been contracted by the Spanish nurse. We're also keen to look at the possible model for infection and how it could spread outside of Africa.

We would love to set up an interview today – either live or pre-recorded. It would be for our new flagship evening programme Sky News Tonight - which is to be an in-depth, serious and intelligent exposition of the day's news. It would set the agenda on Sky News that night and throughout the following days. The presenter is Sky News Editor at Large, Adam Boulton.

Do let me know if this is an option – my direct line is 0044 207 032 0424

Many thanks

Jessica

Information in this email including any attachments may be privileged, confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received it in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. SKY and the SKY marks are trademarks of British Sky Broadcasting Group plc and Sky International AG and are used under licence. British Sky Broadcasting Limited (Registration No. 2906991), Sky-In-Home Service

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, October 07, 2014 7:32 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Fw: Sky News interview

From: Howe, Jessica (Sky News) [mailto:Jessica.Howe@bskyb.com]
Sent: Tuesday, October 07, 2014 06:07 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Sky News interview

Dear Heinz

We are really keen to set up an interview with you this evening, about the spread of Ebola given that it has now been contracted by the Spanish nurse. We're also keen to look at the possible model for infection and how it could spread outside of Africa.

We would love to set up an interview today – either live or pre-recorded. It would be for our new flagship evening programme Sky News Tonight - which is to be an in-depth, serious and intelligent exposition of the day's news. It would set the agenda on Sky News that night and throughout the following days. The presenter is Sky News Editor at Large, Adam Boulton.

Do let me know if this is an option – my direct line is 0044 207 032 0424

Many thanks

Jessica

Information in this email including any attachments may be privileged, confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received it in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. SKY and the SKY marks are trademarks of British Sky Broadcasting Group plc and Sky International AG and are used under licence. British Sky Broadcasting Limited (Registration No. 2906991), Sky-In-Home Service Limited (Registration No. 2067075) and Sky Subscribers Services Limited (Registration No. 2340150) are direct or indirect subsidiaries of British Sky Broadcasting Group plc (Registration No. 2247735). All of the companies mentioned in this paragraph are incorporated in England and Wales and share the same registered office at Grant Way, Isleworth, Middlesex TW7 5QD.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 6:12 PM
To: 'megha@tribweb.com'
Subject: Re: Interview request: The science of Ebola

I am away until the end of the month.

-----Original Message-----

From: Megha Satyanarayana
To: Heinrich (NIH/NIAID) [E] Feldmann
Subject: Interview request: The science of Ebola
Sent: Oct 6, 2014 3:14 PM

Hi Dr. Feldmann –

I'm writing a story about the science of the Ebola virus – how it infects, how it survives the immune system, targets for treatment, how the treatments work, etc., and I was hoping we could talk about the most current knowledge. I'm poring through the literature as we speak, but have a few questions. Would you have time today or tomorrow to chat for a few minutes? I'd appreciate it.

Thanks!

Megha Satyanarayana
Science/Technology Reporter
Pittsburgh Tribune-Review
megha@tribweb.com
(412)-320-7991 (desk)
Personal Info (cell)
Twitter: @meghas
Facebook: facebook.com/meghawiththelonglastname

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 4:03 AM
To: 'delinen@who.int'; 'umalik@who.int'; 'wail@who.int'; 'wertschnigb@who.int'
Cc: 'goarn@who.int'; 'mwanamwenge@who.int'; 'gasasiraa@who.int'; Munster, Vincent (NIH/NIAID) [E]; 'nyonpluer@who.int'; 'mwanamwengea@who.int'
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Many thanks, Heinz

From: FREEMAN DELINE, Nancy [mailto:delinen@who.int]
Sent: Monday, October 06, 2014 05:58 AM Eastern Standard Time
To: UMALI DALANGIN, Khristeen <umalik@who.int>; WAI, Lokky <wail@who.int>; WERTSCHNIG, Brian Adam <wertschnigb@who.int>
Cc: goarn <goarn@who.int>; mwanamwenge@who.int <mwanamwenge@who.int>; GASASIRA, Alex Ntale <gasasiraa@who.int>; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; NYONPLUE, Richard G. <nyonpluer@who.int>; MWANAMWENGE, Abrahams <mwanamwengea@who.int>
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Yes he will be picked up. Richard and Abraham please take note. He will be arriving on SN Brussels.

Regards,
Nancy

From: UMALI DALANGIN, Khristeen
Sent: Monday, October 06, 2014 7:14 AM
To: WAI, Lokky; WERTSCHNIG, Brian Adam
Cc: FREEMAN DELINE, Nancy; goarn; mwanamwenge@who.int; GASASIRA, Alex Ntale; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Lokky, Brian,

Dr Heinz Feldmann is arriving tonight in Monrovia. Could you kindly confirm airport transfer tonight to pick him up? He will arrive with four pieces of luggage including one oversize piece (not too big). As previously requested, the driver needs to bring him to the Kendeja Hotel. Dr Feldmann has already a room at that hotel.

Thanks,

Khristeen

From: WAI, Lokky
Sent: 28 September 2014 22:00
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: FREEMAN DELINE, Nancy; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia


Well noted. Even if you want to stay in the Royal 'whatever' hotel it is not possible as they are all full. The drivers will take the passengers to Kendeja Hotel from the airport as requested. Thank you

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 3:19 AM
To: 'michael.jarvis@plymouth.ac.uk'
Subject: Re: Unpublished

I did read the paper but have trouble getting on internet. I am on my way to Monrovia. I will try to summarize my comments:

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 12:49 AM
To: 'wail@who.int'; 'umalik@who.int'
Cc: 'wertschnigb@who.int'; 'delinen@who.int'; 'goarn@who.int'; 'mwanamwenge@who.int'; 'gasasiraa@who.int'; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Great - many thanks, Heinz

From: WAI, Lokky [mailto:wail@who.int]
Sent: Monday, October 06, 2014 02:17 AM Eastern Standard Time
To: UMALI DALANGIN, Khristeen <umalik@who.int>
Cc: WERTSCHNIG, Brian Adam <wertschnigb@who.int>; FREEMAN DELINE, Nancy <delinen@who.int>; goarn <goarn@who.int>; mwanamwenge@who.int <mwanamwenge@who.int>; GASASIRA, Alex Ntale <gasasiraa@who.int>; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Khristeen,
No problem. The passenger will be picked up and dropped at the Kendeja Hotel as per your request. Thank you Lokky

Sent from my iPhone

On 6 Oct, 2014, at 6:13 am, "UMALI DALANGIN, Khristeen" <umalik@who.int> wrote:

Dear Lokky, Brian,

Dr Heinz Feldmann is arriving tonight in Monrovia. Could you kindly confirm airport transfer tonight to pick him up? He will arrive with four pieces of luggage including one oversize piece (not too big). As previously requested, the driver needs to bring him to the Kendeja Hotel. Dr Feldmann has already a room at that hotel.

Thanks,

Khristeen

From: WAI, Lokky
Sent: 28 September 2014 22:00
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: FREEMAN DELINE, Nancy; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Well noted. Even if you want to stay in the Royal 'whatever' hotel it is not possible as they are all full. The drivers will take the passengers to Kendeja Hotel from the airport as requested. Thank you
Lokky

Sent from my iPhone

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 12:49 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; 'mark.j.wolcott.civ@mail.mil'
Cc: 'william.r.dorman4.civ@mail.mil'; 'david.a.norwood.civ@mail.mil'; Kobinger, Gary (Public Health Agency of Canada); 'Allen.Grolla@phac-aspc.gc.ca'
Subject: Re: Primers (UNCLASSIFIED)

Thanks Darryl.


----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Monday, October 06, 2014 02:28 AM Eastern Standard Time
To: 'Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US)' <mark.j.wolcott.civ@mail.mil>; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US) <william.r.dorman4.civ@mail.mil>; Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US) <david.a.norwood.civ@mail.mil>; Kobinger, Gary (Public Health Agency of Canada); Allen.Grolla@phac-aspc.gc.ca <Allen.Grolla@phac-aspc.gc.ca>
Subject: RE: Primers (UNCLASSIFIED)

Hi Mark,

Sorry for the slow response. I am not sure what you mean by what is the ZEBOV L assay target? The target is the L (polymerase) gene. I will assume you actually want the sequences?

Redacted by agreement



These primers were designed by the National Microbiology Laboratory in Winnipeg, Canada. I have copied Gary Kobinger and Allen Grolla. I would be best to contact them with any design and validation questions.

I will have to get back to you to confirm the sequences for the VSV-N assay.

Best regards,
Darryl

-----Original Message-----

From: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US) [mailto:mark.j.wolcott.civ@mail.mil]
Sent: Thursday, October 02, 2014 1:33 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
Subject: RE: Primers (UNCLASSIFIED)

Classification: UNCLASSIFIED

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, October 06, 2014 12:48 AM
To: 'umalik@who.int'; 'wail@who.int'; 'wertschnigb@who.int'
Cc: 'delinen@who.int'; 'goarn@who.int'; 'mwanamwenge@who.int'; 'gasasiraa@who.int'; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Many thanks - looking forward to seeing the driver at the airport.

Best wishes, Heinz

From: UMALI DALANGIN, Khristeen [mailto:umalik@who.int]
Sent: Monday, October 06, 2014 02:13 AM Eastern Standard Time
To: WAI, Lokky <wail@who.int>; WERTSCHNIG, Brian Adam <wertschnigb@who.int>
Cc: FREEMAN DELINE, Nancy <delinen@who.int>; goarn <goarn@who.int>; mwanamwenge@who.int <mwanamwenge@who.int>; GASASIRA, Alex Ntale <gasasiraa@who.int>; Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Lokky, Brian,

Dr Heinz Feldmann is arriving tonight in Monrovia. Could you kindly confirm airport transfer tonight to pick him up? He will arrive with four pieces of luggage including one oversize piece (not too big). As previously requested, the driver needs to bring him to the Kendeja Hotel. Dr Feldmann has already a room at that hotel.

Thanks,

Khristeen

From: WAI, Lokky
Sent: 28 September 2014 22:00
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: FREEMAN DELINE, Nancy; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Well noted. Even if you want to stay in the Royal 'whatever' hotel it is not possible as they are all full. The drivers will take the passengers to Kendeja Hotel from the airport as requested. Thank you
Lokky

Sent from my iPhone

On 28 Sep 2014, at 18:37, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Please be advised that our team members are not staying at the Royal 'whatever' hotel! This is important and happened to the last team (team 2). Our team stays at the Kendeja hotel and the driver should transport them to the Kendeja as we have rooms booked for Kyle Rosenke, Kristin McNally and myself at the Kendeja.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 11:53 PM
To: 'ali.khan@unmc.edu'
Subject: Re: CMX-001

Redacted by agreement

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 05, 2014 03:21 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: CMX-001

CDC is suggesting we try based on in vitro data.
Let's reconsider a therapeutic trial when you get in Monrovia.
Be safe,
Ali

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Sunday, October 5, 2014 1:56 PM
To: Khan, Ali S
Subject: Re: CMX-001

I do not know. I am on my way to Monrovia. I heard you will receive the

Redacted by agreement

Heinz

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 05, 2014 10:51 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CMX-001

Being used for Ebola?
Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 11:45 PM
To: Shott, Joseph (NIH/NIAID) [E]
Subject: Re: PRO/AH/EDR> Marburg virus disease - Uganda: (KM) RFI

I hope they can contain and control it. On my way to Monrovia.

Best wishes, Heinz

----- Original Message -----

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 10:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: PRO/AH/EDR> Marburg virus disease - Uganda: (KM) RFI

I know you're busy but...

From: promed-edr@promedmail.org [promed-edr@promedmail.org]
Sent: Sunday, October 05, 2014 9:01 PM
To: promed-post@promedmail.org; promed-edr-post@promedmail.org; promed-ahead-post@promedmail.org
Subject: PRO/AH/EDR> Marburg virus disease - Uganda: (KM) RFI

MARBURG VIRUS DISEASE - UGANDA: (KAMPALA), REQUEST FOR INFORMATION

A ProMED-mail post

<<http://www.promedmail.org>>

ProMED-mail is a program of the

International Society for Infectious Diseases <<http://www.isid.org>>

Date: 5 Oct 2014

Source: Reuters [edited]

<<http://www.reuters.com/article/2014/10/05/us-uganda-health-idUSKCN0HU0O120141005>>

A man has died in Uganda's capital after an outbreak of Marburg, a highly infectious hemorrhagic fever similar to Ebola, authorities said on Sunday [5 Oct 2014], adding that a total of 80 people who came into contact with him were quarantined.

Marburg starts with a severe headache followed by hemorrhaging and leads to death in 80 percent or more of cases in about 9 days. It is from the same family of viruses as Ebola, which has killed thousands in West Africa in recent months.

There is no vaccine or specific treatment for the Marburg virus, which is transmitted through bodily fluids such as saliva and blood or by handling infected wild animals such as monkeys.

The health ministry said in a statement that the 30-year-old radiographer died on 28 Sep 2014 while working at a hospital in Kampala. He had started feeling unwell about 10 days earlier, and his condition kept deteriorating. He complained of headache, abdominal pain, vomiting blood and diarrhea.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 1:20 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Yes - even though Darryl seems to have better data with the other type of drugs.

We need the vaccine for the outbreak. I heard that NIH is getting involved in the VS? trial - true? If so, is there a role for us?

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:17 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Also some anti-inflammatory drugs might be helpful.

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:12 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Sounds good. There are some candidate drugs that interfere with coagulation and/or seal the endothelium. One of those might be interesting.

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:06 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Thanks Heinz. We can see how they fair and decide what if any might be the best combination.
K

Sent from my BlackBerry Wireless Handheld

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 1:13 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Sounds good. There are some candidate drugs that interfere with coagulation and/or seal the endothelium. One of those might be interesting.

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 03:06 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Thanks Heinz. We can see how they fair and decide what if any might be the best combination.
K

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 02:42 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

This is not significant at the moment - we have to wait longer. If the animals are surviving or live significantly longer we may want to combine the treatment with a third drug as I don't think the two will do. One might also want to consider

Redacted by agreement

Redacted by agreement

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 01:46 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 12:56 PM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Fw: CMX-001

Do you know this drug? If so - feel free to respond to Ali.

Heinz

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 05, 2014 10:51 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CMX-001

Being used for Ebola?

Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 12:56 PM
To: 'ali.khan@unmc.edu'
Subject: Re: CMX-001

I do not know. I am on my way to Monrovia. I heard you will receive the Redacted by agreement

Heinz

----- Original Message -----

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, October 05, 2014 10:51 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CMX-001

Being used for Ebola?
Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 12:43 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

This is not significant at the moment - we have to wait longer. If the animals are surviving or live significantly longer we may want to combine the treatment with a third drug as I don't think the two will do. One might also want to consider

Redacted by agreement

Redacted by agreement

Heinz

----- Original Message -----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 01:46 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

This is pretty interesting. We know that different IFNs can have different virus specificity. I wonder how much, if any, delay in virus replication might be useful.

Kathy

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 12:40 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: RE: NHP update - day 10

Redacted by agreement

Darryl

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 6:30 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Thanks for the update Darryl

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 12:38 PM
To: Kobinger, Gary (Public Health Agency of Canada); 'twgeisbe@UTMB.EDU'
Subject: Re: Side effects

We don't have the vector either. Sharing might be difficult during phase I - I guess GSK would object. Otherwise, I agree with Gary.

On my way to Monrovia.

Heinz

From: Kobinger, Gary (Public Health Agency of Canada)
Sent: Sunday, October 05, 2014 02:06 PM Eastern Standard Time
To: Geisbert, Thomas W. <twgeisbe@UTMB.EDU>; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Side effects

I don't, I have several simian Ads-ZGP but it would need to be the same to be meaningful. Ask Nancy or is she not sharing? I never asked her any reagents so I don't know.

If she is not sharing then that would be breaking publication agreements, and then she shouldn't publish. Old stuff but never too late to do good (enforce).

Take care
Gary
-----Original Message-----
From: Geisbert, Thomas W.
To: Heinz Feldmann
To: Gary Kobinger
Subject: RE: Side effects
Sent: Oct 2, 2014 20:09

It is hard to say right now with N being so small. Gary, on the ChAd do you know of anyone that has the ChAd3 Ebola GP vectors other than VRC. Someone needs to test that against a 7U virus.

Tom
From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov] **Sent:** Wednesday, October 01, 2014 1:06 PM **To:** Geisbert, Thomas W.; Kobinger, Gary (Public Health Agency of Canada) **Subject:** RE: Side effects Gary – could it be related to the higher dose (1×10^8 ?) compared to the German lady? The Profectus backbone vector obviously did not show any adverse effects if you look at the HIV phase I trial – why do you think there is such a difference? Tom?

From: Geisbert, Thomas W. [<mailto:twgeisbe@UTMB.EDU>] **Sent:** Wednesday, October 01, 2014 6:42 AM **To:** Kobinger, Gary (Public Health Agency of Canada); Feldmann, Heinrich (NIH/NIAID) [E] **Subject:** RE: Side effects

Gary,

Do you mean the German case?

Tom
From: Gary Kobinger [gary.kobinger@phac-aspc.gc.ca] **Sent:** Wednesday, October 01, 2014 3:55 AM **To:** Heinz Feldmann; Geisbert, Thomas W. **Subject:** Side effects

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 12:36 PM
To: Meade-White, Kimberly (NIH/NIAID) [E]
Cc: LaCasse, Rachel (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]
Subject: Re: vaccine study and availability of BSL4 space

this study has priority at the moment as it studies the efficacy of the GMP-produced VSV vaccine that will go into phase I human trials. The study is absolute urgent.

Thanks, Heinz

----- Original Message -----

From: Meade-White, Kimberly (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 02:30 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: LaCasse, Rachel (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: FW: vaccine study and availability of BSL4 space

Good Morning Heinz,

I am looking at the logistics of getting Andrea's vaccine study (2014-066e) going so quickly and on such a short notice (see below). Currently we only have 2 big rooms that are cold (2B139 in B/C with the new biobubbles in it and 2B115 in Suite D) and a smaller room in Suite A, 2B163. In addition there is one big room that is empty, hasn't had agent in it but needs to be deconned (2B131). The occupied rooms include 2B137, contains 6 idol monkeys that are being stored for a future study, 2B135 which is Darryl's Ebola drug treatment study, 2B161 which is Andrea's Vaccine Ebola study. Rodent rooms are 2B133 and 2B113A. So if we are able to start this study on Tuesday which I'm not sure yet if we can, we will have to move animals early tomorrow. I want to confirm with you that there are no conflicts with other studies in LV before we do anythnig, especially since this is such short notice.

Thanks,
Kimberly

-----Original Message-----

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 2:51 PM
To: Meade-White, Kimberly (NIH/NIAID) [E]
Subject: Re: vaccine study

Will do when I get back to work tomorrow.
Don't have it with me.
Thanks, A.

On 10/4/14 1:41 PM, "Meade-White, Kimberly (NIH/NIAID) [E]"
<kmeade-white@niaid.nih.gov> wrote:

>Let me look at the logistics of pulling that together and moving
>animals on such short notice. Also want to make sure there will be

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 9:00 AM
To: 'Helen.Branswell@thecanadianpress.com'
Subject: Re: FYI

I am at Minneapolis airport now until 2:00 PM CST.

----- Original Message -----

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Saturday, October 04, 2014 12:54 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI

Sure, and thanks.
Send me good times to call when you know what will work.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-04-14 12:54 PM
To: Branswell, Helen
Subject: RE: FYI

Can we talk tomorrow? I have time at airports. RT-PCR is all we (they) can do at the moment - sufficient but not absolute perfect. No need to criticise as this is the best they can do.,

-----Original Message-----

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Saturday, October 04, 2014 10:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI

Taylor says they won't be growing the virus - can't. Says they'll be testing by PCR. Not sufficient?
Can we talk briefly? Or are you too busy?

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-04-14 12:41 PM
To: Branswell, Helen
Subject: RE: FYI

No - what they want to know is if the disinfection procedures are sufficient or if they have to change. For this you need infectivity studies - basically growing the virus. Not sure if that is part of the PHAC mission but we have been approached with the same ideas and questions. Unfortunately, we cannot ship any samples out of Liberia.

Of course, there is more to do that can be done with RT-PCR. Knowing PHAC they will most likely contrite on those aspects)for example, environmental contamination).

-----Original Message-----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 8:35 AM
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Cc: 'Anja.WOLZ@geneva.msf.org'; 'Ilia.Semmler@tmf-ev.de'; 'jricht@vet.k-state.edu'
Subject: Re: Berlin

It looks like they are fine now - Ilia and Juergen?

----- Original Message -----

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Sunday, October 05, 2014 08:04 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Anja WOLZ <Anja.WOLZ@geneva.msf.org>; Ilia.Semmler@tmf-ev.de <Ilia.Semmler@tmf-ev.de>; jricht@vet.k-state.edu <jricht@vet.k-state.edu>
Subject: Re: Berlin

Heinz,

Do you need someone back from the field, or someone who can speak for MSF?
I can put you in contact with MSF-Germany, who may well have returned expats who may fit your needs.

Sent from my iPhone

> On Oct 5, 2014, at 1:09 PM, "Feldmann, Heinrich (NIH/NIAID) [E]"
<feldmannh@niaid.nih.gov> wrote:
>
> I guess we have to move on.
>
> Ilia and Juergen, please make necessary changes.
>
> Anja - I may see you in Monrovia. I am on my way.
>
> Heinz
>
> From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
> Sent: Sunday, October 05, 2014 03:15 AM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of
Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de) <Ilia.Semmler@tmf-ev.de>; Juergen Richt <jricht@vet.k-state.edu>
> Subject: RE: Berlin
>
> Dear Heinz, I'm sorry but I have to cancel my participation.
> Again I have to stay longer in West Africa and I will not be back in
> time
for the meeting.
> I'm really sorry for this,
> But maybe Armand you know someone else?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 5:35 AM
To: Personal Info
Subject: Fw: Frage ad Ebola und PS

----- Original Message -----

From: Koch Eva maria [mailto:Personal Info]
Sent: Sunday, October 05, 2014 04:44 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Frage ad Ebola und PS

Sehr geehrter Herr Prof.Feldmann,

bitte verzeihen Sie die Belästigung, ich las in den Medien von Ihnen zu Ebola, und wollte Sie nun als Experten fragen, wie konkret der Ansteckungsweg ist ?

Denn irgendetwas stimmt doch hier bei der Berichterstattung nicht, auch seitens Virologen, einerseits heißt es, es ist nicht so hoch ansteckend, wie z B Influenza, weil nur über Körperflüssigkeiten ansteckend, aber auf der anderen Seite, ist die Ansteckungsrate doch extrem hoch, und die Warnungen (siehe aktuell bei dem USA Patienten, der evtl. mit über 100 Pers. Kontakt hatte) obwohl kein Kontakt zu Körperflüssigkeiten bestand und besteht.

Es aber dennoch ständig zu Ansteckungen kommt.

Was stimmt hier nicht ?

Wieso kommt es ständig zu Ansteckungen auch bei Ärzten und Pflegern ?

Welche Handschuhe sind Ebola sicher ?

Ich machte die Erfahrung, daß zB Latex- Handschuhe Clostridium Difficile durchlässig ist !

Dennoch sieht man sowohl in Österr. Spitälern als auch in den Ebola Gebieten überall auch Latex- Handschuhe.

Wäre Ihnen sehr dankbar für Ihre Antwort.

Mit besten Grüßen
Eva Koch

PS:

bezüglich allg. Statements nun, daß Ebola nur über Blut und Körperflüssigkeiten übertragen wird, und nicht, wie Gerüchte meinten, evtl. auch über Tröpfcheninfektion, wenn diese Ihre Meinung stimmt, wie erklären Sie dann die so extrem hohe Durchseuchungsrate, Ansteckungsrate, diese extremen Vorsichtsmaßnahmen und Warnungen und der Ansteckungen trotzdem ?!

Stimmt dies, dann gleicht ja HIV, Hepatitis C, etc. und diese Ansteckungen und Warnungen und Vorsichtsmaßnahmen sehen ja -zum Glück- ganz anders aus. Wenn auch tragische genug.

Da stimmt doch etwas nicht !

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 5:09 AM
To: 'Anja.WOLZ@geneva.msf.org'
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Ilia.Semmler@tmf-ev.de'; 'jricht@vet.k-state.edu'
Subject: Re: Berlin

I guess we have to move on.

Ilia and Juergen, please make necessary changes.

Anja - I may see you in Monrovia. I am on my way.

Heinz

From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
Sent: Sunday, October 05, 2014 03:15 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de) <Ilia.Semmler@tmf-ev.de>; Juergen Richt <jricht@vet.k-state.edu>
Subject: RE: Berlin

Dear Heinz, I'm sorry but I have to cancel my participation.
Again I have to stay longer in West Africa and I will not be back in time for the meeting.
I'm really sorry for this,
But maybe Armand you know someone else?
Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher,Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de)" <Ilia.Semmler@tmf-ev.de>, Juergen Richt <jricht@vet.k-state.edu>
Date: 23.09.2014 02:17
Subject: RE: Berlin

Anja,
We would like to invite you to present a talk on the Ebola outbreak in West Africa. The presentation is scheduled for Thursday, October 16 in the time from 16:30-17:30h.

Please let us know as soon as possible if you will accept our invitation.

Best wishes and stay safe,
Heinz

-----Original Message-----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, October 05, 2014 5:08 AM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: Re: NHP update - day 10

Thanks.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, October 05, 2014 02:22 AM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: NHP update - day 10

Redacted by agreement

Redacted by agreement

Redacted by agreement

Thanks,
Darryl

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 12:54 PM
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: Sample load

Great.

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 12:35 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: Sample load

Processed 60 samples today. Working on the last 4 now. We also passed sample #2000 today.

Sent from my iPhone

> On Oct 4, 2014, at 4:54 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>

> Thanks.

>

>

> -----Original Message-----

> From: McNally, Kristin (NIH/NIAID) [E]
> Sent: Saturday, October 04, 2014 10:54 AM
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: Expat sample

>

> Kristin [Personal Info]

> Kyle [Personal Info]

>

> Sent from my iPhone

>

>> On Oct 4, 2014, at 4:51 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>>

>> Can you give me a phone number so that I can call you or Kyle if needed?

>>

>> Heinz

>>

>>

>> -----Original Message-----

>> From: McNally, Kristin (NIH/NIAID) [E]
>> Sent: Saturday, October 04, 2014 10:50 AM
>> To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 11:42 AM
To: 'Richard Besserman'
Subject: RE: Immunosignature strategy to safeguard immunologically naive healthcare personnel

I agree with you but as mentioned before we are unable to provide human samples for your studies. Once the MOU with the Liberian government is in place for sample transfer, the best would be to contact CDC as they have the US lead in the country on the Ebola outbreak. They would have to release the samples for you. I would not be able to make that decision. The contact would be the Viral Special Pathogens Branch at CDC in Atlanta.

We and others could do the necessary animal studies with you if you are interested. Unfortunately, my group is currently unable to take on more studies as we have many of our staff in the field. Once this outbreak gets under control animal studies might be possible. In order to get this done sooner you may want to contact the containment lab at UTMB Galveston.

Best wishes,
Heinz

From: Richard Besserman [mailto:Richard.Besserman@asu.edu]
Sent: Saturday, October 04, 2014 11:15 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Immunosignature strategy to safeguard immunologically naive healthcare personnel

I suspected that. There are far too many healthcare workers contracting Ebola. I read somewhere that you share those feelings. For Ebola, we would like to do a proof of principle experiment to detect an immunosignature of early response (1-4 days post infection). We have some data that supports that capability. This unique signature remains constant with infectious diseases. That's why we need samples from close contacts who are isolated prior to development of symptoms. Having samples from those in isolation who develop Ebola could provide some answers. If you would want to learn about the technology would be please to send some references,
Best
RB

On Oct 4, 2014, at 9:07 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Every antiviral therapy will work better with lower viral load. Problem is you hardly ever see a person in the public health system prior to onset of symptoms as that is when people seek medical help. Most vaccine would be used prophylactically – meaning before exposure.

From: Richard Besserman [mailto:Richard.Besserman@asu.edu]
Sent: Saturday, October 04, 2014 9:32 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Immunosignature strategy to safeguard immunologically naive healthcare personnel

Thanks for getting back to me. Have you thought about the other question in my email? Will early identification change treatment strategy?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:54 AM
To: McNally, Kristin (NIH/NIAID) [E]
Subject: RE: Expat sample

Thanks.

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:54 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Expat sample

Kristin Personal Info

Kyle Personal Info

Sent from my iPhone

> On Oct 4, 2014, at 4:51 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>
> Can you give me a phone number so that I can call you or Kyle if needed?

>
> Heinz

>
>
> -----Original Message-----

> From: McNally, Kristin (NIH/NIAID) [E]
> Sent: Saturday, October 04, 2014 10:50 AM
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: Expat sample

>
> Bags r in Monrovia at the Brussels air office (not at the airport). They r closed until Monday. We're working on it.

>
> Sent from my iPhone

>
>> On Oct 4, 2014, at 4:48 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>>
>> Do you know if the bags are in country? I could still bring more but Delta tells us that I can only bring 4 pieces of luggage which I have already and there is hardly any room left for more. I think the problem is not Delta but rather Brussels Air.

>>
>> Keep me in the loop with the driver situation.

>>
>> Heinz

>>
>> -----Original Message-----

>> From: McNally, Kristin (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:54 AM
To: 'Branswell, Helen'
Subject: RE: FYI

Can we talk tomorrow? I have time at airports. RT-PCR is all we (they) can do at the moment - sufficient but not absolute perfect. No need to criticise as this is the best they can do.,

-----Original Message-----

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Saturday, October 04, 2014 10:52 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI

Taylor says they won't be growing the virus - can't. Says they'll be testing by PCR. Not sufficient?
Can we talk briefly? Or are you too busy?

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-04-14 12:41 PM
To: Branswell, Helen
Subject: RE: FYI

No - what they want to know is if the disinfection procedures are sufficient or if they have to change. For this you need infectivity studies - basically growing the virus. Not sure if that is part of the PHAC mission but we have been approached with the same ideas and questions. Unfortunately, we cannot ship any samples out of Liberia.

Of course, there is more to do that can be done with RT-PCR. Knowing PHAC they will most likely contrite on those aspects)for example, environmental contamination).

-----Original Message-----

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Saturday, October 04, 2014 10:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI

I don't think I understand what you are saying.
Is this about trying to figure out if there is something different about the way the virus is spreading?

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-04-14 12:35 PM
To: Branswell, Helen
Subject: RE: FYI

Thanks. I have been talking with Jim Strong about this. One of the problems with the infectivity studies is the fact that one would need to grow virus to make a final conclusion. MSF and others are talking about it. Sierra Leone might be further ahead than Liberia but we, for example, cannot ship any samples to a BSL4 lab outside the country for infectivity

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:51 AM
To: McNally, Kristin (NIH/NIAID) [E]
Subject: RE: Expat sample

Can you give me a phone number so that I can call you or Kyle if needed?

Heinz

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Expat sample

Bags r in Monrovia at the Brussels air office (not at the airport). They r closed until Monday. We're working on it.

Sent from my iPhone

> On Oct 4, 2014, at 4:48 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>

> Do you know if the bags are in country? I could still bring more but Delta tells us that I can only bring 4 pieces of luggage which I have already and there is hardly any room left for more. I think the problem is not Delta but rather Brussels Air.

>

> Keep me in the loop with the driver situation.

>

> Heinz

>

> -----Original Message-----

> From: McNally, Kristin (NIH/NIAID) [E]

> Sent: Saturday, October 04, 2014 10:46 AM

> To: Feldmann, Heinrich (NIH/NIAID) [E]

> Cc: Rosenke, Kyle (NIH/NIAID) [F]; Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]

> Subject: Re: Expat sample

>

> Heavy sample load today with 56 already. ELWA 3 stopped bringing samples in the evening the last 2 days, which makes for busy mornings. We talked with them and they will bring us samples in the evening again. Our cutoff is 6:00 - this allows us to process them and get the pcRs running so we can give them results in the morning and that gets us out around 8 pm if we're lucky! Long days but we are working well as a team. Kyle is struggling without his personal bag and I don't blame him. It looks like the office won't be open until Monday to get them.

>

> Salomon said he's had no contact with his sister or brother.

>

> We are down to 2 boxes of long cuffed medium gloves and a few bags of smart cycled tubes so our bags would be helpful!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:51 AM
To: McNally, Kristin (NIH/NIAID) [E]
Subject: RE: Expat sample

Thanks.

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Expat sample

Bags r in Monrovia at the Brussels air office (not at the airport). They r closed until Monday. We're working on it.

Sent from my iPhone

> On Oct 4, 2014, at 4:48 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>

> Do you know if the bags are in country? I could still bring more but Delta tells us that I can only bring 4 pieces of luggage which I have already and there is hardly any room left for more. I think the problem is not Delta but rather Brussels Air.

>

> Keep me in the loop with the driver situation.

>

> Heinz

>

> -----Original Message-----

> From: McNally, Kristin (NIH/NIAID) [E]

> Sent: Saturday, October 04, 2014 10:46 AM

> To: Feldmann, Heinrich (NIH/NIAID) [E]

> Cc: Rosenke, Kyle (NIH/NIAID) [F]; Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]

> Subject: Re: Expat sample

>

> Heavy sample load today with 56 already. ELWA 3 stopped bringing samples in the evening the last 2 days, which makes for busy mornings. We talked with them and they will bring us samples in the evening again. Our cutoff is 6:00 - this allows us to process them and get the pcrs running so we can give them results in the morning and that gets us out around 8 pm if we're lucky! Long days but we are working well as a team. Kyle is struggling without his personal bag and I don't blame him. It looks like the office won't be open until Monday to get them.

>

> Salomon said he's had no contact with his sister or brother.

>

> We are down to 2 boxes of long cuffed medium gloves and a few bags of smart cycled tubes so our bags would be helpful!

>

> Kristin

>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:48 AM
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]; Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Expat sample

Do you know if the bags are in country? I could still bring more but Delta tells us that I can only bring 4 pieces of luggage which I have already and there is hardly any room left for more. I think the problem is not Delta but rather Brussels Air.

Keep me in the loop with the driver situation.

Heinz

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:46 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]; Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Expat sample

Heavy sample load today with 56 already. ELWA 3 stopped bringing samples in the evening the last 2 days, which makes for busy mornings. We talked with them and they will bring us samples in the evening again. Our cutoff is 6:00 - this allows us to process them and get the pcRs running so we can give them results in the morning and that gets us out around 8 pm if we're lucky! Long days but we are working well as a team. Kyle is struggling without his personal bag and I don't blame him. It looks like the office won't be open until Monday to get them.

Salomon said he's had no contact with his sister or brother.

We are down to 2 boxes of long cuffed medium gloves and a few bags of smart cycled tubes so our bags would be helpful!

Kristin

Sent from my iPhone

> On Oct 4, 2014, at 4:29 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
>
> Kristin & Kyle,
>
> I just talked to Dawn - she is working on the case with absolute priority. She told me that she had talked to Kyle on the phone. I think this will be resolved soon. Please let me know immediately when you hear from them. Please contact me in any case.
>
> Hope things are well otherwise. How is the sample load today?
>
> Best wishes,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:41 AM
To: 'Branswell, Helen'
Subject: RE: FYI

No - what they want to know is if the disinfection procedures are sufficient or if they have to change. For this you need infectivity studies - basically growing the virus. Not sure if that is part of the PHAC mission but we have been approached with the same ideas and questions. Unfortunately, we cannot ship any samples out of Liberia.

Of course, there is more to do that can be done with RT-PCR. Knowing PHAC they will most likely contrite on those aspects)for example, environmental contamination).

-----Original Message-----

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Saturday, October 04, 2014 10:37 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI

I don't think I understand what you are saying.
Is this about trying to figure out if there is something different about the way the virus is spreading?

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-04-14 12:35 PM
To: Branswell, Helen
Subject: RE: FYI

Thanks. I have been talking with Jim Strong about this. One of the problems with the infectivity studies is the fact that one would need to grow virus to make a final conclusion. MSF and others are talking about it. Sierra Leone might be further ahead than Liberia but we, for example, cannot ship any samples to a BSL4 lab outside the country for infectivity testing (we need a MOU with the government in place to do that). RT-PCR is good and very sensitive and certainly better than nothing, but does not tell you much about infectivity.

Heinz

-----Original Message-----

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Saturday, October 04, 2014 10:31 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI

October 4, 2014 Ottawa, ON Public Health Agency of Canada

The Honourable Rona Ambrose, Minister of Health, with Canada's Chief Public Health Officer Dr. Gregory Taylor, announced the deployment of a second mobile lab team to West Africa.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:36 AM
To: McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: FW: Expat sample

Please pass on to Dawn if you can.

-----Original Message-----

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Saturday, October 04, 2014 10:33 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Cc: Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Records Originating Outside of NIAID

Original Message

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 4, 2014 7:29 PM
To: McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Cc: Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: Expat sample

Kristin & Kyle,

I just talked to Dawn - she is working on the case with absolute priority. She told me that she had talked to Kyle on the phone. I think this will be resolved soon. Please let me know immediately when you hear from them. Please contact me in any case.

Hope things are well otherwise. How is the sample load today?

Best wishes,
Heinz

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Dawn is the cdc contact on the ground. I apologize that I don't have her last name

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:35 AM
To: 'Branswell, Helen'
Subject: RE: FYI

Thanks. I have been talking with Jim Strong about this. One of the problems with the infectivity studies is the fact that one would need to grow virus to make a final conclusion. MSF and others are talking about it. Sierra Leone might be further ahead than Liberia but we, for example, cannot ship any samples to a BSL4 lab outside the country for infectivity testing (we need a MOU with the government in place to do that). RT-PCR is good and very sensitive and certainly better than nothing, but does not tell you much about infectivity.

Heinz

-----Original Message-----

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Saturday, October 04, 2014 10:31 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: FYI

October 4, 2014 Ottawa, ON Public Health Agency of Canada

The Honourable Rona Ambrose, Minister of Health, with Canada's Chief Public Health Officer Dr. Gregory Taylor, announced the deployment of a second mobile lab team to West Africa.

Today, the Public Health Agency of Canada deployed a second mobile laboratory and two additional Agency scientists to Sierra Leone to join the Agency's existing team in the field in Kailahun. A third scientist will leave on Tuesday.

One mobile lab team will continue to provide rapid diagnostic support to help local healthcare workers to quickly diagnose Ebola. The second mobile lab team will work with Médecins Sans Frontières (MSF) to monitor the effectiveness of infection prevention procedures such as handwashing stations, face masks and disposal sites to prevent the further spread of Ebola.

On-site laboratory support that produces results in only a few hours is pivotal in responding effectively to an outbreak of Ebola, as it allows for faster isolation of Ebola cases and patient care.

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: October-04-14 12:30 PM
To: Branswell, Helen
Subject: RE: FYI

They were talking about it since a few days or even week(s). Not sure when they finally will deploy that second team. It could be any time now.

-----Original Message-----

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:29 AM
To: McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Cc: Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: Expat sample

Kristin & Kyle,

I just talked to Dawn - she is working on the case with absolute priority. She told me that she had talked to Kyle on the phone. I think this will be resolved soon. Please let me know immediately when you hear from them. Please contact me in any case.

Hope things are well otherwise. How is the sample load today?

Best wishes,
Heinz

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Dawn is the cdc contact on the ground. I apologize that I don't have her last name Personal Info

Sent from my iPhone

> On Oct 4, 2014, at 4:15 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
>
> Kristin,
> Does he have contact with them? Most likely yes. Is he sick as well? You should contact the CDC lead on the ground. I can do that for you if you give me his/her name. You are right, Personal Info
>
> Barry, Stuart and/or Pierre - can you please help here to solve the situation? This is urgent.
>
> Thanks and best wishes,
> Heinz

> -----Original Message-----

> From: McNally, Kristin (NIH/NIAID) [E]
> Sent: Saturday, October 04, 2014 8:54 AM
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:26 AM
To: Fields, Barry (CDC/CGH/DGHP); McNally, Kristin (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID)
Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: Expat sample

I agree.

-----Original Message-----

From: Fields, Barry (CDC/CGH/DGHP)
Sent: Saturday, October 04, 2014 10:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID)
Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Records Originating Outside of NIAID

Sent from my BlackBerry 10 smartphone.

Original Message

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 4, 2014 7:15 PM
To: McNally, Kristin (NIH/NIAID) [E]; Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID)
Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: Expat sample

Kristin,

Does he have contact with them? Most likely yes. Is he sick as well? You should contact the CDC lead on the ground. I can do that for you if you give me his/her name. You are right, the driver should most likely not work any longer.

Barry, Stuart and/or Pierre - can you please help here to solve the situation? This is urgent.

Thanks and best wishes,
Heinz

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 8:54 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:24 AM
To: 'fritz.habekuss@zeit.de'
Subject: RE: Anfrage DIE ZEIT: Ebola

Ja.

-----Original Message-----

From: fritz.habekuss@zeit.de [mailto:fritz.habekuss@zeit.de]
Sent: Saturday, October 04, 2014 3:28 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: Anfrage DIE ZEIT: Ebola

das passt gut, ich rufe durch. Erreiche ich Sie unter dieser Nummer: 406-375-7410?

Herzlich, FH.

Von: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Gesendet: Samstag, 4. Oktober 2014 00:47
An: Habekuss, Fritz
Betreff: RE: Anfrage DIE ZEIT: Ebola

Wie waere morgen (Samstag) gegen 19:00 Uhr MEZ?

DIE ZEIT jetzt am Kiosk.
www.zeit.de/diesewoche

ZEIT ONLINE - Durchschauen Sie jeden Tag.
www.zeit.de

-----Original Message-----

From: fritz.habekuss@zeit.de [mailto:fritz.habekuss@zeit.de]
Sent: Friday, October 03, 2014 3:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: Anfrage DIE ZEIT: Ebola

gerne. wenn Sie mir eine Zeit geben, rufe ich durch. Das ist die Nummer, oder: 406-375-7410?

Herzlich,
Fritz Habekuß

Fritz Habekuß
DIE ZEIT | Ressort Wissen

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:16 AM
To: McNally, Kristin (NIH/NIAID) [E]; Fields, Barry (CDC/CGH/DGHP); Nichol, Stuart T. (CDC/OID/NCEZID); Rollin, Pierre (CDC/OID/NCEZID)
Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: Expat sample

Importance: High

Kristin,

Does he have contact with them? Most likely yes. Is he sick as well? You should contact the CDC lead on the ground. I can do that for you if you give me his/her name. You are right, Personal Info

Barry, Stuart and/or Pierre - can you please help here to solve the situation? This is urgent.

Thanks and best wishes,
Heinz

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 8:54 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Just got a phone call from Personal Info - it's his day off. Personal Info

Personal Info

Not sure if Personal Info

Kristin

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, October 04, 2014 10:08 AM
To: 'Richard Besserman'
Subject: RE: Immunosignature strategy to safeguard immunologically naive healthcare personnel

Every antiviral therapy will work better with lower viral load. Problem is you hardly ever see a person in the public health system prior to onset of symptoms as that is when people seek medical help. Most vaccine would be used prophylactically – meaning before exposure.

From: Richard Besserman [mailto:Richard.Besserman@asu.edu]
Sent: Saturday, October 04, 2014 9:32 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Immunosignature strategy to safeguard immunologically naive healthcare personnel

Thanks for getting back to me. Have you thought about the other question in my email? Will early identification change treatment strategy?

RB

On Oct 3, 2014, at 5:37 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

We do not have any blood samples from Ebola patients. At the moment we are not allowed to ship samples from Liberia where we provide laboratory support.

From: Richard Besserman [mailto:Richard.Besserman@asu.edu]
Sent: Friday, October 03, 2014 5:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Immunosignature strategy to safeguard immunologically naive healthcare personnel

Dear Dr. Feldman,

My colleagues at ASU Biodesign Institute have developed a means of identifying an immune signature of infectious diseases from a drop of blood before symptoms arise. It is about 100 times more sensitive than ELISA. As an interim federal employee, I have been a member of an HHS/ASPR/NDMS team for many years and fully understand the importance of safety when deployed. I suggested to these researchers that they look at EBOLA to see whether they could find a reliable signature that may appear during the first few days following exposure/infection. They have seen it with other viruses.

From a public health perspective, when a healthcare worker shows a conversion from baseline to show an ebola signature that person would be isolated from co-workers even in the absence

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 9:56 PM
To: Munster, Vincent (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Have a safe trip.

----- Original Message -----

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 11:23 PM Eastern Standard Time
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Great work,

Just landed in brussel

Cheers,

Vincent

Sent from my iPhone

> On Oct 4, 2014, at 0:59, "McNally, Kristin (NIH/NIAID) [E]" <mcnallyk@niaid.nih.gov> wrote:

>

> Just wanted to let you know that we got a priority sample from Darlington at ELWA II today after Vincent left. It was apparently from some association to the [Redacted by agreement] The back story was hard to follow but it appeared as if there was no overt exposure, but he was leaving for the US today and wanted to get tested before leaving. I'm guessing this has something to do with [Personal Info,Redacted by agreement]

[Personal Info.Redacted by agreeme] Kyle - please add any info you gleaned? We ran a full panel and all tests (L and NP from us, GP from the Kenyans) came up negative. MS2 was positive. Positive and negative controls were as expected.

>

> Safe travels Heinz.

>

> Kristin

>

> Sent from my iPhone

>

>> On Oct 2, 2014, at 7:02 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>>

>> This is not a MSF person, isn't it?

>>

>> -----Original Message-----

>> From: Munster, Vincent (NIH/NIAID) [E]

>> Sent: Thursday, October 02, 2014 9:29 AM

>> To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 6:53 PM
To: 'Thomas C. Marlovits'
Cc: Marlovits,Thomas; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Question related to cDNAs

I guess Thomas Hoenen would be the best partner here.

From: Thomas C. Marlovits [mailto:marlovits@imp.ac.at]
Sent: Friday, October 03, 2014 6:37 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marlovits,Thomas; Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: Re: Question related to cDNAs

Dear Heinz, we would like to understand the process of replication (central around RNA dep RNA polymerase L and interacting factors).

Best,
Thomas

Sent from my mobile device

On Oct 4, 2014, at 2:35, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Dear Thomas,

What proteins are you interested in? Andrea and Thomas (see cc) can most likely help. If so, we need to do a Simple Letter Agreement' and can ship.

I will be away for the next three weeks. Please communicate with Andrea and Thomas on this issue with copy to me.

Best wishes,

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 6:52 PM
To: Safronetz, David (NIH/NIAID) [E]
Subject: RE: Unpublished
Attachments: Unpublished

Unpublished

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:23 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Unpublished

Unpublished

Dave

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 6:37 PM
To: 'Richard Besserman'
Subject: RE: Immunosignature strategy to safeguard immunologically naive healthcare personnel

We do not have any blood samples from Ebola patients. At the moment we are not allowed to ship samples from Liberia where we provide laboratory support.

From: Richard Besserman [mailto:Richard.Besserman@asu.edu]
Sent: Friday, October 03, 2014 5:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Immunosignature strategy to safeguard immunologically naive healthcare personnel

Dear Dr. Feldman,

My colleagues at ASU Biodesign Institute have developed a means of identifying an immune signature of infectious diseases from a drop of blood before symptoms arise. It is about 100 times more sensitive than ELISA. As an interim federal employee, I have been a member of an HHS/ASPR/NDMS team for many years and fully understand the importance of safety when deployed. I suggested to these researchers that they look at EBOLA to see whether they could find a reliable signature that may appear during the first few days following exposure/infection. They have seen it with other viruses.

From a public health perspective, when a healthcare worker shows a conversion from baseline to show an ebola signature that person would be isolated from co-workers even in the absence of symptoms. Disease management may be one benefit, but I wonder whether there may be any therapeutic strategies (medications, sera, or vaccines) that could might work better on the Ebola virus when the viral load is so minimal, rarely ever seen except potentially in contacts.

We would demonstrate that we can identify a signature by testing a number of inactivated samples of blood from contacts who were asymptomatic when the draw took place, and later went on to develop disease. Do you or anyone who might know, have what we need or can you suggest a surrogate disease that can justify further research in this approach?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 6:35 PM
To: 'Marlovits,Thomas'
Cc: Marzi, Andrea (NIH/NIAID) [E]; Hoenen, Thomas (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Question related to cDNAs

Dear Thomas,

What proteins are you interested in? Andrea and Thomas (see cc) can most likely help. If so, we need to do a Simple Letter Agreement' and can ship.

I will be away for the next three weeks. Please communicate with Andrea and Thomas on this issue with copy to me.

Best wishes,
Heinz

From: Marlovits,Thomas [mailto:Thomas.Marlovits@imba.oeaw.ac.at]
Sent: Friday, October 03, 2014 6:14 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Question related to cDNAs

Dear Dr Feldmann, dear Heinz,

our research focuses on questions related to the mechanism and structure of proteins. Our lab shows interest to investigate some of the proteins present/encoded in viral pathogens in the future. To this end we are looking to find a source for cDNAs of individual proteins of Ebola (We are not looking for a complete viral genome/cDNA as no infection studies will be done). The cDNA will be used to express proteins in E.coli for recombinant protein production. Can you point us to a lab that can help us?

Best regards,
-T Marlovits

Thomas C. Marlovits, PhD, M.A.S.

Professor for Structural and Systems Biology, ISS, UKE, Hamburg, Germany • Member of the Managing Board of Directors @ CSSB, Hamburg.

Germany • IMP, IMBA, Vienna, Austria

The MarlovitsLab — <http://www.marlovitslab.org>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 6:33 PM
To: 'Penny Heaton'
Cc: Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: Ebola

Thanks Penny

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Friday, October 03, 2014 6:32 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: Ebola

As did !! I will be speaking with my colleague in Discovery on Monday and will loop back to you afterwards. Andrea, so nice to meet you albeit virtually.

And Heinz, safe travels!

Best,

Penny

Sent from my Windows Phone

From: [Feldmann, Heinrich \(NIH/NIAID\) \[E\]](#)
Sent: 10/3/2014 3:50 PM
To: [Penny Heaton](#)
Cc: [Marzi, Andrea \(NIH/NIAID\) \[E\]](#)
Subject: RE: Ebola

Dear Penny,

I enjoyed our conversation about Ebola vaccines etc. Just to introduce Andrea – she is copied here. I talked to her in more general terms about our conversation.

We would be very interested in working with you and others.

Best wishes,

Heinz

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Thursday, October 02, 2014 3:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Let's go with 3 pm East Coast time. I am happy to call you.

FYI...if you need to reach me urgently for some reason, you can always call my cell at Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 5:47 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Draft letter
Attachments: Personal Info Reference-2014.doc

Sorry for all the extra work but the draft letter is an outline for the support letter. Feel free to make changes, etc. Let me know if I should address you as Personal Info (I use both in the current draft).

Best wishes,
Heinz

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416
Email: feldmannh@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 5:05 PM
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: Expat sample

Thanks for the update and great job. On the other hand, in future we should most likely not do this unless a person is sick. I will talk to CDC and others about this request as this should not come to us. We should only test clinically symptomatic people and perhaps people that have a legitimate concern for high-risk exposure even though the tests are likely to be negative if no clinical symptoms.

We have done this also doing my time but we need to tackle these requests as they are unjustified. This is not your problem - something that I need to tackle when I get there.

Hope things are going well. I will be leaving on Sunday morning. Looking forward to have a beer with you on Monday evening.

Best wishes,
Heinz

-----Original Message-----

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 4:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: Re: Expat sample

Just wanted to let you know that we got a priority sample from Darlington at ELWA II today after Vincent left. It was apparently from some association [Personal Info.Redacted by agreeme] The back story was hard to follow but it appeared as if there was no overt exposure, but he was leaving for the US today and wanted to get tested before leaving. I'm guessing this has something to do with the [Personal Info.Redacted by agreement]
[Personal Info.Redacted by agreeme] Kyle - please add any info you gleaned? We ran a full panel and all tests (L and NP from us, GP from the Kenyans) came up negative. MS2 was positive. Positive and negative controls were as expected.

Safe travels Heinz.

Kristin

Sent from my iPhone

> On Oct 2, 2014, at 7:02 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>

> This is not a MSF person, isn't it?

>

> -----Original Message-----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 4:51 PM
To: 'Penny Heaton'
Cc: Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: Ebola

Dear Penny,

I enjoyed our conversation about Ebola vaccines etc. Just to introduce Andrea – she is copied here. I talked to her in more general terms about our conversation.

We would be very interested in working with you and others.

Best wishes,
Heinz

From: Penny Heaton [<mailto:Penny.Heaton@gatesfoundation.org>]
Sent: Thursday, October 02, 2014 3:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Let's go with 3 pm East Coast time. I am happy to call you.

FYI...if you need to reach me urgently for some reason, you can always call my cell at **Personal Info**

Looking forward to it. Thanks!

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Thursday, October 02, 2014 2:06 PM
To: Penny Heaton
Subject: RE: Ebola

Between 2:00 – 4:00 PM EST would work for me. Just let me know when and either call me at 406-375-7410 (office) or **Personal Info** (cell). Alternatively, I can call you if you provide me with a number.

Thanks,
Heinz

From: Penny Heaton [<mailto:Penny.Heaton@gatesfoundation.org>]
Sent: Thursday, October 02, 2014 2:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Sure... I can make that work.

The best times would be at either 11:30 am East Coast time or between 2 pm and 4 pm East Coast time. Just let me know a time and the best telephone number to call.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 4:49 PM
To: 'Kelly Keith'; Marzi, Andrea (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]; jim.strong@phac-aspc.gc.ca; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: VSV Ebola vaccine

Kelly,

We just submitted an addendum – as soon as approved Andrea will provide you with the original protocol and the addendum. Please use the documents for internal use only.

Hope things are going well.

Best wishes,
Heinz

From: Kelly Keith [mailto:kelly.keith@phac-aspc.gc.ca]
Sent: Friday, October 03, 2014 12:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]; jim.strong@phac-aspc.gc.ca; Kobinger, Gary (Public Health Agency of Canada)
Subject: VSV Ebola vaccine

Hi Heinz,

Hope this finds you well.

I'm looking for a copy of the protocol being used for this NHP study with the 20 GMP VSV vaccine doses. We want to ensure that the research being done with this precious resource is well co-ordinated.

If someone could send me the document, we would be most appreciative.

Best,
Kelly

(Ms.) G. Kelly Keith

Community Liaison Program Manager / National Microbiology Laboratory / Infectious Disease Prevention and Control Branch
Canadian Science Centre for Human and Animal Health
Public Health Agency of Canada / Government of Canada
kelly.keith@phac-aspc.gc.ca / Tel: 204-789-5028 / Cell: Personal Info

Gestionnaire de programme, Liaison avec la collectivité / Laboratoire national de microbiologie / Prévention et contrôle des maladies infectieuses
Centre scientifique canadien de la santé humaine et animale
Agence de la santé publique du Canada / Gouvernement du Canada
kelly.keith@phac-aspc.gc.ca / Tél. : 204-789-5028 / Tél Cell. : Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 4:47 PM
To: 'fritz.habekuss@zeit.de'
Subject: RE: Anfrage DIE ZEIT: Ebola

Wie waere morgen (Samstag) gegen 19:00 Uhr MEZ?

-----Original Message-----

From: fritz.habekuss@zeit.de [mailto:fritz.habekuss@zeit.de]
Sent: Friday, October 03, 2014 3:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: Anfrage DIE ZEIT: Ebola

gerne. wenn Sie mir eine Zeit geben, rufe ich durch. Das ist die Nummer, oder: Personal Info

Herzlich,
Fritz Habekuß

Fritz Habekuß
DIE ZEIT | Ressort Wissen
Buceriusstraße, Eingang Speersort
20095 Hamburg

Personal Info

twitter: Personal Info

Von: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Gesendet: Freitag, 3. Oktober 2014 20:29
An: Habekuss, Fritz
Betreff: RE: Anfrage DIE ZEIT: Ebola

Hat leider nicht geklappt. Ich fliege am Sonntag nach Monrovia und bin mitten in den Vorbereitungen. Koennen wir am Samstag telefonieren?

Heinz Feldmann

DIE ZEIT jetzt am Kiosk.
www.zeit.de/diesewoche

ZEIT ONLINE - Durchschauen Sie jeden Tag.
www.zeit.de

-----Original Message-----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 3:03 PM
To: 'Hayden, Frederick G *HS'
Cc: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Not us (RML).

-----Original Message-----

From: Hayden, Frederick G *HS [mailto:FGH@hscmail.mcc.virginia.edu]
Sent: Friday, October 03, 2014 12:36 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada)
Subject: Re: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Fully agree- trying to find out where the work was done. Apparently none of you have been directly involved.

Sent from my iPhone

> On Oct 3, 2014, at 14:13, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>

> Let those people speak to it who actually did the mouse studies.

>

>

> -----Original Message-----

> From: Hayden, Frederick G *HS [mailto:FGH@hscmail.mcc.virginia.edu]
> Sent: Friday, October 03, 2014 8:14 AM
> To: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada); Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: FW: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic
> Importance: High

>

> Help - any knowledge (data) on this remarkable formulation of repurposed drugs? Who has done the murine model work? As a Stanford graduate myself, I know it must be good. Please feel free to call me directly Personal Info. Thanks in advance for any insights, fgh

>

>

> From: Shalabh Gupta, MD, MPA [shalabh.gupta@globavir.com]

> Sent: 03 October 2014 02:59

> To: Hayden, Frederick G *HS; fgh@virginia.edu

> Cc: friedem@who.int; kienym@who.int

> Subject: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

>

> Dear Dr. Hayden.

>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 3:03 PM
To: 'Casey, Erin D'; Seydou Doumbia
Cc: Sangare, Djibril; Koita, Ousmane; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]
Subject: RE: Laboratory questions

The assays are the same that the NHI/CDC team uses in Monrovia to support ELWA3 (MSF ward). They target L, NP and GP.

NIH (RML) provided the equipment and training in agreement with CDC-Atlanta.

The first 14 samples were all confirmed by CDC-Atlanta.

From: Casey, Erin D [<mailto:CaseyED@state.gov>]
Sent: Friday, October 03, 2014 12:37 PM
To: Seydou Doumbia
Cc: Sangare, Djibril; Koita, Ousmane; Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Adama, N'Dir (CDC/CGH/DGHA); Polis, Michael (NIH/NIAID) [E]
Subject: RE: Laboratory questions

Records Originating Outside of NIAID



From: Seydou Doumbia [<mailto:sdoumbi@icermali.org>]
Sent: Thursday, October 02, 2014 9:09 PM
To: Casey, Erin D

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 2:45 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Mays, Gary (NIH/NIAID) [E]
Cc: Clifton, Dawn (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]
Subject: RE: Ebola response CAN

Will do.

Thanks,
Heinz

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 2:39 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Mays, Gary (NIH/NIAID) [E]
Cc: Clifton, Dawn (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]
Subject: Re: Ebola response CAN

Heinz
Please do a live link request for this request

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 04:36 PM Eastern Standard Time
To: Mays, Gary (NIH/NIAID) [E]
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Clifton, Dawn (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]
Subject: FW: Ebola response CAN

Hi Gary,

In regards to ordering and tracking purchases for the Ebola outbreak response, I would like to request a CAN specifically for these purchases. Dawn has discussed this with Lynne, who made some excellent points as to the merit of this idea:

- Allows efficient tracking of orders/travel since everything on that CAN is for the response.
- Financial reporting is available as needed.
- Eliminates the need and potential errors in tracking DMT and Ebola costs in separate spreadsheets.
- Reduces the likelihood of exceeding the CR limit on the DMT CAN.

Since this is the beginning of the FY, I feel this would be an appropriate time to set this up. If this is possible, would you please let Dawn know the CAN # and seed it with perhaps \$250,000 to start? Lynne says that approximately \$95,000 has already been spent on the DMT CAN this FY for the response, and Dawn will be placing orders soon to replace supplies taken by Team 1 when we deployed in August. Then Dawn and Lynne can let you know when more may/will need to be added. Overall, given the urgency of this mission, I anticipate the orders/dollars to be significant.

Best wishes,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 2:37 PM
To: Mays, Gary (NIH/NIAID) [E]
Cc: Zoon, Kathryn (NIH/NIAID) [E]; Clifton, Dawn (NIH/NIAID) [E]; Kisling, Lynne (NIH/NIAID) [E]
Subject: FW: Ebola response CAN

Hi Gary,

In regards to ordering and tracking purchases for the Ebola outbreak response, I would like to request a CAN specifically for these purchases. Dawn has discussed this with Lynne, who made some excellent points as to the merit of this idea:

- Allows efficient tracking of orders/travel since everything on that CAN is for the response.
- Financial reporting is available as needed.
- Eliminates the need and potential errors in tracking DMT and Ebola costs in separate spreadsheets.
- Reduces the likelihood of exceeding the CR limit on the DMT CAN.

Since this is the beginning of the FY, I feel this would be an appropriate time to set this up. If this is possible, would you please let Dawn know the CAN # and seed it with perhaps \$250,000 to start? Lynne says that approximately \$95,000 has already been spent on the DMT CAN this FY for the response, and Dawn will be placing orders soon to replace supplies taken by Team 1 when we deployed in August. Then Dawn and Lynne can let you know when more may/will need to be added. Overall, given the urgency of this mission, I anticipate the orders/dollars to be significant.

Best wishes,
Heinz

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416
Email: feldmannh@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 12:29 PM
To: 'fritz.habekuss@zeit.de'
Subject: RE: Anfrage DIE ZEIT: Ebola

Hat leider nicht geklappt. Ich fliege am Sonntag nach Monrovia und bin mitten in den Vorbereitungen. Koennen wir am Samstag telefonieren?

Heinz Feldmann


-----Original Message-----

From: fritz.habekuss@zeit.de [mailto:fritz.habekuss@zeit.de]
Sent: Thursday, October 02, 2014 3:27 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: AW: Anfrage DIE ZEIT: Ebola

Klasse. Wären Sie in der nächsten Stunde zu greifen?

Fritz Habekuß
DIE ZEIT | Ressort Wissen
Buceriusstraße, Eingang Speersort
20095 Hamburg

Personal Info

A yellow rectangular box redacting personal information.

Von: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Gesendet: Donnerstag, 2. Oktober 2014 01:30
An: Habekuss, Fritz
Betreff: RE: Anfrage DIE ZEIT: Ebola

Morgen waere moeglich aber nicht vor 18:00 UHr MEZ.

Heinz Feldmann

DIE ZEIT jetzt am Kiosk.
www.zeit.de/diesewoche

ZEIT ONLINE - Durchschauen Sie jeden Tag.
www.zeit.de

-----Original Message-----

From: fritz.habekuss@zeit.de [mailto:fritz.habekuss@zeit.de]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 12:26 PM
To: 'Michael G. Katze'
Subject: RE: Safe travels to Liberia!

OK – will do.

From: Michael G. Katze [mailto:honey@uw.edu]
Sent: Friday, October 03, 2014 12:21 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Safe travels to Liberia!

Your thoughts and impressions.

Sent from Michael's iPhone

On Oct 3, 2014, at 14:19, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

What should I record?

From: Michael G. Katze [mailto:honey@uw.edu]
Sent: Friday, October 03, 2014 6:27 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Safe travels to Liberia!

Please?

You can record it and we can get it typed out. For future generations of virologists?

Michael G. Katze

Professor of Microbiology

University of Washington

KATZE LAB WEB PAGE

<http://viromics.washington.edu>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 12:25 PM
To: Hensley, Lisa (NIH/NIAID) [E]
Subject: RE: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Not RML either.

-----Original Message-----

From: Hensley, Lisa (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 12:15 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Heinz

This wasn't me - who did the experiment?

Guessing you, Gary or Sina

Lisa E. Hensley
Associate Director, Science
NIH/NIAID/IRF
Ft Detrick MD

ph: 301 631-7205

b berry: Personal Info

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 2:14 PM
To: 'Hayden, Frederick G *HS'; Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Let those people speak to it who actually did the mouse studies.

-----Original Message-----

From: Hayden, Frederick G *HS [mailto:FGH@hscmail.mcc.virginia.edu]
Sent: Friday, October 03, 2014 8:14 AM
To: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic
Importance: High

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 12:19 PM
To: 'Michael G. Katze'
Subject: RE: Safe travels to Liberia!

What should I record?

From: Michael G. Katze [mailto:honey@uw.edu]
Sent: Friday, October 03, 2014 6:27 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Safe travels to Liberia!

Please?

You can record it and we can get it typed out. For future generations of virologists?

Michael G. Katze

Professor of Microbiology

University of Washington

KATZE LAB WEB PAGE

<http://viromics.washington.edu>

From: <Feldmann>, Feldmannh <feldmannh@niaid.nih.gov>
Date: Thursday, October 2, 2014 at 11:29 AM
To: Michael Katze <honey@uw.edu>
Subject: RE: Safe travels to Liberia!

Will give it a try with the commentary but cannot promise.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 12:14 PM
To: 'Hayden, Frederick G *HS'; Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Let those people speak to it who actually did the mouse studies.

-----Original Message-----

From: Hayden, Frederick G *HS [mailto:FGH@hscmail.mcc.virginia.edu]
Sent: Friday, October 03, 2014 8:14 AM
To: Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada); Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic
Importance: High

Help - any knowledge (data) on this remarkable formulation of repurposed drugs? Who has done the murine model work? As a Stanford graduate myself, I know it must be good. Please feel free to call me directly (434-924-9583). Thanks in advance for any insights, fgh

From: Shalabh Gupta, MD, MPA [shalabh.gupta@globavir.com]
Sent: 03 October 2014 02:59
To: Hayden, Frederick G *HS; fgh@virginia.edu
Cc: friedem@who.int; kienym@who.int
Subject: Globavir: Combination of approved drugs, with mice data with 100% survival, ready to go to clinic

Dear Dr. Hayden.

I am taking this opportunity to follow up with you regarding the email chain between you and Dr. John Ryan. Dr. John Ryan is on our Board of Directors as well as has been a mentor to our team to develop our drugs.

I wanted to provide you some details on our company and our drugs.

* Our lead drug, which was licensed from Stanford University, has shown potent efficacy in cellular models of Ebola infection, and further yielded 100% survival in an Ebola mouse model. What sets our therapy apart from other developmental therapies is that our candidate is a combination of two previously approved drugs, and thus safety and manufacturing hurdles are largely mitigated. In the mouse study, for example, the dose given to mice was equivalent to the dosage approved in humans for chronic use. Additionally, our drug targets host pathways hijacked by the virus rather than targeting the virus itself, which provides 2 benefits: 1) Proven broad spectrum activity (in vivo data in Dengue, in vitro against Dengue, West Nile and HCV) and 2) Projected high barrier to viral resistance. Thus we believe that our therapy represents a viable route towards delivering an effective therapy on a very rapid time frame.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 11:09 AM
To: 'Kevin McAleese'
Subject: RE: Interview request

No available for the next three weeks – leaving now.

From: Kevin McAleese [mailto:mcaleesek@featurestory.com]
Sent: Friday, October 03, 2014 8:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview request

Dear Dr Feldmann,

I'm writing from Feature Story News in Washington DC to see if you might be available for a brief telephone interview today on the current Ebola situation both in West Africa and the US.

We produce a daily news radio show which is carried by the Pacificia Network and dozens of stations across the US and internationally.

If you can, we would be delighted to have your contribution on today's show.

Best regards

Kevin

--

Kevin McAleese
Producer & Host FSN Reports
(202) 296 9012

www.featurestorynews.com



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 11:03 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: CTV News Channel Interview Request

Importance: High

Please decline or give to someone else. Thanks

From: Amanda Panacci [mailto:Amanda.Panacci@bellmedia.ca]
Sent: Friday, October 03, 2014 9:55 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: CTV News Channel Interview Request
Importance: High

Hi Heinz,

My name is Amanda Panacci and I am contacting you on behalf of CTV News Channel.

Are you available for an interview with us this afternoon for an interview on Ebola? The interview would focus on experimental ebola vaccines, specially a made-in-Canada experimental Ebola vaccine that has yet to be sent to West Africa.

The interview would be 4 to 5 mins in length and be broadcast live across Canada. Ideally the interview would be in studio, but we can also accommodate a Facetime interview via an Apple device.

Please let me know if you are available to speak with us today. My contact information is below.

Many thanks,
Amanda

Amanda Panacci | Chase Producer
CTV News Channel | t 416.384.4000 | amanda.panacci@bellmedia.ca
9 Channel Nine Crt
Scarborough, ON M1S 4B5
Canada

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 10:52 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: FYI FW: Hardball inquiry

I had already a request regarding the issue but from a different person. I responded by email saying that the situation at the airport has been fixed which is based on reports by Trent and Bob.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 10:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FYI FW: Hardball inquiry
Importance: High

Please don't reply if you hear from this person; I'm taking care of it now and am planning to decline. They are asking to have you on tonight and I think it would be an ambush-type interview with nothing to do with research or science.

Scarlette Whyte
Producer, "Hardball w/ Chris Matthews"
Direct: 202-885-4565
Blackberry: 202-699-0046
Scarlette.Whyte@nbcuni.com



From: Oplinger, Anne (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 10:23 AM
To: Pekoc, Ken (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]
Cc: Routh, Jennifer (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Hardball inquiry

Ken,

I doubt this will happen, but be aware that Chris Matthews was recently pressing hard in an interview with ASF on the subject of how the patient in Dallas left Liberia without saying he'd been near an Ebola patient. I know that other journalists have been mentioning the Q/A Dr. Feldmann did with Science about the conditions in W. African airports, etc. I imagine that might be a topic of continuing interest to MSNBC Hardball.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 10:49 AM
To: Pekoc, Ken (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: Ebola replication cycle and targets

People are starting to look into HIV drugs in regards to Ebola. We do as well – Thomas Hoenen.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 10:48 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Ebola replication cycle and targets

Do you have / know of anything similar?

From: Folkers, Greg (NIH/NIAID) [E]
Sent: Friday, October 03, 2014 8:47 AM
To: Kurilla, Michael (NIH/NIAID) [E]; Repik, Patricia (NIH/NIAID) [E]
Cc: NIAID BUGS; Marston, Hilary (NIH/NIAID) [C]; Folkers, Greg (NIH/NIAID) [E]
Subject: Ebola replication cycle and targets for dyrs

DMID folks

Do you have (or have you seen) a simple graphic/cartoon akin to the one below (for HIV) that show ebolavirus replication cycle and targets for drugs?

Thanks,
Greg

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 4:44 PM
To: 'Penny.Heaton@gatesfoundation.org'
Subject: Re: Ebola

Sounds good.

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Thursday, October 02, 2014 05:08 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Let's go with 3 pm East Coast time. I am happy to call you.

FYI...if you need to reach me urgently for some reason, you can always call my cell at Personal Info

Looking forward to it. Thanks!

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Thursday, October 02, 2014 2:06 PM
To: Penny Heaton
Subject: RE: Ebola

Between 2:00 – 4:00 PM EST would work for me. Just let me know when and either call me at 406-375-7410 (office) or Personal Info (cell). Alternatively, I can call you if you provide me with a number.

Thanks,
Heinz

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Thursday, October 02, 2014 2:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Sure... I can make that work.

The best times would be at either 11:30 am East Coast time or between 2 pm and 4 pm East Coast time. Just let me know a time and the best telephone number to call.

Thanks!

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Thursday, October 02, 2014 1:56 PM
To: Penny Heaton
Subject: RE: Ebola

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 4:42 PM
To: 'Sharon.Begley@thomsonreuters.com'
Subject: Re: airports/reuters query

According to them all procedures have been approved from taking temperature, doing clinical checks and avoiding crowded areas. From what I hear things are much better now. I am going to Monrovia on Sunday and will see myself. I can report when I get back.

From: Sharon.Begley@thomsonreuters.com [mailto:Sharon.Begley@thomsonreuters.com]
Sent: Thursday, October 02, 2014 06:31 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: airports/reuters query

Very sorry to bother you again, but is there any chance you can expand on 'fixed'? I wondered if your colleagues were referring to better use of the devices by the screeners, or better calibration of the devices themselves, or . . .

Sharon Begley
Senior health & science correspondent
Reuters
3 Times Square
New York, NY 10036

646-223-4876



sxbegle

From: Begley, Sharon (Reuters News)
Sent: Thursday, October 02, 2014 2:21 PM
To: 'Feldmann, Heinrich (NIH/NIAID) [E]'
Subject: RE: airports/reuters query

Excellent—thank you!

Sharon Begley
Senior health & science correspondent
Reuters
3 Times Square
New York, NY 10036

646-223-4876



sxbegle

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 3:06 PM
To: 'Penny Heaton'
Subject: RE: Ebola

Between 2:00 – 4:00 PM EST would work for me. Just let me know when and either call me at 406-375-7410 (office) or **Personal Info** (cell). Alternatively, I can call you if you provide me with a number.

Thanks,
Heinz

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Thursday, October 02, 2014 2:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Sure... I can make that work.

The best times would be at either 11:30 am East Coast time or between 2 pm and 4 pm East Coast time. Just let me know a time and the best telephone number to call.

Thanks!

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Thursday, October 02, 2014 1:56 PM
To: Penny Heaton
Subject: RE: Ebola

Any chance of talking tomorrow? I am leaving for Monrovia on Sunday early morning and will be away until the end of October. I can try to call you from Monrovia but the lines are not always working.

Best wishes,
Heinz

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Thursday, October 02, 2014 2:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Dear Heinz,

I have returned and am digging out from the avalanche of emails that awaited me! I would love to catch up – Monday or Tuesday (6th, 7th) afternoon your time would work. I will be traveling to the East Coast on Wednesday. Then I can take a call most anytime on Thursday and Friday (9th, 10th). Just let me know what would work for your schedule.

Many thanks!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 2:56 PM
To: 'Penny Heaton'
Subject: RE: Ebola

Any chance of talking tomorrow? I am leaving for Monrovia on Sunday early morning and will be away until the end of October. I can try to call you from Monrovia but the lines are not always working.

Best wishes,
Heinz

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Thursday, October 02, 2014 2:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Dear Heinz,

I have returned and am digging out from the avalanche of emails that awaited me! I would love to catch up – Monday or Tuesday (6th, 7th) afternoon your time would work. I will be traveling to the East Coast on Wednesday. Then I can take a call most anytime on Thursday and Friday (9th, 10th). Just let me know what would work for your schedule.

Many thanks!

Penny

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Saturday, September 20, 2014 2:57 PM
To: Penny Heaton
Subject: RE: Ebola

Sounds good.

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Saturday, September 20, 2014 3:48 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

No worries. I will reach out the week of the 29th to confirm a time. Again, many thanks!

Sent from my Windows Phone

From: [Feldmann, Heinrich \(NIH/NIAID\) \[E\]](#)
Sent: 9/20/2014 2:20 PM
To: [Penny Heaton](#)
Subject: RE: Ebola

Feldmann, Heinrich (NIH/NIAID) [E]


From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 2:37 PM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: FW: Primers (UNCLASSIFIED)

Can we briefly talk about this?

-----Original Message-----

From: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US) [mailto:mark.j.wolcott.civ@mail.mil]
Sent: Thursday, October 02, 2014 1:33 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
Subject: RE: Primers (UNCLASSIFIED)

Records Originating Outside of NIAID



-----Original Message-----

From: Falzarano, Darryl (NIH/NIAID) [F] [mailto:darryl.falzarano@nih.gov]
Sent: Tuesday, September 30, 2014 8:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US)
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
Subject: RE: Primers (UNCLASSIFIED)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 2:36 PM
To: 'Pardis Sabeti'
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR); Tahmassian, Ara; Rhonda O'Keefe; Corrigan, Mary
Subject: RE: Illumina and Broad partnering for diagnostics and sequencing on ground

They won't be destroyed but the RNA amount may not be optimal.

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Thursday, October 02, 2014 2:23 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR); Tahmassian, Ara; Rhonda O'Keefe; Corrigan, Mary
Subject: Re: Illumina and Broad partnering for diagnostics and sequencing on ground

Hi Heinz,

The samples were frozen immediately after adding ethanol. World Courier will ship on dry ice. We have samples in both Trizol and AVL/ethanol, but based on experience, trizol is terrible for downstream sequencing.

We do also have samples that have not been deactivated, but once we get permissions from the Sierra Leone ethics committee we can send this and the buffy coat to the IRF. If the AVL/ethanol samples are destroyed, we could then at that stage move to extract an aliquot of the serum alone in the BL-4 lab.

Pardis

On Thu, Oct 2, 2014 at 4:17 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Can only tell you about our experience. I would either send 'hot' samples or RNA. If you cannot do that I would recommend to freeze immediately after addition of ethanol and hope for the losses to be minimal. Alternatively, I would recommend to use Trizol instead of the AVL QIAGEN bugger and ship it in Trizol solution. We have tested Trizol as well and it completely inactivates. We did not test Trizol LS.

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Thursday, October 02, 2014 1:24 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 2:18 PM
To: 'Pardis Sabeti'
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Ch@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR)
Subject: RE: Illumina and Broad partnering for diagnostics and sequencing on ground

Can only tell you about our experience. I would either send 'hot' samples or RNA. If you cannot do that I would recommend to freeze immediately after addition of ethanol and hope for the losses to be minimal. Alternatively, I would recommend to use Trizol instead of the AVL QIAGEN bugger and ship it in Trizol solution. We have tested Trizol as well and it completely inactivates. We did not test Trizol LS.

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Thursday, October 02, 2014 1:24 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Ch@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR)
Subject: Re: Illumina and Broad partnering for diagnostics and sequencing on ground

Hi Heinz, that is a major concern. We can not ask the team in Kenema to extract as we are trying to add no extra burden to them in this response, so we should move these samples to the US ASAP. Michael, any updates here will be critical,

Pardis

Sent from my iPhone

On Oct 2, 2014, at 3:08 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Based on our experience it is important to extract the RNA soon after addition of ethanol, otherwise you may have losses of RNA which can be quite substantial. Immediate freezing might prevent bigger losses but our recommendation would be immediate extraction and shipment of frozen RNA.

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Thursday, October 02, 2014 9:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Ch@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR)
Subject: Re: Illumina and Broad partnering for diagnostics and sequencing on ground

Dear Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 2:07 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: Interview - Heinz Feldman - News Talk 770's Calgary Today

I think one of the Canadians can do this one or Andrea.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 1:25 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Interview - Heinz Feldman - News Talk 770's Calgary Today

Heinz, would you like to do, decline, or should I see if Dave or Andrea are interested?

... If so, I'd tell them it's iffy to do today on short notice (and ACUC meeting).

From: Hoffman, Hillary (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:07 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: Interview Request for Today- Heinz Feldman - News Talk 770's Calgary Today

Ken, could you please handle this?

Thanks very much!
Hillary

From: Whitney Deane [<mailto:Whitney.Deane@corusent.com>]
Sent: Thursday, October 02, 2014 1:56 PM
To: NIAID NEWS (NIH/NIAID)
Subject: Interview Request for Today- Heinz Feldman - News Talk 770's Calgary Today

Hi Hilary,

I'm a Producer for News Talk 770's Calgary Today, a radio news talk program. I know he is probably inundated with requests but we've had Dr. Heinz Feldman on one of our other shows a few months ago and are hoping he would be available again to lend his expertise on Ebola and its spread.

The interview would be at 4:20 PM Central Time (3:20 PM Mountain Time), live, over the phone, about 7 minutes long and one on one with Hosts Angela Kokott and Dave Taylor on News Talk 770.

If you could phone or email me back as to whether or not he is available or pass on my request that would be great.

Thanks Hilary,

Whitney

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 2:02 PM
To: 'Pardis Sabeti'; Tahmassian, Ara; Rhonda O'Keefe
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR); Corrigan, Mary
Subject: RE: Illumina and Broad partnering for diagnostics and sequencing on ground

Sounds good.

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Thursday, October 02, 2014 1:57 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Tahmassian, Ara; Rhonda O'Keefe
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR); Corrigan, Mary
Subject: Re: Illumina and Broad partnering for diagnostics and sequencing on ground

Hi Heinz,

I am copying Ara Tahmassian, Mary Corrigan, and Rhonda O'Keefe from our EHS. It is our hope that we can initiate the shipment now, and preserve the samples in -80 here in the US until we can get the certification,

Pardis

On Thu, Oct 2, 2014 at 3:23 PM, Pardis Sabeti <pardis@broadinstitute.org> wrote:
Hi Heinz, that is a major concern. We can not ask the team in Kenema to extract as we are trying to add no extra burden to them in this response, so we should move these samples to the US ASAP. Michael, any updates here will be critical,

Pardis

Sent from my iPhone

On Oct 2, 2014, at 3:08 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Based on our experience it is important to extract the RNA soon after addition of ethanol, otherwise you may have losses of RNA which can be quite substantial. Immediate freezing might prevent bigger losses but our recommendation would be immediate extraction and shipment of frozen RNA.

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Thursday, October 02, 2014 9:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 1:08 PM
To: 'Pardis Sabeti'
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR)
Subject: RE: Illumina and Broad partnering for diagnostics and sequencing on ground

Based on our experience it is important to extract the RNA soon after addition of ethanol, otherwise you may have losses of RNA which can be quite substantial. Immediate freezing might prevent bigger losses but our recommendation would be immediate extraction and shipment of frozen RNA.

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Thursday, October 02, 2014 9:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hensley, Lisa (NIH/NIAID) [E]; Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]; Pan-Pan Jiang; Bergman, Nicholas H. (CTR)
Subject: Re: Illumina and Broad partnering for diagnostics and sequencing on ground

Dear Heinz,

I am sorry that I missed your email somewhere in the thread. All of our samples are now inactivated following Ricki's protocol with 1:4:4 sample:AVL:ethanol. We also perform additional heat inactivation.

The Kenema and Nigeria team all have these samples ready to send and are eager to get these moving.

Michael, thank you so much for your efforts to certify Ricki's results. I would love to know if there are any updates. If we do believe this certification will be a political issue, it would be great to move to send these samples to NBAAC/NIH for first processing, though we recognize this can also create bigger delays.

Pardis

On Sun, Sep 28, 2014 at 7:50 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

If you don't inactivate the samples in country of origin (prior to shipment) you will have to bring them into BSL4 in order to start the inactivation unless you declare the samples 'diagnostic specimens'. If you know that the samples are confirmed Ebola-positive you won't have a choice others than handling them in BSL4.

Heinz


From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Sunday, September 28, 2014 3:40 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:30 PM
To: 'Michael G. Katze'
Subject: RE: Safe travels to Liberia!

Will give it a try with the commentary but cannot promise.

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:28 PM
To: 'Michael G. Katze'; mtferris@email.unc.edu; ANGELA L. RASMUSSEN
Cc: Marcus J. Korth; SEAN PROLL; Mark Heise; Baric, Ralph; Okumura, Atsushi (NIH/NIAID) [V]
Subject: RE: EBOLA RO1

Congrats – fantastic.

From: Michael G. Katze [mailto:honey@uw.edu]
Sent: Thursday, October 02, 2014 7:43 AM
To: mtferris@email.unc.edu; ANGELA L. RASMUSSEN
Cc: Marcus J. Korth; SEAN PROLL; Mark Heise; Baric, Ralph; Okumura, Atsushi (NIH/NIAID) [V]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: EBOLA RO1

Dear Angela and Marty

Personal Info

Cheers
Michael

Michael G. Katze
Professor of Microbiology
University of Washington
KATZE LAB WEB PAGE
<http://viromics.washington.edu>

Feldmann, Heinrich (NIH/NIAID) [E]


From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:28 PM
To: Michael G. Katze; mtferris@email.unc.edu; ANGELA L. RASMUSSEN
Cc: Marcus J. Korth; SEAN PROLL; Mark Heise; Baric, Ralph; Okumura, Atsushi (NIH/NIAID) [V]
Subject: RE: EBOLA RO1

Congratulations.

From: Michael G. Katze [mailto:honey@uw.edu]
Sent: Thursday, October 02, 2014 7:43 AM
To: mtferris@email.unc.edu; ANGELA L. RASMUSSEN
Cc: Marcus J. Korth; SEAN PROLL; Mark Heise; Baric, Ralph; Okumura, Atsushi (NIH/NIAID) [V]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: EBOLA RO1

Dear Angela and Marty

Personal Info



Cheers
Michael

Michael G. Katze
Professor of Microbiology
University of Washington
KATZE LAB WEB PAGE
<http://viromics.washington.edu>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:25 PM
To: Walczynski, Joyce (NIH/NIAID) [C]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: FW: Waiver for Excess Baggage for Mission Critical Trip to Liberia for Ebola Outbreak (KMM38218327V54010L0KM)

Thanks

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Thursday, October 02, 2014 8:51 AM
To: Menk, Kay (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: FW: Waiver for Excess Baggage for Mission Critical Trip to Liberia for Ebola Outbreak (KMM38218327V54010L0KM)
Importance: High

Good Morning,

Delta will not grant excess baggage waivers because it would be considered a partial waiver as you will not be flying on Delta/KLM to the destination.

Joyce Walczynski

Logistics Technician, LV (Contractor)
Rocky Mountain Laboratories
903 South 4th St.
Hamilton, MT 59840
Phone: 406.375.9600
Fax: 406.375.9620
Email: walczynskij@niaid.nih.gov

From: Group Bag Waive Requests [<mailto:bagwaiverqsts.delta@delta.com>]
Sent: Thursday, October 02, 2014 6:48 AM
To: Walczynski, Joyce (NIH/NIAID) [C]
Subject: RE: FW: Waiver for Excess Baggage for Mission Critical Trip to Liberia for Ebola Outbreak (KMM38218327V54010L0KM)

Ms Walczynski,

Thank you for your follow up. We appreciate the work your travelers are doing with the CDC & WHO in Liberia. But we cannot approve any baggage waivers on an itinerary that has a carrier other than Delta or KLM. Our guidelines require waiver be granted only for origin to destination travel; as such we cannot grant a partial waiver on only the Delta/KLM portions.

Sincerely,
Matthew Landers
Delta Air Lines

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:21 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Safronetz, David (NIH/NIAID) [E]
Subject: RE: talking points on Ebola and field work

Thanks.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 11:26 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Cc: Safronetz, David (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: talking points on Ebola and field work

FYI, might be of help. Based on CDC and NIH-OMS info.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:20 PM
To: 'Sharon.Begley@thomsonreuters.com'
Subject: RE: airports/reuters query

From my recently returning colleagues I have heard that the situation at the airport got fixed. This is a very positive development.

From: Sharon.Begley@thomsonreuters.com [mailto:Sharon.Begley@thomsonreuters.com]
Sent: Thursday, October 02, 2014 11:31 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: airports/reuters query

Dr Feldmann, we have not spoken about your Ebola work since the current outbreak began, but I am working on another story in which I would like to cite something you told Science:

<http://news.sciencemag.org/africa/2014/09/confronting-ebola-virologist-liberias-hot-zone>

In particular, can you tell me whether you still have concerns about airport screening in Monrovia et al? Many thanks,

Sharon Begley
Senior health & science correspondent

Reuters

3 Times Square
New York, NY 10036

646-223-4876



sbegle

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 12:07 PM
To: Reynolds, Steven (NIH/NIAID) [E]
Cc: Caldwell, Harlan (NIH/NIAID) [E]
Subject: RE: Uganda

Steve,
Thanks for reaching out to Harlan.

Be in touch hopefully soon regarding Uganda ICER.

Best wishes,
Heinz

-----Original Message-----

From: Reynolds, Steven (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 5:40 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Caldwell, Harlan (NIH/NIAID) [E]
Subject: RE: Uganda

Hi Heinz,

Nice to hear from you. I assumed you were very busy dealing with the current situation in West Africa so not surprised that I didn't hear from you. I hope things start to get better soon.

Harlan, I would be happy to discuss our Rakai site with you anytime. I'll be in the US from Oct 8-15 in case you want to chat by phone.

Best regards,

Steve

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Sunday, September 28, 2014 12:25 AM
To: Reynolds, Steven (NIH/NIAID) [E]
Cc: Caldwell, Harlan (NIH/NIAID) [E]
Subject: RE: Uganda

Dear Steve,

I planned to contact you since quite some time but never got to do it. We were planning to start our Uganda ICER project this summer (August), but our current Ebola involvement in Monrovia, Liberia has changed everything. For a while, we will have at least 2-3 people in Monrovia to support MSF and others with laboratory diagnostics on Ebola. I really have to think about when and how to move the ICER along but I am afraid this it will rather be next year (2015) than this one.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, October 02, 2014 11:33 AM
To: 'Branswell, Helen'
Subject: RE: Experimental Ebola vaccines: outcome of a WHO expert consultation - Situation assessment

I guess we have to wait and see.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Wednesday, October 01, 2014 7:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Experimental Ebola vaccines: outcome of a WHO expert consultation - Situation assessment

Yes. Intentions.

And WHO has a questionable track record on stuff like this. There was a ton of positive talk about donated flu vaccine being distributed to have-none countries during the 2009 pandemic. No vaccine was redistributed till months after WHO projected - and after the threat was over.

Helen Branswell
Medical reporter
The Canadian Press

iPhone. iTypos. iApologize.
(iCribbedThis)

On Oct 1, 2014, at 7:37 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

A lot of good words and thoughts but early 2015? Wonder what the numbers are at that time.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Wednesday, October 01, 2014 9:58 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Experimental Ebola vaccines: outcome of a WHO expert consultation - Situation assessment

Just came in.

From: WorldHealthOrganizationNews@who.int [mailto:WorldHealthOrganizationNews@who.int]
Sent: October-01-14 11:57 AM
Subject: Experimental Ebola vaccines: outcome of a WHO expert consultation - Situation assessment

Situation assessment
Experimental Ebola vaccines: outcome of a WHO expert consultation
1 October

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 7:06 PM
To: 'ANGELA L. RASMUSSEN'; Okumura, Atsushi (NIH/NIAID) [V]
Cc: Michael G. Katze
Subject: RE: Call Friday

Sure – tell Thomas and/or Ian to contact me or Andrea Marzi.

From: ANGELA L. RASMUSSEN [mailto:arasmus@uw.edu]
Sent: Wednesday, October 01, 2014 6:01 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Okumura, Atsushi (NIH/NIAID) [V]
Cc: Michael G. Katze
Subject: Re: Call Friday

Hi Heinz,

I actually had one other thing. Thomas Briesse from Ian Lipkin's group has been in touch with me about getting small volumes

Redacted by agreement

Redacted by agreem Are there potentially archival serum samples from other studies of emerging viruses that could be used for testing these arrays for antibodies to other viruses besides Ebola? Nipah, Hendra, etc? These could be from NHPs, hamsters/guinea pigs, etc...they would just have to be samples from at least day 14 post-infection to have detectable antibody titers. Would any of these types of samples (or small volumes of them) be available for their use?

Thanks,
Angie

From: <Feldmann>, "feldmannh@niaid.nih.gov" <feldmannh@niaid.nih.gov>
Date: Wednesday, October 1, 2014 at 4:53 PM
To: Angela Rasmussen <arasmus@uw.edu>, Atsushi Okumura <atsushi.okumura@nih.gov>
Cc: "'honey@uw.edu'" <honey@uw.edu>
Subject: RE: Call Friday

They told me that the antibody (drug) does not work in rodents. That would only leave the NHP model.

Redacted by agreement

Redacted b If it does not work – low impact. Cannot say anything at this point. Don't put too much effort into it until we know the outcome.

Heinz

From: ANGELA L. RASMUSSEN [mailto:arasmus@uw.edu]
Sent: Wednesday, October 01, 2014 5:47 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Okumura, Atsushi (NIH/NIAID) [V]
Cc: Michael G. Katze
Subject: Re: Call Friday

Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 7:05 PM
To: 'ANGELA L. RASMUSSEN'
Subject: RE: Call Friday

Dave is staying at RML. I can read the revision if you send it.

From: ANGELA L. RASMUSSEN [mailto:arasmus@uw.edu]
Sent: Wednesday, October 01, 2014 6:08 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Call Friday

Also, when you return from this trip, I'll send you a first pass at the Lassa/Lujo paper revisions and reviewer response. We should have a call and discuss then and try to get that finished. Is Dave going with you again to Liberia? If not, perhaps he and I can work on it in the meantime.

From: <Feldmann>, "feldmannh@niaid.nih.gov" <feldmannh@niaid.nih.gov>
Date: Wednesday, October 1, 2014 at 4:53 PM
To: Angela Rasmussen <arasmus@uw.edu>, Atsushi Okumura <atsushi.okumura@nih.gov>
Cc: "'honey@uw.edu'" <honey@uw.edu>
Subject: RE: Call Friday

They told me that the antibody (drug) does not work in rodents. That would only leave the NHP model.

Redacted by agreement

Redacted If it does not work – low impact. Cannot say anything at this point. Don't put too much effort into it until we know the outcome.

Heinz

From: ANGELA L. RASMUSSEN [mailto:arasmus@uw.edu]
Sent: Wednesday, October 01, 2014 5:47 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Okumura, Atsushi (NIH/NIAID) [V]
Cc: Michael G. Katze
Subject: Re: Call Friday

Hi Heinz,

In that case, are you available on Friday afternoon/early evening? Michael should be arriving in Seattle in the late afternoon.

The main agenda item was to discuss the potential drug experiment. It sounds like the CC will unfortunately not be a good option for testing this after all, and that the NHP model might have a lot of problems, so that may be out the window. In that case, maybe we could have a brief call at 10 am PT/11 am MT as originally planned and I can relay our discussion back to Michael. Or we can all have a call after you return from this trip, if that is easier for everyone. In general we are very interested in potential applications of the CC for evaluating therapeutics, and we now have some additional data in the CC-RI mice (which are much easier to obtain) that may make the CC an even more attractive option for this. It might be good to talk anyway and catch up.

Please let me know, I'm very flexible and can accommodate whatever works for you.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 5:53 PM
To: 'ANGELA L. RASMUSSEN'; Okumura, Atsushi (NIH/NIAID) [V]
Cc: Michael G. Katze
Subject: RE: Call Friday

They told me that the antibody (drug) does not work in rodents. That would only leave the NHP model.

Redacted by agreement

Redacted by it does not work – low impact. Cannot say anything at this point. Don't put too much effort into it until we know the outcome.

Heinz

From: ANGELA L. RASMUSSEN [mailto:arasmus@uw.edu]
Sent: Wednesday, October 01, 2014 5:47 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Okumura, Atsushi (NIH/NIAID) [V]
Cc: Michael G. Katze
Subject: Re: Call Friday

Hi Heinz,

In that case, are you available on Friday afternoon/early evening? Michael should be arriving in Seattle in the late afternoon.

The main agenda item was to discuss the potential drug experiment. It sounds like the CC will unfortunately not be a good option for testing this after all, and that the NHP model might have a lot of problems, so that may be out the window. In that case, maybe we could have a brief call at 10 am PT/11 am MT as originally planned and I can relay our discussion back to Michael. Or we can all have a call after you return from this trip, if that is easier for everyone. In general we are very interested in potential applications of the CC for evaluating therapeutics, and we now have some additional data in the CC-RI mice (which are much easier to obtain) that may make the CC an even more attractive option for this. It might be good to talk anyway and catch up.

Please let me know, I'm very flexible and can accommodate whatever works for you.

Thanks,
Angie

PS—I was just about to send this, and I just thought of another thing we might discuss: Redacted by agreement
Darryl is doing. Atsu told me that he will ship me blood samples from up to day 14 on October 8, and I will arrange to have them processed. I know this project is a priority, but if you have any more specific information about timelines for publication, that would help me get those samples processing on our end and I can ensure we have the data to include in the manuscript in a timely manner.

From: <Feldmann>, "feldmannh@niaid.nih.gov" <feldmannh@niaid.nih.gov>
Date: Wednesday, October 1, 2014 at 4:26 PM
To: Angela Rasmussen <arasmus@uw.edu>, Atsushi Okumura <atsushi.okumura@nih.gov>
Cc: "'honey@uw.edu'" <honey@uw.edu>
Subject: RE: Call Friday

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 5:41 PM
To: 'Semmler, Ilia'; Vikki Hyman
Cc: Juergen Richt (jricht@vet.k-state.edu); Anja.WOLZ@geneva.msf.org
Subject: RE: Bedrooms at hotel

Anja is in West Africa and may have only limited options to respond. Anja – please respond as soon as possible if you can.

Heinz

From: Semmler, Ilia [mailto:Ilia.Semmler@tmf-ev.de]
Sent: Wednesday, October 01, 2014 2:42 AM
To: Vikki Hyman
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Juergen Richt (jricht@vet.k-state.edu)
Subject: AW: Bedrooms at hotel

No, she didn't confirm until today. I am in touch with Fabian Leendertz, that he could prolong his talk after he gets the prize. He did the epidemiology of the actual Ebola-Outbreak – tracing from the index patient back to the animals – very interesting. He was twice in Africa for that (and is not infectious any more ;-)). And second I am in touch with M. Gertler (MSF and Robert Koch Institute) to have him as speaker instead of A. Wolz, if she cannot come.

Von: Vikki Hyman [mailto:vikki@target-conferences.com]
Gesendet: Mittwoch, 1. Oktober 2014 10:35
An: Semmler, Ilia
Betreff: Re: Bedrooms at hotel

are you in touch with Anja Wolz - did she confirm she is coming?

Vikki Hyman | Project Manager
Target Conferences Ltd.
65 Derech Menachem Begin
PO Box 51227, Tel Aviv 6713818
Tel: +972 3 517 5150 ext 611 | Fax: +972 73 2067718
www.target-conferences.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 5:38 PM
To: 'Branswell, Helen'
Subject: RE: Experimental Ebola vaccines: outcome of a WHO expert consultation - Situation assessment

A lot of good words and thoughts but early 2015? Wonder what the numbers are at that time.

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Wednesday, October 01, 2014 9:58 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Experimental Ebola vaccines: outcome of a WHO expert consultation - Situation assessment

Just came in.

From: WorldHealthOrganizationNews@who.int [mailto:WorldHealthOrganizationNews@who.int]
Sent: October-01-14 11:57 AM
Subject: Experimental Ebola vaccines: outcome of a WHO expert consultation - Situation assessment

Situation assessment

Experimental Ebola vaccines: outcome of a WHO expert consultation

1 October

WHO Consultation on Ebola vaccines: beyond phase 1 clinical trials

From 29–30 September, WHO organized an expert consultation to assess the status of work to test and eventually license two candidate Ebola vaccines. More than 70 experts, including many from affected and neighbouring countries in West Africa, attended the event.

The expertise represented among participants ranged from the virology of emerging infections, to regulatory requirements that must be met, to medical ethics, public health, and infectious diseases. Heads of clinical research and other executives from the pharmaceutical industry also presented their views.

Some non-African participants came with more than 3 decades of experience working in Africa on other infectious diseases.

Experts on the use of innovative, cutting-edge trial designs also shared their most recent work.

The overarching objective was to take stock of the many efforts currently under way to rapidly evaluate Ebola vaccines for safety and efficacy. The next step is to make these vaccines available as soon as possible – and in sufficient quantities – to protect critical frontline workers and to make a difference in the epidemic's future evolution.

All agreed on the ultimate goal: to have a fully tested and licensed product that can be scaled up for use in mass vaccination campaigns.

Two promising candidate vaccines

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 5:34 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: background / NIAID contract with Tulane, Lassa/Ebola diagnostics

Thanks for the information.

Dave – by the way, nice interview yesterday.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 2:50 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: background / NIAID contract with Tulane, Lassa/Ebola diagnostics

Of interest, background only, Redacted by agreement

Sent: Wednesday, October 01, 2014 2:42 PM
Subject: Media Request: NIAID contract with Tulane, Lassa/Ebola diagnostics

Reporter: Todd Frankel
Organization: Washington Post
Phone #(s): Todd.Frankel@washpost.com, 202-334-6038
Subject: Ebola diagnostics in Sierra Leone/NIAID contract with Tulane
Deadline: today
Spokesperson: general attribution to NIAID
Expected place of publication (print, online, broadcast): print, online
Expected date of publication/airing: unknown
Expected prominence (e.g. front page, Sunday, evening/morning show, etc.): unknown

Todd Frankel is Redacted by agreement

Redacted by agreement

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 5:31 PM
To: 'fritz.habekuss@zeit.de'
Subject: RE: Anfrage DIE ZEIT: Ebola

Morgen waere moeglich aber nicht vor 18:00 UHr MEZ.

Heinz Feldmann

-----Original Message-----

From: fritz.habekuss@zeit.de [mailto:fritz.habekuss@zeit.de]
Sent: Wednesday, October 01, 2014 12:42 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Anfrage DIE ZEIT: Ebola

Lieber Herr Feldmann,

mein Name ist Fritz Habekuß, ich bin Redakteur im Wissens-Ressort der ZEIT und würde mit Ihnen gerne über Ebola reden. Mich interessiert zum einen die Erfahrung, die Sie Science gegenüber geschildert haben - das Exit-Screening am Flughafen von Monrovia, das von den deutschen Behörden als der erste Wall gg Ebola beschrieben wird, nach ihrer Schilderung aber wohl als effektiver Ansteckungsweg in Betracht gezogen werden müsste.


Zum anderen arbeitete ich mit zwei Kollegen am einem größeren Stück zur Epidemiologie und zur Biologie des Virus. Ich würde mich Ihnen gerne über Fragen wie: Was genau macht es im Körper, welche Proteine haben welche Funktion, wie schafft es, die Immunabwehr zu unterdrücken, reden.

Das erste Stück soll in der kommenden Woche erscheinen, das zweite Ende des Monat erscheinen. Hätten Sie morgen oder übermorgen Zeit für ein kurzes Gespräch? Sollte es Ihnen sogar heute noch passen - bis 23 Uhr deutscher Zeit wäre ich noch wach.

Ich würde mich sehr freuen und sende beste Grüße aus Hamburg,

Fritz Habekuß
DIE ZEIT | Ressort Wissen
Buceriusstraße, Eingang Speersort
20095 Hamburg

Personal Info

A yellow rectangular box with a black border, used to redact personal information.

DIE ZEIT jetzt am Kiosk.
www.zeit.de/diesewoche

ZEIT ONLINE - Durchschauen Sie jeden Tag.
www.zeit.de

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 5:21 PM
To: Bloom, Marshall (NIH/NIAID) [E]
Subject: RE: RML E-News: Missoulain story about St Patrick hospital's care and isolation unit

I know – we had indirect contact with them through Jon Towner.

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 4:34 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: RML E-News: Missoulain story about St Patrick hospital's care and isolation unit

This person is a post-doc with Patti from Beijing CDC. Some of her co-workers back in China have gone to Sierra Leone.

From: Chu, Chenyi (NIH/NIAID) [F]
Sent: Wednesday, October 01, 2014 4:23 PM
To: Bloom, Marshall (NIH/NIAID) [E]
Subject: Re: RML E-News: Missoulain story about St Patrick hospital's care and isolation unit

Hey Marshall,

My colleagues are from 2 institutes of Academy of Military Medical Sciences. They went to Sierra Leone and are helping in diagnosis. Really hope to hear the presentation on ebola by RML staff soon. Thanks so much.

Chenyi

From: <Bloom>, "Marshall [E] (NIH/NIAID)" <MBLOOM@niaid.nih.gov>
Date: Wednesday, October 1, 2014 at 1:41 PM
To: "Chu, Chenyi (NIH/NIAID) [F]" <chenyi.chu@nih.gov>
Subject: RE: RML E-News: Missoulain story about St Patrick hospital's care and isolation unit

Hey, Chenyi!

Thanks for your nice note. I am trying to set something up and will announce it as soon as decided.

Where are your colleagues from, where are they going and what are they going to be doing?

Marshall

From: Chu, Chenyi (NIH/NIAID) [F]
Sent: Tuesday, September 30, 2014 4:56 PM
To: Bloom, Marshall (NIH/NIAID) [E]
Subject: Re: RML E-News: Missoulain story about St Patrick hospital's care and isolation unit

Hey Marshall,

I am Chenyi Chu, a postdoc at Patti's lab of LZP. I am from Beijing CDC, and did some field work during H1N1 outbreak in 2009. Now my colleagues in China have already gone to west Africa to help to control ebola outbreak. I really hope to hear the presentation on ebola work by RML staff, since I will be back to my position and continue to do some work on infectious disease prevention and control after training at RML.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 2:39 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: Anfrage DIE ZEIT: Ebola

Thanks - the translation is OK.

-----Original Message-----

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 2:37 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Anfrage DIE ZEIT: Ebola

This is the translation, pretty rough, but I can decipher enough to get clearance. Fine to make arrangements to talk with him.

Dear Mr. Feldmann,

my name is Fritz Habekuß, I'm an editor in the knowledge department of TIME and would like to talk with you about Ebola. What interests me is the one experience that you have described science over - the exit screening at the airport of Monrovia, the gg by the German authorities as the first Wall is Ebola described, should be according to their description but well drawn as an effective transmission route into consideration .

On the other hand, I worked with two colleagues on a larger piece of the epidemiology and biology of the virus. I would be happy about questions such as:

What exactly does it talk in the body, which proteins have the function, as it manages to suppress the immune system.

The first piece to appear in the coming week, appear the second end of the month.

Would you tomorrow or the day time for a quick chat? If you can fit even today - to 23 German clock time I was still awake.

I would be very happy and send best regards from Hamburg,

Fritz Habekuß
THE TIME | department of knowledge
Buceriusstraße, input Speersort
20095 Hamburg

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 2:34 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: Anfrage DIE ZEIT: Ebola

I would do this one before I will leave. Can you translate?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 2:34 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: Anfrage DIE ZEIT: Ebola

I would do this one before I will leave. Can you translate?

-----Original Message-----

From: fritz.habekuss@zeit.de [mailto:fritz.habekuss@zeit.de]
Sent: Wednesday, October 01, 2014 12:42 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Anfrage DIE ZEIT: Ebola

Lieber Herr Feldmann,

mein Name ist Fritz Habekuß, ich bin Redakteur im Wissens-Ressort der ZEIT und würde mit Ihnen gerne über Ebola reden. Mich interessiert zum einen die Erfahrung, die Sie Science gegenüber geschildert haben - das Exit-Screening am Flughafen von Monrovia, das von den deutschen Behörden als der erste Wall gg Ebola beschrieben wird, nach ihrer Schilderung aber wohl als effektiver Ansteckungsweg in Betracht gezogen werden müsste.

Zum anderen arbeitete ich mit zwei Kollegen am einem größeren Stück zur Epidemiologie und zur Biologie des Virus. Ich würde mich Ihnen gerne über Fragen wie: Was genau macht es im Körper, welche Proteine haben welche Funktion, wie schafft es, die Immunabwehr zu unterdrücken, reden.

Das erste Stück soll in der kommenden Woche erscheinen, das zweite Ende des Monat erscheinen. Hätten Sie morgen oder übermorgen Zeit für ein kurzes Gespräch? Sollte es Ihnen sogar heute noch passen - bis 23 Uhr deutscher Zeit wäre ich noch wach.

Ich würde mich sehr freuen und sende beste Grüße aus Hamburg,

Fritz Habekuß
DIE ZEIT | Ressort Wissen
Buceriusstraße, Eingang Speersort
20095 Hamburg

Personal Info

DIE ZEIT jetzt am Kiosk.
www.zeit.de/diesewoche

ZEIT ONLINE - Durchschauen Sie jeden Tag.
www.zeit.de

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 12:02 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: Interview request for this evening (10/1)

Sounds good.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 11:58 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Interview request for this evening (10/1)

I'll tell them you're not available, preparing to leave for West Africa, and will refer them to CDC for the type of message they are seeking.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 11:55 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: Interview request for this evening (10/1)

Can you look into this? Thanks.

From: Jaci Clark [<mailto:jaci.clark@aljazeera.net>]
Sent: Wednesday, October 01, 2014 10:42 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview request for this evening (10/1)

Good afternoon, Dr. Feldmann...I hope all is well. Are you available to tape an interview with America Tonight this evening at 5:00 pm MDT via satellite from there? America Tonight is doing a report that focuses on the Dallas Ebola case and we want to follow up with a conversation about how safe we are. Will you call me when you get this? I can be reached on either of the numbers listed below or you can reply to this email address. Thanks for your help!

Jaci Clark
Interview Producer
America Tonight – Al Jazeera America
202-292-6338 (office)
Personal Info (cell)
jaci.clark@aljazeera.net



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 12:02 PM
To: Marston, Hilary (NIH/NIAID) [C]
Subject: RE: Pep
Attachments: VSV Review.pdf

For Zaire ebolavirus (now called Ebola virus) we only did post-exposure 30 minutes after infection (50% survival) using the homologous vaccine.

For Sudan ebolavirus we only did 30 minutes after infection (100% survival) using the homologous vaccine

For Marburg virus we have done 24 and 48 hrs post infection with 5/6 and 2/6 surviving, respectively - homologous vaccine.

No other studies done as far as I know.

Heinz

-----Original Message-----

From: Marston, Hilary (NIH/NIAID) [C]
Sent: Wednesday, October 01, 2014 7:57 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Pep

Question from me (not from ASF), has vsv delta g EBOV-Z been given as pep to NHPs further out than 20-30 mins? If not, is that being tested now?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 11:55 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: Interview request for this evening (10/1)

Can you look into this? Thanks.

From: Jaci Clark [mailto:jaci.clark@aljazeera.net]
Sent: Wednesday, October 01, 2014 10:42 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Interview request for this evening (10/1)

Good afternoon, Dr. Feldmann...I hope all is well. Are you available to tape an interview with America Tonight this evening at 5:00 pm MDT via satellite from there? America Tonight is doing a report that focuses on the Dallas Ebola case and we want to follow up with a conversation about how safe we are. Will you call me when you get this? I can be reached on either of the numbers listed below or you can reply to this email address. Thanks for your help!

Jaci Clark
Interview Producer
America Tonight – Al Jazeera America
202-292-6338 (office)
Personal Info (cell)
jaci.clark@aljazeera.net



Notice: This email and any files transmitted with it are intended only for the use of the individuals or entities to whom they are addressed and may contain information that is confidential and privileged. If you have received this email in error, please notify the sender as soon as possible and delete this email from your system. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this email is strictly prohibited. Opinions, conclusions and other information in this message that do not relate to the official business of Al Jazeera shall be understood as neither given nor endorsed by Al Jazeera.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 10:11 AM
To: Munster, Vincent (NIH/NIAID) [E]; Juma, Bonventure (CDC/CGH/DGHP); Nordlund, Kristen (CDC/OID/NCEZID); Pekoc, Ken (NIH/NIAID) [E]
Cc: Telfer, Jana L. (CDC/ONDIEH/NCEH); Msfocb-monrovia-emed@brussels.msf.org; Murphree, Rendi (CDC/OPHPR/DSLRL); Panasuk, Brian J. (CDC/OPHPR/DEO)
Subject: RE: NBC News Interest in ELWA Laboratory

I agree with Vincent.

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 3:32 AM
To: Juma, Bonventure (CDC/CGH/DGHP); Nordlund, Kristen (CDC/OID/NCEZID); Pekoc, Ken (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Telfer, Jana L. (CDC/ONDIEH/NCEH); Msfocb-monrovia-emed@brussels.msf.org; Murphree, Rendi (CDC/OPHPR/DSLRL); Panasuk, Brian J. (CDC/OPHPR/DEO)
Subject: Re: NBC News Interest in ELWA Laboratory

Hi Jana, request for cdc needs to be addressed by Kristen nordlund for the cdc, for nih it is ken Pekoc, both are included.

Preferably, a visit today, Thursday or Friday would be possible. Otherwise it needs to be in the following week (starting on Tuesday). We will not be able to do sat-sun-mon,


Kind regards,

Vincent munster
Team lead ELWA lab

Sent from my iPhone


On Oct 1, 2014, at 9:22, "Juma, Bonventure (CDC/CGH/DGHP)" <xwl2@cdc.gov> wrote:

Records Originating Outside of NIAID

A large rectangular area of the email body is redacted with a solid red background.

From: Telfer, Jana L. (CDC/ONDIEH/NCEH)
Sent: Wednesday, October 1, 2014 11:58 AM
To: Msfocb-monrovia-emed@brussels.msf.org
Cc: Murphree, Rendi (CDC/OPHPR/DSLRL); Juma, Bonventure (CDC/CGH/DGHP); Panasuk, Brian J. (CDC/OPHPR/DEO)
Subject: NBC News Interest in ELWA Laboratory

Records Originating Outside of NIAID

A large rectangular area of the email body is redacted with a solid red background.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 9:49 AM
To: Hoenen, Thomas (NIH/NIAID) [F]; Ari Watt (ari.pauline@aggiemail.usu.edu); Mora, Anita (NIH/NIAID) [E]
Subject: RE: Your JoVE Publication

Sounds good.

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, October 01, 2014 9:48 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Ari Watt (ari.pauline@aggiemail.usu.edu); Mora, Anita (NIH/NIAID) [E]
Subject: FW: Your JoVE Publication

Hi guys,

Looks like we will get our article converted to open access for free (usually the journal charges 1200\$ USD for that), which might significantly improve its reach!

All the best, Thomas

From: Matthew Kramer [<mailto:matthew.kramer@jove.com>]
Sent: Wednesday, October 01, 2014 9:29 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: rbazinet@hbagency.com; Steve Perros
Subject: Your JoVE Publication

Hi Thomas,

Firstly, congratulations on your recent JoVE publication.

JoVE would with your permission would like to upgrade your article to "Open Access" at no charge. We believe that with more people seeing the article and reproducing this method may have a positive impact on current Ebola research, JoVE wants to do anything it can to help.

My colleagues Steve and Ruth on cc would like to work with any PR contact you have at the NIH to publicize the availability of this resource, do you have a contact I can refer them to?

Thanks in advance for your feedback, the editors and staff at JoVE are very impressed with your work!

Matt

--

Matthew Kramer, MBA

Director of Business Development

JoVE

1 Alewife Center, Suite 200, Cambridge, MA 02140

Direct: 617 299 1246 | Cell: Personal Info



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, October 01, 2014 9:47 AM
To: [Personal Info] Safronetz, David (NIH/NIAID) [E]
Cc: Koita, Ousmane
Subject: RE: testing for suspected Ebola samples

I like the [Personal Info]

Great to hear that everything is OK.

Heinz

From: [Personal Info]
Sent: Wednesday, October 01, 2014 3:20 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Cc: Koita, Ousmane
Subject: RE: testing for suspected Ebola samples

Dear Dr. Feldmann,
Thank you for your reply.

Yes, I'm fine and [Personal Info]. [Personal Info]

I hope you and family is also fine

Best regards,

[Personal Info]

[Personal Info]

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Wednesday, October 01, 2014 3:53 AM
To: [Personal Info] Safronetz, David (NIH/NIAID) [E]
Cc: Ousmane Koita
Subject: RE: testing for suspected Ebola samples

Bass,
No problem to provide my name and number to your colleagues from Gambia. I can talk to them but I am not sure how much we can invest into Gambia as this is not really one of our sites.

I hope things are going well for you. How is the family?

Best wishes,
Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 11:10 PM
To: 'Rainer Fischer'; Zacharowski, Kai Prof. Dr. Dr.
Subject: RE:

Lieber Herr Fischer,

Vielen Dank fuer das Informationsmaterial. Wir sind gern bereit mit Ihnen auf dem Gebiet der Antikoerper zu kooperieren und entsprechende Tierversuche durchzufuehren. In Sachen FX06 ist das allerdings etwas schwieriger. Als wir ueber das Peptid gesprochen haben, war mir nicht bekannt, dass wir ueber FX06 sprechen. Wir haben zur Zeit hier laufende Versuche mit FX06 im Hantavirus- und Ebola-Hamstermodel - unser Kollaborationspartner ist Dr. Petra Wuelfroth, F4 Pharma GmbH i.G. in Wien. Ich weiss nicht ob wir beide Initiativen verbindne koennen.

Viele Gruesse,
Heinz Feldmann

-----Original Message-----

From: Rainer Fischer [mailto:rainer.fischer@ime.fraunhofer.de]
Sent: Thursday, September 25, 2014 11:38 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Zacharowski, Kai Prof. Dr. Dr.
Subject:

Lieber Herr Feldmann,
ich wollte mich nochmals ganz herzlich für das offene und ernüchternde Gespräch vorgestern Abend bedanken. Wir werden diese Empfehlungen sicherlich in unsere Entscheidungen mit einfließen lassen. Wie versprochen schicke ich Ihnen unser Expose an die EU mit der Bitte um finanzielle Hilfe. Wir muessen da sicherlich deutlich mehr Tierversuche einplanen und wir würden diese gerne sowohl für den Antikörpercocktail als auch das Peptid mit Ihnen machen. Könnten Sie uns dazu falls Interesse Ihrerseits besteht uns dazu ein paar Zeilen sowie einen groben Kostenvoranschlag schicken ? Darin finden Sie auch ein paar Information zum Peptid zur Reduktion von Vascular Leak, welches vom Kollegen Zacharowski in Frankfurt entwickelt wurde. Ich kopiere Herrn Zacharowski auf diese Email damit ihr euch direkt zu diesem Thema abstimmen könnt und eventuel auch eine Probe an Ihr Labor schicken könntet. Nochmals herzlichen Dank für Ihre Unterstützung !
Mit den besten Gruessen

Rainer Fischer

Cc: Prof. Dr. Kai Zacharowski

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 11:03 PM
To: 'Mark Roth'
Cc: Safronetz, David (NIH/NIAID) [E]
Subject: RE: influenza

Dear Mark,

Sorry for the long delay in getting back to you. Yes I am back from Monrovia but will go back on Sunday for the rest of October. All our efforts are currently devoted to Ebola research and outbreak response. I have copied David on this email who works with HPS in hamsters.

Perhaps the two of you can discuss if it would be possible to do the work in the Andes virus hamster model.

Best wishes,
Heinz

From: Mark Roth [mailto:mroth@fhcrc.org]
Sent: Wednesday, September 24, 2014 11:19 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: influenza

Hi Heinz, Are you back yet? I am very interested to do the study we had planned. Are you able to talk on the phone?

Best regards,

Mark

On Aug 28, 2014, at 3:21 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Mark,
We are currently in Monrovia, Liberia for the Ebola outbreak. We can discuss this further when we get back around mid-September.

Best wishes, Heinz

From: Mark Roth [mailto:mroth@fhcrc.org]
Sent: Thursday, August 28, 2014 05:23 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: influenza

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 10:55 PM
To: 'Pete Halfmann'; Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: ASP
Attachments: Systems biology approaches to examine the host response to Ebola virus infection 9-26-14.docx

Pete & Andrea,

Please find attached my comments on the latest version of the ASP. A few more comments:

Redacted by agreement

Redacted by agreement

Let me know if there are any further questions.

Best wishes,
Heinz

From: Pete Halfmann [mailto:halfmanp@svm.vetmed.wisc.edu]
Sent: Monday, September 29, 2014 7:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: ASP

Heinz and Andrea,
Please see the attached ASP, revised after Friday's meeting.

Thanks
Peter

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 10:15 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Banadyga, Logan (NIH/NIAID) [F]; Bloom, Marshall (NIH/NIAID) [E]
Subject: RE: Virology blog: Could the Ebola virus epidemic have been prevented?

He is good and has the right way of thinking and writing.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 12:17 PM
To: Banadyga, Logan (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Subject: FW: Virology blog: Could the Ebola virus epidemic have been prevented?

Nicely done.

Could the Ebola virus epidemic have been prevented?

30 September 2014

• **By Vincent Racaniello**

[Earth's virology Professor](#)

Questions? virology@virology.ws

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 9:53 PM
To: Personal Info; Safronetz, David (NIH/NIAID) [E]
Cc: Koita, Ousmane
Subject: RE: testing for suspected Ebola samples

Bass,
No problem to provide my name and number to your colleagues from Gambia. I can talk to them but I am not sure how much we can invest into Gambia as this is not really one of our sites.

I hope things are going well for you. How is the family?

Best wishes,
Heinz

From: Personal Info
Sent: Monday, September 29, 2014 7:57 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Cc: Koita, Ousmane
Subject: FW: testing for suspected Ebola samples
Importance: High

Dear Dr. Hans,
Hope you are fine.
I have some friends at MRC, the Gambia who are interested to set up the Ebola virus platform in their center, MRC, The Gambia.
I explained that it is you who helped us, and they want me to give your names and contacts, so that they will be in touch with you for assistance.
Please will you allow me to do so, or you are so busy now?

Best regards and I wish you a nice beginning of the week

Personal Info

From: Nwakanma Davis [<mailto:dnwakanma@mrc.gm>]
Sent: Wednesday, September 24, 2014 4:10 PM
To: Personal Info
Cc: Secka Ousman
Subject: RE: testing for suspected Ebola samples
Importance: High

Dear Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 9:38 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: ASP
Attachments: ASP_Hoenen_uORF_CB_DS.doc

Please find attached my comments – we can discuss if needed.

Heinz

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Wednesday, September 24, 2014 11:13 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: ASP

Hi Heinz,

Attached an ASP for a collaborative study with Chris Basler – we discussed it in the Friday meeting a few months ago, and both Chris and Dave have already gone over it. I would like to put it into the October ACUC meeting, but I realize that you have lots of stuff to do, so if you don't get it read in time, that's alright.

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 9:14 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update

Redacted by agreement

Redacted by agreement

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:02 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: IFN/ribavirin NHP update

Heinz

Niaid wants have a meeting to coordinate the ebola work. Please send me a list of all the ongoing and planned studies we are going to do at RML.

Thank you

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 07:45 PM Eastern Standard Time
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: RE: IFN/ribavirin NHP update

This looks not too bad. The question is – can the drugs keep the virus load down (high Ct values) for long enough to pull through.

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, September 28, 2014 5:09 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: IFN/ribavirin NHP update

No significant clinical signs as of yet.

Redacted by agreement

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 9:05 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Zoon, Kathryn (NIH/NIAID) [E]
Cc: Bekisz, Joseph (NIH/NIAID) [E]
Subject: RE: Ebola primate study

Redacted by agreement

Let's hope the best for the other two groups.

-----Original Message-----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Tuesday, September 30, 2014 6:47 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]
Subject: RE: Ebola primate study

Redacted by agreement

Redacted by
agreement

Redacted by agreement

All treated animals look okay, but not great. We'll see what happens in the next few days.

Darryl

-----Original Message-----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 2:44 PM
To: Darren Baker
Cc: Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola primate study

Redacted by agreement

Redacted by agreement

Kathy

-----Original Message-----

From: Darren Baker [mailto:darren.baker@biogenidec.com]
Sent: Tuesday, September 30, 2014 3:41 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Ebola primate study

Kathy

Feldmann, Heinrich (NIH/NIAID) [E]


From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 5:12 PM
To: 'Isaac, Freeda E - APHIS'; Dufficy, Deborah L - APHIS; Menk, Kay (NIH/NIAID) [E]
Cc: Link, Donald B - APHIS
Subject: RE: expedited permit completed

This should be it. Many thanks again for your great support and service.

Best wishes,
Heinz

From: Isaac, Freeda E - APHIS [mailto:Freeda.E.Isaac@aphis.usda.gov]
Sent: Tuesday, September 30, 2014 10:20 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Dufficy, Deborah L - APHIS; Menk, Kay (NIH/NIAID) [E]
Cc: Link, Donald B - APHIS
Subject: RE: expedited permit completed

Records Originating Outside of NIAID




From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Tuesday, September 30, 2014 10:42 AM
To: Dufficy, Deborah L - APHIS; Menk, Kay (NIH/NIAID) [E]
Cc: Link, Donald B - APHIS; Isaac, Freeda E - APHIS
Subject: RE: expedited permit completed

This is fantastic – many thanks for your service and support.

Best wishes,
Heinz Feldmann

From: Dufficy, Deborah L - APHIS [mailto:Deborah.L.Dufficy@aphis.usda.gov]
Sent: Tuesday, September 30, 2014 7:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Cc: Link, Donald B - APHIS; Isaac, Freeda E - APHIS
Subject: expedited permit completed

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 5:09 PM
To: Towner, Jonathan (Jon) (CDC/OID/NCEZID)
Cc: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Shipment to CDC/NIH Lab - Monrovia - Sept. 15, 2014


I am sure CDC has its hand full with that case. All over the news.

Heinz

-----Original Message-----

From: Towner, Jonathan (Jon) (CDC/OID/NCEZID)
Sent: Tuesday, September 30, 2014 5:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Shipment to CDC/NIH Lab - Monrovia - Sept. 15, 2014

Records Originating Outside of NIAID



----- Original Message -----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 10:52 PM
To: Towner, Jonathan (Jon) (CDC/OID/NCEZID)
Cc: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Shipment to CDC/NIH Lab - Monrovia - Sept. 15, 2014

Jon,

As you might know we are using a glove box for the infectious work. Whole blood samples will be handled in the glove box as follows:

- (1) Log-in of sample
- (2) Aliquot 1 ml into a 2 ml cryo tube.
- (3) Take 140 ul of whole blood and add to 560 ul of pre-aliquoted AVL buffer (QIAGEN kit) (make sure you pipet the blood into the solution to avoid contamination of the tube wall)
- (4) Wait 10 minutes
- (5) Take the entire 700 ul and transfer into pre-aliquoted ethanol (make sure you pipet the solution into the ethanol to avoid potential contamination of the tube wall)
- (6) Shake well and transfer into bleach dunk tank
- (7) Wait 10 minutes and remove from glove box

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 5:06 PM
To: 'Sperling.J@zdf.de'
Subject: RE: ZDF
Attachments: Lab Exposure.pdf

Anbei der versprochene Artikel.

Schoene Gruesse,
Heinz Feldmann

From: Sperling.J@zdf.de [mailto:Sperling.J@zdf.de]
Sent: Tuesday, September 30, 2014 8:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: ZDF

Sehr geehrter Herr Feldmann,

ich vermute, Sie sprechen Deutsch (otherwise I would translate this mail).

in der Süddeutschen Zeitung von gestern las ich, daß Prof. Stephan Becker, Uni Marburg / Sie selbst an einem Ebola-Impfstoff arbeiten in Konkurrenz zu Glaxo Smith Kline. Weiter las ich, das Beckers Bemühungen um Erhalt der kanadischen Impfdosen aus unklaren Gründen verzögert werden, weil das Unternehmen, das die Rechte hat (New Link Genetics), nicht agiert.

Wir recherchieren an der Frage, ob die WHO sich (immer noch wie bei der Schweinegrippe) bei Epidemien von Lobbyisten instrumentalisieren läßt. In den Spenderlisten der WHO taucht Glaxo mit grob überschlagen 15 -20 Millionen US\$ auf. Haben Sie Hinweise, daß New Link Genetics entweder absichtlich oder unter Druck von außen die Weitergabe der Impfdosen verzögert?

Sehen Sie andere Ungereimheiten im Zusammenhang mit der Ebola-Impfstoff-Forschung in der Konkurrenz beider Unternehmen?

Darüber würde ich gern mit Ihnen sprechen. Sie erreich mich unter der Büronummer unten oder unter 0173-3410384.

Gruss
Joe Sperling

ZDF
Joe Sperling
Red. Frontal 21
10887 Berlin
Deutschland

Telefon: +49 30 2099-1044
Telefax: +49 30 2099-1260
E-Mail: Sperling.J@zdf.de
Web: zdf.de

Mit dem Zweiten sieht man besser

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 5:01 PM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: addendum
Attachments: Addendum Request 2014-066.1E.docx

Made a few minor changes – unfortunately no tracking.

From: Marzi, Andrea (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 12:46 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: addendum

Heinz,

Attached is the addendum.

Please let me know if it's ok to send to Patrick or if you have changes, comments etc.

Thanks,
Andrea

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 4:54 PM
To: 'Rezabek, Grant'
Subject: RE: **Personal Info**

Grant,

Many thanks for your quick response. Laura is an excellent candidate and she has my highest recommendation. I am leaving again for Monrovia on Sunday. Terrible outbreak – I hope it can be contained at some point.

Best wishes,
Heinz

From: Rezabek, Grant [mailto:grant.rezabek@okstate.edu]
Sent: Tuesday, September 30, 2014 4:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: **Personal Info**

Dr. Feldmann:

This document and e-mail are sufficient. Thank you for the support of this candidate. Good luck with your efforts on the Ebola outbreak.

Grant.

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Tuesday, September 30, 2014 5:48 PM
To: Rezabek, Grant
Subject: RE: **Personal Info**

Dear Dr. Rezabek,

I am very sorry for the delay in getting this important document to you. Please find attached my Letter of Reference for **Personal Info** I hope that my delayed response will not impact on her application. Since beginning of this Ebola outbreak things are not normal any longer and it is hard to keep up with other things.

Many thanks for your understanding. Please let me know if there is anything else that you would need from me. if you do not mind, please provide a quick confirmation by email. Please let me also know if you need the original document.

Good luck with your search -
Best wishes,
Heinz Feldmann

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 4:53 PM
To: Towner, Jonathan (Jon) (CDC/OID/NCEZID)
Cc: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Shipment to CDC/NIH Lab - Monrovia - Sept. 15, 2014

Jon,

As you might know we are using a glove box for the infectious work. Whole blood samples will be handled in the glove box as follows:

- (1) Log-in of sample
- (2) Aliquot 1 ml into a 2 ml cryo tube.
- (3) Take 140 ul of whole blood and add to 560 ul of pre-aliquoted AVL buffer (QIAGEN kit) (make sure you pipet the blood into the solution to avoid contamination of the tube wall)
- (4) Wait 10 minutes
- (5) Take the entire 700 ul and transfer into pre-aliquoted ethanol (make sure you pipet the solution into the ethanol to avoid potential contamination of the tube wall)
- (6) Shake well and transfer into bleach dunk tank
- (7) Wait 10 minutes and remove from glove box
- (8) The remaining steps of the protocol are done under BSL2 conditions using a face shield to protect mucosal membranes and eyes for splashes

Note, AVL and ethanol are pre-aliquoted into tubes (2 ml cryo tubes) with different colored lids to avoid errors during pipetting

We have safety tested the procedure using in vitro (tissue culture) and in vivo systems (mouse model). It is safe to remove after the ethanol step but not prior to the ethanol step. The procedure is exactly the same as outlined by the manufacturer - the difference is that we remove from containment after the ethanol step.

Hope this helps,
Heinz

-----Original Message-----

From: Towner, Jonathan (Jon) (CDC/OID/NCEZID)
Sent: Tuesday, September 30, 2014 4:49 PM
To: Munster, Vincent (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Shipment to CDC/NIH Lab - Monrovia - Sept. 15, 2014

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 4:48 PM
To: 'Rezabek, Grant'
Subject: RE: [Personal Info]
Attachments: LOR [Personal Info] 2014.pdf

Dear Dr. Rezabek,

I am very sorry for the delay in getting this important document to you. Please find attached my Letter of Reference for [Personal Info]. I hope that my delayed response will not impact on her application. Since beginning of this Ebola outbreak things are not normal any longer and it is hard to keep up with other things.

Many thanks for your understanding. Please let me know if there is anything else that you would need from me. if you do not mind, please provide a quick confirmation by email. Please let me also know if you need the original document.

Good luck with your search -
Best wishes,
Heinz Feldmann

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416
Email: feldmannh@niaid.nih.gov

From: Rezabek, Grant [mailto:grant.rezabek@okstate.edu]
Sent: Saturday, September 20, 2014 10:45 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: [Personal Info]

Certainly, whenever it is available will be fine.

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, September 17, 2014 9:07 PM
To: Rezabek, Grant
Subject: RE: [Personal Info]

Dear Dr. Rezabek,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 4:26 PM
To: 'Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US)'; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
Subject: RE: Primers (UNCLASSIFIED)


Darryl,
Can you please advise?

Thanks,
Heinz

-----Original Message-----

From: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US) [mailto:mark.j.wolcott.civ@mail.mil]
Sent: Tuesday, September 30, 2014 2:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
Subject: RE: Primers (UNCLASSIFIED)

Records Originating Outside of NIAID



-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Tuesday, September 30, 2014 2:35 PM
To: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US)
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Lane, Cliff (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Primers (UNCLASSIFIED)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 4:23 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: (FYI) RE: CNN Breaking News

Thanks

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 4:15 PM
To: Bloom, Marshall (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: (FYI) RE: CNN Breaking News

Just FYI for consistency if asked: Dr. Fauci has said in numerous recent interviews that it would not be surprising if a case were to arise in the U.S. from a returning traveler. The U.S. health care system has appropriate infection control procedures to care for infected persons with limited exposure or risk to the public. He is aware of the case.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 3:59 PM
To: Bloom, Marshall (NIH/NIAID) [E]; Kellar, Joshua (NIH/NIAID) [E]
Subject: FW: CNN Breaking News

In case you hadn't heard already.

From: CNN Breaking News [<mailto:BreakingNews@mail.cnn.com>]
Sent: Tuesday, September 30, 2014 2:56 PM
To: textbreakingnews@ema3lsv06.turner.com
Subject: CNN Breaking News

A patient at a Dallas, Texas, hospital is the first case of Ebola virus diagnosed in the United States, according to the CDC.

Other Americans were diagnosed in West Africa and then brought to the United States for treatment.

Get complete coverage of breaking news on [CNN TV](#), [CNN.com](#) and CNN Mobile.

Choose your news. Watch CNN live or On Demand. Go on-air or online at the same time. Watch live now at [CNN.com/go](#)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 12:35 PM
To: 'Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US)'
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Lane, Cliff (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Primers (UNCLASSIFIED)

Any Zaire ebolavirus strain should work as a control for the Ebola primer sets - you must have controls for your own assay which was used previously on the patient's blood.

In regards to VSV, Peter may have some left over from the VSV vaccine work he did with Bob. A lot of people use VSV as a control for lab studies - you may want to ask Peter Collins or others on site. USAMRIID most likely has VSV. We can send VSV control RNA but it would take another day.


Let us know what you need. We would have to ship in the next two hours.

Heinz

-----Original Message-----

From: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US) [mailto:mark.j.wolcott.civ@mail.mil]
Sent: Tuesday, September 30, 2014 11:28 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Dorman, William R (Bill) CIV USARMY MEDCOM USAMRIID (US); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Lane, Cliff (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Subject: FW: Primers (UNCLASSIFIED)

Records Originating Outside of NIAID



-----Original Message-----

From: Lane, Cliff (NIH/NIAID) [E] [mailto:CLANE@niaid.nih.gov]
Sent: Tuesday, September 30, 2014 10:39 AM
To: Wolcott, Mark J CIV USARMY MEDCOM USAMRIID (US)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 11:08 AM
To: Caldwell, Harlan (NIH/NIAID) [E]
Subject: RE: Uganda

Sounds good.

Heinz

-----Original Message-----

From: Caldwell, Harlan (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 10:58 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Uganda

Yes we should do that - I am busy the rest of the week but let's partake when you get back. Grant is planning to visit sometime soon. I will let him know that you will be gone until late October and perhaps he can come then. Have a safe trip!

Harlan D. Caldwell, Ph.D
Chief and Senior Investigator
Laboratory of Intracellular Parasites
Rocky Mountain Laboratory
National Institute of Allergy and Infectious Diseases
903 South 4th Street
Hamilton, MT 59840

Email: hcaldwell@niaid.nih.gov
Phone: 406-363-9333
FAX: 406-363-9355

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 8:40 AM
To: Caldwell, Harlan (NIH/NIAID) [E]
Subject: RE: Uganda

We should go for a beer or dinner one of these days. Usually only happens when Grant is town - any plans for him to come back?

Leaving again for Monrovia on Sunday - be back by the end of October.

Good luck,
Heinz

-----Original Message-----

From: Caldwell, Harlan (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 8:11 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 9:58 AM
To: Munster, Vincent (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

Thanks.

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 9:22 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]
Subject: Re: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

An actual update on last nights count: 90. So nowhere near the reported 300. Maybe this is what they are expecting. They just rotated as well, randy and Jamie are back.


Sent from my iPhone

On Sep 29, 2014, at 22:23, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Vincent – how many samples does the LIBR lab do every day? Do they really do 300 samples? They must be working day and night or do they have automated extraction?

From: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
[\[mailto:david.a.norwood.civ@mail.mil\]](mailto:david.a.norwood.civ@mail.mil)
Sent: Monday, September 29, 2014 1:58 PM
To: Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Nichol, Stuart T. (CDC/OID/NCEZID); Smith, Michael A CIV (US); Stroehrer, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); Pimentel, Guillermo CDR USN NAVMEDRSCHCEN (US)
Cc: Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US)
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 9:51 AM
To: 'Kai Kupferschmidt'
Subject: RE: vaccine story

Danke fuer den Artikel. Wir fangen naechste Woche an.

From: Kai Kupferschmidt [mailto:KaiKupferschmidt@gmx.de]
Sent: Tuesday, September 30, 2014 5:00 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: vaccine story

Hallo Heinz,

war dann gestern schon im Bett als die story online gegangen
ist: <http://news.sciencemag.org/africa/2014/09/ebola-vaccine-tests-needlessly-delayed-researchers-claim>

Hast du anfangen können, den Impfstoff gegen den Guinea strain zu testen?

Gruß und viel Erfolg!
Kai

Feldmann, Heinrich (NIH/NIAID) [E]


From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 8:42 AM
To: 'Dufficy, Deborah L - APHIS'; Menk, Kay (NIH/NIAID) [E]
Cc: Link, Donald B - APHIS; Isaac, Freeda E - APHIS
Subject: RE: expedited permit completed

This is fantastic – many thanks for your service and support.

Best wishes,
Heinz Feldmann

From: Dufficy, Deborah L - APHIS [mailto:Deborah.L.Dufficy@aphis.usda.gov]
Sent: Tuesday, September 30, 2014 7:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Cc: Link, Donald B - APHIS; Isaac, Freeda E - APHIS
Subject: expedited permit completed

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 8:40 AM
To: Caldwell, Harlan (NIH/NIAID) [E]
Subject: RE: Uganda

We should go for a beer or dinner one of these days. Usually only happens when Grant is town - any plans for him to come back?

Leaving again for Monrovia on Sunday - be back by the end of October.

Good luck,

Heinz

-----Original Message-----

From: Caldwell, Harlan (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 8:11 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Uganda

Thank you -

Harlan D. Caldwell, Ph.D
Chief and Senior Investigator
Laboratory of Intracellular Parasites
Rocky Mountain Laboratory
National Institute of Allergy and Infectious Diseases
903 South 4th Street
Hamilton, MT 59840

Email: hcaldwell@niaid.nih.gov
Phone: 406-363-9333
FAX: 406-363-9355

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 3:25 PM
To: Reynolds, Steven (NIH/NIAID) [E]
Cc: Caldwell, Harlan (NIH/NIAID) [E]
Subject: RE: Uganda

Dear Steve,

I planned to contact you since quite some time but never got to do it. We were planning to start our Uganda ICER project this summer (August), but our current Ebola involvement in Monrovia, Liberia has changed everything. For a while, we will have at least 2-3 people in Monrovia to support MSF and others with laboratory diagnostics on Ebola. I really have to think about when and how to move the ICER along but I am afraid this it will rather be next year (2015) than this one.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 8:38 AM
To: Menk, Kay (NIH/NIAID) [E]; Isaac, Freeda E - APHIS
Subject: RE: Permit application 14268054

This is fantastic – we highly appreciate your service and support.

Best wishes,
Heinz Feldmann

From: Menk, Kay (NIH/NIAID) [E]
Sent: Tuesday, September 30, 2014 8:19 AM
To: Isaac, Freeda E - APHIS; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Permit application 14268054

Good morning Dr. Isaac.
Thank you so much for your assistance in expediting the VSV permit. The permit has been received.
Have a great day.

Kay

Kay R. Menk, Laboratory Operations Specialist, LV
Rocky Mountain Laboratories
903 South 4th Street
Hamilton, MT 59840
Phone: (406) 375-9624
Fax: (406) 375-9620
Email: menkk@niaid.nih.gov

The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this email in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Isaac, Freeda E - APHIS [<mailto:Freeda.E.Isaac@aphis.usda.gov>]
Sent: Tuesday, September 30, 2014 7:07 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Permit application 14268054

Hello Dr. Feldman and MenK,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 6:54 PM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

I know – I was wondering about the number as well. Still 150 is a big number.

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 5:56 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

150 tops, where does the number 300 comes from? Remind you that the do everything in "containment", so no inactivation etc.


Sent from my iPhone

On Sep 29, 2014, at 22:23, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Vincent – how many samples does the LIBR lab do every day? Do they really do 300 samples? They must be working day and night or do they have automated extraction?

From: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
[\[mailto:david.a.norwood.civ@mail.mil\]](mailto:david.a.norwood.civ@mail.mil)
Sent: Monday, September 29, 2014 1:58 PM
To: Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Nichol, Stuart T. (CDC/OID/NCEZID); Smith, Michael A CIV (US); Stroeher, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); Pimentel, Guillermo CDR USN NAVMEDRSCHCEN (US)
Cc: Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US)
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 5:45 PM
To: 'Lucas,Alexandra Rose'
Subject: RE: question
Attachments: Feldmann Bibliography BSC 2014.doc; Feldmann NIH Biosketch 2014.docx

Here you go.

We should most likely talk about the sabbatical in regards to project outline.

From: Lucas,Alexandra Rose [mailto:Alexandra.Lucas@medicine.ufl.edu]
Sent: Saturday, September 27, 2014 2:59 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: question

Interesting would u be willing to share your cv or bio sketch ? The dept chair wants to see what the sabbat site might be like al

Sent from my iPhone

On Sep 27, 2014, at 1:37 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

In principle it is possible to do a sabbatical. I guess I need the signature of my boss, Dr. Kathryn Zoon.

From: Lucas,Alexandra Rose [mailto:Alexandra.Lucas@medicine.ufl.edu]
Sent: Tuesday, September 23, 2014 7:00 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: question

Hi Heinz I do think bsl2 more realistic for a 4 sabbat al

Sent from my iPhone

On Sep 23, 2014, at 8:19 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

I would have to ask if this is possible. Just keep in mind, if you consider BSL4 work that needs a lot of paperwork and training. BSL2 work is much easier.

Best wishes,
Heinz

From: Lucas,Alexandra Rose [mailto:Alexandra.Lucas@medicine.ufl.edu]
Sent: Tuesday, September 23, 2014 12:36 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: question

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 5:32 PM
To: Safronetz, David (NIH/NIAID) [E]
Subject: RE: updated FX06 ASP
Attachments: Safronetz FX06 Ebola pilot (NIAID ACUC ASP Form May 2014)pwh.doc

Looks good – just a few suggestions. Please submit.

From: Safronetz, David (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 6:18 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: updated FX06 ASP

Hi Heinz,
Patrick provided some good suggestions on the FX06 ASP. The attached version addresses his comments.

Dave


Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 4:24 PM
To: Munster, Vincent (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]
Subject: FW: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

Vincent – how many samples does the LIBR lab do every day? Do they really do 300 samples? They must be working day and night or do they have automated extraction?

From: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US) [mailto:david.a.norwood.civ@mail.mil]
Sent: Monday, September 29, 2014 1:58 PM
To: Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Nichol, Stuart T. (CDC/OID/NCEZID); Smith, Michael A CIV (US); Stroeher, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); Pimentel, Guillermo CDR USN NAVMEDRSCHCEN (US)
Cc: Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US)
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

Records Originating Outside of NIAID



-----Original Appointment-----

From: Flynn, Jesse M CTR OSD OUSD ATL (US)
Sent: Monday, August 18, 2014 2:00 PM
To: Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); 'stn1@cdc.gov'; Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Smith, Michael A CIV (US);

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 4:19 PM
To: 'Geisbert, Thomas W.'; YOSHIHIROKAWAOKA; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

Juergen,
Let's do this on Wednesday - can you please provide call in information? If Lynn and Vikki cannot participate you will have to brief them.

Thanks,
Heinz

-----Original Message-----

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 29, 2014 12:20 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

That would be fine with me

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Monday, September 29, 2014 1:19 PM
To: YOSHIHIROKAWAOKA; Geisbert, Thomas W.; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

How about Wednesday (October 1) at 10:30 AM CST. In case Lynn and Vikki cannot make this one (too late in the day for them) perhaps the four of us can discuss and Juergen can inform Target later.

Heinz

-----Original Message-----

From: YOSHIHIROKAWAOKA
Sent: Monday, September 29, 2014 12:16 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'Geisbert, Thomas W.'; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

next Monday and Tuesday are not good for me - travelling Asia.

.

Yoshi

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Handle: Feldmann, Heinrich (NIH/NIAID) [E] Mail Address: feldmannh@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 3:19 PM
To: Walczynski, Joyce (NIH/NIAID) [C]
Subject: RE: Call with Atsu, Michael Katze, Angie, and Heinz

Fine.

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Monday, September 29, 2014 2:35 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Call with Atsu, Michael Katze, Angie, and Heinz

Hi Heinz,

Rose Howard has contacted us because they would like to schedule a phone call prior to you leaving this weekend. It is a call with you, Angie, Atsu, and Michael. Is it okay with you if I try to get something scheduled in any available time you do not have anything else scheduled? I know that you are very busy, so I don't want to impose on some time you have set aside for something else.

Thanks.

Joyce Walczynski
Logistics Technician, LV (Contractor)
Rocky Mountain Laboratories
903 South 4th St.
Hamilton, MT 59840
Phone: 406.375.9600
Fax: 406.375.9620
Email: walczynskij@niaid.nih.gov

From: Rose M. Howard [<mailto:rmhoward@uw.edu>]
Sent: Monday, September 29, 2014 2:27 PM
To: Walczynski, Joyce (NIH/NIAID) [C]
Subject: Re: Call with Heinz

Angie, Atsu, Michael and Heinz will be in the call
Rose Howard
Professional Assistant to Professor Michael G. Katze
Lab Administrator
Department of Microbiology
Katze Lab
www.viromics.washington.edu
Office: 206.732.6183

Proud to be a UW employee for 15+ years

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 12:20 PM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

OK – thanks.

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 12:17 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

We had those here and I just gave them to MSF, so far cholera doesn't seem to be an issue

Sent from my iPhone

On Sep 29, 2014, at 18:09, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

They were talking about a lateral flow assay for cholera earlier.

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 12:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

I think a lateral flow assay which for Ebola,

Probably not very sensitive so your only going to pick- up the high viral load cases

Sent from my iPhone

On Sep 29, 2014, at 17:34, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

What is LFI?

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 8:04 AM
To: Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Smith, Michael A CIV (US); Stroehrer, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); Pimentel, Guillermo CDR USN NAVMEDRSCHCEN (US);

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 12:10 PM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

They were talking about a lateral flow assay for cholera earlier.

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 12:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

I think a lateral flow assay which for Ebola,

Probably not very sensitive so your only going to pick- up the high viral load cases

Sent from my iPhone

On Sep 29, 2014, at 17:34, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

What is LFI?

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 8:04 AM
To: Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Smith, Michael A CIV (US); Stroehler, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); Pimentel, Guillermo CDR USN NAVMEDRSCHCEN (US); Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US); Ervin, Elizabeth (CDC/OID/NCEZID) (CTR)
Subject: Re: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

If this is deemed useful, we could test them as well at the cdc-nih elwa lab.

Tried to call in from Monrovia, but couldn't hear anything,

Regards,

Vincent Munster

Sent from my iPhone

On Sep 29, 2014, at 13:46, "Nichol, Stuart T. (CDC/OID/NCEZID)" <stn1@CDC.GOV> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:34 AM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: FW: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

What is LFI?

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 8:04 AM
To: Nichol, Stuart T. (CDC/OID/NCEZID)
Cc: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Smith, Michael A CIV (US); Stroehler, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); Pimentel, Guillermo CDR USN NAVMEDRSCHCEN (US); Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US); Ervin, Elizabeth (CDC/OID/NCEZID) (CTR)
Subject: Re: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

If this is deemed useful, we could test them as well at the cdc-nih elwa lab.

Tried to call in from Monrovia, but couldn't hear anything,

Regards,

Vincent Munster

Sent from my iPhone

On Sep 29, 2014, at 13:46, "Nichol, Stuart T. (CDC/OID/NCEZID)" <stm1@CDC.GOV> wrote:

Records Originating Outside of NIAID

From: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US)
[\[mailto:david.a.norwood.civ@mail.mil\]](mailto:david.a.norwood.civ@mail.mil)
Sent: Monday, September 29, 2014 9:45 AM
To: Flynn, Jesse M CTR OSD OUSD ATL (US); Bartee, Maureen S CIV (US); Watson, Ian D CIV (US); Newman, Carl I CIV (US); Nichol, Stuart T. (CDC/OID/NCEZID); Smith, Michael A CIV (US); Stroehler, Ute (CDC/OID/NCEZID); Geibe, Jesse R. (CDC/OPHPR/OD); Montgomery, Joel M. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Smith, Jennifer B CIV (US); Pimentel, Guillermo CDR USN NAVMEDRSCHCEN (US)
Cc: Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); Dorau, Andrew C CIV DTRA J3-7 (US)
Subject: RE: Weekly DoD-CDC-NIH Ebola Lab Synchronization Call (UNCLASSIFIED)

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:32 AM
To: 'Geisbert, Thomas W.'; YOSHIHIROKAWAOKA; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

I am leaving for Monrovia on Sunday. I can try to call in from Monrovia but there is no guaranty that it will work.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 29, 2014 11:28 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

Unfortunately, I cannot do the early mornings this week. What about Tuesday, Wednesday, or Thursday of next week?

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Monday, September 29, 2014 11:48 AM
To: Geisbert, Thomas W.; YOSHIHIROKAWAOKA; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

Tom,

Target is located in Israel – they cannot do later in the day. We would need you on the phone call - any chance to make it happen earlier in the day?

Heinz

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 29, 2014 10:36 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

I don't think I can make that time on these days but please go ahead without me. I could do Wednesday or Friday but more in the block of time between 10:30 am and 4 pm Central time,

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Monday, September 29, 2014 10:46 AM
To: YOSHIHIROKAWAOKA; Geisbert, Thomas W.; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: conference call - Ebola conferenc ein Washington

Dear ALL,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:30 AM
To: 'Geisbert, Thomas W.'; Robert Levitt
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

I cannot find the final version. I have one which looks like the galley proofs.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 29, 2014 11:18 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Robert Levitt
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

Heinz,

I have what I think is a final proof. Do you have the pdf of the final article?

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Monday, September 29, 2014 12:03 PM
To: Geisbert, Thomas W.; Robert Levitt
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

I don't see a problem but it should not be further distributed.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 29, 2014 7:53 AM
To: Robert Levitt; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

Dr. Levitt,

The Fields Chapter does contain additional information. I have cc'd Dr. Feldmann to see what is needed in regard to the Fields Chapter.

Heinz,

Do you see any problems with providing a pdf file of the Fields Chapter to WHO? Do we need permission from the publisher? I can't see how this would be a problem given the outbreak as I don't see where anyone would profit from this.

Many thanks!

Tom

From: Robert Levitt [Personal Info]
Sent: Sunday, September 28, 2014 2:29 PM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:28 AM
To: 'Robert Levitt'; Geisbert, Thomas W.
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

Tom – do you have the pdf handy?

From: Robert Levitt [mailto:[Personal Info](#)]
Sent: Monday, September 29, 2014 11:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Geisbert, Thomas W.
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

Dr. Feldmann and Dr. Geisbert:

[Redacted by agreement](#)

I will only distribute my personal summary of the Fields' Chapter to WHO and to yourselves. If I make any errors in my summary, please notify me by email. (Dr. Sabeti and Dr. Sullivan do the same for my Evening Updates to WHO on Ebola).

Thank you,
Robert G. Levitt, M.D.

From: feldmannh@niaid.nih.gov
To: twgeisbe@UTMB.EDU; [Personal Info](#)
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO
Date: Mon, 29 Sep 2014 17:03:21 +0000

[Redacted by agreement](#)

From: Geisbert, Thomas W. [<mailto:twgeisbe@UTMB.EDU>]
Sent: Monday, September 29, 2014 7:53 AM
To: Robert Levitt; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

Dr. Levitt,

[Redacted by agreement](#) contain additional information. I have cc'd Dr. Feldmann to see what is needed in regard to the Fields Chapter.

Heinz,

Do you see any problems with providing a pdf file of the Fields Chapter to WHO? Do we need permission from the publisher? I can't see how this would be a problem given the outbreak as I don't see where anyone would

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:27 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Redacted

Thanks

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:04 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Redact

Thanks Heinz. Did not know any of this. I will check with Cliff on the vaccine.
Kathy

Sent from my BlackBerry Wireless Handheld

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 12:46 PM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Redacte

Kathy,

Redacted by agreement

Redacted by agreement

Redacted by

Best wishes,
Heinz

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:53 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Redacte

Not much of a collegial attitude considering that we are supposed to share all results and information with them. Redact

Redacted by agreement

Redacte
d by agr All other entities in the outbreak (see MSF) are readily sharing information on confidential level.

Anyway, I am not totally surprised and keep his answer in mind for future communication.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:03 AM
To: 'Geisbert, Thomas W.'; Robert Levitt
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

I don't see a problem but it should not be further distributed.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 29, 2014 7:53 AM
To: Robert Levitt; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

Dr. Levitt,

Redacted by agreement does contain additional information. I have cc'd Dr. Feldmann to see what is needed in regard to the Fields Chapter.

Heinz,

Do you see any problems with providing a pdf file of the Fields Chapter to WHO? Do we need permission from the publisher? I can't see how this would be a problem given the outbreak as I don't see where anyone would profit from this.

Many thanks!

Tom

From: Robert Levitt **Personal Info**
Sent: Sunday, September 28, 2014 2:29 PM
To: Geisbert, Thomas W.
Subject: TO: Dr T. Geisbert: Evening Update, Sat, 9/27 on Ebola for WHO

Dear Dr. Geisbert:

In a round about way, the task of updating daily WHO's Dr. Chan via her associate Ms. Kindhauser has become my contribution to the response to the Ebola crisis. Nothing very dramatic or dangerous as your work, but it is something that I have experience in doing (situational awareness and analysis). I send Ms. Kindhauser an evening update of what Ebola news appears in U.S. newspapers and medical and current affairs journals and PloS and NEJM and Science. An example is below for your review. Drs. Sabeti and Sullivan vet the emails daily and correct my errors (I'm a diagnostic radiologist who has become an infection control person for BJC Health System and Tenet Health Care).

WHO administrators have no time this year to keep up on the news and journals re: Ebola so I try to help WHO out. I purchased the wrong virology textbook to read more about Ebola ('Understanding Virology by Teri Shors). I am wanting to read your ref 1 in your Nature article this summer, but \$454 for the 2 volume 'Fields' Virology 6th Edition' is too expensive for me right now. Is there anyway I could be sent page 923-956 as an attachment? I have read your Lancet article on Ebola Hemorrhagic Fever in 2011 and need to know if the

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 11:00 AM
To: 'Warren Marcus'
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert

OK – we will have to use either cynomolgus or rhesus macaques. Will this work according to your data? NHP work is expensive and we may have to discuss how to perform a potential study and who will cover what expenses. Let me know if you are still interested.

Best wishes,
Heinz

From: Warren Marcus [mailto:warrenmarcus@altorbioscience.com]
Sent: Sunday, September 28, 2014 8:10 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: Re: Seeking research help from Ebola expert

Dr. Wong (our CEO) and I discussed this today. Unfortunately, this will not work in a rodent model. That is why all of the preclinical studies that led to the IND's for ALT-836 were all performed in NHPs (chimpanzees, baboons, and cynomolgus monkey's).

The safety studies were predominantly performed in the monkey and was not published. But here are two publications involving a baboon model and a chimpanzee model:

<http://ajplung.physiology.org/content/ajplung/290/1/L21.full.pdf>

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927860/pdf/nihms162815.pdf>

Both of these studies demonstrate the efficacy of ALT-836s blocking of tissue factor-initiated downstream events. If you look at the sepsis model performed in the baboon, there is a significant decrease in many of the hallmark characteristics of inflammation, including proinflammatory cytokines. The cytokine storm has been linked to the mortality caused by Ebola.

Therefore, since the increased expression of TF was the primary premise behind using rNAPc2 in the rhesus macaque model by Geisbert, then a proven inhibitor of the downstream events caused by the over expression of TF should also validate the use of ALT-836 in a NHP model.

Thanks,
Warren

Sent from my iPad

On Sep 27, 2014, at 4:35 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 10:53 AM
To: 'Karen Weintraub'
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: Question about Broad Ebola study

I can only comment on the science of the paper as I was not involved in the study and things around it. In case you want an interview on the science please contact Ken Pekoc to make necessary arrangements.

Best wishes, Heinz

From: Karen Weintraub [mailto:[Personal Info](#)]
Sent: Monday, September 29, 2014 9:10 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Question about Broad Ebola study

Hi. Last month I chose not to write about the Broad study of how the Ebola virus is mutating, because a few scientists I interviewed raised questions off the record about the ethics of the research. One told me that the researchers "had blood on their hands" for prioritizing their data over the lives of Ebola patients. I noticed last week that the WHO has held the research up as an example of important work during this epidemic:

<http://www.who.int/csr/disease/ebola/ebola-6-months/sierra-leone/en/>

I went back to the scientists I had spoken with last month, who eventually suggested I reach out to you. I'm not looking for a "gotcha" piece, but if there's a larger lesson the public should learn from this, I'm interested in writing about it.

I'm a freelancer based in Cambridge - so I know the Broad folks fairly well. I write regularly for USA Today and also for NationalGeographic.com - which is who I was writing the initial piece about the Broad work for.

Thanks,
Karen

--

Website: karenweintraub.com

Twitter: [Personal Info](#)

Phone: 617-283-8476

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 10:50 AM
To: 'Branswell, Helen'
Subject: RE: hi and FMI

I am leaving on Sunday for Monrovia. Redacted by agreement

Redacted by agreement

From: Branswell, Helen [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Monday, September 29, 2014 10:12 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: hi and FMI

Heinz;

Hi there. How are you?

I took last week off and feel much better for having done so. But I'm ready to get back at Ebola. Where do things stand? How is your work going?

Are you going back sometime soon? I think you said "October" which is coming very soon.

Best,

Helen

Helen Branswell

Medical Reporter

The Canadian Press

Direct line: 416-507-2142

Twitter: @HelenBranswell

Email: helen.branswell@thecanadianpress.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 10:48 AM
To: 'Geisbert, Thomas W.'; YOSHIHIROKAWAOKA; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

Tom,

Target is located in Israel – they cannot do later in the day. We would need you on the phone call - any chance to make it happen earlier in the day?

Heinz

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 29, 2014 10:36 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; YOSHIHIROKAWAOKA; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: RE: conference call - Ebola conferenc ein Washington

I don't think I can make that time on these days but please go ahead without me. I could do Wednesday or Friday but more in the block of time between 10:30 am and 4 pm Central time,

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Monday, September 29, 2014 10:46 AM
To: YOSHIHIROKAWAOKA; Geisbert, Thomas W.; Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: conference call - Ebola conferenc ein Washington

Dear ALL,

Lynn and Vikki from target and Juergen and I had a quick conference call this morning and I briefed them about the discussion I had with Yoshi and Tom last week. Since I am leaving for Monrovia on Sunday, would it be possible to have a conference call with all of us this week (Tuesday, Wednesday or Friday preferred)? The preferred time would be 8:45 AM CST USA. Friday and Saturday are not very good for Vikki and Lynn.

Please let us know as soon as possible and Juergen will provide call in information.

Thanks and best wishes,
Heinz

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 10:47 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: RE: Redact

Kathy,

Redacted by agreement

Redacted by agreement

Redacted by

Best wishes,
Heinz

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:53 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Redacte

Not much of a collegial attitude considering that we are supposed to share all results and information with them. Reda

Redacted by agreement

Redacted All other entities in the outbreak (see MSF) are readily sharing information on confidential level.

Anyway, I am not totally surprised and keep his answer in mind for future communication.

Heinz

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416
Email: feldmannh@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 10:28 AM
To: Redac
Subject: RE: Vsv vaccine

Dear Reda

I just talked to a colleague and friend of mine from Winnipeg, Dr. Jim Strong. Jim is a pediatrician and involved in the development of the VSV vaccine. If you wish, please give him a call at Personal Info

Redacted by agreement

Best wishes,
Heinz

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 8:36 AM
To: Redact
Subject: RE: Vsv vaccine

Dear Redact

Redacted by agreement

Redacted by agreement

Redacted by agreement

I am fairly confident that this will go away.

Good luck and all the best,
Heinz

-----Original Message-----

From: Redacted by agreement
Sent: Monday, September 29, 2014 3:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Vsv vaccine

Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 9:58 AM
To: YOSHIHIROKAWAOKA; Geisbert, Thomas W. (twgeisbe@UTMB.EDU)
(twgeisbe@UTMB.EDU)
Subject: RE: FW: Greetings from the International Journal of Ebola Virus and Research

Me too

-----Original Message-----

From: YOSHIHIROKAWAOKA
Sent: Monday, September 29, 2014 9:53 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Geisbert, Thomas W. (twgeisbe@UTMB.EDU) (twgeisbe@UTMB.EDU)
Subject: Re: FW: Greetings from the International Journal of Ebola Virus and Research

I am going to ignore this.

Yoshi

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Handle: Feldmann, Heinrich (NIH/NIAID) [E] Mail Address: feldmannh@niaid.nih.gov
Subject: FW: Greetings from the International Journal of Ebola Virus and Research
To: YOSHIHIROKAWAOKA <kawaokay@svm.vetmed.wisc.edu>, Geisbert, Thomas W. (twgeisbe@UTMB.EDU)
(twgeisbe@UTMB.EDU) <twgeisbe@UTMB.EDU>
CC: --
Date: Mon, 29 Sep 2014 15:42:31 +0000
Date Local: 2014/09/30 0:42:31
Message:

> I guess you got this as well – what is this all about? Do you know the people?

>

>

> From: ijevr@sciforschenonline.org [mailto:ijevr@sciforschenonline.org]

> Sent: Monday, September 29, 2014 9:22 AM

> To: Feldmann, Heinrich (NIH/NIAID) [E]

> Subject: Greetings from the International Journal of Ebola Virus and

> Research

>

>

>

>

> Dear Dr. Heinz Feldmann,

>

>

>

> Greetings from the International Journal of Ebola Virus and

> Research<<http://sciforschenonline.org/journals/ebola-research/index.ph>

> p>,

>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 9:57 AM
To: freed.a.e.isaac@aphis.usda.gov
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Permit application 14268054

Dear Dr. Isaac,

I would highly appreciate if this permit request could be addressed as soon as possible. I hate to ask you for this special treatment, but the material is needed for a vaccine trial regarding the current Ebola virus strain causing the disastrous outbreak in West Africa. WHO and other organization are very keen to learn if the vaccine, which is based on a different strain, will also protect against this new strain. As sooner as we can start the experiment as better it would be for outbreak response and the beginning human clinical trial with the vaccine candidate. We have an approved animal study protocol and the animals are already sitting ready to go. Winnipeg is ready to ship immediately we are just awaiting the USDA import permit (we do have the CDC import permit).

If you have any questions, please feel free to contact me any time by email (see above) or phone (office: 406-375-7410; BB phone Personal Info)

Many thanks for your cooperation - best wishes,
Heinz Feldmann

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416
Email: feldmannh@niaid.nih.gov

From: Menk, Kay (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 9:49 AM
To: freed.a.e.isaac@aphis.usda.gov
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Permit application 14268054

Good morning Dr. Isaac,

I am sorry to bother you but we have sent in an URGENT request for a permit to import VSV from Winnipeg. I had left a voicemail this morning for you and am following up with this email. This is URGENT due to the nature of the current

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 9:46 AM
To: YOSHIHIROKAWAOKA; Geisbert, Thomas W. (twgeisbe@UTMB.EDU) (twgeisbe@UTMB.EDU); Juergen Richt; 'Vikki Hyman'; Lynn Lipschitz
Subject: conference call - Ebola conferenc ein Washington

Dear ALL,

Lynn and Vikki from target and Juergen and I had a quick conference call this morning and I briefed them about the discussion I had with Yoshi and Tom last week. Since I am leaving for Monrovia on Sunday, would it be possible to have a conference call with all of us this week (Tuesday, Wednesday or Friday preferred)? The preferred time would be 8:45 AM CST USA. Friday and Saturday are not very good for Vikki and Lynn.

Please let us know as soon as possible and Juergen will provide call in information.

Thanks and best wishes,
Heinz

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416
Email: feldmannh@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 29, 2014 9:43 AM
To: YOSHIHIROKAWAOKA; Geisbert, Thomas W. (twgeisbe@UTMB.EDU)
(twgeisbe@UTMB.EDU)
Subject: FW: Greetings from the International Journal of Ebola Virus and Research

I guess you got this as well – what is this all about? Do you know the people?

From: ijevr@sciforschenonline.org [mailto:ijeivr@sciforschenonline.org]
Sent: Monday, September 29, 2014 9:22 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Greetings from the International Journal of Ebola Virus and Research

Dear Dr. Heinz Feldmann,

Greetings from the [International Journal of Ebola Virus and Research](#),

We take great delight in inviting you to join the **Editorial Board** of the [International Journal of Ebola Virus and Research](#), which is an open access, peer reviewed journal managed by [Sci Forschen](#). Ensuring quality and accuracy for every submitted article is the top most priority for [Sci Forschen](#), and we genuinely believe that someone with the knowledge and experience, such as yourself, can really make a huge difference for us.

The [International Journal of Ebola Virus and Research](#), publishes cutting edge research work submitted by scholars from all over the world, and we believe that your presence will polished up with the help of illustrious experts in research field.

We are always striving to involve eminent personalities like you and your standing in the global community makes us confident.

Kindly let us know your valuable response and acceptance if possible with in 48 hours.

Please kindly submit your following particulars to update in our journal website

1. Updated CV
2. Passport Size Photo
3. Short Biography
4. Research Interest

Looking forward for your valuable and soon response.

Regards,

Editorial Office

International Journal of Ebola Virus and Research

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 7:51 PM
To: Menk, Kay (NIH/NIAID) [E]
Subject: Pubclear form

Kay,
Can you please send me the latest Pubclear form(s)?

Can you also please call USDA again about the urgency of the VSV permit – Ebola outbreak response; vaccine efficacy testing against new virus strain from West Africa. I can call them if you give me a phone number and contact person.

Thanks,
Heinz

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)
Division of Intramural Research (DIR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Rocky Mountain Laboratories (RML)
903 South 4th Street
Hamilton, MT 59840
Tel.: +1-406-375-7410
Fax: +1-406-375-7416
Email: feldmannh@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 5:51 PM
To: 'Pardis Sabeti'; Hensley, Lisa (NIH/NIAID) [E]
Cc: Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]
Subject: RE: Illumina and Broad partnering for diagnostics and sequencing on ground

If you don't inactivate the samples in country of origin (prior to shipment) you will have to bring them into BSL4 in order to start the inactivation unless you declare the samples 'diagnostic specimens'. If you know that the samples are confirmed Ebola-positive you won't have a choice others than handling them in BSL4.

Heinz

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Sunday, September 28, 2014 3:40 PM
To: Hensley, Lisa (NIH/NIAID) [E]
Cc: Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Feldmann, Heinrich (NIH/NIAID) [E]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); May_C_Chu@ostp.eop.gov; Giovanni, Maria (NIH/NIAID) [E]
Subject: Re: Illumina and Broad partnering for diagnostics and sequencing on ground

Hi Lisa,

Thank so much. We had a good talk with Jens and Nick Bergmann of NBAAC about this, and discussed the possibility. While it is a good solution, they had raised the concern that the bringing into BL-4 and then taking back out would create its own set of complications and delays, and so were working to another solution. But would love to get your thoughts, and would of course be very thankful to do it if the certification of Ricki's method runs into issues.

On that note though, we do have a large number of active serum samples that we did hope to send to the IRF for other types of studies. That will take a longer time to get the necessary approvals, but would be thrilled if NIH IRF would be the home there. Tom Geisbert, the CDC, and others would also like the samples, but my thought is that the IRF would be the best central hub that can connect with all parties.

Pardis

On Sun, Sep 28, 2014 at 5:27 PM, Hensley, Lisa (NIH/NIAID) [E] <lisa.hensley@nih.gov> wrote:
All

If needed we could do the extractions if that helps.

Lisa

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Sunday, September 28, 2014 05:25 PM
To: Kurilla, Michael (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Feldmann, Heinrich (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Towner, Jonathan (Jon) (CDC/OID/NCEZID); Chu, May <May_C_Chu@ostp.eop.gov>
Cc: Giovanni, Maria (NIH/NIAID) [E]
Subject: Re: Illumina and Broad partnering for diagnostics and sequencing on ground

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 5:44 PM
To: 'jack woodall'; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Question regarding your comment to ProMED post "EBOLA VIRUS DISEASE - WEST AFRICA (177) - [4] Vaccine delivery dilemma"

IND – attenuated.

From: jack woodall [mailto:Personal Info]
Sent: Sunday, September 28, 2014 5:37 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Question regarding your comment to ProMED post "EBOLA VIRUS DISEASE - WEST AFRICA (177) - [4] Vaccine delivery dilemma"

You are both very welcome.

BTW, is the VSV vector NJ or IND?

Best
Jack

On Sun, Sep 28, 2014 at 5:14 PM, Hoenen, Thomas (NIH/NIAID) [F] <thomas.hoenen@nih.gov> wrote:
Dear Jack,

Thank you very much for your email, and the update on ProMED. Heinz and I very much appreciate the clarification!

All the best, Thomas

From: jack woodall [mailto:Personal Info]
Sent: Saturday, September 27, 2014 10:08 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Question regarding your comment to ProMED post "EBOLA VIRUS DISEASE - WEST AFRICA (177) - [4] Vaccine delivery dilemma"

Dear Dr Hoenen,

That was a serious error on my part, which I will correct in tomorrow's update (posting to ProMED is closed for tonight).

Thank you for pointing it out. All the public had heard is that it is a live vaccine, without the context that it is not live EBOV. But I should have checked.

And thank you for your kind words.

Best regards.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 2:30 PM
To: 'Vickie Groth'; YOSHIHIROKAWAOKA; twgeisbe@utmb.edu
Subject: RE: Unpublished
Attachments: Unpublished

Unpublished

Vickie

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 2:02 PM
To: 'WAI, Lokky'
Cc: FREEMAN DELINE, Nancy; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Great – highly appreciated.

Best wishes,
Heinz

From: WAI, Lokky [mailto:wai@who.int]
Sent: Sunday, September 28, 2014 2:00 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: FREEMAN DELINE, Nancy; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Well noted. Even if you want to stay in the Royal 'whatever' hotel it is not possible as they are all full. The drivers will take the passengers to Kendeja Hotel from the airport as requested. Thank you
Lokky

Sent from my iPhone

On 28 Sep 2014, at 18:37, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Please be advised that our team members are not staying at the Royal 'whatever' hotel! This is important and happened to the last team (team 2). Our team stays at the Kendeja hotel and the driver should transport them to the Kendeja as we have rooms booked for Kyle Rosenke, Kristin McNally and myself at the Kendeja.

Please let us (me) know if there are problems with this. Otherwise, we (I) assume that the will be transported to the Kendeja.

Thanks and best wishes,
Heinz

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 10:54 AM
To: 'FREEMAN DELINE, Nancy'; WAI, Lokky; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; DAVIS, Raphael
Cc: GRAAFF, Peter Jan; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Not sure what RLJ stands for.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 1:56 PM
To: 'asall@pasteur.sn'
Cc: Safronetz, David (NIH/NIAID) [E]
Subject: RE: News from Senegal

Dave - what do you think about Amadou's suggestion (see below)?

Best, Heinz

-----Original Message-----

From: asall@pasteur.sn [mailto:asall@pasteur.sn]
Sent: Sunday, September 28, 2014 1:23 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]
Subject: RE: News from Senegal

Dear Heinz,

Thanks for your message, prompt positive feed back. Thanks for the good job you guys are doing in Liberia, the hottest place now. I am also getting ready to go back to Conakry for another shift up to end of October.

The document you sent is great and will be integrated in the letter of intent I will submit on October 2nd. I will send it to you latest Tuesday for your review and insights.

I did not know that you had a project in Mali. If you think that may be of interest to your collaborators there to join the consortium, they may get some money to do research. Wellcome trust initiative focuses on getting African scientists to play key role. So do not hesitate if some of your collaborators with some track record on VHF want to get involved.

I'll be more than happy to welcome you and your colleague in Dakar and discuss collaborations or any activities you are interested in. Let me know when you are ready to come.

Best,

Amadou

> Dear Amadou,

>

> Great to hear from you. Yes, we are operating a lab in Monrovia
> supporting ELWA3 run by MSF. The lab is a joint effort between CDC
> and NIH - currently we are running it with three people from Rocky
> Mountain Laboratories and two from CDC Nairobi. I am going back next
> Sunday for another term and stay until the end of October. During
> that time I will only have limited internet access.

>

> I would be more than happy to support your initiative. Please see
> attached document for the information.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 1:05 PM
To: Personal Info
Subject: RE: Hospital bed problem

Jennifer,

Your thoughts are right on and well appreciated. MSF is largely operating out of tent structures with patients laying on mattresses on the floor (up to 40 patients per tent). This is as basic as it can get and any treatment is extremely difficult under those conditions. Given the poor conditions in those tent structures we still do not have enough basic beds in Monrovia and other places.

Thanks for your thoughts and worries,
Heinz

From: Personal Info
Sent: Sunday, September 28, 2014 11:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Hospital bed problem

Dear Dr. Feldmann,

First, thank you for taking the risk and going to West Africa to deal with Ebola. I truly admire what you and other health workers are doing.

I won't take much of your time and get right to the point. I recently read "We, Band of Angels" about a group of nurses stranded on Bataan before and during the fall of Bataan and after. The casualties near the end of the battle were overwhelming. They improvised a field hospital for over 2000 men. I'm sure the requirements are extraordinary for treating Ebola, but I am wondering if, in waiting for the "perfect" hospital beds, people are remaining in the community exposing others to the disease. Perhaps less than perfect "beds" but greater numbers in isolation would be better than "perfect" beds and lots of people staying outside the compound.

Just a thought.

Sincerely,

Jennifer Personal

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:58 PM
To: 'Jeffrey Meshulam'
Subject: RE: Welcome home

We are actually starting to test three HIV nucleoside analogues in vitro and in vivo here at RML. Hard to say at this point as I haven't seen any data.

Thanks,
Heinz

-----Original Message-----

From: Jeffrey Meshulam [mailto:meshulam@profectusbiosciences.net]
Sent: Sunday, September 28, 2014 11:06 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Welcome home

Redacted by agreement

I will keep everyone going over and especially you in my thoughts and prayers. I was at the who meeting and i came back soooo frustrated. All the intense discussion around the experiment therapies with such tiny numbers available I found ridiculous. The Africans were looking for hope and it's not coming from the current therapies I see.

Redacted by agreement

Be well
Sent from iPhone.

> On Sep 28, 2014, at 12:58 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

>

> Jeff,

> I am well and back since almost three weeks now. Thanks for all your worries and thoughts - highly appreciated. But I am leaving again for another term in Monrovia on Sunday (a week from now).

Redacted by agreement

Redacted by agreement

>

> No clue about what is going on between PHAC and NewLink - only heard from multiple people that everyone is pissed at NewLink.

>

> Best wishes,

> Heinz

>

>

> -----Original Message-----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:41 PM
To: 'jack woodall'
Cc: Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Question regarding your comment to ProMED post "EBOLA VIRUS DISEASE - WEST AFRICA (177) - [4] Vaccine delivery dilemma"

Jack, we met a few times – last I believe at Bob Shope's memorial meeting at UTMB Galveston. I was a postdoc at CDC under CJ, started the BSL4 work in Marburg, Germany, started the BSL4 program in Winnipeg and now run the BSL4 program at the Rocky Mountain Laboratories. Hamilton hasn't changed much but the grass and the silver dollars are gone. I will not be at the IMED.

Yes, we are in Monrovia with a team supporting MSF with lab diagnostics.

Best wishes,
Heinz

From: jack woodall [mailto:Personal Info]
Sent: Sunday, September 28, 2014 12:36 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Question regarding your comment to ProMED post "EBOLA VIRUS DISEASE - WEST AFRICA (177) - [4] Vaccine delivery dilemma"

Heinz,

I'm afraid I don't -- at what meeting was it?

The last time I was at RML was in 1963 -- 50 years ago! Hamilton had grass growing in the middle of main street, and they still used silver dollars...

Will you be at IMED?

Are you or Thomas going to West Africa? I volunteered but changed my mind -- I have enough stress trying to keep up with the Ebola media avalanche! Thanks you for your kind words.

Best
Jack

On Sun, Sep 28, 2014 at 2:17 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:
Jack,

Not sure if you remember me - Thomas and I work together on Ebola and other things here at the Rocky Mountain Laboratories. Thanks for all your hard work on ProMed.

Hope things are going well.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:37 PM
To: 'FREEMAN DELINE, Nancy'; 'WAI, Lokky'; 'goarn'; 'WERTSCHNIG, Brian Adam'; 'mwanamwenge@who.int'; 'DAVIS, Raphael'
Cc: 'GRAAFF, Peter Jan'; 'GASASIRA, Alex Ntale'; 'UMALI DALANGIN, Khristeen'; Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Please be advised that our team members are not staying at the Royal 'whatever' hotel! This is important and happened to the last team (team 2). Our team stays at the Kendeja hotel and the driver should transport them to the Kendeja as we have rooms booked for Kyle Rosenke, Kristin McNally and myself at the Kendeja.

Please let us (me) know if there are problems with this. Otherwise, we (I) assume that the will be transported to the Kendeja.

Thanks and best wishes,
Heinz

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 10:54 AM
To: 'FREEMAN DELINE, Nancy'; WAI, Lokky; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; DAVIS, Raphael
Cc: GRAAFF, Peter Jan; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Not sure what RLJ stands for.

In regards to the hotel booking we will continue to use the same three hotel rooms at the Kendaja. We will just keep these rooms until the end of the mission unless we move away from that hotel. The hotel is perfect for us as it is only 10 minutes away from ELWA, the location of the lab. Vincent Munster (copied here) will take care for the hotel booking.

Best wishes,
Heinz

From: FREEMAN DELINE, Nancy [<mailto:delinen@who.int>]
Sent: Sunday, September 28, 2014 10:50 AM
To: WAI, Lokky; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; DAVIS, Raphael
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; GRAAFF, Peter Jan; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Khristeen,
Kindly let us know under whose name is the RLJ booked because Wannie and I paid a visit on Saturday to RLJ and mentioned the names of the team members and they told us there were no names as such booked there. Please let us know the date and time this booking was done so we can follow up.
Regards,
Nancy

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:33 PM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Thanks.

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 11:01 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Probably the royal, this was the hotel where we ended up the first night ,

Cheers,

Vincent

Sent from my iPhone

On Sep 28, 2014, at 16:54, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Not sure what RLJ stands for.

In regards to the hotel booking we will continue to use the same three hotel rooms at the Kendaja. We will just keep these rooms until the end of the mission unless we move away from that hotel. The hotel is perfect for us as it is only 10 minutes away from ELWA, the location of the lab. Vincent Munster (copied here) will take care for the hotel booking.

Best wishes,
Heinz

From: FREEMAN DELINE, Nancy [<mailto:delinen@who.int>]
Sent: Sunday, September 28, 2014 10:50 AM
To: WAI, Lokky; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; DAVIS, Raphael
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; GRAAFF, Peter Jan; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Khristeen,
Kindly let us know under whose name is the RLJ booked because Wannie and I paid a visit on Saturday to RLJ and mentioned the names of the team members and they told us there were no names as such booked there. Please let us know the date and time this booking was done so we can follow up.
Regards,
Nancy

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:33 PM
To: 'Dorian Bevec, PhD'; Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: testing

We should get going on this as others obviously proceeding the same way.

From: Dorian Bevec, PhD [mailto:dorian.bevec@therametrics.com]
Sent: Sunday, September 28, 2014 9:18 AM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: testing

Hello Thomas,
no questions, all clear. I am proceeding with all the administrative steps.
Best greetings,
Dorian

From: Hoenen, Thomas (NIH/NIAID) [F] <thomas.hoenen@nih.gov>
Sent: Saturday, September 27, 2014 1:43 AM
To: Dorian Bevec, PhD
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: testing

Hi Dorian,

Please find attached a short description of the experimental testing method I intend to use for testing your guys' antivirals – subject to discussion, of course. Please let me know if you have any questions, or require additional information.

All the best, Thomas

From: Dorian Bevec, PhD [mailto:dorian.bevec@therametrics.com]
Sent: Thursday, September 25, 2014 2:41 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: testing

super, thank you!
greetings, Dorian

From: Hoenen, Thomas (NIH/NIAID) [F] <thomas.hoenen@nih.gov>
Sent: Thursday, September 25, 2014 10:35 PM
To: Dorian Bevec, PhD
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: testing

Dear Dorian,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:32 PM
To: 'Amadou Alpha Sall'
Cc: Safronetz, David (NIH/NIAID) [E]
Subject: RE: News from Senegal
Attachments: Feldmann wtp057113.docx

Dear Amadou,

Great to hear from you. Yes, we are operating a lab in Monrovia supporting ELWA3 run by MSF. The lab is a joint effort between CDC and NIH – currently we are running it with three people from Rocky Mountain Laboratories and two from CDC Nairobi. I am going back next Sunday for another term and stay until the end of October. During that time I will only have limited internet access.

I would be more than happy to support your initiative. Please see attached document for the information.

When this is all over (Ebola) I want to come and visit your place. You may know that we have a project in Mali operating out of Bamako. Dave Safronetz and I are talking about visiting you since a while. Of course, you could also visit us at Point G in Bamako. You may know some of our collaborators. Dave will introduce them to you.

Good luck with the application, Heinz

From: Amadou Alpha Sall [<mailto:asall@pasteur.sn>]
Sent: Sunday, September 28, 2014 9:13 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: News from Senegal

Dear Heinz,

How are you, I hope you are doing well since we last met quite long ago in South Africa. I heard that you are or were in Liberia recently. I am contacting you today because i am submitting a grant to Wellcome Trust as part of their DELTAS programme to reinforce health research and training in Africa (see attached information), to build in West Africa a network that will focuses on viral hemorrhagic fever. I would like to know whether you would agree to help the Network as a mentor and trainer for scientist and student on Viral hemorrhagic fever. Looking forward to your feed back.

Amadou

=====

Dr Amadou Alpha SALL
Institut Pasteur de Dakar
36, Avenue Pasteur, BP 220
Dakar (SENEGAL)
Tel: +221338399223
Mobile: Personal Info
Fax: +221338399210
Email: asall@pasteur.sn

=====

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:18 PM
To: Personal Info
Cc: Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Question regarding your comment to ProMED post "EBOLA VIRUS DISEASE - WEST AFRICA (177) - [4] Vaccine delivery dilemma"

Jack,

Not sure if you remember me - Thomas and I work together on Ebola and other things here at the Rocky Mountain Laboratories. Thanks for all your hard work on ProMed.

Hope things are going well.

Best wishes,
Heinz

-----Original Message-----

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Sunday, September 28, 2014 9:07 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Question regarding your comment to ProMED post "EBOLA VIRUS DISEASE - WEST AFRICA (177) - [4] Vaccine delivery dilemma"

FYI.

All the best, Thomas

From: jack woodal Personal Info
Sent: Saturday, September 27, 2014 10:08 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: Re: Question regarding your comment to ProMED post "EBOLA VIRUS DISEASE - WEST AFRICA (177) - [4] Vaccine delivery dilemma"

Dear Dr Hoenen,

That was a serious error on my part, which I will correct in tomorrow's update (posting to ProMED is closed for tonight).

Thank you for pointing it out. All the public had heard is that it is a live vaccine, without the context that it is not live EBOV. But I should have checked.

And thank you for your kind words.

Best regards.
Jack (ProMED Mod.JW)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:14 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: Text für SZ

FYI – in German but I guess you have a program that will do the translation. I am only cited twice (bold).

From: Kai Kupferschmidt [mailto:mail@kaikupferschmidt.de]
Sent: Sunday, September 28, 2014 4:25 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Text für SZ

Hallo Heinz,

anbei nur kurz zur Kenntnis der Text wie er in der SZ erschienen soll. Deine Zitate sind gefettet. Sind nur zwei Sätze, wie **zuvor** besprochen und sollte alles in Ordnung sein.

Gruß
Kai

Stephan Becker hält das Warten kaum noch aus. Seit Wochen bereitet der Virologe von der Universität Marburg eine Studie vor, um in Deutschland einen Impfstoff gegen Ebola zu testen. Aber es geht nur langsam voran. Mehr als 800 Dosen des experimentellen Impfstoffs, vor sechs Wochen von der kanadischen Regierung der Weltgesundheitsorganisation (WHO) geschenkt, liegen immer noch in Kanada. Die benötigten Unterlagen sind immer noch nicht vollständig. „Ich bin richtig durch den Wind“, sagt Becker. „Das macht mich kirre, dass wir hier sitzen und etwas tun könnten, aber es geht nicht voran.“

Legt man normale Maßstäbe an, passiert eigentlich gerade alles unfassbar schnell. Aber normale Maßstäbe spielen längst keine Rolle mehr, wenn es um Ebola geht. Mindestens 6553 Menschen in Guinea, Sierra Leone und Liberia haben sich mit dem tödlichen Virus angesteckt, mehr als 3000 sind gestorben. Was Helfer vor Ort berichten ist grausam: In Monrovia treiben Leichen in den Flüssen. Todkranke Menschen werden an den Toren der überfüllten Kliniken abgewiesen und zurück nach Hause geschickt, wo sie Familie, Verwandte und Nachbarn anstecken. Die Pressemitteilungen von Ärzten ohne Grenzen sind Dokumente der Wut und der Verzweiflung: „Anstatt neue Ebola-Behandlungszentren in Liberia aufzubauen, sind wir gezwungen, Krematorien zu errichten“, heißt es in einer. Und noch immer verdoppelt sich alle drei Wochen die Zahl der Kranken und Toten. Epidemiologen rechnen vor, wann der Erreger 10,000, 100,000, 1 Million Menschen infiziert hat, wenn es so weitergeht.

So grausam die Krankheit ist, so wenig wichtig schien lange Zeit ein Impfstoff, sagt Becker. Vor dem jetzigen Ausbruch hat das Virus in fast vier Jahrzehnten insgesamt weniger als 2500 Menschen infiziert, in einigen der ärmsten Länder der Welt. Forscher hätten sich zu Recht darauf konzentriert, Impfstoffe gegen häufige Krankheiten wie Meningitis und Malaria, Typhus oder Tuberkulose zu entwickeln, sagt Becker. „Das war bei uns allen im Kopf, dass Ebolaausbrüche zwar schlimm sein können für ein Dorf oder mehrere Dörfer, aber das sich das gut in den Griff kriegen lässt.“

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 12:12 PM
To: 'Kai Kupferschmidt'
Subject: RE: Text für SZ

Sehr schoener Artikel – keine Einwaende von meiner Seite.

Viel Glueck,
Heinz

From: Kai Kupferschmidt [mailto:mail@kaikupferschmidt.de]
Sent: Sunday, September 28, 2014 4:25 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Text für SZ

Hallo Heinz,

anbei nur kurz zur Kenntnis der Text wie er in der SZ erschienen soll. Deine Zitate sind gefettet. Sind nur zwei Sätze, wie gestern besprochen und sollte alles in Ordnung sein. Kniffliger und wichtiger wird sicher der ausführlichere Text für Science.

Ich schicke dir die Zitate dafür heute im Laufe des Abends zu.

Gruß
Kai

Stephan Becker hält das Warten kaum noch aus. Seit Wochen bereitet der Virologe von der Universität Marburg eine Studie vor, um in Deutschland einen Impfstoff gegen Ebola zu testen. Aber es geht nur langsam voran. Mehr als 800 Dosen des experimentellen Impfstoffs, vor sechs Wochen von der kanadischen Regierung der Weltgesundheitsorganisation (WHO) geschenkt, liegen immer noch in Kanada. Die benötigten Unterlagen sind immer noch nicht vollständig. „Ich bin richtig durch den Wind“, sagt Becker. „Das macht mich kirre, dass wir hier sitzen und etwas tun könnten, aber es geht nicht voran.“

Legt man normale Maßstäbe an, passiert eigentlich gerade alles unfassbar schnell. Aber normale Maßstäbe spielen längst keine Rolle mehr, wenn es um Ebola geht. Mindestens 6553 Menschen in Guinea, Sierra Leone und Liberia haben sich mit dem tödlichen Virus angesteckt, mehr als 3000 sind gestorben. Was Helfer vor Ort berichten ist grausam: In Monrovia treiben Leichen in den Flüssen. Todkranke Menschen werden an den Toren der überfüllten Kliniken abgewiesen und zurück nach Hause geschickt, wo sie Familie, Verwandte und Nachbarn anstecken. Die Pressemitteilungen von Ärzte ohne Grenzen sind Dokumente der Wut und der Verzweiflung: „Anstatt neue Ebola-Behandlungszentren in Liberia aufzubauen, sind wir gezwungen, Krematorien zu errichten“, heißt es in einer. Und noch immer verdoppelt sich alle drei Wochen die Zahl der Kranken und Toten. Epidemiologen rechnen vor, wann der Erreger 10,000, 100,000, 1 Million Menschen infiziert hat, wenn es so weitergeht.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 10:54 AM
To: 'FREEMAN DELINE, Nancy'; WAI, Lokky; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; DAVIS, Raphael
Cc: GRAAFF, Peter Jan; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen; Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Not sure what RLJ stands for.

In regards to the hotel booking we will continue to use the same three hotel rooms at the Kendaja. We will just keep these rooms until the end of the mission unless we move away from that hotel. The hotel is perfect for us as it is only 10 minutes away from ELWA, the location of the lab. Vincent Munster (copied here) will take care for the hotel booking.

Best wishes,
Heinz

From: FREEMAN DELINE, Nancy [mailto:delinen@who.int]
Sent: Sunday, September 28, 2014 10:50 AM
To: WAI, Lokky; goarn; WERTSCHNIG, Brian Adam; mwanamwenge@who.int; DAVIS, Raphael
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; GRAAFF, Peter Jan; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Khristeen,
Kindly let us know under whose name is the RLJ booked because Wannie and I paid a visit on Saturday to RLJ and mentioned the names of the team members and they told us there were no names as such booked there. Please let us know the date and time this booking was done so we can follow up.
Regards,
Nancy

From: WAI, Lokky
Sent: Sunday, September 28, 2014 11:14 AM
To: goarn; WERTSCHNIG, Brian Adam; FREEMAN DELINE, Nancy; mwanamwenge@who.int; DAVIS, Raphael
Cc: Feldmann, Heinrich (NIH/NIAID) [E] (feldmannh@niaid.nih.gov); GRAAFF, Peter Jan; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Yes we received your message, loud and clear. Over

Lokky

From: goarn
Sent: 28 September 2014 12:11
To: WERTSCHNIG, Brian Adam; WAI, Lokky; FREEMAN DELINE, Nancy; mwanamwenge@who.int; DAVIS, Raphael
Cc: Feldmann, Heinrich (NIH/NIAID) [E] (feldmannh@niaid.nih.gov); GRAAFF, Peter Jan; GASASIRA, Alex Ntale; goarn; UMALI DALANGIN, Khristeen
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Colleagues,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 10:47 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Redacted b

Redacted by agreement

-----Original Message-----

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 9:48 AM
To: Bekisz, Joseph (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fw: Redacted

Redacted by agreement

Sent from my BlackBerry Wireless Handheld

----- Original Message -----

From: Eleanor Fish [mailto:en.fish@utoronto.ca]
Sent: Sunday, September 28, 2014 08:20 AM Eastern Standard Time
To: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Redacted

Good morning Kathy.

Redacted by agreement

Redacted by agreement

Redacted by agreement

Best wishes,
Eleanor

Canada Research Chair in Immunobiology and Women's Health.
Director, AARC, University Health Network, Toronto.
Professor of Immunology, University of Toronto

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 28, 2014 10:46 AM
To: 'UMALI DALANGIN, Khristeen'; WAI, Lokky
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Thanks to everyone – it is so re-assuring and important to have people taking care of the incoming troops. I highly appreciate all your help and efforts.

Best wishes,
Heinz

From: UMALI DALANGIN, Khristeen [mailto:umalik@who.int]
Sent: Sunday, September 28, 2014 4:15 AM
To: WAI, Lokky
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Great! Thanks Lokky!!

Best,

Khristeen

From: WAI, Lokky
Sent: 28 September 2014 12:14
To: goarn; WERTSCHNIG, Brian Adam; FREEMAN DELINE, Nancy; mwanamwenge@who.int; DAVIS, Raphael
Cc: Feldmann, Heinrich (NIH/NIAID) [E] (feldmannh@niaid.nih.gov); GRAAFF, Peter Jan; GASASIRA, Alex Ntale; UMALI DALANGIN, Khristeen
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Yes we received your message, loud and clear. Over

Lokky

From: goarn
Sent: 28 September 2014 12:11
To: WERTSCHNIG, Brian Adam; WAI, Lokky; FREEMAN DELINE, Nancy; mwanamwenge@who.int; DAVIS, Raphael
Cc: Feldmann, Heinrich (NIH/NIAID) [E] (feldmannh@niaid.nih.gov); GRAAFF, Peter Jan; GASASIRA, Alex Ntale; goarn; UMALI DALANGIN, Khristeen
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear Colleagues,

We would like to make sure that you received the message from Dr Heinz Feldmann regarding airport transfer. Could you kindly confirm if this has been arranged?

Many thanks,

Khristeen for GOARN

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 3:25 PM
To: Reynolds, Steven (NIH/NIAID) [E]
Cc: Caldwell, Harlan (NIH/NIAID) [E]
Subject: RE: Uganda

Dear Steve,

I planned to contact you since quite some time but never got to do it. We were planning to start our Uganda ICER project this summer (August), but our current Ebola involvement in Monrovia, Liberia has changed everything. For a while, we will have at least 2-3 people in Monrovia to support MSF and others with laboratory diagnostics on Ebola. I really have to think about when and how to move the ICER along but I am afraid this it will rather be next year (2015) than this one.

I also wanted to introduce you to Dr. Harlan Caldwell, Chief of the Laboratory of Intracellular Parasites here at the Rocky Mountain Laboratories. Among other interest research topics, Dr. Caldwell works on an exciting Chlamydia vaccine. He is looking for clinical study sites for his vaccine and I told him about Rakai in Uganda. Steve - I hope it is OK if Harlan will contact you with questions and need for information.

I hope things are going well for you. Looking forward to seeing you soon.

Best wishes,
Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 2:46 PM
To: Redacted by agreement
Cc: Redacted by agreeme
Subject: RE: Personal & Confidential | Personnel & Confidential Redacted by agreement

Dear Redacted by

Redacted by agreement

Best wishes,
Heinz Feldmann

From: Redacted by agreement
Sent: Tuesday, September 23, 2014 9:25 AM
To: Redacted by agreement
Cc: Redacted by
Subject: Personal & Confidential | Personnel & Confidential : Redacted by agreement

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 2:35 PM
To: 'Warren Marcus'
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert
Attachments: Blank SLA1.doc

Would this work in rodent models – we have mouse, hamster and guinea pig for Ebola. It would be great to test it first in a rodent model prior to going into a nonhuman primate model. We would prefer the hamster.

I have attached a Simple Letter Agreement (SLA) from the NIH. You may not agree with this but it would have the advantage that I can sign on our end as the authoritative person. If we take a different MTA I will have to give it to Bethesda for their approval. This usually takes about two weeks. In case you go for the attached SLA please work with Kay (copied here) – she will prepare the SLA from our end.

Best wishes,
Heinz

From: Warren Marcus [<mailto:warrenmarcus@altorbioscience.com>]
Sent: Tuesday, September 23, 2014 9:27 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Seeking research help from Ebola expert

Hello Dr. Feldmann,

Does this mean that you/your group would be willing to do the experiments?
If so, perhaps the best way to expedite this would be for us to send an MTA asap so that we can ship you the ALT-836?

Sent from my iPad

On Sep 23, 2014, at 6:03 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

That sounds doable.

From: Warren Marcus [<mailto:warrenmarcus@altorbioscience.com>]
Sent: Tuesday, September 23, 2014 8:59 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Seeking research help from Ebola expert

Hello Dr. Feldmann,

I just spoke to our CEO, Hing Wong, since the baboon experiments were performed before I came to Altor. He said that continuous infusion was used by Dr. Welty because she was following a protocol from previous experiments. Those experiments used compounds that were not stable and had short

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 2:30 PM
To: 'Pardis Sabeti'
Cc: Feldmann, Ricki (NIH/NIAID) [C]; Robert Garry
Subject: RE: connection at RML

Sounds good.

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Tuesday, September 23, 2014 10:23 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Feldmann, Ricki (NIH/NIAID) [C]; Robert Garry
Subject: Re: connection at RML

Hi Heinz,

Thank you so much to you and Ricki for all of this. We have shared this with our safety committees. As you saw, the NIH is trying to certify these results, and they may be in touch in the process. I am hopeful that this will satisfy the issue so we can move forward. Once we get through a few of these barriers we would love to ship out these samples, and also our live virus samples. We are thinking of going to the IRF, with the promise they will then send out from there. Let us know if that all sounds all right. We want to get you in a position to do whatever you need quickly,

Pardis

On Sun, Sep 21, 2014 at 6:55 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

I see that you already have the poster from the Galveston meeting which shows all the details and results on the inactivation testing. This should be sufficient for getting approval to ship your samples.

Best wishes,

Heinz

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Wednesday, September 17, 2014 11:31 PM
To: Feldmann, Ricki (NIH/NIAID) [C]; Feldmann, Heinrich (NIH/NIAID) [E]; Robert Garry

Subject: Re: connection at RML

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:34 PM
To: Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Thanks.

From: Rosenke, Kyle (NIH/NIAID) [F]
Sent: Saturday, September 27, 2014 12:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

I think we are ok. I'll send an email tomorrow when we board.

Sent from my iPhone

On Sep 27, 2014, at 12:23 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

OK – let me know if you need any help. Send me mail tomorrow morning when you are boarding if you don't mind.

From: Rosenke, Kyle (NIH/NIAID) [F]
Sent: Saturday, September 27, 2014 12:23 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

I have it now.

Sent from my iPhone

On Sep 27, 2014, at 12:21 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

OK. Did you receive the package?

From: Rosenke, Kyle (NIH/NIAID) [F]
Sent: Saturday, September 27, 2014 12:08 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Had to verify hep b vaccination. Got the all clear early this morning. Was told Sue sent in the vaccine records again yesterday but it sounds like they got lost in the shuffle again.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:24 PM
To: Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

OK – let me know if you need any help. Send me mail tomorrow morning when you are boarding if you don't mind.

From: Rosenke, Kyle (NIH/NIAID) [F]
Sent: Saturday, September 27, 2014 12:23 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

I have it now.

Sent from my iPhone

On Sep 27, 2014, at 12:21 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

OK. Did you receive the package?

From: Rosenke, Kyle (NIH/NIAID) [F]
Sent: Saturday, September 27, 2014 12:08 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Had to verify hep b vaccination. Got the all clear early this morning. Was told Sue sent in the vaccine records again yesterday but it sounds like they got lost in the shuffle again.

Sent from my iPhone

On Sep 27, 2014, at 10:14 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Not sure what this message means.

From: UMALI DALANGIN, Khristeen [<mailto:umalik@who.int>]
Sent: Saturday, September 27, 2014 12:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Dear Heinz, Kay,

Personal medical is approved. Health clinic sent message to Kyle to obtain more info. Pls follow-up.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:22 PM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

Well

-----Original Message-----

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:22 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

Redacted by agreement

Sent from my iPhone

> On Sep 27, 2014, at 17:59, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>

> Obviously not - he is also the one pushing the issue that

Redacted by agreement

>

> -----Original Message-----

> From: Munster, Vincent (NIH/NIAID) [E]
> Sent: Saturday, September 27, 2014 11:44 AM
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Cc: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
> Subject: Re: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

>

> Guess they know it all better,

>

> Thought you were buddy buddy with cliff :-),

>

> Cheers,

>

> Vincent

>

> Sent from my iPhone

>

>> On Sep 27, 2014, at 16:54, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>>

>> Interesting and very collegial approach, isn't it?

>>

>> -----Original Message-----

>> From: Lane, Cliff (NIH/NIAID) [E]
>> Sent: Saturday, September 27, 2014 10:47 AM
>> To: Feldmann, Heinrich (NIH/NIAID) [E]
>> Cc: Zoon, Kathryn (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:22 PM
To: Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

OK. Did you receive the package?

From: Rosenke, Kyle (NIH/NIAID) [F]
Sent: Saturday, September 27, 2014 12:08 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Had to verify hep b vaccination. Got the all clear early this morning. Was told Sue sent in the vaccine records again yesterday but it sounds like they got lost in the shuffle again.

Sent from my iPhone

On Sep 27, 2014, at 10:14 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Not sure what this message means.

From: UMALI DALANGIN, Khristeen [<mailto:umalik@who.int>]
Sent: Saturday, September 27, 2014 12:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Dear Heinz, Kay,

Kristin's medical is approved. Health clinic sent message to Kyle to obtain more info. Pls follow-up.

Thanks,

Khristeen

Sent from my iPhone

On 26 Sep 2014, at 19:30, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Khristeen,
They are working on it.

What do you need from me? I have been deployed earlier (August – September) and will return on October 5. Anything needed from my end or all good? I never had a chance to sign the contract and cannot find the email any longer (still looking). Would it be possible to re-send the contract for me to sign?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:01 PM
To: McNally, Kristin (NIH/NIAID) [E]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Great.

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:00 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Khristeen just emailed and said all is approved.

Sent from my iPhone

On Sep 27, 2014, at 11:58 AM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Thanks

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 11:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Heinz - I resent the certificates to Khristeen this morning. Hopefully that will do.

Kristin

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:14 PM
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: FW: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

See message below – they are looking for your security training. Did you sent the certificates for both Un security courses?

Kyle – please make sure that Kristin gets this message.

Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:00 PM
To: Munster, Vincent (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: RE: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

Obviously not - he is also the one pushing the issue that Redacted by agreement

-----Original Message-----

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 11:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: Re: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

Guess they know it all better,

Thought you were buddy buddy with cliff :-),

Cheers,

Vincent

Sent from my iPhone

> On Sep 27, 2014, at 16:54, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>

> Interesting and very collegial approach, isn't it?

>

> -----Original Message-----

> **From:** Lane, Cliff (NIH/NIAID) [E]

> **Sent:** Saturday, September 27, 2014 10:47 AM

> **To:** Feldmann, Heinrich (NIH/NIAID) [E]

> **Cc:** Zoon, Kathryn (NIH/NIAID) [E]

> **Subject:** Re: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

>

> At present we are not planning to release any information outside of the team directly involved. I appreciate the interest and things may change over the next few days. As appropriate we will eventually be in a position to share information and even samples in accordance with the protocol and in a setting of strict patient confidentiality.

> Cliff

>

>> On Sep 27, 2014, at 12:32 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>>

>> Any more detailed information on this one? Is this an exposure or a confirmed infection? What clinical study will the patient be enrolled in?

>>

>> -----Original Message-----

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 11:59 AM
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Thanks

From: McNally, Kristin (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 11:38 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Heinz - I resent the certificates to Khristeen this morning. Hopefully that will do.

Kristin

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 12:14 PM
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: FW: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

See message below – they are looking for your security training. Did you sent the certificates for both Un security courses?

Kyle – please make sure that Kristin gets this message.

Heinz

From: UMALI DALANGIN, Khristeen [<mailto:umalik@who.int>]
Sent: Saturday, September 27, 2014 2:21 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Dear Heinz,

All ok for the medicals. I need security trainings for Kristin.

Thanks,

Khristeen

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 11:09 AM
To: 'Kai Kupferschmidt'
Subject: RE: call

I can talk to you now if you want but I am afraid I won't have answers to most of your questions.

Best wishes, Heinz

From: Kai Kupferschmidt [<mailto:mail@kaikupferschmidt.de>]
Sent: Saturday, September 27, 2014 11:07 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: call

Heinz,

I'm writing a story about the VSV vaccine and I have heard some pretty bad things about how NewLink Genetics has been handling this (a lot of it off the record). If you have a few minutes to talk to me or do write me a few answers, that would be very helpful. I would really like to get your view on some of this: I am trying to understand, what exactly NewLink has been doing. Is it right, that they have not really developed the vaccine in the last few years?

Why are the doses still in Canada when Stephan Becker tells me he could already be testing them in a phase I trial?

Also: What is going on in terms of testing this vaccine against the circulating strain in West Africa in animals? Should NewLink be doing this? Will you?

Should the license to NewLink be put on hold so that investigation of the vaccine can start in these extraordinary circumstances?

It seems to me that vaccines are looking more and more important in this and anything you can tell me to illuminate what is actually going on would be helpful!

I'm finishing my story Sunday night, but if you have time today, that would be great.

Best regards from Berlin
Kai

On 19.09.2014, at 02:40, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

It's fine. Just don't like to be in the spot light.

From: Kai Kupferschmidt [<mailto:mail@kaikupferschmidt.de>]
Sent: Thursday, September 18, 2014 3:05 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: call

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 11:01 AM
To: 'Robert and Sylvia Kahn'
Cc: Juergen Richt; Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Ebola and MERS (via Bob K)--Letter to The Economist?

Bob,

There is no evidence for aerosol transmission in human outbreaks. Having said that you can infect animals by aerosol exposure. The general believe is that if you keep a 'two-meter' distance and protect your mucosal membranes by a face mask (minimum surgical mask – better N95) you should be fine. If someone sneezes at you droplets could be generated and if the person has a high viral load exposure could occur if your mucosal membranes and eyes are not properly protected. However, these are not regular transmission routes.

Hope things are going well for you and your wife.

Best wishes,
Heinz

From: Robert and Sylvia Kahn [mailto:Personal Info]
Sent: Wednesday, September 24, 2014 10:22 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Juergen Richt; Munster, Vincent (NIH/NIAID) [E]
Subject: Ebola and MERS (via Bob K)--Letter to The Economist?

Dear Heinz,

The current issue of The Economist has a lead editorial that is attached which suggests that Ebola cannot be transmitted by a cough or a sneeze [near the end of the article, statement in bold].

Surely that is wrong, is it not? Would it be appropriate for you to either write an appropriate letter to The Economist or alert someone else to do so?

A sensible summary statement on MERS-CoV in the current issue of The Lancet Infectious Diseases out today is also attached for your information.

Best wishes

Bob

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:54 AM
To: Munster, Vincent (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]
Subject: FW: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

Interesting and very collegial approach, isn't it?

-----Original Message-----

From: Lane, Cliff (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:47 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Zoon, Kathryn (NIH/NIAID) [E]
Subject: Re: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

At present we are not planning to release any information outside of the team directly involved. I appreciate the interest and things may change over the next few days. As appropriate we will eventually be in a position to share information and even samples in accordance with the protocol and in a setting of strict patient confidentiality.
Cliff

> On Sep 27, 2014, at 12:32 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>

> Any more detailed information on this one? Is this an exposure or a confirmed infection? What clinical study will the patient be enrolled in?

>

> -----Original Message-----

> **From:** Exec Sec1 (NIH/OD)

> **Sent:** Saturday, September 27, 2014 9:56 AM

> **To:** NIH-STAFF@LIST.NIH.GOV

> **Subject:** Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

>

> Dear Staff,

>

> We expect that tomorrow, Sunday, September 28, the NIH will admit a patient with an exposure to the Ebola virus. The patient is an American physician who was volunteering services in an Ebola treatment unit in Sierra Leone. The patient is being admitted to the NIH Clinical Center for observation and to enroll in a clinical study.

>

> Out of an abundance of caution, the patient will be admitted to the NIH Clinical Center's special clinical studies unit that is specifically designed to provide high-level isolation capabilities and is staffed by infectious diseases and critical care specialists. The unit staff is trained in strict infection control practices optimized to prevent spread of potentially transmissible agents such as Ebola. In addition, access to the unit will be strictly controlled.

>

> It is also important to remember that Ebola patients can be safely cared for at any hospital that follows CDC's infection control recommendations and can isolate a patient in a private room. We are taking every precaution to ensure the safety of patients, NIH staff, and the public. This situation is of minimal risk to NIH staff and the public.

>

> Thank you for your cooperation and understanding.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:32 AM
To: Zoon, Kathryn (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: FW: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

Any more detailed information on this one? Is this an exposure or a confirmed infection? What clinical study will the patient be enrolled in?

-----Original Message-----

From: Exec Sec1 (NIH/OD)
Sent: Saturday, September 27, 2014 9:56 AM
To: NIH-STAFF@LIST.NIH.GOV
Subject: Message From the Director, NIH - NIH Clinical Center to Receive Patient Exposed to Ebola for Observation

Dear Staff,

We expect that tomorrow, Sunday, September 28, the NIH will admit a patient with an exposure to the Ebola virus. The patient is an American physician who was volunteering services in an Ebola treatment unit in Sierra Leone. The patient is being admitted to the NIH Clinical Center for observation and to enroll in a clinical study.

Out of an abundance of caution, the patient will be admitted to the NIH Clinical Center's special clinical studies unit that is specifically designed to provide high-level isolation capabilities and is staffed by infectious diseases and critical care specialists. The unit staff is trained in strict infection control practices optimized to prevent spread of potentially transmissible agents such as Ebola. In addition, access to the unit will be strictly controlled.

It is also important to remember that Ebola patients can be safely cared for at any hospital that follows CDC's infection control recommendations and can isolate a patient in a private room. We are taking every precaution to ensure the safety of patients, NIH staff, and the public. This situation is of minimal risk to NIH staff and the public.

Thank you for your cooperation and understanding.

Sincerely yours,

Francis S. Collins, M.D., Ph.D.
Director, NIH

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:19 AM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: FW: Update on return flight for GOARN NIH/Lab experts (#2nd rotation), Ebola response, Liberia / change on flight details

FYI – how is the day? Did you want to write an article for the JID Supplementum? If yes, we would need a tentative title as soon as possible.

Thanks,
Heinz

From: WERTSCHNIG, Brian Adam [mailto:wertschnigb@who.int]
Sent: Saturday, September 27, 2014 5:29 AM
To: goarn; FREEMAN DELINE, Nancy; MWANAMWENGE, Abrahams; DAVIS, Raphael
Cc: WAI, Lokky; KOLLIE, Robert K.; FREEMAN DELINE, Nancy; Pierre Formenty; SACRISTAN LLOBET, Jordi; DRURY, Patrick Anthony; SHOC; SAIKAT, Soheli; NAIDOO, Dhamari; Feldmann, Heinrich (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Bushmaker, Trenton (NIH/NIAID) [E]; Fischer, Robert (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]; GASASIRA, Alex Ntale; GRAAFF, Peter Jan
Subject: RE: Update on return flight for GOARN NIH/Lab experts (#2nd rotation), Ebola response, Liberia / change on flight details

Dear Goarn colleagues,

For visa, lodging, and airport transfer arrangements please ensure messages are sent to myself at wertschnigb@who.int, Lokky Wai at wail@who.int and Nancy Freeman Deline (for visa and hotel) at delinen@who.int, and Abrahams Mwanamwenge (for Airport transfer) at mwanamwenge@who.int and Raphael Davis (also For Airport transfer) at davisr@who.int

Copying the WR Dr Peter Graaff at graaffp@who.int and Alex Gasasira at gasasiraa@who.int.

Note, for incoming deployments please always send a copy of the national passport and/or UNLP along with the flight itinerary to assist us in facilitating smooth on-entry arrangements.

Many thanks and kind regards,

Brian A. Wertschnig,
HR Specialist

From: goarn
Sent: 27 September 2014 11:40
To: GRAAFF, Peter Jan; GASASIRA, Alex Ntale
Cc: WAI, Lokky; WERTSCHNIG, Brian Adam; DAVIS, Raphael; KOLLIE, Robert K.; FREEMAN DELINE, Nancy; DAVIS, Raphael; goarn; FORMENTY, Pierre B.H.; SACRISTAN LLOBET, Jordi; DRURY, Patrick Anthony; goarn; SHOC; SAIKAT, Soheli; NAIDOO, Dhamari; Feldmann, Heinrich (NIH/NIAID) [E] (feldmannh@niaid.nih.gov); munstervj@niaid.nih.gov; Bushmaker, Trenton (NIH/NIAID) [E]; fischerro@niaid.nih.gov; Menk, Kay (NIH/NIAID) [E] (menkk@niaid.nih.gov)
Subject: RE: Update on return flight for GOARN NIH/Lab experts (#2nd rotation), Ebola response, Liberia / change on

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:18 AM
To: 'travers menhinick'
Subject: RE: Greetings

Travers,

Sounds good. Let me know when time comes to visit.

Heinz

-----Original Message-----

From: travers menhinick [mailto:travers.menhinick@pirbright.ac.uk]
Sent: Saturday, September 27, 2014 4:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Greetings

Dear Heinz,

Thank you for your reply, please do not apologise, there is no fault on your end. I am at the mercy of Pirbright politics, an environment I do not always grasp.. I too was under the belief that an invitation from your elevated position would have sufficed - it was personally embarrassing to ask for more.

However I remain hopeful that I will be able to visit at some point in the future.

Thank you once again for your time and patience and I apologise for any frustrations I may have caused.

I wish you luck with the current situation in Monrovia.

Kind regards,

Travers

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: 26 September 2014 19:22
To: travers menhinick
Cc: Shupert, W. Lesley (NIH/NIAID) [E]
Subject: RE: Greetings

Travers,

I am very sorry to hear this. I apologize for not acting properly on your request due to my absence as I was deployed to Monrovia. Soon after my return I tried to get the requested letter from the director and run into some roadblocks.

If you consider visiting at a later time point, you may want to convince your people that a letter from me as the 'Chief Scientist of the RML BSL4 laboratories' would be sufficient. We would be more than happy to host you and I had already discussions with facility staff and other groups to meet with you during your visit. Insisting on an invitation from Bethesda will unnecessary prolong any request to visit.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:16 AM
To: 'Erika Hayden'
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: FW: (reminder) RE: Nature interview

I will call you.

From: erikacheckhaydennature@gmail.com [mailto:erikacheckhaydennature@gmail.com] On Behalf Of Erika Hayden
Sent: Friday, September 26, 2014 9:05 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: FW: (reminder) RE: Nature interview

perfect - let me know a number where I can ring you or give me a call on Personal Info at 4:30pm Eastern on Monday, 29 September.
Erika

Erika Check Hayden
Reporter, Nature
415-403-9025

On Fri, Sep 26, 2014 at 5:59 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

How about Monday at 4:30 PM Eastern?

From: erikacheckhaydennature@gmail.com [mailto:erikacheckhaydennature@gmail.com] On Behalf Of Erika Hayden
Sent: Friday, September 26, 2014 5:34 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: FW: (reminder) RE: Nature interview

Possibilities:

Saturday or Sunday this weekend, Sept. 27-28, 10 or 10:30am Eastern

Monday Sept. 29 anytime between 2pm-7:30PM Eastern

Tuesday Sept. 30, 10 or 10:30 AM Eastern OR anytime between 1pm-7:30pm Eastern

Any of these work for you?

ECH

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:15 AM
To: Rosenke, Kyle (NIH/NIAID) [F]
Subject: FW: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Not sure what this message means.

From: UMALI DALANGIN, Khristeen [<mailto:umalik@who.int>]
Sent: Saturday, September 27, 2014 12:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Dear Heinz, Kay,

Kristin's medical is approved. Health clinic sent message to Kyle to obtain more info. Pls follow-up.

Thanks,

Khristeen

Sent from my iPhone

On 26 Sep 2014, at 19:30, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Khristeen,
They are working on it.

What do you need from me? I have been deployed earlier (August – September) and will return on October 5. Anything needed from my end or all good? I never had a chance to sign the contract and cannot find the email any longer (still looking). Would it be possible to re-send the contract for me to sign?

Thanks and best wishes,
Heinz

From: UMALI DALANGIN, Khristeen [<mailto:umalik@who.int>]
Sent: Friday, September 26, 2014 4:54 AM
To: Menk, Kay (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia
Importance: High

Dear Kay, Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:14 AM
To: McNally, Kristin (NIH/NIAID) [E]
Cc: Rosenke, Kyle (NIH/NIAID) [F]
Subject: FW: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

See message below – they are looking for your security training. Did you sent the certificates for both Un security courses?

Kyle – please make sure that Kristin gets this message.

Heinz

From: UMALI DALANGIN, Khristeen [mailto:umalik@who.int]
Sent: Saturday, September 27, 2014 2:21 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Dear Heinz,

All ok for the medicals. I need security trainings for Kristin.

Thanks,

Khristeen

From: UMALI DALANGIN, Khristeen
Sent: 27 September 2014 08:30
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Dear Heinz, Kay,

Kristin's medical is approved. Health clinic sent message to Kyle to obtain more info. Pls follow-up.

Thanks,

Khristeen

Sent from my iPhone

On 26 Sep 2014, at 19:30, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:13 AM
To: 'goarn'; GRAAFF, Peter Jan; GASASIRA, Alex Ntale
Cc: WAI, Lokky; WERTSCHNIG, Brian Adam; DAVIS, Raphael; KOLLIE, Robert K.; FREEMAN DELINE, Nancy; UMALI DALANGIN, Khristeen; SEOCC; SHOC; Pierre Formenty; NAIDOO, Dhamari; DRURY, Patrick Anthony; SAIKAT, Sohel; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]
Subject: RE: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia

Dear ALL,

Hotel room reservation at the Kendaja has already been done for all three travelers. We would appreciate pick up at the airport upon arrival and transport to the Kendaja hotel.

Kyle Rosenke and Kristin McNally travel with eight pieces of luggage (regular size suitcase; no overweight). Heinz Feldmann will be travelling with four pieces of luggage – one oversize package. Please make sure to have the right car for the transport to accommodate travelers and luggage.

Thanks and best wishes,
Heinz

From: goarn [mailto:goarn@who.int]
Sent: Saturday, September 27, 2014 3:05 AM
To: GRAAFF, Peter Jan; GASASIRA, Alex Ntale
Cc: goarn; WAI, Lokky; WERTSCHNIG, Brian Adam; DAVIS, Raphael; KOLLIE, Robert K.; FREEMAN DELINE, Nancy; UMALI DALANGIN, Khristeen; SEOCC; goarn; SHOC; Pierre Formenty; NAIDOO, Dhamari; DRURY, Patrick Anthony; SAIKAT, Sohel; Feldmann, Heinrich (NIH/NIAID) [E]; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; Menk, Kay (NIH/NIAID) [E]
Subject: Arrival of GOARN/NIH lab experts (team#3), Ebola outbreak, Liberia
Importance: High

Dear WR, Dr Gasasira,

We wish to inform you of the flight details for the next rotation of GOARN lab experts (team#3) from the National Institute for Health, USA:


Team#3 consists of:

1. **Dr Kristin McNally** will arrive in Monrovia **on Monday (29 September 2014) at 19h20** on flight SN1247 from Brussels. She will depart Monrovia on 20 October 2014 at 20h40 via flight SN1247.
2. **Dr Kyle Rosenke** is traveling on the same flight as Dr Kristin McNally **arriving on Monday (29 September 2014) at 19h20** on flight SN1247 from Brussels, and will depart Monrovia on 20 October.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 27, 2014 10:05 AM
To: 'Vickie Groth'
Cc: YOSHIHIROKAWAOKA; twgeisbe@utmb.edu
Subject: RE: Unpublished

Unpublished



Vickie

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 7:41 PM
To: YOSHIHIROKAWAOKA
Cc: HALFMANP@SVM.VETMED.WISC.EDU; neumannng@vetmed.wisc.edu
Subject: RE: Re: short commentary on Ebola
Attachments: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 7:23 PM
To: 'Christina Sartori'
Subject: RE: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses
Attachments: Prof. Feldmann Zitat Konferenz.docx

Christina,

Ich habe das Interview umgeschrieben und hoffe, dass Sie damit einverstanden sind.

Viele Gruesse,
Heinz

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Friday, September 26, 2014 6:08 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Heinz,

Für eine Pressemitteilung zur Konferenz wurde vorab ein Zitat gewünscht - auf Englisch. Ich habe Ihre entsprechende Antwort ins Englische übersetzt, möglichst so, dass es sich nach gesprochenem Wort anhört. Gucken Sie mal, ob das okay ist oder was Sie ändern möchten? Sorry, ich hätte das Interview gleich auf Englisch führen sollen.
Best wishes
Christina

"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> hat am 20. September 2014 um 20:25 geschrieben:

Christina,

I will try to call at 10:00 AM MST which would be 18:00 MEZ.

Best wishes,
Heinz

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Friday, September 19, 2014 2:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Thank you for answering so quickly and making this so easy to plan: Tuesday would be fine for me, I'm at my desk anyway for the whole afternoon (15.00 - 19.00). Maybe it is more convenient for you, if you

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 6:59 PM
To: 'Erika Hayden'
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: FW: (reminder) RE: Nature interview

How about Monday at 4:30 PM Eastern?

From: erikacheckhaydennature@gmail.com [mailto:erikacheckhaydennature@gmail.com] **On Behalf Of** Erika Hayden
Sent: Friday, September 26, 2014 5:34 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: FW: (reminder) RE: Nature interview

Possibilities:

Saturday or Sunday this weekend, Sept. 27-28, 10 or 10:30am Eastern

Monday Sept. 29 anytime between 2pm-7:30PM Eastern

Tuesday Sept. 30, 10 or 10:30 AM Eastern OR anytime between 1pm-7:30pm Eastern

Any of these work for you?

ECH

Erika Check Hayden
Reporter, Nature
415-403-9025

On Fri, Sep 26, 2014 at 3:53 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Erika,

Let me know when you prefer to do this one.

Best wishes,

Heinz

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 9:34 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 6:58 PM
To: Okumura, Atsushi (NIH/NIAID) [V]
Subject: RE: Seeking research help from Ebola expert

Sounds good.

-----Original Message-----

From: Okumura, Atsushi (NIH/NIAID) [V]
Sent: Friday, September 26, 2014 6:26 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Seeking research help from Ebola expert

Hi Heinz,

I apologize to bother you when you are busy. I talked to Angie a summary of this project and Michael has interest in this project.

He might contact you to discuss when you back.

Thanks,
Atsu

From: Okumura, Atsushi (NIH/NIAID) [V]
Sent: Thursday, September 25, 2014 8:10 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Seeking research help from Ebola expert

Thanks, Michael will talk with Heinz.

Otherwise, if you need the buddy backup, please let me know. I would be happy to do that.

Thanks,
Atsu

-----Original Message-----

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Tuesday, September 23, 2014 6:55 PM
To: Okumura, Atsushi (NIH/NIAID) [V]
Subject: FW: Seeking research help from Ebola expert

Attached is the entire communication chain.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 4:02 PM
To: 'Warren Marcus'; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Seeking research help from Ebola expert

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 4:53 PM
To: 'erikacheckhaydennature@gmail.com'
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: (reminder) RE: Nature interview

Erika,
Let me know when you prefer to do this one.

Best wishes,
Heinz

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 9:34 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: (reminder) RE: Nature interview

Just a reminder about this before you leave next week ... feel free to contact her to arrange a convenient time to talk. This week or next works for her.

Erika Hayden, Nature
[415-403-9025](tel:415-403-9025)
erikacheckhaydennature@gmail.com

Ken: there are really only three questions:

1. what have we learned about Ebola in the past decade thanks to i.e. biodefense funding
2. what are the most pressing questions - say 3 to 5 - ahead about the virus
3. and what (research?) is needed to answer these.

From: erikacheckhaydennature@gmail.com [<mailto:erikacheckhaydennature@gmail.com>] On Behalf Of Erika Hayden
Sent: Wednesday, September 17, 2014 3:28 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: schedule a time to speak about big questions in Ebola research?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 4:49 PM
To: Munster, Vincent (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: Assistance for Lab Team 3 for Ebola response

I have a flight now.

Heinz

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 1:06 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Fwd: Assistance for Lab Team 3 for Ebola response

Hi Heinz,

See email below, in case you think this is useful ,

Cheers,

Vincent

Sent from my iPhone

Begin forwarded message:

From: Alec Hail Personal Info
Date: September 26, 2014 at 18:42:17 GMT
To: "Munster, Vincent (NIH/NIAID) [E]" <munstervj@niaid.nih.gov>
Subject: Re: Assistance for Lab Team 3 for Ebola response

Vincent, I don't think I do, but did meet the medical planner for the Army the other day. Here is his Email. Contact him, tell him who you are officially, what your need is and copy the operations NCO at the Embassy's Defense attaches office, the second email below. They will tell you yes or no.

CPT Rich Demarais med planner Richard.s.demarais.mil@mail.mil

TSGT Kenisah Chase chasekl@state.gov

Alec

On Fri, Sep 26, 2014 at 4:38 PM, Munster, Vincent (NIH/NIAID) [E] <munstervj@niaid.nih.gov> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 3:50 PM
To: 'UMALI DALANGIN, Khristeen'
Cc: Menk, Kay (NIH/NIAID) [E]; Walczynski, Joyce (NIH/NIAID) [C]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia
Attachments: ItineraryXD60FW_26SEP.pdf

What do you need for confirmation? Who needs to confirm?

I can confirm that I am scheduled to go back on October 5, 2014; my itinerary is attached. Would be great if someone can arrange for pick up at the airport and drop off at the Kendeja hotel.

All my other documents should be still valid.

Best wishes,
Heinz

From: UMALI DALANGIN, Khristeen [mailto:umalik@who.int]
Sent: Friday, September 26, 2014 12:11 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Re: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Dear Heinz,

Can you confirm that your mission in Libéria has been extended? If so, i need to extend your contract as well.

All good except signature of contract. I will send a copy again.

Best,

Khristeen

Sent from my iPhone

On 26 Sep 2014, at 19:30, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Khristeen,
They are working on it.

What do you need from me? I have been deployed earlier (August – September) and will return on October 5. Anything needed from my end or all good? I never had a chance to sign the contract and cannot find the email any longer (still looking). Would it be possible to re-send the contract for me to sign?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 12:25 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Hoenen, Thomas (NIH/NIAID) [F]
Subject: FW: Your article has been published in final version in BMC Biology

FYI

-----Original Message-----

From: BioMed Central [mailto:post-publication@biomedcentral.com]
Sent: Thursday, September 25, 2014 9:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Your article has been published in final version in BMC Biology

MS: 1112140361140754

Title: Ebolavirus in West Africa, and the use of experimental therapies or vaccines

Authors: Hoenen Thomas, Feldmann Heinz,

Journal: BMC Biology

Dear Dr Heinz Feldmann,

We are delighted to confirm that your article is now available in final version format in BMC Biology, with the following citation:

BMC Biology.2014, 12:80

DOI: 10.1186/s12915-014-0080-6

URL: <http://www.biomedcentral.com/1741-7007/12/80>

Do you want to promote your article and spread the word about your research?
You can share your article with colleagues quickly and easily from the article page:
<http://www.biomedcentral.com/1741-7007/12/80/email?from=email>

Simply forward via email, share on social media platforms such as twitter and facebook, or add to reference managers such as Papers and citeulike using the 'share' buttons on the right hand side of the article page.

If you haven't already, then remember to share your article with colleagues using the 'share' buttons on the right hand side of the article page.

To keep up to date with very latest articles published by BMC Biology sign up to receive free email article alerts <http://www.biomedcentral.com/bmcbiol/alerts>. You can also set up stored searches to be emailed directly to your inbox.

Feldmann, Heinrich (NIH/NIAID) [E]


From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 12:25 PM
To: Menk, Kay (NIH/NIAID) [E]
Subject: FW: USDA/APHIS/VS Permit Application Number 14268054
Attachments: 2014-09-26_474402_Acknowledgement_of_Application_Fee_Receipt_TO.pdf

Would you please call our contact at USDA and remind them that this is a real urgent request for vaccine testing in response to the outbreak of Ebola in West Africa. The shipment is ready to go and all approval for in vitro and in vivo work is in place here at RML. Any help to expedite the import permit would be extremely highly appreciated. I can also call if you give me a number. If they ask for a shipment date – next week would be preferred.

Thanks,
Heinz

From: epermits.automated.message@aphis.usda.gov [mailto:epermits.automated.message@aphis.usda.gov]
Sent: Friday, September 26, 2014 9:20 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: USDA/APHIS/VS Permit Application Number 14268054

Records Originating Outside of NIAID



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 12:22 PM
To: 'travers menhinick'
Cc: Shupert, W. Lesley (NIH/NIAID) [E]
Subject: RE: Greetings

Travers,

I am very sorry to hear this. I apologize for not acting properly on your request due to my absence as I was deployed to Monrovia. Soon after my return I tried to get the requested letter from the director and run into some roadblocks.

If you consider visiting at a later time point, you may want to convince your people that a letter from me as the 'Chief Scientist of the RML BSL4 laboratories' would be sufficient. We would be more than happy to host you and I had already discussions with facility staff and other groups to meet with you during your visit. Insisting on an invitation from Bethesda will unnecessary prolong any request to visit.

My apologies - best wishes,
Heinz

-----Original Message-----

From: travers menhinick [mailto:travers.menhinick@pirbright.ac.uk]
Sent: Friday, September 26, 2014 3:28 AM
To: Shupert, W. Lesley (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Greetings

Dear Les/Heinz,

It is with regret that I have to cancel my trip to RML on this occasion.
I would like to thank you both for the time and effort you have put in to arranging my visit and hope that my cancellation has not caused an undue disruption.

Once again, thank you for the offer.

Kind regards,

Travers

-----Original Message-----

From: Shupert, W. Lesley (NIH/NIAID) [E] [mailto:WLSHUPERT@niaid.nih.gov]
Sent: 02 September 2014 21:47
To: travers menhinick
Subject: Re: Greetings

Kevin said he will be gone from the 10th thru 17th of October.

Les

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 12:07 PM
To: Ebihara, Hideki (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: Unpubli manuscript

Thanks

From: Ebihara, Hideki (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 9:18 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Unpublished manuscript

Heinz:

Unpublished

Hideki

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 11:47 AM
To: Munster, Vincent (NIH/NIAID) [E]
Cc: Rollin, Pierre (CDC/OID/NCEZID); Mahoney, Frank (CDC/CGH/GID)
Subject: RE: CT Value report and sharing results from LIBR

I have no problem reporting Ct values as long as they understand what it means and how to correctly interpret the data. I am a bit doubtful that this will be done properly, particularly when staff at MSF is changing. I would strongly recommend to meet briefly and discuss cases for discharge between the ward and the lab as this is most likely the better procedure. Of course, this only works for ELWA and may not work for other sites.

In regards to new patients coming from other clinical centers with previous Ebola diagnostic, I would highly recommend to MSF to re-test. It does not make much sense to rely on previous testing if you wish to compare Ct values and disease progression.

I would also warn people to compare Ct values from different labs which run different assays – this does not work and will cause confusion.

MSF at ELWA is in a good position with having the lab next door. They should take advantage of communication on certain patient issue such as discharge. I am much more in favor of providing them with a definite lab diagnosis – positive, negative or equivocal (i.e. one target positive, one negative).

Please feel free to pass this on to anyone you think would be interested in my comments.

I will be back in Monrovia on October 5/6 latest to replace Vincent. Looking forward to meet Frank and others.

Best wishes,
Heinz

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 9:30 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fwd: CT Value report and sharing results from LIBR

FYI

Sent from my iPhone

Begin forwarded message:

From: "Rollin, Pierre (CDC/OID/NCEZID)" <pyr3@CDC.GOV>
Date: September 26, 2014 at 15:13:08 GMT
To: MedCo Monrovia <msfocb-monrovia-Emed@brussels.msf.org>, "Munster, Vincent (NIH/NIAID) [E]" <munstervj@niaid.nih.gov>, "librlab@gmail.com" <librlab@gmail.com>, Angela Cannas <acannas@hotmail.com>, "Foya MTL (msfch-foya-mtl)" <msfch-foya-mtl@geneva.msf.org>, "guillermo.pimentel@med.navy.mil"

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 11:33 AM
To: Safronetz, David (NIH/NIAID) [E]
Subject: FW: Sacace Biotechnologies information
Attachments: Ebola Zaire Real TM ENG PCR.pdf; CATALOGO 2014 EN.pdf

CCHF might be of interest.

From: Paolo Vismara [mailto:marketing@sacace.com]
Sent: Friday, September 26, 2014 2:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Sacace Biotechnologies information

Dear Dr. Heinz Feldmann

My name is Paolo Vismara Marketing Manager Sacace. We have a complete RealTyme Catalogue for Virology and Microbiology. One month ago we launched a new kit for Ebola Diagnosis. We have one kit for Congo Crimea diagnosis etc...

I will enclose our catalogue in PDF.

If you need information please don't hesitate to contact me.

Best Regards
Paolo Vismara

Marketing Manager

SACACE Biotechnologies s.r.l.

Via Scalabrini 44

20021 Como CO

Phone office : +39 031 4892927 Fax office +39 031 4892926

Phone / Fax home office : Personal Info

Mobile phone : Personal Info

e-mail : marketing@sacace.com / Personal Info

skype : vismara.paolo

web site : www.sacace.com

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Friday, September 26, 2014 11:31 AM
To: 'UMALI DALANGIN, Khristeen'
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia

Khristeen,
They are working on it.

What do you need from me? I have been deployed earlier (August – September) and will return on October 5. Anything needed from my end or all good? I never had a chance to sign the contract and cannot find the email any longer (still looking). Would it be possible to re-send the contract for me to sign?

Thanks and best wishes,
Heinz

From: UMALI DALANGIN, Khristeen [mailto:umalik@who.int]
Sent: Friday, September 26, 2014 4:54 AM
To: Menk, Kay (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: UPDATE: MEDICALS FOR NIH STAFF TRAVELING ON 28 SUNDAY / LAB ROTATION #3 - Ebola response, Liberia
Importance: High

Dear Kay, Heinz,

For info., I just spoke to our colleague in Staff Health and Wellbeing Services shws@who.int and they have informed me that they need complimentary medical information from Kristi & Kyle. SHW has sent them individual email. Kindly follow-up urgently.

Kindly note that without the medical approval, we cannot process WHO/GOARN contracts. For the next and future lab rotations, may we suggest that a copy of the medical form and the **updated** vaccination record for each NIH staff be sent directly to our health clinic either by email or by fax at +41 22 791 4120.

Thanks,

Khristeen

From: Menk, Kay (NIH/NIAID) [E] [mailto:menkk@niaid.nih.gov]
Sent: 25 September 2014 17:59
To: UMALI DALANGIN, Khristeen
Subject: FW: KM Travel - medical documentation

Hi Khristeen,
Attached are Kristin McNally's. Hopefully soon I will have Kyle's.

Team 4 emails.
marzia@niaid.nih.gov (Team Lead)
darryl.falzarano@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 6:19 PM
To: Hoenen, Thomas (NIH/NIAID) [F]
Subject: RE: Long Term Vision and Impact
Attachments: CV_english_US_format_140912.doc; Research Goals.docx

Personal Info

Good luck,
Heinz

From: Hoenen, Thomas (NIH/NIAID) [F]
Sent: Monday, September 22, 2014 3:13 PM
To: Best, Sonja (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Martin, Scott (NIH/NCATS) [C]
Subject: Long Term Vision and Impact

Dear all,

As promised you find attached the **Unfunded** application. Also, since I got some very helpful feedback from you, I have updated the other documents, which are attached. Again, any help, insight, corrections, suggestions etc. are more than welcome!

All the best, Thomas

Thomas Hoenen, PhD
Disease Modelling and Transmission - Laboratory of Virology, NIAID, NIH
RML - Rocky Mountain Laboratories, 2A120A
903 S 4th St
Hamilton, MT
Phone: +1.406.375.7408
Email: thomas.hoenen@nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 5:50 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: Time: The 5 Biggest Mistakes in the Ebola Outbreak (So Far)

Yes – but some of the points are old, applied to previous outbreaks and do not really explain what is happening now. They also do not acknowledge at all the contribution of MSF.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 2:47 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Time: The 5 Biggest Mistakes in the Ebola Outbreak (So Far)

Interesting points below; Tom G. included.

Sent: Thursday, September 25, 2014 12:49 PM

The 5 Biggest Mistakes in the Ebola Outbreak (So Far)

[Alexandra Sifferlin @acsifferlin](#)

Experts weigh in on how the outbreak got this out of control

The Centers for Disease Control and Prevention (CDC) recently [projected](#) that if trends continue unimpeded, cases of Ebola could pass the million mark by January. While that's an unlikely scenario, many are still wondering: how on earth did it get this bad? We canvassed experts for some clues.

1. The response was far too slow

There was a period in April when it appeared that the Ebola outbreak had subsided, prompting a collective sigh of relief. Guinea's Ministry of Health even [said](#) that country's caseload appeared to be under control. But the outbreak didn't subside. Instead, it barreled through interconnected towns and villages in more populated areas of Guinea, Liberia and Sierra Leone. And after the outbreak's perceived lull, however, came one of the largest flare-ups. Some scientists say that during that time, their warnings were ignored.

One such scientist is Robert Garry, a Tulane University virologist who had visited a hospital in Sierra Leone caring for some of his colleagues, including Dr. Sheik Humarr Khan—one [of the first doctors to die of the disease](#) in Sierra Leone. Garry then warned various groups, including the State Department, that the outbreak was highly concerning. No one, he says, really listened to him. "Their response was cordial, but nothing really happened," says Garry. "I was really concerned about the lack of attention. I caught a lot of flack for saying I didn't think the numbers [of reported cases and deaths caused by Ebola] were accurate. Some of us realized this was not going to be controlled."

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 2:33 PM
To: 'Thomas Arminio'
Subject: RE: Hello

If they want to use a reference lab such as CDC or Winnipeg for diagnostics they would ship the live sample. If they prefer to run molecular diagnostics (RT-PCR) in country they would inactivate the sample using standard protocols. We can provide those protocols if needed.

Hope things are going well and you have a good time in Cuba. Please say hello to George and Maria.

Best wishes,
Heinz

From: Thomas Arminio [mailto:Personal Info]
Sent: Wednesday, September 24, 2014 5:39 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Hello

Hi Heinz,
Cuba is quite fantastic! Have you been?
So after talking yesterday with PAHO and the folks here I believe the question is if Cuba were to receive a suspected case of Ebola and needed to transport the sample for testing would they want to first inactivate it. I think the receiving lab would prefer a live sample but there also seems some potential problem with shipping couriers too.
Any thoughts would be appreciated.
I met a Maria Guzman who said to say hello. She is a dengue expert.
Best
Thomas

Live Fearlessly

Sent from my iPhone

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 2:21 PM
To: 'Ali Mirazimi'
Cc: Clifton, Dawn (NIH/NIAID) [E]
Subject: RE:

I can most likely come up with antibodies that we can use. Unfortunately, I am leaving for Monrovia next week and will be gone until the end of October. Please communicate with Dawn Clifton on administrative issues but she is also very busy at the moment as we are at the end of our fiscal year.

Sorry but this is a bad time for us – we will try our best.

From: Ali Mirazimi [mailto:Ali.Mirazimi@folkhalsomyndigheten.se]
Sent: Thursday, September 25, 2014 1:45 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re:

Hi Hienz!

Ok- Are you available within coming few days, we have to make some administration within the commission- if not, can you put someone of your administration in contact with me which can help me if I need some doc from your side!

My deadline is 6th of Oct (70 pages!)-

Best
Ali

25 sep 2014 kl. 18:39 skrev Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>:

Not from our group. I work with a Japanese fellow who generates antibodies – Ayato Takada.

From: Ali Mirazimi [mailto:Ali.Mirazimi@folkhalsomyndigheten.se]
Sent: Thursday, September 25, 2014 2:47 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject:

Hi Hienz,

Have you any Ab which can be used for Ag detection of Ebola? There is a company (we have very good experience within the CCH fever program) which are experts to set up Line assay!?

Best
Ali

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 2:19 PM
To: 'ANGELA L. RASMUSSEN'
Subject: RE: Letter of support, manuscript forms, and upcoming studies

We most likely will have permission to use the strain within one week.

From: ANGELA L. RASMUSSEN [mailto:arasmus@uw.edu]
Sent: Thursday, September 25, 2014 12:24 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Letter of support, manuscript forms, and upcoming studies

Thank you so much, Heinz! Would you like me to set up a call about the anti-tissue factor drug? I can start arranging for CC mice to be bred for that if you'd like to go that direction.

I don't think Michael was offended—he's just extremely eager to use it, as I am sure you are as well (and everyone else in the world doing Ebola work). A major theme of the Science paper's reviews has been looking at the Guinea isolate versus Mayinga, and he's just trying to think of creative ways to start using the more current isolate as soon as possible. It sounds like everyone in the field is waiting for some kind of direction/permission to do these studies. Certainly Michael and I both would want to get approval to synthesize the Guinea strain, but frankly neither of us are aware of the particulars of getting the approval needed to synthesize an infectious clone of a tier 1 select agent. I can assure you that nobody here wants to go to prison!! I imagine that getting approval for that would run into the same IP issues as getting permission to use the Guinea isolate, plus potentially issues with CDC/any other agency that oversees those approvals.

Thank you again!

From: <Feldmann>, "feldmannh@niaid.nih.gov" <feldmannh@niaid.nih.gov>
Date: Thursday, September 25, 2014 at 11:04 AM
To: Angela Rasmussen <arasmus@uw.edu>
Subject: RE: Letter of support, manuscript forms, and upcoming studies

Here you go – good luck,
Heinz

PS: Was Michael offended by my comment on the synthesizing the new Guinea strain? I hope not – but I think you cannot do this without proper approval as this one is a select agent and Tier 1 pathogen.

From: ANGELA L. RASMU
SSEN [mailto:arasmus@uw.edu]
Sent: Wednesday, September 24, 2014 2:57 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Letter of support, manuscript forms, and upcoming studies

Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 12:04 PM
To: Personal Info
Subject: Personal Info
Attachments: Personal Info

Here you go – good luck,
Heinz

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 11:26 AM
To: 'Geisbert, Thomas W.'; 'Vincent Racaniello'
Subject: RE: EV question

Thanks Tom - Vincent, I hope this will help.

-----Original Message-----

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Thursday, September 25, 2014 6:50 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'Vincent Racaniello'
Subject: RE: EV question

Redacted by agreement

Tom

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, September 24, 2014 6:13 PM
To: 'Vincent Racaniello'
Cc: Geisbert, Thomas W.
Subject: RE: EV question

Dear Vincent,

Please find two papers below that touch on the issue of infection of the respiratory epithelium. I copied Tom Geisbert on this email as he may know better than me

Redacted by agreement

Best wishes,
Heinz

Medina MF, Kobinger GP, Rux J, Gasmi M, Looney DJ, Bates P, Wilson JM. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther. 2003 Nov;8(5):777-89.
Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, Smith G, Tierney K, Patel A, Weingartl HM. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis. 2011 Jul 15;204(2):200-8.

-----Original Message-----

From: Vincent Racaniello [mailto:vrr1@columbia.edu]
Sent: Wednesday, September 24, 2014 2:04 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 11:24 AM
To: Munster, Vincent (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Bushmaker, Trenton (NIH/NIAID) [E]; Fischer, Robert (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]
Subject: FW: Report on presumed exposure

FYI

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 11:23 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Hensley, Lisa (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Report on presumed exposure

FYI

Armand, many thanks for your collegial attitude and prompt response. We highly appreciate your effort to clarify the situation and your willingness to discuss the issue and provide the insight into MSF's operation.

Looking forward to a continuing fruitful collaboration in Monrovia and elsewhere.

Best wishes,
Heinz

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Thursday, September 25, 2014 8:52 AM
To: Hensley, Lisa (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Report on presumed exposure

Hi Lisa & Heinz,

As you both had concerns brought your way, I thought I would pass this along to you. It has been cleared for sharing with partners, so feel free to pass within NIH if needed.

- Armand

Contamination of an expatriate by Ebola virus, Monrovia, Liberia; September 2014
Conclusions of the analysis of this incident

Short summary of the case

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 11:23 AM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); Hensley, Lisa (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Report on presumed exposure

FYI

Armand, many thanks for your collegial attitude and prompt response. We highly appreciate your effort to clarify the situation and your willingness to discuss the issue and provide the insight into MSF's operation.

Looking forward to a continuing fruitful collaboration in Monrovia and elsewhere.

Best wishes,
Heinz

From: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Sent: Thursday, September 25, 2014 8:52 AM
To: Hensley, Lisa (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Report on presumed exposure

Hi Lisa & Heinz,

As you both had concerns brought your way, I thought I would pass this along to you. It has been cleared for sharing with partners, so feel free to pass within NIH if needed.

- Armand

Contamination of an expatriate by Ebola virus, Monrovia, Liberia; September 2014
Conclusions of the analysis of this incident

Short summary of the case

Personal Info

Process followed with any case of positivity in the staff (nat or expat)

Each time a staff MSF is found + for Ebola, an investigation is done, by experienced people, to determine the exact circumstances of contamination: time, place, detailed of the incident.

A specific focus is put on the verification of the bio security measures in place in the MSF project, to verify their efficacy, if they are well implemented and well respected.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 10:40 AM
To: 'Ali Mirazimi'
Subject: RE:

Not from our group. I work with a Japanese fellow who generates antibodies – Ayato Takada.

From: Ali Mirazimi [mailto:Ali.Mirazimi@folkhalsomyndigheten.se]
Sent: Thursday, September 25, 2014 2:47 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject:

Hi Hienz,

Have you any Ab which can be used for Ag detection of Ebola? There is a company (we have very good experience within the CCH fever program) which are experts to set up Line assay!?

Best
Ali

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 9:50 AM
To: Menk, Kay (NIH/NIAID) [E]; 'UMALI DALANGIN, Khristeen'
Cc: Rosenke, Kyle (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia

Please resend the medicals to Kkristeen.

From: Menk, Kay (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 9:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'UMALI DALANGIN, Khristeen'
Cc: Rosenke, Kyle (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia

Hi Heinz,
Kristin's have been sent directly to the health clinic this morning.
Kay

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 9:45 AM
To: 'UMALI DALANGIN, Khristeen'
Cc: Menk, Kay (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia

Kyle & Kristin,

Please send your medicals to Khristeen as soon as possible.

I never managed to sign my contract with WHO/GOARN and I cannot find it. Can you please resend the contract for me so that I can sign before I leave? Printing, scanning etc is very difficult in Monrovia for us. Do I need a new medical for my next turn?

Best wishes,
Heinz

From: UMALI DALANGIN, Khristeen [<mailto:umalik@who.int>]
Sent: Thursday, September 25, 2014 7:33 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia
Importance: High

Dear Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 9:49 AM
To: Safronetz, David (NIH/NIAID) [E]; 'Petra Wülfroth'
Subject: RE: animal protocol

Day 3 sounds good to me if the dose is set. Day 4 may be too late. You could also think about doing day 2 and day 4 or day 4 and day 5 (most likely too late) but could serve as a control.

Heinz

From: Safronetz, David (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 8:53 AM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: animal protocol

Okay. I have the animal protocol about half done. I spoke with the ACUC coordinator yesterday about requesting an expedited review for next week (unfortunately the next ACUC meeting is exactly one month from today). I explained the situation and he feels that it should be no problem. I will present a rough outline of the proposed experiments and why it is important to get it done ASAP.

It is my understanding that in the Dengue model increased doses of [Redacted by agreement]
[Redacted by agreement] We could consider adding a group which receives treatment at 3 days post-challenge. Do you think initiating treatment with a loading dose [Redacted by agreement] would make sense?

Dave

From: Petra Wülfroth [<mailto:petra.wuelfroth@accella-advisors.com>]
Sent: Thursday, September 25, 2014 4:01 AM
To: Safronetz, David (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: animal protocol

Hi Dave

drug amount is not a problem (we would even have enough drug to treat around 2000 patients).

It makes sense to treat the animals for 10 days. Heinz suggested to add a second dosage and/or treatment starting point.

When animals die after 5-7 days, when are first disease signs observed?

Saline would work as vehicle/ control.

regards

Petra

Dr. Petra Wuelfroth
accella advisors GmbH
Stoeckenweidstr. 11
CH-8738 Uetliburg

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 9:45 AM
To: 'UMALI DALANGIN, Khristeen'
Cc: Menk, Kay (NIH/NIAID) [E]; Rosenke, Kyle (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia

Kyle & Kristin,

Please send your medicals to Khristeen as soon as possible.

I never managed to sign my contract with WHO/GOARN and I cannot find it. Can you please resend the contract for me so that I can sign before I leave? Printing, scanning etc is very difficult in Monrovia for us. Do I need a new medical for my next turn?

Best wishes,
Heinz

From: UMALI DALANGIN, Khristeen [<mailto:umalik@who.int>]
Sent: Thursday, September 25, 2014 7:33 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Menk, Kay (NIH/NIAID) [E]
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia
Importance: High

Dear Heinz,

Message well received.

So far our health clinic has not received the medical forms for Kyle and Kristin. This is very critical in order to process the contract.

Thanks,


Khristeen

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: 25 September 2014 01:44
To: Fuller, Serena (CDC/CGH/DGHP); LORENZIN, Egle
Cc: Neatherlin, John C. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Montgomery, Joel M. (CDC/CGH/DGHP); Osanya, Cynthia A. (CDC/CGH/DGHP); UMALI DALANGIN, Khristeen; GURRY, Celine; goarn; GDD-OUTBREAK (CDC); CDC IMS Deployment Coordinator (CDC); Nichol, Stuart T. (CDC/OID/NCEZID); Rosenke, Kyle (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 9:41 AM
To: 'Geisbert, Thomas W.'; Kobinger, Gary (Public Health Agency of Canada)
Subject: RE: Unpublished

Unpublished



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 25, 2014 9:39 AM
To: Kobinger, Gary (Public Health Agency of Canada); Geisbert, Thomas W.
Subject: RE: Unpublished

Unpublished

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 5:58 PM
To: Zoon, Kathryn (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Hemisphere request

Kathy,

They contacted me regarding Ebola and I referred them to you. We have tested their product against MERS-CoV. Darryl will look at the results one more time but it Redacted by agreement We are currently doing the in vitro work for Ebola using their product.

I agree with you – no need to do anything in vivo if there is no efficacy in the current study.

Best wishes,
Heinz

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 7:41 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Hemisphere request

Heinz

Got a letter from Bill Carter who is the CEO who said he was working with you with on the MERS CoV using ampligen. Basically he wants us to test it for ebola. I think if the interferon doesn't work, neither will this. What do you think? Did it have any increased activity with the MERS CoV over the interferon?

Kathy

Kathryn C. Zoon, Ph.D.
Director, Division of Intramural Research, NIAID
NIAID Scientific Director
33 North Drive
Bldg 33, Rm 2N09G
Bethesda, MD 20892
kzoon@niaid.nih.gov

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 5:44 PM
To: Fuller, Serena (CDC/CGH/DGHP); LORENZIN, Egle
Cc: Neatherlin, John C. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Montgomery, Joel M. (CDC/CGH/DGHP); Osanya, Cynthia A. (CDC/CGH/DGHP); UMALI DALANGIN, Khristeen; GURRY, Celine; goarn; GDD-OUTBREAK (CDC); CDC IMS Deployment Coordinator (CDC); Nichol, Stuart T. (CDC/OID/NCEZID); Rosenke, Kyle (NIH/NIAID) [F]; McNally, Kristin (NIH/NIAID) [E]; Menk, Kay (NIH/NIAID) [E]
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia

Dear ALL,

The next team members of the NIH team will be:

Kyle Rosenke (arrive in Monrovia September 29 on Brussels Air)
Kristin McNally (arrive in Monrovia September 29 on Brussels Air)
Please arrange pick-up for the two team members – please instruct the driver to bring them to the Kendeja Hotel (no other hotel please).

Heinrich (Heinz) Feldmann (arrive in Monrovia either on October 3 or 4 – we will confirm itinerary as soon as it will be finalized).

Please indicate if there is missing paperwork. I (Heinz) have been in Monrovia from August to September 2014 – is there anything that you need from me in addition to the previous paperwork?

Best wishes,
Heinz

From: Fuller, Serena (CDC/CGH/DGHP)
Sent: Wednesday, September 24, 2014 2:58 PM
To: LORENZIN, Egle
Cc: Neatherlin, John C. (CDC/CGH/DGHP); Fields, Barry (CDC/CGH/DGHP); Feldmann, Heinrich (NIH/NIAID) [E]; Montgomery, Joel M. (CDC/CGH/DGHP); Osanya, Cynthia A. (CDC/CGH/DGHP); UMALI DALANGIN, Khristeen; GURRY, Celine; goarn; GDD-OUTBREAK (CDC); CDC IMS Deployment Coordinator (CDC)
Subject: RE: GOARN Pre-deployment package for Drs Bonventure Juma & Melvin Ochieng (CDC Lab experts), Ebola outbreak, Liberia

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 5:20 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Banadyga, Logan (NIH/NIAID) [F]
Subject: RE: Virology blog/Racaniello: What we are not afraid to say about Ebola virus <http://bit.ly/1misaEQ>

I had seen it already – great response. I thanked him already for this comment.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 2:29 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Cc: Banadyga, Logan (NIH/NIAID) [F]
Subject: FW: Virology blog/Racaniello: What we are not afraid to say about Ebola virus <http://bit.ly/1misaEQ>

Want to make sure you don't miss this ... a nice counterpoint to Osterholm's recent column in the NY Times.

What we are not afraid to say about Ebola virus

18 September 2014

• By Vincent Racaniello

[Earth's virology Professor](#)

Questions? virology@virology.ws

In a recent *New York Times* OpEd entitled [What We're Afraid to Say About Ebola](#), Michael Osterholm wonders whether Ebola virus could go airborne:

You can now get Ebola only through direct contact with bodily fluids. If certain mutations occurred, it would mean that just breathing would put one at risk of contracting Ebola. Infections could spread quickly to every part of the globe, as the H1N1 influenza virus did in 2009, after its birth in Mexico.

Is there any truth to what Osterholm is saying?

Let's start with his discussion of Ebola virus mutation:

But viruses like Ebola are notoriously sloppy in replicating, meaning the virus entering one person may be genetically different from the virus entering the next. The current Ebola virus's hyper-evolution is unprecedented; there has been more human-to-human transmission in the past four months than most likely occurred in the last 500 to 1,000 years.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 5:20 PM
To: Haddock, Elaine (NIH/NIAID) [E]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: FW: conference call re hyperthermia treatment for ebola virus

Elaine (Ricki),

Can we include the conditions in the middle paragraph in our in vitro inactivation testing?

Thanks,
Heinz

From: Roger Vertrees [mailto:roger@verthermia.com]
Sent: Wednesday, September 24, 2014 1:20 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Z Forwarding Account for JW
Cc: Jan Winetz
Subject: Re: conference call re hyperthermia treatment for ebola virus

Dr. Feldman, thanks for the call today it helped us immensely in the understanding of the problem. I would like Dr. Strong's contact information as we would like to pursue this at least through the original heat-dose benching testing phase.

Minimally, we would like the sample to be Redacted by agreement

Redacted by agreement

Redacted by agreement

Again, thanks so much for the chat and looking forward to hearing the results of this work. If we do get a reduction that peaks your interest, in our opinion the best next step is to do a full-heat dose study. It is 9-separate trials at temps from 40 through 48C with samples at hourly intervals over a 6-hour run.

Roger Vertrees, Ph.D.
Jan Winetz, MD
Verthermia, Inc.
San Jose CA

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: Sunday, September 21, 2014 10:20 AM
To: Z Forwarding Account for JW; Roger Vertrees
Cc: Jan Winetz
Subject: RE: conference call re hyperthermia treatment for ebola virus

Call me in the office at 406-375-7410. If that does not work – try the BB phone

Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 5:19 PM
To: 'Roger Vertrees'; Z Forwarding Account for JW
Cc: Jan Winetz
Subject: RE: conference call re hyperthermia treatment for ebola virus

Dr. Jim Strong (Jim.Strong@phac-aspc.gc.ca)

I will try to arrange for the pilot in vitro study.

Best wishes,
Heinz

From: Roger Vertrees [<mailto:roger@verthermia.com>]
Sent: Wednesday, September 24, 2014 1:20 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Z Forwarding Account for JW
Cc: Jan Winetz
Subject: Re: conference call re hyperthermia treatment for ebola virus

Dr. Feldman, thanks for the call today it helped us immensely in the understanding of the problem. I would like Dr. Strong's contact information as we would like to pursue this at least through the original heat-dose benching testing phase.

Minimally, we would like the sample to be Redacted by agreement

Redacted by agreement

Redacted by

Again, thanks so much for the chat and looking forward to hearing the results of this work. If we do get a reduction that peaks your interest, in our opinion the best next step is to do a full-heat dose study. It is 9-separate trials at temps from 40 through 48C with samples at hourly intervals over a 6-hour run.

Roger Vertrees, Ph.D.
Jan Winetz, MD
Verthermia, Inc.
San Jose CA

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: Sunday, September 21, 2014 10:20 AM
To: Z Forwarding Account for JW; Roger Vertrees
Cc: Jan Winetz
Subject: RE: conference call re hyperthermia treatment for ebola virus

Call me in the office at 406-375-7410. If that does not work – try the BB phone Personal Info

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 5:13 PM
To: 'Vincent Racaniello'
Cc: Geisbert, Thomas W. (twgeisbe@UTMB.EDU) (twgeisbe@UTMB.EDU)
Subject: RE: EV question

Dear Vincent,

Please find two papers below that touch on the issue of infection of the respiratory epithelium. I copied Tom Geisbert on this email as he may know better than me. Tom - do you have NHP data of Ebola infecting respiratory epithelium?

Best wishes,
Heinz

Medina MF, Kobinger GP, Rux J, Gasmi M, Looney DJ, Bates P, Wilson JM. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. *Mol Ther*. 2003 Nov;8(5):777-89.
Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, Smith G, Tierney K, Patel A, Weingartl HM. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. *J Infect Dis*. 2011 Jul 15;204(2):200-8.

-----Original Message-----

From: Vincent Racaniello [mailto:vrr1@columbia.edu]
Sent: Wednesday, September 24, 2014 2:04 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: EV question

Hello Heinz,

EV question - is the virus believed to replicate in the human respiratory epithelium? I understand that virus can be found in respiratory secretions, but is the origin of this virus known? Thanks.

Vincent

Vincent Racaniello, Ph.D. | Higgins Professor Department of Microbiology & Immunology Columbia University, New York

virology.ws | twiv.tv

"Tanto sa ciascuno quanto opera"

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 4:55 PM
To: Safronetz, David (NIH/NIAID) [E]; 'Petra Wülfroth'
Subject: RE: animal protocol

Would it be helpful to do either do two different doses or two time points of treatment start?

From: Safronetz, David (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 3:17 PM
To: 'Petra Wülfroth'
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: animal protocol

Hi Petra,

I think for the initial proof of concept experiment we should Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

Redacted by agreement

We can always reduce the number of days that we treat for (i.e., 7 instead of 10?); however we risk losing the hamsters if the effect isn't long lasting. You would likely know more about this than me. If the experiment works, the follow-up studies would focus on how late the compound could be administered and still retain activity (i.e., similar groups of animals with treatments beginning 2, 3 and 4 days post-challenge).

If you think you can get us enough compound, I am willing to ask the ACUC if they would allow us to submit an emergency protocol next week for expedited review.

Please let me know what you think

Dave

From: Petra Wülfroth [<mailto:petra.wuelfroth@accella-advisors.com>]
Sent: Wednesday, September 24, 2014 5:54 AM
To: Safronetz, David (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: animal protocol

Hi Dave

I can imagine that you are terribly busy these times. But could you please send me the animal protocol? I will be in holidays from Wednesday on next week and I would like to prepare everything for you to start before I leave.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 4:33 PM
To: 'Katy Graef'
Cc: Jennifer Dent
Subject: RE: Introduction

I know I wasn't too much of a help but hopefully could give you some insight.

I am glad to hear that you are doing well.

Best wishes,
Heinz

From: Katy Graef [mailto:kgraef@bvgh.org]
Sent: Wednesday, September 24, 2014 4:02 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jennifer Dent
Subject: RE: Introduction

Dear Heinz,

Thank you very much for taking time out of your busy afternoon to speak with Jennifer and me. We really appreciate all of the ideas and insights that you provided. As Jennifer said, we will keep you apprised of any advancements.

Best wishes to you and your lab,
Katy

Katy M. Graef
kgraef@bvgh.org
206-732-2122

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, September 22, 2014 5:01 PM
To: Katy Graef
Cc: Jennifer Dent
Subject: RE: Introduction

Please call that number. In case you do not get me on the phone, please call Personal Info

From: Katy Graef [mailto:kgraef@bvgh.org]
Sent: Monday, September 22, 2014 3:48 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jennifer Dent
Subject: RE: Introduction

Dear Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 12:15 PM
To: Munster, Vincent (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]
Subject: RE: ebola titration

We can do that – actually did talk about it earlier this week. We don't have any data from previous experiments.

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 2:33 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Falzarano, Darryl (NIH/NIAID) [F]; Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; De wit, Emmie (NIH/NIAID) [E]
Subject: ebola titration

Hi Heinz,

would it make sense to do some testing looking at the relationship of infectious virus and CT values with the NHP experiments your now running?

cheers,

Vincent Munster, PhD
Chief, Virus Ecology Unit
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH
903 South 4th street
Hamilton, MT 59840

406-375-7489



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Wednesday, September 24, 2014 11:00 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: AW: Gruß aus Washington

Thanks

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 7:53 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fwd: AW: Gruß aus Washington

Fine to do if you have the time.

Begin forwarded message:

From: Koch Stefan <stefan.koch@haz.de>
Date: September 23, 2014 at 7:25:48 PM MDT
To: "Pekoc, Ken (NIH/NIAID) [E]" <kpekoc@niaid.nih.gov>
Subject: AW: Gruß aus Washington

Dear Ken!

Thank you very much for your email.
I would like to talk to Prof. Feldmann about his experience in Westafrica and about the vaccine, which is insufficiently tested.
My deadline tomorrow is at 11 am.

Thank you for your help

Best regards,
Stefan Koch

Von: Pekoc, Ken (NIH/NIAID) [E] [kpekoc@niaid.nih.gov]
Gesendet: Dienstag, 23. September 2014 23:20
An: Koch Stefan
Betreff: FW: Gruß aus Washington

Hi Stefan ... I am assisting Dr. Feldmann in arranging his schedule; since his return from Liberia assisting with Ebola diagnostic testing he is behind in some research projects and trying to catch up.

Can you clarify for me what you would like from Dr. Feldmann, a general interview about Ebola (sample questions?), or a specific reaction to something former President Kohler published?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 7:09 PM
To: 'Guido van der Groen'
Subject: RE: Ebola

Guido,

We are involved in Monrovia doing basic laboratory support for ELWA3, the biggest MSF isolation ward that I have ever seen in an outbreak. Currently there is no time for research – all work is devoted to diagnose patients. So far we have not been allowed to take samples out of the country for further analysis. The discussion on doing so are still ongoing. We operate under CDC and in case one of us would get infected they will evacuate us to a treatment center in the US.

I hope that when the situation settles one day we will be able to do more research but who knows when that will be. For now this is strictly public health response.

The situation in Monrovia is grim and the extent of the outbreak is unbelievable. Not sure what will make the big change in future but happy to be a small part of the operation. Never thought that Ebola could become that important one day.

Best wishes,
Heinz

From: Guido van der Groen [mailto:gvdgroen@scarlet.be]
Sent: Tuesday, September 23, 2014 3:47 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola

Dear Heinz,

I received from Ken Peacock a nice video describing an elegant method to monitor antibodies against Ebola in feces samples of non human primates, in which a few of my Yambuku 1976 shots were used.
How was your trip? Did you also use the faeces samples to extract Ebola genetic material ? Any news on new reservoirs for Ebola ? Did you also sampled bushmeat used by the local population? Certain animals with a high prevalence of Ebola infections?

Are you also involved in genetic characterization of circulating Ebola strains? Any indications that Ebola can be spread by aerosols in the Liberian setting?
How were the working conditions? Did you have an evacuation plan in case one of you became infected?
Must have been a fascinating experience!?

Warm regards,

Guido

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 6:37 PM
To: 'Ali Mirazimi'
Subject: RE: Ebola funds

I am but not sure how much of a help I will be over the next couple of weeks as I am scheduled to go to Monrovia. What do you want to do – what is the project?

Best wishes,
Heinz

From: Ali Mirazimi [mailto:Ali.Mirazimi@folkhalsomyndigheten.se]
Sent: Tuesday, September 23, 2014 8:53 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola funds

Dear Heinz!

See below! Are you interested to be part in this action!?

I need a urgent response!
Best
Ali

Skickat från min iPhone

Vidarebefordrat brev:

Från: <Birgit.Van-Tongelen@ec.europa.eu>
Datum: 23 september 2014 16:44:14 CEST
Till: <Ali.Mirazimi@folkhalsomyndigheten.se>
Ämne: RE: Names

Ali,

The funds currently available for urgent Ebola research are very limited and they will have to be allocated to proposals that address urgent gaps in Ebola research, in accordance to the priorities delineated by the WHO 'Consultation on potential therapies and Vaccines'.

If you wish to apply, the following steps will have to be followed.

- We must receive an official letter from the coordinator of the proposed project , indicating that you want to submit a proposal outside a call and explain why (Ebola crisis) including a short outline of what you want to do. The official letter should be sent to our Director Ms. Draghia-Akli by email (Ruxandra.DRAGHIA-AKLI@ec.europa.eu).
- The Commission will reply to you and explain what you need to do in order to submit the final proposal.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 6:09 PM
To: 'Anja.WOLZ@geneva.msf.org'
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt
Subject: RE: Berlin

I hope you can do it. Please copy everyone on your decision.

Thanks,
Heinz

-----Original Message-----

From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
Sent: Tuesday, September 23, 2014 1:16 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt
Subject: RE: Berlin

I will let you know as soon as I can confirm it Thanks for the invitation

Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher,Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de)" <Ilia.Semmler@tmf-ev.de>, Juergen Richt <jricht@vet.k-state.edu>
Date: 23.09.2014 02:17
Subject:RE: Berlin

Anja,
We would like to invite you to present a talk on the Ebola outbreak in West Africa. The presentation is scheduled for Thursday, October 16 in the time from 16:30-17:30h.

Please let us know as soon as possible if you will accept our invitation.

Best wishes and stay safe,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 6:00 PM
To: 'Kley, Nils'
Subject: RE: Nachwuchsfrühstück

Leider kann ich nicht an der Tagung teilnehmen. Ich bin zu der Zeit in Monrovia wegen des Ebola-Ausbruchs. Ich nehme mal an, dass Sie Ersatz haben, wenn nicht dann fragen Sie doch bitte Juergen Richt.

Gruss,
Heinz

From: Kley, Nils [mailto:Nils.Kley@fli.bund.de]
Sent: Tuesday, September 23, 2014 3:04 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Nachwuchsfrühstück
Importance: High

Sehr geehrter Herr Dr. Feldmann,

ich wollte kurz nachfragen, ob Sie beim Symposium im Berlin anwesend sein und am Nachwuchsfrühstück als Senior Scientist teilnehmen werden. Falls ja: könnten Sie bitte das angeheftete Folie ausfüllen? Falls nein, bitte ich um möglichst schnelle Rückmeldung Ihrerseits, damit ich zeitnah einen Ersatz nominieren kann.

Vielen Dank im Voraus für Ihre Antwort.

Beste Grüße

Nils Kley

Dr. Nils Kley, MRCVS
wiss. Referent
Nationale Forschungsplattform für Zoonosen

c/o Friedrich-Loeffler-Institut
Bundesforschungsinstitut für Tiergesundheit
Federal Research Institute for Animal Health
Südufer 10 | 17493 Greifswald - Insel Riems
Tel: +49 38351 7 1198 | Fax: +49 38351 7 1524 |
<http://www.zoonosen.net>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 5:56 PM
To: Shupert, W. Lesley (NIH/NIAID) [E]
Subject: FW: PHAC Transfer form
Attachments: SES-F-052A-3 SES Transfer Request RML.doc

Did you finish this?

-----Original Message-----

From: Shane Jones [mailto:Shane.Jones@phac-aspc.gc.ca]
Sent: Tuesday, September 23, 2014 7:31 AM
To: Shupert, W. Lesley (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Hoe, Nancy (NIH/OD/ORS) [E]; Feldmann, Ricki (NIH/NIAID) [C]; Kobinger, Gary (Public Health Agency of Canada)
Subject: PHAC Transfer form

Hi Les,

Attached is the transfer form for the upcoming shipment. Can you please check to ensure the information is correct and then sign and send back to me either by fax or email. I will start on the other paper work and when I have it all in order I will copy you on the request to World Courier on setting up a shipment date.

Any questions please let me know.

Cheers,

Shane Jones
Technician
Special Pathogens
National Microbiology Laboratory
Canadian Science Centre for Human and Animal Health
1015 Arlington St., Rm H2405
Winnipeg, MB, R3E 3R2
ph: (204) 789-6029
fax: (204) 789-2140
email: shane_jones@phac-aspc.gc.ca

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 5:55 PM
To: Walczynski, Joyce (NIH/NIAID) [C]
Subject: RE: 20th Anniversary Celebration

Let's discuss this tomorrow. If I leave for David this would not be a problem.

From: Walczynski, Joyce (NIH/NIAID) [C]
Sent: Tuesday, September 23, 2014 8:46 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: 20th Anniversary Celebration

Hi Heinz,

I sent an e-mail to Dr. Comella and received a response from Fran Garcia below. I wanted to find out what time you would have to be there on the 21—since that is the day of the celebration. It looks like you need to be in Barcelona by 11 a.m. on November 21, and it is approx.. an hour drive from the airport to the hospital.

I looked at flights yesterday, and I did not see a Delta flight that would get you into Barcelona prior to 11 a.m. on the 21; therefore, you would need to arrive on the 20th, which means departing on the 19th of November. This does not give you 10 days from when you arrive back in Montana from Monrovia—although it is very close—counting the 11th and the 19th, it gives you 9 days.

Thanks.

Joyce Walczynski

Logistics Technician, LV (Contractor)
Rocky Mountain Laboratories
903 South 4th St.
Hamilton, MT 59840
Phone: 406.375.9600
Fax: 406.375.9620
Email: walczynskij@niaid.nih.gov

From: Fran Garcia [<mailto:fran.garcia@vhir.org>]
Sent: Tuesday, September 23, 2014 5:42 AM
To: Walczynski, Joyce (NIH/NIAID) [C]
Cc: joan.comella@vhir.org; 'Lidia Ale Ruiz'; 'Ana Lucia Roman Mora'
Subject: RE: 20th Anniversary Celebration

Dear Joyce,

I'm Fran Garcia, Head of Communications at VHIR. We are very happy with your answer and wishing to have here Dr. Feldmann with us.

Answering your questions:

The meeting starts at 11 am and his conference will begin around 12. This will be the main academic event of our 20th Anniversary. There will be speakers talking about the 20 years of our institution and the special guest will be Dr.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 4:04 PM
To: 'Dorian Bevec, PhD'
Subject: RE: VHF

Sensitivity: Confidential

Donnerstag um 1:00 Uhr hier – nochmals Entschuldigung fuer heute Morgen.

Gruss,
Heinz

From: Dorian Bevec, PhD [mailto:dorian.bevec@therametrics.com]
Sent: Tuesday, September 23, 2014 8:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: VHF
Sensitivity: Confidential

Ok, kein Problem! Könne wir am Donnerstag am Abend dutscher Zeit reden? gegen 21-22Uhr (das wäre gegen 1pm Deiner Zeit?

Beste Grüsse,
Dorian

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: Tuesday, September 23, 2014 4:53 PM
To: Dorian Bevec, PhD
Subject: Re: VHF

Dorian,
Es tut mir leid, aber ich habe ein Problem hier und kann nicht telefonieren. Vielleicht koennen wir am Donnerstag miteinander sprechen.

Heinz

From: Dorian Bevec, PhD [mailto:dorian.bevec@therametrics.com]
Sent: Saturday, September 20, 2014 11:12 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: VHF

Hallo Heinz,
wenn Du hier den Anweisungen folgst, dann können wir praktisch gratis miteinander reden in guter Qualität, wenn es nicht klappt rufe ich Dich an.
Bis Dienstag, greetings,
Dorian

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 4:03 PM
To: 'Warren Marcus'; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Seeking research help from Ebola expert

That sounds doable.

From: Warren Marcus [<mailto:warrenmarcus@altorbioscience.com>]
Sent: Tuesday, September 23, 2014 8:59 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Seeking research help from Ebola expert

Hello Dr. Feldmann,

I just spoke to our CEO, Hing Wong, since the baboon experiments were performed before I came to Altor. He said that continuous infusion was used by Dr. Welty because she was following a protocol from previous experiments. Those experiments used compounds that were not stable and had short half-lives, Redacted by agreement

Redacted by agreement

Redacted by agreement

Is there interest to perform this study?

Thanks,
Warren

From: Feldmann, Heinrich (NIH/NIAID) [E] [<mailto:feldmannh@niaid.nih.gov>]
Sent: Monday, September 22, 2014 8:32 PM
To: Warren Marcus; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Seeking research help from Ebola expert

Continuous infusion is currently impossible here at RML as we do not have the set-up and have never done it before. If this is the only way to administer the drug I think we would have a problem.

From: Warren Marcus [<mailto:warrenmarcus@altorbioscience.com>]
Sent: Sunday, September 21, 2014 5:57 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert

Thank you very much for forwarding my request, Dr. Feldmann.

Dr. Falzarano,

We have not performed any comparison testing between these two drugs. From what I can tell, the company shifted their focus, and rNAPc2 is not even available anymore.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 3:49 PM
To: Nichol, Stuart T. (CDC/OID/NCEZID); Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); 'feldmannh@niaid.nih.gov'; Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); 'anna.honko@nih.gov'; Geisbert, Tom (tom.geisbert@utmb.edu); Kobinger, Gary (Public Health Agency of Canada)
Cc: Ervin, Elizabeth (CDC/OID/NCEZID) (CTR)
Subject: RE: Ct versus virus isolation

We do not have any good data on this topic. However, in general terms I would support the decision to discharge an asymptomatic person with a blood Ct values of 36 or higher. What would be the consequence at the moment - you keep a healthy person in the ward that is unlikely to be a source of infection for others versus a symptomatic infected person that you return into the community due to a lack of hospital beds. This person is certainly of higher risk for the community.

I am also not sure if NHP experiments on this topic will necessarily tell us what we are facing with human cases. I think we need to test this when we have the time and capacity in the labs in West Africa.

Heinz

-----Original Message-----

From: Nichol, Stuart T. (CDC/OID/NCEZID)
Sent: Tuesday, September 23, 2014 8:47 AM
To: Norwood, David A Jr CIV USARMY MEDCOM USAMRIID (US); 'feldmannh@niaid.nih.gov'; Hensley, Lisa (NIH/NIAID) [E]; Woollen, Neal E LTC USARMY MEDCOM USAMRIID (US); 'anna.honko@nih.gov'; Geisbert, Tom (tom.geisbert@utmb.edu); Kobinger, Gary (Public Health Agency of Canada)
Cc: Ervin, Elizabeth (CDC/OID/NCEZID) (CTR)
Subject: Ct versus virus isolation

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 3:03 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: Gruß aus Washington

I would be willing to do that.

-----Original Message-----

From: Koch Stefan [mailto:stefan.koch@haz.de]
Sent: Tuesday, September 23, 2014 1:55 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Gruß aus Washington

Sehr geehrter Professor Feldmann,

der Madsack-Verlag (Hannoversche Allgemeine Zeitung, aber auch die Oberhessische Presse in Marburg und 20 weitere Zeitungen in Nord- und Ostdeutschland) veröffentlicht am Donnerstag einen Aufruf von Altbundespräsident Horst Köhler zur Ebola-Epidemie.

Diesen Gastbeitrag möchte ich gern mit einem Text aus den USA ergänzen. Könnten wir zu diesem Thema ein kurzes Telefoninterview führen?

Mit freundlichen Grüßen aus DC

Stefan Koch

USA-Korrespondent des Madsack Verlags
phone
202-4362686
office
1627 Minnesota Avenue SE
Washington DC 20020

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 3:00 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: interview - Ebola

Sounds good.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 2:34 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: interview - Ebola

I have not heard back from her and saw that she wrote a story overnight, so I think you can disregard her request.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 6:05 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: interview - Ebola

OK – I will wait.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 6:05 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview - Ebola

I'm a little leery of her and would like to get more details tomorrow. I'll let you know. Bethesda likes her but I'm skeptical because she's fairly new.

On Sep 22, 2014, at 5:57 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Do you want me to go ahead?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 4:18 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview - Ebola

First I've heard of her since July. The one in July was cleared.

On Sep 22, 2014, at 4:02 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Just to confirm – this one was approved, wasn't it?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 11:27 AM
To: Menk, Kay (NIH/NIAID) [E]
Subject: RE: URGENT REQUEST

Thanks

From: Menk, Kay (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 9:13 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: URGENT REQUEST

FYI. This has been forwarded to CDC.
Kay

From: Quarantine Permit Service Office (NIH/ORS)
Sent: Tuesday, September 23, 2014 9:08 AM
To: CDC Import Permit
Cc: Menk, Kay (NIH/NIAID) [E]; Quarantine Permit Service Office (NIH/ORS)
Subject: FW: URGENT REQUEST

To Whom It May Concern,

The NIH Quarantine Permit Service Office (QPSO) requests a CDC Etiologic Agent Import or Transfer Permit (as necessary) for the attached application.

**Please expedite this URGENT request for Import of Biological Agent into the US
This is needed for the Monrovia Ebola outbreak response.**

Please contact NIH QPSO (qpso@mail.nih.gov) for all correspondence involving this application.

Sincerely,

QPSO Staff

Andrew LaClair, SLS ASCP
Division of Occupational Health and Safety
Building 13, Room 3K04
Office: 301-496-2346

Help promote a culture of safety, not silence, by reporting unsafe or unhealthful workplace conditions, anonymously if desired, at <http://www.ors.od.nih.gov/sr/dohs/HealthAndSafety/Pages/Report-of-Unsafe-Condition.aspx>. To receive useful safety and health information, visit <http://www.ors.od.nih.gov/sr/dohs> or join "A HEALTHY SAFE NIH" LISTSERV at <https://list.nih.gov/cgi-bin/wa.exe?A0=ahealthysafenih>.

The attached information may be confidential. It is intended only for the addressee(s) identified above. If you are not the addressee(s), or an employee or agent of the addressee(s), please note that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please destroy and/or permanently delete the information and notify the sender of the error.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 10:47 AM
To: 'Katy Graef'
Subject: Accepted: Call between NIH and BVGH re: Ebola antibody therapeutic

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 23, 2014 8:53 AM
To: 'dorian.bevec@therametrics.com'
Subject: Re: VHF

Sensitivity: Confidential

Dorian,

Es tut mir leid, aber ich habe ein Problem hier und kann nicht telefonieren. Vielleicht koennen wir am Donnerstag miteinander sprechen.

Heinz

From: Dorian Bevec, PhD [mailto:dorian.bevec@therametrics.com]
Sent: Saturday, September 20, 2014 11:12 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: VHF

Hallo Heinz,

wenn Du hier den Anweisungen folgst, dann können wir praktisch gratis miteinander reden in guter Qualität, wenn es nicht klappt rufe ich Dich an.

Bis Dienstag, greetings,

Dorian

Please join my meeting, Sep 23, 2014 at 5:00 PM CEST.

<https://global.gotomeeting.com/join/776564629>

2. Use your microphone and speakers (VoIP) - a headset is recommended. Or, call in using your telephone.

Germany: Personal Info

United States: Personal Info

Access Code: Redacted by agree

Audio PIN: Shown after joining the meeting

Meeting ID: Redacted by agreement

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: Saturday, September 20, 2014 4:14 PM
To: Dorian Bevec, PhD
Subject: RE: VHF

Wirst Du mich anrufen?


Buero: Personal Info

Handy:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 9:02 PM
To: YOSHIHIROKAWAOKA
Cc: HALFMANP@SVM.VETMED.WISC.EDU; neumannng@vetmed.wisc.edu
Subject: RE: Re: short commentary on Ebola
Attachments: Ebola virus commentary Unpublished

Unpublished



>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 8:39 PM
To: 'Thomas Arminio'
Subject: RE: Hello and a question

Glad to hear that you have arrived safely.

The question does not have an easy and simple answer as it depends on what you wish to do with the sample.

Virus isolation: you cannot inactivate - need BSL4.

Serology: best is gamma-irradiation on dry-ice (5 Mrads if considered positive).

Immunofluorescence: 4% paraformaldehyde fixation

RT-PCR: guanidinium-isothiocyanate buffers

We can provide a more detailed protocol when they let you know what they are planning.

Best wishes,
Heinz

-----Original Message-----

From: Thomas Arminio Personal Info
Sent: Monday, September 22, 2014 8:09 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Hello and a question

Hi Heinz,

A question. Can you send me the protocol on how you inactivate clinical samples of Ebola?

There are many questions here in Cuba, especially about the possibility of a case presenting here and a domestic lab needing to inactivate a clinical sample.

Thanks
Thomas

Live Fearlessly

Sent from my iPhone

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 6:32 PM
To: 'Warren Marcus'; Falzarano, Darryl (NIH/NIAID) [F]
Subject: RE: Seeking research help from Ebola expert

Continuous infusion is currently impossible here at RML as we do not have the set-up and have never done it before. If this is the only way to administer the drug I think we would have a problem.

From: Warren Marcus [mailto:warrenmarcus@altorbioscience.com]
Sent: Sunday, September 21, 2014 5:57 PM
To: Falzarano, Darryl (NIH/NIAID) [F]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert

Thank you very much for forwarding my request, Dr. Feldmann.

Dr. Falzarano,

We have not performed any comparison testing between these two drugs. From what I can tell, the company shifted their focus, and rNAPc2 is not even available anymore.

Although there was a small sample size, the 6% survival seen in the untreated historical control group vs. the 33% survival seen in the treatment group was indeed statistically significant ($p=0.0226$). Additionally, they also mentioned, "Since two of the treated animals showed evidence of anaemia, possibly triggered by bleeding from the uterine lining, we postulate that a more aggressive clinical-care strategy—eg, transfusion—would further increase survival rates when used in conjunction with rNAPc2." Historically, anti-tissue factor drugs have had an issue with bleeding as a severe adverse event. However, we are glad to say that ALT-836, which as I mentioned has been used in 142 patients, has not had this SAE. So in this regard, we expect that ALT-836 would be better than rNAPc2.

While both drugs are effectively factor Xa inhibitors, rNAPc2 is a protein that binds to factor Xa with an affinity of 1-10 nM. ALT-836 is an antibody, with an affinity to the factor VIIa/tissue factor complex of 0.1 nM. Therefore it binds its target tighter. (Note: factor VIIa/TF binds to factor X, thus creating factor Xa).

Therefore, although we do not have a side by side comparison of the two drugs, ALT-836 is an antibody that binds its target tighter. It has also been proven safe in humans and has shown no major bleeding episodes.

As for administration, it would likely follow the same route as our previous baboon model (note: cH36 was the previous name of ALT-836):

<http://ajplung.physiology.org/content/ajplung/290/1/L21.full.pdf>

where an iv bolus would be followed by continuous infusion. I would discuss this with our research VP head before finalizing, however, if there is interest. I think there is sufficient anecdotal evidence that ALT-836 will be more effective than rNAPc2 in a NHP Ebola model, and to save time and ultimately garner WHO support, the NHP model will be needed.

Thank you for your response and hope to hear from you soon.

Cheers,
Warren

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 6:18 PM
To: 'Anja.WOLZ@geneva.msf.org'
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt
Subject: RE: Berlin

Anja,
We would like to invite you to present a talk on the Ebola outbreak in West Africa. The presentation is scheduled for Thursday, October 16 in the time from 16:30-17:30h.

Please let us know as soon as possible if you will accept our invitation.

Best wishes and stay safe,
Heinz

-----Original Message-----

From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
Sent: Saturday, September 20, 2014 12:54 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt
Subject: RE: Berlin

Dear Heinz for me it would be no problem to do an presentation but I don't know what is your timing I will be minimum 2 weeks in Liberia (maybe longer depend on the situation) Tell me what you think

Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher,Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de)" <Ilia.Semmler@tmf-ev.de>, Juergen Richt <jricht@vet.k-state.edu>
Date: 20.09.2014 20:23
Subject: RE: Berlin

Dear Anja,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 6:05 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: interview - Ebola

OK – I will wait.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 6:05 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview - Ebola

I'm a little leery of her and would like to get more details tomorrow. I'll let you know. Bethesda likes her but I'm skeptical because she's fairly new.

On Sep 22, 2014, at 5:57 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Do you want me to go ahead?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 4:18 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview - Ebola

First I've heard of her since July. The one in July was cleared.

On Sep 22, 2014, at 4:02 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Just to confirm – this one was approved, wasn't it?

From: julia.belluz@sbnation.com [<mailto:julia.belluz@sbnation.com>] On Behalf Of Julia Belluz
Sent: Monday, September 22, 2014 3:13 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview - Ebola

Hey Heinz
Long time no talk.. I am wondering if there's any chance you're available this evening or tomorrow for a quick call about Ebola?
Have some questions for you.

On Wed, Jul 30, 2014 at 5:56 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Dear Julia,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 6:02 PM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: FW: Touch base for Ebola challenge study

What do you think?

From: Haifeng Song [mailto:Hsong@Novavax.com]
Sent: Monday, September 22, 2014 10:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Touch base for Ebola challenge study

Dear Dr. Feldmann,

This is Haifeng Song, an immunologist from Novavax Inc. in Maryland. I'm writing you for the possibility to collaborate to test our Ebola-nanoparticle vaccine candidate in your virus challenge model (starting from rodents to NHPs). Novavax develops vaccine candidates in insect cell expression system. We have influenza vaccines including pandemic and seasonal Flu vaccines, and RSV vaccines at different stages of clinical trials. In addition, we also develop CoV-MERS vaccine and Ebola vaccine candidates and now try to find collaborator to test our Ebola vaccine in animal model. We would appreciate very much for an opportunity to work together with your team. We can discuss more if you think it is possible.

By the way, we are a frequent collaborator with NIAID for vaccine development.

Thank you very much,

Haifeng

*Haifeng Song, PhD
Senior Manager, Immunology department
Novavax Inc.
20 Firstfield Road
Gaithersburg, MD20878
Phone 240-268-2083*

Confidentiality Notice: This email message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential, proprietary, or privileged information. Any unauthorized review, use, disclosure, or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and you are hereby notified that the copying, use, disclosure, or distribution of any information or materials transmitted in or with this message is strictly prohibited.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 6:01 PM
To: 'Katy Graef'
Cc: Jennifer Dent
Subject: RE: Introduction

Please call that number. In case you do not get me on the phone, please call Personal Info

From: Katy Graef [mailto:kgraef@bvgh.org]
Sent: Monday, September 22, 2014 3:48 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jennifer Dent
Subject: RE: Introduction

Dear Heinz,

3pm on Wednesday works for us. To confirm, this would be 3pm MDT/2pm PDT? We will call you at: Personal Info
unless you would prefer a different phone number.

Thank you very much!

Best wishes,
Katy

Katy M. Graef
kgraef@bvgh.org
206-732-2122

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Monday, September 22, 2014 2:42 PM
To: Katy Graef
Cc: Jennifer Dent
Subject: RE: Introduction

How about Wednesday at 3:00 PM?

From: Katy Graef [mailto:kgraef@bvgh.org]
Sent: Monday, September 22, 2014 2:13 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jennifer Dent
Subject: RE: Introduction

Dear Heinz,

It is very nice to hear from you, too. This week would be perfect to speak with you. Looking at our calendars, we are free on:

Tuesday, Sept. 23rd from 12pm - 5pm PDT (1pm – 6pm MDT)
Wednesday, Sept. 24th from 2pm - 5pm PDT (3pm - 6pm MDT)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 5:57 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: interview - Ebola

Do you want me to go ahead?

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 4:18 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview - Ebola

First I've heard of her since July. The one in July was cleared.

On Sep 22, 2014, at 4:02 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Just to confirm – this one was approved, wasn't it?

From: julia.belluz@sbnation.com [<mailto:julia.belluz@sbnation.com>] On Behalf Of Julia Belluz
Sent: Monday, September 22, 2014 3:13 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview - Ebola

Hey Heinz

Long time no talk.. I am wondering if there's any chance you're available this evening or tomorrow for a quick call about Ebola?

Have some questions for you.

On Wed, Jul 30, 2014 at 5:56 PM, Feldmann, Heinrich (NIH/NIAID) [E]
<feldmannh@niaid.nih.gov> wrote:

Dear Julia,

I was told that you did request an interview with someone from NIAID on Ebola. I just called **Personal Info** but no answer. I assume that you are home as it is 6:00 PM EST. If you get this email, please respond and let me know if you are still interested in the interview and when you wish to do this. I am in the office for another 1.5 hours today. E can also do this tomorrow if it has time.

Sorry for being so late on my response, but I have been on the phone for scheduled interviews all day.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 5:57 PM
To: 'Mikael Klingeborn, Ph.D.'
Subject: RE: [Personal Info] address

Please say hello to [Personal Info]

Best wishes,
Heinz

From: Mikael Klingeborn, Ph.D. [mailto:mikael.klingeborn@duke.edu]
Sent: Monday, September 22, 2014 3:46 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: [Personal Info] address

Thanks Heinz,

[Personal Info] is flying out from The Gambia today and if everything goes smoothly she should be back in North Carolina tomorrow night.

It is great and really important that you have been able to help out with diagnostic and other lab support in Liberia. Hopefully the promised field hospitals from the US and WHO can slow the transmission in the coming months although it doesn't appear to be enough to stop it.

Talk to you soon and I will give [Personal Info] your best wishes.

/Mikael

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Sunday, September 21, 2014 12:56
To: Mikael Klingeborn, Ph.D.
Subject: RE: [Personal Info] - address

Dear Mikael,

Thanks for the email. Great to hear about your future plans [Personal Info] already mentioned it to me when we talked on the phone last time.

I am really glad to hear that [Personal Info] has successfully finished her project and that she and everyone else on her team are safe. I can imagine that it is stressful to live with the fear of something like Ebola.

Liberia is a disaster with Ebola all over the place. I got back 10 days ago but will most likely return in October. We run a lab for the biggest treatment/isolation ward MSF has ever operated during a filovirus outbreak. No idea when this will end.

Looking forward to the card – our postal address is: [Personal Info]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 4:03 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: FW: interview - Ebola

Just to confirm – this one was approved, wasn't it?

From: julia.belluz@sbnation.com [mailto:julia.belluz@sbnation.com] **On Behalf Of** Julia Belluz
Sent: Monday, September 22, 2014 3:13 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview - Ebola

Hey Heinz

Long time no talk.. I am wondering if there's any chance you're available this evening or tomorrow for a quick call about Ebola?

Have some questions for you.

On Wed, Jul 30, 2014 at 5:56 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

Dear Julia,

I was told that you did request an interview with someone from NIAID on Ebola. I just called 857-0269-0658 but no answer. I assume that you are home as it is 6:00 PM EST. If you get this email, please respond and let me know if you are still interested in the interview and when you wish to do this. I am in the office for another 1.5 hours today. E can also do this tomorrow if it has time.

Sorry for being so late on my response, but I have been on the phone for scheduled interviews all day.

Best wishes,

Heinz

Heinz Feldmann, M.D.

Chief, Laboratory of Virology (LV)

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 3:42 PM
To: 'Katy Graef'
Cc: Jennifer Dent
Subject: RE: Introduction

How about Wednesday at 3:00 PM?

From: Katy Graef [mailto:kgraef@bvgh.org]
Sent: Monday, September 22, 2014 2:13 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jennifer Dent
Subject: RE: Introduction

Dear Heinz,

It is very nice to hear from you, too. This week would be perfect to speak with you. Looking at our calendars, we are free on:

Tuesday, Sept. 23rd from 12pm - 5pm PDT (1pm – 6pm MDT)
Wednesday, Sept. 24th from 2pm - 5pm PDT (3pm - 6pm MDT)
Thursday, Sept. 25th 8am - 3pm PDT (9am - 4pm MDT) (with the exception of 11am-12pm PDT/12 – 1pm MDT).

Please let me know if one of these time slots fits with your schedule and I will send out an Outlook invitation. Additionally, if you have a preferred phone number, please let me know.

I suggest during this call we utilize the time to introduce our proposal in more detail, discuss potential project logistics, and answer any questions you might have.

Thank you very much for your response. I look forward to speaking with you soon!

Best wishes,
Katy

Katy M. Graef
kgraef@bvgh.org
206-732-2122

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Thursday, September 18, 2014 6:34 PM
To: Katy Graef
Cc: Jennifer Dent; cstocks@theraclone-sciences.com
Subject: RE: Introduction

Dear Katy,

Good to hear from you. We would be interested in testing monoclonal antibodies and a discussion on this would be good. Perhaps some time next week.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 3:38 PM
To: Jahrling, Peter (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]
Subject: RE: Update: Offer to Pay for NIH Hotel Costs from the U.S. Embassy Monrovia

Wes Carter from the LIBR team mentioned it when we were in Monrovia. No sure if anyone followed up on this.

Heinz

From: Jahrling, Peter (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 2:21 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Pineda, Mark (NIH/NIAID) [E]
Subject: RE: Update: Offer to Pay for NIH Hotel Costs from the U.S. Embassy Monrovia

Heinz,

Our folks are traveling on orders from DTRA and they are covering all expenses. It seems like a reasonable thing for the Embassy to pay hotel expenses for your team but I'm afraid I don't have any insider information.

Peter

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 3:39 PM
To: Pineda, Mark (NIH/NIAID) [E]
Cc: Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Update: Offer to Pay for NIH Hotel Costs from the U.S. Embassy Monrovia

The people on the IRF/USAMRIID team brought this up. Peter – how do your people pay the hotel bill?

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 9:59 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Update: Offer to Pay for NIH Hotel Costs from the U.S. Embassy Monrovia

Heinz:

We are trying to follow up on the question of whether the Embassy would be willing to cover the cost of housing for USG technical staff, as I understand you told Kathy was a possibility. Can you advise from whom you heard this? I ask because none of our contacts seems to be aware of this offer. Please advise.

On another matter, a link to the article about Joseph Fair is attached below.

Sincerely,

MARK

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 3:36 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: Nature interview this week

Sounds good.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 2:53 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: Nature interview this week

Please do plan to do this. To have it cleared I'll tell HHS your message will be:

- Significant advances have been made but much more must be done to prevent another situation like West Africa is experiencing.
- Once the outbreak is under control actual research on the virus is needed to try and determine its genetic makeup in comparison to the other Ebov types; and ultimately to learn how this type entered the West African region; and how it acts in animal models / responds to countermeasures being studied.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:38 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: Nature interview this week

I can do this one if wished. Haven't thought about what to answer. We can discuss if wished.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 10:53 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Nature interview this week

Heinz, do you have time to do this? She is a top, well-respected writer. If you could share a few thoughts with me about how you'd respond, I'll need those for HHS to approve. Thanks

Andrea, Dave, sharing as background, good Qs to think about. I've got another interview request pending with the Toronto Globe-Mail that might involve you as well as Heinz.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 2:15 PM
To: Bloom, Marshall (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: article about winnipeg

Good for Winnipeg.

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:46 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: article about winnipeg

<http://www.brandonsun.com/national/breaking-news/why-winnipeg-how-canadas-national-lab-became-an-ebola-research-powerhouse-275932691.html>

Marshall E. Bloom, M.D.
Associate Director
Division of Intramural Research
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: 406-375-9707
FAX: 406-375-9661
email: mbloom@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 2:14 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: USA Today: New lab incidents fuel fear, safety concerns in Congress

The problem is the IBC minutes as far as I understand. Those minutes are in public domain – any reporter can request them and make a story out of it.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:47 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: USA Today: New lab incidents fuel fear, safety concerns in Congress

I was under the impression that RML consulted with CDC about whether this was a breach of primary containment and was told yes, that we needed to report.

Is that not the case?

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:37 PM
To: Bloom, Marshall (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: RE: USA Today: New lab incidents fuel fear, safety concerns in Congress

The mastomys issue should have never been recorded in any minutes as it was a non-issue. Even CDC thought it wasn't. This was not a release nor was it an escape of containment. People need to learn what to record/report and what not.

Big mistake on our end – hopefully we will learn from it.

Heinz

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 12:34 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: RE: USA Today: New lab incidents fuel fear, safety concerns in Congress

We saw this already.
Not exactly a dispassionate report. Vintage Ed Hammond.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 12:32 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: FW: USA Today: New lab incidents fuel fear, safety concerns in Congress

FYI

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:39 PM
To: Pineda, Mark (NIH/NIAID) [E]
Cc: Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Update: Offer to Pay for NIH Hotel Costs from the U.S. Embassy Monrovia

The people on the IRF/USAMRIID team brought this up. Peter – how do your people pay the hotel bill?

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 9:59 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Update: Offer to Pay for NIH Hotel Costs from the U.S. Embassy Monrovia

Heinz:

We are trying to follow up on the question of whether the Embassy would be willing to cover the cost of housing for USG technical staff, as I understand you told Kathy was a possibility. Can you advise from whom you heard this? I ask because none of our contacts seems to be aware of this offer. Please advise.

On another matter, a link to the article about Joseph Fair is attached below.

Sincerely,

MARK

http://www.washingtonpost.com/world/a-virus-hunter-faces-the-big-one-ebola/2014/09/14/e763cb62-3a07-11e4-8601-97ba88884ffd_story.html

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:38 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: Nature interview this week

I can do this one if wished. Haven't thought about what to answer. We can discuss if wished.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 10:53 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Nature interview this week

Heinz, do you have time to do this? She is a top, well-respected writer. If you could share a few thoughts with me about how you'd respond, I'll need those for HHS to approve. Thanks

Andrea, Dave, sharing as background, good Qs to think about. I've got another interview request pending with the Toronto Globe-Mail that might involve you as well as Heinz.

From: erikacheckhaydennature@gmail.com [<mailto:erikacheckhaydennature@gmail.com>] **On Behalf Of** Erika Hayden
Sent: Thursday, September 18, 2014 12:51 PM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: Re: FW: schedule a time to speak about big questions in Ebola research?

Ken: there are really only three questions:

1. what have we learned about Ebola in the past decade thanks to i.e. biodefense funding
2. what are the most pressing questions - say 3 to 5 - ahead about the virus
3. and what (research?) is needed to answer these.

Any time this week would be fine, and I'm roughly available between 10:30am-8pm Eastern time, though I could talk on an evening or weekend if I can plan at least a day ahead (for childcare). I'm three hours behind you so 10:30am Eastern is about the earliest I can talk.

I had reached out to Gene Olinger but have not heard back.

Erika

Erika Check Hayden
Reporter, Nature
415-403-9025

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:37 PM
To: Bloom, Marshall (NIH/NIAID) [E]; Zoon, Kathryn (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: RE: USA Today: New lab incidents fuel fear, safety concerns in Congress

The mastomys issue should have never been recorded in any minutes as it was a non-issue. Even CDC thought it wasn't. This was not a release nor was it an escape of containment. People need to learn what to record/report and what not.

Big mistake on our end – hopefully we will learn from it.

Heinz

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 12:34 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: RE: USA Today: New lab incidents fuel fear, safety concerns in Congress

We saw this already.
Not exactly a dispassionate report. Vintage Ed Hammond.

From: Zoon, Kathryn (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 12:32 PM
To: Pekoc, Ken (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]; Feldmann, Heinrich (NIH/NIAID) [E]; Elkins, Randy (NIH/NIAID) [E]; Gardner, Don (NIH/NIAID) [E]
Subject: FW: USA Today: New lab incidents fuel fear, safety concerns in Congress

FYI

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:45 PM
To: Zoon, Kathryn (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]; Blaney, Joe (NIH/NIAID) [E]; Hoe, Nancy (NIH/OD/ORS) [E]
Subject: FW: USA Today: New lab incidents fuel fear, safety concerns in Congress

RML is discussed

From: Folkers, Greg (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:45 PM
Subject: USA Today: New lab incidents fuel fear, safety concerns in Congress

New lab incidents fuel fear, safety concerns in Congress

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:32 PM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: RE: Confidential

That's good.

-----Original Message-----

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:05 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Confidential

Redacted by

Cheers, we'll almost done for today.

Sent from my iPhone

> On Sep 22, 2014, at 18:57, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>

> Great - thanks. Was this a response to a potential exposure or a sick person? In the first case they should provide a follow-up sample.

>

> ----- Original Message -----

> From: Munster, Vincent (NIH/NIAID) [E]
> Sent: Monday, September 22, 2014 02:39 PM Eastern Standard Time
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Re: Confidential

>

> Don't know, I guess they contacted MSF.

>

> She was nicely negative for all assays, and the ms2 came up normally, so no Ebola

>

> Sent from my iPhone

>

>> On Sep 22, 2014, at 17:15, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>>

>> Why does it come to you and not to LIBR? Redacted by agreement Let me know about the results if you have the time.

>>

>> -----Original Message-----

>> From: Munster, Vincent (NIH/NIAID) [E]
>> Sent: Monday, September 22, 2014 8:04 AM
>> To: Feldmann, Heinrich (NIH/NIAID) [E]
>> Subject: Confidential

>>

>> Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:29 PM
To: 'Denys, Gerald A'
Cc: Steve Stephens; Peter O'Hanley
Subject: RE: Ebola virus antiviral testing


I am sure it is important but we do not have the time and capacity in the near future.

Best wishes,
Heinz


From: Denys, Gerald A [mailto:gdenys@iupui.edu]
Sent: Monday, September 22, 2014 1:16 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Steve Stephens; Peter O'Hanley
Subject: Ebola virus antiviral testing

Dear Dr. Feldmann,

Redacted by agreement



Redacted by agreement



Regards,

Gerald A. Denys, Ph.D., D(ABMM)
Indiana University School of Medicine
Department of Pathology and Laboratory Medicine
350 West 11th Street, Room 6027B
Indianapolis, IN 46202
P. 317-491-6296
F. 317-491-6649
E-mail; gdenys@iupui.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 1:01 PM
To: Safronetz, David (NIH/NIAID) [E]
Subject: Re: USA Today: New lab incidents fuel fear, safety concerns in Congress

To be expected but the fault lays in our system.

From: Safronetz, David (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 02:55 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: USA Today: New lab incidents fuel fear, safety concerns in Congress

They clearly had more info then I/we thought. The story is, as expected, an over exaggeration of the situation.

d.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 12:41 PM
To: Hoe, Nancy (NIH/OD/ORS) [E]; Bloom, Marshall (NIH/NIAID) [E]; Priola, Sue (NIH/NIAID) [E]; Anderson, Rebecca (NIH/OD/ORS) [C]
Cc: Safronetz, David (NIH/NIAID) [E]; Morgan, Megan (NIH/OD/ORS) [E]
Subject: RE: USA Today: New lab incidents fuel fear, safety concerns in Congress

Really disappointing. Playing into irrational fears. Problem is, now other outlets will think this is a story that they missed or we kept from them ... probably only a matter of time before the local media calls and this becomes a 2-3 day story.

Really annoyed at the secretive tone of the article, yet they state these meeting minutes are all available to the public. And they didn't clarify that we asked CDC if we had to file because we weren't sure it was a breach of primary containment, so we did the right thing and got CDC advice, then filed when they said "yes."

When I explained this last week to three of our CLG members when I met with them/BU folks (thinking the story was coming on Friday), everyone just shrugged and said "no big deal."

Marshall, do you want to enews to staff with an intro note clarifying some of the sensational points, and as a reminder to everyone how much we're under the spotlight. I can draft something if you want.

From: Hoe, Nancy (NIH/OD/ORS) [E]
Sent: Monday, September 22, 2014 12:11 PM
To: Bloom, Marshall (NIH/NIAID) [E]; Pekoc, Ken (NIH/NIAID) [E]; Priola, Sue (NIH/NIAID) [E]; Anderson, Rebecca (NIH/OD/ORS) [C]
Subject: RE: USA Today: New lab incidents fuel fear, safety concerns in Congress

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 12:58 PM
To: Munster, Vincent (NIH/NIAID) [E]
Subject: Re: Confidential

Great - thanks. Was this a response to a potential exposure or a sick person? In the first case they should provide a follow-up sample.

----- Original Message -----

From: Munster, Vincent (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 02:39 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Confidential

Don't know, I guess they contacted MSF.

She was nicely negative for all assays, and the ms2 came up normally, so no Ebola

Sent from my iPhone

> On Sep 22, 2014, at 17:15, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

>

> Why does it come to you and not to LIBR? Personal Info Let me know about the results if you have the time.

>

> -----Original Message-----

> From: Munster, Vincent (NIH/NIAID) [E]
> Sent: Monday, September 22, 2014 8:04 AM
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: Confidential

>

> Hi Heinz,

>

> Redacted by agreement

> I'll keep you posted,

>

> Cheers,

>

> Vincent

>

> Sent from my iPhone

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 11:47 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]; Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Toronto Globe and Mail

Dave, Darryl or Andrea should do this as I am a part of Helen's story.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 01:42 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Marzi, Andrea (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: Toronto Globe and Mail

Heinz, what about this request, story about Canada's research contributions on Ebola over the years. She would like to speak to you and others at RML who worked with you in Winnipeg (Andrea and Dave would be ideal) this week before 5 p.m. on Thursday.

Samples of her work: <http://www.theglobeandmail.com/authors/kelly-grant>

She is aware of Helen's story from the weekend ...

From: Grant, Kelly [mailto:KGrant@globeandmail.com]
Sent: Monday, September 22, 2014 10:44 AM
To: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: Interview request for Dr. Feldmann

Hi Ken:

Thanks for getting back to me. It would be great to speak to both Dr. Feldmann and anyone who worked with him in Winnipeg. I just spoke with my editor and we're now looking at doing a long piece for this Saturday, which means I could do the interview any time before 5 p.m. Thursday. Would the extra time help?

Thanks, Kelly

From: Pekoc, Ken (NIH/NIAID) [E] [mailto:kpekoc@niaid.nih.gov]
Sent: September-22-14 12:38 PM
To: Grant, Kelly
Subject: RE: Interview request for Dr. Feldmann

I can sure check with him, but if he is not available would one of his staff members who worked with him in Winnipeg be an alternative for you?

Since he returned from Liberia he has been trying to catch up on research projects, so he has been doing a few interviews (some on weekends) and trying to delegate some to other members of his research group.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 7:59 AM
To: 'Geisbert, Thomas W.'
Subject: RE: p1 stock

Can you send me a copy (pdf) of that MTA? We may not need a new one.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 22, 2014 6:14 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: p1 stock

Heinz,

Is this something different than the MTA that we already have?

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Saturday, September 20, 2014 5:51 PM
To: Menk, Kay (NIH/NIAID) [E]
Cc: 'Jensen, Victoria M. (CTR)'; Geisbert, Thomas W.
Subject: RE: p1 stock

Kay,

Please prepare a SLA with Vicki Jensen and another one with Tom Geisbert.

Material: Zaire ebolavirus – Guinea strains (passage 1 tissue culture). The material will be used for in vitro and in vivo research studies. No commercial purpose.

Please communicate with Vicki and Tom on the receiver and authoritative person at their end. You may also have this from previous SLAs.

Thanks,
Heinz

From: Jensen, Victoria M. (CTR) [mailto:Victoria.Jensen@NBACC.DHS.GOV]
Sent: Friday, September 19, 2014 2:40 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: p1 stock

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Monday, September 22, 2014 7:58 AM
To: 'Geisbert, Thomas W.'
Subject: RE: Washington Post

Trying to.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Monday, September 22, 2014 6:33 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Washington Post

I saw the Q&A with you in Science. That was great. Realize we have telecon this morning with Andrea and Gary. Guessing you will be on that?

Tom

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Saturday, September 20, 2014 8:20 AM
To: Geisbert, Thomas W.
Subject: RE: Washington Post

Things are fine. We can talk any time you want.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Friday, September 19, 2014 8:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Washington Post

Is everything OK? Maybe we can talk this weekend.

Sent via the Samsung GALAXY S® 5, an AT&T 4G LTE smartphone

----- Original message -----

From: "Feldmann, Heinrich (NIH/NIAID) [E]"
Date: 09/19/2014 12:18 PM (GMT-06:00)
To: "Geisbert, Thomas W."
Subject: RE: Washington Post

Thanks.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Friday, September 19, 2014 11:10 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Washington Post

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 3:00 PM
To: 'gierhake@gmail.com'
Subject: Re: 14-9

Ich hoffe, dass ich fuer 18:00 Oquito wieder zurueck bin.

From: Klaus Gierhake [mailto:gierhake@gmail.com]
Sent: Sunday, September 21, 2014 01:29 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: 14-9

Hallo Heinz
meine Telefon 00593-2-2446741 Redacted by agreement

Sagen wir zwischen 1700 - 1800 Uhr Quito (das wäre 2400 - 100 Uhr Deutschland... damit Du Deine Zeitzone ausrechnen kannst)

Klaus

Am 21. September 2014 18:57 schrieb Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>:

Klaus,

Ich kann immer noch nicht mit dem Labtop arbeiten. Was war noch mal Deine Telephonnummer? Ich koennte spaeter mal anrufen wenn Du noch nicht unterwegs bist.

Gruss,

Heinz

From: Klaus Gierhake [mailto:gierhake@gmail.com]
Sent: Tuesday, September 16, 2014 9:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: 14-9

Hallo Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 2:31 PM
To: 'honey@uw.edu'
Subject: Re: GREAT interview with SCIENCE!

We have to clarify the IP and ethics issues first before we can send out any material.

Heinz

From: Michael G. Katze [mailto:honey@uw.edu]
Sent: Sunday, September 21, 2014 01:31 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: GREAT interview with SCIENCE!

I will take my chances Herr Professor. It will be cool to do genomics. Please?

Michael G. Katze

Professor of Microbiology

University of Washington

KATZE LAB WEB PAGE

<http://viromics.washington.edu>

From: <Feldmann>, Feldmannh <feldmannh@niaid.nih.gov>
Date: Sunday, September 21, 2014 at 9:30 AM
To: Michael Katze <honey@uw.edu>
Subject: RE: GREAT interview with SCIENCE!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 2:28 PM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: Re: Seeking research help from Ebola expert

Do you want to talk to them? In was thinking of combined therapy.

Heinz

From: Falzarano, Darryl (NIH/NIAID) [F]
Sent: Sunday, September 21, 2014 02:25 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Seeking research help from Ebola expert

I think it probably suffers the same fate as rNAPc2 but a little more information may be useful.

And yes I am back.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:59 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: FW: Seeking research help from Ebola expert
Importance: High

I may have sent this to you already – what do you think? Are you back in Hamilton?

Heinz

From: Warren Marcus [mailto:warrenmarcus@altorbioscience.com]
Sent: Tuesday, September 16, 2014 9:27 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Seeking research help from Ebola expert
Importance: High

Dear Dr. Feldmann,

As I'm sure you are aware, there is a an extremely heartbreaking outbreak of Ebola occurring in West Africa right now. Here at Altor, we strongly believe that we have a treatment that would offer a major clinical benefit to those dealing with the infection. We have reached out to the World Health Organization, and after explaining the mechanism of action of our drug, they are encouraged but will not offer full support behind it since we do not have a NHP model using it.

Redacted by agreement

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 2:27 PM
To: 'gvogel@aaas.org'
Subject: Re: Ebola in Guinea

140 ul of whole blood for the assays we are running. The volume may change depending on the assay.

Thanks,
Heinz

From: Gretchen Vogel [mailto:gvogel@aaas.org]
Sent: Sunday, September 21, 2014 03:14 PM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola in Guinea

Thanks again for your time today! One question I forgot to ask: How much blood does the PCR test require?

Here is the newspaper piece that I mentioned:

<http://www.thueringer-allgemeine.de/startseite/detail/-/specific/Z0R0003737334>

All the best,
Gretchen

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Saturday, September 20, 2014 3:34 PM
To: Gretchen Vogel
Subject: RE: Ebola in Guinea

I was away for the afternoon and evening yesterday. If you still want to talk, please let me know when and what number to call.

From: Gretchen Vogel [mailto:gvogel@aaas.org]
Sent: Friday, September 19, 2014 9:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola in Guinea

Dear Dr. Feldmann,

Thank you for all the help you have been to Science's Ebola coverage already. The interview that Kai did was very interesting.

I'm afraid I have yet another request: I'm working on a piece that explores why it's hard to make a rapid diagnostic test for Ebola, one you could use in remote villages so you wouldn't have to transport samples back to a lab. A couple of people said you'd be able to contribute some helpful thoughts. Any chance you'd have time to talk later today (evening, my time)?

Thanks very much,

Gretchen Vogel

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 11:26 AM
To: 'Joan X. Comella'
Cc: Walczynski, Joyce (NIH/NIAID) [C]
Subject: RE: Invitation Vall d'Hebron Institute of Research - Conference on Ebola - 21 November

Dear Prof. Comella,

First I would like to apologize for not responding on time, but I just returned from Monrovia, Liberia. I also had to check my schedule prior to responding to your kind invitation. The invitation is a big honor to me and it is my great pleasure to accept.

I will copy Joyce on my response who will be working with your administration on travel arrangements. There might be a need for some more information as government foreign travel is highly regulated in the US.

I am looking forward to be part of your exciting celebration.

Best wishes,
Heinz Feldmann

From: Joan X. Comella [mailto:director@vhir.org]
Sent: Friday, September 19, 2014 9:33 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RV: Invitation Vall d'Hebron Institute of Research - Conference on Ebola - 21 November

Dear Prof. Feldmann,

Please, let us know your availability regarding our invitation as soon as possible. It would be an honour for us if you accept.

If you need more information please don't hesitate to contact us.

With kind regards,

Prof. Joan X. Comella MD, PhD
Director
Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
Institut de Neurociències i Departament de Bioquímica i Biologia Molecular
Universitat Autònoma de Barcelona
Passeig de la Vall d'Hebron, 119-129, 2a planta, Ed. Mediterrània
08035 Barcelona
Telèfon: 93 489 41 89
director@vhir.org
<http://www.vhir.org>



Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 11:20 AM
To: 'Helen Branswell'
Subject: RE: my story about the Winnipeg lab

It is a great story - I like it, I also like Harvey's involvement who's input get forgotten at times.
Heinz

-----Original Message-----

From: Helen Branswell [mailto:Helen.Branswell@thecanadianpress.com]
Sent: Sunday, September 21, 2014 11:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: my story about the Winnipeg lab

Hi. This is the story I wrote. It just went out so should start appearing on websites the afternoon.
I hope I haven't embarrassed you! Thanks again for your time.
Best,
Helen

Forwarded from The Canadian Press Staff by user HB

Why Winnipeg? How Canada's national lab became an Ebola research powerhouse (Ebola-Canada-Research) Sep 21 12:58 - CP - The Canadian Press

By Helen Branswell

THE CANADIAN PRESS

TORONTO _ When Dr. Frank Plummer talks about the first experimental Ebola drug used in an outbreak, he pronounces it ``Zed Map."

``I do it consciously," says Plummer, who retired this year after serving for nearly 14 years as the head of Canada's National Microbiology Laboratory in Winnipeg.

The rest of the world says the first letter of the drug ZMapp the way Americans do, calling the concoction of three Ebola antibodies ``Zee Map." But the cocktail was created in Winnipeg and Plummer thinks the name of a made-in-Canada drug ought to pronounced the Canadian way.

Winnipeg. Half a world away from the countries in Africa where Ebola, and its viral cousin, Marburg, occasionally slip out of their animal reservoir to start infecting and killing people, as Ebola is now doing in West Africa.

They are two of the worst viruses known to humankind, as evidenced by the current outbreak, which has infected at least 5,335 people and killed at least 2,622. To date, fortunately, there has never been a case of either viral hemorrhagic fever infections within Canadian borders.

So why then is Canada's national lab an Ebola research powerhouse? Why is a facility on the edge of the Prairies, near North America's longitudinal centre, the site from whence some of the most promising Ebola research emanates?

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 11:01 AM
To: Marzi, Andrea (NIH/NIAID) [E]
Subject: FW: ebola testing

Are you interested or not?

From: Jan Balzarini [mailto:Jan.Balzarini@rega.kuleuven.be]
Sent: Thursday, September 18, 2014 4:20 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: ebola testing

Dear Dr. Feldmann,

We have a few compounds that may be active against Ebola virus by blocking entry of the virus in its target cells. The compounds may also block DC SIGN directed capture of Ebola virus particles. These assumptions are based on our findings on HIV inhibitory effects of the compounds we obtained . Therefore, I believe it would be very important to have these compounds tested in your in vitro models. For a few compounds, we might have enough to perform mice experiments if the data in vitro look promising. One of the compounds have been tested many years ago in patients (for an entirely different pathogen), and thus, such a compound, IF active in your models , might be a good candidate for accelerated clinical administration.

I would therefore be grateful if you could perform testing of these compounds in your laboratories. Please let me know if you are interested in,

Best regards,

Yours Sincerely,

Jan Balzarini

ps , I ever talked about such testing with Andrea Marzi several years agobut I never sent the compounds to her for testing. Hope she still remembers me.

Prof. Jan Balzarini
Rega Institute for Medical Research
Laboratory of Virology and Chemotherapy
Minderbroedersstraat 10
B 3000 Leuven, Belgium
Tel : 32 16 337352 (office)
32 16 337367 (secretary)
Fax : 32 16 337340

Be a virus, see the world

There is no greater impotence in all the world like knowing you are right and that the wave of the world is wrong, yet the wave crashes upon you. - Norman Mailer

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 11:00 AM
To: 'Khan, Ali S'
Subject: RE: Redacted by agreement

I talked to Armand Sprecher from MSF Belgium; they are skeptical but interested.

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Wednesday, September 17, 2014 8:36 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Redacted by agreement

Yes. We would need infrastructure. Do you think they will support?
Chat soon.
Ali

* UNMC College of Public Health
Bringing innovative solutions to
healthier communities in Nebraska
and worldwide

On Sep 17, 2014, at 9:02 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Ali,

Sorry for the delay in getting back to you. Thanks for the information – this is very helpful. I am excited about the good news from the patient – this is fantastic.

Let me know when you have time to discuss the plasma trial in Liberia. Would it be good to involve MSF as they manage the patients?

Best wishes,
Heinz

From: Khan, Ali S [mailto:ali.khan@unmc.edu]
Sent: Sunday, September 14, 2014 4:12 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Redacted by agreement

Hi! Glad you are back safely.
Routine clinical testing in our own labs.
Sent 3 samples to CDC for viral load. Rest here waiting for a full testing plan.

Redacted by agreement
Convalescent plasma and RNA product.

Let's chat about a conv plasma to other trial in Liberia. I think I can put together a clinical team from here.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:59 AM
To: Falzarano, Darryl (NIH/NIAID) [F]
Subject: FW: Seeking research help from Ebola expert

Importance: High

I may have sent this to you already – what do you think? Are you back in Hamilton?


Heinz

From: Warren Marcus [mailto:warrenmarcus@altorbioscience.com]
Sent: Tuesday, September 16, 2014 9:27 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Seeking research help from Ebola expert
Importance: High

Dear Dr. Feldmann,

As I'm sure you are aware, there is a an extremely heartbreaking outbreak of Ebola occurring in West Africa right now. Here at Altor, we strongly believe that we have a treatment that would offer a major clinical benefit to those dealing with the infection. We have reached out to the World Health Organization, and after explaining the mechanism of action of our drug, they are encouraged but will not offer full support behind it since we do not have a NHP model using it.

Redacted by agreement



Since we are a small company with no revenue, all of our capital is already earmarked to further our oncology drugs. I reached out to the NIAID to see if there was some rapid funding mechanism in place to support this study, as I planned to contact Dr. Geisbert (who I assume you probably know) to perform the studies. However, Natalia Kruchinin, an SBIR coordinator there at NIAID suggested that I contact you.

We currently have over 100 vials available and ready to ship to help out at least the medical community trying to combat the crisis. WHO support would be essential for this to happen, however. Therefore is it possible to collaborate with you and your lab to perform these studies, which would likely lead to this support?

Thank you for your time and hope to hear from you soon.

Best regards,

Warren D. Marcus, Ph.D.
Scientist
Business Development Associate

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:57 AM
To: 'Klaus Gierhake'
Subject: RE: 14-9

Klaus,

Ich kann immer noch nicht mit dem Laptop arbeiten. Was war noch mal Deine Telephonnummer? Ich koennte spaeter mal anrufen wenn Du noch nicht unterwegs bist.

Gruss,
Heinz

From: Klaus Gierhake [mailto:[Personal Info](#)]
Sent: Tuesday, September 16, 2014 9:52 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: 14-9

Hallo Heinz
ich bin morgen bis ca Mittag zu Hause, dann wieder abends
Immerhin zeigt Skype immer wieder das Zeichen "R Feldmann erreichbar" .

Afrika / Ebola - es ist wohl für Außenstehende gar nicht zu begreifen, was dort passiert

Nächste Woche fliege ich nach Mexico - mein Projekt dort zu diskutieren

Klaus

Am 16. September 2014 17:20 schrieb Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>:

Ich bin zurueck – versuch Dich morgen mal anzurufen. Nicht sicher ob ich skypen kann da unser Laptop nicht mehr funktioniert.

Gruss,

Heinz

From: Klaus Gierhake [mailto:[Personal Info](#)]
Sent: Sunday, September 14, 2014 7:48 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: 14-9

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:56 AM
To: 'Mikael Klingeborn'
Subject: RE: [Personal Info] - address

Dear Mikael,

Thanks for the email. Great to hear about your future plans. [Person] already mentioned it to me when we talked on the phone last time.

I am really glad to hear that [Personal] has successfully finished her project and that she and everyone else on her team are safe. I can imagine that it is stressful to live with the fear of something like Ebola.

Liberia is a disaster with Ebola all over the place. I got back 10 days ago but will most likely return in October. We run a lab for the biggest treatment/isolation ward MSF has ever operated during a filovirus outbreak. No idea when this will end.

Looking forward to the card – our postal address is: [Personal Info]

Best wishes and say hello to [Persona]
Heinz

From: Mikael Klingeborn [mailto:mikael.klingeborn@duke.edu]
Sent: Tuesday, September 16, 2014 11:26 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: [Personal Info] - address

Dear Heinz,

I hope all is well with you. Are you and part of your lab still in Liberia? Hopefully you have been able to help out and get useful samples and data too. Sounds like it is somewhat chaotic in Liberia at the moment.

On a very different subject: [Personal Info]

[Personal Info]

Thanks and talk soon,
Mikael

PS. [Personal Info] is coming back to the US next week and she was able to collect data on all of the bleedings throughout the iron supplementation trial she was following. With that EVD case in Dakar recently it looks like its edging closer to Gambia so it is good that she was able to finish for the time being. DS.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:50 AM
To: 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt; Lothar.Wieler@fu-berlin.de
Subject: RE: Berlin

What do you want me to do? Invite her or not? What again was the day of the talk - October?

Best wishes,
Heinz

-----Original Message-----

From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
Sent: Saturday, September 20, 2014 12:54 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt
Subject: RE: Berlin

Dear Heinz for me it would be no problem to do an presentation but I don't know what is your timing I will be minimum 2 weeks in Liberia (maybe longer depend on the situation) Tell me what you think

Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
To: "'Anja.WOLZ@geneva.msf.org'" <Anja.WOLZ@geneva.msf.org>
Cc: "Sprecher,Armand (Médecins Sans Frontières Operational Center of Brussels)" <armand.sprecher@brussels.msf.org>, "'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de)" <Ilia.Semmler@tmf-ev.de>, Juergen Richt <jricht@vet.k-state.edu>
Date: 20.09.2014 20:23
Subject: RE: Berlin

Dear Anja,

I got in contact with the committee. We would like to ask you if you are able and willing to present on the current Ebola outbreak in West Africa from the perspective of MSF - patient management etc. Ilia will be involved in any further arrangements.

Please let us know as soon as possible. I realize that you are in Liberia at the moment.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:48 AM
To: Kindrachuk, Jason (NIH/NIAID) [C]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: SOP

I did send Peter and Mike Holbrook the data in form of a poster which was presented at the Filovirus meeting in Galveston. You may have to convince USAMRIID as well.

In former days (Winnipeg) we always removed the specimen in AVL buffer and never had a problem with it. When CDC questioned the inactivation potency of AVL we did the safety testing. Unfortunately, we indeed had break-through with the AVL only; after adding the ethanol the samples were always completely inactivated.

Best wishes,
Heinz

From: Kindrachuk, Jason (NIH/NIAID) [C]
Sent: Sunday, September 21, 2014 10:44 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: SOP

Fantastic Heinz, that definitely helps. I don't know how well I'll be able to sell this to those back home but based on the constraints of our space and increasing sample numbers I think that this would be a logical approach moving forward.
Cheers,
Jason

--
Jason Kindrachuk, PhD
Principal Research Scientist
Supporting the Integrated Research Facility
NIAID Division of Clinical Research
8200 Research Plaza, Fort Detrick
Frederick, MD, USA, 21703
Phone: (301) 631-7256
Email: kindrachuk.kenneth@nih.gov

The contents of this electronic communication may be confidential by law and cannot be released to an unauthorized person. This communication is only for the intended recipient. You may not forward or otherwise distribute this communication or its contents without my express authorization. If you are not the intended recipient or have otherwise received this in error, please notify me and delete this communication and any attachments immediately.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 12:42 PM
To: Kindrachuk, Jason (NIH/NIAID) [C]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: SOP

Jason,
As you might know we are using a glove box for the infectious work. Whole blood samples will be handled in the glove box as follows:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:45 AM
To: 'Vincent Racaniello'
Subject: RE: American Society for Virology

Vincent,

Looking forward to the meeting. I really enjoyed your commentary on the potential aerosol transmissibility of Ebola. This was much needed and coming from someone like you will weigh much more. The field really appreciates your comment and insight. People like Osterholm sometimes do more harm than good.

Best wishes, Heinz

-----Original Message-----

From: Vincent Racaniello [mailto:vr1@columbia.edu]
Sent: Thursday, September 18, 2014 7:45 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: American Society for Virology

Dear Heinz,

I'm so glad you can make it. I'll have more information about the meeting next year.

No problem missing me at RML, I fully understand. I had a great visit.

Vincent

On Sep 18, 2014, at 9:00 PM, Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov> wrote:

> Dear Vincent,
>
> Got back a few days ago from Monrovia - sorry for not responding but I hadn't gone through all my emails.
>
> I feel delighted and honored by the invitation and it is my great pleasure to accept.
>
> I also wanted to let you know that I felt terrible for missing you when you came to RML. I
>
> Many thanks and best wishes,
> Heinz
>
>
> -----Original Message-----
> From: Vincent Racaniello [mailto:vr1@columbia.edu]
> Sent: Thursday, September 18, 2014 2:00 PM
> To: Feldmann, Heinrich (NIH/NIAID) [E]
> Subject: American Society for Virology

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:42 AM
To: Kindrachuk, Jason (NIH/NIAID) [C]; Safronetz, David (NIH/NIAID) [E]
Subject: RE: SOP

Jason,

As you might know we are using a glove box for the infectious work. Whole blood samples will be handled in the glove box as follows:

- (1) Log-in of sample
- (2) Aliquot 1 ml into a 2 ml cryo tube.
- (3) Take 140 ul of whole blood and add to 560 ul of pre-aliquoted AVL buffer (QIAGEN kit – same than you are using) (make sure you pipet the blood into the solution to avoid contamination of the tube wall)
- (4) Wait 10 minutes
- (5) Take the entire 700 ul and transfer into ethanol (make sure you pipet the solution into the ethanol to avoid potential contamination of the tube wall)
- (6) Shake well and transfer into bleach dunk tank
- (7) Wait 10 minutes and remove from glove box
- (8) The remaining steps of the protocol are done under BSL2 conditions using a face shield to protect mucosal membranes and eyes for splashes

Note, AVL and ethanol are pre-aliquoted into tubes (2 ml cryo tubes) with different colored lids to avoid errors during pipetting

We have safety tested the procedure using in vitro (tissue culture) and in vivo systems (mouse model). It is safe to remove after the ethanol step but not prior to the ethanol step.

Hope this helps,
Heinz

From: Kindrachuk, Jason (NIH/NIAID) [C]
Sent: Friday, September 19, 2014 2:56 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Safronetz, David (NIH/NIAID) [E]
Subject: SOP

Morning Heinz and Dave,

Vincent had mentioned that one of you may have an SOP for the inactivation of Ebola virus following addition of sample to AVL and ethanol. We're trying to figure out a way to streamline our sample processing here and minimize our time in PAPRs in the lab. Right now we're performing the entire extraction procedure and setting up our qPCR plates within the containment section of our lab and then bringing the plates out to the cold side to run on the ABI. With only two of us in the lab on our current team it would likely increase our output if there's a way to get samples out of the suite faster than what we're doing with our current method and we've seen a spike this week in the number of samples we're receiving daily (well over 100 yesterday).

Thanks in advance for any insight you might have,
Jason

--

Jason Kindrachuk, PhD
Principal Research Scientist
Supporting the Integrated Research Facility
NIAID Division of Clinical Research

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 10:31 AM
To: 'Michael G. Katze'
Subject: RE: GREAT interview with SCIENCE!

I am assuming you talk about the Guinea strain experiment, correct? This was a pilot study comparing Mayinga '76 versus Guinea '14 strains (3 animals each). We reused animals from previous depletion studies which could have impacted on the outcome even though we did not see any obvious issue. In this experiment both infections were lethal with the Mayinga '76 animals euthanized at day 5-6 and the Guinea '14 animals at day 7-8. The biggest difference was an increased lung gross pathology with the Guinea strain.

Not sure how helpful genomics will be on this set of animals. We are currently not considering publication. The follow-up experiment is a vaccine one testing time to immunity in NHPs. We haven't decided what strain to use for challenge in that experiment.

Heinz

From: Michael G. Katze [mailto:honey@uw.edu]
Sent: Sunday, September 21, 2014 8:18 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: GREAT interview with SCIENCE!

Something like that would be perfect for our text!

Any progress on Andrea's NHP-Ebola experiment? Want us to analyze the RNA?

Is the virus attenuated as you suggest?

Michael G. Katze
Professor of Microbiology
University of Washington
KATZE LAB WEB PAGE
<http://viromics.washington.edu>

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 9:28 AM
To: 'Erwin Duizer'; becker@staff.uni-marburg.de; guenther@bni.uni-hamburg.de; Swanepoel, Bob (Africa/NICD); m.koopmans@erasmusmc.nl
Cc: Ana Maria de Roda Husman
Subject: RE: ebolavirus in stool: is it infectious?

We cannot help here as we do not have any data regarding the listed questions.

Sorry - best wishes,
Heinz

From: Erwin Duizer [mailto:erwin.duizer@rivm.nl]
Sent: Friday, September 19, 2014 7:07 AM
To: becker@staff.uni-marburg.de; guenther@bni.uni-hamburg.de; Swanepoel, Bob (Africa/NICD); Feldmann, Heinrich (NIH/NIAID) [E]; m.koopmans@erasmusmc.nl
Cc: Ana Maria de Roda Husman
Subject: ebolavirus in stool: is it infectious?

Dear all,

For the WHO Collaborating Centre for Risk Assessment of Pathogens in Water and Food we are working on a document on potential transmission of ebolavirus through excreta, waste water and grey water.

We wish to compile data on stability and likelihood of transmission by these water-routes. We have performed a literature review that did yield some information but some rather basic questions remain.

1/ Has ebolavirus been cultured from stool? (ie is it still infectious in stool, have culture been attempted at all in stool, and or has stool been shown to be a source of infection?)
In the paper by Bausch et al, 4 stools were analyzed but no growth was shown.

2/ Has there ever before, or during this current outbreak, been an indication that water/sewage was involved in the transmission? Was it studied or not considered at all?

3/ Is anything known about the survival of ebolavirus under real life (ie aerobic non sterile) conditions in water/sewage?

We are looking for additional and/or not yet published data. All data submitted will be treated confidential, the purpose is merely to make a guidance document for excreta and wastewater management.

Hoping for you collaboration,

Kind regards,

Ana Maria de Roda Husman and Erwin Duizer,
Centre for Infectious Diseases, The Netherlands and

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 9:20 AM
To: 'JAN WINETZ'; Roger Vertrees
Cc: Jan Winetz
Subject: RE: conference call re hyperthermia treatment for ebola virus

Call me in the office at 406-375-7410. If that does not work – try the BB phone Personal Info

From: JAN WINETZ [mailto:Personal Info]
Sent: Saturday, September 20, 2014 7:56 PM
To: Roger Vertrees
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Jan Winetz
Subject: Re: conference call re hyperthermia treatment for ebola virus

That would be 9 o'clock Pacific time on Wednesday and that will work well for me

Sent from my iPhone

On Sep 20, 2014, at 4:28 PM, Roger Vertrees <roger@verthermia.com> wrote:

Works for me. Tlx

Jan?

Sent from my iPhone

On Sep 20, 2014, at 1:30 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

How about Wednesday at 10:00 AM MST?

Heinz

From: Roger Vertrees [<mailto:roger@verthermia.com>]
Sent: Thursday, September 18, 2014 1:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jan Winetz; Roger Vertrees
Subject: conference call re hyperthermia treatment for ebola virus

Sir,

You requested that I contact you in the second half of Sept. If at all possible we would like to schedule a conference call with you at your convenience for some day next week (Sept 22-26). Please choose a time that is best for you and we will accommodate.

Thanks

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 9:16 AM
To: 'Samy, Abdallah Mohammed'
Subject: RE: Ebola question

Good work but largely speculation. This is not my field of expertise – cannot say anything to environmental factors. Of course, they will have a certain degree of influence on many infectious diseases in the tropics and subtropics. I am not a discussion partner on these issues.

Best wishes and good luck with your work,
Heinz

From: Samy, Abdallah Mohammed [mailto:samy@ku.edu]
Sent: Saturday, September 20, 2014 7:10 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola question

Then! how you can explain the distinct predictability of several outbreaks to each other. For example, if you used the previous outbreak data and a time-specific data, it will refer to the outbreak of 2014 and vice *versa*. Also, what is your comment about the new article published by Eurosurveillance <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20892>. Your comments will be appreciated and will be interesting for my research. Thanks.

Cheers
AMS

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Saturday, September 20, 2014 5:44 PM
To: Samy, Abdallah Mohammed
Subject: RE: Ebola question

Hard to say – the main transmission route is through direct contact with patients, patient fluids and deceased people.

From: Personal Info On Behalf Of Abdallah Samy
Sent: Sunday, August 24, 2014 11:19 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola question

Hello Dr. Feldman;
I read your article on the New England Journal of Medicine on ebola with interest. It is really amazing article that provide some good information about past and current ebola outbreaks. I am wondering if you see if there are environmental factors that contribute the current disease outbreak? do you see any environmental associations between the outbreaks sites. I will be happy to receive your response.

Best regards
Abdallah

Abdallah M. Samy
Member of ASTMH, and ISID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 9:12 AM
To: Shupert, W. Lesley (NIH/NIAID) [E]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: RE: Query

Thanks – please provide an update to Glenn Marsh if you don't mind.

From: Shupert, W. Lesley (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 6:50 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Feldmann, Ricki (NIH/NIAID) [C]
Subject: Re: Query

Have been working with Adam Clarkson for the permit from Commerce Dept. They just called this week with questions so it is moving forward.

Led

On Sep 20, 2014, at 4:46 PM, "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> wrote:

Has this been shipped?

From: Glenn.Marsh@csiro.au [<mailto:Glenn.Marsh@csiro.au>]
Sent: Sunday, August 24, 2014 4:12 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Query

Thanks Heinz,

I have attached an import permit that will permit this (same permit from the original isolates that you sent to us). This is all that we need on this end. Is there some one at RML I can contact to start the process for n MTA and the paperwork on the US end?

Best wishes and stay safe in Liberia

Glenn

From: <Feldmann>, Heinrich Feldmann <feldmannh@niaid.nih.gov>
Date: Sunday, 24 August 2014 7:40 pm
To: Glenn Marsh <Glenn.Marsh@csiro.au>
Subject: Re: Query

We have a mouse and guinea pig adapted version of Zaire ebolavirus based on Mayinga (1976). The rodent models are a good start but with low predictive value for efficacy in NHPs - guinea pig better than mouse. You can also use IFNR knockouts for wildtype viruses (non-adapted) but I don't like the

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 9:11 AM
To: Pekoc, Ken (NIH/NIAID) [E]; 'Achenbach, Joel L'
Subject: RE: photos?

I would appreciate if you could make use of the group photo as this shows best the joint effort in laboratory response. I would not like you to use the personal photos. The other two photos are from the isolation ward – not sure if we need permission from MSF to show them.

Heinz

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 6:45 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'Achenbach, Joel L'
Subject: RE: photos?

Joel, here are a few others that I received from a member of Dr. Feldmann's deployment group. He can provide descriptions as needed; I don't have the caption information with me at home.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:41 PM
To: 'Achenbach, Joel L'
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: photos?

Dear Joel,

Please find attached a photo showing the entire Lab team supporting ELWA hospital. This is one of two current foreign Lab teams in Monrovia. The other team is supported by the NIAID/USAMRIID.

From left to right: bottom row: Barry Fields, CDC Nairobi, Kenya), Clayton Onyango (CDC, Nairobi, Kenya) and David Safronetz (LV, DIR, NIAID). Upper row: Heinz Feldmann (LV, DIR, NIAID) and Andrea Marzi (LV, DIR, NIAID)

Ken – please feel free to provide a different photo if you have a better or more appropriate one. Please inform me prior to publishing any photo so that I can inform the colleagues.

We stay at a Resort Hotel about 10 minutes away from the ELWA hospital complex (don't want to name the place – it should not matter for the story.

We eat from the menu of the restaurant – food is safe and good.

We work as long as needed - a common work day is about 10-11 hours.

We have our own US embassy vehicle with a driver that stays with us all day.

We work under the CDC leadership in the country (lead at the time we were there: Joel Montgomery, CDC, Nairobi, Kenya). Our customers are almost exclusively ELWA2 (run by the ELWA hospital operation) and ELWA3 (run by MSF). Liberian counterparts are the Ministry of Health and other Ministries of the Liberian government.

Best wishes,
Heinz

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 9:06 AM
To: Fischer, Elizabeth (NIH/NIAID) [E]; Munster, Vincent (NIH/NIAID) [E]; Fischer, Robert (NIH/NIAID) [F]; De wit, Emmie (NIH/NIAID) [E]; Bushmaker, Trenton (NIH/NIAID) [E]; Cara Ryan; Feldmann, Ricki (NIH/NIAID) [C]
Subject: RE: a happy "nugget"

Great video.

-----Original Message-----

From: Fischer, Elizabeth (NIH/NIAID) [E]
Sent: Sunday, September 21, 2014 7:19 AM
To: Munster, Vincent (NIH/NIAID) [E]; Fischer, Robert (NIH/NIAID) [F]; De wit, Emmie (NIH/NIAID) [E]; Bushmaker, Trenton (NIH/NIAID) [E]; Cara Ryan; Feldmann, Ricki (NIH/NIAID) [C]; Feldmann, Heinrich (NIH/NIAID) [E]
Subject: a happy "nugget"

<http://www.npr.org/blogs/goatsandsoda/2014/09/20/349975149/watch-the-boy-who-danced-in-the-face-of-ebola>

Keep up the good work guys!

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:57 PM
To: Holbrook, Michael (NIH/NIAID) [C]
Subject: FW: Inactivation & Removal of BSL-4 Select Agents from Containment
Attachments: galveston 2014 newer.pdf

FYI

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:57 PM
To: Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Inactivation & Removal of BSL-4 Select Agents from Containment

Please find attached the remaining of the safety testing. This was presented at the filovirus meeting in Galveston. Again, we are still planning to publish all the results.

Best wishes,
Heinz

From: Jahrling, Peter (NIH/NIAID) [E]
Sent: Tuesday, September 16, 2014 9:29 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Inactivation & Removal of BSL-4 Select Agents from Containment
Importance: High

Dear Heinz,

The DSAT program is going to tip me over the edge very soon. We need to start drug screens for Ebola as directed by our scientific steering committee and Debbie insists we use validated protocols for trizol extraction. Could you please share the details of your protocol so we don't reinvent the wheel and get started without going to jail? I would really appreciate it. Also, if you have cobalt irradiation data for Ebola, that might give us a leg up on that process as well. Thank you.

Peter

From: Barr, Jason (NIH/OD/ORS) [E]
Sent: Tuesday, September 16, 2014 11:17 AM
To: Jahrling, Peter (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]
Cc: Flint, Kelly (NIH/OD/ORS) [E]; Ragan, Angela (NIH/OD/ORS) [E]
Subject: FW: Inactivation & Removal of BSL-4 Select Agents from Containment

FYI. When Nancy says "we are not requiring the IBC to review the data", she means the sterility/safety/validation testing. They do review and approve the inactivation SOPs.

From: Hoe, Nancy (NIH/OD/ORS) [E]
Sent: Tuesday, September 16, 2014 11:01 AM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:57 PM
To: Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Inactivation & Removal of BSL-4 Select Agents from Containment
Attachments: galveston 2014 newer.pdf

Please find attached the remaining of the safety testing. This was presented at the filovirus meeting in Galveston. Again, we are still planning to publish all the results.

Best wishes,
Heinz

From: Jahrling, Peter (NIH/NIAID) [E]
Sent: Tuesday, September 16, 2014 9:29 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: FW: Inactivation & Removal of BSL-4 Select Agents from Containment
Importance: High

Dear Heinz,

The DSAT program is going to tip me over the edge very soon. We need to start drug screens for Ebola as directed by our scientific steering committee and Debbie insists we use validated protocols for trizol extraction. Could you please share the details of your protocol so we don't reinvent the wheel and get started without going to jail? I would really appreciate it. Also, if you have cobalt irradiation data for Ebola, that might give us a leg up on that process as well. Thank you.

Peter

From: Barr, Jason (NIH/OD/ORS) [E]
Sent: Tuesday, September 16, 2014 11:17 AM
To: Jahrling, Peter (NIH/NIAID) [E]; Hensley, Lisa (NIH/NIAID) [E]; Olinger, Gene (NIH/NIAID) [C]
Cc: Flint, Kelly (NIH/OD/ORS) [E]; Ragan, Angela (NIH/OD/ORS) [E]
Subject: FW: Inactivation & Removal of BSL-4 Select Agents from Containment

FYI. When Nancy says "we are not requiring the IBC to review the data", she means the sterility/safety/validation testing. They do review and approve the inactivation SOPs.

From: Hoe, Nancy (NIH/OD/ORS) [E]
Sent: Tuesday, September 16, 2014 11:01 AM
To: Barr, Jason (NIH/OD/ORS) [E]; Morgan, Megan (NIH/OD/ORS) [E]
Subject: RE: Inactivation & Removal of BSL-4 Select Agents from Containment

Jason,

I sent the attached email to our PIs about a month ago. We are not requiring the IBC to review the data, just any updated SOPs. I only needed to send the email to the BSL-3 PIs as for BSL-4, Heinz provided DSAT (Christine) with tabulated results of his validation tests as part of an amendment review process. He used Ebola as a representative

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:55 PM
To: 'Pardis Sabeti'
Cc: Feldmann, Ricki (NIH/NIAID) [C]; Robert Garry
Subject: RE: connection at RML
Attachments: galveston 2014 newer.pdf

I see that you already have the poster from the Galveston meeting which shows all the details and results on the inactivation testing. This should be sufficient for getting approval to ship your samples.

Best wishes,
Heinz

From: Pardis Sabeti [mailto:pardis@broadinstitute.org]
Sent: Wednesday, September 17, 2014 11:31 PM
To: Feldmann, Ricki (NIH/NIAID) [C]; Feldmann, Heinrich (NIH/NIAID) [E]; Robert Garry
Subject: Re: connection at RML

Hi Ricki,

I thought I would follow up on my email as I am sure you have many, and also copy Heinz and Bob in case you have any questions or concerns.

As background, we have numerous samples from Nigeria already in AVL and ethanol, and in Sierra Leone in AVL where ethanol can be added. We have obtained ethical approvals to ship these samples, and have them prepared to send. However, we have been held up with those questions raised on AVL. We have figured out a mechanism to send them to the NIH IRF for extraction but our colleagues there believe it will make it endlessly complicated, and take many additional weeks/months, and lesser quality.

Our safety boards have seen us safely work with AVL for years, and knowing we additionally perform heat inactivation. But with your new evidence on AVL and ethanol would like to just have documentation from your lab on this procedure to move forward. It can just be like the one attached from USAMRIID or even simpler.

The NIH IRF are willing to begin this safety testing themselves to help speed things along, and Francis Collins and Tony Fauci have specifically requested we move on getting more sequence out asap. The IRF are all ready to move on that safety testing, but if you have it available it would be an extraordinary help and speed things along. We also have permissions to send live virus on any samples we sequence in case you and Heinz want to do any testing their on any of those, and are just seeking an additional letter to share those more broadly. We are happy to include RLM on the request.

Thank you so much for your consideration.

Pardis

On Tue, Sep 16, 2014 at 10:56 PM, Pardis Sabeti <pardis@broadinstitute.org> wrote:

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:51 PM
To: Menk, Kay (NIH/NIAID) [E]
Cc: 'Jensen, Victoria M. (CTR)'; Geisbert, Thomas W. (twgeisbe@UTMB.EDU)
(twgeisbe@UTMB.EDU)
Subject: RE: p1 stock

Kay,

Please prepare a SLA with Vicki Jensen and another one with Tom Geisbert.


Material: Zaire ebolavirus – Guinea strains (passage 1 tissue culture). The material will be used for in vitro and in vivo research studies. No commercial purpose.

Please communicate with Vicki and Tom on the receiver and authoritative person at their end. You may also have this from previous SLAs.

Thanks,
Heinz

From: Jensen, Victoria M. (CTR) [mailto:Victoria.Jensen@NBACC.DHS.GOV]
Sent: Friday, September 19, 2014 2:40 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: p1 stock

Records Originating Outside of NIAID



From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Wednesday, September 17, 2014 6:34 PM
To: Jensen, Victoria M. (CTR)
Subject: RE: p1 stock

No idea when a shipment could happen. I currently do not have a form2 in place. Does this mean you do not need an SLA with us? If I ship Winnipeg samples to you, you may need an MTA with Winnipeg. Winnipeg's MTAs have been difficult to sign in the past – not sure if that will impact on you. It might be easier to do an SLA with us instead.

Let me know what you want.

From: Jensen, Victoria M. (CTR) [mailto:Victoria.Jensen@NBACC.DHS.GOV]
Sent: Wednesday, September 17, 2014 4:28 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: p1 stock

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:46 PM
To: Shupert, W. Lesley (NIH/NIAID) [E]; Feldmann, Ricki (NIH/NIAID) [C]
Subject: FW: Query
Attachments: Import Permit IP13013454.pdf

Has this been shipped?

From: Glenn.Marsh@csiro.au [mailto:Glenn.Marsh@csiro.au]
Sent: Sunday, August 24, 2014 4:12 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Query

Thanks Heinz,

I have attached an import permit that will permit this (same permit from the original isolates that you sent to us). This is all that we need on this end. Is there some one at RML I can contact to start the process for n MTA and the paperwork on the US end?

Best wishes and stay safe in Liberia

Glenn

From: <Feldmann>, Heinrich Feldmann <feldmannh@niaid.nih.gov>
Date: Sunday, 24 August 2014 7:40 pm
To: Glenn Marsh <Glenn.Marsh@csiro.au>
Subject: Re: Query

We have a mouse and guinea pig adapted version of Zaire ebolavirus based on Mayinga (1976). The rodent models are a good start but with low predictive value for efficacy in NHPs - guinea pig better than mouse. You can also use IFNR knockouts for wildtype viruses (non-adapted) but I don't like the model very much. We like the hamster and think it shows the disease better, but we do not have much data on the predictive value for NHPs.

We can share the viruses. I am currently in Liberia for outbreak response - sould be back mid-September. Can you get the paperwork in place?

Heinz

From: Glenn.Marsh@csiro.au [mailto:Glenn.Marsh@csiro.au]
Sent: Sunday, August 24, 2014 05:26 AM Eastern Standard Time
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Query

Hi Heinz,

I am sure that the current ebolavirus outbreak is keeping you busy. I hope that you are not having to travel too much for it.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:44 PM
To: 'Abdallah Samy'
Subject: RE: Ebola question

Hard to say – the main transmission route is through direct contact with patients, patient fluids and deceased people.

From: Personal Info On Behalf Of Abdallah Samy
Sent: Sunday, August 24, 2014 11:19 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Ebola question

Hello Dr. Feldman;

I read your article on the New England Journal of Medicine on ebola with interest. It is really amazing article that provide some good information about past and current ebola outbreaks. I am wondering if you see if there are environmental factors that contribute the current disease outbreak? do you see any environmental associations between the outbreaks sites. I will be happy to receive your response.

Best regards
Abdallah

Abdallah M. Samy
Member of ASTMH, and ISID
University of Kansas, USA
Ain Shams University, Egypt
Email: samy@ku.edu

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 4:42 PM
To: 'Achenbach, Joel L'
Cc: Pekoc, Ken (NIH/NIAID) [E]
Subject: RE: photos?
Attachments: Liberia_Aug2014_87.jpeg

Dear Joel,

Please find attached a photo showing the entire Lab team supporting ELWA hospital. This is one of two current foreign Lab teams in Monrovia. The other team is supported by the NIAID/USAMRIID.

From left to right: bottom row: Barry Fields, CDC Nairobi, Kenya), Clayton Onyango (CDC, Nairobi, Kenya) and David Safronetz (LV, DIR, NIAID). Upper row: Heinz Feldmann (LV, DIR, NIAID) and Andrea Marzi (LV, DIR, NIAID)

Ken – please feel free to provide a different photo if you have a better or more appropriate one. Please inform me prior to publishing any photo so that I can inform the colleagues.

We stay at a Resort Hotel about 10 minutes away from the ELWA hospital complex (don't want to name the place – it should not matter for the story.

We eat from the menu of the restaurant – food is safe and good.

We work as long as needed - a common work day is about 10-11 hours.

We have our own US embassy vehicle with a driver that stays with us all day.

We work under the CDC leadership in the country (lead at the time we were there: Joel Montgomery, CDC, Nairobi, Kenya). Our customers are almost exclusively ELWA2 (run by the ELWA hospital operation) and ELWA3 (run by MSF). Liberian counterparts are the Ministry of Health and other Ministries of the Liberian government.

Best wishes,
Heinz

From: Achenbach, Joel L [mailto:Joel.Achenbach@washpost.com]
Sent: Saturday, September 20, 2014 1:30 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: photos?

Hi, thanks again for the interview this morning. Do you have photos from your trip to Liberia? Even just snapshots? I don't need to reproduce them. It will just help me tell the story.

I'd like to know a bit more about logistics there. Where exactly do you stay, what do you eat, how do you make sure the food is safe, what hours do you work, what vehicle do you drive (do you have a driver?), and perhaps most importantly, we need to know who your Liberian medical contacts are so we can follow up with them, too (we have a reporter and a photographer on the ground there fyi). Thanks much for all the help! Best, Joel

Joel Achenbach
National Enterprise Reporter
The Washington Post
202-334-7261 - office

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 3:57 PM
To: 'Penny Heaton'
Subject: RE: Ebola

Sounds good.

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Saturday, September 20, 2014 3:48 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

No worries. I will reach out the week of the 29th to confirm a time. Again, many thanks!

Sent from my Windows Phone

From: [Feldmann, Heinrich \(NIH/NIAID\) \[E\]](#)
Sent: 9/20/2014 2:20 PM
To: [Penny Heaton](#)
Subject: RE: Ebola

Dear Penny,

Sorry but I missed this email as I was busy with seminar, meetings and PhD defense. Any time in the week of September 29 would work for me – just let me know.

Best wishes,
Heinz

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Thursday, September 18, 2014 8:08 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Dear Heinz,

Oh my...I can only imagine what it must be like in Monrovia. I appreciate so much you getting back to me. Are you on the East Coast now? If so, I could talk at 11 am your time tomorrow. I will be certain to end the call early enough to give you plenty of time to support your student in her PhD defense!

I am out of the office next week. If we don't connect tomorrow, then basically anytime on the 30th or October 1st, 2nd, 3rd would be good. Just let me know.

And again, many thanks in advance!

Best regards,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 12:31 PM
To: 'Roger Vertrees'
Cc: Jan Winetz
Subject: RE: conference call re hyperthermia treatment for ebola virus

How about Wednesday at 10:00 AM MST?

Heinz

From: Roger Vertrees [mailto:roger@verthermia.com]
Sent: Thursday, September 18, 2014 1:31 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Jan Winetz; Roger Vertrees
Subject: conference call re hyperthermia treatment for ebola virus

Sir,
You requested that I contact you in the second half of Sept. If at all possible we would like to schedule a conference call with you at your convenience for some day next week (Sept 22-26). Please choose a time that is best for you and we will accommodate.

Thanks
Roger Vertrees, Ph.D.
Jan Winetz, MD

ThermalCore (Verthermia), Inc

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 12:26 PM
To: 'Christina Sartori'
Subject: RE: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Christina,

I will try to call at 10:00 AM MST which would be 18:00 MEZ.

Best wishes,
Heinz

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Friday, September 19, 2014 2:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Thank you for answering so quickly and making this so easy to plan: Tuesday would be fine for me, I'm at my desk anyway for the whole afternoon (15.00 - 19.00). Maybe it is more convenient for you, if you call me anytime in this time frame, whenever it suits you the best. I guess the interview will take no more than 15 minutes. And of course: we can always reschedule, if anything urgent comes up.

Best wishes,
Christina

My phone number: +49 - (0)30 - 89391473

"Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov> hat am 18. September 2014 um 18:48 geschrieben:

I don't have Skype – the time difference is 8 hours – some time next week would work for me. The best would be around 8:15 AM in the morning which would be 16:15 MEZ. Wednesday and Friday mornings are not good for me.

From: Christina Sartori [mailto:info@christina-sartori.de]
Sent: Thursday, September 18, 2014 1:07 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Interview für German Symposium on Zoonoses Research and International Conference on Emerging Zoonoses

Sure - wherever you are at the moment, what is the time difference to Europe? Is it possible for you to skype?

Best wishes,
Christina

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 12:24 PM
To: 'Semmler, Ilia'
Cc: ZOO; Wieler, Lothar H.; Juergen Richt
Subject: RE: Ebola-Talk

I did invite her (see previous email).

I am back since a week but are scheduled to go back to Monrovia mid-October.

Best wishes,
Heinz

From: Semmler, Ilia [mailto:Ilia.Semmler@tmf-ev.de]
Sent: Friday, September 19, 2014 1:04 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: ZOO; Wieler, Lothar H.; Juergen Richt
Subject: Re: Ebola-Talk

Good idea! Please contact her - I will try meanwhile to get Max Gertler. So we can hope to get at least one of both. :-)

All the best for you - are you still in Africa?

Ilia

Am 19.09.2014 um 03:12 schrieb "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>:

Dear Ilia,
Sorry for the delay but Ebola people are difficult to contact these days.

I spoke with Armand Sprecher yesterday. He does not really want to commit to anything as he may have to go back to Monrovia during that time. He highly recommended a German MSF person – Anja Wolz. She has been working in Kailahun, Sierra Leone on Ebola and is currently in Geneva. If you want me to contact her I will do immediately. In case you wish a different person, please let me know.

Best wishes,
Heinz

From: Semmler, Ilia [<mailto:Ilia.Semmler@tmf-ev.de>]
Sent: Thursday, September 18, 2014 3:54 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]; 'ZOO'
Cc: Wieler, Lothar H.; Juergen Richt
Subject: AW: Ebola-Talk

Hi Heinz,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 12:24 PM
To: 'Anja.WOLZ@geneva.msf.org'
Cc: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels); 'Semmler, Ilia' (Ilia.Semmler@tmf-ev.de); Juergen Richt
Subject: RE: Berlin

Dear Anja,

I got in contact with the committee. We would like to ask you if you are able and willing to present on the current Ebola outbreak in West Africa from the perspective of MSF - patient management etc. Ilia will be involved in any further arrangements.

Please let us know as soon as possible. I realize that you are in Liberia at the moment.

Best wishes,
Heinz

-----Original Message-----

From: Anja.WOLZ@geneva.msf.org [mailto:Anja.WOLZ@geneva.msf.org]
Sent: Thursday, September 18, 2014 10:33 PM
To: Sprecher, Armand (Médecins Sans Frontières Operational Center of Brussels)
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: Berlin

Hahaha Armand, love your humor
Hello Heinz, I'm available for any question, but I'm going today for 2 weeks to Liberia.
Tell me what you need or how I can help you all the best

Anja Wolz
Operational Adviser Ebola
MSF-Switzerland
+41 796186933

From: Armand SPRECHER/BRU/U/MSF
To: Anja WOLZ/GVA/U/MSF@MSF, "Heinz Feldmann"
<feldmannh@niaid.nih.gov>
Date: 18.09.2014 23:08
Subject: Berlin

Hi Anja,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 12:21 PM
To: 'Penny Heaton'
Subject: RE: Ebola

Dear Penny,

Sorry but I missed this email as I was busy with seminar, meetings and PhD defense. Any time in the week of September 29 would work for me – just let me know.

Best wishes,
Heinz

From: Penny Heaton [mailto:Penny.Heaton@gatesfoundation.org]
Sent: Thursday, September 18, 2014 8:08 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola

Dear Heinz,

Oh my...I can only imagine what it must be like in Monrovia. I appreciate so much you getting back to me. Are you on the East Coast now? If so, I could talk at 11 am your time tomorrow. I will be certain to end the call early enough to give you plenty of time to support your student in her PhD defense!

I am out of the office next week. If we don't connect tomorrow, then basically anytime on the 30th or October 1st, 2nd, 3rd would be good. Just let me know.

And again, many thanks in advance!

Best regards,

Penny

From: Feldmann, Heinrich (NIH/NIAID) [E] [mailto:feldmannh@niaid.nih.gov]
Sent: Thursday, September 18, 2014 6:27 PM
To: Penny Heaton
Subject: RE: Ebola

Dear Penny,

Thanks for your email and apologies for the delayed response. I just got back from Monrovia, Liberia and things are a bit crazy at the moment. I would love to discuss our vaccine efforts and capacity to perform NHP studies on Ebola and related pathogens with you. I am available all next week, but could also do tomorrow morning from 10:00 – 11:30 AM. One of my students will defend her PhD tomorrow afternoon and I won't be available during that part of tomorrow.

Looking forward to talking to you.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 12:17 PM
To: 'Gretchen Vogel'
Subject: RE: Ebola in Guinea

How about tomorrow morning at 9:00 AM my time (17:00 MEZ, your time)?

Best wishes, Heinz

From: Gretchen Vogel [mailto:gvoegel@aaas.org]
Sent: Saturday, September 20, 2014 8:11 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola in Guinea

Would later today sometime work? I can be fairly flexible--up until 10 pm my time, 2 pm in Colorado. Or if tomorrow is better, that would work too. I'm supposed to have my story done by Monday mid-day my time, which is early morning where you are.

I'm reachable at Personal Info or Personal Info

Thank you for your willingness to help!

I should mention: The story, it seems, will be about progress toward a rapid diagnostic test, since apparently at least two are going into trials in Guinea and Sierra Leone in the next two weeks. I'll be very interested to hear your thoughts on the advantages, possible pitfalls, and challenges of the approach.

All the best,
Gretchen

From: Feldmann, Heinrich (NIH/NIAID) [E] [feldmannh@niaid.nih.gov]
Sent: Saturday, September 20, 2014 3:34 PM
To: Gretchen Vogel
Subject: RE: Ebola in Guinea

I was away for the afternoon and evening yesterday. If you still want to talk, please let me know when and what number to call.

From: Gretchen Vogel [mailto:gvoegel@aaas.org]
Sent: Friday, September 19, 2014 9:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola in Guinea

Dear Dr. Feldmann,

Thank you for all the help you have been to Science's Ebola coverage already. The interview that Kai did was very interesting.

I'm afraid I have yet another request: I'm working on a piece that explores why it's hard to make a rapid diagnostic test for Ebola, one you could use in remote villages so you wouldn't have to transport samples back to a lab. A couple of

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 9:38 AM
To: Menk, Kay (NIH/NIAID) [E]
Subject: FW: Form 2
Attachments: Form 2 CEA006877 9-19-14.pdf

For our records.

-----Original Message-----

From: Hoe, Nancy (NIH/OD/ORS) [E]
Sent: Friday, September 19, 2014 3:14 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Shupert, W. Lesley (NIH/NIAID) [E]
Cc: 'gary_kobinger@phac-aspc.gc.ca'; Feldmann, Ricki (NIH/NIAID) [C]; steven.guercio@phac-aspc.gc.ca
Subject: RE: Form 2

Attached find the Form 2 for this transfer. The expiration date is 10/19.

Les - I left a copy on your chair.

Please let me know when you would like to ship.

Thanks,

Nancy

Nancy P. Hoe, Ph.D., CBSP, NRCM(SM)
Biosafety Officer/Responsible Official for Rocky Mountain Laboratories Division of Occupational Health and Safety Office
of Research Services, Office of the Director National Institutes of Health
903 South 4th St.
Hamilton, MT 59840
Tel: 406-363-9334
Fax: 406-375-9705

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 16, 2014 8:59 AM
To: Hoe, Nancy (NIH/OD/ORS) [E]; Shupert, W. Lesley (NIH/NIAID) [E]
Cc: 'gary_kobinger@phac-aspc.gc.ca'; Feldmann, Ricki (NIH/NIAID) [C]
Subject: RE: Form 2

Will do.

Heinz

-----Original Message-----

From: Hoe, Nancy (NIH/OD/ORS) [E]
Sent: Tuesday, September 16, 2014 8:52 AM

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 9:38 AM
To: 'gary_kobinger@phac-aspc.gc.ca'; Kobinger, Gary (Public Health Agency of Canada)
Cc: Feldmann, Ricki (NIH/NIAID) [C]; steven.guercio@phac-aspc.gc.ca; Shupert, W. Lesley (NIH/NIAID) [E]; Hoe, Nancy (NIH/OD/ORS) [E]
Subject: RE: Form 2

Gary,
Whenever you are ready we can ship p1 of the Guinea isolates.

Thanks and best wishes,
Heinz

-----Original Message-----

From: Hoe, Nancy (NIH/OD/ORS) [E]
Sent: Friday, September 19, 2014 3:14 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Shupert, W. Lesley (NIH/NIAID) [E]
Cc: 'gary_kobinger@phac-aspc.gc.ca'; Feldmann, Ricki (NIH/NIAID) [C]; steven.guercio@phac-aspc.gc.ca
Subject: RE: Form 2

Attached find the Form 2 for this transfer. The expiration date is 10/19.

Les - I left a copy on your chair.

Please let me know when you would like to ship.

Thanks,

Nancy

Nancy P. Hoe, Ph.D., CBSP, NRCM(SM)
Biosafety Officer/Responsible Official for Rocky Mountain Laboratories Division of Occupational Health and Safety Office
of Research Services, Office of the Director National Institutes of Health
903 South 4th St.
Hamilton, MT 59840
Tel: 406-363-9334
Fax: 406-375-9705

-----Original Message-----

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Tuesday, September 16, 2014 8:59 AM
To: Hoe, Nancy (NIH/OD/ORS) [E]; Shupert, W. Lesley (NIH/NIAID) [E]
Cc: 'gary_kobinger@phac-aspc.gc.ca'; Feldmann, Ricki (NIH/NIAID) [C]
Subject: RE: Form 2

Will do.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 9:36 AM
To: 'Baden, Lindsey'
Subject: RE: New England Journal of Medicine

The situation in Monrovia is grim and the outbreak is out of control. Liberia needs any help it can get to get out of this outbreak.

Best wishes, Heinz

-----Original Message-----

From: Baden, Lindsey [mailto:lbaden@nejm.org]
Sent: Friday, September 19, 2014 11:49 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: New England Journal of Medicine

all set here.
Thank you.

How was Monrovia?

On 9/19/14, 12:25 PM, "Feldmann, Heinrich (NIH/NIAID) [E]"
<feldmannh@niaid.nih.gov> wrote:

>I guess this comes too late by now. I just got back from Monrovia. I
>would do the review if you are still looking for someone.

>
>Sorry for the delay in responding,
>Heinz

>
>
>-----Original Message-----
>From: onbehalfof+lbaden+nejm.org@manuscriptcentral.com
>[mailto:onbehalfof+lbaden+nejm.org@manuscriptcentral.com] On Behalf Of
>lbaden@nejm.org
>Sent: Tuesday, September 16, 2014 2:30 AM
>To: Feldmann, Heinrich (NIH/NIAID) [E]
>Subject: New England Journal of Medicine

>
>Dear Dr. Feldmann:
>
>I should receive a manuscript shortly regarding the Ebola outbreak in
>the DRC. Given the public health importance might you be able to review
>this for us in 48 hours?

>
>Sincerely,

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 9:34 AM
To: Pekoc, Ken (NIH/NIAID) [E]; Achenbach, Joel L
Subject: RE: interview with Heinz Feldmann

Did the interview this morning. Trying to come out for the game this afternoon.

From: Pekoc, Ken (NIH/NIAID) [E]
Sent: Friday, September 19, 2014 12:18 PM
To: Achenbach, Joel L
Cc: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: interview with Heinz Feldmann

Of course ... There was a nice Q and A with him this week in ScienceInsider if you need background

On Sep 19, 2014, at 11:18 AM, "Achenbach, Joel L" <Joel.Achenbach@washpost.com> wrote:

Dear Ken Pekoc:

Heinz Feldmann has graciously agreed to speak with me pending your approval. We are hoping to do this tomorrow morning. Our story is about the history of the outbreak of Ebola and the response to it, and is a collaboration among a number of reporters and photographers, to run sometime in the next few weeks.

Please let me know if this is okay and I'll move forward. Thanks so much. Best, Joel

Joel Achenbach
National Enterprise Reporter
The Washington Post
202-334-7261 - office

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 9:33 AM
To: 'Dorian Bevec, PhD'
Subject: RE: VHF

Sensitivity: Confidential

Alles klar.

From: Dorian Bevec, PhD [mailto:dorian.bevec@therametrics.com]
Sent: Saturday, September 20, 2014 9:12 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: VHF
Sensitivity: Confidential

Hallo Heinz,
wenn Du hier den Anweisungen folgst, dann können wir praktisch gratis miteinander reden in guter Qualität,
wenn es nicht klappt rufe ich Dich an.
Bis Dienstag, greetings,
Dorian

Please join my meeting, Sep 23, 2014 at 5:00 PM CEST.
<https://global.gotomeeting.com/join/776564629>

2. Use your microphone and speakers (VoIP) - a headset is recommended. Or, call in using your telephone.

Germany: [Redacted by agreement]
United States: [Redacted by agreement]

Access Code: [Redacted by agr]
Audio PIN: Shown after joining the meeting

Meeting ID: [Redacted by agre]

From: Feldmann, Heinrich (NIH/NIAID) [E] <feldmannh@niaid.nih.gov>
Sent: Saturday, September 20, 2014 4:14 PM
To: Dorian Bevec, PhD
Subject: RE: VHF

Wirst Du mich anrufen?

Buero: [Redacted by agree]
[Redacted by agreement]

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 8:25 AM
To: Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Growth of Guinean Ebola

In the range of other Zaire ebolaviruses. We usually harvest between days 5-8.

From: Jahrling, Peter (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 8:19 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Growth of Guinean Ebola

Heinz,

Yes this is very helpful. Thank you. I wonder why it is so slow.

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 9:52 AM
To: Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Growth of Guinean Ebola

Redacted by agreement

Hope this helps,
Heinz

From: Jahrling, Peter (NIH/NIAID) [E]
Sent: Friday, September 19, 2014 2:45 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Growth of Guinean Ebola

Heinz,

Redacted by agreement

Redacted by agreement

Pete

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 8:15 AM
To: 'dorian.bevec@therametrics.com'
Subject: RE: VHF

Sensitivity: Confidential

Wirst Du mich anrufen?

Buero: Redacted by

Redacted by agreement

From: dorian.bevec@therametrics.com [mailto:dorian.bevec@therametrics.com]
Sent: Friday, September 19, 2014 11:21 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: VHF
Sensitivity: Confidential

Super, dienstag 9am montana zeit ist perfekt, wir brauchen weniger als 1 stunde. Falls ok, organisiere ich the go-to-meeting KOnferenz, greetings, dorian
Inviato dal mio BlackBerry® Smartphone di Swisscom.

From: "Feldmann, Heinrich (NIH/NIAID) [E]" <feldmannh@niaid.nih.gov>
Date: Fri, 19 Sep 2014 17:11:23 +0000
To: 'Dorian Bevec, PhD' <dorian.bevec@therametrics.com>
Subject: RE: VHF

Dienstag kann ich nur in der Zeit von 9:00 – 11:00 Uhr und Mittwoch in der Zeit von 10:00 – 12:00 Uhr. Ichnehme mal an, dass es nichtlaenger als eine Stunde braucht alles zu besprechen – oder?

Gruss,
Heinz

From: Dorian Bevec, PhD [mailto:dorian.bevec@therametrics.com]
Sent: Thursday, September 18, 2014 11:25 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Re: VHF
Sensitivity: Confidential

Lieber Heinz,
nächster Dienstag, 23 September 9-12am your time, oder Mittwoch 24 September 9-12am your time?
Bitte gib mir Bescheid, dann sende ich Dir die go-to-meeting Koordinaten.
Beste Grüsse,
Dorian

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 7:52 AM
To: Jahrling, Peter (NIH/NIAID) [E]
Subject: RE: Growth of Guinean Ebola

Redacted by agreement

Hope this helps,
Heinz

From: Jahrling, Peter (NIH/NIAID) [E]
Sent: Friday, September 19, 2014 2:45 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Growth of Guinean Ebola

Heinz,

Redacted by agreement

Redacted by

Pete

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 7:42 AM
To: Shott, Joseph (NIH/NIAID) [E]
Cc: Pineda, Mark (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]
Subject: RE: TOMORROW, 9/19/14 - Dr. Daniel Bausch on Ebola Virus infection - will be videocast

Sorry – did see the email too late. I was away yesterday afternoon for the thesis defense of one of my students.

Dan is an old friend and knows Ebola and Lassa very well. Should have been a good lecture.

Sorry again,
Heinz

From: Shott, Joseph (NIH/NIAID) [E]
Sent: Friday, September 19, 2014 4:58 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Cc: Pineda, Mark (NIH/NIAID) [E]; Barron, Karyl (NIH/NIAID) [E]
Subject: FW: TOMORROW, 9/19/14 - Dr. Daniel Bausch on Ebola Virus infection - will be videocast
Importance: High

Is this worth attending Heinz?

From: Palmore, Tara (NIH/CC) [E]
Sent: Thursday, September 18, 2014 7:38 PM
To: List NIHVIG-L
Subject: TOMORROW, 9/19/14 - Dr. Daniel Bausch on Ebola Virus infection - will be videocast
Importance: High

Dr. Daniel Bausch will present a talk entitled, "Ebola Virus in West Africa: How did we get here and what do we do now?"² tomorrow, Friday, September 19, 2014 at 12:00 noon in Masur auditorium. Dr. Bausch, a Filovirus expert with extensive field experience in previous Ebola and Marburg outbreaks, has been intimately involved in control efforts for the WHO in the current Ebola outbreak in West Africa. Now stationed at WHO in Geneva, he is a coordinator of their efforts supporting therapeutics, vaccines and clinical research studies of Ebola in the current outbreak.

The talk will be videocast: <http://videocast.nih.gov/>

Biography:

Daniel Bausch, MD, MPH&TM, is an Associate Professor in the Department of Tropical Medicine and Section of Infectious Diseases, Department of Internal Medicine, at the Tulane University Health Sciences Center. He is board-certified in internal medicine and infectious diseases with a Masters of Public Health degree in tropical medicine. Although still actively participating in teaching and other scholarly activities at Tulane, Dr. Bausch is presently seconded to the U.S. Naval Medical Research Unit 6 in Lima, Peru, where he is the Director of the Emerging Infections Department. He specializes in the research and control of emerging tropical viruses. Formerly with the CDC Special Pathogens Branch, Dr. Bausch has extensive experience in sub-Saharan Africa, Latin America, and Asia combating pathogens such as Ebola and Lassa viruses, hantavirus, and SARS coronavirus. He serves as a frequent consultant for the World Health Organization, United Nations, and National Institutes of Health. Dr. Bausch places a strong emphasis on capacity building in all his projects and also has a keen interest in the role of the scientist in promoting health and human rights.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 7:40 AM
To: 'Allen Grolla'
Subject: RE: Reuters.com - French nurse for medical charity MSF contracts Ebola in Liberia

Yes – a little too close but something that I expected to happen given the size of the MSF operation. They do not know yet how the exposure happened. The person is in France doing reasonably well. She is treated with Tekmira product (siRNA).

Glad to hear that everyone is fine and back home.

Best wishes,
Heinz

From: Allen Grolla [mailto:grolla@mymts.net]
Sent: Thursday, September 18, 2014 9:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Reuters.com - French nurse for medical charity MSF contracts Ebola in Liberia

That is also a bit too close for comfort, you always have to be careful. Redacted by agreement

Redacted by agreement

I am fine (as was Darwyn and Brittany), no problems at all health wise but very bored at home isolated away for 2.5 weeks. Back at work now to give Shane a hand again. We have been getting several suspect samples every week now and that will likely increase as Montreal and Toronto will put more screening in place for returning travelers from West Africa. I am back on the list for future teams, I think I may be going back out for Oct or Nov.

Shane sent me your Science Insider article, looking pretty fashionable in the rain coat!

Allen

From: feldmannh@niaid.nih.gov
To: gary.kobinger@phac-aspc.gc.ca; Jim.Strong@phac-aspc.gc.ca; George.Risi@providence.org; grolla@mymts.net
Subject: FW: Reuters.com - French nurse for medical charity MSF contracts Ebola in Liberia
Date: Fri, 19 Sep 2014 01:19:20 +0000

FYI – Redacted by agreement As far as I know no idea about the exposure incidence.

Redacted by agreement

Allen – how are you and the others? Haven't heard from you since a while.

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 7:34 AM
To: 'Gretchen Vogel'
Subject: RE: Ebola in Guinea

I was away for the afternoon and evening yesterday. If you still want to talk, please let me know when and what number to call.

From: Gretchen Vogel [mailto:gvoel@aaas.org]
Sent: Friday, September 19, 2014 9:09 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Ebola in Guinea

Dear Dr. Feldmann,

Thank you for all the help you have been to Science's Ebola coverage already. The interview that Kai did was very interesting.

I'm afraid I have yet another request: I'm working on a piece that explores why it's hard to make a rapid diagnostic test for Ebola, one you could use in remote villages so you wouldn't have to transport samples back to a lab. A couple of people said you'd be able to contribute some helpful thoughts. Any chance you'd have time to talk later today (evening, my time)?

Thanks very much,

Gretchen Vogel

Gretchen Vogel
Contributing correspondent, Science
Idsteiner Str. 16
14163 Berlin
Germany

+49 30 8101 3082 phone
+49 30 8101 3083 fax

gvoel@aaas.org
www.sciencemag.org

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 7:25 AM
To: Menk, Kay (NIH/NIAID) [E]; Walczynski, Joyce (NIH/NIAID) [C]
Cc: Ervin, Elizabeth (CDC/OID/NCEZID) (CTR); Thorne, Gregory Immel (CDC/CGH/DGHA); Rollin, Pierre (CDC/OID/NCEZID); Reed, Christie (CDC/CGH/DPDM); Arlotta, Dawn (CDC/ONDIEH/NCCDPHP)
Subject: RE: (SBU) USAID-OFDA West Africa Ebola Outbreak Update

Kay & Joyce,

Can you please contact Dep. of State when travel arrangements have been finalized and report who is going? Not sure how this will work when personnel will change but we will see. The CDC team head in Monrovia knows the members of the lab team anyway.

Heinz

From: Ervin, Elizabeth (CDC/OID/NCEZID) (CTR)
Sent: Friday, September 19, 2014 3:00 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]; Rollin, Pierre (CDC/OID/NCEZID); Thorne, Gregory Immel (CDC/CGH/DGHA); Arlotta, Dawn (CDC/ONDIEH/NCCDPHP); Reed, Christie (CDC/CGH/DPDM)
Subject: RE: (SBU) USAID-OFDA West Africa Ebola Outbreak Update

Records Originating Outside of NIAID

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 7:20 AM
To: 'Geisbert, Thomas W.'
Subject: RE: Washington Post

Things are fine. We can talk any time you want.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Friday, September 19, 2014 8:33 PM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: RE: Washington Post

Is everything OK? Maybe we can talk this weekend.

Sent via the Samsung GALAXY S® 5, an AT&T 4G LTE smartphone

----- Original message -----

From: "Feldmann, Heinrich (NIH/NIAID) [E]"
Date: 09/19/2014 12:18 PM (GMT-06:00)
To: "Geisbert, Thomas W."
Subject: RE: Washington Post

Thanks.

From: Geisbert, Thomas W. [mailto:twgeisbe@UTMB.EDU]
Sent: Friday, September 19, 2014 11:10 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Washington Post

I gave your contact info to a Washington Post reporter named Joel Achenbach. They are doing a major story on the Ebola outbreak for one of their Sunday editions. I don't know how this works on your end if you are allowed to do this now that you are back?

Tom

Feldmann, Heinrich (NIH/NIAID) [E]

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 7:15 AM
To: Pineda, Mark (NIH/NIAID) [E]
Subject: RE: (SBU) USAID-OFDA West Africa Ebola Outbreak Update

Thanks for the note.

I hope things are going well. If you have some time we should talk next week.

Best wishes,
Heinz

From: Pineda, Mark (NIH/NIAID) [E]
Sent: Saturday, September 20, 2014 6:58 AM
To: Feldmann, Heinrich (NIH/NIAID) [E]
Subject: Fw: (SBU) USAID-OFDA West Africa Ebola Outbreak Update

Heinz:

Forgot to mention your friend Joseph Fair made the front of the Wah Post earlier this week. Will try to forward it. Mark

From: Feldmann, Heinrich (NIH/NIAID) [E]
Sent: Thursday, September 18, 2014 02:34 PM
To: Bloom, Marshall (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [C]; Pineda, Mark (NIH/NIAID) [E]
Cc: Rollin, Pierre (CDC/OID/NCEZID); Montgomery, Joel M. (CDC/CGH/DGHP); Towner, Jonathan (Jon) (CDC/OID/NCEZID); Nichol, Stuart T. (CDC/OID/NCEZID); Munster, Vincent (NIH/NIAID) [E]
Subject: RE: (SBU) USAID-OFDA West Africa Ebola Outbreak Update

As we are under CDC leadership I expect CDC to do the communication regarding the embassy. This would be more appropriate and less confusing.

CDC folks – please let us know if you disagree.

From: Bloom, Marshall (NIH/NIAID) [E]
Sent: Thursday, September 18, 2014 11:17 AM
To: Handley, Gray (NIH/NIAID) [E]; Jahrling, Peter (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [C]; Pineda, Mark (NIH/NIAID) [E]
Cc: Feldmann, Heinrich (NIH/NIAID) [E]; Bloom, Marshall (NIH/NIAID) [E]
Subject: RE: (SBU) USAID-OFDA West Africa Ebola Outbreak Update

Heinz,
Can you please respond to this for the people going to Liberia from RML?
Thanks
Marshall